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**C. W. Tai**

Ministry of Health Malaysia, Jalan Mahmoodiah Johor Bahru, Malaysia

**Aims**: The National Diabetes Registry (NDR) is an initiative taken by the Ministry of Health (MOH) of Malaysia to monitor the quality of care in patients with diabetes who are managed at public primary care clinics. The purpose of this study was to evaluate the impacts and outcomes of diabetes care on patients with Type 2 diabetes mellitus (T2DM) in primary care services at Malaysia through analysis of NDR Database. The results can help us to understand T2DM management over time and across geographical locations. Furthermore, it can help to improve patient management and future outcomes through the assessment of process indicators, medications use and clinical outcomes data captured for audited patients from NDR.

**Methods**: This is a cross‐sectional study using audit dataset extracted from NDR from 2012 to 2016 for 13 primary health clinics located at Johor Bahru (JB) district, Malaysia. The NDR annual Diabetes Clinical Audit was conducted through random sampling from the registration dataset of active patients with T2DM. Different samples of patients are drawn every year. Patients sampled in the previous year have an equal chance of being selected in the subsequent years.

**Results**: Five samples of 1314, 702, 778, 774 and 761 patients with T2DM (2012--2016) were studied. Only 23.3% of patients achieved a target of haemoglobin A1c ≤ 6.5% (48 mmol/mol) in 2016 with a mean reading of 8.1% (65 mmol/mol). Suboptimal control of blood pressure (BP), lipid profile and body mass index were noted. Increased usage of oral anti‐diabetes agents (OAD), insulin, anti‐hypertensive agents (AHA) and anti‐lipid agents (ALA) was observed.

**Conclusion**: Majority of the T2DM patients managed in the primary health clinics in JB do not achieve optimal glycaemic control and other parameters for the past 5 years. Improvements are seen in terms of treatment target achievement among T2DM patients. However, increasing use of OAD, insulin, AHA and ALA do not translate into clinical benefits. A structured and coordinated effort is necessary at the basic primary care level in order to reduce the risk of diabetes complications.
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**L. Xiahong, X. Jinting, H. Yinqiong, F. Jinwen, C. Xiaoyu, W. Xiaohong and B. Xuefeng**
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**Objectives**: To analyze the expression profile of the complement system in the kidney tissue of SD rats with type 2 diabetic nephropathy.

**Methods**: Five‐week‐old SPF male SD rats were given high‐fat and high‐energy feed and then an intraperitoneal injection of 1% STZ to establish the animal models of type 2 diabetes (T2DM) and diabetic nephropathy (DN). The blood glucose (BG) was detected by Roche glucometer. The fasting insulin (FINS) and urinary albumin concentration were measured with enzyme‐linked immunosorbent assay (ELISA). Hematoxylin‐eosin and periodic acid schiff staining were applied to observe the morphological changes of the kidney tissue, and the mesangial index (MI), arteriosclerosis index (AI), and percentage of the tubular area (PTA) of kidney tissue were determined with specific software. Immunohistochemistry and western blot (WB) were used to detect the expression level of the components of complement system.

**Results**: The BG of the DM group and DN group elevated significantly compared to the control group. The level of urinary albumin and renal the weight/body weight (mg/g) in the DN group significantly increased than that in the DM group and control group. The MI, AI, and PTA in DN group were higher than the other two groups. Most components of complement system universally elevated in the DN group than the other two groups, wherever, there are no significant difference between the DM group and the control group. The expression level, detected with immunohistochemistry, of most components of complement system including C1q, MBL, factor B, C3, and C5b‐9 elevated significantly. As well, the expression level of three components, including MBL, MASP‐2, and C3, detected with WB, also increased. Interestingly, the expression of most of components including C1q, MBL, MASP‐2, factor B and C5b‐9 mainly increased in renal tubules rather than glomerulus.

**Conclusions**: The expression of most components of the complement system in kidney tissue universally elevated in type 2 diabetic nephropathy. The activation of complement system might play important roles in diabetic nephropathy, especially in renal tubular injury.

PP‐3 {#jdi12939-sec-0006}
====

Diurnal rhythm of follicle‐stimulating hormone is associated with nonalcoholic fatty liver disease in a Chinese elderly population {#jdi12939-sec-0007}
----------------------------------------------------------------------------------------------------------------------------------

**X. Li, P. Zhu and G. Chen**
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**Objective**: Previous studies have found that impairment of the circadian clock appears to contribute to the development of nonalcoholic fatty liver disease (NAFLD) and the circulating follicle‐stimulating hormone (FSH) level showed a diurnal cycle. A recent study reported that a lower FSH level was associated with NAFLD. However, the effects of the diurnal rhythm of FSH on NAFLD have not been reported. The aim of this study was to evaluate whether the diurnal rhythm of FSH was associated with NAFLD in an elderly population. Study design: We performed a cross‐sectional study among 71 elderly patients between August 2015 and November 2015 at Fujian Provincial Hospital. Anthropometrics and tests for laboratory were performed for each patient. FSH was determined by radioimmunoassay. The FSH receptor (FSHR) expression was identified in liver and ovary tissue by immunohistochemical staining. NAFLD was diagnosed by sonographic features.

**Results**: Of the 71 patients, 33 (42.9%) had NAFLD on their ultrasound. There were no significant differences between subjects with NAFLD and those without NAFLD in terms of age, sex, body mass index, waist‐to‐hip ratio, fasting plasma glucose, postload plasma glucose, liver enzyme, triglycerides, total cholesterol, high‐density lipoprotein‐cholesterol and low‐density lipoprotein‐cholesterol. Both the serum FSH levels of 8AM and 0AM showed no differences between the groups. The proportion of the 'normal' diurnal rhythm of FSH was higher among the patients with NAFLD (78.1% vs.52.6%, *P* = 0.027). After adjusting for all potential confounders, the fully adjusted odds ratios (OR) of diurnal rhythm of FSH for NAFLD was 3.86 (95%CI: 1.01, 14.81, *P* = 0.049). Immunohistochemical staining showed that the FSHR protein was detected in human ovarian and hepatic tissues.

**Conclusions**: These results suggest that the 'normal' diurnal rhythm of FSH was independently associated with NAFLD in an elderly population. This study provides a novel insight into the diurnal rhythm of FSH in the pathogenesis of NAFLD.
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**H. Zhang**

First Affiliated Hospital of Harbin Medical University, Harbin, China

**Aims**: We investigated the safety and tolerability of empagliflozin in East Asian patients with type 2 diabetes (T2DM).

**Methods**: Data were pooled from patients with T2DM randomized 1:1:1 to placebo, empagliflozin 10 mg, or empagliflozin 25 mg in 15 Phase I--III trials. Adverse events (AEs) were analyzed in the subgroup of patients from East Asian countries.

**Results**: In total, 709, 724 and 708 East Asian patients received placebo, empagliflozin 10 mg and empagliflozin 25 mg, respectively; total exposure was 953, 1072, and 1033 patient‐years in these groups, respectively. The incidence of any AEs, severe AEs, serious AEs, and AEs leading to discontinuation was not higher in patients treated with empagliflozin than placebo. The incidence of hypoglycemia differed according to glucose‐lowering medication used at baseline. The incidence of events consistent with urinary tract infection was numerically lower with empagliflozin (5.3--5.8/100 patient‐years) than placebo (7.2/100 patient‐years). Events consistent with genital infection occurred more frequently with empagliflozin (1.5--1.7/100 patient‐years) than placebo (0.2/100 patient‐years). The incidence of AEs consistent with volume depletion was similar across treatment groups (0.8--1.4/100 patient‐years) but higher with empagliflozin 25 mg vs. placebo in patients aged ≥65 years (3.5 vs. 2.0/100 patient‐years). Rates of bone fractures, renal AEs, venous thromboembolic events, hepatic injury, lower limb amputation and diabetic ketoacidosis were similar or not higher with empagliflozin than placebo.

**Conclusions**: In this pooled analysis, empagliflozin was well tolerated in East Asian patients with T2DM based on \>3,000 patient‐years' exposure, consistent with results from the overall analysis population.
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**Aim**: To evaluate the value of hemoglobin A1c (HbA1c) and fasting blood glucose (FBG) in screening diabetes and impaired glucose regulation in patients with hyperthyroidism, and identify the optimal HbA1c cut‐off point.

**Methods**: Five hundred and eight hyperthyroidism who carried out oral glucose tolerance test were recruited into the study, and HbA1c were measured at the same time. ROC curve was made to identify the optimal HbA1c cut‐off and positive likelihood ratio and negative likelihood ratio.

**Results**: (1) The levels of HbA1c, FPG、PBG in NGT group, IGR group and DM group were increased gradually with statistical difference (*P \< *0.001). (2) According to ROC curve, the optimal cut‐off point of HbA1c for diagnosis of IGR was 5.4%, where the sensitivity was 55.9% and the specificity was 64.39%. The optimal cut‐off point of HbA1c for diagnosis of diabetes (DM) in patients with hyperthyroidism was 5.5%, where the sensitivity was 79.71% and the specificity was 73.16%.

**Conclusion**: HbA1c can reflect the different glucose metabolism in patients with hyperthyroidism correctly, and the optimal cut‐off point of HbA1c for screening IGR and DM is 5.4% and 5.5%, respectively.
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SGLT2 inhibitor (SGLT2i) enhances glucose excretion into urine and reduces blood glucose (BG). In addition, SGLT2i has been reported to ameliorate dyslipidemia, hepatic dysfunction and hypertension, and may have potentials of other physiologically beneficial effects as well. Sympathetic nerve activity (SNA) is involved in energy metabolism, and its activation enhances peripheral glucose uptake. In spite of those findings, the effects of SGLT2i on SNA have not been documented well. In the present study, we evaluated the response of peripheral SNA to BG elevation in rats treated with SGLT2i, and compared with that of non‐treated, control rats. Male rats fed on a standard laboratory chow were divided into two groups at 8 weeks of age: SGLT2i treated group (Dapa, *n* = 6) orally administered 1 mg/kg/day dapagliflozin for 7 weeks, and control group (*n* = 6) administered vehicle only. At 15 weeks of age, we recorded peripheral SNA in the unilateral sciatic nerve with a microelectrode under anesthetic condition, and evaluated action potential (AP) rate, in addition to BG and plasma insulin (PI) levels. Then, single intravenous administration of glucose (400 mg/kg) was conducted, and those data were monitored at 20‐min intervals for 60 min. The results showed no significant difference in BG or PI levels, nor AP rate between both the groups measured before the glucose load (baseline). After the glucose load, BG and PI levels rose transiently, and then gradually decreased toward the baseline; area under the curve of each level was somewhat lower in the Dapa group than in the control one (BG, *P* \< 0.01; PI, *P* = 0.06) probably due to enhancement of glucose excretion into urine rather than increase in glucose uptake. While AP rate changed little even after the glucose load in the control group, the rate in the Dapa group was transiently diminished 20 min after the glucose load (*P* \< 0.05 vs. the baseline). Although the rate gradually increased thereafter, it remained lower than that of the control group (*P* \< 0.05). The response in the Dapa group may rather imply suppression of acute glucose uptake. In conclusion, SGLT2 inhibition did not affect the basal SNA but diminished it in response to glucose stimulation.
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Alexandra Health Pte Ltd‐khoo Teck Puat Hospital, Singapore

**Background**: Maturity‐onset diabetes of the young (MODY) is a form of monogenic diabetes that is clinically heterogeneous. Genetic testing is necessary to determine the causal gene mutation and confirm the clinical diagnosis. Biomarkers may help to improve the nomination of candidates for genetic testing. To date, no good biomarkers for MODY have been identified except for hs‐CRP which did not fare as well in our local population. We hypothesize that the disparate etiologies of MODY will be reflected in their metabolic profiles, and aim to determine the key metabolites that will differentiate MODY from obese Type 2 diabetes (ObT2D).

**Methods**: Potential MODY patients were subjected to genetic testing and a genetic diagnosis was established if variant (s) identified were classified to be likely pathogenic/pathogenic according to ACMG guidelines. ObT2D cohort comprises of severely obese T2D patients who were indicated for metabolic surgery. Corresponding plasma samples from MODY and pre‐surgery ObT2D cohorts were subjected to targeted metabolome analysis (acylcarnitines, amino acids and lipids) using liquid and gas chromatography‐mass spectroscopy. Statistical analyses were performed using SPSS Ver. 22 and MetaboAnalyst 4.0.

**Results**: Partial least squares‐discriminant analysis (PLS‐DA) performed on HNF1A/HNF4A/GCK‐mutation positive (MODY, *n *= 12) and ObT2D (*n *= 12) samples matched for age, gender and ethnicity identified 3 very long chain ceramides: Cer (d18:1/24:1(15Z)), Cer (d18:1/26:1(17Z)) and Cer (d18:0/24:1(15Z)), each of which was capable of delineating the two groups (AUC 1.0, CI 1.0--1.0, *P* \< 0.0001) and was \>10‐fold higher in MODY cohort. Histidine, the only amino acid identified in the comparison (AUC 1.0, CI 1.0--1.0, *P* \< 0.0001) was ˜2.5‐fold higher in the MODY cohort. Individually and in combination, these 4 metabolites could classify patients (MODY, *n *= 7 and ObT2D, *n *= 29) into their respective groups with an accuracy of \>97%. Discussions &

**Conclusions**: Very long chain ceramides are shown to be protective towards cellular injury and apoptosis and histidine is negatively associated with inflammation and metabolic syndrome. Our findings that these 4 metabolites are found at higher levels in MODY than ObT2D patients reflect the pathobiological basis underlying these 2 extreme diabetes types and pave the way for further search within related pathways to unravel biomarkers for different types of diabetes.
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**J. G. Kim, G.‐H. Kim, N.‐G. Lee, J.‐S. Lee and S.‐S. Yoon**

Division of Biological Science and Technology, Yonsei University, Wonju, Republic of Korea

**Introduction**: Recently, *Bacillus cereus* commonly exists in nature and is well known to be responsible for several food poisoning outbreaks. Because of its high probability of causing food poisoning, there is increasing consumer anxiety related to the safety of food. Therefore, new methods of ensuring food safety are required. Some phages have been designated as Generally‐Recognized‐As‐Safe (GRAS) by the US Food and Drug Administration (FDA). Moreover, the FDA recommends the spraying of phage culture on the food surface, which is cheaper than using synthetic antibiotics.

**Aim**: The aim of the present study was to isolate and identify a phage with activity against B. cereus, which was reported to frequently contaminate infant formula and baby foods as an opportunistic foodborne pathogen. B. cereus might be effectively controlled by the phage identified in this study, which could then be applied as a biocontrol agent in the food manufacturing process or extended storage.

**Methods**: Bacteriophage particles were analyzed with transmission electron microscopy. Factors influencing adsorption were carried out with a double‐layer plaque assay. Sodium dodecyl sulfate‐polyacrylamide gel electrophoresis was conducted to measure the size of major structural proteins. The complete genome of the phage was analyzed.

**Results**: Bacteriophage particles (100‐nm icosahedral head and 200‐nm contractile tail) were identified as Myoviridae. ΦBC01 had host specificity to B. cereus. Major structural proteins of ΦBC01 showed two abundant bands of 99 kDa and 56 kDa, respectively. The 158,385‐bp genome sequence of ΦBC01 was determined: 56 of the 305 open reading frames were annotated indicating involvement in bacteriophage DNA manipulation, cell lysis, packaging, structural proteins, and others.

**Conclusion**: In this study, we focused on the molecular characteristics of the phage and its physiological stabilities to environmental factors. This basic study of a B. cereus phage is expected to provide critical reference information to achieve better control of the food‐associated pathogen in the manufacturing of liquid‐ or powder‐type foods.
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**R. Shi, S. Zhao and Z. Sun**
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**Background and Aims**

Glycemic dysregulation and insulin resistance are common threads in the progression from obesity to diabetes. Here, we attempted to explore a new molecular mechanism mediated by Clec11a (C‐type lectin domain family 11, member A) in prevention of islets disfunction during obesity.

**Materials and Methods**

C57BL/6 mice aged 5 weeks fed a high‐fat diet or standard diet for 14 weeks. Transcriptomic sequencing was performed with the islets of diet‐induced obesity (DIO) C57BL/6 mice and normal food fed control mice. Differential gene transcription was confirmed by real‐time PCR, and protein translation was verified by western blot and immunofluorescence. The proliferation of MIN6 cells was measured by CCK8. The insulin secretion was measured by ELISA.

**Results**: The body weight (*P* \< 0.01), fasting blood glucose (*P *\< 0.01), and insulin level in plasma (*P *\< 0.01) were higher in DIO mice than those of control mice. Moreover, the results of oral glucose tolerance test (OGTT) and insulin tolerance test (ITT) exhibited the impaired glucose tolerance and insulin resistance in DIO mice (*P *\< 0.05). The mRNA of Clec11a significantly decreased in islets of DIO mice in RNA‐Seq experiment by 5 folds and confirmed by real‐time PCR. Clec11a staining is localized in islets. Palmic acid (PA)‐treated cultured isolated islets expressed less Clec11a in a dose‐dependent manner. We then chose 0.5 mM PA as the concentration in time course experiment. The protein expression of Clec11a demonstrated an waved trend with upregulated peak at 12 h and then declined until a reversed level comparing to free fat acid (FFA‐BSA) at 48 h. The expression of Clec11a in MIN6 is also downregulated by PA in a dose‐dependent manner measured by real‐time PCR and western blot. Additionally, PA treatment inhibited the proliferation and the secretion of insulin in MIN6. The treatment of Clec11a protein containing medium rescued the proliferation (*P *\< 0.01), the secretion of insulin in high glucose (*P *\< 0.01). Moreover, the phosphorylation level of Akt was elevated by Clec11a protein containing medium in PA‐treated MIN6 cells by 2 folds (*P *\< 0.05).

**Conclusion**: Clec11a might protects the islets function injured by lipotoxicity via a mechanism of regulating pancreatic beta cell proliferation and secretion.
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**Objective**: Apolipoprotein B/Apolipoprotein A‐1 ratio (Apo B/Apo A‐1) and lipoprotein (a) (Lp (a)) are known to be associated with atherosclerotic vascular disease. We investigated the influence of Apo B/Apo A‐1 and Lp (a) on coronary artery calcification (CAC) among healthy Korean adults.

**Methods**: A total of 1081 participants underwent cardiac computed tomography in health promotion center were enrolled. Anthropometric profiles and multiple cardiovascular risk factors, including Apo B, Apo A‐1, and Lp (a), were measured. Multi‐detector CT was used to measure coronary artery calcium score (CACS) and CACS\>0 was defined as the presence of CAC. Adjusted Odds ratios for the presence of CAC according to Lp(a) and Apo B/Apo A‐1 tertiles were estimated using logistic regression.

**Results**: Subjects were grouped according to Lp(a) and Apo B/Apo A‐1 levels. There were significant differences in cardiovascular parameters among the groups and the prevalence of CAC significantly increased with Lp(a) and Apo B/Apo A‐1 levels. In the logistic regression analysis adjusted for multiple risk factors, odds ratio (95% CI) for the prevalence of CAC comparing the lowest Lp(a) and Apo B/Apo A‐1 group to the highest group was 2.554 (1.256--5.201) (*P* \< 0.05).

**Conclusion**: These results show that Apo B/Apo A‐1 and Lp(a) have a synergistic impact on prevalence of CAC, which suggests that individuals with elevated Lp(a) and Apo B/Apo A‐1, should be more closely monitored to allow a better risk assessment for subclinical atherosclerosis.
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Gangnam Severance Hospital, Yonsei University College of Medicine, Republic of Korea

**Objective**: FSTL1, an extracellular glycoprotein, is a novel myokine that is secreted by skeletal muscle. However, its functions in metabolism remain unclear. Adipose tissue is one of the important organs for maintaining energy homeostasis. FSTL1 is known to induce inflammatory response and inhibit insulin‐mediated Akt signaling pathway, and we aimed to investigate whether FSTL1 plays metabolic roles in human adipose tissue. We hypothesized that FSTL1 increases lipolysis through its putative receptor DIP2A (Disco interacting protein 2 homolog A).

**Methods**: Human primary adipocytes were treated with recombinant FSTL1 in dose and time‐dependent manner. To determine its lipolytic activity, pHSL ser^563,565,660^, perilipin, AMPK, PKA were determined by western blot and the rate of free fatty acid was assessed. Expression of DIP2A was determined by PCR and western blot. DIP2A was knocked‐down to examine whether it mediates metabolic effects of FSTL1.

**Results**: FSTL1 did not affect catecholamine‐induced lipolysis via PKA. FSTL1, however, increased lipolysis through AMPK activation and, subsequently, HSL ser^565^ phosphorylation in dose‐dependent manner. It was found that DIP2A expression did not change during differentiation of human primary adipocyte, suggesting that it is not involved in adipocyte maturation.

**Conclusion**: FSTL1 increased basal lipolysis through AMPK activation. AMPK is well‐known sensor of the intracellular energy state and serves to regulate various signals. Its activation provides ATP by FA oxidation. Therefore, FSTL1 may play an important in the regulation of energy homeostasis. FSTL1 also has effect through DIP2A. These findings suggest that DIP2A plays important roles in FSTL1‐mediated lipolysis.
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**Background**: Endothelial dysfunction is posited as an early manifestation of atherosclerosis, a chronic inflammatory disease that confers significant morbidity and mortality in type 2 diabetes (T2D). Dysfunction of the vascular endothelium is initiated by inflammatory activation of endothelial cells. Inflammatory mediators consisting of intercellular adhesion molecule‐1 (ICAM‐1) and vascular adhesion molecule‐1 (VCAM‐1), matrix metalloproteinase‐2 (MMP‐2), c‐reactive protein (CRP) and leucine‐rich alpha‐2‐glycoprotein‐1 (LRG‐1) have been previously documented to contribute to endothelial damage. Zinc‐alpha‐2‐glycoprotein (ZAG) is a soluble major histocompatibility complex class I glycoprotein implicated to have beneficial effects on cellular processes such as glucose and lipid metabolism, inflammation, and fibrosis. Here, we postulate an inverse relationship between ZAG and endothelial dysfunction in T2D.

**Methods**: This cross‐sectional analysis involved 381 T2D subjects of the SMART2D cohort. Forearm microvascular endothelium‐dependent and endothelium‐independent function was assessed by laser Doppler imaging with iontophoresis of acetylcholine (ACh) and sodium nitroprusside (SNP), respectively, corrected by subtracting the baseline resting forearm blood flow. Plasma concentrations of ZAG and inflammatory mediators were determined using immunoassay. Statistical analyses including Spearman\'s correlation and linear regression were conducted.

**Results**: ZAG showed significant correlation with endothelial biomarkers ICAM‐1 (rho = −0.287, *P *\< 0.001), VCAM‐1 (rho = −0.202, *P *\< 0.001), MMP‐2 (rho = −0.155, *P* = 0.002), CRP (rho = −0.102, *P* = 0.047) and LRG‐1 (rho = 0.129, *P* = 0.012). Among the circulating biomarkers, ZAG had the strongest association with ACh‐induced endothelium‐dependent vasodilation univariately (β = 0.144, 95%CI: 0.080--0.462, *P* = 0.006). The relationship between ZAG1 and forearm vascular reactivity to ACh persisted after adjustment for age, gender, ethnicity, T2D duration, systolic blood pressure, low‐density lipoprotein‐cholesterol, HbA1c, and medications including insulin, statins and renin‐angiotensin system inhibitors (β = 0.167, 95%CI: 0.123--0.507, *P* = 0.001). In contrast, ZAG was not associated with endothelium‐independent vasodilation to SNP in the univariate model (β = 0.067, 95%CI: −0.049--0.236, *P* = 0.198), although the relationship emerged marginally significant after multivariate adjustment (β = 0.105, 95%CI: 0.001--0.291, *P* = 0.049).

**Conclusions**: ZAG is correlated with various biomarkers of endothelial function. Moreover, the soluble glycoprotein is linked to increased endothelium‐dependent dilation, suggesting a protective role against pathogenesis of micro‐ and macro‐angiopathy in T2D.
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**Background**: Islet stellate cells (ISCs) can be activated by environmental stimuli to proliferate and generate fibrotic extracellular matrix (ECM). They play a critical role in islet fibrosis, which contributes to progression of type 2 diabetes. Existing ISC biological studies have focused on fibrotic‐associated activated ISCs obtained by standard islet explant techniques. However, in vitro models of quiescent ISCs (qISCs) are lacking.

**Aims**: To explore ways to isolate and identify qISCs and evaluate part of the phenotype during qISC activation.

**Methods**: The location of ISCs was detected by co‐staining desmin, insulin, and glucagon in normal human, rat and mouse islets through immunofluorescence. qISCs were isolated from rat islets using density gradient centrifugation and identified by ISC markers. Activation markers (SREBF, PPAR‐γ, αSMA), ECM molecules (FN, Col‐I, Col‐III), and inflammation factors (IL‐1α, IL‐1β, TGF‐β, CCL2, CCL7) of qISCs were assessed by q‐PCR at different activation states. ISCs obtained by two different methods were observed by light microscopy and oil red O staining to examine morphology and lipid droplet alterations. The differences in activation degree and proliferation and migration abilities of the ISCs were compared by immunoblotting and transwell migration assay.

**Results**: Desmin‐positive ISCs existed in normal human, rat, and mouse islets. Freshly isolated qISCs displayed a polygonal appearance with refringent cytoplasmic lipid droplets and expressed multiple ISC markers. In qISCs, SREBF, PPAR‐γ, and IL‐1β were highly expressed, and α‐SMA, Col‐I, Col‐III, FN, IL‐1α, IL‐1β, TGF‐β, CCL2, and CCL7 were lowly expressed. With prolonged culture time, the expression of SREBF, PPAR‐γ, and IL‐1β decreased, and that of α‐SMA, Col‐I, Col‐III, FN, IL‐1α, TGFβ, CCL2, and CCL7 increased. Regular polygonal‐shaped qISCs contained more lipid droplets than outgrowth spindle‐shaped ISCs. The expression levels of activation markers and ECM molecules and proliferation and migration abilities of passaged qISCs were significantly lower than those of outgrowth ISCs.

**Conclusion**: This study established a stable extraction technology for isolating qISCs from rat islets. qISCs show similar phenotypic characteristics with ISCs in vivo. qISC preparations provide a useful in vitro tool to study the biology of ISCs in their physiological state.
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**Objective**: Peroxisome proliferator‐activated receptor α (PPARα) is a vital subtype of PPARs nuclear receptor superfamily, which is able to maintain energy balance and regulate various biochemical reactions. CP775146, a new‐highly selective PPARα agonist, was understood few. This study was firstly to investigate the effects on the disorder of body lipid metabolism, CP775146, was utilized vto intervene in the normal and obese mice.

**Methods**: Establish an obesity mouse model induced by high‐fat diet. C57BL/6J male mice were randomized into five groups: (1) normal blank group; (2) normal control group; (3) normal‐CP775146 group; (4) obese control group and (5) obese‐CP775146 group. Saline and CP775146 were administered by intraperitoneal injection once per day for 3 days. Then, body weight and content/morphology of the liver were monitored, serum lipid (TG, HDL‐C, LDL‐C) and the liver function (ALS, AST) were measured. Expression of genes related to lipolysis (Acadl, Cpt‐1β, Ehhadh) and synthesis (Fasn, ACC‐1, Scd‐1) in liver was detected by WB and qRT‐PCR.

**Results**: Alimentary obesity models: (1) The liver pathological changes were apparently improved in HFD intervention group by H&E staining. (2) The level of serum TG in the HFD CP775146 group was dramatically reduced (*P *\< 0.05) in an obvious dose‐dependent way. Furthermore, the level of serum LDL‐C was significantly decreased. (3) The liver enzymes (ALT, AST) exhibited remarkable reduction in the drug treatment group (*P *\< 0.05). (4) According with HFD control group, the expression of genes connected with liver lipolysis and lipid synthesis was notably upregulated (*P *\< 0.05). Chow diet mice, 1) As for liver function, only when CP775146 was greater than 1.0 mg/kg, did the level of ALT in the serum of intervention group become remarkably elevated compared with control group (*P *\< 0.05). 2) Compared to normal control group, the level of serum TG and LDL‐C in intervention group notably reduced (*P *\< 0.001).

**Conclusion**: Highly selective PPARα agonist, CP775146, has a remarkable effect on reducing serum triglyceride, liver protection and degrading hepatic enzymes by activating lipid β‐oxidation pathway in liver. This study provided a new laboratory basis for the treatment of hyperlipidemia with CP775146.
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Waist‐hip ratio (WHR) is the pivotal predicting risk factor for chronic kidney disease via eGFR change in type 2 diabetes {#jdi12939-sec-0031}
-------------------------------------------------------------------------------------------------------------------------

**L.‐Y. Hung and P.‐L. Hung**

Department of Internal Medicine, Far‐Eastern Memorial Hospital, New‐Taipei, Taiwan

Chronic kidney disease (CKD) in type 2 diabetes is one of the most important microvascular complications in Taiwan because its sever results eplacement therapy even kidney. About 23.6% of type 2 diabetic patients in Taiwan suffered from microalbuminuria 20% of type 2 diabetes diagnosed stage 3 CKD via calculation of eGFR (glomerular filtration rate). Therefore, it is very important earl predicting parameter probable candidates of CKD in type 2 diabetic patients. Prior reports revealed obesity seemed to be a prominent risk factor for CKD in type 2 diabetes. We whether body mass index (BMI) or waist‐hip ratio (WHR) earl detectors. During the period between January and March, 207 consecutive type 2 diabetic patients (N = 207, mean age: 58.4 ± 11.9 years of age; Male/Female: 113/94, mean age: 57.1 ± 12.3/59.9 ± 11.4 years of age) received diabetes education and data survey in our diabetes education unit medical center in northern Taiwan. The waist circumference revealed M/F: 97.7 ± 11.1/92.8 ± 11.6 cm, (N = 207, 95.4 ± 11.6 cm), and BMI as M/F: 27.6 ± 4.4/ 26.9 ± 4.7, (N = 207, 27.3 ± 4.6), and WHR as M/F: 0.98 ± 0.06/0.96 ± 0.07, (N = 207, 0.95 ± 0.07). The eGFR showed M/F: 86.6 ± 30.6/91.2 ± 31.5, (N = 207, 88.8 ± 30.0). Statistical analysis indicates that WHR revealed significant correlation with eGFR (*P* = 0.0138, *R* ^2^ = 0.0292) and CKD staging, but not serum creatine levels; while BMI, waist circumference, and body weight had no statistical significance with CKD or GFR change. We that WHR is the pivotal and predicting risk factor for CKD in type 2 diabetes.
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A long‐term high‐starch diet induces glucokinase‐dependent expansion of pancreatic beta‐cell mass {#jdi12939-sec-0033}
-------------------------------------------------------------------------------------------------

**K. Tsuchida^1^, A. Nakamura^1^, H. Miyoshi^2^, S. Kawata^1^, K. Omori^1^, K. Takahashi^1^, H. Kameda^1^, Y. Seino^3^, Y. Terauchi^4^ and T. Atsumi^1^**

^1^Departments of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, ^2^Division of Diabetes and Obesity, Faculty of Medicine, Hokkaido University, Sapporo, Japan, ^3^Department of Endocrinology and Metabolism, Fujita Health University School of Medicine, Toyoake, Japan, ^4^Department of Endocrinology and Metabolism, Graduate School of Medicine, Yokohama City University, Japan, Yokohama, Japan

**Purpose**: A mouse model of high‐fat (HF) diet‐induced expansion of pancreatic beta‐cell mass (PBCM) has been widely used. We investigated if glucokinase is required for PBCM expansion induced by a long‐term high‐starch (HS) diet, as has been shown in long‐term HF diets.

**Methods**: Eight‐week‐old wild‐type (WT) or beta cell‐specific glucokinase haploinsufficient (Gck^+/−^) male mice were exposed to standard chow (SC) or a HS diet. After 15 weeks, we investigated body weight, glucose tolerance, insulin sensitivity, insulin secretion, and the morphology of the islets of pancreatic beta cells.

**Results**: There was no significant difference in food intake among the four groups. WT and Gck^+/−^ mice showed increased body weight in the HS‐diet group compared with the SC group. Blood glucose levels after feeding were markedly higher in Gck^+/−^ mice than in WT mice in SC and HS conditions, but an increase in blood glucose levels in response to a HS diet was not found in WT nor Gck^+/−^ mice. The glucose‐lowering effect of insulin in the HS group was equivalent to that in the SC group in WT and Gck^+/−^ mice. During the oral glucose tolerance test, plasma insulin levels 15 min after glucose loading were significantly higher in the HS group compared with those in the SC group in WT mice, but not in Gck^+/−^ mice. PBCM increased significantly in the HS group compared with the SC group in WT mice, but not in Gck^+/−^ mice (WT mice in the SC group: 1.57 ± 0.66 mg; WT mice in the HS group: 2.61 ± 1.22 mg; Gck^+/−^ mice in the SC group: 1.88 ± 0.76 mg; Gck^+/−^ mice in the HS group: 1.85 ± 0.77 mg; WT mice in the SC group vs. WT mice in the HS group: *P* = 0.032).

**Conclusion**: A long‐term HS diet can induce PBCM expansion, and the mechanism underlying this expansion involves a glucokinase‐dependent pathway.
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The mechanism of age‐associated deterioration in glucose tolerance {#jdi12939-sec-0035}
------------------------------------------------------------------

**X. Zou, X. Zhou and L. Ji**

Peking University People\'s Hospital, Beijing, China

**Objective**: To clarify the role of insulin resistance (IR) and beta cell failure in age‐associated deterioration of glucose tolerance.

**Methods**: Thirty‐four thousand one hundred and eight participants without diabetes were selected from the China National Diabetes and Metabolic Disorders Study, a national cross‐sectional survey conducted from June 2007 to May 2008. Subjects were divided in to five age groups with a 10‐year gap. The gender specific top 25% of homeostasis model assessment for insulin resistance (HOMA‐IR) and bottom 25% of beta cell function (HOMA‐B) and dispose index (DI) in participant with normal glucose tolerance were used to define insulin resistance, beta cell failure and impaired glucose disposal, respectively.

**Results**: Compared to participants aged 20--29 years, the OR (95% confidence interval) \[OR (95% CI)\] for IFG is 1.74 (1.23, 2.45), 2.29 (1.64, 3.18), 2.07 (1.47, 2.92) and 2.54 (1.79, 3.59) in men (*P *\< 0.001, for trend test) and 1.13 (0.84, 1.52), 1.52 (1.15, 2.02), 1.39 (1.03, 1.87) and 1.52 (1.10, 2.11) in women (*P* = 0.002) in participants aged 30‐ 39, 40‐ 49, 50--59 and ≥ 60 years. The corresponding OR for IGT increased strongly with age, being 1.91 (1.53, 2.38), 2.86 (2.31, 3.54), 3.78 (3.06, 4.68) and 5.82 (4.70, 7.20) in men (*P *\< 0.001), and 2.20 (1.79, 2.71), 3.94 (3.24, 4.80), 5.84 (4.79, 7.10), 8.75 (7.15, 10.71) in women (*P *\< 0.001), respectively. In the continuous latter four age groups, the OR for IR was reduced with age in men and was 1.09 (0.98, 1.21), 1.13 (1.02, 1.25), 1.36 (1.23, 1.52) and 1.46 (1.30, 1.65) in women (*P *\< 0.001), and the OR for beta cell failure was 1.51 (1.32, 1.72), 1.99 (1.74, 2.27), 2.40 (2.09, 2.75), 2.23 (1.94, 2.58) in men (*P *\< 0.001) and increased similarly in women. The OR for DI followed the same pattern with HOMA‐B.

**Conclusion**: HOMA‐B, DI and IFG are similarly associated with age in non‐diabetes participants and HOMA‐IR and IFG are similarly associated with age in women. The increased risk of IGT in the elderly subjects cannot be fully explained by HOMA‐IR, HOMA‐B or DI since the association between these index and age was weaker than that for IGT.
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Preliminary report on the KTPH‐NHG Monogenic Diabetes Registry: Prevalence, characteristics and gene‐based diagnosis of commoner forms of monogenic diabetes {#jdi12939-sec-0037}
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**S. H. C. Tan^1^, S. F. Ang^1^, C. W. J. Fong^1^, X. Lian^2^, Y. C. W. Kon^2^ and S. C. Lim^3,4^**

^1^Clinical Research Unit, Khoo Teck Puat Hospital, Republic of Singapore, ^2^Department of Endocrinology, Tan Tock Seng Hospital, Republic of Singapore, ^3^Diabetes Centre, Khoo Teck Puat Hospital, Singapore, ^4^Saw Swee Hock School of Public Health, National University of Singapore, Republic of Singapore

**Background**: Maturity‐onset diabetes of the young (MODY) is a genetically heterogeneous condition, usually resulting in beta‐cell dysfunction and diabetes arising in adolescents and young adults. Clinically, MODY may masquerade as other commoner forms of diabetes (type 1 and type 2) that also affect the young. Therefore, a firm genetic diagnosis is required to accurately identify affected individuals. Common subtypes of MODY that are clinically actionable are caused by mutations in transcription factor genes HNF1A, HNF1B and HNF4A, and the glycolytic enzyme gene, GCK which together account for \>90% of MODY cases. HNF1A‐ and HNF4A‐ MODY patients are sensitive to low‐dose sulphonylureas while patients with GCK‐MODY can maintain durable good glycaemic control without pharmacotherapy. We hypothesize that, informed by appropriate phenotyping algorithm in the clinic; the prevalence of MODY is non‐trivial in Asians. We therefore aim to unravel the allelic spectrum of MODY in our local population.

**Methods**: Our clinical criteria for genetic testing were refined (based on previous findings) to facilitate a cost‐effective diagnostic yield for MODY: age of onset ≤ 35 years old, BMI\<32.5 kg/m^2^, and negative autoantibodies (no antibodies to GAD65) (N = 119). 16 MODY genes (including GCK, HNF1A, HNF1B, HNF4A) were sequenced using Ion Torrent PGM™. Multiplex‐ligation‐dependent probe amplification (MLPA) was employed to uncover gene dosage variants. Variant classification was based on criteria adapted from American College of Medical Genetics. Performance of the Exeter MODY probability calculator (with positive‐predictive threshold set at \>62.4%) was also evaluated.

**Results**: In 119 subjects, 16 (13%) were efficaciously genetically diagnosed with common subtypes of MODY. We identified 8 novel mutations in HNF1A, HNF4A and GCK. Generally, the mean age of onset (19 ± 6.1 years) and BMI (23.2 ± 3.3 kg/m^2^) are typically low and 94% of subjects have parental history of diabetes. Performance of the MODY calculator was as follows: sensitivity 0.56, specificity 0.65 (*P* = 0.11) and negative predictive value 0.88, suggesting room for improved algorithm in our local clinics.

**Conclusion**: The importance of diagnosing MODY is increasingly recognized by clinicians due to the potential for clinical interventions. While technological advances in molecular genetics allows us to perform large‐scale nucleotide‐sequencing for MODY, more efficient clinical algorithm is needed to improve the diagnostic yield for MODY.
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Pressurized culture suppress adipocytes differentiation on 3T3‐L1 cells {#jdi12939-sec-0039}
-----------------------------------------------------------------------

**Y. Tsuchihashi^1^, L. Miyamoto^1^, M. Shono^2^ and K. Tsuchiya^1^**

^1^Department of Medical Pharmacology, Institute of Biomedical Sciences, Tokushima University Graduate school, Tokushima, Japan, ^2^Support Center for Advanced Medical Sciences, Institute of Biomedical Sciences, Tokushima University Graduate School, Japan, Tokushima, Japan

**Background**: Aerobic and anaerobic exercise prevent onset and progress of lifestyle‐related diseases. However, it is difficult to achieve aerobic exercise that gives enough effect to those suffering from pain or injuries of tissue such as feet and hips. Hyperbaric treatment is thought to have a similar effect to aerobic exercise. Previous studies have suggested that a rise in dissolving O2 concentration in the body under high pressure air might lead to fat reduction though, its underlying mechanisms are still unknown. Therefore, we investigated the effect of pressurization on cultured 3T3‐L1 preadipocytes in order to clarify how air pressure directly affects metabolism and differentiation of adipose cells.

**Methods**: 3T3‐L1 preadipocytes were cultured in DMEM supplemented with 10% FBS and antibiotics. Cells were induced to differentiate by adding adipogenic agents, then kept the cells under the normal pressure (760 mmHg) or pressurization (845 mmHg) environment (95% air, 5% CO2) for 0--14 days. Cell viability was examined by MTT assay, intracellular triglyceride concentration was evaluated by Oil Red O staining and expressions of adipogenic genes were determined by real‐time PCR.

**Results**: According from the MTT assay, pressurization gave no effect on cell viability. On the other hand, lipid droplet and the intracellular triglyceride concentration decreased in pressurized culture compared to the normal pressure. Concomitantly, the decrease in the expression of mRNA of PPAR‐gamma, CD36, ap2, SREBP1c, and PPAR‐alpha was observed by pressurization. Then phenomena may suggest that lipid synthesis and fatty acid oxidation are suppressed by pressurization.

**Conclusions**: Our data demonstrate that pressurized culture inhibits adipocyte differentiation by suppressing expression of adipogenic genes, which induces a decrease in intracellular lipid droplet and fatty acid oxidation.
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Lower circulating miR‐122 level in patients with HNF1A variant‐induced diabetes compared with type 2 diabetes {#jdi12939-sec-0041}
-------------------------------------------------------------------------------------------------------------

**X. Huang, Y. Ma, S. Gong, X. Cai, L. Zhou, Y. Luo, M. Li, W. Liu, S. Zhang, X. Zhang, Q. Ren, Y. Zhu, X. Zhou, R. Zhang, L. Chen, X. Han and L. Ji**

Peking University People\'s Hospital, Beijing, China

**Background**: MiR‐122 was recently reported to be associated with type 2 diabetes (T2DM) and hepatocellular carcinoma, which was regulated by several transcription factors such as HNF1A. HNF1A variants could cause diabetes and might involve in the development of primary liver neoplasm. The difference of miR‐122 among different types of diabetes has not been studied. This study aimed to investigate the changes of serum miR‐122 levels in different forms of diabetes patients including T2DM, type 1 diabetes (T1DM) and HNF1A variant‐induced diabetes (HNF1A‐DM), glucokinase variant‐induced diabetes (GCK‐DM), mitochondrial A3243G mutation‐induced diabetes (MDM) in Chinese population.

**Methods**: Twelve HNF1A‐DM patients, and 24 gender, age and body mass index‐matched (1:2) T2DM patients and 24 healthy subjects were included in this study. Additional 30 monogenic diabetes (11 GCK‐DM and 19 MDM) and 17 T1DM patients were also included. Fasting blood biochemistry and miR‐122 were measured.

**Results**: The HNF1A‐DM patients had lower miR‐122 levels \[0.046(0.023, 0.121)\] than those of T2DM patients \[0.165(0.036, 0.939), *P* = 0.02\] and healthy controls \[0.249(0.049, 1.234), *P* = 0.019\]. The area under the curve of the receiver operating characteristic curve for miR‐122 was 0.687 (95% CI: 0.52--0.86, *P* = 0.07) to discriminate HNF1A‐DM and T2DM. There was no difference of serum miR‐122 among HNF1A‐DM, GCK‐DM, MDM and T1DM patients.

**Conclusion**: Lower miR‐122 in HNF1A‐DM patients is a unique feature different from T2DM patients, which might also partially explain an increased risk for liver neoplasm and abnormal lipid metabolism in HNF1A‐DM patients.
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Response to insulin, glucagon and incretin to oral glucose tolerance test {#jdi12939-sec-0043}
-------------------------------------------------------------------------

**B. Byambatsooj**

Ulaanbaatar, Mongolia

**Introduction**: Diabetes mellitus is caused by decreased insulin secretion and insulin resistance. Blood glucose levels increased during the loss of b‐cell function. The oral glucose tolerance test (OGTT) is gold standard for pancreatic endocrine function. Insulin secretion and insulin sensitivity are determined by the HOMA‐IR, HOMA‐B, and HOMA‐S. Objective

The aim of study was to evaluate the insulin, glucagon and incretin response to OGTT in type 2 diabetic (T2DM) patients and healthy subjects HS. MATERIALS AND

**Methods**: Case control study included 30 patients with type 2 diabetes and 30 healthy controls. Physical examination and laboratory tests were determined. Glucose, insulin, glucagon, and incretin (GLP‐1, GIP) were measured in 0, 30, 60 and 120 min of 75 gr OGTT. Were calculated HOMA‐IR, HOMA‐B, HOMA‐S index

**Results**: Mean age 39.62 ± 10.7, male 47.6%, female 52.4%, Mean anthropometric results in T2DM and HS were body mass 87.9 kg and 66.3 kg (*P* = 0.001); Body mass index (BMI) 31.6 ± 3.8 kg/m^2^ and 26.84 ± 6.0 kg/m^2^ (*P *\< 0.001); BF 35.2% and 31.8%; VF 12 ± 4.3 and 8.5 ± 3.6% (*P* = 0.02); BM 28 ± 3.2 бa 23 ± 3.3% Results of 0, 30, 60, 120 min OGGT was different between T2DM and HS. Blood glucose 10.4 ± 3.5 and 5.2 ± 0.5 mmol/L (*P *\< 0.001); 17.4 ± 4.5 and 8.1 ± 1.9 mmol/L (*P *\< 0.001); 20.1 ± 4.5 and 7.8 ± 1.9 mmol/L (*P *\< 0.001); 19.8 ± 6.1 and 6.2 ± 0.8 mmol/L (*P *\< 0.001); Insulin 14.3 ± 7.5 and 9.8 ± 3.0 uU/mL (*P* = 0.1116), 44.6 ± 40.5 and 63.9 ± 34.4 uU/mL (*P* = 0.17), 53.6 ± 51.1 and 2 ± 36.2 uU/mL (*P *\< 0.60), 55.8 ± 58.7 and 59.0 ± 46.9 uU/mL (*P* = 0.87); Glucagon 72.6 ± 38.7 and 49.1 ± 26.8 pg/mL (*P* = 0.0257), 82.6 ± 40.6 and 29.9 ± 16.0 pg/mL (*P *\< 0.001), 62.6 ± 34.6 and 25.9 ± 12.9 pg/mL (*P *\< 0.001), 44.7 ± 21.9 and 21.2 ± 10.4 pg/mL (*P *\< 0.001) GLP‐1 28.7 and 15.8 (*P *\< 0.053); 90.8 and 39.0 (*P *\< 0.001); 64.9 and 36.7(p0.0023); 31.3 and 21.6 (*P *\< 0.052); GIP 19.5 and 12.6 (*P *\< 0.012); 80.9 and 64.5 (*P *\< 0.05); 77.9 and 63.5 (*P *\< 0.05); 56.0 and 62.9 (*P *\< 0.05). HOMA‐IR 2.17 and 0.98 (*P* = 0.053); HOMA‐β 50.14 and 87.2 (*P *\< 0.055); HOMA‐S 58.8 and 118.0 (*P *\< 0.001), in the 30th minute 44.6 ± 40.5 бa 63.9 ± 34.4 uU/mL (*P* = 0.17),

**Conclusion**: 1. Increased glucagon secretion and insulin resistance in T2DM patients.

2\. Tend to increased insulin, glucagon, incretin levels were OGTT.
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Blood viscosity was lower in type 2 diabetes mellitus patients with clopidogrel therapy {#jdi12939-sec-0045}
---------------------------------------------------------------------------------------

**M. Rosyid Narendra, S. Murtiwi, A. S. Soebagjo and A. Tjokroprawiro**

Surabaya Diabetes And Nutrition Center -- Dr. Soetomo Teaching Hospital -- Faculty of Medicine Airlangga University, Surabaya, Indonesia

**Background**: Patient with Type 2 diabetes mellitus have higher cardiovascular morbidity. A study report that higher blood glucose and platelet activation can alter blood viscosity (BV). High BV could contribute to raise cardiovascular disease risk. Diabetic patients who had coronary artery disease (CAD) received antiplatelet agent such as clopidogrel. In a study, diabetic patient with CAD who received clopidogrel, had platelet inhibited, and could result in alteration of BV.

**Objective**: This study has been undertaken to know the comparison of blood viscosity in type 2 diabetes mellitus with clopidogrel or not.

**Method**: A retrospective study from medical recorded in January 2000--2018 by recording demographic data and laboratory results from private endocrinologist clinic\'s type 2 DM patients in Surabaya. All data were analyzed to see the comparison between the two groups, clopidogrel group (*n *= 44) and non‐clopidogrel group (*n *= 62), using Independent Mann‐Whitney test.

**Result**: From 106 subjects, mean age 59.68 + 12.49; the majority of male 68 people (72.08%), divided into two groups, patients who received clopidogrel and without, 44 people (41,5%), 62 people (58,5%), respectively. Mean blood viscosity was 4.42 + 0.945 mPa.s. Clopidogrel group had a significantly lower values of blood viscosity (4.17 + 0.918 vs. 4.60 + 0.935, *P* = 0.023).

**Conclusion**: Type 2 diabetes patients with clopidogrel therapy, had lower blood viscosity level compared to those not given clopidogrel therapy.
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Early pregnancy dietary pattern (DP)s were associated risk of gestational diabetes mellitus (GDM): Findings of the SECOST Project {#jdi12939-sec-0047}
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**H. Y. Yong^1^, Z. M. Shariff^1^, Z. Rejali^2^, B. N. M. Yusof^1^, G. Appannah^1^, J. Bindels^3^, Y. Y. S. Tee^4^ and E. M. van der Beek^3,5^**

^1^Universiti Putra Malaysia, Serdang, Malaysia, ^2^Danone Nutricia Research, Uppsalalaan 12, The Netherlands, ^3^Danone Dumex (M) Shn Bhd, Nilai, Malaysia, ^4^University of Groningen, The Netherlands

**Introduction**: Although several studies have reported associations of dietary patterns (DP)s with the risk of GDM, few studies examined the association with DPs throughout pregnancy and the risk of GDM. This study aims to determine the association between DPs before and during pregnancy and the risk of gestational diabetes mellitus (GDM) in Malaysian pregnant women.

**Methods**: This study was a prospective cohort study in which a total of 452 pregnant women with normal glycemia were recruited from three Maternal and Child Health (MCH) clinics in Seremban District, Negeri Sembilan and followed up until delivery. A standard 75 g Oral Glucose Tolerance Test was performed between 24 and 32nd weeks of gestation. DPs were derived by using principal component analysis of the consumption of 136 food and beverage items, which was assessed by a validated semi‐quantitative food frequency questionnaire. Generalized Linear Mixed Model (GLMM) was performed to estimate odds ratios of risk of GDM with MCH clinics and gestational week at OGTT as the random effect.

**Results**: About 10.6% (*n *= 48) of pregnancy women in the present study were diagnosed with GDM. Three different DPs were identified at each time point: pattern 1 (mainly plant‐based), pattern 2 (mainly comprising sugar, spread & creamer, condiments & spices and oils & fats), and pattern 3 (mixed foods). Women who high adhered to pattern 2 before (adjusted OR: 2.38, 95% CI: 1.12 -- 5.08) and first trimesters (adjusted OR: 2.65, 95% CI: 1.17 -- 6.03) were significantly associated with the risk of GDM compared with women who low adhered. Other DPs were not appreciably associated with the risk of GDM.

**Conclusions**: The consumption of the pattern 2 at pre‐pregnancy and first trimester may increase the risk of GDM. The study findings suggested that an earlier dietary guidance at pre‐conception or early pregnancy may help curtail the risk of GDM. Future studies with randomized controlled trials are warranted.
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Serum ferritin independently predicts the new onset of chronic kidney disease and rapid eGFR decline in male tibetan patients with type 2 diabetes mellitus {#jdi12939-sec-0049}
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**Z. Chenghui, W. Suyuan and W. Yunhong**

Hospital of Chengdu office of People\'s Government of Tibetan Autonomous Region, Chengdu, China

**Background and Aims**

Vitamin D has been recently reported to have potent immunomodulatory effects, and its deficiency is associated with several autoimmune diseases including type 1 diabetes (T1DM). In addition, patients with autoimmune thyroid disease (AITD) had been reported to have lower vitamin D status. However, studies examining whether the coexistence of AITD and T1DM leads to further decrease in vitamin D status are limited. In the present study, we evaluated the vitamin D status in young T1DM patients with and without AITD.

**Patients and Methods**

We recruited 78 young Japanese T1DM patients (23.6 ± 5.4 years old, 30 men and 48 women) who had annual medical checkups for diabetic complications at the Diabetic Clinic of Osaka University Hospital and the Osaka Police Hospital during summer. AITD includes Graves' disease (GD) and Hashimoto\'s thyroiditis (HT). Vitamin D status was evaluated by measuring the serum 25(OH)D3 levels using the radioimmunoassay test.

**Results**: Clinical characteristics in T1DM patients with and without AITD were as follows: duration of diabetes, 19.8 ± 6.6 years; body mass index, 23.1 ± 2.9 kg/m^2^; HbA1c, 7.7 ± 1.7%; total daily dose of insulin, 0.80 ± 0.23 U/kg; thyroid‐stimulating hormone, 2.23 ± 1.86 μU/mL; FT3, 3.19 ± 1.23 pg/mL; FT4, 1.33 ± 0.44 ng/dL; and 25(OH)D3, 26.3 ± 9.6 ng/mL. Among the 78 T1DM patients, 23 (29.5%) had AITD (GD: 3 and HT: 20). Although thyroid function was not different between the two groups, serum 25(OH)D3 levels in T1DM patients with AITD were significantly lower than those without AITD (23.0 ± 8.0 ng/mL vs. 27.8 ± 9.9 ng/mL, *P *\< 0.05). In contrast, serum 25(OH)D3 levels were not significantly associated with serum antithyroid antibody levels in patients with AITD.

**Conclusion**: Serum vitamin D levels were significantly lower in T1DM patients with AITD than in those without AITD. Although the direct role of vitamin D in T1DM patients with AITD should be examined by further studies, aggravation of vitamin D deficiency may lead to the increased association of T1DM with AITD.

PP‐25 {#jdi12939-sec-0050}
=====

Disruption of light‐dark cycle in late gestation does not affect offspring birth weight in mice {#jdi12939-sec-0051}
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**T. Yasuoka, M. Licht, T. Yuki, S. Tsubasa, M. Shiori and T. Koichiro**

Department of Medical Pharmacology, Institute of Biomedical Sciences, Tokushima University, Tokushima, Japan

**Background and Purpose**

Recent studies have suggested a relevance between maternal nutrition and offspring diseases, and it has been demonstrated that maternal malnutrition can be a risk factor for adult diseases in the offspring. However, most of the reports focused on nutrients without paying attention to the environment during pregnancy. We presumed that late pregnancy environment could affect both maternal and offspring. Therefore, in this study, we examined the effect on the circadian rhythm disruption of late pregnancy to the offspring.

**Methods**: Over seven‐week‐old C57BL/6J mice were mated, and isolated female mice on the basis of having a vaginal septum. The dam mice were divided into control and disruption groups at the late pregnancy, then circadian disruption was conducted by controlling light/dark cycle. The animals were kept under controlled temperature, and food and water were provided ad libitum during the experiments. We monitored the changes of body weight and food intake of dam mice, and measured birthweight and changes in the fetal body weight for 20 weeks.

**Results**: Maternal body weight and food intake were unaffected irrespective of the light‐dark conditions. Likewise, no significant difference was found in birthweight and postnatal weight gain regardless of disorder of the circadian rhythm of dam mice. There was no evidence of low body weight or overweight at birth due to the disruption of the circadian rhythm of dam mice.

**Conclusion**: Circadian rhythm disruption during late maternal period did not cause aberrant birth weight of offspring. Our findings suggest that the circadian rhythm disruption during late gestation is not the major reason for birthweight‐associated metabolic disorder in offspring.
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BBR promotes insulin secretion through ERG channel {#jdi12939-sec-0053}
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**M. Zhao and J. Yang**

Department of Endocrinology, Beijing Tongren Hospital, Capital Medical University, Beijing, China

**Background**: Berberine (BBR) is a traditional Chinese medicine used in treating DM for hundreds of years in China. Many studies have confirmed its glucose‐lowering effect. However, the direct binding target and the detailed mechanism remains unknown. Here, we identified ERG, a voltage‐gated potassium channel, as a BBR‐binding protein.

**Objective**: To investigate the binding target of BBR in pancreatic β‐cells and explore the precise mechanism of BBR in the glucose‐lowering process.

**Methods**: High‐performance affinity beads were employed to perform single‐step affinity purification of drug target proteins from crude INS‐1 cell extracts. Whole‐cell patch clamp was performed to measure the ERG K^+^ currents. Pancreatic islets perifusion and glucose‐stimulated insulin secretion (GSIS) were performed to examine the insulin promoting effect of BBR. We employed high‐fat diet (HFD) ERG knockout (KO) and wild‐type (WT) mice to further confirmed the insulinotropic effect in vivo by intraperitoneal glucose tolerance test (IPGTT) and intraperitoneal insulin release test (IPIRT).

**Results**: We identified ERG as a BBR‐binding protein by affinity purification using FG beads and examined by western blot using the ERG‐specific antibody. We employed whole‐cell patch clamp and found that BBR inhibited the ERG K^+^ currents in a dose‐dependent manner. BBR reduced the total voltage‐gated potassium channel currents of INS‐1 cells by 40%. This blockage was contributed to ERG currents, verified by ERG channel antagonist E‐4031 and Erg gene knockdown. Additionally, BBR prolonged the action potential duration of INS‐1 cells. (*P \< *0.01) GSIS results indicated that BBR could enhance insulin secretion in a dose‐dependent manner both in INS‐1 cells and pancreatic islets, and could increase insulin release about 1.7--2‐folds. (*P \< *0.001) Islets perifusion also confirmed the insulinotropic effects of BBR. (*P \< *0.05) Furthermore, this effect was not seen in KO islets. (*P *=* *0.923). *In vivo* IPIRT and IPGTT proved BBR could augment insulin secretion in HFD WT mice (*P* \< 0.05) but did no effects in HFD KO mice (*P* = 0.48), the reduced blood glucose effects were also seen only in HFD WT mice (*P \< *0.05).

**Conclusion**: BBR could promote insulin secretion by binding ERG channel and inhibiting its currents.
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Dysregulated Urocortin 3 expression, a novel insulin secretion regulator and its modulation with physical exercise in adult humans with obesity and diabetes {#jdi12939-sec-0055}
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**S. Kavalakatt, A. Khadir and A. Tiss**

Research Division, Dasman Diabetes Institute, Kuwait

**Background and Aim**

Obesity and Type 2 diabetes (T2D) are characterized by inflammation, disturbed insulin secretion and insulin resistance due to reduced insulin action in target tissues such as muscle, liver and adipose tissue. Urocortin3 (Ucn3) is a molecular marker for mature pancreatic β‐cells that regulates glucose‐stimulated insulin secretion. However, their release and expression by human adipose tissue and role in obesity and diabetes is unclear. The aim of this study was to assess the effects of obesity and diabetes on circulating Ucn3 and its expression in adipose tissue. Also, to further assess if these levels are affected by physical exercise.

**Methods**: Adult male and female human subjects consisting of 41 non‐diabetic normal‐weight (20≤BMI\<25 kg/m2) and 205 overweight (25 ≤ BMI\<40 kg/m2, 107 non‐diabetic and 98 diabetic) were enrolled in the study followed by a 3‐month moderate exercise program. Subcutaneous adipose tissue (SAT) biopsies and venous peripheral blood were collected before and after exercise along with anthropometric measurements and blood biochemistry analysis. Plasma levels of inflammatory and metabolic markers were measured using Bioplex‐200 system. The expression and circulating levels of Ucn3 were assessed using ELISA, RT‐PCR, western blot and confocal microscopy.

**Results**: Ucn3 release was significantly decreased in non‐diabetic overweight when compared to normal weight subjects and increased in diabetic compared to non‐diabetic overweight. On the contrary, in SAT, Ucn3 expression was increased in non‐diabetic and decreased with diabetic overweight. Physical exercise increased the levels of circulating Ucn3 in non‐diabetic overweight concomitantly with reduced insulin levels. Furthermore, significant decrease of Ucn3 levels was observed in the SAT of both diabetic and non‐diabetic overweight subjects. In nondiabetic subjects, Ucn3 levels negatively correlated with insulin, C‐peptide and HOMA1. Interestingly, Ucn3 circulating levels strongly correlated with Visfatin in both diabetic and non‐diabetic subjects.

**Conclusion**: Expression of Ucn3 is disrupted in established diabetic subjects and overweight non‐diabetic where glucose tolerance is only minimally impaired. Also, following physical exercise insulin levels were inversely related with circulating Ucn3 in both diabetic and non‐diabetic subjects. These data suggest that Ucn3 might be a key player in the pathophysiology of diabetes and hence further studies are warranted to investigate its role in the onset and progression of diabetes.
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The role of pyruvate carboxylase in islet β cell proliferation {#jdi12939-sec-0057}
--------------------------------------------------------------

**X. Li, M. Hong and X. Li**

Zhongshan Hospital, Fudan University, Shanghai, China

β‐cell proliferation and compensatory hyperplasia is an important mechanism under the pathological conditions and contributes to maintaining the glucose homeostasis. Pyruvate carboxylase (PC) is one of the key enzymes from Krebs cycle in mitochondrial and regulates insulin secretion in β cell. This study investigates the effect of PC on the proliferation of islet β cells. Here, we show that the expression of PC is elevated in islet β‐cell in high‐fat diet‐induced obese mice than chow diet mice by immunofluorescence staining of paraffin section. In female pregnant mice, the expression of PC in islet β‐cell is also gradually increased by gestational days. However, the expression of PC in the islet β‐cell of db/db mice was lower than lean mice, and the expression level gradually decreased with the progress of diabetes. Among above 3 animal models, the expression of PC is all positively correlated with the expression of proliferation marker Ki67 in β‐cell. In vivo results show that both mRNA and protein levels of PC expression significantly increase after treated with 15 mM glucose. Over expression of PC via adenovirus system significantly up‐regulate the proliferation rate of MIN6 cells, which are measured by CCK‐8 assay. The proportion of BrdU positive cells also significantly increased in MIN6 cell with over expression of PC. To be consistent, knockdown of PC by PC shRNA via lenti‐virus system in MIN6 cells significantly reduce the proliferation rate and proportion of BrdU‐positive cells. Furthermore, QPCR and western blotting results show that mRNA and protein levels of MDM2 are both significantly increased in MIN6 cells overexpressed PC, and significantly decreased in MIN6 cells knockdown of PC; protein levels of p53 are significantly decreased in MIN6 cells overexpressed PC, and significantly increased in MIN6 cell knockdown of PC, but mRNA levels p53 are not altered. Our preliminary results indicate that PC may involve in the regulation of pancreatic β‐cell proliferation, especially in the condition of insulin resistance. p53 has well established as a key regulator of β‐cell proliferation, the effects of PC may be mediated by MDM2‐p53 axis.

**Funding**: This work was supported by the National Science Foundation of China (81500624, 81770770).
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Dynamic observation of skin tissue changes in Bama minipig models with metabolic syndrome {#jdi12939-sec-0059}
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**G. Yunyi^1^, L. Yan^1^, L. Yujie^1^, Y. Mengyu^2^ and R. Xingwu^1^**

^1^West China Hospital, Chengdu, Sichuan, China, ^2^Chengdu tianfu new district people\'s hospital, Chengdu, Sichuan, China

**Objective**: To observe the dynamic structural changes of skin tissue in Bama minipigs with metabolic syndrome (MetS).

**Method**: Eight male Bama minipigs (3 months of age) were randomly divided into experimental group (high‐fat and high‐sucrose diet) and two in control group (control diet). The MetS models were successfully induced after 10 months by feeding and then continued feeding for 10.5 months. A full‐thickness dorsal skin biopsy (diameter 1 cm) was performed every 6 weeks from their 4‐ to 23.5 months old. Skin tissues (interval of 12 weeks) were used for pathological observation from the models\'5.5 month old. Generally, morphologic changes and ultrastructure of tissues were investigated with HE dye, picric‐sirius red, IHC and electron microscopy. Differences between two groups were analyzed by Two‐way repeated‐measures ANOVA. One‐way repeated measure ANOVA was performed to analyze the skin parameters (epidermis /dermis thickness, college type I/III, microvessel density (MVD), and intra dermal nerve fiber density (IDNFD)) within experimental group at different time points, *P *≤ 0.05 was considered statistically significant.

**Results**: 1. During the induction period of MetS models, the epidermal thickness, the ratio of collagen type I/III, MVD and IDNFD in experimental group were increased along with time, and reached to peak level when the 14.5 month old\'s body weight reached the adult standard. While the dermis thickness decreased and was lower than that of control group. 2. After successful establishment of MetS models (13‐months‐old), skin parameters were significantly reduced except dermis thickness. 3. Under the light microscope, the pathological changes (such as superficial edema and collagen denaturation) were more likely to occur in individuals with greater body weight, SBP, and dyslipidemia. Under the electron microscope, dermal microvascular endothelial damage and collagen fiber disruption only happened at the models\'23.5 months of age.

**Conclusion**: 1. With the growth of minipigs, skin thickness, ratio of collagen type I/III, MVD, and IDNFD are increasing and reaching to peak levels in adulthood, while the low growth of dermis thickness may be related to high fat and high sugar diet. 2. Thinner epidermal thickness, decreased collagen type I, MVD, and IDNFD have been occurred in 'healthy' skin of MetS minipigs, with an increase in dermal thickness. MetS minipigs might also develop partial pathological changes.
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Metformin attenuates glucotoxicity--induced apoptosis and ERS in osteoblasts via AMPK‐dependent suppression of PPARγ {#jdi12939-sec-0061}
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**X. Shen^1^, L. Yang^3^ and S. Yan^2^**

^1^Diabetes Research Institute of Fujian Province, Fuzhou, China, ^2^ Endocrinology Department, the First Affiliated Hospital of Fujian Medical University, Fuzhou, China

**Objective**: To determine the effect of metformin on hyperglycemia‐induced apoptosis and endoplasmic reticulum stress (ERS) in osteoblasts and to explore its relationships with the PPARγ signaling pathway and AMPK activity.

**Methods**: A mouse osteoblast cell line, MC3T3‐ E1, and a diabetic rat model were used to investigate the protective effects of metformin on hyperglycemia‐induced damage.

**Results**: Metformin reduced apoptosis in glucotoxicity osteoblast cells; increased the cell viability, osteoblast differentiation and the expression of pAMPK; and inhibited the expression of PPARγ in a dose‐dependent manner. The levels of PPARγ expression are negatively correlated with the protective effect of metformin in glucotoxicity osteoblast. 2. Increased expression or activity of PPARγ attenuated the protective effect of metformin on cell viability, osteoblast differentiation and apoptosis in glucotoxicity osteoblasts, whereas down‐regulated expression or inhibited activity of PPARγ demonstrated the opposite effect. 3. Increasing PPARγ expression reduced the metformin‐mediated decrease in PERK, ATF4, and CHOP expression; silencing of PPARγ expression promoted this effect of metformin. Similarly, this influence of PPARγ on metformin was reproduced under conditions of ESR in osteoblasts cells that were induced using β‐thapsigargin. 4. Inhibiting the activity of AMPK weakened the protective effects of metformin on osteoblasts. 5. In vivo, metformin increased the secretion of ALP and expression of pAMPK, decreased the secretion of TRAP5b, improved bone shapes, and decreased the expression of PPARγ, PERK, ATF4 and CHOP in the femur of diabetic rat.

**Conclusions**: Metformin attenuates glucotoxicity‐induced apoptosis and ERS in osteoblasts by inhibiting PPARγ, and this was mostly dependent of AMPK activity.
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**L. Chen^1^, Y. Li^2^, F. Zhang^1^, S. Zhang^1^, X. Zhou^1^ and L. Ji^1^**

^1^Peking University People\'s Hospital, Beijing, China, ^2^Pinggu Hospital, Beijing, China

**Purpose**: Diabetes is a challenging worldwide public‐health burden because of its high prevalence and concomitant risks of various complications. Our previous cross‐sectional study showed that with the increase of serum ferritin concentrations there were higher FBG and HbA1c levels. Other studies have shown an association between ferritin and type 2 diabetes independent of traditional risk factors such as age, obesity, family history, and so on. But the results from prospective studies are inconsistent, especially the lack of large‐sample studies among Chinese. Our purpose is to explore the association between serum ferritin levels and the risk of incident type 2 diabetes in a Chinese population.

**Method**: This study assessed 2,225 Chinese participants, aged 25--75 years, which were followed up for 20 months. Diabetes mellitus (DM) was diagnosed using the 1999 WHO definition. Cox proportional hazard models were used to estimate adjusted hazard ratios (HRs) and 95% confidence intervals (CI) for incident diabetes when serum ferritin concentrations increase for one standard deviation.

**Results**: During the follow‐up period, 112 cases of diabetes were identified, which consists of 62 men and 50 women. Baseline serum ferritin levels in diabetic group were higher than in non‐diabetic group. Cox regression analysis showed that after adjusting for age, BMI, systolic blood pressure,fasting plasma glucose, HbA1c, total cholesterol, triglycerides, family history of DM, red meat consumption, neutrophil/lymphocyte ratio, education and annual household income, hazard ratios for incident diabetes are 1.25 (1.10, 1.42) for the total population and 1.30 (1.09, 1.55) for men and 1.10 (0.89, 1.36) for women corresponding to a one standard deviation increase in serum ferritin levels.

**Conclusions**: High serum ferritin levels are associated with increased risk of incident type 2 diabetes independently of conventional diabetes risk factors in men.
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The relationship between pancreatic beta cell functions and anti‐glutamic acid decarboxylase antibody (GADA) measurement by both Radioimmunoassay (RIA) and Enzyme‐linked immunosorbent Assay (ELISA) in Japanese individuals with diabetes {#jdi12939-sec-0065}
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**T. Haraguchi^1,2^, S. Okamoto^1,2^, H. Kuwata^1,2^, Y. Hamamoto^1,2^, D. Yabe^2^ and Y. Seino^1,2^**

^1^Center for Diabetes, Endocrinology and Metabolism, Kansai Electric Power Hospital, Osaka, Japan, ^2^Yutaka Seino Distinguished Center for Diabetes Research, Kansai Electric Power Medical Research Institute, Kobe, Japan

**Aims**: Anti‐glutamic acid decarboxylase antibodies (GADA) are islet cell autoantibodies that are sensitive markers for type 1 diabetes. Up until December 2015, they were measured using the radioimmunoassay (RIA) kit in Japan. However, since then, the kit was changed to enzyme‐linked immunosorbent assay (ELISA). Recently, a discrepancy in their titers and pathophysiology has been reported, especially in RIA weakly positive patients (R±; ≥1.5 U/mL and \<10.0 U/mL). In this study, we examined the differences in GADA of both measurements, and the beta cell functions.

**Materials and Methods**

A retrospective analysis was done on 451 patients whose GADA were measured by both the RIA and ELISA kit. The relationship between GADA and the beta cell functions was examined by fasting plasma glucose (FPG) and C‐peptide immunoreactivity (CPR) before and after the day of both measurements. Data were analyzed using t‐test. Values are shown as mean±SD.

**Results**: In 45 RIA‐positive patients (R+; ≥10.0 U/mL), 35 were positive by ELISA measurement (E+; ≥5.0 U/mL) and 10 were negative (E‐; \<5.0 U/mL). In 66 RIA weakly positive patients, 23 were E+ and 43 were E‐. In 340 RIA‐negative patients (R‐; \<1.5 U/mL), 9 were E+ and 331 were E‐. The CPR of R±E+ and R+E+ groups tended to be low (R±E+:0.57 ± 0.72 ng/mL, R+E+:0.61 ± 0.57 ng/mL) compared to other groups (R‐E‐:1.23 ± 0.78 ng/mL, R‐E+:1.39 ± 1.30 ng/mL, R±E‐:1.27 ± 0.89 ng/mL, R+E‐:0.92 ± 0.65 ng/mL). In 66 R± patients, 38 had FPG and CPR between one year before and after the day of both RIA and ELISA measurements (measurement interval: 2.59 ± 2.03 years). At the point of RIA measurement, there was no significant difference in the C peptide index (CPI) between R±E+ and R±E‐, but at ELISA measurement, the CPI was significantly lower in R±E+ (0.63 ± 0.72 vs. 1.22 ± 0.63). At ELISA measurement, the proportion of insulin‐dependent patients (CPR \<0.5 ng/mL) was significantly higher in R±E+ patients than in R±E‐ patients (59.0% vs. 4.8%).

**Conclusions**: In our study, it is suggested that the R±E‐ patients did not show a decrease in beta cell functions compared to the R±E+ patients. The E factor might be involved this difference in beta cell functions.
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Correlation of fasting insulin level and blood viscosity in type 2 diabetes patients {#jdi12939-sec-0067}
------------------------------------------------------------------------------------

**M. Rosyid Narendra, H. Susanto, D. Ardiani and A. Tjokroprawiro**

Surabaya Diabetes And Nutrition Center‐Dr. Soetomo Teaching Hospital‐Faculty of Medicine Airlangga University, Surabaya, Indonesia

**Background**: Patient with Type 2 diabetes mellitus have higher cardiovascular morbidity. Patient with insulin resistance tend to have high fasting insulin level. A study report that. Insulin levels affect blood viscosity (BV) by modulating hematological parameters and fibrinogen levels, in addition to lipid parameters. High BV could contribute to raise cardiovascular disease risk.

**Objective**: This study has been undertaken to know the correlation of fasting insulin level and blood viscosity in type 2 diabetes patients.

**Method**: A retrospective study from medical recorded in January 2017--2018 by recording demographic data and laboratory results from type 2 diabetes patients in private diabetes clinic in Surabaya. All data were normally distributed, and analyzed to see the correlation of fasting insulin level and blood viscosity, using Pearson Correlation 2 tailed Test.

**Result**: From 59 subjects, mean age 59.68 + 12.49; the majority of male 40 people (67.8%). The mean of fasting plasma glucose level was 158.2 + 23.1 mg/dL and 2‐h plasma glucose level was 191.1 + 89.3 mg/dL. The mean of fasting insulin level was 55.6 + 46.3 pmol/L and blood viscosity was 4.42 + 0.945 mPa.s. There was significant correlation between fasting insulin level and blood viscosity with coefficient correlation 0.327 (*P *\< 0.05).

**Conclusion**: In type 2 diabetes patients, fasting insulin level correlates with blood viscosity.
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Recovery effect of peri‐insular microenvironments by RGD‐elastin polypeptide on Islet xenotransplantation in streptozotocin‐induced diabetic mice {#jdi12939-sec-0069}
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**K.‐m. Lee and W. Jeon**

Companion Diagnostics and Medical Technology Research Group, Daegu Gyeongbuk Institute of Science & Technology, Daegu, Republic of Korea

Successful islet transplantation critically depends on the isolation of healthy islets. Paradoxically, the islet isolation procedure contributes to islet death due to the destruction of intra‐ and peri‐islet extracellular matrices (ECMs) during digestion. We investigated an integrin ligand RGD‐containing elastin‐like polypeptide named REP with the sequence of TGPG\[VGRGD (VGVPG)6\]20WPC as a self‐assembling matrix to replenish damaged or missing ECMs. Immediately following isolation, islets were coated with REP coacervate particles via isothermal adsorption of REP solution followed by thermal gelation. Both the viability and insulin secretory capacity of REP ‐coated islets were markedly increased during the pre‐transplant culture, whereas control islets were progressively decreased the viability and secretory function. Co‐transplantation of REP‐coated islets and REP beneath the renal sub‐capsule produced peri‐insular coacervate environments encompassing islet transplants, which restored normoglycemia and serum insulin levels in streptozotocin‐induced diabetic mice. Compared to islet‐only transplants, mice that received co‐transplants had a longer euglycemia maintenance time, sustained xenogeneic graft survival, and lower invasion of macrophages. Moreover, concomitant b‐cell proliferation and generation of a rich vasculature were observed at the co‐transplantation sites. In conclusion, the REP‐based coacervation strategy provides the therapeutic potential for improving the ECMs for graft survival and functions, and most importantly to increase the outcomes of extrahepatic islet transplantation.18‐LC‐01, 18‐BT‐01.
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**L. Luo, C. Dong, Z. Li, M. Niu and Z. Gao**

Dalian Municipal Central Hospital Affiliated Of Dalian Medical University, Dalian Liaoning Province, China

**Objective**: To explore the correlation between lipid accumulation product index and blood pressure in middle‐aged and elderly people in Dalian area.

**Methods**: Selected Dalian community residents aged over 40 who participated in the REACTION study initiated by the Chinese Medical Association from July to December 2011. A total of 9,913 subjects were included, including life history, dyslipidemia, hypertension and medication history. Height, weight, waist circumference (WC), systolic blood pressure (SBP), diastolic blood pressure (DBP) and heart rate (HR) were measured. Detection of triglyceride (TG), total cholesterol (TC), low‐density lipoprotein cholesterol (LDL‐C), high‐density protein cholesterol (HDL‐C), serum creatinine (Cr), fasting blood glucose (FBG), fasting insulin and glycated hemoglobin (HbA1c), etc. Calculated the lipid accumulation product index (LAP) \[male: LAP = (WC‐65)\*TC, female: LAP = (WC‐58)\*TC). According to the gender group, each group according to LAP quartile was respectively divided into Q1, Q2, Q3 and Q4 and q1, q2, q3 and q4 group, the prevalence rates of hypertension in each group were compared, and the correlation between systolic and diastolic blood pressure and LAP were analyzed, as well as whether LAP was an independent risk factor for hypertension. The threshold point of LAP for hypertension prediction was calculated by ROC curve.

**Results**: 1. There were 4948 patients with hypertension, at a prevalence rate of 49.9%, and the prevalence rate of hypertension among males was 54.6%(1,494 cases), and that of females was 48.1%(3,454 cases), the prevalence rate difference of hypertension between male and female subjects had significant statistical differences (χ^2^ = 33.264, *P *\< 0.001),as compared to that of females, it was 1.135 times as high as that of males \[OR = 1.297, 95%CI : \[1.297(1.187--1.416)\]. The hypertension prevalence rates of male groups Q1, Q2, Q3 and Q4, respectively were 40.4% (276 cases), 55.8% (382 cases), 59.8% (410 cases) and 62.5% (426 cases). Except Q2 and Q3, Q3 and Q4 groups, Differences of prevalence rates between other groups had significant statistical differences (Q1 and Q2, Q1 and Q3, Q1 and Q4, Q2 and Q4, Chi‐squares, respectively, were χ^2^ = 32.901, *P *\< 0.001, χ^2^ = 51.646, *P *\< 0.001, χ^2^ = 66.844, *P *\< 0.001, χ^2^ = 6.185, *P* = 0.013), as compared to that of Q1 group, it was 2.460 times as high as that of Q4 group (OR = 2.460, 95%CI : \[2.460(1.979--3.058)\]. The prevalence rates of hypertension in female groups q1, q2, q3 and q4, respectively, were 29.7% (533 cases), 42.7% (769 cases), 57.1% (1021 cases) and 63.0% (1131 cases),differences of prevalence rates have significant statistical differences between groups (q1 and q2, q1 and q3 and q4 and q1, q2 and q3, q2 to q4, q3 and q4 group Chi‐squares, respectively, were χ^2^ = 65.634, *P *\< 0.001, χ^2^ = 273.570, *P *\< 0.001, χ^2^ = 400.771, *P *\< 0.001, χ^2^ = 74.467, *P *\< 0.001, χ^2^ = 149.288, *P *\< 0.001, χ^2^ = 3.176, *P *\< 0.001). The prevalence rate of hypertension in q4 group was 4.036 times that in q1 group \[OR = 4.036, 95%CI : 4.036 (3.511--4.640). 2. Among males, the Spearman correlation analysis showed that SBP and LAP, HR, age, BMI, LDL‐C, Cr, FBG, HbA1c, HOMA‐IR and smoking were positively correlated,while DBP with age, BMI, LAP, HR, Cr, FBG, HOMA‐IR and smoking were positively correlated and negatively correlated with alcohol. Among females, the Spearman correlation analysis showed that SBP and LAP, HR, age, BMI, LDL‐C, Cr, FBG, HbA1c, HOMA‐IR, smoking and drinking were positively correlated and negatively correlated with HDL‐C, while DBP with age, BMI, LAP, HR, LDL‐C, Cr, FBG, HbA1c and HOMA‐IR were positively correlated and negatively correlated with HDL‐C. 3. Taking LAP as the independent variable and hypertension as the dependent variable, then carried out binary Logistic regression analysis. The results showed the following: Among males, for each one additional standard deviation of LAP, the risk of hypertension increased 1.289 times (OR = 1.289, 95%CI : 1.183--1.404, *P *\< 1.183). After the further adjustment for age, HR, BMI, smoking and drinking, LDL‐C, HDL‐C, Cr, FBG, HbA1c and HOMA‐IR, for each one additional standard deviation of LAP, the risk of hypertension increased 1.166 times (OR = 1.166, 95%CI : 1.055--1.288, *P* = 0.003). Among females, for each one additional standard deviation of LAP, the risk of high blood pressure increased 1.706 times (OR = 1.706, 95%CI :1.609--1.808, *P *\< 0.001). After the adjustment for age, HR, BMI, smoking and drinking, LDL‐C, HDL‐C, Cr, FBG, HbA1c and HOMA‐IR, for each one additional standard deviation of LAP, the risk of hypertension increased 1.182 times (OR = 1.182, 95%CI : 1.110--1.259, *P *\< 0.001). 4. Taking LAP as the independent variable and hypertension as the dependent variable, the working characteristic curve of the subject was drawn to show: Male area under the curve was 0.595 (0.574--0.617), *P *\< 0.001). Female area under the curve was 0.657 (0.644--0.669), *P *\< 0.001. Males with LAP\>29.36, the sensitivity of diagnosis of hypertension was 0.70, specificity was 0.46. Females with LAP\>39.54, the sensitivity of diagnosis of hypertension was 39.54, specificity was 0.63.

**Conclusion**: 1. With the increase of LAP, systolic blood pressure, diastolic blood pressure increase gradually, prevalence rates of hypertension increase gradually. LAP was an independent risk factor of hypertension in the middle‐aged and elderly people. 2. The LAP in the middle‐aged and elderly males with LAP\>29.36 and females with LAP\>39.54 are the best threshold value to predict the diagnosis of hypertension.
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**C. Dong, L. Luo and Z. Gao**

Dalian Municipal central Hospital Affiliated Of Dalian Medical University, Dalian, China

**Objective**: To investigate the relationship between non‐HDL‐C, LDL‐C and cardiovascular risk factors in the residents of Dalian.

**Methods**: Our sample was derived from the REACTION study, which was launched by the China medical association. These data were collected from August 2011 to December 2011 in Dalian city, up to 10,207 subjects. History was collected from all the subjects especially drug history and history of smoking. Physical examination and biochemical inspection were completed. Non‐high‐density lipoprotein cholesterol was calculated by total cholesterol and high‐density lipoprotein cholesterol. The follow‐up data collected from July 2014 to December 2014, the follow‐up rate reached 91%. Excluded the subjects whose clinical information were incomplete, the final analysis consisted of 4954 subjects. The subjects were divided into respective four groups according to the quartiles of non‐HDL‐C and LDL‐C, respectively, to compare the cardiovascular risk factors and other clinical parameters between the groups. Spearman correlation analysis, partial correlation analysis and binary Logistic regression model were used to analyze the relationship between non‐HDL‐C, LDL‐C and cardiovascular risk factors, and the developments of cardiovascular risk factors clustering were compared in quartiles with Cox regression. Compare the diagnostic value of non‐HDL‐C and LDL‐C for cardiovascular risk factors clustering with ROC curve analysis.

**Results**: 1. When comparing cardiovascular risk factors clustering with the non‐HDL‐C quartile level, there was statistically significant difference (*P *\< 0.001). The difference between the group of Q4 and Q1, the group of Q4 and Q2, the group of Q4 and Q3, the group of Q3 and Q1, the group of Q2 and Q1 were significantly (*P *\< 0.05). Compare with Q1 group, Q4 group increased the risk of cardiovascular risk factors clustering 1.792 times (χ^2^ = 51.032, *P *\< 0.001, 95% CI:1.526--2.104). When comparing cardiovascular risk factors clustering with the LDL‐C quartile level, there was statistically significant difference (*P *\< 0.001). The difference between the group of q4 and q1, the group of q4 and q2, the group of q4 and q3 were significantly (*P *\< 0.05). Compare with q1 group, q4 group increased the risk of cardiovascular risk factors clustering 1.396 times (χ^2^ = 17.024, *P *\< 0.001, 95% CI: 1.191--1.636). 2. According to Spearman correlation analysis cardiovascular risk factors clustering was positively and significantly correlated with both non‐HDL‐C and LDL‐C (*r* = 0.109, *r* = 0.057, *P *\< 0.05). According to partial correlation analysis adjusting for age, sex and smoking, analysis cardiovascular risk factors clustering was positively and significantly correlated with both non‐HDL‐C and LDL‐C (*r* = 0.092, *r* = 0.046, *P *\< 0.05). 3. With non‐HDL‐C or LDL‐C levels as the independent variable, respectively, baseline cardiovascular risk factors clustering subjects as the dependent variable, binary Logistic regression was conducted. Among the subjects, increase of one standard deviation non‐HDL‐C or LDL‐C, increased the risk of cardiovascular risk factors clustering, respectively, 1.255 times, 1.145 times (*P *\< 0.001). After adjusting for age, sex and smoking status, increased one standard deviation of non‐HDL‐C or LDL‐C, the risk of cardiovascular risk factors clustering increased respectively 1.223 times, 1.121 times (*P *\< 0.001). Non‐HDL‐C and LDL‐C were both positively correlated with cardiovascular risk factors, and the regression equation was as follows: CRF = −4.678 + 0.201 non‐HDL‐C + 0.63 age -- 0.208 gender + 0.742 smoking; CRF = −4.368 + 0.115 LDL‐C + 0.65 age -- 0.165 gender + 0.755 smoking. 4. Define the development of cardiovascular risk factors clustering in 2014 as the endpoint with Cox regression analysis. It showed that both non‐HDL‐C and LDL‐C, with age and smoking status into the equation, the differences were statistically significant (*P *\< 0.05). HR (95% CI) of non‐HDL‐C, age, smoking status were 1.248(1.181--1.318), 0.988(0.980--0.996), 1.616(1.285--2.033); HR (95% CI) of LDL‐C, age, smoking status were 1.236(1.159--1.319), 0.990(0.982--0.997), 1.627(1.293--2.046) .5. ROC curve analysis showed that the AUCs of non‐HDL‐C and LDL‐C for cardiovascular risk factors clustering were 0.563 and 0.533 respectively. The diagnostic value of non‐HDL‐C and LDL‐C for cardiovascular risk factors clustering was significantly (*P *\< 0.05). Non‐HDL‐C \> 3.95 mmol/L was the best cut‐off point for diagnosing cardiovascular risk factors clustering. The sensitivity was 0.5871 and the specificity was 0.5074. LDL‐C \> 3.30 mmol/L was the best cut‐off point for diagnosing cardiovascular risk factors clustering. The sensitivity was 0.5048 and the specificity was 0.5552.

**Conclusion**: 1. With the increase of non‐HDL‐C or LDL‐C levels, the prevalence rate of cardiovascular risk factors clustering increases accordingly in the residents of Dalian. 2. Both non‐HDL‐C and LDL‐C are independent risk factors for cardiovascular risk factors clustering, while non‐HDL‐C shows a better correlation compare with LDL‐C in the residents of Dalian..3. Compare with LDL‐C, non‐HDL‐C shows a better diagnostic value to cardiovascular risk factors clustering in the residents of Dalian.
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Screening of HNF1A and HNF4A mutation and clinical phenotype analysis in a large cohort of Chinese patients with maturity‐onset diabetes of the young {#jdi12939-sec-0075}
-----------------------------------------------------------------------------------------------------------------------------------------------------

**X. Wang, T. Wang, M. Yu, H. Zhang, F. Ping, Q. Zhang, K. Feng and X. Xiao**

Department of Endocrinology, Peking Union Medical College Hospital, Diabetes Research Center of Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

**Background**: Maturity‐onset diabetes of the young (MODY) is a rare monogenic disorder. While the number of diabetes have ranked number one in China worldwide, the reports on MODY1 and MODY3 families in Chinese population were limited.

**Objectives**: To screen the HNF1A and HNF4A mutation in a large Chinese cohort of high clinical suspicion MODY patients and characterize the clinical features of those patients. The study also evaluated the performance of hsCRP as a biomarker to differentiate MODY3 from early onset T2DM.

**Methods**: A total of 74 patients with a strong clinical suspicion of MODY from 59 families and 33 newly diagnosed early‐onset T2DM were included. HNF1A and HNF4A mutations were analyzed by Sanger sequencing. ROC curves were used to identify the optimal cutoff of hsCRP.

**Results**: One novel (c.864_865insG) and six recurrent HNF1A mutations (R203H, R263H, P379T, L422P, P519L and c.873delC) in 17 patients from 8 families (13.6%), as well as one novel HNF4A (R331H) mutation were identified. 84.2% patients were misdiagnosed with other types of diabetes. Nonspecific clinical presentations were observed in MODYX compared to MODY3 patients. MODY3 subjects exhibited with younger, lower BMI, TG, fasting and postprandial C‐peptide, higher HDL than T2DM. Particularly, we confirmed serum hsCRP was lower in MODY3 than T2DM. ROC curve showed a good discrimination with an AUC of 0.852 and identified a cutoff hsCRP of 0.79 (75% sensitivity and 83% specificity). Good glycemic control was observed in all identified patients after switching to glimepiride therapy.

**Conclusions**: The prevalence of HNF1A mutation was relatively lower in Mainland China and HNF4A mutation was rare. Serum hsCRP concentrations were lower in MODY3 than T2DM and performed well in discriminating MODY3 from T2DM. Molecular diagnosis of MODY3/1 did transform management in clinical practice and facilitated the glycemic control.
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Protective effect and mechanism of umbilical cord mesenchymal stem cells on macrovascular disease in mice with type 1 diabetes mellitus {#jdi12939-sec-0077}
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**Y. G. Wang, B. Chen and C. Z. Kong**

Department of Endocrinology and Metabolism, The Affiliated Hospital of Qingdao University, Qingdao, China

**Objective**: We observe the effect of the treatment of diabetic macroangiopathy in T1DM mice and explore the effect of hUCMSCs on reducing vascular endothelial cell damage and the possible mechanism in T1DM mice.

**Methods**: The experimental mice of T1DM were randomly divided into 4 groups.

1\) There are not any interventions after the onset of the disease in this group;

2\) Mice in this group were treated with Glargine, according to the situation of blood glucose to adjust the amount.

3\) Mice in this group were treated with an intravenous infusion of hUCMSCs through vena caudalis after diagnosis.

4\) NOD mice without diagnosis were selected as normal control group after 8 weeks of detection.

**Results**:

\(1\) After the diagnosis of diabetes, all groups of mice developed more food, more drink, and more urine.

\(2\) hUCMSCs treatment group, body weight in early stage of disease decreased significantly, weight recovered afterwards, and had returned to normal group mice by the end of the experiment.

\(3\) On the 56th day after onset, the insulin group and stem cells, there was no significant difference between the blood glucose level and the normal group;

\(4\) in the hUCMSCs‐treated mice, the aorta of the mice was better than other groups.

\(5\) AGEs were highest in the diabetic group and lowest in the normal group. The expression of AGEs in the mesenchymal stem cells group was significantly lower than that in the diabetic group. There was no significant difference in the expression of the expression, the expression of AGEs in the mesenchymal stem cell group was significantly lower than that in the insulin group and the diabetic group;

\(6\) the RAGE, IL‐6, VCAM‐1, and P65 expressions were highest in the diabetes group.

**Conclusions**:

\(1\) Umbilical cord mesenchymal stem cells can reduce the damage of vascular endothelium, delay the atherosclerosis of vascular endothelium, and protect large vessels of diabetes.

\(2\) Umbilical cord mesenchymal stem cells inhibit the expression of AGEs/RAGE induced by hyperglycemia, reduce the incidence of vascular atherosclerosis.
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Differences in body fat and intestinal flora between Han‐Chinese graduates and international students from East African in China {#jdi12939-sec-0079}
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**B. Xu, P. Nizigiyimana and M. Lei**

Xiangya Hospital of Central South University, Changsha, China

**Objective**: The aim of this study was to detect the differences in body fat and gut flora between Han‐Chinese university students and international students from East Africa, and the relationship between body fat and gut flora in human subjects.

**Methods**: A total of 27 Han‐Chinese students and 29 students from East Africa were included in the study. We measured whole body fat from regions of interest by using the dual‐energy bone densitometer (DEXA)to automatically record the whole body fat and the regions of interest of local body composition. We also collected fresh stool samples for assessment of gut flora composition through fecal DNA extraction, amplification and sequencing of the bacterial 16s rDNA gene in V3V4 region by using Polymerase chain reaction (PCR) methods and Illumina sequencing method (Illumina MiSeq).

**Results**:

\(1\) The total protein and globulin were higher in the East African Students Group compared with the Han‐Chinese Students Group, while albumin, Albumin/Globulin (A/G) Ratio, total bilirubin, direct bilirubin, and urea were sightly lower, but no apparent statistical significant was seen between groups.

\(2\) There were statistically significant differences in gut flora composition between Han‐Chinese students and East African students. When compared bacterial groups at the classification level of phylum, there was 1 type differed between HC and EA groups,also at the level of class was 1 type differed between groups as well as at classification level of order, 3 types differed between groups at the family level of classification, and 5 types at genus level and 11 types at species level of classification.

\(3\) The A/G (Android To Gynoid) ratio, %Fat Trunk /%Fat Legs, and trunk/limb fat mass ratio were statistically higher in Han‐Chinese students than East African students.

\(4\) The 5 bacterial species differed between groups at the classification level of genus and body fat showed racial differences, by Bacteroides being positively correlated with trunk/limb fat mass ratio, and Coprococcus being negatively correlated with A/G ratio, %Fat Trunk /%Fat Legs, and trunk/limb fat mass ratio.

**Conclusions**:

\(1\) The index of body fat distribution A/G ratio, %Fat Trunk /%Fat Legs, and trunk/limb fat mass ratio were different between groups, and higher in the Han‐Chinese students than the East African students.

\(2\) There were statistically significant differences of 5 bacterial species in gut flora of Han‐Chinese students and East African students when compared bacterial groups at the classification level of genus, which may be related to racial/ethnic differences in genetic background.

\(3\) The relative abundance of bacterial, which have positive correlations with A/G ratio, %Fat Trunk /%Fat Legs, and trunk/limb fat mass ratio, was higher in Han‐Chinese students than East African students. On the contrary, the relative abundance of bacterial which have negative correlations with the three above‐mentioned indicators was lower in Han‐Chinese students than East African students. This may contribute to the differences in body fat between the two groups.
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LncRNA‐ES3/miR‐34c‐5p/BMF axis is involved in regulating high‐glucose‐induced calcification/senescence of VSMCs {#jdi12939-sec-0081}
---------------------------------------------------------------------------------------------------------------

**X. Lin, J.‐K. Zhan and Y.‐S. Liu**

The Second Xiangya Hospital, Central South University, Changsha, China

**Aim**: Vascular calcification/aging is common in diabetes and is associated with increased morbidity and mortality. High glucose stimulates calcification/senescence in culture of vascular smooth muscle cells (VSMCs), but the underlying mechanisms remain obscure. Here, we focused on discussing the role and molecular mechanisms of miR‐34c in regulating calcification/senescence of HA‐VSMCs.

**Methods**: HA‐VSMCs were induced by high glucose (30 mM) as the calcification/senescence cell model. The expression of non‐coding RNAs and genes was detected by qRT‐PCR. Western blot analysis was used to detect the expression level of proteins. Alizarin red S staining and senescence‐associated‐β‐galactosidase (SA‐β‐gal) staining were performed to verify the calcification and senescence of HA‐VSMCs, respectively. The luciferase reporter assay and RNA pull‐down assay were carried out to test the interact reaction between miR‐34c‐5p and lncRNA‐ES3 or Bcl‐2 modified factors (BMF). Meanwhile, through using specific RNA mimics, inhibitor or siRNAs, the roles of the candidate miR‐34c‐5p and lncRNA‐ES3 and BMF in high‐glucose‐induced calcification and senescence of HA‐VSMC were assessed.

**Results**: miR‐34c‐5p not miR‐34c‐3p was suppressed significantly in HA‐VSMCs during high‐glucose‐induced calcification/senescence, which was proved by the formation of mineralized nodules and SA‐β‐gal staining positive cells. Overexpression of miR‐34c‐5p alleviated high‐glucose‐induced calcification/senescence of HA‐VSMCs, whereas inhibition of miR‐34c‐5p got the opposite results. Further mechanical explorations showed that BMF was a functional target of miR‐34c‐5p and it was involved in the process of miR‐34c‐5p mediating calcification/senescence of HA‐VSMCs. Besides, lncRNA‐ES3 acted as a competing endogenous RNA (ceRNA) of miR‐34c‐5p to enhance BMF expression. Moreover, knocking down lncRNA‐ES3 suppressed calcification/senescence of HA‐VSMCs following the treatment of high glucose and lncRNA‐ES3 inhibited miR‐34c‐5p expression by direct interaction.

**Conclusion**: Our results show for the first time that miR‐34c‐5p is acted as a key regulator in the process of high‐glucose‐induced calcification/senescence of HA‐VSMCs and the mechanism may be involved of lncRNA‐ES3 /miR‐34c‐5p/BMF axis. This finding might offer a new insight of diagnostic and therapeutic approach for arterial calcification/aging in patients with diabetes.
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Notch3 +  exosomes from hyperglycemia‐stimulated vascular endothelial cells regulate calcification/aging in vascular smooth muscle cells {#jdi12939-sec-0083}
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**J.‐K. Zhan, X. Lin and Y.‐S. Liu**

The Second Xiangya Hospital, Central South University, Changsha, China

**Background**: Diabetic vascular calcification/aging can lead to various serious diabetic vascular complications. High glucose can cause calcification/aging in vascular smooth muscle cells (VSMCs) of tunica media and then result in diabetes vascular calcification/aging; however, the mechanisms are still unknown.

**Methods**: Exosomes were isolated from high glucose stimulated human umbilical vein endothelial cells (HUVECs) by super speed centrifugation. The effects of exosomes on calcification/aging in VSMCs were observed. Proteomic analysis was used to identify proteins that were differentially expressed in exosomes.

**Results**: Exosomes isolated from high glucose‐stimulated HUVECs induced calcification/senescence in VSMCs. The proteomics analysis showed that the Notch3 protein was enriched in exosomes, and Western blot analysis verified the overexpression of Notch3 in exosomes isolated from high glucose‐stimulated HUVECs. Inhibiting the expression of Notch3 with inhibitor decreased the expression and activation of mTOR and calcification/aging in VSMCs.

**Conclusions**: Exosomes secreted from hyperglycemia‐stimulated endothelial cells carry Notch3 which regulate calcification/aging in VSMCs through mTOR signaling pathway. This mechanism may be involved in the diabetic vascular calcification/senescence.
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The value of waist circumference, waist height ratio and lipid accumulation index in predicting new prediabetes in women over 40 years old in Dalian {#jdi12939-sec-0085}
----------------------------------------------------------------------------------------------------------------------------------------------------

**Y. Zhang, X. Gu and Z. Gao**

Dalian Municipal Central Hospital Affiliated Of Dalian Medical University, Dalian, China

**Objective**: To investigate the predictive value of waist circumference, waist height ratio and lipid accumulation index for new onset prediabetes in women over 40 years of age.

**Methods**: The samples were derived from the REACTION study which was held by Chinese Medical Association. The age, sex, history of drug using, the history of smoking and drinking, family history, diet and exercise were collected. The waist circumference (WC), height, weight, heart rate, systolic pressure and diastolic pressure were measured. The fasting blood glucose (FBG), glycosylated hemoglobin (HbA1c) and blood lipids were measured in the morning fasting state. And 2‐h blood glucose was measured by oral glucose tolerance test (OGTT 2hPG). According to the inclusion and exclusion criteria, a total of 2725 subjects were included, three years later, 2486 participants were included in the follow‐up study, with a follow‐up rate of 91.2%. Eventually, there were 2044 subjects whose the follow‐up data were complete were included in the study. According to the four quartile of baseline WC, WHtR and LAP, the subjects were divided into four groups. Analysed the difference in prediabetes incidence after 3 years, and then investigated the relationship between the WC, WHtR, LAP and the new onset prediabetes among the women over 40 years old with normal blood glucose by the binary Logistic regression analysis. Finally, analysed and compare the diagnostic value of WC, WHtR and LAP to predict the new onset prediabetes and delimit the suitable cutting points by the ROC curve. The Z test proved that the predictive efficiency of LAP was better than that of WC and WHtR.

**Results**:

1\. There were 317 subjects developed prediabetes after three years follow‐up, the incidence was 15.51%.

2\. According to the WC four quartile, the subjects were divided into four groups: Q1, Q2, Q3 and Q4. The incidence rates of the four groups were 8.08%, 13.64%, 18.62% and 20.18%, respectively. There was a statistical difference among groups (*χ* ^2^ = 32.73, *P \< *0.05) .There were statistical differences between group Q1 and Q2, Q3, Q4 (*χ* ^2^ = 7.468, *P \< *0.05; *χ* ^2^ = 22.014, *P \< *0.05; χ^2^ = 28.105, *P \< *0.05); group Q2 and Q3, Q4 (χ^2^ = 4.833, *P \< *0.05; *χ* ^2^ = 8.256, *P \< *0.05). However, there was no statistical difference between group Q3 and Q4. Binary Logistic regression analysis showed that WC was a risk factor for new onset prediabetes, after adjusting age, smoking, weight, FBG, LDL‐C and BMI (OR = 1.023, 95% CI : 1.004--1.042, *P \< *0.05).

3\. According to the WHtR four quartile, the subjects were divided into four groups: W1, W2, W3 and W4. The prevalence rates of the four groups were 8.66%, 13.35%, 20.63% and 19.41%, respectively. There were statistical differences among the four groups (χ^2^ = 36.133, *P \< *0.05). There were statistical differences between group W1 and group W2, W3, W4 (*χ* ^2^ = 5.733, *P \< *0.05; χ^2^ = 29.12, *P \< *0.05; χ^2^ = 24.36, *P \< *0.05); group W2 and W3,W4 (χ^2^ = 9.659, *P \< *0.05; χ^2^ = 6.903, *P \< *0.05). And there was no statistical difference between group W3 and W4. Binary Logistic regression analysis showed that WHtR was a risk factor for prediabetes, after adjusting age, smoking, weight, FBG, LDL‐C and BMI (OR = 1.534, 95%CI 1.047--2.248, *P \< *0.05).

4\. According to the LAP four quartile, the subjects were divided into four groups: L1, L2, L3 and L4. The prevalence rates of the four groups were 8.02%, 12.18%, 17.74% and 24.07%, respectively. There were statistical differences between every two groups. Binary Logistic regression analysis showed that LAP was a risk factor for prediabetes, after adjusting age, smoking, weight, FBG, LDL‐C and BMI (OR = 1.012, 95% CI 1.008--1.017, *P \< *0.05).

5\. ROC curve analysis showed that the AUCs of WC, WHtR and LAP for predicting new prediabetes were 0.598, 0.602 and 0.646, respectively. The diagnostic value of WC, WHtR and LAP for new prediabetes was significantly (*P \< *0.05). WC\>82.5 cm was the best cut‐off point for predicting new prediabetes. The sensitivity was 79.8 and the specificity was 39.7. WHtR\>0.55 was the best cut‐off point for predicting new prediabetes. The sensitivity was 63.1 and the specificity was 54.3. LAP\>34.84 was the best cut‐off point for predicting new prediabetes. The sensitivity was 63.4 and the specificity was 60.1.

**Conclusions**:

1\. WC, WHtR and LAP were independent risk factors for prediabetes in community women.

2\. The cut‐off point of WC, WHtR and LAP for predicting prediabetes were 82.5 cm, 0.55 and 34.84 respectively.

3\. Compare with WHtR and WC, LAP shows a better diagnostic value to predict new prediabetes.

PP‐43 {#jdi12939-sec-0086}
=====

The risk factors of impaired glucose tolerance in normal glucose tolerance of dalian residents {#jdi12939-sec-0087}
----------------------------------------------------------------------------------------------

**H. Ma, X. Liu and Z. Gao**

Dalian Municipal Central Hospital Affiliated Of Dalian Medical University, Dalian, China

**Objective**: To investigate the risk factors for impaired glucose tolerance in normal glucose tolerance of Dalian residents.

**Methods**: The samples were derived from the REACTION study, initiated by the Chinese Medical Association from August 2011 to December 2011. A total of 5231 participants with complete clinical data, diagnosed NGT by OGTT test, were selected as the subjects of this study. Questionnaire surveys were conducted on personal histories such as age, gender, smoking, drinking, and family history. Height, weight, waist circumference, systolic blood pressure and diastolic blood pressure were measured. HbA1c, fasting insulin and OGTT were measured. Triglycerides, total cholesterol, low‐density lipoprotein cholesterol, high‐density lipoprotein cholesterol, alanine transaminase, aspartate aminotransferase, serum creatinine, urine protein, blood uric acid and other biochemical indicators were measured. Body mass index, ratio of waist circumference to height, insulin resistance index, islet beta cell function, urinary protein and creatinine ratio were calculated. Follow‐up was conducted between July 2014 and December 2014. The follow‐up rate was 91%. Subjects with incomplete data were excluded. Finally, 2679 subjects were included in the study analysis. According to the age, subjects were divided into five groups: age\<45, age≥45 -- \<55, age≥55 -- \<65, age≥65 -- \<75 and age≥75 years old. According to the average systolic blood, subjects were divided into five groups: average systolic blood\<120, average systolic blood≥120 -- \< 140, average systolic blood≥140 -- \<160, average systolic blood≥160 -- \<180 and average systolic blood≥180 mmHg. According to the average diastolic pressure, subjects were divided into five groups: average diastolic pressure blood\<80, average diastolic pressure blood≥80 -- \<90, average diastolic pressure blood≥90 -- \<100, average diastolic pressure blood≥100 -- \<110 and average diastolic pressure blood≥110 mmHg. According to the BMI, subjects were divided into five groups: BMI \<18.5, BMI≥18.5 -- \<24, BMI≥24 -- \<28 and BMI≥28 points. The other data were divided into four groups by quartiles. Binary logistic regression analysis was performed to analyze each factor. ROC curve analysis was used to analyze the best cut‐off point of risk factors for predicting IGT.

**Result**:

1\. Comparing the incidence of IGT of HbAlc, FPG, 2hPG, FINS, HOMA‐β, HOMA‐IR, SBP, DBP, TG, TC, LDL‐C, HDL‐C, ALT, AST, Scr, UA, UACR, BMI, WHtR and Age showed that among the above indicators, HbAlc (χ^2^ = 40.925, *P* = 0.000), FPG (χ^2^ = 52.901, *P* = 0.000), 2hPG (χ^2^ = 86.489, *P* = 0.000), FINS (χ^2^ = 30.341, *P* = 0.000), HOMA‐IR (χ^2^ = 33.053, *P* = 0.000), SBP (χ^2^ = 36.666, *P* = 0.000), TG (χ^2^ = 40.216, *P* = 0.000), WHtR (χ^2^ = 30.131 *P* = 0.000), BMI (χ^2^ = 21.453, *P* = 0.000) and Age (χ^2^ = 14.715, *P* = 0.005) have statistically significant differences in the incidence of IGT between groups. With the increasing of the above indicators, the incidence of IGT was gradually increasing.

2\. Spearman correlation analysis was performed on 2hPG, FPG, HbA1c, HOMA‐IR, TG, SBP, WHtR, FINS, BMI and Age. The results showed that the occurrence of IGT was positively correlated with the above indicators (*r* = 0.506,*r* = 0.478,*r* = 0.449,*r* = 0.372,*r* = 0.358,*r* = 0.341,*r* = 0.185,*r* = 0.184,*r* = 0.149,*r* = 0.121,*P \< *0.05).

3\. Substituting the above indicators into the binary logistic regression equation, the results showed that the risk factors for IGT were mainly HbA1c (OR 2.562, 95% CI 1.812--3.364, *P *\< 0.01), 2hPG (OR 1.651, 95% CI 1.231--2.251, *P *\< 0.01), FPG (OR 1.531, 95% CI 1.043--1.924, *P *\< 0.01), HOMA‐IR (OR 1.421, 95% CI 1.033--1.663, *P *\< 0.05), TG (OR 1.342, 95% CI 1.042--1.613, *P *\< 0.01), SBP (OR 1.321, 95% CI 1.052--1.611, *P *\< 0.01) and age (OR 1.182, 95% CI 1.031--1.484, *P *\< 0.01).

4\. ROC curve analysis was used to analyze the best cut‐off point of risk factors for predicting IGT. The results shows that the best cut‐point values of HbAlc is 5.4% (AUC 0.607, sensitivity 77.1%, specificity 38.7%), and the best cut‐point values of FPG is 5.2 mmol/L (AUC is 0.624, sensitivity is 70.5%, specificity is 48.4%).

**Conclusion**:

1\. According with the increasing of HbAlc, 2hPG, FPG, HOMA‐IR, BMI, TG, SBP, Age, WHtR and FINS, the incidence of IGT is gradually increasing in Normal Glucose Tolerance of Dalian Residents

2\. HbAlc, 2hPG, FPG, HOMA‐IR, TG, SBP and Age are independent risk factors for IGT.

3\. The best cut‐point value of HbAlc and FPG to predict IGT are HbAlc 5.4%, FPG 5.2 mmol/L respectively.
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Overexpression SIRT1 ameliorates hyperglycemia‐induced apoptosis by reducing mitochondrial dysfunction in human umbilical vein endothelial cells {#jdi12939-sec-0089}
------------------------------------------------------------------------------------------------------------------------------------------------

**R. Qin and L. Guo**

Beijing Hospital, Beijing, China

**Aim**: Sustained hyperglycemia is related to the pathogenesis of diabetes mellitus‐induced cardiovascular complications. Silent information regulator T1 (SIRT1), a mammalian sirtuin, has been previously reported to protect endothelial cells against hyperglycemia‐induced apoptosis. We aimed to investigate whether overexpression of SIRT1 could ameliorate hyperglycemia‐induced apoptosis by reducing mitochondrial dysfunction in human umbilical vein endothelial cells (HUVEC).

**Methods**: In the present study, HUVEC were treated with D‐glucose or mannitol. Overexpression of SIRT1 was induced by infection with SIRT1‐overexpressing adenovirus vectors. The levels of SIRT1, cell viability, cell apoptosis, apoptosis‐related proteins (cleaved‐caspase3, PARP), mitochondrial apoptosis pathway‐related proteins (Caspase 9, Bax, Bad, Bcl‐2, x‐IAP), ROS, mitochondrial membrane potential, cytochrome c, mPTP were measured.

**Results**: The overexpression of SIRT1 protected HUVEC against hyperglycemia‐induced apoptosis, as indicated by the reduction of cleaved‐caspase 3, PARP expression and TUNEL positive cells and the increasing of cell viability. Furthermore, SIRT1 overexpression significantly attenuated mitochondrial dysfunction by reducing the level of ROS, maintaining the stability of the mitochondrial membrane, preventing hyperglycemia‐induced mPTP opening. Moreover, overexpression of SIRT1 inhibited the expression of caspase 9, Bax, Bad, and the expression levels of anti‐apoptotic proteins Bcl‐2, x‐IAP were markedly upregulated in HUVEC transfected with SIRT1‐overexpressing adenovirus vectors in high glucose conditions.

**Conclusion**: Our findings indicate that SIRT1 overexpression could protect HUVEC against apoptosis by modulating mitochondrial function.
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Association Between non‐HDL‐C and Insulin Resistance in the Residents of Dalian {#jdi12939-sec-0091}
-------------------------------------------------------------------------------

**X. Ding, L. Luo and Z. Gao**

Dalian Municipal Central Hospital Affiliated Of Dalian Medical University, Dalian, China

**Objective**: To investigate the relationship between non‐HDL‐C and insulin resistance in the residents of Dalian.

**Methods**: Our sample was derived from the REACTION study, which was launched by the China medical association. These data were collected from August 2011 to December 2011 in Dalian city, up to 10,207 subjects. History was collected from all the subjects especially drug history and history of smoking. Physical examination and biochemical inspection were completed. Non‐high‐density lipoprotein cholesterol was calculated by total cholesterol and high‐density lipoprotein cholesterol. Excluded the subjects whose clinical information were incomplete, the final analysis consisted of 9888 subjects. The subjects were divided into respective four groups according to the quartiles of non‐HDL‐C, to compare clinical parameters between the groups. One‐way analysis of variance (ANOVA) was used to compare HOMA‐IR between four groups. Spearman correlation analysis and multivariate linear stepwise regression analysis were used to analyze the correlation between non‐HDL‐C and insulin resistance. ROC curve analyzed the significance of non‐HDL‐C in the diagnosis of insulin resistance.

**Results**: There was significantly difference between these four groups in BMI, weight, MSBP, MDBP, FPG, 2hPG, HbA1c, FINS, HDL‐C and other indicators (*P *\< 0.05). The HOMA‐IR values of the Q1, Q2, Q3, and Q4 groups were 1.68 (1.15 to 2.45), 1.91 (1.34 to 2.82), 2.15 (1.48 to 3.15), and 2.30 (1.59 to 3.28) respectively (*P *\< 0.05). With the increase of non‐HDL‐C, the degree of insulin resistance gradually increased.

2\. Spearman correlation analysis showed a significant positive correlation between HOMA‐IR and non‐HDL‐C, age, BMI, MSBP, MDBP, HbA1c, TG, and LDL‐C (*r* = 0.208, *r* = 0.095, *r* = 0.136, *r* = 0.483, *r* = 0.270, *r* = 0.239, *r* = 0.389, *r* = 0.430, *r* = 0.106, *P *\< 0.05), while negatively correlated with HDL‐C (*r* = −0.298, *P *\< 0.05).

Multiple linear stepwise regression analysis was performed using HOMA‐IR as the dependent variable and non‐HDL‐C as the independent variable. The results showed that non‐HDL‐C was associated with HOMA‐IR (*P *\< 0.05). Similar results were observed in models that adjusted for HbA1c, BMI, FPG, 2hPG, age, SBP, DBP, TG, and HDL‐C (*P *\< 0.05). Non‐HDL‐C was positively correlated with HOMA‐IR. The regression equation was: HOMA‐IR = −0.463 −0.005 Age -- 0.004 SBP‐ 0.004 DBP -- 0.367 HDL‐C + 0.035 non -- HDL‐C + 0.035 HbA1c + 0.139 BMI + 0.188 TG.

4\. The top quartile of HOMA‐IR was defined as the insulin resistance group (HOMA‐IR ≥ 2.96). ROC curve analysis showed that non‐HDL‐C ≥ 3.9 mmol/L predicted insulin resistance in the population, resulting in an area ender the curve of 0.590 (*P *\< 0.001). When non‐HDL‐C was 3.9 mmol/L, the sensitivity of HOMA‐IR was predicted to be 65.3% and the specificity was 51.2%.

**Conclusions**:

1\. With the increase of non‐HDL‐C, the degree of insulin resistance increased.

2\. Non‐HDL‐C has predictive value for insulin resistance.

PP‐46 {#jdi12939-sec-0092}
=====

High glucose affects HepG2 cell biological behavior through LncRNA MEG3 -- mir‐483‐3p‐ ERP29 pathway {#jdi12939-sec-0093}
----------------------------------------------------------------------------------------------------

**S. Zhou, X. Li, R. Zhang, Y. Hong and P. Yu**

The Metabolism Disease Hospital Of Tianjin Medical University, Tianjin, China

Liver cancer is one of the most common cancers with poor prognosis. Metabolic factors, such as obesity and diabetes, were reported to be a risk factor for the aggravation and prognosis in liver cancer, but the detailed mechanism is unknown. This study is to clarify how high glucose affect Hepatocellular Carcinoma Cells biological behavior which started with the analysis of Effects of High Glucose on Endoplasmic Reticulum Proteins of Human Hepatocellular Carcinoma Cell Line (HepG2) by using Label‐free Proteomics. The bioinformatics was used to analyze the candidate proteins and Endoplasmic reticulum resident protein 29 (ERP29) was one of the candidates. High glucose can inhibit the expression of ERP29 which was decreased in hepatocellular carcinoma with diabetes. Overexpression of ERP29 inhibited HepG2 cell proliferation and migration and changed the expression levels of epithelial‐mesenchymal transition‐related proteins with E‐cadherin Vimentin decreased and N‐cadherin increased .And vice versa. And then, we predicted possible binding miRNAs related to ERP29 by using the miRNA databases (Tarbase v8, TargetScanHuman Release 7.1, miRTargetLink Human et al.). miR‐483‐3p was selected. miR‐483‐3p overexpression suppressed ERP29 protein expression, and miR‐483‐3p inhibition improved the expression of ERP29 protein which could also improve cell proliferation and migration and miR‐483‐3p inhibition decreased cell proliferation and migration. And then, possible binding LncRNA relevant to miR‐483‐3p predicted by using the LncRNA database (LncBase v.2, Starbase v2.0). And LncRNA MEG3 was selected. LncRNA MEG3 overexpression suppressed the expression level of miR‐483‐3p, and the expression of ERP29. And, at the same time, the cell proliferation and migration were inhibited. Our study indicates that high glucose could mediates the expression LncRNA MEG3 which regulate the expression of ERP29 through miR‐483‐3p to change the HepG2 epithelial‐mesenchymal transition, the lead to the loss of polarity in liver cancer cells and increase the ability of migration and mobility.
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Hypoglycemic drugs protect memory by regulating cerebral metabolism in high‐fat diet mice {#jdi12939-sec-0095}
-----------------------------------------------------------------------------------------

**Y. Cao, X. Gang, Z. Li and G. Wang**

The First Hospital of Jilin University, Changchun, China

Purpose: Nowadays, both animal models and clinical observations have revealed that central insulin resistance impaired memory and cognition. The mechanisms involve inflammatory, oxidative stress, synaptic transmission, and neuronal apoptosis. Unfortunately, what roles cerebral metabolism play is unknown. This study focused on the effects of hypoglycemic drugs, alogliptin, exenatide and pioglitazone, on astrocyte‐neuron metabolic cooperation in high‐fat diet mice. That may provide theoretical basis for clinical treatment of diabetes‐related cognitive dysfunction.

**Methods**: Male C57BL/6J mice were randomly divided into control group (Ctrl), high‐fat group (HF), alogliptin (ALO) group, exenatide (EXE) group and pioglitazone (PIO) group. Ctrl group was served normal diet, and then the others were served high‐fat diet for 12 weeks. Then, ALO group, EXE group and PIO group were, respectively, treated with alogliptin (25 mg/kg/day), exenatide (30ug/kg/day) and pioglitazone (10 mg/kg/day) for 4 weeks. The memory was tested using the Morris Water Maze test after 16 weeks. Then, mice were killed and the brains were removed to detect insulin signaling and metabolic parameters. All data were presented as mean±SD and *P *\< 0.05 was considered statistically different.

**Results**:

1\. Hypoglycemic drugs improved insulin signaling, IRS1/PI3K/Akt pathway in hippocampus and cortex.

2\. Comparative analysis indicated that the latency in finding the platform significantly decreased, while frequency of crossing platform were increased in ALO group (3.75 ± 1.14), EXE group (3.33 ± 1.07) and PIO group (4.00 ± 1.71) compared to HF group (1.66 ± 1.23) (*P *\< 0.05).

3\. The results showed that the expression of glucose transporter (GLUT) 1, GLUT3, monocarboxylate transporter (MCT)1, MCT2 and MCT4 in HF group were significantly lower than those in Ctrl group, no matter in hippocampus and cortex. ALO group, EXE group and PIO group obviously reversed metabolic parameters compared to HF group.

**Conclusions**: These findings indicate that high‐fat diet induced central insulin resistance in C57BL/6J mice. We demonstrated that reprogramming metabolic pathways is an elaborate way by which neural cells respond to central insulin resistance. And hypoglycemic drugs can reverse metabolic pathways to protect memory.
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Palmitic acid promotes dysfunction of human umbilical vein endothelial cells {#jdi12939-sec-0097}
----------------------------------------------------------------------------

**J. Liu^1^, Q. Ma^2^ and R. Niu^2^**

^1^Department of Endocrinology, Gan Su Province Hospital, Lanzhou, China, ^2^First Clinical Medicine College, Lan Zhou University, Lanzhou, China

**Objective**: In this study, we attempt to evaluate the effect of palmitic on human umbilical vein endothelial cells.

**Methods**: HUVECs were isolated from freshly collected umbilical cords, stimulated with palmitic acids. HUVECs survival rate was calculated by MTT assay, the levels of NO and nitric oxide synthase (NOS) were detected by colorimetric analysis, contents of endothelin‐1(ET‐1)were detected by ELISA. Real‐time PCR measure the mRNA expression of eNOS and ET‐1.

**Results**: Palmitic acids significantly induced decrease in expression of NO and NOS, and EMs can antagonize the damage. In addition, the palmitic acids induced increase in the production of ET‐1 and the expression of ET‐1 mRNA; decrease the expression of eNOSmRNA.

**Conclusions**: We propose that palmitic acid promotes the dysfunction of human umbilical vein endothelial cells.
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Gemigliptin inhibits IL‐1β‐induced endothelial‐mesenchymal transition via BMP2/Smad/MAPK/Runx2 pathway {#jdi12939-sec-0099}
------------------------------------------------------------------------------------------------------

**H.‐S. Kwon, O.‐K. Hong, M.‐K. Kim, K.‐H. Baek, S.‐J. Yoo and K.‐H. Song**

The Catholic University Of Korea, Seoul, South Korea

**Objectives**: Endothelial‐to‐mesenchymal transition (EndMT) contributes to inflammatory conditions inducing conversion of endothelial cells (ECs) into activated fibroblasts, promoting fibrotic diseases. Pro‐inflammatory cytokine interleukin (IL)‐1β is the most potent inducer of EndMT. We investigated inhibition of IL‐1β‐induced EndMT by gemigliptin, a dipeptidyl peptidase‐IV inhibitor.

**Methods**: We exposed human umbilical vein ECs (HUVECs) to 10 ng/mL IL‐1β/20 uM gemigliptin and analyzed the expression of endothelial, smooth muscle, mesenchymal, and osteoblastic markers, bone morphogenetic protein (BMP), Smad, and non‐Smad signaling pathway proteins.

**Results**: Morphological changes showed gemigliptin blocked IL‐1β‐induced EndMT, upregulated EC markers, and downregulated smooth muscle and mesenchymal markers. IL‐1β activation of HUVECs is initiated by the BMP/Smad and canonical BMP signaling pathways. Gemigliptin inhibited IL‐1β induction of BMP2 and 7, activin receptor type IA, BMP receptor type IA, and BMP receptor II. Reversal of IL‐1β‐mediated inhibition of BMP‐induced Smad1/5/8, Smad2, and Smad3 phosphorylation by gemigliptin suggests involvement of the Smad pathway in gemigliptin action. In the canonical BMP pathway, gemigliptin treatment significantly increased the deactivation of ERK, p38, and JNK by IL‐1β. Gemigliptin treatment suppressed BMP‐2‐induced expression of key osteoblastic markers including osterix and runt‐related transcription factor 2 during IL‐1β‐induced EndMT.

**Conclusions**: We demonstrated a novel protective mechanism of gemigliptin against fibrosis by suppressing IL‐1β‐induced EndMT.
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Correlations between serum 25‐hydroxyvitamin D and pancreatic islet function in type 2 diabetics {#jdi12939-sec-0101}
------------------------------------------------------------------------------------------------

**N. Li^1,2^, M. Chen^1,2^, J. Dong^1,2^, S. Yang^1,2^, L. Xu^1,2^, Y. Wang^1,2^, H. Sun^1,2^, H. Li^1,2^ and S. Qu^1,2^**

^1^Department of Endocrinology and Metabolism, Shanghai Tenth People\'s Hospital, Tongji University School of Medicine, Shanghai, China, ^2^National Metabolic Management Center, Shanghai, China

**Objective**: The relation between type 2 diabetes mellitus (T2DM) and serum‐25‐hydroxyvitamin D (25\[OH\]D) is unclear. We aimed to explore the association of 25(OH)D with islet β cell function and insulin resistance in patients with T2DM.

**Methods**: A total of 466 patients with T2DM and 364 healthy people in our hospital from 2016 to 2017 were enrolled. The difference of 25(OH)D between T2DM group and non‐DM group was compared. Patients with T2DM were divided into low 25(OH)D group (LVD group, \<47.7 nmol/L, *n *= 326) and normal 25(OH)D group (NVD group, \>47.7 nmol/L, *n *= 140). The correlation between fasting plasma glucose (FPG), fasting insulin (FINS), fasting c‐peptide (FCP), glycosylated hemoglobin (HbAlc), HOMA‐IR, HOMA‐β and 25(OH)D were compared.

**Results**: Serum level of 25(OH)D in T2DM group was significantly lower than non‐DM group (42.33 ± 13.79 vs.69.16 ± 10.78, *P *\< 0.001). Levels of FPG, FINS, FCP, HbAlc, HOMA‐IR, and HOMA‐β in LVD group were higher than NVD group, but there was no significant difference. Correlative analysis showed that there was negative correlation between 25(OH)D and FCP (*r* = −0.101, *P* = 0.03), but there was no significant correlation with FPG, FINS, HbAlc, HOMA‐IR and HOMA‐β (*r* = −0.87, 0.043, −0.290, 0.032, 0.017, all *P *\> 0.05). The 25(OH)D of Duration ≥ 5 years was lower than the Duration \< 5 years (42.39 ± 13.96 vs. 42.46 ± 13.45, *P* = 0.964). The 25(OH)D of HbAlc ≥ 7% was lower than HbAlc \< 7% (42.02 ± 13.85 vs. 44.19 ± 13.50, *P* = 0.192). The 25(OH)D in microvascular group was lower than non‐microvascular group (40.86 ± 13.82 vs. 43.35 ± 13.72, *P* = 0.059). The 25(OH)D in macrovascular group was higher than non‐macrovascular group (42.49 ± 13.95 vs. 42.09 ± 13.23, *P* = 0.807).

**Conclusion**: The 25(OH)D in patients with T2DM is lower than healthy people and is downtrend with the increase of diabetic duration and HbAlc. There is no definite.
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Endogenous GLP‐1 attenuate islet β cell dedifferentiation in a type 2 diabetes mouse model {#jdi12939-sec-0103}
------------------------------------------------------------------------------------------

**D. Hongjun and Y. Li**

Union Hospital, Tongji Medical College, Huazhong University Of Science And Technology, Wuhan, China

**Objection**: Mature pancreatic α cell is found to produce more GLP‐1 during metabolic stress. In this study, we aim to examine the possible role of islet endogenous GLP‐1 in reducing β cell dedifferentiation in type 2 diabetes.

**Methods**: First, a lineage tracing experiment was performed to track β cell in a high fat diet combined with streptozocin inducing type 2 diabetes mouse model. Second, islet endogenous GLP1、GLP1 receptor and Dipeptidyl peptidase 4(DPPIV) were evaluated in the type 2 diabetes model. Islet function was evaluated through intraperitoneal glucose tolerance tests (IPGTT) and intraperitoneal insulin tolerance tests (IPITT). Phenotypic changes in βcell were detected through immunofluorescence and RT‐PCR. Finally, the effects of GLP‐1 were explored in type 2 diabetes mouse model and isolated mouse islets exposed to 0.5 mmol/L palmitic acid.

**Results**: Approximately 85% β cells were labeled by eGFP. Pancreatic β cell dedifferentiation occured both in vivo and in vitro, accompanying by α cell hyperplasia and increasing production of GLP‐1. Approximately 34% β cells were dedifferentiation in the type 2 diabetes mouse model. GLP1 receptor (GLP1R) and DPPIV were dominant expressed in pancreatic β cells,while overt decreasing expression could be seen during metabolic stress. 0.8 mg/Kg liraglutide daily injection significantly improved islet function as well as islet architecture. Liraglutide intervention enhanced the expression of key transcription factors (MAFA/PDX1/NKX6.1) so as to attenuate β cell dedifferentiation both in vivo and in vitro.

**Conclusion**: Pancreatic β cells are dedifferentiated instead of apoptosis during metabolic stress. Meanwhile, a self‐protective mechanism in islet is activated during metabolic stress to improving local GLP‐1 concentration through increasing α cell GLP‐1 production and decreasing β cell DPPIV expression .Endogenous GLP‐1 exerts a protective effect by attenuating β cell dedifferentiation.
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Establishment of electrochemiluminescence assay for detection of islet antibodies in chinese han population and its clinical significance {#jdi12939-sec-0105}
-----------------------------------------------------------------------------------------------------------------------------------------

**L. Qian**

The Affiliated Sir Run Run Hospital Of Nanjing Medical University, Nanjing, China

**Objective**: To establish a standard for the detection of islet autoantibodies by electrochemiluminescence assay, and to explore its application in the prediction and diagnosis of type 1 diabetes (T1DM).

**Methods**: Improved electrochemiluminescence assay was used to measure GAD65‐Ab, IAA and IA2‐Ab, the results were shown as GAD65‐Ab, IAA‐Ab and IA2‐Ab index. One hundred and seventeen healthy controls were screened for these three autoantibodies, and the normal upper range limit was defined as 98.5%. Serum levels of GAD65‐Ab, IAA‐Ab and IA2‐Ab were also measured in 106 patients with type 1 diabetes.

**Results**: The intra‐assay coefficients of variation (CV) were 3.8%‐9.7%, inter‐assay CV were 3.7%‐11.1%. The positive cut‐off point for GAD65‐Ab is 0.05, IAA‐Ab 0.015 is and IA2‐Ab is 0.018. The prevalence of islet autoantibodies (GADA 58.7%, IAA 29%, IA‐2A 27.4%) was markedly higher than healthy controls (*P *\< 0.01).

**Conclusions**: Electrochemiluminescence assay for islet autoantibodies assessment has a high sensitivity, strong specificity, good consistency and repetition. It may be used to predict and diagnose type 1 diabetes in clinical practice.
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The effects of glucagon‐like peptide on myocardial microstructure in diabetes rats {#jdi12939-sec-0107}
----------------------------------------------------------------------------------

**B. Duan**

Heilongjiang Provincial Hospital, Harbin, China

**Objective**: To observe the effects of glucagon‐like peptide on expression of myocardial hypoxia inducible factor ‐1alpha (HIF‐1a), vascular endothelial growth factor (VEGF) and myocardial microstructure in diabetes rats.

**Methods**: A total of 30 male Wister rats were randomly divided into three groups: normal group, non‐intervention diabetes group and intervention diabetes group, 10 rats in each group. The two diabetes groups were given high glucose and high fat diets for one month. Intervention diabetes group was given glucagon‐like peptide analogue (liraglutide) injection. After 14 weeks, the rats hearts was taken to observe the myocardial morphological changes and microvessel density after HE coloratura. The expression of HIF‐1a and VEGF protein was detected by blot Western method.

**Results**: The microvessel density in intervention group was higher than in non‐intervention group (*t* = 3.254,*P *\< 0.05). The expression of HIF‐1 and VEGF protein in intervention group was all higher than in non‐intervention group (*t* = 3.139, *P *\< 0.05;*t* = 3.012, *P *\< 0.05).

**Conclusion**: GLP‐1 increases the density of microvessel and up‐regulate the expression of HIF‐1a and VEGF in diabetes rats myocardium.
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Circulating micro‐RNA 21, micro‐RNA 25, microRNA‐146a, microRNA‐181a as potential biomarkers for diagnosis and pathogenesis of autoimmune diabetes {#jdi12939-sec-0109}
--------------------------------------------------------------------------------------------------------------------------------------------------

**Y. Liu and Y. Li**

Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy Of Medical Sciences, Beijing, China

**Purpose**: To explore potential role of circulating micro‐RNA 21, micro‐RNA 25, microRNA‐146a, microRNA‐181a for diagnosis and pathogenesis of autoimmune diabetes.

**Methods**: We compared the difference of expression levels of serum micro‐RNA 21, micro‐RNA 25, microRNA‐146a, microRNA‐181a between autoimmune diabetes patients (29 type 1 diabetes (T1D) and 25 latent autoimmune diabetes of adults (LADA))and controls (48 type 2 diabetes (T2D), and 34 normal glucose tolerance (NGT) individuals) determined by quantitative Real‐time polymerase chain reaction (qRT‐PCR). Furthermore, discriminatory performances of the 4 miRNAs were determined by receiver‐operating characteristic (ROC) curves. Additionally, we predicted the potential involvement in pathogenesis of autoimmune diabetes with bioinformatics analysis, including miRNA targets genes, Gene ontology (GO) and pathway‐based over‐enrichment tests for miRNA target genes. Multiple logistic regression analysis was performed to determine the independent risk predictive factors for autoimmune diabetes, and further a risk prediction nomogram model was established and its predictive performance was evaluated by internal validation.

**Results**:

1\. The expression levels of serum micro‐RNA 21, micro‐RNA 25, microRNA‐146a, microRNA‐181a of autoimmune diabetes was significantly downregulated compared with T2D and NGT individuals (*P *\< 0.001) and the area under ROC curves (AUCs) of the 4 microRNAs \>0.80 (*P *\< 0.001), respectively.

2\. Bioinformatics analysis revealed that the predictive target genes of 4 microRNAs were enriched in the signaling pathways involving in autoimmunity and inflammation, cell proliferation, apoptosis and function, as well as metabolism, all of which were involved in regulation of pathogenesis of autoimmune diabetes.

3\. Multiple logistic regression analysis indicated that microRNA‐25(OR 0.001, *P *\< 0.05), microRNA‐146a (OR 0.136, *P *\< 0.05), fasting C peptide levels (OR 0.064, *P *\< 0.05) were risk predictive factors for autoimmune diabetes and the corresponding risk prediction nomogram model was validated internal validation to have good predictive performance for autoimmune diabetes (AUC 0.968, 95%CI 0.922--0.989).

**Conclusions**: Circulating micro‐RNA 21, micro‐RNA 25, microRNA‐146a, microRNA‐181a may serve as potential biomarkers for diagnosis and pathogenesis of autoimmune diabetes.
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Mechanisms of octanoic acid potentiation of insulin secretion in isolated islets {#jdi12939-sec-0111}
--------------------------------------------------------------------------------

**T. Zhang^1^, P. Chen^2^, C. A. Stanley^2^ and C. Li^2^**

^1^Endocrinology Department of Peking University First Hospital, Peking, China, ^2^Division of Endocrinology and Diabetes of The Children\'s Hospital of Philadelphia, Philadelphia, USA

**Objective**: In order to further explore the mechanisms of octanoic acid stimulation or potentiation of insulin secretion.

**Methods**: We used wild‐type (WT), short‐chain 3‐hydroxyacyl‐CoA dehydrogenase knockout (hadh^−/−^), and sulfonylurea receptor 1 knockout (Sur1^−/−^) mouse islets. For islet perfusions, 150 islets were handpicked after culture and perfused with different stimuli. For batch incubation, batches of 5 isolated cultured islets of similar size were handpicked and placed in a 96‐well plate format. After incubation, supernatant was collected for measurements of insulin by HTRF assay. Cytosolic Ca^2+^(\[Ca^2+^\]i) dynamics were measured by dual‐wavelength fluorescence microscopy using Fura‐2AM as Ca^2+^ indicator.

**Results**: An octanoic acid ramp only stimulated a 2‐to 3‐fold increase of insulin secretion with a threshold of 3 mM in WT mouse islets, suggesting that OA alone is a weak insulin secretagogue. However, octanoic acid at 1 mM strongly potentiated fuel stimulated insulin secretion, including glucose‐ and α‐ketoisocaproate‐stimulated insulin secretion. The potentiation effect on fuel‐stimulated insulin secretion did not require fatty acid β‐oxidation, because octanoic acid also potentiated amino acid‐stimulated insulin secretion in islets isolated from hadh^−/−^ mice, which cannot fully oxidize octanoic acid. Further studies using Sur1^−/−^ islets indicated that the potentiation effect of octanoic acid on fuel‐stimulated insulin secretion is calcium‐dependent and requires β‐cell depolarization and may also involve the calcium calmodulin complex. Studies using DCPIB to inhibit volume‐sensitive anion channels (VSAC) in SUR1^−/−^ islets demonstrated that the potentiation effects of octanoic acid on insulin secretion are medicated by activation of VSAC.

**Conclusion**: Octanoic acid alone is a weak insulin secretagogue, but that octanoic acid potentiates insulin secretion at a site distal to β‐cell depolarization and that the potentiation effect is dependent on elevated cytosolic calcium and appears to involve modulation of volume sensitive anion channels.
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Serum insulin, glucagon and ratio of insulin to glucagon in relation to different glucose categories {#jdi12939-sec-0113}
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**L. Zhang^1,2^, Q. Wang^1^, J. Wang^1^, L. Liu^1^, X. Yin^1^ and Y. Dong^1,2^**

^1^Qingdao Endocrine & Diabetes Hospital, Qingdao, China, ^2^Weifang Medical University, Weifang, China

**Objectives**: To investigate serum insulin, glucagon and insulin/glucagon levels in relation to different glucose categories.

**Methods**: A total of 81 patients with newly diagnosed type 2 diabetes (DM), 35 with impaired glucose regulation (IGR) and 38 with normal glucose tolerance (NGT) were enrolled. All subjects received oral glucose tolerance test with measurement of plasma glucose, insulin and glucagon at fasting and 30, 60, 120 and 180mins after 75 g glucose load.

**Results**: There was no difference on fasting insulin among NGT, IGR and DM. Compared with NGT or IGR, DM had decreased insulin levels at 30' and 60' after glucose tolerance (*P *\< 0.01). IGR had increased insulin level at 120' compared with NGT (*P *\< 0.05). The area under the curve (AUC) of insulin was increased in IGR compared with DM (*P *\< 0.01). DM patients had increased level of glucagon at fasting, 30', 60' and 120' after glucose tolerance compared with NGT or IGR. In patients with NGT or IGR, the glucagon level at 30' and 60' decreased compared with that of fasting level. DM had the largest AUC of glucagon among the three groups (*P *\< 0.05). The AUC of glucagon was positively associated with body weight, waist, BMI, HbA1c, serum creatinine and uric acid (*P *\< 0.05). The ratio of insulin to glucagon was decreased at fasting, 30' and 60' compared with NGT or IGR group.

**Conclusions**: Glucagon secretion is impaired in DM patients accompanying with beta cell dysfunction. The ratio of insulin to glucagon may be a better parameter reflecting the pancreatic alpha and beta cell dysfunction.
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Exosomes derived from mesenchymal stromal cells pretreated with advanced glycation end product‐bovine serum albumin inhibit calcification of vascular smooth muscle cells {#jdi12939-sec-0115}
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**Y. Wang**

Zhongda Hospital, Southeast University, Nanjing, China

**Background**: The osteogenic differentiation of vascular smooth muscle cell (VSMCs) is important for the development of vascular calcification (VC), particularly in diabetes. Exosomes derived from Mesenchymal Stromal Cells (MSCs) are effective against cardiovascular diseases, yet their role in VC remains unclear. Advanced glycation end products (AGEs) inhibit bone marrow stromal cell osteogenesis by targeting osteogenesis‐associated genes. Thus, we investigated the role of exosomes derived from MSCs pretreated with AGE‐BSA in VC and its potential mechanisms.

**Methods**: Primary VSMCs and MSCs were isolated from the aorta and bone marrow of Sprague‐Dawley rats, respectively. VSMCs were cultured with AGEs‐BSA to induce osteogenic differentiation. Exosomes were harvested from MSCs by ultracentrifugation. MSCs and VSMCs were cocultured in Transwells, and exosomes were added to VSMC culture medium to assess their effects on osteogenic differentiation. Double luciferase reporter assay was applied to confirm that miR‐146a directly targets the 3' UTR of the thioredoxin‐interacting protein (TXNIP) gene.

**Results**: Pretreatment of VSMCs with AGEs‐BSA increased the expression of thioredoxin‐interacting protein (TXNIP) by inhibiting that of miR‐146a, resulting in enhanced ROS production and VSMC calcification. By contrast, the expression of miR‐146a in MSCs was increased by AGEs‐BSA treatment. Thus, miR‐146a was transferred from AGEs‐BSA‐pretreated or miR‐146a‐transfected MSCs to VSMCs via exosomes. After coculture with miR‐146a‐containing exosomes, the AGEs‐BSA‐mediated increase in VSMC calcification was diminished, accompanied by decreased TXNIP expression and ROS production. Furthermore, TXNIP overexpression counteracted the anti‐calcification effects of MSC‐derived miR‐146a‐containing exosomes. In addition, TXNIP was identified as a target gene of miR‐146a, and the results of double luciferase reporter assay confirmed that TXNIP was the direct target gene of miR‐146a.

**Conclusions**: Exosomes secreted by MSCs pretreated with AGE‐BSA contained a high level of miR‐146a, which was transferred to VSMCs and inhibited AGEs‐BSA‐induced calcification in a TXNIP‐dependent manner. Thus, miR‐146a‐containing exosomes may be a potential therapeutic target for VC.
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Racial/Ethnic differences in incretins and gut microbiota between Han‐Chinese university students and international students from East Africa {#jdi12939-sec-0117}
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**P. Nizigiyimana, B. Xu, Z. Liu, C. Li and M. Lei**

Department of Endocrinology, Xiangya Hospital, Central South University, Changsha, Hunan, China

**Aims**: We investigated whether differences in GLP‐1 levels may account for the increased islet β‐cell activity to expound racial differences in insulin and glucose responses, we also examined whether gut microbiota composition might explain this disparities of GLP‐1 levels in the two groups.

**Methods**: A total of 30 Han‐Chinese university students with age (25.1 ± 1.5),BMI (22.7 ± 2.8) and 30 Inter‐national students from East Africa with age (26.4 ± 4.5),BMI (22.5 ± 3.5) healthy subjects were recruited for the study. GLP‐1, Insulin and glucose levels were measured via 3 h‐OGTT at 0,30,60,120 and 180 min by using Double Antibody Sandwich ELISA, Chemiluminescence Microparticle Immuno Assay and Hexokinase method, respectively. Gut microbiota composition was assessed through fecal DNA extraction, amplification and sequencing of the bacterial 16s rDNA gene in V3V4 region by using PCR and Illumina MiSeq methods. Trapezoidal method, T‐test, Mann‐Whitney U test, ANOVA, Wilcoxon and Kruskal‐Wallis rank sum test, Pearson and Spearman correlation were applied for data analysis.

**Results**: Four subjects reported glucose intolerance and were accordingly excluded. The 27 Han‐Chinese and 29 International students eligible subjects, results were as follows:

\(1\) Hip circumference (90.66 ± 9.10 vs. 95.82 ± 9.26), *P *\< 0.05;

\(2\) Area Under The Curve for GLP‐1 (30013.79 ± 32797.89 vs. 20731.87 ± 10819.39), Insulin (2677.78 ± 1586.45 vs. 2386.76 ± 961.04), Glucose (577.26 ± 64.35 vs. 589.41 ± 79.82),all *P *\< 0.01;

\(3\) Insulin resistance (IR) at 30 min (1.27 ± 0.18 vs. 1.14 ± 0.27), respectively, *P *\< 0.05 and no statistical differences were seen in Islet β‐cell function and insulin sensitivity, both *P *\< 0.05.

\(4\) Five Bacterial species, Bacteroides (0.4283 ± 0.0388 vs. 0.2216 ± 0.0368), Coprococcus (0.0015 ± 0.0003 vs. 0.0044 ± 0.0009), Parasutterella (0.0175 ± 0.0042 vs. 0.0043 ± 0.0025), Clostridium (0.0081 ± 0.0019 vs. 0.0037 ± 0.0005), Dorea (0.0017 ± 0.0003 vs. 0.00034 ± 0.0006) respectively (all, *P *\< 0.05). There was a significant correlation relationship between GLP‐1 and two species of gut flora (all, *P *\< 0.01).

**Conclusions**: This study reveals the differences in incretin hormone GLP‐1, Insulin and Glucose levels as well disparities in gut microbiota composition between the two races. These differences in insulin and glucose levels may be the result from the disparities in gut microbiota composition to influence GLP‐1 secretion and expression in islet β‐cells to make different mechanisms, which in turn may prone Chinese to develop T2DM more than any other race/ethnicity. Genetic background and/or body composition such as body fat also may paly a role. These two bacterial communities that showed correlation relationship with GLP‐1 may serve as important biomarkers for gut flora and GLP‐1 secretion.
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The effect of liraglutide on hepatic adenylate cyclase 3 with respect to insulin resistance in mice {#jdi12939-sec-0119}
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**L. Zhengming and L. Yuzhen**

Department of Endocrinology and Metabolism, Second Affiliated Hospital of Guangxi Medical University, Nanning, China

**Objective**: To observe the effects of liraglutide on hepatic adenylate cyclase 3 (HAC3), body weight and the metabolism of carbohydrates and lipids and to investigate the relationship between AC3 and insulin resistance in mice.

**Methods**: A total of 24 C57BL/6J mice were divided into 2 groups. A control group fed with a standard chow diet, and the HFD group, fed with an obesogenic diet for 12 weeks. Body weight (BW) and blood glucose were measured weekly. After the obese mouse model was established, all mice were subdivided into the following groups (*n *= 6 per group): N+saline (N+S), N+liraglutide (N+L), O+saline (O+S) and O+liraglutide (O+L). After 8 weeks' drug intervention, HAC3 mRNA expression levels were measured by real‐time qPCR. HAC3 protein expression levels were measured by western blotting. Serum levels of triglycerides (TGs), glycerol, free fatty acids (FFAs) and insulin were determined via enzymatic methods using commercial kits.

**Results**: BW, HOMA‐IR scores and the levels of serum insulin, TGs, glycerol and FFAs were significantly higher in obese mice than in normal control mice (*P *\< 0.01). Liraglutide treatment decreased the BW, HOMA‐IR scores and the levels of serum insulin, TGs and FFAs and increased serum glycerol levels (*P *\< 0.01 in all cases). The effects of liraglutide on BW, insulin, HOMA‐IR scores, TGs, glycerol and FFA levels in obese mice were higher than that in normal control mice (*P *\< 0.05 in all cases). HAC3 mRNA and protein levels were lower in obese mice than in normal control mice (*P *\< 0.01) and liraglutide treatment increased these levels (*P *\< 0.05). HAC3 mRNA and protein levels in obese mice increased higher than that in normal control mice (*P *\< 0.05). HAC3 mRNA and protein levels were correlated negatively with BW (*r* = −0.441, *P* = 0.031; *r* = −0.672, *P* = 0.000) and the HOMA‐IR scores (*r* = −0.654, *P* = 0.001; *r* = −0.665, *P* = 0.000), respectively.

**Conclusions**: Liraglutide treatment can improve insulin resistance and promote lipolysis which may be explained partly by upregulation of AC3 by the drug.

PP‐60 {#jdi12939-sec-0120}
=====

Overexpression SIRT1 ameliorates hyperglycemia‐induced apoptosis by reducing mitochondrial dysfunction in human umbilical vein endothelial cells {#jdi12939-sec-0121}
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**R. Qin^1,2,3,4,5^ and L. Guo^4,5^**

^1^Peking Union Medical College, Beijing, China, ^2^Chinese Academy of Medical Sciences, Beijing, China, ^3^Graduate School of Peking Union Medical College, Beijing, China, ^4^Beijing Hospital, Beijing, China, ^5^National Center of Gerontology, Beijing, China

**Aim**: Sustained hyperglycemia is related to the pathogenesis of diabetes mellitus‐induced cardiovascular complications. Silent information regulator T1 (SIRT1), a mammalian sirtuin, has been previously reported to protect endothelial cells against hyperglycemia‐induced apoptosis. We aimed to investigate whether overexpression SIRT1 could ameliorate hyperglycemia‐induced apoptosis by reducing mitochondrial dysfunction in human umbilical vein endothelial cells (HUVEC).

**Methods**: In the present study, HUVEC were treated with D‐glucose or mannitol. Overexpression of SIRT1 was induced by infection of SIRT1‐overexpressing adenovirus vectors. The levels of SIRT1, cell viability, cell apoptosis, apoptosis‐related proteins (cleaved‐caspase3, PARP), mitochondrial apoptosis pathway‐related proteins (Caspase9, Bax, Bad, Bcl‐2, x‐IAP), ROS, mitochondrial membrane potential, cytochrome c, mPTP were measured.

**Results**: The overexpression of SIRT1 protected HUVEC against hyperglycemia‐induced apoptosis, as indicated by the reduction of cleaved‐caspase3, PARP expression and TUNEL positive cells and the increasing of cell viability. Furthermore, SIRT1 overexpression significantly attenuated mitochondrial dysfunction by reducing the level of ROS, maintaining the stability of the mitochondrial membrane, preventing hyperglycemia‐induced mPTP opening. Moreover, overexpression of SIRT1 inhibited the expression of caspase9, Bax, Bad, and the expression levels of anti‐apoptotic proteins Bcl‐2, x‐IAP were markedly upregulated in HUVEC transfected with SIRT1‐overexpressing adenovirus vectors in high glucose conditions.

**Conclusion**: Our findings indicate that SIRT1 overexpression could protect HUVEC against hyperglycemia‐induced apoptosis by modulating mitochondrial function.
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Sil1 Rescurd the cognition impairment via reducing Tau Hyperphosphorylation in Neuron and neuronal apoptosis in the Rats Model of Diabetes encephalopathy (DE) {#jdi12939-sec-0123}
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**Z.‐c. Liu, L.‐l. Zhang, S. Liu and Z.‐y. Zhao**

The Shijiazhuang Second Hospital, Shijiazhuang City, China

Diabetes is a one of the high risks of Alzheimer\'s disease (AD). Diabetes encephalopathy (DE) has AD‐like pathological changes (hyperphosphorylated tau and neuronal apoptosis and cognitive disorder. Endocytoplasmic reticulum (ER) stress induces the hyperphosphorylation of tau and neuronal apoptosis in AD. It is not clear that ER stress may contribute to neuronal injury in DE. Expression of Binding immunoglobulin protein (Bip), also named Glucose‐regulated protein 78(GRP78), increased in ER stress, which is regarded as one of the molecular markers. The nucleotide exchange factor Sil1 is one important molecular chaperone of Bip, which plays an important role in ER. In our research, in the hippocampus of diabetes encephalopathy rat model or in the N2a cells treated by high glucose, we have found the following: with the increased expression of Bip, GSK‐3β are excessively activated (The inhibitory site Ser9 expression was decreased); meanwhile, the combination of GSK‐3β and tau can also be elevated. And the rats model of DE has cognitive disorder (bad Water maze). But if Sil1 is overexpressed in brain of the diabetes encephalopathy rat model or in N2a cells, the binding of GSK‐3β and tau can be lowered and the activity of GSK‐3β can be reduced, so hyperphosphorylation of tau can be reversed. And the cognitive of DE rats model is rescurded. Additionally, we also find with the decreased expression of Sil1in brain of the diabetes encephalopathy rat model or in the N2a cells treated by high glucose,, the expression of GADD153/CHOP and Caspase‐12 two apoptosis factors is increased, but if excessive expression of Sil1, the two apoptosis factors reversed. And our another research show increased expression of Bip, decreased expression of sil1 in the brain of Tg2576, a transgenic mouse model of AD, possibly related with decreased expression of sil1 in ER stress that leads to hyperphosphorylated tau and neuronal apoptosis. So we think that Sil1 plays a key role in hyperphosphorylated tau generating and neuronal apoptosis in neurodegeneration such as DE and AD and Sil1 can be a molecular target in treating neurodegeneration disease like DE and AD.
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Aryl hydrocarbon receptor deficiency causes a diabetes‐related vascular pathology---the actual title of her resubmitted abstract {#jdi12939-sec-0125}
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**M.‐L. Sheu**

Institute of Biomedical Sciences, National Chung Hsing University, Taichung, Taiwan

**Aims**: Diabetic retinopathy (DR) is typically characterized by retinal inflammation, vascular leakage, blood‐retinal barrier breakdown and neovascularization. However, the molecular mechanisms underlying the inflammation signaling contributes to the progression of DR remain unclarified. Aryl hydrocarbon receptor (AhR) is a ligand‐activated transcription factor that has been implicated in inflammation and pathological vascular angiogenesis. Materials and

**Methods**: As AhR contributes to vascular dysfunction; we speculate that AhR might play a role in microangiopathies, such as diabetic retinopathy (DR). Therefore, we investigated the impact of AhR on retinal vascular damage using AhR knockout mice (AhRKO) during the development of DR and its possible mechanisms. ELISA detected NƐ‐carboxymethyllysine (CML) and inflammatory cytokines levels in the serum from human samples and several diabetic murine models, especially the latter also used LC/MS/MS analysis the whole eye tissue. Immunofluorescence staining identified CML expression on retinal pigment epithelium (RPE) layer and endothelial cells. Furthermore, intravitreal injection (IVI) of pharmacological inhibitors or agonists for diabetic rat model, and observed pathological features by retinal leukostasis, optical coherence tomography (OCT) and H&E staining. Pericyte loss and acellular capillary formation were assessed in streptozotocin‐induced diabetic AhRKO and wild‐type (WT) mice. Expressions of immune cells were assessed by immunofluorescence in the diabetic retinas as well as in retinal endothelial cells depleted of AhR by siRNA and stimulated with CML.

**Results**: Similar to diabetic WT retinas, non‐diabetic AhRKO retinas showed a significant decrease in pericyte coverage in comparison with non‐diabetic WT retinas. Hyperglycemia or diabetes condition further aggravates pericyte loss in diabetic AhRKO retinas. Acellular capillary formation was detected in the diabetic AhRKO retinas. In cultured primary retinal endothelial cells, stimulation with CML and AhRKO depletion comparably increased immune cells expression.

**Conclusions**: Our data identify AhR as a protective factor in the retina, which controls immune cells expression. AhRKO‐deficient mice are a suitable model for studying mechanisms underlying diabetic retinal vascular damage.
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Liraglutide inhibits IAPP‐IDF‐WPR‐induced IL‐1 beta production from islets {#jdi12939-sec-0127}
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**T. Zhu^1^, Y. Jin^1^, D. Li^2^, X. Zhao^1^ and Y. zhang^1^**

^1^Tianjin Medical University General Hospital, Tianjin, China, ^2^Tianjin Medical University Metabolic Disease Hospital, Tianjin, China

**Background**: IL‐1 beta plays an important role in islet pathology in type 2 diabetes. Human islet amyloid polypeptide (IAPP), which aggregates into either insoluble amyloid or small oligomer, triggers IL‐1 beta production from islets. The glucagon‐like peptide‐1 receptor agonist liraglutide can cross the blood brain barrier and reduce the local inflammation, which is related to the reduced Abeta amyloid levels in Alzheimer\'s disease. Whether liraglutide can inhibit IAPP‐IDF‐WPR‐induced IL‐1 beta and IAPP aggregates production remains unknown.

**Aims**: To evaluate liraglutide\'s ability to inhibit IAPP‐IDF‐WPR‐associated IL‐1beta production and explore its effect on IAPP aggregation.

**Method**: Islets were isolated and exposed to IAPP in the presence or absence of liraglutide, and IL‐1 beta was assessed by quantitative PCR and ELISA. The cell death were detected by Annexing V/ propidium iodide double‐staining test. The real‐time characterization of IAPP aggregation kinetics was tested by Thioflavin T (ThT)‐binding assay. The electron microscopy assay was also used to detect the effect of liraglutide on IAPP fibrillation.

**Results**: Liraglutide significantly inhibited IAPP‐IDF‐WPR‐mediated IL‐1 beta expression and secretion from islets. The islet cell death caused by IAPP reduced in liraglutide group. ThT‐binding assays showed liraglutide hindered hIAPP fibrils formation in a dose‐dependent manner. The electron microscopy assays further confirm fibrils, which formed by IAPP, were reduced in the presence of liraglutide. Discussion: IAPP deposition is associated with inflammation in pancreatic islets. liraglutide inhibited IL‐1 beta production. The consequence of this is the preservation of islet cell viability. Liraglutide can directly inhibit hIAPP aggregation and reduce toxic aggregates production. We therefore propose that liraglutide may play protective role against IAPP.
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Concentration‐dependent effects of metformin on endothelial function {#jdi12939-sec-0129}
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**C. Triggle and H. Ding**

Weill Cornell Medicine‐Qatar, Doha, Qatar

Metformin is the first‐choice drug for the treatment of type‐2 diabetes (T2DM) and is used on a daily basis by approximately 150 million people. A major benefit of metformin is the reduction in cardiovascular morbidity and mortality; interestingly, retrospective analysis of clinical data also indicates that people treated with metformin have a reduced incidence of certain forms of cancer. In this study, we asked the question: Are the anti‐cancer effects of metformin associated with concentration‐dependent effects on endothelial function with higher concentrations having an anti‐angiogenic effect thus reducing both cell survival and tumour growth?

**Methods**: We assessed the effects of a low micromolar (50 μM -- a concentration that compares with plasma levels when used for T2DM) vs. 2 mM metformin on endothelial function. Protocols included the following: 1. myograph studies of acetylcholine‐mediated endothelium‐dependent vasodilation (EDV) in vessels from db/db (leptin‐receptor mutant) diabetic mice. 2. Cell culture protocols with mouse microvascular endothelial cells (MMECs) maintained under normoglycaemic (NG) vs. hyperglycaemic (HG; to mimic in vivo glucose levels) conditions, and western blot analysis of eNOS, the deacetylase, sirtuin‐1 (protein product of putative anti‐ageing gene, SIRT1), the anti‐angiogenic thrombospondin‐1 (TSP‐1) as well as assays of matrigel tube assays of angiogenesis.

**Results**: 1. In the myograph studies of EDV, the presence of 50 μM metformin significantly (*P *\< 0.05) improved EDV in aortae from db/db mice. 2. In MMECs cultured in HG vs. NG, the presence of 50 μM metformin significantly (*P *\< 0.05) protected the expression of eNOS, phosphorylated eNOS and sirtuin‐1 against the negative effects of HG. Similarly, in matrigel tube assays, 50 μM metformin protected against the negative effects of HG. In contrast, 2 mM, but not 50 μM, metformin significantly (*P *\< 0.05) lowered the expression of sirtuin‐1, raised TSP‐1 levels, disrupted matrigel tube formation and reduced MMEC viability.

**Conclusion**: Whilst endothelium‐protective effects of metformin could be observed at clinically appropriate levels of metformin the anti‐proliferative/autophagy effects were only evident with mM levels. These results suggest that an anti‐angiogenic action of metformin could contribute to the putative anti‐cancer effects of metformin; however, such an action would require the cellular accumulation of metformin in the tumour vasculature.
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FADS1‐FADS2 genetic polymorphisms are associated with fatty acid metabolism through changes in DNA methylation and gene expression {#jdi12939-sec-0131}
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**H. Zhang, Z. He, R. Zhang, F. Jiang, A. Zhao, B. Xu, L. Jin, T. Wang, W. Jia, C. Hu and W. Jia**

Shanghai Diabetes Institute, Shanghai Jiao Tong University Affiliated Sixth People\'s Hospital, Shanghai, China

**Background**: Genomewide association studies (GWASs) have shown that genetic variants are important determinants of free fatty acid levels. The mechanisms underlying the associations between genetic variants and fatty acid levels are incompletely understood. Here, we aimed to identify genetic markers that could influence diverse fatty acid levels in a Chinese population and uncover the molecular mechanisms in terms of DNA methylation and gene expression.

**Results**: We identified strong associations between single‐nucleotide polymorphisms (SNPs) in the fatty acid desaturase (FADS) region and multiple polyunsaturated fatty acids. Expression quantitative trait loci (eQTL) analysis of rs174570 on FADS1 and FADS2 mRNA levels proved that minor allele of rs174570 was associated with decreased FADS1 and FADS2 expression levels (*P *\< 0.05). Methylation quantitative trait loci (mQTL) analysis of rs174570 on DNA methylation levels in three selected regions of FADS region showed that the methylation levels at four CpG sites in FADS1, one CpG sites in intragenic region and three CpG sites in FADS2 were strongly associated with rs174570 (*P *\< 0.05). Then, we demonstrated that methylation levels at three CpG sites in FADS1 were negatively associated with FADS1 and FADS2 expression, while two CpG sites in FADS2 were positively associated with FADS1 and FADS2 expression. Using mediation analysis, we further show that the observed effect of rs174570 on gene expression was tightly correlated with the effect predicted through association with methylation.

**Conclusions**: Our findings suggest that genetic variants in the FADS region are major genetic modifiers that can regulate fatty acid metabolism through epigenetic gene regulation.
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Glucagon variation in meal tolerance test of diabetes mellitus type 2 cases {#jdi12939-sec-0133}
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**T. Kondo**

Kondo Clinic, Tokyo, Japan

Brief statement of the purpose of the study: Glucagon had been incorrectly measured in the past 40 years. In August 2017, Sandwich ELISA kit method was reported a good correlation with LC‐MS/MS method in glucagon measurement, performed remarkably better than other several kits. The result suggested the decrease in glucagon level after meal. The aim of the study was to discuss the glucagon level variation after meal. Method used: My clinic initiated 75gr glucose tolerance test for 3 T2DM patients and mixed‐meal tolerance test (carbohydrate 32 g, protein 11 g, lipid 4.4 g) for 8 T2DM patients, then recorded the preload level and afterload (30, 60, 90, 120 min) level of blood sugar, insulin, and glucagon. After blood draw, the blood samples were collected into BD P800 Blood Collection System and centrifuge the tubes by Eppendorf Microcentrifuge 5430 R. Then, the tubes were stored at −20 degrees Celsius before measurement. Result observed: After 75gr glucagon tolerance test, blood sugar, insulin, glucagon remains the same level as expected. Meanwhile, an increasing trend is observed as the average glucagon level (pg/mL): 16.4(initiation), 32.0 (30 min), 31.6 (60 min), 19.0 (90 min), 21.4(120 min), after meal tolerance test. Conclusions based upon the

**Results**: In 75gO‐GTT cases, it can be rationally observed that the glucagon suppression avoids the increase of blood glucose level. However, in meal tolerant cases, the reason why glucagon level still increases along with the increase of blood glucose level is not yet understood. In May 2018, it was presented that the increase of glucagon level was only observed in protein‐only diet cases. Furthermore, both protein‐included diet and fasting cases, the data showed positive correlation between glucagon level and BUN level. BUN is already known for final metabolic products of protein. Taking a meal activates protein metabolism, which results in more production of ammonia. The result suggests that the increase of glucagon level after meal in relevant to the stabilization of ammonia level, which is to say, glucagon may function to stabilize the ammonia level.
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Non‐invasive longitudinal evaluation of GPR119 agonist‐induced β‐cell mass preservation using GLP‐1 receptor‐targeting imaging technique {#jdi12939-sec-0135}
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**T. Murakami^1^, H. Fujimoto^2^, N. Fujita^1^, K. Hamamatsu^1^, K. Matsumoto^3^ and N. Inagaki^1^**

^1^Department of Diabetes, Endocrinology and Nutrition, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ^2^Radioisotope Research Center, Agency of Health, Safety and Environment, Kyoto University, Kyoto, Japan, ^3^End‐Organ Disease Laboratories, Daiichi Sankyo, Tokyo, Japan

**Aims**: Progressive loss of pancreatic β‐cell mass (BCM) is a central feature of Type 2 diabetes mellitus (T2DM). However, longitudinal changes of BCM remain challenging since non‐invasive techniques for BCM quantification in vivo have not been established. For the purpose of quantification of BCM non‐invasively, we developed a glucagon‐like peptide 1 (GLP‐1) receptor‐targeting probe, \[Lys^12^(^111^In‐BnDTPA‐Ahx)\]exendin‐4 (^111^In‐Ex4), whose radioactive isotope accumulations in the pancreas could be measured with single photon emission computed tomography (SPECT). Previous studies showed the stimulation of G protein‐coupled receptor 119 (GPR119) might induce β‐cell replication, which suggested some preferable effects of long‐term GPR119 stimulation on BCM in vivo. Therefore, we investigated whether GPR119 stimulation could affect BCM in diabetic mice and at the same time verified the accuracy of our ^111^In‐Ex4 SPECT/CT technique in terms of evaluating such BCM changes in vivo.

**Method**: DS8500a, which is a full agonist of GPR119 and whose glycemic lowering effect was not deteriorated for 28 days in Phase II studies, was used to stimulate GPR119 in vivo continually. Male db/db mice were assigned to the following two groups: mice fed with normal chow (group C) and those administered with DS8500a (group D). We performed 8‐week interventions with DS8500a. ^111^In‐Ex4 SPECT/CT was performed every four weeks. After 8 weeks, ex‐vivo pancreatic RI intensities, together with pathological and immunohistochemical analysis of BCM were also examined to compare with ^111^In‐Ex4 SPECT/CT results.

**Results**: As for ^111^In‐Ex4 SPECT/CT, pancreatic RI intensities in group D, at the time of both 4‐ and 8‐week interventions, were significantly higher than those of group C. Moreover, ex‐vivo pancreatic RI intensities as well as conventional pathological BCM analysis revealed similar results as ^111^In‐Ex4 SPECT/CT analysis.

**Conclusion**: , ^111^In‐Ex4 SPECT/CT showed DS8500a, a GPR119 agonist, could attenuate the progression of BCM loss in diabetic mice. The results of , ^111^In‐Ex4 SPECT/CT were corroborated by the conventional pathological method and ex‐vivo pancreatic RI analysis, which indicated the accuracy and usefulness of , ^111^In‐Ex4 SPECT/CT evaluations on BCM.
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Sitagliptin attenuates endothelial dysfunction of diabetic rats: regulation of the apoptosis and autophagy {#jdi12939-sec-0137}
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**X. Chang^1^ and L. Guo^2^**

^1^Peking Union Medical College, Beijing Hospital, Beijing, China, ^2^Beijing Hospital, Beijing, China

Although the contributions of sitagliptin to endothelial function in diabetes mellitus were previously reported, the potential mechanisms still remain undefined. Our research was intended to explore the underlying mechanisms of protective effects of sitagliptin treatment on endothelial dysfunction in Diabetic rats. Experimental diabetes was induced through administration with combination of high‐fat diet and intraperitoneal injection of streptozotocin. Rats were randomly divided into three groups, including controls, diabetes, diabetes+sitagliptin (10 mg/kg/day). Eventually, endothelial damage, markers of apoptosis and autophagy were measured. The morphology study showed severe endothelial injuries in thoracic aortas of diabetic rats. After 12 weeks of administration, sitagliptin attenuated these changes. The results of terminal deoxynucleotidyl transferase (TdT)‐mediated dUTP nick end labeling (TUNEL) staining showed that sitagliptin decreased the apoptosis of endothelial cells in diabetic rats. Through immunohistochemical analysis and western blotting, we found that sitagliptin decreased the expression of microtubule‐associated protein 1 light chain 3 (LC3) in diabetic rats. What is more, sitagliptin increased the expression of BCL‐2 protein, inhibited the expression of c‐Jun N‐terminal kinase and Beclin‐1 protein. In conclusion, our study indicated that sitagliptin treatment can attenuate the endothelial impairment of diabetic rats. The protective effects of sitagliptin are possibly related to the inhibition of apoptosis and autophagy. JNK‐BCL‐2‐Beclin‐1 signaling pathway may be the intervention targets of sitagliptin to protect aortic endothelium.
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Application of bone marrow mesenchymal stem cells: in the treatment of diabetic wound healing {#jdi12939-sec-0139}
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**N. Takzaree^1^, A. Partoazar^2^, N. Daneshvar^2^ and A. Takzaree^2^**

^1^Tehran University Of Medical Sciences, School Of Medicine, Anatomy Department, Tehran, Iran, ^2^Faculty Of Medicine, Tehran University Of Medical Sciences, Tehran, Iran

Background: Wound healing is a process that occurs after skin injury .One of the medical science objectives is attempting to heal a wound in a shorter time span, with fewer side effects. Clinicians have been searching for ways to obtain 'super normal' wound healing. MSC populations in cells derived from Bone Marrow tissue has been studied as an alternative source of MSCs, providing multipotent differentiation. We aimed to evaluate the wound contraction and stem cell properties on managing full‐thickness wounds in vivo.

**Methods**: This experimental study was carried out on 54 adult male diabetic Wistar rats weighing 200--250 gr, and ages of 3--4 months. A square 1.5\*1.5 wound was made on the back of the neck. The rats were divided into control and two experimental groups. Additionally, the control and experimental groups were separated into three subgroups corresponding to 4, 7, and 14 days of study. Mesenchymal stem cells isolated from Bone Marrow, Cell collected and cultured. The control group did not receive any treatment. In first experimental group, MSCs was used once on the wound. The second experimental group received 1% phenytoin cream on the wound. For histological studies, samples were taken from the wound and adjacent skin. This tissue was examined using histological staining (H&E). Wound surface and wound healing were evaluated. Data were analyzed by using one‐way ANOVA with post hoc Tukey test and (*P *\< 0.05) was significant.

**Results**: The results of microscopic study showed histological parameters in wounds bed (the number of fibroblasts, blood vessels, neutrophils and macrophages) in the experimental group were significantly different than the control group. The macroscopic and microscopic evaluations showed that the percentage of wound healing on different days in the control and experimental group were significant (*P *\< 0.05).

**Conclusion**: The beneficial activity of MSCs in wound healing is complemented by the effects of growth factors and ECM produced by the native placenta tissue cells. Using Mesenchymal stem cells, on open wounds will accelerate the healing process.
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^1^Shanghai Jiaotong University Affiliated Sixth People\'s Hospital, Shanghai, China, ^2^Shanghai Diabetes Institute, Shanghai, China, ^3^Shanghai Key Laboratory of Diabetes Mellitus, Shanghai, China, ^4^Shanghai Clinical Center for Metabolic Disease, ^5^Department of Endocrinology

**Aims**: Glucokinase (GCK) plays a central role in glucose regulation. The heterozygous mutations of GCK can cause a monogenic form of diabetes, maturity‐onset diabetes of the young (MODY) directly. In our study, we aimed to explore the mechanism of the novel mutation GCK p.Ala259Thr leading to glucokinase deficiency and hyperglycemia.

**Methods**: Thirty early‐onset diabetes pedigrees were referred for genetic testing. We obtained purified wild‐type and mutant GCK proteins form E.coli systems. The expressed GCK protein was then subjected to the kinetic and thermal stability analysis to test the effects of the missense mutation on GCK activity.

**Results**: One novel missense mutation GCK p.Ala259Thr was identified and co‐segregated with diabetes in a Chinese MODY2 pedigree. The kinetic analysis showed that this mutation result in a decreased affinity and catalytic capability for glucose. The thermal stability analysis also indicated that the mutant protein presented dramatically decreased activity at the same temperature.

**Conclusions**: Our data firstly identified a novel MODY2 mutation in Chinese diabetes pedigrees. The kinetic and thermal stability analysis confirmed that this mutation caused hyperglycemia through severely damaging the enzyme activities and protein stability.
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We performed this study to identify factors related to intact incretin levels in patients with type 2 diabetes (T2D). We cross‐sectionally analyzed 336 patients with T2D. Intact glucagon‐like peptide 1 (iGLP‐1) and intact glucose‐dependent insulinotropic polypeptide (iGIP) levels were measured in a fasted state and 30 min after ingestion of a standard mixed meal. The differences between 30 and 0 min iGLP‐1 and iGIP levels were indicated as ΔiGLP‐1 and ΔiGIP. After ingestion of a mixed meal, iGLP‐1 (5.5 ± 3.0 to 10.4 ± 7.0 pmol/L; *P *\< 0.001) and iGIP (3.8 ± 3.8 to 21.5 ± 7.1 pmol/L; *P *\< 0.001) levels increased by 190% and 570%, respectively. In simple correlation analyses, fasting iGLP‐1 was positively correlated with glucose (*r* = 0.199; *P *\< 0.001), C‐peptide (*r* = 0.137; *P *\< 0.05), creatinine (*r* = 0.124; *P *\< 0.05) and triglyceride (*r* = 0.112; *P *\< 0.05) levels, and negatively correlated with eGFR (*r* = −0.139; *P *\< 0.05). ΔiGLP‐1 was positively correlated only with ΔC‐peptide levels (*r* = 0.194; *P *\< 0.001). Fasting iGIP showed positive correlations with HbA1c (*r* = 0.146; *P *\< 0.01), fasting glucose (*r* = 0.126; *P *\< 0.05) and C‐peptide (*r* = 0.153; *P *\< 0.01) levels, and negative correlations with ΔC‐peptide (*r* = −0.183; *P *\< 0.01) and HDL cholesterol (*r* = −0.124; *P *\< 0.05) levels. ΔiGIP was negatively correlated with diabetes duration (*r* = −0.118; *P *\< 0.05) and HbA1c (*r* = −0.196; *P *\< 0.001) levels, and positively correlated with ΔGlucose (*r* = 0.210; *P *\< 0.001) and ΔC‐peptide (*r* = 0.238; *P *\< 0.01) levels. In multivariate analyses adjusting for age, sex, and covariates, fasting iGLP‐1 levels were significantly related to fasting glucose (β = 0.189, *P *\< 0.01) and creatinine (β = 0.158, *P *\< 0.05) levels, ΔiGLP‐1 levels were positively related to ΔC‐peptide levels (β = 0.194, *P *\< 0.001), fasting iGIP levels were related to fasting C‐peptide levels (β = 0.160, *P *\< 0.01) and female sex (β = 0.124, *P *\< 0.05), and ΔiGIP levels were positively related to ΔC‐peptide (β = 0.165, *P *\< 0.01) and Δglucose (β = 0.138, *P *\< 0.05) levels. Taken together, intact incretin levels are primarily related to C‐peptide and glucose levels. This result suggests that glycemia and insulin secretion are the main factors associated with intact incretin levels in T2D patients.
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Meta‐analysis of genomewide association studies identifies novel genetic variants associated with coronary heart disease in Chinese patients with type 2 diabetes {#jdi12939-sec-0145}
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Coronary heart disease (CHD) is the leading cause of death among patients with type 2 diabetes (T2D). Previous studies demonstrated that genetic factors play a role in CHD, with more than 100 genetic loci being identified in genome‐wide association studies (GWAS) for CHD by far. However, the genetic basis for CHD in patients with T2D remains unclear. This study aimed to uncover genetic variants that affected CHD in Chinese patients with T2D. We also examined the associations of 97 SNPs in 69 reported gene regions identified from previous GWAS with CHD. We performed a meta‐analysis of GWAS using data generated from the Hong Kong Diabetes Register (HKDR) study and the Hong Kong Diabetes Biobank (HKDB). CHD was defined as acute myocardial infarction or death due to coronary disease, or other nonfatal CHD (including revascularisation). We have examined a total of 2374 cases in T2D patients with CHD, and 6246 controls with duration of T2D more than 10 years and free from cardiovascular diseases including CHD, stroke and peripheral vascular disease. DNA samples were genotyped using the Illumina HumanOmni2.5Exome‐8 BeadChip and the Illumina Infinium^®^ Global Screening Array (GSA) in HKDR and HKDB studies, respectively. We imputed the genotypes using minimac 3, with 1000 Genome Project phase III data as reference panel. Within gender, ˜6.6 million high‐quality common SNPs (MAF ≥1%) were examined using logistic regression model, with the adjustments for age and principal components. Results of sex‐specific association in the two studies were combined by meta‐analysis. A total of 233 SNPs were associated with CHD at threshold of *P* \< 10^−5^ from 10 distinct genomic regions, including two previously reported loci (WDR12 and CDKN2A/B) and eight novel loci on chromosomes 1, 2, 12, 14, 15, 20 and 22. Among 69 reported loci from published studies, we confirmed the associations of 9 loci with CHD (2.0 × 10^−4^ \< *P *\< 0.0322), but none of them reached genomewide significance. We have identified eight novel suggestive loci associated with CHD in Chinese patients with T2D. Our findings also support the important contribution of the reported loci for CHD in T2D patients compared with general population.
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Background: Environmental risk factors such as physical activity, obesity, diet and aging have been recognized as important non‐genetic risk factors for T2D. Epigenetic has been suggested as a crucial interface to explain the effects between environmental exposure and risk of developing T2D. Our study aimed to investigate DNA methylation changes in peripheral blood from Malay with T2D.

**Methods**: The methylation profiles of 22 gene promoters involved in T2D were assessed in 12 T2D patients and 11 non‐diabetic controls (NDC) using a customized real‐time polymerase chain reaction array (EpiTect^®^ Methyl II Custom PCR Array). Differences in methylation levels were evaluated using non‐parametric Mann--Whitney tests. The independent t‐test was used for comparison between two groups. Pearson analyses were conducted to determine correlations with continuous variables. Statistical significance was defined as the value of below 0.05. All analyses were performed using PASW Statistic Base 18 (SPSSInc, Chicago, USA).

**Results**: In total, 22 genes related to T2D were included in this study. However, only PTX3 gene showed different DNA methylation levels between NDC and T2D (Pvalue\<0.05). PTX3 showed higher percentage of unmethylated DNA in T2D compared to subjects with NDC (Pvalue\<0.05). Further investigation using pyrosequencing confirmed low levels of PTX3 DNA methylation in T2D contrast to NDC, but no significant difference was found. Lower levels of DNA methylation at PTX3 gene promoter were associated with higher levels of PTX3 protein. Again, no significant difference was observed due to inadequate sample size. There was a positive correlation between plasma PTX3 levels and HbA1c in T2D patients (r: 0.762, Pvalue\<0.001).

**Conclusions**: The present study provides evidence that decreased DNA methylation levels of PTX3 gene may associated with Malays T2D patients. The increase of inflammatory responses by elevated PTX3 protein levels may uphold T2D.
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Background: Beta cell function and beta cell mass (BCM) play important roles in insulin secretion. Cross‐sectional studies on harvested pancreas have reported that BCM decreases in patients with type 2 diabetes. Thus, a method to quantify BCM non‐invasively and longitudinally will enable us to improve our understanding on the pathophysiology of diabetes. However, the method has still not been established. Therefore, we aim to examine whether BCM can be quantified non‐invasively using a glucagon‐like polypeptide‐1 receptor (GLP‐1R) targeting probe labeled with radioisotope, ^111^Indium‐labeled Exendin (^111^In‐Ex), with single‐photon emission computed tomography (SPECT). Materials and

**Methods**: We evaluated the specificity of ^111^In‐Ex toward β‐cells by autoradiography with pancreatic sections of transgenic MIP‐GFP mice, expressing green fluorescent protein under the control of mouse insulin 1 gene promotor. We also performed a blocking study with a pre‐injection of an excess amount of non‐radiolabeled GLP‐1R ligand, Exendin (9--39). Next, we intravenously injected ^111^In‐Ex to NOD mice and performed SPECT 30 min later, repeating this with a 2‐week interval. After the second SPECT scan, we harvested the pancreas and calculated BCM from pancreatic sections by staining immunohistochemically with an anti‐insulin antibody.

**Results**: Specific accumulation of ^111^In‐Ex in β‐cells was confirmed by autoradiography and the blocking study. A significant correlation was obtained between the radioactive and the fluorescent intensity, indicative of BCM in pancreatic sections from the MIP‐GFP mice. We succeeded in performing twice SPECT with a 2‐week interval. All the investigated mice were euglycemic at the first SPECT scan, but some mice became hyperglycemic during the 2‐week interval. The radioactive signal from the pancreas in the second SPECT scan significantly correlated with BCM calculated from immuno‐stained pancreatic sections. We developed a regression equation to estimate BCM from the radioactive signals from the pancreas in SPECT scans. With the regression equation, estimated BCM in hyperglycemic mice dramatically decreased while that in euglycemic increased during the interval.

**Conclusions**: BCM can be quantified non‐invasively and longitudinally by SPECT image with ^111^In‐Ex. This technique successfully demonstrated longitudinal changes in BCM in NOD mice before and after hyperglycemia.
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**Objective**: The purposes of the study were to investigate the effect of forkhead box C2 (FOXC2) gene C‐512T polymorphism on the glycolipid metabolism and insulin resistance. FOXC2 transcription factors and silent expression vector were built and tested the ability of cells to differentiate into fat cells.

**Methods**: FOXC2 promoter region 512 mutants and wild‐type gene sequences were amplified, and, respectively, connected to the luciferase expression vector, then transferred adipose tissue‐derived stromal cells. Luciferase activity was detected in cells under different conditions of insulin concentrations induced, at same time, the protein of FOXC2 expression was detected by western blot. FOXC2 transcription factor was built, and then expressed in preadipocytes; and silent expression FOXC2 was interfered by siRNA. We tested the abilities of cells to differentiate into fat cells under insulin induced.

**Results**: Insulin could effectively induce the expression of FOXC2 protein in adipose mesenchymal stem cells on the differentiation condition. Insulin could significantly induce activity of Foxc2‐pro‐512‐T promoter. The insulin sensitivity of Foxc2‐pro‐512‐C was significantly lower than that of Foxc2‐pro‐512‐T. It was suggested that insulin resistance was related to the activity of the TT genotype of FOXC2. After interfered with FOXC2 expression by the siRNA, the adipocyte differentiation increased significantly. If expression of FOXC2, the fat was decrease. These showed that FOXC2 could repress the adipocyte differentiation of adipose derived stem cell and reduced the number of fat cells, which may be the mechanism of the FOXC2 preventing insulin resistance.

**Conclusions**: Insulin could effectively induce the expression of FOXC2 protein in adipose mesenchymal stem cells on the differentiation condition. Insulin could significantly induce Foxc2‐pro‐512‐T promoter activity, and then reduced insulin resistance. FOXC2 maybe had the effect of inhibiting the adipocyte differentiation of adipose derived stem cell and thus played a role in antagonizing again obesity and insulin resistance.
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**Introduction**: The prevalence of diabetes has increased worldwide. Screening is crucial as Type 2 Diabetes (T2DM) often asymptomatic in its early stages and can remain undiagnosed for many years. Early screening may help people to avoid the more serious complications of this disease.

**Objective**: To observe the participants that were involved in health screening in conjunction with World Diabetes Day 2017. METHODOLOGY: Participants were screened by performing Capillary Blood Glucose (CBG) testing. As in Clinical Practice Guideline, Type 2 Diabetes 2015. CBG more than 5.6 mmol/L needs further assessment. Other information regarding the weight, waist circumference, physical activity and other comorbidities were also taken.

**Results**: There were 376 subjects mostly female (57.7%). The highest subjects by races were Malay (90.42%). There were 26 -- 80 years old where most of them were between 26 -- 36 years old. The screening has shown that 41.8% subjects were with Capillary Blood Glucose (CBG) more than 5.6 mmol/L and 42.67% subjects was referred to Public Health for further assessment. More than half of the subjects (56.11%) has Blood Pressure (BP) more than 135/75 mmHg and 10.4% has been diagnosed with diabetes and hypertension. In female, there were 49.3% with Waist Circumference (WC) more than 80 cm. In Male, there were 47.16% with WC more than 90 cm. Diabetes is associated with an increased waist‐to‐hip ratio despite normal Body Mass Index (BMI). 76.32% has BMI more than 23 kg/m² and only 13% of them were active in physical activities. Factors such as overweight, obesity and lack of activity will lead to increase the risk of Type 2 Diabetes T2DM). Total of 376 subjects, 86.17% were nonsmoker.

**Conclusions**: More research needs to be conducted for the better understanding in healthcare problem.
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Background: Hypoglycemia following OGTT during diabetes screening had been well described in patients with cystic fibrosis, post‐bariatric surgery patients, and some patients with impaired glucose tolerance. Exaggerated insulin secretion associated with increased incretin levels is regarded as a possible mechanism of reactive hypoglycemia in these patients. This paradox phenomenon in non‐diabetic subjects had been linked with higher future risk of developing diabetes and preclinical atherosclerosis as assessed by carotid intima--media thickness. The aim of this study was to study incidence and clinical characteristics of this phenomenon in healthy patients who underwent OGTT as a screening tool for diabetes. Materials and

**Methods**: A retrospective study of patients who underwent a three‐point (fasting, 1‐h, and 2‐h) OGTT over an 11‐year period (2007--2017) was reviewed and patients with normal glucose tolerance who had a hypoglycemic 2‐h plasma glucose level (less than 70 mg/dL) after OGTT were identified. The clinical characteristics of patients, validated Thai diabetes risk score and Thai cardiovascular risk score were compared with normal glucose tolerance patients.

**Results**: A total of 512 OGTT data during study period were reviewed. Based on OGTT results, hypoglycemia following OGTT was observed only in 8 patients (1.6%). These group of patients composed of 5 female and 3 male. The identified patients tended to be younger and more obese when compared with normal OGTT patients (mean age 42.0 ± 12.5 yrs vs. 50.4 ± 12.7 yrs, BMI 26.9 ± 5.3 kg/m^2^ vs. 26.5 ± 4.6 kg/m^2^). Regarding validated Thai diabetes risk score and Thai cardiovascular risk score, there was no difference between patients with an entirely normal, non‐hypoglycemic OGTT response and those with a hypoglycemic response to the OGTT. However, the elevated 1‐hr glucose following OGTT (≥ 155 mg/dL) was found in half of these patients.

**Conclusions**: Our study revealed that OGTT‐induced hypoglycemia in non‐diabetic patients was a rare phenomenon and clinical significance remained to be seen. Cardiovascular risk score as assessed by validated Thai CV risk score did not show a significant difference from normal glucose tolerance patients without this phenomenon. Further prospective study should be done in order to clarify the exact pathogenesis and clinical significance of hypoglycemia encountered during OGTT procedure.
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**Background**: Multiple intensive insulin protocols have been developed to manage hyperglycemia in ICU and CCU settings; however, no single protocol has been universally accepted. Implementation of an insulin infusion protocol could paradoxically increase the rate of hypoglycemia if underlying medical conditions that may alter changes in insulin requirements have not been assessed. Objective

This retrospective study aimed to explore the pitfalls and causes of hypoglycemia from a nurse‐managed intravenous insulin protocol which had been implemented in ICU and CCU at Theptarin hospital, a specialized diabetes center in Bangkok, since April 2017. Materials and

**Methods**: We conducted a retrospective analysis from 3 consecutive problematic cases from a nurse‐managed modified Yale insulin infusion protocol (target blood glucose level 120--160 mg/dL). All relevant clinical data had been collected and discussed with patients‐care team.

**Results**: A total of 3 patients with type 2 diabetes (one ICU patient and two CCU patients) from 4 patients who received an intensive insulin protocol since implementation had been analyzed in details. All patients had been received insulin infusion correctly from trained nursing staffs. However, one patient developed hypoglycemia after starting intravenous insulin protocol for 12 h. The detailed analysis revealed that prior blood glucose levels which were slightly higher than threshold glucose levels (within 10% of highest target threshold in each category) led to subsequent insulin rate adjustments at very high rate (7 units/hour). Then, the protocol directed the insulin rates to reduce but hypoglycemia (blood glucose 64 mg/dL) occurred after stopping insulin infusion 1 h. No adverse consequence developed but this patient with underlying ischemic heart disease developed frequent PVCs during hypoglycemia. In other 2 patients, the pre‐hypoglycemic ranges (blood glucose 75--99 mg/dL) were also occurred from the same reason.

**Conclusion**: No one protocol fits all patients and not all intensive patients are suitable for an insulin infusion protocol. Some institutions are better served with more than one protocol. From our early experience with insulin infusion protocol, adjusting insulin infusions based on blood glucose which was slightly higher than threshold glucose levels without consideration of clinical data may lead to hypoglycemia in vulnerable patients.
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**Background and Objective**

Identification of individuals with impaired awareness of hypoglycemia (IAH) is important to allow modification of glycemic targets and to adjust insulin therapy to minimize hypoglycemia risk. Data on adults with type 1 diabetes mellitus (T1DM) in Thailand are sparse. This cross‐sectional study aimed to evaluate the prevalence and clinical characteristics of adult T1DM with IAH. Materials and

**Methods**: All cases of T1DM were recruited at Theptarin hospital, which is one of largest diabetes centers in Bangkok. All completed a questionnaire to assess awareness of hypoglycemia using the Gold\'s criteria (the respondent rated a 7‐point Likert scale, with 1 representing 'always aware' and 7 representing 'never aware', a score of ≥ 4 implies IAH). We also explored the risk factors for IAH with therapy goals and validated diabetes‐specific nutrition knowledge (THEPTARIN DM questionnaire).

**Results**: A total of 75 adults with T1DM (female 53.3%, mean age 42.7 ± 13.1 years, duration of diabetes 17.8 ± 10.7 years, A1C 7.6 ± 1.4%) were studied. Personalized A1C target was set in 60 patients (range from less than 6.5% to 8.5%, A1C ≤ 7.0% was set in 65% of patients). The prevalence of IAH in overall patients was 33.3%. A higher (41.9%) prevalence was observed in long‐standing (≥15 years) T1DM patients. Almost half of patients (44.0%) experienced nocturnal hypoglycemia during study period. The incidence of severe hypoglycemia in the year preceding the study was much higher in those identified as having IAH (12% vs. 4%, odds ratio 3.27). Only 17.3% of patients had a high scores on validated diabetes‐specific nutrition knowledge. No association was found between knowledge scores and the occurrence of IAH, severe hypoglycemia, or nocturnal hypoglycemia.

**Conclusion**: Impaired awareness of hypoglycemia (IAH) represents a great challenge for both the patient and the healthcare professional. About one‐third of Thai adults patients with T1DM have this condition which leaded to more episodes of severe hypoglycemia. Identification of IAH in routine clinical practice and structured education program should be aimed at rigorous avoidance of recurrent hypoglycemia without relaxing overall control.
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**Objective**: To investigate the relationship between walking exercise and pulmonary function in subjects with type 2 diabetes mellitus.

**Methods**: The data from the Korea National Health and Nutrition Examination Survey (KNHANES) conducted from 2009 to 2013 were analyzed. In total, 33,605 subjects 19 years or older, 17,542 were finally included after excluding missing values. The subjects were divided into three groups, diabetes, prediabetes, and normal. The difference in pulmonary function, including predicted forced vital capacity (pFVC) and predicted forced expiratory volume in one second (pFEV1) among three groups were compared. Subjects with T2DM were divided into three groups according to walking time 150 and 300 min/week, and relationship between glycemic control and pulmonary function in T2DM group was also analyzed.

**Results**: pFVC% and pFEV1% were significantly lower in T2DM than other two groups even after adjusting for age, sex, body mass index (BMI), and waist circumference (pFVC%, 88.6 ± 11.8; pFEV1%, 90.1 ± 13.8, *P *\< 0.001). In regression analysis, a 1% increase in HbA1c was associated with a 1.19% and 0.84% decrease in pFVC% and pFEV1%, respectively, and a 10 mg/dL increase of FPG was associated with a 0.27% and 0.22% decrease in FVC% and pFEV1%, respectively. T2DM subjects walk ≥ 300 min/week showed higher pFVC and pFEV1 than other groups walking \<150 min/week and 150≤, and \<300 min/week (pFVC%, 94.1 ± 12.0, pFEV1%, 92.8 ± 13.5, *P* = 0.001, *P *= 0.021, respectively).

**Conclusion**: Reduced pulmonary function was independently associated with diabetes and their glycemic control. Walking exercise can be prevent decline of pulmonary function in T2DM.
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Purpose: Obesity is associated with insulin resistance and increased risk of developing type 2 diabetes. Accumulating evidences have demonstrated that renal threshold for glucose (RT) is increased in patients with diabetes. Few data exist on the association between obesity and RT. Waist‐hip ratio (WHR) is a simple measure for abdominal obesity. This study was aimed to investigate the association between WHR and RT in subjects with newly diagnosed diabetes.

**Methods**: The present study included 629 subjects with newly diagnosed diabetes after confirming their oral glucose tolerance test. Demographic characteristics and clinical parameters were assessed. RT was calculated for every subject. Multiple linear regression analysis and multivariate logistic regression analysis were performed to determine the association of WHR with RT.

**Results**: All subjects were divided into two groups, 503 subjects with low RT (\<180 mg/dl), and 126 with high RT (≥180 mg/dl). The high RT group exhibited significantly higher blood glucose, urine glucose excretion, systolic blood pressure, and WHR than low RT group (*P *\< 0.001), while high‐density lipoprotein--cholesterol significantly lower than low RT group. Pearson\'s correlation analysis showed a significant positive correlation of WHR with RT (r = 0.212, *P *\< 0.001). Multiple linear regression analyses with RT as a dependent variable, WHR were positively associated with RT when adjusted for age, sex, blood pressure, heart rate, triglycerides, total cholesterol, low‐density lipoprotein--cholesterol and high‐density lipoprotein--cholesterol (β=180.34, SE: 38.54, 95% CI: 104.65 to 256.03, *P *\< 0.001). Multivariable logistic regression model showed that WHR was significantly associated with an increased odds ratio of high RT (*P *= 0.009).

**Conclusions**: High WHR was associated with an increased risk of high RT in subjects with newly diagnosed diabetes. The data suggest that individuals with high WHR may have increased renal glucose resorption. Longitudinal studies are needed to confirm the result of this study.
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**H. Aziz, R. Nuruddin, N. Mohammed, I. Azam and M. Rasheed**
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Hyperglycemia in pregnancy (HIP) may lead to programming of certain brain loci and altered neurodevelopment. HIP is considered as high risk as fetal and neonatal complications and congenital malformations are directly related to poor glycemic control throughout pregnancy. Neurodevelopmental outcomes are closely linked to the developing brain which can be assessed in early years of live using different assessment tools. Clinical observations alone are often inadequate to detect subtle neurodevelopmental delays, and these delays are unrecognized by the time child enters the school. Purpose:

To determine association between hyperglycemia in pregnancy and neurodevelopment of infants and children using Ages and Stages Questionnaires.

**Methods**: Participants were HIP mothers (Type II & Gestational) and their infants aged 4 to 36 months. HIP exposure was determined from antenatal records of Aga Khan Hospital Karachi. Neurodevelopmental assessment of 155 children was performed in 5 domains (Communication, Gross Motor, Fine Motor, Problem Solving, and Personal‐Social) using Ages & Stages Questionnaire and overall health assessment by using Multiple Indicator Cluster Surveys Questionnaire.

**Results**: Mean age of mothers in HIP group was 32.62 (SD=5.13) and of non‐HIP group was 29.28 (SD=4.94) years. Mean age of child assessed for neurodevelopmental scores in HIP group was 16.22 (SD=10.08), and for children in non HIP group was 18.75 (SD=9.25) months. One‐fourth 18 (25.00%) in HIP, and almost one‐third 30 (36.14%) in the non HIP group were attending either day care or pre‐school. In HIP group (*n *= 72), aggregate neurodevelopmental scores were significantly lower 214.72 (SD=41.94) compared to in non‐HIP group \[235.96 (SD=42.73) (p value 0.002)\]. Other impaired domains were gross motor (p value 0.001), personal social (p value \<0.001), and communication (p value 0.019). After adjustment for relevant maternal and child factors, HIP was associated with altered aggregate neurodevelopment (β‐coeff −26.65, 95% CI: −41.09,−12.20), communication (β‐coeff −6.19, 95% CI: −10.62, −1.75), gross motor (β‐coeff −7.69, 95% CI:‐11.80, −3.57), and personal social (β‐coeff −6.73, 95% CI:‐10.99, −2.47) domains.

**Conclusion**: HIP is associated with altered neurodevelopment in infants and children independent of maternal and child characteristics. We recommend that children born to mothers with hyperglycemia should undergo routine neurodevelopmental assessment during preschool age.
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**Background and Aims**

The prevalence of early‐onset type 2 diabetes (T2DM) is increasing rapidly worldwide. Previous studies showed that patients with early‐onset T2DM had a higher risk of vascular complications as compared to later‐onset T2DM counterparts. We aim to profile clinical and cardio‐ metabolic risk factors in patients with early‐onset T2DM to identify potential intervention strategies and treatment gaps for prevention of vascular complications in this subpopulation. Participants: A total of 2057 T2DM participants were enrolled in SMART2D cohort (N = 2057) between 2011 and 2014. T2DM onset (diagnosis) age was 46 + /‐ 12 years old in the cohort. To identify modifiable risk factors in early stage of disease, only participants with duration of diabetes shorter than 10 years were included in the current study. Early‐onset T2DM was defined as diabetes diagnosis age between 18 and 35 years old (N = 107). Those with T2DM onset age within 1 SD of the cohort (35‐ 58 years old) were taken as controls (N = 884).

**Results**: Participants with early‐onset T2DM were more likely to be current smokers (16.8% versus 9.2%, *P *= 0.02). Despite 20 years younger, their BMI, waist circumference, HOMA‐IR, aspartate transaminase, alanine transaminase and C‐reactive protein levels were all significantly higher as compared to later‐onset controls. Notably, participants with early‐onset T2DM had a poorer glycaemic control (HbA1c 9.5 + /‐ 3.0 versus 7.9 + /‐ 2.5%, *P *\< 0.001). They also had a lower HDL, higher triacylglycerol and higher LDL cholesterol levels but were less likely on statin treatment (66.4% versus 77.5%, *P *= 0.02). Remarkably, their age‐adjusted pulse wave velocity (PWV), an established marker of subclinical macro‐vascular damage, was 0.7 m/s (95% CI 0.2‐ 1.3, *P *= 0.01) higher than their later‐onset counterparts.

**Conclusions**: Patients with early‐onset T2DM carry greater burden of obesity and insulin resistance. Their cardio‐metabolic risk factors including hyperglycaemia and dyslipidemia are less adequately controlled as compared to those with later‐ onset T2DM. Given that they have already demonstrated subclinical macrovascular injury, aggressive global vascular risk‐factors reduction, that is, intensive lipids and glycaemic control, smoking cessation and weight management (including gastro‐intestinal metabolic surgery) may be warrantied.
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Background: Type 2 diabetes (DM) is a rapid surging chronic disease throughout the world, which is closely associated with obesity. Diabetic patients had higher risk of developing diabetic retinopathy (DR), which can cause visual impairment and blindness.

**Aims**: To find out the prevalence of obesity (defined by body mass index \[BMI\] and waist circumference \[WC\]) in type 2 diabetic patients in Hong Kong public primary care setting, and to assess the association between obesity and DR.

**Method**: Patients' demographic factors, physical measurement, laboratory tests were collected. The prevalence of obesity, as defined by BMI and WC, in type 2 diabetic patients, was identified. The association of BMI and WC with DR were assessed using multivariable logistic regression model adjusting for risk factors.

**Results**: Among the total 14,129 diabetic patients, the prevalence of general obesity was 54.0% (*n *= 7623) and central obesity was 73.6%(*n *= 10,399). In multivariable models, BMI was inversely associated with the presence of DR when analysed as continuous variables. (Odds ratio\[OR\], 0.97;95% CI, 0.95--0.99). When BMI was analysed as categories, obesity patients (BMI≥25 kg/m2) were associated with lower odds of DR. (Odds ratio\[OR\],0.86;95% CI, 0.75--0.99). No statistical significant association was found between WC and DR when WC was analysed as continuous or categorical variables. (*P *\> 0.05).

**Conclusion**: This study showed a high prevalence of general and central obesity in type 2 diabetic patients in Hong Kong public primary care setting. General obese diabetic patients were less likely to have diabetic retinopathy. And central obesity was not associated with the presence of diabetic retinopathy.
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**S. Liu^1^, J.‐J. Liu^1^, R. L. Gurung^1^, C. Chan^1^, R. W. Choo^2^, S. L. Wee^2^ and S. C. Lim^3,4^**

^1^Clinical Research Unit, Khoo Teck Puat Hospital, Singapore, Singapore, ^2^Geriatric Education and Research Institute, Singapore, Singapore, ^3^Diabetes Centre, Khoo Teck Puat Hospital, Singapore, Singapore, ^4^Saw Swee Hock School of Public Heath, Singapore, Singapore

**Background**: Mortality rate in people with type 2 diabetes (T2DM) is 2‐fold higher than those without diabetes. While CVD death has been considered as the main contributor to premature mortality in people with T2DM, attributable risks of deaths from other causes vary significantly in different populations. Information on specific causes of mortality in South East Asia is still scarce. Singapore as a microcosm of Asia with three ethnicities, that is, Chinese, Malay and South Asian provides a good representation to study cause‐specific mortality in multiethnic South East Asians with T2DM. Aim: We aim to study cause‐specific mortality and the associated risk factors in South East Asians with T2DM in a multi‐ethnic cohort.

**Method**: 2061 individuals with T2DM (Chinese 63%, Malay 20% and South Asian 17%) were recruited from a regional hospital in Singapore between March 2004 and December 2015. The cohort was followed for an average of 5.5 (SD 2.9) years. Mortality events and the specific causes were ascertained by linkage with Singapore Birth and Death Registry. Multivariable Cox proportional hazard regression models were fitted to study potential risk factors associated with the specific causes of mortality.

**Result**: In a total of 10,909 patient‐years follow‐up, 365 participants were deceased in which 158 (44%) was attributed to CVD. Malays (hazard ratio HR 1.7; 95%CI 1.1--2.6) and South Asian (HR 1.8; 95%CI 1.1--2.9) had higher risk of CVD mortality as compared with Chinese. Among non‐CVD deaths, 60 (17%) was attributable to renal disease, 62 (17%) infection, 49 (14%) cancers and 36 (8%) due to other causes. The presence of diabetic kidney disease was a strong independent predictor for deaths caused by CVD, renal disease and infection. Remarkably, HbA1c level independently predicted the risk of all specific causes of mortality.

**Conclusion**: Mortality is mainly attributable to CVD, followed by renal disease, infection and cancer in South East Asians with T2DM. Whilst living in the same community, specific causes of mortality may vary among ethnic groups. Our study reinforces the importance of glycaemic control and prevention of diabetic kidney disease in preventing premature mortality in Asians with T2DM.
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Harmonics of radial pulse could be risk factors for renal function loss in patients with type 2 diabetes {#jdi12939-sec-0173}
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**K.‐M. Liao^1^, Y.‐C. Chen^1^, S.‐H. Wang^2^, G.‐C. Wang^3^ and C.‐W. Chang ^4^**

^1^Division of Endocrinology & Metabolism of Zhongxiao Branch of Taipei City Hospital, Taipei, Taiwan, ROC, ^2^Biophysics Laboratory, Institute of Physics, Academia Sinica, Taipei, Taiwan, ROC, ^3^JinMu Health Technology, Taipei, Taiwan, ROC, ^4^Graduate Institute of Biomedical Electronics and Bioinformatics, National Taiwan University, Taipei, Taiwan, ROC

Background: Renal function loss is the sign of diabetic nephropathy and the risk of adverse renal events. The earlier detection of renal function decline can lead to earlier intensive treatment, which will result in slowing the progression to end‐stage renal disease (ESRD). Aim: The aim of the study was to examine whether the spectrum characteristic of the radial pressure wave is associated with the tradition index of renal function, including albumin‐creatinine ratio (ACR) and estimated glomerular filtration rate (eGFR), in patients with Type 2 diabetes.

**Method**: Radial pressure wave was measured by a piezoresistive sensor in 1956 (Male: 1167, Female: 789) Type 2 diabetic patients recruited from the Division of Endocrinology & Metabolism of Zhongxiao Branch of Taipei City Hospital. For each patient, spectrum analysis of radial pressure wave was calculated and transformed into harmonics of amplitude (Cn), Phase (Pn), and variations of harmonic amplitudes (Cn_CV). Different level of renal function loss according to ACR and eGFR were examined.

**Results**: The means of C1, C4_CV of radial pulse increased along with the increment of ACR, from normal (C1:0.97 ± 0.13, C4_CV: 8.6%±6.8%) through microalbuminuria (C1:0.98 ± 0.13, C4_CV: 9.3%±8.0%) to macroalbuminuria (C1:0.99 ± 0.14, *P *\< 0.1; C4_CV: 9.3%±8.0%, *P *\< 0.05), whereas P2 decreased with the increment of ACR (*P *\< 0.05). The means of C4_CV of radial pulse increased when the EGFR decreased from stage 1(C4_CV: 8.3%±6.5%) to stage 5(C4_CV: 13.5%±7.3%, *P *\< 0.01) of renal disease, whereas P2 decreased when EGFR decreased (*P *\< 0.01). Discussion: The preliminary findings from the study identified the C1, C4_CV, and P2 of radial pressure wave could be a set of important predictors for early diagnosis of renal function loss in type 2 diabetic patients. The greater values of C1 and C4_CV and the lower values of P2 may indicate the need for further investigation of renal function.
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Purpose: Hyperglycemia is a well‐established risk factor for kidney complications in Type 2 Diabetes Mellitus (T2DM). However, the contribution of Hemoglobin A1c (HbA1c) patterns over time to kidney disease progression is unclear. We aim to characterize HbA1c trajectories and examine their associations with progression of albuminuria.

**Methods**: This was a prospective cohort study on 481 patients with T2DM and no macroalbuminuria (urinary albumin‐to‐creatinine ratio (uACR) \<300 mg/g) at baseline attending a Diabetes Centre in 2002--2017. Group‐based trajectory modeling was used to identify HbA1c trajectories. Cox proportional hazards models were used to examine association between the trajectories and albuminuria progression defined as worsening uACR categories-- normoalbuminuria (uACR\<30 mg/g) to microalbuminuria (uACR=30--299 mg/g), normoalbuminuria to macroalbuminuria or microalbuminuria to macroalbuminuria. We adjusted for demographics, T2DM duration, use of insulin, use of renin‐angiotensin system antagonist, blood pressure, HbA1c, estimated glomerular filtration rate and uACR at baseline.

**Results**: We identified 4 HbA1c trajectories: 'low stable', 'moderate stable', 'moderate‐increasing' and 'high‐decreasing'. Over a mean period of 7.2 ± 3.0 years, albuminuria progression occurred in 37.8% of patients, distributed across the 4 groups as 45.6%, 39.6%, 6.6% and 8.2% respectively. When stratified by albuminuria status at baseline, the moderate‐increasing group had a significantly higher hazards of progression compared to the low stable group with HR 3.06 (95%CI 1.28--7.28; *P *= 0.012) among those with baseline normoalbuminuria in the fully adjusted model. There was no such association in those with baseline microalbuminuria. There was no association between the other HbA1c trajectories and albuminuria progression in the fully adjusted model.

**Conclusions**: The deteriorating HbA1c trend independently predicted albuminuria progression in patients with normoalbuminuria at baseline, suggesting that it is an early marker of renal deterioration. Intensive management may be needed to alter HbA1c trend in reducing this risk. Sustained good glycemic control confers the lowest risk for renal progression.
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**H. Su, J. Tang, X. Ma, X. He, L. Ying, Y. Wang, Y. Bao, J. Zhou and W. Jia**

Shanghai Jiao Tong University Affiliated Sixth People\'s Hospital, Shanghai, China

Background: In previous epidemiological screening in China, glycated albumin (GA) was mostly detected during the fasting state. This strict restriction causes some problems with diabetes screening. It is unclear if GA could help to improve the efficiency of screening for diabetes for subjects who are not in the fasting state.

**Methods**: The present study analyzed the differences between fasting and postload (30, 60, 120, and 180 min) GA levels. Agreement statistical analysis methods included mountain plot and Bland‐Altman difference plots. The receiver operating characteristic curve was plotted to assess the power of the postload GA as a screening test to discriminate diabetes patients from non‐diabetes patients.

**Results**: A total of 691 participants were enrolled in present study. The AREs for postload GA levels at all measurement time points (30, 60, 120, and 180 min postload) were all within 5%. The Bland‐Altman difference plots revealed that 95.4%, 94.8%, 93.6%, and 93.9% of data points were within the limits of agreement for each time point. The receiver operating characteristic curve showed that the area under the curve (AUC) for baseline GA and postload GA for every time point were 0.822 (95% CI 0.791--0.849), 0.821 (95% CI 0.790--0.848), 0.833 (95% CI 0.803--0.860), 0.840 (95% CI 0.811--0.867), and 0.840 (95% CI 0.810--0.867), with sensitivities of 67.5%, 68.1%, 69.3%, 71.6%, and 69.3%, respectively. There was no difference between the baseline and postload GA levels in either AUC or sensitivity (all *P *\> 0.05).

**Conclusions**: Postload serum GA levels were in good agreement with those at baseline, and thus, it may be reasonable to employ non‐fasting measurements of GA levels for diabetes screening.
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**L. Xu**

Shanghai Jiao‐tong University Affiliated Sixth People\'s Hospital, Shanghai, China

**Objective**: Diabetic foot ulcers developed with the deviation of plantar pressure. It is difficult to interpret the alteration of plantar pressure under different conditions of type 2 diabetes mellitus. This work aims to gain a better insight into the variation of plantar pressure as diabetes duration prolongs. Subjects and

**Methods**: Plantar pressure was examined among 1,196 participants with or without T2DM. Subjects with normal glucose tolerance (NGT) and impaired glucose tolerance (IGT) were taken as control groups, patients with T2DM were divided into 5 groups according to their diabetes duration as less than 2 years, 2--5 years, 5--10 years, 10--15 years, and over 15 years. The clinical characteristics, plantar peak pressure and pressure‐time integral (PTI) were compared among the seven groups, and the associated factors of the peak pressure and pressure‐time integral were analyzed.

**Results**: Peak pressure exhibited an uptrend at hallux within 5 years of diabetes duration, followed by a remarkable downward slope with further progression of diabetes (trend analysis, *P *\< 0.05). And an unevenly distribution of peak pressure at other locations was displayed, but ultimately lower than the two control groups (*P *\< 0.05). No obvious trend was noted for PTI among patients with different diabetes durations. However, patients with diabetes more than 10 years manifested a significantly sharp increase of PTI at metatarsus (11.63Ns/cm2, *P *\< 0.05) and heel (14.12Ns/cm2, *P *\< 0.05) than hallux (8.76Ns/cm2). Besides, a fluctuation of PTI at hallux and midfoot was detected, broadly flat when compared with the controls. In stepwise multiple regression analysis, the variation of plantar pressure was independently associated with age, BMI and VPT (*P *\< 0.05).

**Conclusions**: Longer diabetes duration indicates a decreased peak pressure for hallux, and suggests an increased pressure‐time integral for metatarsus and heel among diabetes more than 10 years. The reduced pressure of hallux is supposed to transfer to the metatarsus. Age, BMI and VPT were distinct risk factors for abnormal plantar pressure.
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**M. Liu**

Chinese PLA General Hospital, Beijing, China

Purpose: This study aimed to assess the impact of baseline bilirubin (TBiL) on the incidence of diabetic retinopathy (DR) based on five‐year\'s cohort study consisted of 5323 Chinese male diabetic patients. Design: Cohort study.

**Methods**: Both baseline TBiL and follow‐up changes were measured. Cox proportional risk model was used to calculate relative risk (RR) of TBiL for DR risk. Main outcome: DR incidence. The association was calculated as RRs.

**Results**: During the follow‐up period, there were 269 new DR cases. The incidence of five‐year follow‐up was 5.1% (95% CI: 4.5% ˜ 5.6%). The TBiL level in diabetic retina were lower than those of diabetic retina (12.51 + 1.20 mol / L and 13.11 + 1.32 Mu mol / L, *P *= 0.033).And more interestingly, along with the quintiles of baseline TBiL, there showed a U‐shaped curve with DR incidence. And the RRs were 0.928(95%CI: 0.646--1.331), 0.544(95%CI: 0.365--0.811), 0.913(95%CI: 0.629--1.324), 1.035(95%CI: 0.725--1.479) for the second, third, fourth and fifth quintiles of baseline TBiL levels, respectively, compared with the first quintile. For follow‐up TBiL changes, after adjusted for related co‐variables and baseline TBiL levels (as continuous variable) in the model, the RRs for DR were 1.411(95%CI: 1.081--1.842) for those who had decreased TBiL level and 0.858(95%CI:0.770--0.947) for those who had increased TBiL level during follow‐up. And this association was more prominent among those with lower baseline TBiL level.

**Conclusions**: Serum TBiL had a U‐shaped relationship with DR incidence, which was independent of control status of diabetes and other related co‐variates.
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**X. Ma, X. He, L. Ying, Y. Shen, H. Su, J. Peng, Y. Wang, Y. Bao, J. Zhou and W. Jia**

Department of Endocrinology and Metabolism, Shanghai Clinical Center for Diabetes, Shanghai Diabetes Institute, Shanghai Jiao Tong University Affiliated Sixth People\'s Hospital, Shanghai, China

Background: In subjects who present a first fasting plasma glucose (FPG1) ≥ 7.0 mmol/L without classic symptoms of diabetes, diagnosis of diabetes will likely be missed without an additional oral glucose tolerance test (OGTT) in the Chinese population. Recent studies have shown that glycated albumin (GA) has advantages in reflecting postprandial hyperglycemia. Therefore, the present study evaluated whether additional measurement of GA could reduce the rate of missed diagnosis of diabetes.

**Methods**: A total of 1287 participants (711 men, 576 women) with a FPG1 ≥ 7.0 mmol/L without classic symptoms of diabetes were enrolled and underwent a 75‐g OGTT. Serum GA was measured by a liquid enzyme method. Diabetes was diagnosed based on the 2010 American Diabetes Association (ADA) criteria.

**Results**: A total of 992 (77.08%) participants were diagnosed diabetes by OGTT and glycated hemoglobin A1c (HbA1c). The diagnostic validity of 2‐h postload plasma glucose (2hPG) was superior to other glycemic index (the diagnostic sensitivity of 2hPG, HbA1c, the second FPG (FPG2) was 87.50%, 73.99%, 63.21%, respectively). Without 2hPG after OGTT, repeat testing of FPG2 alone would result in missed diagnosis of 36.79% of diabetic participants, whereas testing FPG2 with HbA1c was associated with a missed diagnosis rate of 14.31%. While using the combined criteria of FPG2 ≥ 7.0 mmol/L and/or HbA1c ≥ 6.5% and/or GA ≥ 17.1%, the rate of missed diagnosis was merely 9.48%. That is, the rate of missed diagnosis was reduced by 33.75% with the addition of GA measurement. The k value reflecting the consistency of diagnosis between the FPG2 and/or HbA1c and/or GA criteria and the 2010 ADA criteria was 0.788.

**Conclusion**: For subjects with FPG1 ≥ 7.0 mmol/L without classic symptoms of diabetes, additional measurement of GA can help to prevent missed diagnosis of diabetes in Chinese population.
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Chinese PLA General Hospital, Beijing, China

Background: This study aimed to examine the relationship between 25‐hydroxyvitamin D (25OHD) and chronic kidney disease (CKD) incidence.

**Methods**: All the elderly who had participated both in the 2011--2012 survey and 2014 survey in the Chinese Longitudinal Healthy Longevity Survey (CLHLS), and have biomarker data were included in the analysis. We studied those without CKD with complete data at 2011--2012 wave (*n *= 1037, mean age 81.64 years; 48.9% were female). Serum 25‐Hydroxyvitamin D was assessed at baseline. Cox proportional risk model was used to evaluate associations between serum 25‐Hydroxyvitamin D and CKD (including both albuminuria and impaired eGFR) incidence after adjusted for potential confounders.

**Results**: During the follow‐up years, 255 incident cases of CKD were diagnosed. Those who developed CKD had relatively lower serum 25OHD (mean 37.63 vs.51.36 nmol/L, *P *\< 0.001) compared with those who remained free of CKD. Each 1 nmol/L increase in 25OHD was associated with 3.2% reduced risk of CKD (HR=0.968, 95%CI: 0.961--0.974) after adjusted for related covariates. The HRs of each 1 nmol/L increase in 25‐OHD for albuminuria and impaired eGFR were 0.957(95%CI: 0.947--0.967) and 0.973(95%CI: 0.965--0.980), respectively. When use the classifications (sufficiency, insufficiency, deficiency) or quintiles of baseline 25(OH)D levels in the Cox model, the corresponding HRs showed an increasing trend along with the decrease of baseline 25(OH)D levels (p for trend \<0.001)

**Conclusions**: Higher 25OHD levels were inversely and independently associated with CKD incidence among Chinese elderly. The trend for the observed linear relationship b was most pronounced among the lowest quintile.
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Introduction: Diabetes mellitus (DM) is a group of metabolic diseases which if not controlled can cause life‐threatening complications. We hypothesize IGF‐1 and Magnesium level can be used as a Biomarker for early diagnosing cardiovascular complications in the Type 2 Diabetic patients in the rural region of Vidarbha, Maharashtra, India. Methods and Materials: Fasting (FBS) and Postmeal blood sugar (PMBG), total cholesterol (TC), high‐density lipoprotein (HDL), low‐density lipoprotein (LDL), very low‐density lipoprotein (VLDL), triglyceride (TG), Insulin‐Like Growth Factor‐1 (IGF‐1) and Magnesium (Mg) levels were evaluated. Total sample size was 80, which was divided into 40 study group with type 2 DM who attended the Medicine OPD of AVBRH Hospital and 40 age‐ and sex‐matched healthy controls included in the study. Statistical Analysis: Software used in the analysis was SPSS 22.0 version and GraphPad Prism 6.0 version.

**Results**: Serum lipid profile showed higher mean of TC, TG and LDL in patients with diabetes.

IGF‐1 and Magnesium concentrations were significantly lower in subjects with diabetes as compared to the controls (*P *\< 0.0001). In multivariate regression analysis between IGF‐1 and other parameters, we have found only Magnesium correlates with IGF‐1 level and it is statistically significant.

**Conclusions**: Early detection of IGF‐1, Magnesium and lipid profile abnormalities can minimize the risk for the development of cardiovascular complications in the type II diabetic patients. IGF‐1 and Magnesium levels may be a useful marker for identifying subjects at risk of cardiovascular disease in the Type 2 diabetics.
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Introduction: Diabetes mellitus (DM) is a group of metabolic diseases which if not controlled can cause life threatening complications.

**Aim & Objectives**

Our objectives were to evaluate Fasting (FBG) and Postmeal blood sugar (PMBS), Glycated hemoglobin (HbA1c), Vitamin D, Calcium and Magnesium levels in the type II diabetics. Methods and Materials: Fasting (FBS) and Postmeal blood sugar (PMBG), Glycated haemoglobin (HbA1c), Calcium (Ca), Vitamin D (Vit D) and Magnesium (Mg) levels were evaluated. Study design was case control study. Total sample size was 60, 30 study group with known history of type II DM and 30 age, sex matched healthy controls included in the study. Study period was from September 2017 to February 2018. Statistical analysis was done by SPSS 17 version.

**Results**: Mean value for Magnesium, Calcium and Vitamin D level in the study group were 1.06 + 0.25, 7.91 + 0.76, 15.56 + 2.01 respectively, which were significantly lower in the cases as compared to the controls (*P *\< 0.0001). HbA1c has negative correlation with Magnesium and Vitamin D.

**Conclusions**: Early detection of serum Magnesium, Calcium and Vitamin D level abnormalities can minimize the risk for development of osteoporosis in the type II diabetics.
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Aim: Studies on a novel point‐of‐care device for nerve conduction study called DPNCheck have been limited to Westerners. We aimed to clarify Japanese normal limits of nerve action potential (Amp) and conduction velocity (CV) by DPNCheck (Investigation‐I), and validity of DPNCheck to identify diabetic symmetric sensorimotor polyneuropathy (DSPN) (Investigation‐II).

**Methods**: Investigation‐I: 463 non‐neuropathic Japanese subjects underwent DPNCheck examinations. Regression formulas calculating normal limits of Amp and CV (Japanese regression formulas: JRF) were determined by quantile regression and then compared with those of US subjects (USRF). Investigation‐II: In 92 Japanese diabetic patients, 'Probable DSPN' was diagnosed and nerve conduction abnormalities (NCA1: one or more abnormalities and NCA2: two abnormalities in Amp and CV) were determined. Validity of NCAs to identify 'Probable DSPN' was evaluated by determining sensitivity, specificity, reproducibility (kappa‐coefficient) and area under the curve (AUC) of receiver operating characteristic (ROC) curves.

**Results**: Investigation‐I: JRF was different from USRF, and normal limits by JRF were higher than that of USRF. Prevalence of Amp abnormality calculated by JRF was significantly higher than that of USRF. Investigation‐II: Sensitivity, specificity and reproducibility of NCA1 and NCA2 judged from JRF were 85%, 86%, 0.57 and 43%, 100%, 0.56, respectively. These values of JRF were higher than those of USRF. AUC of JRF (0.89) was larger than USRF (0.82).

**Conclusions**: Significant difference in normal limits of nerve conduction parameters by DPNCheck between Japanese and US subjects was suggested. Validity to identify DSPN of NCAs may improve by changing judgement criteria from USRF to JRF.
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**C. Siriniyomchai**
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This action research aimed to study the process of community for Promoting to Foot Care Behaviors Among Diabetic Persons with Peripheral Neuropathy at Chiang Mai was used as follows: 1) finding the problems by conducting a meeting to inform the problem of follow‐up Foot Care Behaviors Among Diabetic Persons with Peripheral Neuropathy 2) Reflect the importance of Foot Care Behaviors Among Diabetic Persons with Peripheral Neuropathy. 3) selecting appropriate healthcare activities by arranging meetings to inform the participants about patients' and care takers' needs, and encourage them to share about the problem resolution before collaboratively developing a work plan; and 4) maintaining the effective practices by evaluation and appreciation support. The study was supported by Thai Health Promotion Foundation Fund. Thirty participants were purposively selected to the study. Observations, focus‐group interviews, and group discussions were used to collect data. The research tools used were semi‐structural observations form, focus‐group interviewing guide, and group discussion guide. Data were analyzed using content analysis and classification conclusion. Descriptive statistics were used to analyze quantitative data consisting of frequency and percentage. The research results Models for Promoting Foot Care Behaviors Among Diabetic Persons with Peripheral Neuropathy, and could reduce a rate of foot ulcer from 40% to 0.68%. Also, this could promote community collaboration and build an innovative network of Diabetic patient care in the community.
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**Background**: Diabetes is a known complication of iron overload in thalassemia patients. Prevalence of diabetes and impaired glucose tolerance in transfusion‐dependent thalassemia (TdT) patients varies between 0.05% and 17%. Anaemia, insulin secretory defects, insulin resistance and collagen deposition secondary to increased activity of iron dependent protocollagen proline hydroxylase enzyme with disturbed microcirculation in pancreas are some of the pathophysiology of diabetes in these patients. Unfortunately, HbA1C is not helpful as defect in globin chain in thalassemia affects the results. Alternative markers correlate better to blood sugar as it is albumin‐bound. This study intends to establish the relationship of blood sugar and fructosamine level in TdT. Material and

**Methods**: Thirty‐three patients attending thalassemia clinic with iron overload were randomized. Three patients were excluded (1 ESRF, 1 pregnant, 1 refused to participate). Bloods for fasting blood sugar, 2‐h post prandial glucose, ferritin, and serum fructosamine were taken at recruitment. Diagnosis of DM is based on serum FBS≥7 mmol/L or 2HPP≥11.1 mmol/L. Data are recorded and analysed with SPSS version 22.0. Linear regression was used to determine the association between blood sugar (FBS and 2HPP) and serum fructosamine.

**Results**: Prevalence of diabetes in this cohort is 11.5%. Mean FBS among DM patients is 7.80 mmol/L vs. non‐DM 4.74 mmol/L (*P *= 0.27). The mean 2HPP glucose among DM patients is 9.75 mmol/L vs. 5.45 mmol/L for non‐DM (*P *\< 0.0001). No significant difference observed in ferritin level among DM and non‐DM (5173 μg/L vs. 4867 μg/L). There is significant linear relationship for serum fructosamine and FBS (B = 0.847, *P *\< 0.0001). Similarly, fructosamine and 2HPP glucose also demonstrated linear relationship (B = 0.605, *P *= 0.003). No linear relationship can be demonstrated between ferritin and FBS or 2HPP. Discussion: Serum fructosamine appears to be a good predictor of blood sugar in thalassemia patients. Ferritin is a marker for iron overload; however, usage for blood sugar prediction is unreliable. The wide variability can be due to treatment with iron chelation. Future study with bigger samples is helpful to improve the precision of the test.
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**Y. W. Chow, S. S. Wong and F. Alberto**

Department of Medicine, Pantai Hospital Ayer Keroh, Melaka, Malaysia

Purpose of the study: Hypoglycaemia is the most common adverse effect of diabetes treatment and is associated with considerable health consequences. Unfortunately, very few real‐world studies have been conducted to assess the incidence of diabetes‐related hypoglycaemia. This is the first reported real‐world hypoglycaemia prevalence in patients with Type 2 diabetes mellitus (T2DM) in Malaysia.

**Method**: A 12 month non‐interventional prospective study using self‐assessment questionnaires and patient diaries in outpatient patients aged ≥ 18 years with T2DM was carried out. Primary endpoint was the percentage of patients experiencing ≥ 1 hypoglycaemic event during the prospective observational period. Predictive factors contributing to hypoglycaemia risk were explored.

**Results**: A total of 82 patients completed the questionnaires. 48.8% of patients were male. Mean age was 57.9 ± 12.3 years. Duration of diabetes was 13.3 ± 12.3 years with mean Hba1c of 10.1 ± 1.8%. Charlson Comorbidity Index (CCI) was 2.1 ± 1.0. Mean estimated GFR was 45.5 ± 25.7 ml/min/1.73 m^2^ with 51.2% of patients having Chronic Kidney Disease (CKD) Stage 3 and above. There were a total of 53 hypoglycaemic episodes during this observational period. Prevalence of hypoglycaemia was 34.2% (Capillary blood sugar (CBS) \< 3.9 mmol/L) with 8.5% reporting a CBS level of \< 3.0 mmol/L. One patient had neuroglycopaenic symptoms. All patients with hypoglycaemia were on either sulphonylureas or insulin therapy. Hypoglycaemia was more common in patients with premix or basal bolus insulin regimen (*P *= 0.03). There were no significant differences in age, sex, number or choice of oral anti diabetic agents, CCI, CKD stage, duration of diabetes, mean Hba1c with risk of hypoglycaemia.

**Conclusion**: This real‐world study revealed a high prevalence of hypoglycaemia among outpatient adults with T2DM. In‐depth studies are required to ascertain strategies to mitigate this common complication.
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**Y. W. Chow^1^, S. S. Wong^1^, F. Alberto^1^, S. Azfaniza^1^, P. T. Ng^2^, P. J. Ang^2^, L. C. Gan^2^ and N. Ahmad^2^**

^1^ Department of Medicine, Pantai Hospital Ayer Keroh, Melaka, Malaysia, , ^2^ AMS Haemodialysis Centre, Melaka, Malaysia

Introduction: Glucose levels will often be lower during haemodialysis (HD) it is common practice to advice patients to omit or reduce their anti‐diabetic drugs doses on HD days to avoid hypoglycaemia.

**Methods**: This is a prospective study involving 48 Type 2 Diabetes Mellitus patients with End Stage Renal Disease undergoing HD (18--85 years of age undergoing at least 3 months of regular HD). Primary endpoint was hypoglycaemic events. Predictors of hypoglycaemia and effect of HD on glycaemic variability were analysed. Blood glucose (BG) samples were obtained before the start (T0) and during the 2nd (T2) and 4th hour (T4) of HD for 3 consecutive HD sessions.

**Results**: A total of 48 patients completed the study. Mean age was 64.4 ± 9.3 years. Duration of diabetes was 16.0 ± 7.8 years. Mean Hba1c was 7.8 ± 1.7%. ADA used included sulphonylureas (12.5%), dipeptidyl‐peptidase‐4 (DPP4) inhibitors (12.5%), DPP4 inhibitors and premix insulin (4.2%), premix insulin (52.1%) and basal bolus insulin (14.6%). 10.4% took full dose and 4.2% halved the dose of anti diabetic agents (ADA) before HD. At T0, 58.9%, 24.8% and 16.3% of patients had BG of \<12.0 mmol/L, 12.0--20.0 mmol/L and \>20.0 mmol/L, respectively. BG decreased during dialysis from 12.8 ± 7.1 mmol/L (T0) to 8.6 ± 3.2 mmol/L (T2) and 8.1 ± 3.0 mmol/L (T4). 5 hypoglycaemic episodes were observed (3.5%) which included 2 episodes of severe hypoglycaemia (BG \<2.0 mmol/L). Patients with hypoglycaemia had a significant lower BG at T0 (8.5 ± 4.9 vs. 13.1 ± 7.2 mmol/L, *P *= 0.009), T2 (6.7 ± 4.8 vs. 8.9 ± 2.9 mmol/L, *P *= 0.01) and T4 (6.6 ± 3.0 vs. 8.3 ± 2.7 mmol/L, *P *= 0.02). There was no significant difference in age, duration of T2DM, choice of ADA, serum albumin, serum phosphate and Hba1c and the risk of hypoglycaemia.

**Conclusion**: Hypoglycaemia is uncommon during HD. Advice given to HD patients to omit or dose reduce their ADA should therefore not be generalised. Dosing of ADA should be individualised.

PP‐100 {#jdi12939-sec-0200}
======

Achieved LDL cholesterol level is more important than Intensity of Statin in Patients with Diabetes {#jdi12939-sec-0201}
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**S. Suh^1^, J. S. Moon^2^, S. S. Kim^3^ and S. O. Song^4^**

^1^Division of Endocrinology, Dong‐A University College of Medicine, Busan, Republic Korea, ^2^Division of Endocrinology, Yeungnam University College of Medicine, Daegu, Republic Korea, ^3^Division of Endocrinology and Metabolism, Pusan National University College of Medicine, Busan, Republic Korea, ^4^Division of Endocrinology and Metabolism, National Health Insurance Service Ilsan Hospital, Goyang, Republic Korea

We sought to determine cardiovascular disease (CVD) development and mortality by intensity of statin therapy for patients with diabetes without previous CVD using the Korean National Health Insurance Service (NHIS) database. The National Health Insurance Service‐Health Screening Cohort (NHIS‐HEALS) is a cohort of participants who participated in health screening programs provided by the NHIS in the Republic of Korea. We used database from 2009 to 2010 as a baseline because results on LDL‐C levels were available from that period (*n *= 350,041). We excluded people who had been diagnosed with cardiovascular disease, cerebrovascular disease. In addition, patients with malignant tumor were excluded from the analysis before study entry with preexisting diagnosis of other cancer (C code, C00‐C97) according to the International Classification of Diseases, 10th edition (ICD‐10). Use of statin was defined as receipt of a prescription for the drug during the study period. We only included the patients who were prescribed with the same dose and kind of statin for more than 180 days consecutively at least during the last 1 year before LDL cholesterol measurement in 2009 and 2010. Among them, patients who had been hospitalized with a principal discharge diagnosis of CVD were identified by using the ICD‐10 codes. A total of 13,348 participants at baseline from 2009 were followed up to 2013 for a mean duration of 305.6 ± 63.9 days. The mean age of all participants at baseline was 62.1 ± 8.7 years and 43.9% of whom were male. In that time, a total of 265 deaths occurred, with 23 (8.7%) resulting from CVD. In addition, these subjects had 222 hospitalizations for primary CVD (86 coronary artery disease and 136 strokes). The results indicated no significant difference in the incidence of death and CVD according to intensity of statin compared with the reference group. In patients with diabetes, there were no significant differences in the incidence of death or CVD among those in the high‐intensity statin group compared with low‐intensity statin group. High‐intensity statins are not superior in preventing CVD for Korean patients with diabetes without previous CVD.
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**Y.‐c. Chen^1^, S.‐H. Wang^2^, G.‐C. Wang^3^, C.‐W. Chang ^2,\ 4^ and K.‐m. Liao^1^**

^1^Division of Endocrinology & Metabolism of Zhongxiao Branch of Taipei City Hospital, Taipei, Taiwan, ROC, ^2^Mii‐Ann Technology, Taipei, Taiwan, ROC, ^3^JinMu Health Technology, Taipei, Taiwan, ROC, ^4^Graduate Institute of Biomedical Electronics and Bioinformatics, National Taiwan University, Taipei, Taiwan, ROC

Background: Coronary artery disease (CAD) and silent CAD (SCAD) contributed to a considerable proportion of morbidity and mortality in patients with type 2 diabetes mellitus (T2DM). Early predictors of CAD and SCAD can lead to an early diagnosis and medical treatment to prevent adverse cardiovascular events. Aim: To evaluate glycated haemoglobin (Hba1c), ankle‐brachial index (ABI), and radial pulse spectrum as predictors of CAD in patients with T2DM.

**Method**: A total of 118 diabetic patients at high risk of CAD were enrolled. All subjects underwent invasive coronary angiography (ICA) and radial pressure wave measurement. Spectrum analysis of radial pressure wave was calculated and transformed into Fourier series coefficients Cn and Pn.

**Results**: The risks of CAD (OR:3.16, *P *\< 0.01) and SCAD (OR: 3.43, *P *\< 0.05) increase with C2. Multivariable regression analysis showed that CAD was associated with C2 (*P *= 0.04), male gender (*P *\< 0.01), and ankle‐brachial index (ABI, *P *\< 0.01) and that SCAD was associated with C2 (*P *= 0.02), P5 (*P *= 0.05), male gender (*P *\< 0.01), duration of diabetes (*P *= 0.07), BMI (*P *\< 0.03), and Hba1c (*P *\< 0.01). Furthermore, the coronary artery disease score (CADS), combining Hba1c, ABI, and pulse information (C2, C3, and C5), presented excellent diagnostic performance in identifying patients with CAD (OR:6.14, *P *\< 0.01) and with SCAD (OR:21.3, *P *\< 0.01). The area under ROC curves for CADS were 0.69 in identifying CAD and were 0.82 in identifying SCAD, respectively. Discussion: In patients with T2DM, male gender and C2 were independently associated both with the extent of CAD and with the extent of SCAD in multivariable regression analysis. Odds ratio reflected that C2 could be an important marker for the risk stratification of SCAD. Furthermore, new score CADS could significantly improve diagnostic performance of SCAD compared with the traditional risk score ASCVD.
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**J. Chen^1^ and Z. Sun^1^**

^1^Medical School, Southeast University, Nanjing, China, ^2^Department of Endocrinology, Zhongda Hospital, Institute of Diabetes, Medical School, Southeast University, Nanjing, China

**Background and Aims**

When plasma glucose levels exceed the maximal resorptive capacity of the renal tubules, glycosuria occurs. Several studies demonstrate that renal glucose reabsorption is increased in patients with type 2 diabetes mellitus. Our aim was to analyze the association between serum insulin level and urine glucose excretion (UGE) in subjects with newly diagnosed diabetes (NDD) and evaluate the effect of insulin on glucose uptake in tubular epithelial cells. Materials and

**Methods**: The present study included 303 subjects with NDD after confirming their oral glucose tolerance test, and divided them into two groups, 53 subjects with low UGE (LUGE), and 250 with high UGE (HUGE). Urine samples were collected within 2 h of oral glucose loading for the quantitative measurement of glucose. Fasting serum insulin was measured. Homeostatic model assessment of insulin resistance (HOMA‐IR) was assessed. Multivariable logistic regression analysis was used to identify factors influencing UGE. Furthermore, human renal tubular epithelial cells (HK‐2) were directly treated with insulin, glucose uptake was assessed, sodium glucose cotransporter 2 (SGLT2) was measured by western blot and quantitative real‐time polymerase chain reaction.

**Results**: In a multivariable logistic regression model including age, sex, BMI, plasma glucose, total cholesterol, triglycerides, high‐density lipoprotein cholesterol and low‐density lipoprotein cholesterol, increasing serum insulin level were significantly associated with a decreased risk of HUGE (*P *= 0.004). An independent inverse relationship was also observed between the HOMA‐IR and the risk of HUGE. In addition, insulin significantly stimulated glucose uptake and upregulated the expression of SGLT2 in HK‐2 cells.

**Conclusion**: Increased serum insulin level was associated with a decreased risk of HUGE in subjects with NDD, partly due to enhanced glucose reabsorption via upregulation of SGLT2. A better understanding of the role of insulin in glucose reabsorption may lead to new insights into the development of diabetes.
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**M. Kusunoki^1^, Y. Natsume^1^, Y. Oshida^1^ and T. Miyata^2^**

^1^Nagoya University, Nagoya, Japan, ^2^Sanno Medical Center, Tokyo, Japan

Sodium glucose co‐transporter‐2 (SGLT2) inhibitors have been reported to improve the blood lipid levels in type 2 diabetic patients, and reduction of insulin secretion by SGLT2 inhibitors has been pointed out as the mechanism underlying this effect. In this study, we divided 201 patients with type 2 diabetes mellitus (age 54 ± 11 years, disease duration 11 ± 7 years) into the (1) \<50 years age group (*n *= 78, 58 males and 20 females), (2) 50--64 years age group (*n *= 84, 64 males and 20 females) and (3) ≥65 years age group (*n *= 39, 22 males and 17 females). The patients received 2.5 mg luseogliflozin, 5 mg dapagliflozin, 20 mg tofogliflozin, 10 mg empagliflozin or 100 mg canagliflozin once daily, and the body weight, body mass index (BMI), hemoglobin A1c (HbA1c) levels, visceral fat area, fasting blood glucose levels, fasting plasma insulin levels, homeostasis model assessment of insulin resistance (HOMA‐IR), serum lipid levels and serum adiponectin levels were compared between before and after 6 months of treatment. The results revealed improvement of the body weight and BMI in all 3 groups. The HbA1c, fasting blood glucose, serum insulin and HOMA‐IR improved significantly in the groups (1) and (2), but only tended to decrease, with the difference not reaching statistical significance, in the group (3). In contrast, the visceral fat area improved in all the groups. The serum high‐density lipoprotein (HDL) cholesterol did not improve in the group (1), but improved in the groups (2) and (3), with the degree of improvement being higher in group (3) than in the group (2). The serum low‐density lipoprotein (LDL) cholesterol/HDL cholesterol ratio showed no improvement in the groups (1) and (2), but improved in the group (3).
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**S.‐W. Kim, E. Jeon, J.‐H. Lee and H.‐S. Shon**

Department of Internal Medicine, Daegu Catholic University Medical Center, Daegu, South Korea

**Objective**: Abnormality of thyroid function is well known to be associated with an impaired glucose homeostasis. However, there is little information about the effect of thyroid hormone levels within physiological range on carbohydrate metabolism. This study aimed to evaluate whether free thyroxine influences to serum glucose levels and the prevalence of prediabetes in euthyroid subjects.

**Methods**: The present study was a cross‐sectional survey based on the Korea National Health and Nutrition Examination Survey (KNHANES) from 2013 to 2015. Among male participants over 20 years of age, we excluded subjects with abnormal results of free thyroxine (FT4) and thyrotropin, criteria of diabetes in fasting blood glucose (FBG) and hemoglobin A1c (HbA1c), past history of thyroid disease and diabetes, and incomplete data. Finally, we enrolled 2399 men on euthyroid state and non‐diabetes. The associations of serum FT4 levels with FBG and HbA1c levels were examined using analysis of covariance. We also evaluate the association between FT4 and the prevalence of prediabetes and metabolic syndrome by using multivariate logistic analysis.

**Results**: Higher FT4 levels were observed in participants with prediabetes compared with those of participants without prediabetes, but TSH levels did not. We stratified the study population into tertiles according to FT4 levels. After adjusting confounding factors, HbA1c levels significantly decreased according to FT4 tertiles, whereas FBG was not associated with FT4 tertiles (HbA1c, *P *\< 0.01 in T3 than in T1; FBG, *P *= 0.489 in T3 than in T1). The prevalence of high‐risk HbA1c (defined as HbA1c 5.7--6.4%) was significantly higher in the tertile with lowest level of FT4 (*P *\< 0.01, OR=1.495; 95% CI, 1.178 -- 1.896). The prevalence of metabolic syndrome was significantly higher in the lowest FT4 tertile (*P *\< 0.01, OR 1.678; 95% CI, 1.242 -- 2.268).

**Conclusion**: Subjects with low normal FT4 had high HbA1c levels and the prevalence of high‐risk HbA1c and metabolic syndrome. These results suggest that low FT4 levels are a potential risk factor for prediabetes and metabolic syndrome even though thyroid function is within normal range. It seems that the screening of prediabetes in subjects with low normal FT4 is required to use HbA1c.
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**C. P. Ooi^1^ and M. N. Mustafa^2^**

^1^Endocrine Unit, Department of Medicine, Universiti Putra Malaysia, Serdang, Malaysia, ^2^Endocrine Unit, Department of Medicine, Pusat Perubatan Universiti Kebangsaan Malaysia, Cheras, Malaysia

**Background**: The goals of diabetes care are to safely reduce the risk of short‐ and long‐term complications and improve health‐related quality of life. Intensive glycaemic control may reduce microvascular and macrovascular complications but carries a recognised hypoglycaemia burden. The seriousness of this acute complication has led to the development of the Hypoglycaemia Blueprint in 2016 to guide the addressing the issue at all level of the healthcare system. Since care for patients with type 2 diabetes mellitus is continuously evolving with new evidence, appropriate performance measures beyond glycosylated haemoglobin to monitor the improvement of care are advocated. We aimed to assess the current quality measures used in diabetes care.

**Method**: We identified studies through PubMed (1st January 2017 to 31st May 2018). We included the studies assessing quality improvement targeting health systems, healthcare professionals, or patients to improve management of adult outpatients with diabetes. Findings: We reviewed 21 studies. A total of 12 studies had quality improvement initiatives targeting the different level of the health systems, four studies at healthcare professionals and five at patients' level. Interventions were dependent on the objectives of the quality improvement initiative. Glycosylated haemoglobin (A1c) was the most common targeted outcome (16/21) followed by cardiovascular risk markers (7/21). Few sets included indicators of lifestyle counseling, patient experiences, healthcare structure or access to healthcare providers. Hypoglycaemia was the primary outcome in only two studies.

**Conclusion**: The sets of quality indicators are diverse in number, content, and definitions. This diversity reflects a lack of uniformity in the concept of diabetes care quality, hinders the interpretation of and comparison between quality assessments. Quality improvement efforts were focussed predominantly on glycaemic control. Considering the substantial morbidity, associated mortality, and decreased the quality of life caused by hypoglycemia, its prevention should be an integral part of patient‐centered diabetes care along with A1c control. Adding hypoglycaemia as a counterbalancing measure of quality in any quality improvement, effort is important to optimize and individualize glycemic control fully.
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**Y. C. Kuan^1^, P. L. Chan^1^, X. T. Tiong^2^ and F. Tan^1^**
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**Introduction**: Hypoglycemia in hospitalized diabetic patients has been associated with increased morbidity and mortality. Local compliance to guideline for hypoglycemia management is unknown. We implemented the Hypoglycemia Action Sheet (HAS) in our hospital to guide doctors in managing hypoglycemia. Ward staff were instructed to fill in HAS for any episode of inpatient hypoglycemia identified.

Objective

To assess compliance in using HAS in management of inpatient hypoglycemia.

**Patients and Method**

We reviewed HAS forms collected from medical wards from Nov 2017 to May 2018 and assessed compliance to the following process measures---A: administration of simple sugar (SS), B: rechecking of capillary blood glucose (CBG) in 15 min, C: administration of complex carbohydrate (CC) after hypoglycemia correction, D: action plan to prevent recurrent hypoglycemia which include identification of cause, instruction for subsequent CBG monitoring, adjustment of antidiabetic medication and drip or feeding, and hypoglycemia education to patient or carer.

**Results**: Total of 88 HAS were used for 68 unique patients. Fourteen (20.6%) patients had recurrent hypoglycemia. The highest number of recurrent episodes in a patient is 6. Lowest CBG was 1.7 mmol/L. A: SS was given in 65.9% of cases. CC was given without SS in 34.1%.

B: Only 28.4% had a CBG recheck in 15 min, 27.1% recheck in 15--30 min. Seven had no CBG recheck at all. The longest time to recheck was 120 min. C: Only 5 (5.7%) were given CC after correction of hypoglycaemia with SS. D: Although doctors attempt to complete this step in 52 (59.0%) of the forms reviewed, no cause was determined in 46.6%. Out of the 52 forms, only 13 (14.8%) gave plan for adjustment of antidiabetic medication, 17 (19.3%) for monitoring of CBG and 15 (17.0%) for modification of drip or feeding. In only 1 case was hypoglycemia education reinforced.

**Conclusion**: Compliance to HAS is poor, with majority omitting step B and C. There is lack of action plan to prevent recurrent hypoglycemia (20.6% in the study) with poor attempt to identify causes or adjust antidiabetic medication or nutritional intake. Patient education was hardly performed. Measures to improve HAS implementation are needed.
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**J. Shin**

Yonsei University, Wonju College of Medicine, Wonju‐si, South Korea

Non‐alcoholic fatty liver disease (NAFLD) is known to be associated with cardiovascular disease (CVD). However, the association between liver fibrosis and CVD in individuals with NAFLD is not fully documented. In this study, we investigated whether liver fibrosis was associated with arterial stiffness in Korean patients with type 2 diabetes. A total of 466 subjects were enrolled in this study. NAFLD was diagnosed in 389 of total subjects using NAFLD liver fat score (cut‐off≥‐1.413). A severity of liver fibrosis was determined by Fib‐4 index. The presence of liver fibrosis was defined as a cut‐off value of Fib‐4 ≥ 1.45 because individuals with advanced fibrosis were only 3. Arterial stiffness was measured by brachial‐ankle pulse wave velocity (ba‐PWV). We defined the high ba‐PWV as ≥ the 66.7th percentile of maximal ba‐PWV. Appendicular skeletal muscle mass (ASM) was measured using dual‐energy X‐ray absorptiometry. Sarcopenia was identified as an ASM /body mass index (BMI) \<0.789 in men and \<0.521 in women. Liver fibrosis was documented in 118 of 389 patients (30.3%). Patients with liver fibrosis were more likely to be elderly and current smoking, have higher values of aspartate aminotransferase (AST), ba‐PWV, and prevalence of sarcopenia, and have lower values of BMI, waist circumference (WC), and estimated glomerular filtration rate (eGFR) compared to those without fibrosis. The prevalence of high ba‐PWV was higher in subjects with liver fibrosis than those without liver fibrosis (26.2% vs. 50.0%, *P *\< 0.001). Fib‐4 index was positively correlated with ba‐PWV (Pearson\'s correlation coefficient = 0.257, *P *\< 0.001). The odds ratio (OR) of the presence of liver fibrosis for high ba‐PWV was 2.82 (95% C.I = 1.79--4.42, *P *\< 0.001). After further adjusting for gender, BMI, WC, AST, eGFR, and sarcopenia, the relationship remained significant.

We found that liver fibrosis was associated with ba‐PWV in Koran patients with type 2 diabetes independent of gender, BMI, WC, eGFR, and sarcopenia. Further studies were needed to find out underlying causal relationship.
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**Aims**: Our study examined whether osteocalcin contributed to identifying carotid intima‐media thickness (C‐IMT) over the atherosclerotic cardiovascular disease (ASCVD) risk score.

**Methods**: We recruited 618 middle‐aged and elderly men from communities in Shanghai. Serum osteocalcin levels were determined using an electrochemiluminescence immunoassay. C‐IMT was measured by ultrasonography. C‐IMT values above the 75th percentile of the study population (≥ 0.77 mm) were considered elevated.

**Results**: The study included 245 men with low ASCVD risk and 373 men with moderate‐to‐high ASCVD risk. Serum osteocalcin levels were lower in the moderate‐to‐high risk versus low‐risk men (*P *= 0.042). Multivariate stepwise regression analysis showed that body mass index and glycated hemoglobin were predictors for reduced osteocalcin levels (both *P *\< 0.001). Among all subjects, the proportion with an elevated C‐IMT was higher in the low‐osteocalcin group than in the high‐osteocalcin group (*P *= 0.042), and the significance of this result was greater when considering only subjects with a moderate‐to‐high ASCVD risk (*P *= 0.011). The recognition rate of elevated C‐IMT was superior with both low osteocalcin and moderate‐to‐high ASCVD risk versus either parameter alone (*P *\< 0.001 and *P *= 0.015, respectively). Osteocalcin was independently and inversely associated with elevated C‐IMT after adjusting for the 10‐year ASCVD risk score (*P *= 0.004). The negative relationship remained statistically significant in subjects with a moderate‐to‐high ASCVD risk in particular (β  =  --0.104, *P *= 0.044).

**Conclusions**: In middle‐aged and elderly men, serum osteocalcin levels strengthen identifying subclinical atherosclerosis over ASCVD risk score, especially among subjects with a moderate‐to‐high ASCVD risk.

PP‐109 {#jdi12939-sec-0218}
======

Risk factors for periodontitis in diabetic patients with or without metabolic syndrome {#jdi12939-sec-0219}
--------------------------------------------------------------------------------------

**S. Hong^1^ and S. Park^2^**
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Introduction: This study examined prevalence and risk factors for periodontitis in representative samples of Korean adults, with and without diabetes mellitus (DM). Additionally, we did subgroup analysis in diabetic patients with or without metabolic syndrome.

**Methods**: This study analyzed data from the 2010 to 2015 the Korea National Health and Nutrition Examination Survey (KNHANES) in South Korea which include periodontitis and the parameter of metabolic syndrome (MS). MS was defined according to the National Cholesterol Education Program Adult Treatment Panel III (NCEP‐ATP III). Among data collected from 22,737 respondents, propensity score matching of sex and age was applied and the data were analyzed.

**Results**: A total of 4,706 subjects after propensity score matching of sex and age, including 2,060 with periodontitis and 2,646 without periodontitis, were analyzed. Periodontitis was present in 43.7% of the total.

When compared to the no periodontitis group, the periodontitis group was older (63 ± 10.4), had more males (58.8%), a lower number of subjects who had higher education (56.3%), low‐income families (32.1%), higher fasting plasma glucose (122.3 ± 39.2), and higher waist circumference (86 ± 9). Moreover, systolic blood pressure, body mass index, and plasma triglycerides were higher in the periodontitis group, whereas HDL cholesterol was lower (*P *\< 0.001). Many of those in the periodontitis group had hypertension (57.6%) and diabetes mellitus (55.5%), and metabolic syndrome (46.3%). It showed the same tendency more like in diabetes group. In multiple regression analysis of the risk factors for periodontitis, the risk increased when MS was present (OR 1.12, 95% CI 1.01˜1.24), when diabetes mellitus was present (OR 1.19, 95% CI 1.02˜1.38), and when there was history of smoking (OR 1.63, 95% CI 1.46˜1.81). In particular, for MS in DM, the risk of periodontitis increased as the number of MS components became higher (*P *\< 0.001).

**Conclusion**: The risk of periodontitis was 1.19‐fold higher when DM was present than when it was not. The risk was particularly higher when MS was also present and in those that smoke. Moreover, the risk of periodontitis also increased as number of the MS components became higher. Thus, diabetic patients with periodontitis may benefit when they control metabolic parameters.
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Fibroblast growth factor 21 (FGF21), an endocrine factor, is a distinctive member of the FGF family. In mice, administration of FGF21 has pharmacological effects including body weight loss, lipid‐lowering effect, increase in insulin sensitivity, and increase in glucose uptake of adipose tissue and these effects of FGF21 may be derived, at least partially, from increased secretion of adiponectin from adipocytes. However, pathophysiological roles of FGF21 in glucose intolerance and dyslipidemia in human remain unknown. In this study, the relationship among FGF21, adiponectin, glucose metabolism, and lipid metabolism was analyzed in 75 individuals with various degrees of glucose tolerance. The 75‐g OGTT was carried out in 75 Japanese individuals not taking diabetes medications \[age: 65 ± 11 (mean±SD); BMI: 24.9 ± 3.8 (mean±SD)\]. Participants were classified into normal glucose tolerance (NGT), impaired glucose tolerance (IGT) and diabetes mellitus (DM) groups (each group: *n *= 25). Matsuda Index (MI) as an index of insulin sensitivity was calculated. Fasting serum levels of FGF21 and adiponectin were assayed by ELISA. Normally distributed loge‐transformed (ln‐) values were used for regression analysis in some cases. In simple regression analysis, ln‐FGF21 was positively correlated with ln‐triglyceride (TG) (r = 0.456), but not with ln‐MI, glucose level 120 min after glucose load (G120) or ln‐adiponectin. On the other hand, ln‐adiponectin was correlated with age (r = 0.427), sex (r = −0.407), G120 (r = −0.291), ln‐MI (r = 0.445), and ln‐TG (r = −0. 460). In stepwise multiple regression analysis, ln‐TG was independently predicted by ln‐adiponectin (β=‐0.380) and ln‐FGF21 (β=0.352), accounting for 32.9% (*P *\< 0.0001) of the variability of the dependent variable. In conclusion, the relationship between insulin sensitivity and FGF21 has remained obscure in individuals including glucose‐intolerant subjects. Triglyceride levels were found to be independently predicted by adiponectin and FGF21. In human, the hypothesis that FGF21 acts via adiponectin is not supported and a lipid‐regulation mechanism of FGF21, independent of adiponectin, is suggested in human in pathophysiological conditions.

PP‐111 {#jdi12939-sec-0222}
======

Statin for primary prevention in adults aged 75 years and older: A nationwide population‐based case‐control study in Korea {#jdi12939-sec-0223}
--------------------------------------------------------------------------------------------------------------------------

**J. E. Jun^1^, I.‐J. Cho^1^, K. Han^2^, I.‐K. Jeong^1^, K. J. Ahn^1^, H. Y. Chung^1^ and Y.‐C. Hwang^1^**
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Background: The evidence is inadequate to establish statin treatment for primary prevention in the elderly. This study aimed to evaluate whether statins are beneficial for primary prevention of cardiovascular disease (CVD) and all‐cause death in adults aged ≥75 years.

**Methods**: A nationwide, nested case‐control study was conducted with data from the National Health Insurance Service‐National Sample Cohort 2002--2015 in Korea. Individuals who developed cardiovascular disease \[CVD\] including myocardial infarction \[MI\], stroke, or death from all‐causes were matched to controls based on duration of the follow‐up, age, and sex at index date. The statin administration data in both groups were retrospectively collected from the index date to before 5 years. Odds ratios (ORs) and 95% confidence intervals (CIs) for composite and individual outcomes associated with statin treatment were estimated by multivariable logistic regression analyses.

**Results**: In total, 11,017 cases were matched to 55,085 control subjects. Current use of statin was significantly associated with a reduced risk of composite outcomes (AOR 0.77; 95% CI 0.71--0.84), compared with non‐users. For individual components of the composite, current use of statin also reduced the risks of stroke (adjusted OR \[AOR\] 0.74; 95% CI 0.61--0.89) and all‐cause death (AOR 0.73; 95% CI 0.66--0.81), but not with MI. However, former use of statin had no effect on primary prevention for CVD or all‐cause death. There were significant decreasing trends in the incidence of composite outcomes and individual stroke or all‐cause death with longer duration of statin treatment (p for trend \<0.001).

**Conclusions**: Current statin treatment has a beneficial effect on primary prevention for composite outcomes and individual outcome of stroke or all‐cause death in the elderly aged ≥ 75 years.
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**K. Sugai^1^, J. Sasaki^2^, Y. Wada^1^, N. Shimizu^1^, T. Ishikawa^2^, K. Yanagi^2^, A. Tanaka^1^ and M. Odawara^2^**

^1^Toda Chuo General Hospital General Internal Medicine, Toda City/ Honcho, Japan, ^2^Tokyo Medical University, Shinjuku‐ku/ Nishi‐shinjuku, Japan

**Objective**: Diabetes Mellitus (DM) is associated with urinary tract infection (UTI) and lower urinary tract dysfunction. However, very few studies have focused on bacteriuria in DM patients. There has been concern that SGLT2 inhibitors (SGLT2i) have the possibility to increase the risk of UTI. We investigated the association of age, sex, treatment, lower urinary tract symptoms and dysfunction, HbA1c and the other blood biochemistry to bacteriuria.

**Method**: We evaluated outpatients who had DM and bacteriuria in urinary sediment examination. From all subjects, a urine culture and self‐administered questionnaires containing OAB symptom score (OABSS), International Prostate symptom score (I‐PSS), International Consultation on Incontinence Questionnaire Short Form (ICIQ‐SF) were obtained. Those with positive urine culture were assessed by abdominal ultrasonography to inspect residual urine and prostate volume.

**Result**: Sixty three subjects were identified for evaluation. The mean age of the subjects was 63.7 years, 69.8% were women, mean BMI was 25.9, mean HbA1c was 6.9%, and 14(22.2%) received SGLT2i. Thirty one subjects were positive in a urine culture. Subjects with positive urine culture were older age, lower BMI, higher ACE/ARB use, higher urgency score in OABSS, and larger number of subjects with lower urinary tract dysfunction compared to those with negative urine culture. No significant differences in blood biochemistry were detected between the two groups. Thirty‐three subjects had lower urinary tract dysfunction or UTI including OAB, acute cystitis, benign prostatic hyperplasia and neurogenic bladder. They were older age, lower BMI, higher ACE/ARB use, higher score (IPSS, OABSS and ICIQ‐SF), and larger number of subjects with positive urine culture compared to those without the dysfunction. Though residual urine was more often detected among SGLT2i users, no significant differences were observed in terms of positive urine culture and lower urinary tract dysfunction between SGLT2i users and non‐users.

**Conclusions**: Aged patients with DM and bacteriuria appear to be associated with UTI and lower urinary dysfunction. In the patients with bacteriuria, questionnaires are useful tools for screening of lower urinary tract dysfunction. The anxiety about UTI caused by SGLT2i is little and we can use it safety in DM patients with bacteriuria.
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^1^Far Eastern Memorial Hospital, New Taipri City, Taiwan, ^2^Catholic Mercy Hospital, Hsinchu County, Taiwan, ^3^National Cheng Kung University, Tainan, Taiwan

Background: Population‐based study comparing age‐ and sex‐specific risk estimates of heart failure (HF) between patients with type 2 diabetes and non‐diabetic subjects was scarce. Additionally, the risks of HF in association with type 2 diabetes in people with various coronary heart diseases (CHD) have rarely been investigated. This study used a nationally representative cohort selected from Taiwan\'s National Health Insurance (NHI) to clarify the above‐mentioned research questions.

**Methods**: Totally 873,498 patients with type 2 diabetes identified from ambulatory care claims (2002--03) and 884,712 age, sex, and calendar year matched controls from the registry of NHI beneficiaries were linked to inpatient claims (2002--11) to identify the possible admissions for HF (ICD‐9‐CM: 428). With Cox proportional hazard regression model, we compared the relative hazards of HF in relation to type 2 diabetes according to various age‐ and sex‐stratifications. We also compared the relative hazard of HF between type 2 diabetes and controls with and without past histories of various CHD and coronary revascularization procedures.

**Results**: Compared with the control subjects, type 2 diabetes was significantly associated with increased hazard of HF \[adjusted hazard ratio (aHR): 2.61, 95% confidence interval (CI) 2.58--2.64\]. In both genders, the type 2 diabetes aged \<45 years had the highest increased hazard of HF, with an aHR of 6.85 (95% CI 6.03--7.78) and 14.72 (95% CI 11.68--18.54) for men and women, respectively. Compared with the control subjects without any CHD, type 2 diabetes patients without prior CHD had increased hazards of HF (aHR: 2.57, 95% CI 2.52--2.62 in men and aHR:2.73, 95% CI 2.69--2.78 in women), which were lower than those found in men but comparable to women control subjects with previous histories acute myocardial infarction.

**Conclusions**: Type 2 diabetes may increase the risk of HF in both men and women, as well as in all age groups especially in young patients. People with type 2 diabetes without CHD posed a greater increase in risks of HF than control subjects with CHD.
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**X. Huang^1^, X. Zhang^1^, Y. Li^2^ and L. Ji^1^**

^1^Peking University People\'s Hospital, Beijing, China, ^2^Beijing Pinggu Hospital, Beijing, China

Background: To investigate the epidemiological characteristics of thyroid dysfunction (TD) in different status of glucose tolerance in a community‐based Chinese population and to understand the association between thyroid function and glucose metabolism.

**Methods**: A community‐based population study of metabolic disease was conducted from June 2013 to September 2014 in Beijing in north of China, 6583 inhabitants aged 26--76 years were selected using multi‐stage stratified random sampling process according to sex and age composition. Among 4002 residents answered the survey, 3986 subjects were legally included in this analysis. All subjects undertook the tests of serum thyroid function and thyroid‐associated antibody. 75 g‐oral glucose tolerance test (OGTT) was used to determine the status of glucose tolerance. Chi‐square test was used to compare the differences on the prevalence of TD among different glucose tolerance status. Multivariate logistic regression analysis was used to determine the impact of insulin resistance (IR) on thyroid function.

**Results**: The prevalence of type 2 diabetes (T2DM) and pre‐diabetes (Pre‐DM) was 18.59% and 26.79%, respectively, in this analyzed population. The overall prevalence of TD was 8.81%, with overt hyperthyroidism 0.38%, subclinical hyperthyroidism 1.86%, overt hypothyroidism 0.70% and subclinical hypothyroidism 5.87%, respectively. The prevalence of TD increased with the deteriorate glucose tolerance (7.63% in NGT, 9.27% in Pre‐DM and 11.61% in T2DM), both in male and female. Subclinical hypothyroidism was more common especially in female. Each unit higher homeostasis model assessment of insulin resistance (HOMA‐IR) was associated with 7% higher likelihood of having subclinical hypothyroidism.

**Conclusion**: The co‐existence of TD in patients with T2DM and Pre‐DM were exceedingly high, which indicated that thyroid disease might be closely related with glucose metabolism.
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^1^Department of General Medicine, IPGME&R, Kolkata, India, ^2^Department of Endocrinology, NRS Medical College, Kolkata, India

Introduction: Mauriac syndrome is a rare complication of uncontrolled type 1 Diabetes Mellitus (T1DM). It is characterized by poor glycemic control, hepatomegaly, cushingoid features and delayed puberty. Since the introduction of longer acting insulin, cases of Mauriac syndrome are rarely reported. Case Report: A 15 year old girl,was referred for poor glycemic control .She was diagnosed as Type 1 Diabetes Mellitus two years ago following an episode of Diabetic ketoacidosis. Since then, she was on premixed insulin twice daily (42 units/day). However, due to poor compliance to therapy and ignorance about glucose monitoring, she had undergone frequent hospitalizations for titration of insulin dosage and schedule. Recently, she also complained of abdominal heaviness and a dull aching abdominal pain which is hampering her quality of life significantly. Other history was noncontributory except that she did not attained menarche yet. On examination, she was significantly short for his age (133 cm, \<3rd percentile),weighed 33kgs (\<3rd percentile) with a BMI of 19.88 kg/m2. She had moon facies but no icterus, oedema or goiter. Her vital signs were normal and her SMR was B3P1. Abdominal examination revealed massive firm nontender hepatomegaly with a liver span of 18 cms. However, there was no free fluid in the abdomen or any evidence of hepatocellular failure. She had lipohypertrophy at the injection sites. Other systemic examination including ophthalmoscopy was normal. Investigations revealed a normal complete hemogram, renal and thyroid function tests. Liver function tests revealed elevated transaminases with preserved synthetic function. She had hyperlipidemia and coeliac screening was negative. Glycated hemoglobin (HbA1c) was 13%. Her IGF1 was decreased significantly and bone age was delayed. Imaging in the form of Ultrasound of abdomen confirmed massive hepatomegaly with increased hepatic parenchymal echogenicity. Liver biopsy revealed findings consistent with diffuse glycogen‐rich cytoplasm and glycogenated nuclei of hepatocytes without any steatosis, fibrosis or inflammation. A provisional diagnosis of Mauriac Syndrome was made. After starting her on basal bolus insulin regimen, in addition to achievement of glycemic optimization, her liver functions normalized and hepatomegaly decreased substantially.

**Conclusion**: The incidence of Mauriac syndrome is still quite common in the developing world. However, increased awareness and timely intervention is fundamental since most clinical features are reversible with improvement of glycemic control.
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**J. Xu^1^, D. Luo^2^, D. Yan^1^, M. Zhu^1^, H. Wang^1^, Z. Gu^1^, Z. Lin^1,2^, W. He^1^ and T. Yang^1^**

^1^The First Affiliated Hospital Of Nanjing Medical University, Department Of Endocrinology, Nanjing, China, ^2^Nanjing Medical University, School of Nursing, Nanjing, China

Background: Subcutaneous lipohypertrophy (LH) is a common skin‐related complication among insulin‐injecting patients, which disturbs regular insulin absorption and glycemic control. Examinations are currently made by inspection and palpation. Due to the lack of diagnostic criteria, the prevalence of LH ranges from 20 to 70%. B‐ultrasound was applied by several researches, but no consensus has been established.

**Methods**: The cross‐sectional design was used. A total of 124 diabetic patients who accepted insulin treatment at least one year were enrolled from diabetic clinic or ward in a Chinese Class 3 academic hospital. Each patient underwent both inspection, palpation and B‐ultrasound to find the existence of subcutaneous LH. Pearson\'s χ2 test or Fisher\'s exact test were used to compare the ability of B‐ultrasound and routine inspection in finding LH. Risk factors for lipohypertrophy were evaluated by stepwise logistic regression meanwhile.

**Results**: The average age of 124 patients was 25 years old, and 48.3% were male. Areas of subcutaneous lipohypertrophy were classified by B‐ultrasound as: a) Subcutaneous fat layer thickening, b) Hyperechogenic or Hyperechogenic area, and c) Hypoechogenic. The LH prevalence was 67.74% under B‐ultrasound scan and the figure dropped to 32.26% by inspection palpation (χ^2^ = 32.663, *P *\< 0.001). Results of stepwise logistic regression showed that needle reuse (odds ratios \[OR\]=0.062, *P *\< 0.001) and incorrect site rotation (odds ratios \[OR\]=0.089, *P *\< 0.05) are associated with LH incidence.

**Conclusions**: B‐ultrasound can be used to identify the existence of subcutaneous LH in clinical practice. Compared to routine inspection and palpation and, it could identify LH earlier or accurately, which may help to give promise in preventing and dealing with the problem.
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Purpose: To clarify the relevance between smoking and diabetic retinopathy in patients with type 1 and type 2 diabetes mellitus.

**Methods**: Published evidence was searched in MEDLINE and EMBASE from the databases began until Feb. 2017. Studies evaluating the association between smoking and diabetic retinopathy or evaluating the risk factors of diabetic retinopathy including smoking were included.

**Results**: Totally 73 studies were identified, among which 19 studies included type 1 diabetes patients and 56 studies included type 2 diabetes patients. In type 1 diabetes, compare with non‐smokers, the risk of diabetic retinopathy significantly increased in smokers (risk ratio (RR) =1.23, 95%CI 1.14, 1.33, *P *\< 0.001), and the risk of proliferative diabetic retinopathy also significantly increased in smokers (RR=1.48, 95%CI 1.20, 1.81, *P *\< 0.001). In type 2 diabetes, compare with non‐smokers, the risk of diabetic retinopathy significantly decreased in smokers (RR=0.92, 95%CI 0.86, 0.98, *P *= 0.02) and the risk of proliferative diabetic retinopathy also significantly decreased in smokers (RR=0.68, 95%CI 0.61, 0.74, *P *\< 0.001).

**Conclusions**: Compare with non‐smokers, the risk of diabetic retinopathy significantly increased in smokers in type 1 diabetes while significantly decreased in smokers in type 2 diabetes. However, this result did not change the importance of smoking cessation for public health.
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**A. Nakamura^1^, H. Miyoshi^1^, S. Ukawa^1^, K. Nakamura^1^, T. Nakagawa^2^, Y. Terauchi^3^, A. Tamakoshi^1^ and T. Atsumi^1^**

^1^Hokkaido University, Sapporo, Japan, ^2^The Hokkaido Centre for Family Medicine, Sapporo, Japan, ^3^Yokohama City University, Yokohama, Japan

**Aims**: In the current population‐based study, we investigated the association between glucose tolerance and beta cell function, as evaluated by five estimation methods, in Japanese participants. Materials and

**Methods**: In this cross‐sectional study, we analyzed data from residents in one rural community of Hokkaido, Japan. Study participants, aged between 35 and 79 years, provided fasting blood samples. Of these participants, those who were using insulin and/or oral hypoglycemic agents were excluded. Beta cell function was estimated by homeostasis model assessment of beta‐cell function (HOMA‐□%), C‐peptide (CPR) index, proinsulin (PI), proinsulin‐to‐C‐peptide ratio (PI/CPR) and proinsulin‐to‐insulin ratio (PI/I). Data on all five parameters were normalized by natural logarithmic transformation.

**Results**: A total of 489 participants (263 females) were divided into three groups: a normal glucose tolerance (NGT) group (*n *= 328), a prediabetes (PDM) group (*n *= 113), and a diabetes (DM) group (*n *= 48). Using one‐way analysis of variance, HOMA‐□% in the DM group, but not in the PDM group, was significantly lower than in the NGT group. There was no significant difference in CPR index among the three groups. PI/I in the DM group, but not in the PDM group, was significantly higher than in the NGT group. Moreover, PI and PI/CPR in the DM group were significantly higher than in the PDM and NGT group; these parameters in the PDM group were significantly higher than in the NGT group. Using analysis of covariance incorporating, similar results were observed for PI and PI/CPR, after adjustment for age and sex. However, when the participants were classified into non‐obese (body mass index (BMI) \< 25 kg/m^2^) and obese groups (BMI ≥ 25 kg/m^2^), PI, but not PI/CPR, in the PDM group was significantly higher than in the NGT group in the obese group.

**Conclusion**: Our data demonstrated that fasting PI levels were increased in prediabetic participants in a Japanese population‐based study. Considering the potential deterioration of beta cell function in prediabetes, PI could serve as an early marker of beta cell dysfunction, especially in obese individuals. Further prospective observational studies are needed to elucidate the causal association.
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**Aims**: Optimal blood pressure (BP) for prevention of cardiovascular (CV) events in people with diabetes mellitus remains. We investigated the association of BP with the risk of CV outcomes in people with diabetes.

**Methods**: A retrospective cohort study was conducted on 48,438 people with diabetes and no prior diagnosis of cardiovascular disease using the Korean National Health Insurance Service‐National Health Screening Cohort from 2002 to 2003 and was followed until 2013. Baseline systolic BP (SBP) and diastolic BP (DBP) were divided into 10‐mmHg, respectively. The major adverse cardiovascular event (MACE) endpoint was the composite of CV death, MI, or stroke. Using Cox models, adjusted hazard ratio (HR) was calculated by SBP and DBP for MACE.

**Results**: During a median of 10.7 years of follow‐up, there was 7360 MACE. Baseline SBP ≥140 mmHg was associated with a higher MACE risk compared with SBP 120--129 mmHg. (140--149 mmHg, HR 1.11, 95% confidence interval \[CI\] 1.03--1.20; 150--159 mmHg, HR 1.16, 95% CI 1.07--1.26; ≥160 mmHg, HR 1.22, 95% CI 1.13--1.33). However, SBP 130--139 mmHg had no statistically significant association with MACE (HR 1.05, 95% CI 0.97--1.13). A baseline DBP ≥90 mmHg was associated with the a higher MACE risk compared with DBP 70--79 mmHg (90--99 mmHg, HR 1.12; 95% CI, 1.04--1.20; 100--109 mmHg, HR 1.15; 95% CI, 1.05--1.27; 110--119 mmHg, HR 1.24; 95% CI, 1.06--1.45; ≥120 mmHg, HR 1.43, 95% CI, 1.12--1.83). However, DBP 80--89 mmHg had no statistically significant association with MACE (adjusted HR 1.00; 95% CI 0.94--1.07).

**Conclusions**: Our findings support a SBP/DBP treatment target of 140/90 mmHg in people with diabetes. A randomized control trial is still needed to confirm these findings.
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Aim: Prospective clinical studies have shown strong relationships between time‐averaged mean levels of glycemia as reflected by HbA1c and diabetes complications. Additionally, recent epidemiological studies suggest visit‐to‐visit glucose and HbA1c variability, represented by coefficient of variation (HbA1c‐CV), are associated with cognitive decline. Our study aims to determine whether glycemic variability predicts the development of dementia, irrespective of baseline HbA1c and other traditional risk factors in a Chinese population.

**Methods**: A retrospective cohort study of 75,348 Chinese subjects with type 2 diabetes, aged 60 years or above, with no known dementia were included. All cases of incident dementia were identified by the commencement of pharmacotherapy during follow‐up. Demographics, comorbidity, metabolic parameters, and the use of other medications at baseline were considered as possible confounders. Intra‐individual mean and standard deviation (SD) of HbA1c, based on values obtained during the 5‐year period prior to recruitment, were calculated. The HbA1c‐CV was calculated as the ratio of SD and mean. The association between HbA1c variability and incident dementia were evaluated using multivariable Cox regression analysis.

**Results**: After a median follow‐up of 6 years, 1,424 (1.89%) subjects were commenced on dementia pharmacotherapy, with a crude incidence rate of 3.01/1,000 person‐years. Compared to the control group, subjects with incident dementia were older (76.5 + 6.7 years vs. 71.0 + 7.5); *P *\< 0.001, with a greater proportion of female gender (71.3% vs. 55.5); *P *\< 0.001, but had similar baseline HbA1c (7.21 + 1.24% vs. 7.26 + 1.17); *P *= 0.07. Of note, there was no significant difference in prevalence of hypertension, dyslipidemia, coronary artery disease. The index group had a higher prevalence of stroke and severe hypoglycemia episode, 11.0% vs. 8.8, *P *= 0.003 and 2.0% vs. 0.9, *P *\< 0.001, respectively. On multivariable Cox regression analysis, HbA1c‐CV significantly predicts the development of dementia, with an adjusted hazard ratio of 1.20 (95% confidence intervals: 1.03--1.40); *P *= 0.017 for the fourth tertile, independent of other traditional risk factors, and the history of stroke or severe hypoglycemia.

**Conclusion**: Glycemic variability, independent of traditional risk factors, predicts the development of cognitive decline in our Chinese cohort. Further studies should focus on whether improving glycemic stability can retard or ameliorate the cognitive decline in type 2 diabetes.
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Objectives Home blood pressure (HBP) control can reduce the risk of increased urinary albumin excretion (UAE) in patients with diabetes. We examined the association of isolated high home systolic blood pressure (IH‐HSBP) with the progression of diabetic nephropathy among patients with type 2 diabetes.

Methods In KAMOGAWA‐HBP study, 1414 patients with type 2 diabetes were recruited. We excluded patients without adequate HBP data, patients whose data regarding UAE were not available at the time of or two years after the HBP measurements, patients who were newly prescribed or stopped renin angiotensin system inhibitors during the two‐year follow‐up, and patients whose UAE at the time of study entry was greater than 30 mg/g Cr. Normal HBP was defined as HSBP \< 125 mmHg, and home diastolic blood pressure \<75 mmHg. The change from baseline stage of diabetic nephropathy, defined by level of UAE, to a higher stage in follow‐up was defined as progression of diabetic nephropathy. Results Patients had a median (interquartile range) age of 66.0 (60.0--72.0) years and hemoglobin A1C of 7.0 (6.6--7.7) % \[52.8 (48.3--60.6) mmol/mol\]. During the two‐year follow‐up period, 63 patients had progression of diabetic nephropathy. Compared to normal HBP, multivariable‐adjusted odds ratios (95% confidence intervals) for progression of diabetic nephropathy associated with IH‐HSBP was 2.11(1.07--4.14). Conclusion Among patients with type 2 diabetes, IH‐HSBP has the association with progression of diabetic nephropathy. These findings highlight the importance of treatment of HSBP in patients with type 2 diabetes in order to prevent the onset or progression of diabetic nephropathy in patients with type 2 diabetes.
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**Aim/Objective**

Methylcobalamin has long been used for treatment of peripheral neuropathy. This study aimed to examine the effect of Methylcobalamin in the treatment of diabetic mellitus peripheral neuropathy (DPN) by performing a meta‐analysis of all available relevant randomized controlled trials (RCTs).

**Methods**: Electronic database were searched for RCTs with methylcobalamin in DPN published in English and Chinese up to February 28, 2018. Studies without any type of control were excluded. A random or a fixed effect model was used to analyse outcomes which were expressed as risk ratios (RRs) or mean difference (MD). I^2^ statistic was used to assess heterogeneity.

**Results**: A total of 43 relevant RCTs were included. Methylcobalamin significantly improved the signs and symptoms of DPN (RR: 1.43, 95%CI: 1.31--1.56) and increased conduction velocities of Peroneal Nerve (sensory: SMD: 1.71, 95%CI: 1.28--2.15; motor: SMD: 1.09, 95%CI: 0.78--1.40) and Median Nerve (sensory: SMD: 1.01, 95%CI: 0.65--1.38; motor: SMD: 1.13, 95%CI: 0.28--1.97). Besides, methylcobalamin was superior to vitamin B agents in the improvement of the signs and symptoms of DPN (RR: 1.87, 95%CI: 1.58--2.21), or in the increase of conduction velocities of Peroneal Nerve (sensory: SMD: 0.73, 95%CI: 0.42--1.04; motor: SMD: 0.64, 95%CI: 0.35--0.93) and Median Nerve (sensory: SMD: 0.73, 95%CI: 0.54--0.92; motor: SMD: 0.66, 95%CI: 0.49--0.84).

**Conclusions**: Methylcobalamin is effective and better than vitamin B agents in DPN treatment. However, larger well‐designed studies are required to confirm this conclusion.
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Aim: In Japan, the prevalence of type 2 diabetes mellitus (T2DM) has been increasing with the growth of the oldest‐old population; hence, measures for medical comorbidities (e.g., bone fractures of postmenopausal female patients) are urgently needed. T2DM patient are known to have elevated lumbar spine and femoral neck bone mineral density (BMD) on dual energy X‐ray absorptiometry. However, few studies have been conducted using radioabsorptiometry (digital image processing \[DIP\]), a simpler means of BMD assessment that has become widely available recently. Therefore, we investigated BMD in postmenopausal female patients using DIP.

**Method**: The subjects were 200 postmenopausal female patients aged ≥60 years currently receiving treatment at our hospital. We examined whether there was any difference in BMD relative to the young adult mean (YAM) depending on the presence/absence of T2DM via one‐way analysis of variance. For statistical analysis, we used SPSS version 25.

**Results**: The mean values were as follows: age, 78.3 ± 7.9 years; body mass index (BMI), 24.5 ± 4.1 kg/m^2^, HbA1c, 5.9 ± 0.6%; grip strength, 21.0 ± 5.0 kg; and YAM, 65.3 ± 11.3%. Forty‐seven patients had T2DM. YAM values were 69.04 ± 11.78% and 64.11 ± 10.86% in patients with and without T2DM, respectively, with a significantly higher YAM in T2DM (*P *= 0.008). Comparison among T2DM showed that elderly patients aged ≥75 years (*P *= 0.003) who were shorter (*P *= 0.038) and had decreased grip strength (*P *= 0.003) had higher risk of having YAM \<70%. Conversely, there were no significant differences in YAM values depending on the patients' weight, BMI, and HbA1c values or simple intelligence test scores.

**Conclusion**: DIP, which is quite simple, can also be used for BMD screening. Although BMD values are significantly elevated in patients with T2DM, confirmation of patients' age, height, and grip strength is considered useful for the prediction of a decrease in YAM and fracture risk. In reality, however, the incidence of bone fractures in T2DM is high, which is presumably associated with bone quality rather than bone density. Therefore, a method that can further facilitate the prediction of bone quality should be developed in future.
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Association Between Glycated Hemoglobin and Blood Viscosity in Type 2 Diabetes Patients {#jdi12939-sec-0249}
---------------------------------------------------------------------------------------

**A. P. Restu, A. Pranoto, A. Sutjahjo and A. Tjokroprawiro**

Surabaya Diabetes and Nutrition Center, Dr. Soetomo Teaching Hospital Faculty of Medicine Airlangga University, Surabaya, East Java, Indonesia

**Background and Aim**

Glycated hemoglobin (HbA1C) is one of the criteria used to diagnosed diabetes. It is also used to evaluate glycemic control for the preceding two to three months. Blood viscosity (BV) is increase in diabetic patients. Elevated levels of both HbA1C and BV are regarded to correlate with an increased risk for cardiovascular diseases. There have been limited data between HbA1C and BV. The purpose of this study was to analyze the correlation of HbA1C and BV in Type 2 Diabetes Patients.

**Methods**: This study was a retrospective study using medical records from a private diabetic clinic. There were 106 subjects with type 2 diabetes. The HbA1C and blood viscosity data were taken from the medical records.

**Results**: The subjects were mostly male (*n *= 70) with a mean age (years) of 61.1 ± 10.8. The mean for HbA1C (%) and blood viscosity (centipoise) level were 7.96 ± 1.95 and 4.42 ± 0.95, consecutively. The levels of HbA1C was correlated with blood viscosity (r = 0.369, *P * =  \< 0.001). From regression analysis, we calculated that every 1% increase in HbA1C level, BV will raise 0.179 centipoise.

**Conclusion**: The levels of HbA1C are positively correlated with BV, so therefore poor glycemic control in diabetic patients could increase BV.
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**A. P. Restu, A. Pranoto, A. Sutjahjo, A. Tjokroprawiro**
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**Background and Aim**

Type 2 diabetes is a global health problem with its many complication. Dyslipidemia aggravates cardiovascular diseases (CVD) risk which is already increased in diabetes itself. Lipid abnormalities and higher blood glucose can result in the alteration of blood viscosity (BV). High BV could also contribute to raise CVD risk. Statins, besides their lipid‐lowering effects, have a rheological effect, but there have been limited data between statins and BV. The purpose of this study was to compare BV in dyslipidemic type 2 diabetes patients with and without statin therapy.

**Methods**: This study was a retrospective study using medical records from a private diabetic clinic. There were 94 type 2 diabetes patients with dyslipidemia (total cholesterol \> 200 mg/dL, and/or triglyceride \> 150 mg/dL, and/or LDL cholesterol \> 100 mg/dL). They were divided into the statin group (*n *= 40) and non‐statin group (*n *= 54). Lipid profile and blood viscosity data were taken from the patients' medical record.

**Results**: The subjects were mostly male (*n *= 61) and had a mean age (years) of 61.1 ± 11.1. Lipid profile was similar in the two groups. Statin group had a significantly lower values of blood viscosity (4.19 ± 0.98 vs. 4.61 ± 0.93, *P *= 0.039).

**Conclusions**: Type 2 diabetes patients with statin therapy, even though treatment goals not yet achieved, has lower blood viscosity level compared to those not given statin therapy.
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**S. Wang, C. Hu and W. Jia**

Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai Clinical Center for Diabetes, Shanghai Jiao Tong University Affiliated Sixth People\'s Hospital, Shanghai, People\'s Republic of China

**Background**: Serum haptoglobin (Hp) has been shown in close relationship with cardio‐cerebrovascular diseases in patients with type 2 diabetes. We investigated a metabolic profile associated with circulating Hp via a targeted metabolomic approach to provide insight into potential mechanisms.

**Methods**: A total of 120 patients with type 2 diabetes were recruited from the Shanghai Diabetes Institute Inpatient Database. A targeted metabolic profiles of serum metabolites (acylcarnitines, glycerophospholipids, sphingolipids, amino acids, biogenic amines and hexoses) were determined using AbsoluteIDQTM p180 Kit (BIOCRATES Life Sciences AG, Innsbruck, Austria). Ultrasound of bilateral common carotid artery was applied to measure intima‐media thickness and inter‐adventitial diameter (IAD). Serum Hp levels were tested by enzyme‐linked immunosorbent assay.

**Results**: We found that serum Hp tertiles were associated with carotid IAD severity (*P *= 0.0042). The levels of 17 metabolites were observed to be significantly lower in the upper serum Hp tertile group compared with the lower tertile (*P *\< 0.05). Of which, 10 metabolites were identified to be significantly associated with serum Hp tertiles and lipid traits (*P *\< 0.05). Among them, phosphatidylcholine acyl‐alkyl C32:2 (PC ae C32:2) was shown to be significantly correlated with carotid IAD (*P *= 0.0143). Furthermore, metabolite ratio of valine to PC ae C32:2 was demonstrated to be correlated with total cholesterol (*P *= 0.0011), triglycerides (*P *= 0.0067), low density lipoprotein‐cholesterol (*P *= 0.0040), serum Hp levels (*P *= 0.0115) and carotid IAD (*P *= 0.0052) significantly.

**Conclusions**: Targeted metabolomic analyses from Chinese patients with type 2 diabetes might provide a new insight into potential mechanisms of the association between serum Hp and carotid arterial functions.
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**J. Prajitno, S. A. Soelistijo and A. Pranoto**

Surabaya Diabetes and Nutrition Centre‐dr. Soetomo Teaching Hospital_faculty of Medicine Airlangga University, Surabaya, Indonesia

Background: Hyperglycemic condition may cause pathologic and functional changes in various target tissues, and the most important molecular mechanisms involved in hyperglycemia‐induced tissue damage are as follows: activation of protein kinase‐C. Cardiovascular diseases (CVD), are the major macrovascular complication of T2DM that caused 50% of deaths. The more poorly uncontrolled blood sugar level, the more severe the degree of chronic inflammation occurs. Low‐grade inflammation is believed to be the underlying process of atherosclerosis which occurs in most of T2DM patients. Various markers of systemic inflammatory processes are used as an early detection of CVD, but the most promising one is the high sensitivity C‐reactive protein (hsCRP).

**Methods**: This cross‐sectional study carried out in 37 patients with type 2 DM outpatient clinics, and free from any active or chronic inflammatory disease, not taking any anti‐inflammatory drugs. From the first involved in this study, they measured for HbA1C using high‐performance liquid chromatography and High sensitivity CRP was analyzed using Cobas C 501 analyzer immuno turbidimetri methods, with CRPHS reagan by Roche. We evaluate the relationship of HbA1c levels and the low‐grade inflammation (hs‐CRP).

**Result**: The mean of age was 48,98 ± 12,28 years, and the mean of HbA1c level: 7,09 ± 1,08%. The mean of hs‐CRP: 3.19 ± 0,688 mg/dL. Test results showed the correlation between HbA1c level and hs‐CRP and it is significant (r = 0,043; *P *\< 0,05).

**Conclusion**: There was a significant correlation between Glycaemic control and low‐grade inflammation in T2DM population
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**S. Hata**

Osaka Police Hospital, Osaka Kansai, Japan

**Background and Aims**

Recent studies have shown that sarcopenia, which is characterized by age‐related loss of skeletal muscle mass and function, resulting in physical disability, cardiovascular disease, and mortality, is associated with type 2 diabetes. However, the association between sarcopenia and type 1 diabetes, especially young‐adult type 1 diabetes, is entirely unclear. Therefore, this study aimed to evaluate the risk factors associated with low skeletal muscle mass in young‐adult patients with type 1 diabetes. Patients and

**Methods**: A total of 75 (men: 24, women: 51) young‐adult Japanese patients with type 1 diabetes were recruited. The skeletal muscle mass was measured with multifrequency impedance body composition analyzer. Skeletal muscle mass index (SMI, %) was calculated by dividing the extremity skeletal muscle by height squared. Low skeletal muscle mass was defined as an SMI% below 7.0 and 5.7 kg/m^2^ for men and women, respectively, according to the Asian Working Group for Sarcopenia diagnostic algorithm. Risk factors associated with sarcopenia were evaluated based on age, body mass index (BMI), waist circumference (WC), duration of diabetes, total daily dose (TDD) of insulin, blood pressure, hemoglobin A1c (HbA1c) levels, lipid parameters, estimated glomerular filtration rate, insulin‐like growth factor 1 (IGF‐1; SD score), 25(OH)D, and free testosterone levels.

**Results**: Clinical characteristics of the patients were as follows: mean age, 33.4 ± 6.2 years; BMI, 23.6 ± 3.5 kg/m^2^; HbA1c, 7.6 ± 1.1%; and duration of diabetes, 24.4 ± 7.5 years. The prevalence of low skeletal muscle mass defined as SMI below the cut‐off value was 4% for both men and women. Univariate regression analyses revealed that BMI, WC, and TDD in both sexes and IGF (SD score) in women were significantly positively associated with SMI, and serum high‐density lipoprotein‐cholesterol levels were significantly negatively associated with SMI. Multiple regression analyses revealed that BMI in men (*β* = 0.65, *P *=* *0.001) and women (*β* = 0.62, *P *\<* *0.001) and IGF‐1 (SD score) in women (*β* = 0.26, *P *=* *0.04) were positively associated with SMI.

**Conclusion**: These findings suggest that low BMI in both sexes and low IGF‐1 in women may contribute to the progression of sarcopenia in young‐adult patients with type 1 diabetes.

PP‐129 {#jdi12939-sec-0258}
======

Characteristics and outcomes of diabetic ketoacidosis and hyperosmolar hyperglycemic state: a retrospective single‐facility study in Japan {#jdi12939-sec-0259}
------------------------------------------------------------------------------------------------------------------------------------------

**H. Adachi^1^, S. Ito^1^, A. Kawaguchi^1^, T. Kondo^2^, A. Sako^1^ and H. Yanai^1^**

^1^National Center for Global Health and Medicine Kohnodai Hospital (Department of Internal Medicine), Ichikawa, Japan, ^2^National Center for Global Health and Medicine Kohnodai Hospital (Department of Psychiatry), Ichikawa, Japan

Background: Diabetic ketoacidosis (DKA) and hyperglycemic hyperosmolar state (HHS) are diabetic emergencies with high morbidity. We aimed to elucidate the characteristics and clinical course of DKA and HHS.

**Methods**: We retrospectively reviewed records of patients admitted to our hospital for DKA or HHS from January 2010 to September 2017. We compared patients with DKA and those with HHS using the t‐test and chi‐square test and analyzed survival rates using the Kaplan‐Meier method.

**Results**: There were 59 admissions (DKA, 27; HHS, 32) of 50 patients. In total, 7, 10, 16, and 26 patients were admitted in spring, summer, autumn, and winter, respectively, indicating seasonal fluctuation. Mean age was significantly younger in the DKA patients than the HHS patients (52.0 vs. 65.8 years). In the DKA patients, 59.3% had type 1 diabetes, 37.0% had type 2 diabetes, and 3.7% had pancreatic diabetes; for HHS, only 3.1% had type 1 diabetes and 96.9% had type 2 diabetes. Mean body mass index was 22.5 kg/m^2^ and 23.1 kg/m^2^ in the DKA and HHS patients, respectively. There was no difference in vital signs or symptoms including nausea, vomiting, thirst, fatigue, and weight loss. In both groups, 44% of patients had altered consciousness with 3 coma patients in the HHS group alone. Plasma glucose was 703 mg/dL and 711 mg/dL and HbA1c was 11.3% and 11.0% in the DKA and HHS patients, respectively. Potassium was significantly higher in the DKA patients than the HHS patients (5.4 vs. 4.7 mmol/L). Blood gas analysis showed significantly lower pH, pCO2, and HCO3‐ in the DKA patients. Blood pH was 7.15 and 7.38 in DKA and HHS, respectively. Duration of stay differed significantly between DKA and HHS patients (19.8 vs. 42.8 days). In‐hospital mortality rate was lower in DKA (0%) than HHS (9.4%), with no significance; the 3‐year mortality rate differed significantly between the DKA and HHS patients (4.4% vs. 50.0%).

**Conclusion**: The HHS patients had older mean age and longer duration of stay. Three‐year survival rate was also significantly lower in HHS patients.
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**Z. Chenghui, W. Suyuan, W. Yunhong**

Hospital of Chengdu office of People\'s Government of Tibetan Autonomous Region, Chengdu, China

Background: Body iron store is related in many chronic diseases. Our previous study revealed an increase in serum ferritin (SF) level in subjects from Tibetan Plateau. However, whether the increased SF level could be one of related factors of the presence of chronic kidney disease (CKD) remains unclear in male Tibetan patients with T2DM.

**Methods**: We conducted a cross‐sectional study including a total of 1071 male Tibetan patients with T2DM from Tibetan Plateau. SF and other clinical characteristics were collected. Estimated glomerular filtration rate (eGFR) was calculated using the abbreviated Modification of Diet in Renal Disease formula modified for the Chinese subjects. CKD was defined as eGFR \<60 ml/min per 1.73 m^2^ and/or urinary albumin/creatine ratio (ACR) ≥ 30 mg/g. Macroalbuminuria was defined as ACR ≥300 mg/g. Subjects were categorized into four groups according to the level of SF. Multiple logistic regression was used to determine the association in diagnosed CKD and macroalbuminuria.

**Results**: Of all patients, 335 patients (31.3%) had CKD and 102 patients (9.5%) had macroalbuminuria. SF quartile was divided at 373.9 ng/ml, 625.6 ng/ml, 918.7 ng/ml, 1388.0 ng/ml. The presence of CKD in four groups was 14.6%, 27.0%, 42.3% and 41.3%, respectively (*P *\< 0.001). The presence of macroalbuminuria was 4.9%, 7.2%, 12.9% and 13.5%, respectively (*P *\< 0.001). Compared with first quartile, the adjusted OR for CKD was 2.87 (95%CI, 1.74 to 4.71, *P *\< 0.001) in second quartile, 6.08 (95%CI, 3.75 to 9.85, *P *\< 0.001) in third quartile and 6.17 (95%CI, 3.81 to 9.99, *P *\< 0.001) in fourth quartile. The adjusted OR for macroalbuminuria was 1.63 (95%CI, 0.68 to 3.86, *P *= 0.27) in second quartile, 3.71 (95%CI, 1.71 to 8.05, *P *\< 0.001) in third quartile and 4.25 (95%CI, 1.95 to 9.30, *P *\< 0.001) in fourth quartile.

**Conclusion**: An independent relationship between SF and CKD was observed in this study. This finding highlight that the increased SF level might be one of the independent contributor to CKD which needs to be intervened in male patients with T2DM from Tibetan plateau.
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^1^Sanofi, Paris, France, , ^2^University of Texas Southwestern Medical Center, Dallas, USA, ^3^Sanofi, Bridgewater, USA, , ^4^AMCR Institute, Escondido, USA

**Background and Aims**

The LIGHTNING study aims to utilize real‐world electronic health record data, representative of the general population and real‐life practice, to assess hypoglycemia rates in patients with type 2 diabetes (T2DM) prescribed first‐ (glargine 100 U/mL \[Gla‐100\], detemir \[IDet\]) or second‐generation (degludec \[IDeg\], glargine 300 U/mL \[Gla‐300\]) basal insulin (BI) analogs.

**Methods**: We collected data for BI treatments between April 1, 2015 and December 31, 2016. This preliminary analysis focuses on patients switching BIs, to validate findings from previous real‐world Gla‐300 studies. Propensity score matching (PSM) for variables including BI start date, diabetes duration, patient demographics, comorbidities, and baseline HbA1c, ensured similar baseline characteristics between treatment groups, minimizing potential confounders. The unit of analysis was the period of BI use. The main endpoints were severe hypoglycemia event rate and HbA1c change from baseline to 76--180 days follow‐up.

**Results**: Severe hypoglycemia rates were significantly lower in patients switching from any BI to Gla‐300 versus those switching to Gla‐100 (mean estimated event rate 3.6 vs. 9.7 events/100 patient‐years, respectively; *P *= 0.009) or IDet (mean estimated event rate 3.6 vs. 15.1 events/100 patient‐years, respectively; *P *= 0.002). Rates were comparable between patients switching to Gla‐300 and those switching to IDeg (mean estimated event rate 3.4 vs. 5.3 events/100 patient‐years, respectively; *P *= 0.370). Between‐treatment difference in HbA1c reduction was ≤0.09% for all comparisons; HbA1c reduction for each comparison was 0.59% versus 0.56% for Gla‐300 versus Gla‐100, 0.59% versus 0.50% for Gla‐300 versus IDet, and 0.80% versus 0.89% for Gla‐300 versus IDeg.

**Conclusions**: Findings from the LIGHTNING study PSM analysis indicate significantly lower rates of severe hypoglycemia for Gla‐300 versus first‐generation BIs, and comparable rates versus IDeg, without compromising HbA1c reduction, in patients with T2DM switching from any previous BI. These results are consistent with previous randomized controlled trials and other real‐world analyses of Gla‐300. Further analyses are planned to correlate the different incidence of severe hypoglycemia with clinical and economic outcomes.
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Background: Our previous study revealed an increase in serum ferritin (SF) level and an independently association between SF and the presence of chronic kidney disease (CKD) in male Tibetan patients with type 2 diabetes mellitus (T2DM). This retrospective cohort study was conducted to study whether SF may predict the new onset of CKD and the rapid eGFR decline in this population.

**Methods**: Subjects without CKD in baseline were divided into four groups according to the level of SF. New onset of CKD was defined as eGFR \< 60 ml/min per 1.73 m^2^ and/or urinary albumin/creatine ratio (ACR) ≥ 30 mg/g. Rapid eGFR decline was defined when the slope of eGFR change was greater than 5 ml/min per 1.73 m^2^/year.

**Results**: A total of 191 cases were enrolled with a mean age of 51.1 years old. Over a median follow‐up period of 23 months, 30 patients (15.7%) had new onset of CKD and 71 patients (37.2%) had rapid eGFR decline. The median level of SF in four groups was 319.2 ng/ml, 582.1 ng/ml, 810.1 ng/ml, and 1260.5 ng/ml, respectively. In multivariable Cox models, a 100 ng/ml increment in SF was associated with a 1.13‐fold (95%CI, 1.03--1.24) higher adjusted risk of new onset of CKD and a 1.09‐fold (1.02--1.15) for rapid eGFR decline. The adjusted hazard ratio (HR) of CKD was 1.47 (0.35--6.22) for those in the second quartile, 3.43 (1.00--1.17) for those in the third quartile, 2.68 (0.76--9.48) for those in the fourth quartile compared with the subjects in the first quartile. The adjusted HR of rapid eGFR decline was 1.99 (0.89--4.48) for those in the second quartile, 2.30 (1.05--5.06) for those in the third quartile, 2.41 (1.16--5.02) for those in the fourth quartile compared with the subjects in the first quartile.

**Conclusion**: SF independently predicts both new onset of CKD and rapid eGFR decline in male Tibetan patients with T2DM. High levels of SF may play a part in the pathologic pathway leading to development of CKD in T2DM.

PP‐133 {#jdi12939-sec-0266}
======

The Correlation Analysis of soluble high‐mobility group box‐1 and cognition, brain functional imaging in type 1 diabetes mellitus {#jdi12939-sec-0267}
---------------------------------------------------------------------------------------------------------------------------------
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**Objective**: To explore the relationship between type 1 diabetes mellitus (T1DM) and cognitive function by cognitive tests, and to detect metabolic changes in the hippocampus and brain functional connectivity changes used proton magnetic resonance spectrum (^1^H‐MRS) and resting‐state functional magnetic resonance imaging (fMRI). We also analysis the level of soluble high‐mobility group box‐1(HMGB1) by enzyme‐linked immunosorbent assay (ELISA) and HbA1C, blood glucose fluctuation in the type 1 diabetes patients in order to find the brain structure changes, the risk factors and biological indicators of the cognitive impairment.

**Methods**: 1. The 66 participants were recruited at the People\'s Hospital of Zhengzhou University, they were divided two groups: T1DM group, normal control group. 2. Recorded general information of participants such as age, height and other data. The levels of HMGB1, interleukin‐1β (IL‐1β), interleukin‐6 (IL‐6) and tumor necrosis factor‐α (TNF‐α) in serum were measured by ELISA. The continuous glucose monitoring system (CGMS) device was used to obtain 72 h glycemic data. 2. A battery of cognitive tests was chosen to measure cognitive function: Digit Symbol Substitution Test (DSST), Digit span test (DST), Trail Making Test A / B (TMT‐A/TMT‐B), Rey Auditory Verbal Learning Tests (RAVLT), Rey‐Osterrieth Complex Figure (ROCF). 3. The NAA, Cho, Cr of hippocampus were determined by ^1^H‐MRS. All participants underwent 3.0 Tesla fMRI examination in resting state, the functional connection between other brain regions and left hippocampus (seed region) was analyzed by Granger analysis. 4. All statistical analyses were performed using SPSS19.0 software package.

**Results**: Comparison in two groups by the clinical information and lipid and inflammatory cytokines. No significant differences were find between two groups in age, sex, smoking, education level, BMI (*P *\> 0.05), the T1DM group had a significantly lower mean score of LDL‐C than normal control group (*P *\< 0.05), The T1DM had higher level of HMGB1, IL‐1β, TNF‐α and IL‐6 than those in normal control group (*P *\< 0.05). Diabetes duration and HbA1C and glycemic fluctuation of T1DM patients. The average T1DM duration was 9.2 ± 6.0 years,HbA1C of the T1DM group was 9.44 ± 2.41%, glucose fluctuation parameters of the T1DM group: the mean blood glucose (MBG) was 9.43 ± 2.44 mmol/L,the glucose excursions (MAGE) was 6.20 ± 2.24 mmol/L, the mean of daily differences (MODD) was 3.87 ± 1.58 mmol/L, the standard deviation of blood glucose (SDBG) was 2.39 ± 0.85 mmol/L, low blood glucose index (LBGI) was 2.50 ± 2.44, the lower than 3.9 mmol/L (glu70) was 3.37 ± 3.88%. The differences in two groups in cognition and hippocampal metabolism, brain functional connections. The T1DM group had lower mean score of DSST, sum of RAVLT trials(1--5) and ROCF copy than normal control group (*P *\< 0.05). There were no significant group differences on TMT, RAVLT delayed recall, DST and ROCF delayed recall (*P *\> 0.05). Decreased NAA/Cr was observed in the T1DM group relative to normal control group in left hippocampus (*P *\< 0.05). No significant differences were detested between two groups in NAA/Cr in the right hippocampus and bilateral Cho/Cr (*P *\> 0.05).The T1DM group showed increased functional connectivity of the right angular gyrus, the bilateral superior parietal gyrus, partial Wernicke\'s area with left hippocampus (*P \< *0.05). The T1DM group showed decreased functional connectivity of the bilateral subcuneiform nucleus, the bilateral superior frontal lobe and the bilateral middle frontal lobe, the left superior occipital lobe, supplementary motor area, the bilateral precentral gyrus, the bilateral postcentral gyrus with left hippocampus (*P \< *0.05). 1. Correlation analysis of T1DM group---The level of education, HbA1C, MAGE, SDBG, HMGB1, TNF‐α, the level of Cho/Cr in right hippocampus were correlated with DSST(*P \< *0.05). MODD、SDBG were related to DST(P* \< *0.05). The level of education, MAGE, HMGB1, TNF‐α were related to TMT‐B(P* \< *0.05). The level of education, MAGE, SDBG, HMGB1, IL‐1β, IL‐6, the level of NAA/Cr in left hippocampus were correlated with sum of RAVLT trials(1--5)(P* \< *0.05). HMGB1, IL‐1β, IL‐6 were related to RAVLT delayed recall(P* \< *0.05). Age, LBGI were related to ROCF copy(P* \< *0.05). MAGE was related to HMGB1(P* \< *0.05), there was no association between HbA1C and HMGB1(P* \< *0.05). HMGB1 were related to IL‐1β、TNF‐α、IL‐6(P* \< *0.05). MODD, glu70, were related to the level of NAA/Cr in left hippocampus(P* \< *0.05), GLU70 was related to the level of Cho/Cr in left hippocampus(P* \< *0.05), HMGB1 was not related with hippocampal metabolism(P* \< *0.05).

Multivariate linear regression analysis: The level of education and HbA1C, SDBG, HMGB1 was risk factors of DSST. MODD and HbA1C were risk factors for DST. The level of education and HMGB1 were risk factors of TMT‐B. MAGE and SDBG, the level of NAA/Cr in left hippocampus were risk factors for sum of RAVLT trials (1--5). MODD and HMGB1 were risk factors for RAVLT delayed recall. Age, HMGB1 and the level of NAA/Cr in left hippocampus were risk factors for ROCF copy.

**Conclusion**: 1. The T1DM patients have lower cognitive function in three domains: information processing speed, memory and visuospatial. 2. The T1DM patients have lower compared with the normal person in the level of NAA in the left hippocampus decrease. The T1DM patients show the function connection changes of the left hippocampus and some brain areas. The reduction of NAA in left hippocampus is the factors of short term memory. These may be the structural basis of cognitive decline in T1DM patients. 3. HbA1C and glucose fluctuation are the factors of type 1 diabetes mellitus with cognitive decline. Glucose fluctuation relate to cognition decline which the HMGB1‐mediated inflammatory pathways was involved in these effects.
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**Objective**: To investigate the epigenetic and proteomic modifications contribute to the development of type 2 diabetes (T2DM) in NAFLD patients and explore the potential novel treatment target in diabetes.

**Method**: We performed genomewide methylome and proteomic analysis in steatosis‐stage‐matched liver tissues from biopsy‐proven NAFLD patients with or without T2DM (*n *= 10 in each group). DNA methylation analysis was validated by pyrosequencing. The mRNA expression of P4HB was measured in liver biopsy tissues and circulating levels of P4HB were measured with ELISA assay. The effects of overexpression or knockdown of P4HB on hepatic glucose metabolism were tested in liver of high fat‐diet mice and db/db mice.

**Result**: Among the genes with altered expression and DNA‐methylation, we identified P4HB as a potential regulator and epigenetic marker involved in hepatic glucose metabolism. The DNA methylation levels in the promoter region of P4HB gene were high, whereas the protein levels were lower in the liver tissues from NAFLD patients with T2DM, as compared to those without T2DM. Meanwhile, hepatic mRNA expression of P4HB was lower in NAFLD with T2D. Importantly, circulating levels of P4HB was positively correlated with its mRNA expression. Moreover, P4HB expression in plasma and liver tissue of NAFLD patients was negatively correlated with fasting glucose, postprandial blood glucose, HbA1c levels after adjustment for age and body mass index (*P *\< 0.05). In multiple logistic regression analyses, decreased plasma P4HB was associated with higher risk of diabetes (odds ratios, 0.60; 95% confidence intervals, 0.41--0.88; *P *= 0.01). In mouse models, hepatic P4HB overexpression significantly prevented the development of insulin resistance of high fat‐diet mice and db/db mice. The inhibition of excessive hepaticglycogen degradation was observed with increased hepatic P4HB expression, resulting in lower fasting glucose level.

**Conclusion**: NAFLD patients with or without T2DM have distinct alterations in the hepatic methylome and proteome. Notably, we found decreased hepatic P4HB expression is strongly associated with the impaired glucose metabolism, and the hypermethylation of its specific CpG site may be the epigenetic marker. Our results support that P4HB is a novel molecular in the development of impaired glucose metabolism in NAFLD.
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**L. Yujie and R. Xingwu**

West China Hospital, Chengdu, China

**Aims**: The clinical characteristics of malignant melanoma combined with diabetes were analyzed to better identify and reduce the misdiagnosis rate.

**Methods**: We conducted a retrospective case review of lower‐extremity melanoma with diabetes mellitus at Department of Endocrinology and Metabolism, Diabetic Foot Care Center, West China Hospital, Sichuan University, between January, 2011 and October, 2017.

**Results**: The cohort of patients totaled 27 cases, with a female ratio of nearly 1.25:1. Patients' age ranged from 34--87 years, with a mean age of 62.7 years. 15 were initially misdiagnosed including eczema, wart, pigmented nevus, ankle abscess, paronychia, basal cell carcinoma, hemangioma, inflammation and diabetic foot. Of the misdiagnosed, 9 were clinically ulceration and 4 were misdiagnosed as DFU. The majority lesions were located on the plantar surface. A total of 21 lesions were pigmentation, 4 non‐pigmented. The most initial lesions of the foot were pigmented nevus or spots(*n *= 11). Secondly was the mass(*n *= 5), others(*n *= 9) including changes in skin color, hematoma under toenail, seepage of toenail groove, skin splits, nodules and pimples. Data on the time from the patient firstly recognizing something on their foot to diagnosis was available for 20 patients. And the median delay was 12 months (average about 40 months). Lesion thickness available (*n *= 11) at diagnosis ranged from 2.5 mm to 12 mm. 5 cases without acquisition of stage, the proportions of melanoma at clinical stage II, III and IV (AJCC) were 18.5% (*n *= 5), 44.4%(*n *= 12), 18.5%(*n *= 5), respectively. The prognosis of patients by telephone follow‐up showed 7 lost, 9 survived and 11 died. The mean time of 11 died cases from diagnosis to death was 27.9 months.

**Conclusion**: AM is easily misdiagnosed as other benign lesions due to atypical manifestation. When it is characterized by foot ulcers and with diabetes, it is easily misdiagnosed as diabetic foot. Delayed diagnosis and treatment lead to poor prognosis, and therefore, physicians need to be vigilant for chronic foot ulcers. At the same time, the patient\'s knowledge of AM is popularized so that patients can be in time to outpatient department.
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**Y. Li^1^, Y. Gao^1^, Y. Gao^1^, D. Chen^1^, C. Wang^1^, G. Liu^2^, X. Yang^3^ and X. Ran^1^**

^1^West China Hospital, Chengdu, Sichuan, China

**Aims**: To investigate type Cryoglobulinemia vasculitis, a rare cause of extremities gangrene, to deepen the knowledge of the differential diagnosis of diabetic foot, and to reduce misdiagnosis in diabetic patients.

**Methods**: To retrospective analysis the first case of typeIICryoglobulinemia vasculitis gangrene mimicking diabetic foot. Through literature review, focus on the difficulties of diagnosis and treatment.

**Results**: A female patient aged 60 years was presented to our center with pain and dark toes on her left foot. Diabetic foot was considered as the primary diagnosis. The screening of peripheral neuropathy and PAD showed mild lesions without infection, but the gangrenes failed to improve after 1 month\'s therapy, with right hand fingers affected. Further examinations revealed that she had untreated hepatitis B, with serum presence of cryoglobulins. Serum electrophoresis showed albumin decreased, gamma globulin elevated with normal alpha and beta bands, which was suggestive of Type Cryoglobulinemia vasculitis. The patient was put on oral prednisone 60 mg once daily, reduced by 5 mg every week until to 5 mg once daily, and cyclophosphamide 1 g monthly by intravenous infusion for 4 months. Entecavir was used as 0.5 mg once daily in the context of HBV replication and immunosuppressive therapy. The local treatment was mainly exchange dressings until gangrene fell off which histopathologic examination showed leucocytoclastic vasculitis. After treatment, the wound healed, and the serum cryoglobulins became persistent negative, serum HBV viral load was lower than reference value. Now the patient treats with 5 mg prednisone and 300 mg tenofovir once daily and followed up in outpatient.

**Conclusions**: Though rare, Type II Cryoglobulinemia vasculitis should be taken in the differential diagnosis for work up in a case of atypical diabetic foot ulcers or gangrene. Entecavir combines with cyclophosphamide and prednisone can successfully treat and control HBV‐related cryoglobulinemic vasculitis.
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**X. M. LV^1^, P. Ning^2^, Y. Luo^1^ and L. Yang^2^**

^1^Peking University People\'s Hospital, Beijing, China, ^2^People\'s Hospital of Tibet Autonomous Region, Lhasa, China

**Objectives**: To evaluate the association between type 2 diabetes and osteoporosis in Tibetan population living at high plateau area and to further investigate the risk factors for patients with both type 2 diabetes and osteoporosis in this population.

**Methods**: We collected the data from patients hospitalized in People\'s Hospital of Tibet Autonomous Region from Jan. 2016 to Mar. 2018. The major inclusion criteria are as followed: (1) Type 2 diabetes; (2) age over 18; (3) Tibetan population; (4) underwent DXA examination during hospitalization. Firstly, we divided all the participants into three groups (normal, osteopenia and osteoporosis) according to their DXA results. Somatometric measurement and laboratory biochemical index were compared among three groups. We then further investigate the risk factors for osteoporosis in this population by regression test.

**Results**: There were 456 patients recruited into our study. A total of 286 of them were male patients, while 170 were female. The mean age of the participants was 55.7 ± 11.3 years old. Significant differences were detected in age, diabetes duration, body mass index (BMI), uric acid and high‐density lipoprotein cholesterol (HDL‐C) among three groups (*P *\< 0.05). There were no differences with fasting glucose level, HbA1c, calcium level, parathyroid hormone (PTH) and 25OHD level among groups. Further logistic regression test showed that decreased uric acid level was an independent risk factor for lumbar vertebral osteoporosis. Older age, low BMI and decreased uric acid level were risk factors for femoral neck osteoporosis.

**Conclusion**: Older age, low BMI and decreased uric acid level were risk factors for osteoporosis in Tibetan type 2 diabetes living at high plateau area.
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**Q. Jin**

Peking University First Hospital, Beijing City, China

Objection: Diabetes has been the main cause of end‐stage renal disease in developed countries and is increasing at an epidemic rate in developing countries. The study was conducted to find early clinical indicators for diabetic nephropathy.

**Methods**: Patients with type 2 diabetes mellitus (T2DM) and underwent renal biopsy were screened. The included patients were categorized according to diabetic retinopathy (DR) and the classification of diabetic nephropathy (DN). The clinical characteristics, laboratory parameters and pathological data of patients were collected and compared.

**Results**: A total of 188 patients were included in this study. With a mean duration of about 9 years of type 2 diabetes mellitus (T2DM), most of the patients had nephrotic‐range proteinuria (mean 24‐h urinary protein 6.27 ± 5.04 g/24 h), renal dysfunction (mean eGFR 49.611 ± 29.747 ml/min/1.73 m^2^) while with mean value of 7.05 ± 1.61% of HbA1c. There were 31.9% (*n *= 60) of the patients with pure diabetic nephropathy (DN). Compared with patients in classification I or II of DN, those in classification III or IV of DN were more likely to accompanied with DR, had higher level of 24‐h urinary protein, urinary α1‐microglobulin and urinary N‐acetyl‐β‐d‐glucosaminidase (3.69 ± 2.79 vs. 6.94 ± 5.57 g/24 h, *P *= 0.023; 26.02 ± 20.06 vs. 59.22 ± 54.63 mg/L, *P *= 0.042; 33.14 ± 21.05 vs. 57.42 ± 45.00 U/L, *P *= 0.027, respectively), and had lower value of eGFR and complement C3 (78.628 ± 25.719 vs. 52.710 ± 28.677 ml/min/1.73 m^2^, *P *= 0.006; 1.122 ± 0.180 vs. 0.894 ± 0.212 g/L, *P *= 0.003).

**Conclusion**: There were about 19.1% (188/986) of the T2DM patients who underwent renal biopsy in our hospital turning out with DN (pure DN or combined with non‐diabetic renal disease (NDRD)), and about 30% of those patients with pure DN. We found that DR had more relationship with rather later classification of DN (classification III or IV), indicating that DR was not an appropriate early predicator for DN. T2DM patients in classification III or IV of DN had severer renal tubular interstitial lesion and complement C3 may be involved in the progression of DN.177
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Valsartan protects diabetic nephropathy by inhibiting mir‐21‐induced renal tubular epithelial to mesenchymal transition {#jdi12939-sec-0279}
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**J. Wang, L. Tian, Q. Guo, S. Wei, Y. Wei, R. Niu and J. Liu**

Department of Endocrinology, Gansu Provincial People\'s Hospital, Gansu Key Laboratory of Endocrine and Metabolism, Lanzhou, China

Epithelial to mesenchymal transition (EMT) plays a critical role in diabetic nephropathy (DN). The role of miR‐21 is closely linked to EMT. Angiotensin II receptor blocker (ARB) valsartan has renoprotective effects on DN by inhibiting EMT. However, it remains elusive whether valsartan protects DN by inhibiting miR‐21‐induced renal tubular EMT. In this study, Real‐time RT‐PCR, cell transfection and in situ hybridization (ISH) and laser confocal microscopy were used, respectively. Our ISH and/or RT‐PCR results exhibited that valsartan lowered miR‐21 expression in renal cortical tissue and renal tubular cell in the dose‐dependent manner. Luciferase report gene assays demonstrated that smad7 was a validated target of miR‐21. MiRNA transfected experiments showed that miR‐21 overexpression can enhance a‐SMA expression and decrease E‐cadherin expression by directly downregulating smad7 expression. Interestingly, valsartan also increased E‐cadherin expression and decreased a‐SMA expression by regulating miR‐21 expression. More importantly, valsartan decreased GBM, GA and albumin creatinine ratio (ACR), whereas, increased creatinine clearance ratio (Ccr). These results demonstrated that valsartan ameliorated renal structure and function by regulating miR‐21‐induced EMT, and that miR‐21 may be a new possible therapeutic target for valsartan in DN.
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**C. P. Lin^1^, K. Y. Chien^1^, T. X. Ting^2^ and F. Tan^1^**

^1^Department of Medicine, Sarawak General Hospital, Kuching, Malaysia, ^2^Clinical Research Centre, Sarawak General Hospital, Kuching, Malaysia

Introduction: Hypoglycaemia in hospitalized diabetic patients is a limiting factor in achieving good glycaemic control and is associated with increased morbidity, mortality and prolonged hospitalisation. Data on inpatient hypoglycaemia are lacking locally. We prospectively studied the causes, risk factors and recurrence rate for hospitalized diabetic patients experiencing hypoglycaemia in Sarawak General Hospital. Patients and

**Method**: We screened and identified diabetic inpatients with capillary blood glucose \<4.0 mmol/L admitted to the surgical, orthopaedic and medical wards from February 2017 to June 2017. Patients were interviewed and baseline data obtained. They were reviewed for recurrent hypoglycaemia until discharge.

**Result**: A total of 358 episodes of hypoglycaemia occurred in 142 diabetic patients (70 males, 72 females). The mean age of patients was 61.2 ± 14 years. 63% had impaired renal function with an estimated glomerular filtration rate (eGFR) \<60 ml/min. 31.7% had antecedent hypoglycaemia, a third of which were severe hypoglycaemia requiring assistance. The occurrence of hypoglycaemia was equal between medical (50.7%) and non‐medical wards (49.4%). Main diagnosis on admission was related to infection (59.2%). Hypoglycaemia was reported more in those on insulin (57.7%). Half the patients had poor oral intake, majority (80%) were not on intravenous dextrose fluid during hypoglycaemia while steroid withdrawal, inappropriate insulin and mistiming of insulin were minor contributing factors. Recurrent hypoglycaemia occurred in 53.5% of patients with mean of 2.5 episodes per patient (range 1--19). The risk of having more than 3 episodes of hypoglycaemia was significantly associated with an eGFR of \<30 ml/min, OR 3.16 (95% CI 1.3--7.8, *P *= 0.013). Patients who reported history of hypoglycaemia prior to admission were also at increased risk of recurrent hypoglycaemia OR 2.2 (95% CI 1.06--4.6, *P *= 0.034). 23% of our patients had delayed recurrent hypoglycaemia occurring after 48 h from the first episode Overall mortality in the entire cohort was 5.6% at the time of discharge.

**Conclusion**: Diabetic patients with impaired renal function are susceptible to hypoglycaemia during hospitalisation. This group of patients as well as those with antecedent hypoglycaemia are prone to recurrent hypoglycaemia. Identifying these high‐risk patients and instituting a more structured management plan may aid in reducing inpatient hypoglycaemia and prevent recurrence.
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**S.‐A. Cha, H.‐S. Kwon, J.‐S. Yun, Y.‐B. Ahn, Y.‐J. Lee and S.‐H. Ko**

Division of Endocrinology and Metabolism, Department of Internal Medicine, St. Vincent\'s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

**Aims**: We analyzed time‐ and frequency‐domain measures (power spectral analysis) of HRV (Heart Rate Variability) and evaluated the association between HRV variables and CV outcome in patients with T2DM.

**Methods**: A total of 655 patients with T2DM who underwent cardiovascular autonomic function testing were consecutively recruited and followed up prospectively. Time‐ and frequency‐domain HRV were assessed for 5 min by beat‐to‐beat heart rate recording. We estimated the development of CVD events during a follow‐up period.

**Results**: During a median follow‐up of 7.8 years, 9.6% (*n *= 49) of patients developed CVD (10.6 per 1,000 patient‐years). The mean age and diabetes duration were 54.9 ± 8.6 years and 9.4 ± 7.3 years, respectively. The median value and interquartile range of total power (TP), low‐frequency (LF), high‐frequency (HF), and LF/HF ratio were 309.5 (153.8--345.8) ms^2^, 46.4 (19.9--104.9) ms^2^, 62.1 (26.2--153.4) ms^2^, and 2.4 (0.7--2.9), respectively. The mean heart rate, median value, and interquartile range of SD of the normal‐to‐normal interval (SDNN) and the root mean square of differences between adjacent R‐R intervals (RMSSD) in HRV were 76.1 ± 12.1 beats/min, 25.4 (18.1--33.7) ms and 14.3 (10.0--21.8) ms, respectively. Patients who had cardiovascular autonomic neuropathy (CAN) had decreased HRV compared with those with normal autonomic function. There were significantly reduced trends of HRV variables according to the CAN stage, SDNN (p for trend \< .001), RMSSD (p for trend \< .001), TP (p for trend = .001), HF power (p for trend = .001), and LF power (p for trend \< .001). Multivariable cox hazard regression analysis revealed the lowest 10th percentile of the SDNN (HR 2.62; 95% CI 1.30--5.31), TP (HR 2.81; 95% CI 1.37--5.79), LF power (HR 2.68; 95% CI 1.28--5.59), and HF power (HR 2.24; 95% CI 1.09--4.59) were significant predictors for developing CVD in patients with T2DM.

**Conclusions**: Time‐ and frequency‐domain measures of HRV independently predicted cardiovascular outcome in patients with T2DM.

PP‐142 {#jdi12939-sec-0284}
======
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^1^Department of Diabetes and Endocrinology, Kochi Health Sciences Center, Kochi, Japan, ^2^Department of Nutrition, Kochi Health Sciences Center, Kochi, Japan, ^3^IT center, Kochi Health Sciences Center, Kochi, Japan

**Purpose**: Vitamin D deficiency is an important public global health problem, and it confers a significant risk for both skeletal and non‐skeletal disorders such as cardiovascular disease, cancer, infectious diseases, neurological disorders, metabolic syndrome, and diabetes. Vitamin D deficiency is defined as a 25‐hydroxyvitamin D (25(OH)D) level below 20 ng/ml, while vitamin D insufficiency is a 25(OH)D level of 21--29 ng/ml. We clarify the relationship of vitamin D deficiency with type 2 diabetes.

**Method**: In total, 231 type 2 diabetes patients (age 55 ± 15 years, 116 males), whose creatinine levels were below 1.2 mg/dl, were recruited from December 2012 to November 2017 in our hospital. We estimated the levels of serum 25(OH)D using radioimmunoassay kits and divided into a deficiency group (serum 25(OH)D \< 20 ng/ml) and a non‐deficiency group (serum 25(OH)D ≥ 20 ng/ml).

**Results**: The rate of vitamin D deficiency was 56%, while only 10% of patients were vitamin D‐sufficient. The deficiency group (*n *= 130, 50 males) was significantly younger than the non‐deficiency group (*n *= 101, 66 males), (52.9 ± 15.7 and 57.9 ± 14.6 years, respectively; *P *\< 0.05). The rate of female patients (62%) of the deficiency group was significantly higher than that of the non‐deficiency group (35%) (*P *\< 0.001). Dietary vitamin D intake was significantly lower in the deficiency group than in the non‐deficiency group (32.6 ± 25.0 μg/week and 48.4 ± 34.3 μg/week, respectively; *P *\< 0.05). The eicosapentaenoic acid to arachidonic acid ratio (EPA/AA) of the deficiency group was significantly lower than that of the non‐deficiency group (0.28 ± 0.19 and 0.38 ± 0.23, respectively; *P *\< 0.001). There was no significant difference between the groups for diabetes duration, body mass index, hours of sunshine exposure, systolic blood pressure, diastolic blood pressure, body fat percentage, body muscle percentage, fasting plasma glucose, HbA1c, total cholesterol, triglyceride levels, HDL‐cholesterol, LDL‐cholesterol, homocysteine, eGFR, u‐albumin, the prevalence of retinopathy, and the proportion of insulin users.

**Conclusions**: The lack of vitamin D also spreads in type 2 diabetes in Japan and these results suggest a connection with age, sex, and EPA/AA.
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^1^Khoo Teck Puat Clinical Research Unit, Singapore, Singapore, ^2^Admiralty Medical Centre / Diabetes Centre, Singapore, Singapore, ^3^Khoo Teck Puat Hospital / Department of Medicine, Singapore, Singapore, ^4^Khoo Teck Puat Hospital / Vascular Surgery, Singapore, Singapore, ^5^National University of Singapore / Saw Swee Hock School of Public Health, Singapore, Singapore, ^6^Nanyang Technological University / Lee Kong Chian School of Medicine, Singapore, Singapore

INTRODUCTION: Peripheral Artery Disease (PAD) is ischemia of the lower limb vessels, associated with high risk of myocardial infarction, stroke and vascular death in Type 2 Diabetes (T2D) patients. High‐sensitivity C‐reactive protein (HsCRP) is an inflammation marker and Growth Differentiation Factor‐15 (GDF15) has been shown to play a role in cardiomyocyte repair in response to tissue inflammation. We aimed to explore the relationship of both these markers, before and after angioplasty and endarterectomy.

**Methods**: Patients with T2D were recruited on the day of surgery. Plasma were collected before and after angioplasty (*n *= 52) and endarterectomy (*n *= 5) (ie.Pre‐surgery, Day1, Day7, Day30 post‐procedure). GDF15 and HsCRP were measured using Enzyme‐Linked Immunosorbent Assay. Data analysis was performed using SPSS version‐22 and STATA and *P *\< 0.05 was considered significant.

**Results**: 57 patients were recruited: mean age (62.0 ± 15.0)years, 78.9% males, ethnic distribution: 50.9% Chinese, 26.3% Malays, and 22.8% Indians. Mean diabetes duration was 13.0(8.0--21.5) years, HbA1c:(8.3 ± 2.0)%, serum creatinine: 108(76.0 -- 505.5)mmol/L, *n *= 19 (33.9%) were on dialysis, 29.8% ex‐smokers and 10.5% current smokers, 28.1% had history of foot ulcers, 42.0% and 16.3% had toe and below knee amputation. Spearman correlation showed that GDF15 was positively associated with HsCRP(rho=0.347; *P *= 0.03), serum creatinine (rho=0.740; *P *\< 0.0001), Urine ACR (rho =0.552; *P *= 0.005). GDF15 was negatively associated with LDL cholesterol(rho=‐0.287;*P *= 0.041), HbA1c (rho=‐0.343; *P *= 0.015). For both HbA1c and LDL, the significance of correlation was attenuated after adjustment for Metformin and statin, respectively. Post Hoc analysis showed higher HsCRP in Malay as compared to Chinese while no significant difference between gender for both biomarkers. While HsCRP was significantly reduced (*P *= 0.001), GDF15 was significantly increased (*P *\< 0.0001) after surgery (Pre‐surgery, Day‐1, Day‐7 and Day‐30 post‐procedure): HsCRP 62.3(15.0--100)μg/ml, 65.9(34.4--105.4)μg/ml, 40.2(13.2 -- 96.3)μg/ml, 19.6(2.9 -- 44.8)μg/ml and GDF15: 3.45 (2.14 -- 2.85)pg/ml, 4.17 (2.57 -- 5.95)pg/ml, 4.14 (2.77 -- 7.72)pg/ml, 3.99 (2.23 -- 5.72)pg/ml, respectively, after adjusting for baseline age, gender, ethnicity, BMI, smoking status, HbA1c, duration of diabetes, LDL‐c, SBP, Serum Creatinine and statin use.

**Conclusion**: Inflammatory load reduced significantly post‐surgery. Significance of increase in GDF15 might provide insights to its pathophysiology in PAD. Long‐term follow‐up of the cohort will provide more clues to the temporal changes in GDF15.
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^1^Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan, ^2^Murakami Memorial Hospital, Asahi University, Gifu, Japan

Background: Patients with chronic kidney disease (CKD) have insulin resistance from early stage, even when the glomerular filtration rate (GFR) is within the normal range. The homeostasis model assessment of insulin resistance is often used as evaluation of insulin resistance. On the other hand, the triglyceride‐glucose index (TyG index), which is calculated with fasting plasma glucose and triglycerides, has been suggested as a marker of moderate insulin resistance. Thus, we aimed to investigate the association between TyG index and incident CKD.

**Methods**: In this historical cohort study of 23,955 participants (13,846 men and 10,109 women), we investigated the effect of TyG index on incident CKD. CKD was defined as estimated GFR less than 60 ml/min/1.73 m^2^ or proteinuria detected by dipstick test in fasting morning urine (positive: ≥1 + ). TyG index was calculated as ln\[fasting triglycerides (mg/dL) × fasting plasma glucose (mg(dL)/2\]. After dividing the participants into two groups according to sex, we divided them into quartiles according to TyG index. Cox proportional hazards models were performed to investigate the effect of TyG index on incident CKD, adjusting for age, body mass index, smoking status, exercise, alcohol consumption, waist circumference, creatinine, hypertension and hyperuricemia.

**Results**: During the median 4.6‐year follow‐up duration for men and 4.2‐year follow‐up duration for women, 2,864 participants (1827 men and 1037 women) developed CKD. In Cox proportional hazards models, the highest quartile (men; 8.78--12.87, women; 8.13--11.02) in both men and women was revealed to be a significant risk for incident NAFLD, compared to the lowest quartile (men; 5.95--7.93, women; 5.63--7.36) (men; hazard ratio \[HR\] 1.17, 95% confidential intervals \[95% CI\] 1.01--1.36, *P *= 0.038, women; HR 1.28, 95% CI 1.02--1.53, *P *= 0.020).

**Conclusion**: This is the first study to reveal that TyG index is a predictor of incident CKD. For the prevention of CKD, we should focus more on TyG index.
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Purpose: We aimed to identify details of the cognitive impairment and brain atrophy attributable to obstructive sleep apnea (OSA) severity in diabetes patients.

**Methods**: A total of 832 participants with type 2 diabetes in the Korean Genome and Epidemiology Study were included. According to apnea--hypopnea index (AHI) measured by polysomnography, they were stratified into non‐OSA (AHI \<5), mild OSA (5 ≤ AHI \<15), moderate to severe OSA (AHI ≥15) groups. Cognitive performance was determined by a comprehensive neuropsychological battery. Brain Magnetic Resonance Imaging was taken and brain volume was calculated by BRAINS Auto‐Workup, in collaboration with the University of Iowa. We conducted multivariate linear regression analyses after stratifying the subjects according to OSA severity and grey matter (GM) volume (small: quartile 1 vs. normal: 2--4) with non‐OSA and normal GM volume group as reference.

**Results**: In brain volume, only severe OSA group (AHI ≥30) showed significantly decreased GM volume in frontal, parietal, and temporal lobe and white matter of frontal area after adjustment for age, sex, higher education, and intracranial volume. Significant negative associations with immediate story recall (β= --3.573), delayed story recall (β= --4.302), verbal fluency‐phonemic (β= --3.879), and stroop‐word reading (β= --7.308) were found in individuals with both small GM volume and moderate‐to‐severe OSA, after adjustment for age, sex, higher education, intracranial volume, current smoker, current drinker, exercise, sleep duration, insomnia, duration of diabetes, hypertension, and anti‐hyperlipidemic drug. There were significant interactions between brain volume and the severity of OSA for verbal fluency‐phonemic and stroop word reading test (*P *= 0.002 and 0.008, respectively).

**Conclusions**: This study demonstrated that diabetic patients with GM atrophy and moderate to severe OSA exhibited decreased function in verbal memory, language processing, sustained attention, and executive functioning. These findings suggest that negative impact of OSA on cognitive function was modulated by the presence or absence of GM atrophy.
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**Objective**: To investigate the difference in telomere length between type 2 diabetes mellitus (T2DM) patients with or without extreme cardio‐cerebral vascular events. Subjects &

**Methods**: We collected 553 patients with T2DM randomly from the outpatient of Tongji Hospital, Tongji Medical College, Huazhong university of Science and Technology. T2DM was diagnosed based on standards posted by American Diabetes Association in 2017 (hemoglobin A1c ≥6.5%, or fasting glucose ≥7.0 mmol/L). Patients were divided into vascular event group and control group judging by their history of extreme cardio‐cerebral vascular events. Extreme cardio‐cerebral vascular events consist of major cardiovascular events such as: coronary heart disease, angina, myocardial infarction, and cerebrovascular accidents such as cerebral infarction, cerebral ischemia, cerebral atrophy disease. Leukocyte telomere length was measured by Southern blot and telomere shorten rate was calculated with telomere length.

**Results**: Leukocyte telomere length decreased with age in T2DM patients. The mean telomere length in vascular event group and control group were 6028 ± 76.09 base pair (bp) and 6316 ± 34.54 bp, respectively. Telomere length in vascular event group was shorter than control group (t = 2.83, *P *\< 0.005). In addition, telomere shortening rate was about‐13.67 ± 6.31 bp/year in vascular event group, and 12.53 ± 2.32 bp/year in control group. The telomere shortening rate in vascular event group was faster than control group (t = 2.78, *P *\< 0.05).

**Conclusion**: We found that telomere length in diabetic patients with extreme cardio‐cerebral vascular diseases was shorter and was shorten faster. So we speculated that telomere length could be used as biomarker of aging in diabetic patients. Furthermore, telomere shortening rate could be a risk predictor for extreme cardio‐cerebral vascular events in diabetic patients.
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**Objective**: To investigate the morbidity and comorbidity of non‐alcoholic fatty liver disease (NAFLD) and different glucose intolerance status in a community‐based population in northern China.

**Methods**: A community‐based cohort established for Pinggu Metabolic Disease Study in suburb region of Beijing, China was conducted from Jun 2013 to Sep 2014 using multiple‐stage random sampling method. Participants were eligible if they were born in Pinggu and have lived there for 5 or more years, with age 26--76 years. General information, basic disease history and biochemical parameters were obtained via questionnaires, physical examinations and laboratory examinations. All subjects undergone 75 g‐oral glucose tolerance test (OGTT) to determine the status of glucose tolerance. Unenhanced abdominal CT scan was performed to determine NAFLD. Appropriate non‐parametric statistical tests were used to compare the observed proportions between study groups. Multivariate logistic regression analyses were used to assess the impact of different degrees of impaired glucose tolerance on the risk of NAFLD.

**Results**: A total of 3122 subjects were included in this analysis. The prevalence of NAFLD was 26.85%, 19.97% and 22.68% in male, female and both together, respectively. The prevalence of type 2 diabetes (T2DM) was 20.86%, 16.23% and 18.05% in male, female and both together, respectively. Up to 7.21% of residents coexisted T2DM and NAFLD. 31.78% of NAFLD patients accompanied by T2DM and 39.96% of diabetes combined with NAFLD. Nearly a quarter of residents were in a pre‐diabetic state and one‐third of them had NAFLD. Compared with NGT adults, the risk of NAFLD in T2DM patients increased more than four times after adjusting for gender and age. (OR=4.345, 95% CI 3.457--5.461, *P *\< 0.001). NAFLD was also more common in pre‐diabetes, especially in patients with IGT (OR=2.71, 2.11--3.47) or IFG+IGT (OR=3.44, 2.42--4.89).

**Conclusion**: This study quantified the morbidity and comorbidity of NAFLD and different glucose intolerance status in a community‐based population in northern China, emphasizing the importance of promoting the prevention and treatment of chronic metabolic diseases.
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**Objective**: To investigate the difference between telomere length in type 2 diabetes patients with or without extreme cardiovascular and cerebrovascular events. Subjects &

**Methods**: We selected type 2 diabetes patients randomly from the outpatient of Tongji Hospital, Tongji Medical College, Huazhong university of Science and Technology. In 553 participants, diabetes status was determined based on a previous diagnosis, hemoglobin A1c ≥6.5%, or fasting glucose ≥7.0 mmol/L. According to their medical history and laboratory examination, we divided the diabetic patients into 2 groups. Diabetes patient was diagnosed with major cardiovascular events such as: coronary heart disease, angina, myocardial infarction, or cerebrovascular accidents such as cerebral infarction, cerebral ischemia, cerebral atrophy disease will be assigned to disease group and patient without any cardiovascular diseases and cerebrovascular diseases was assigned to control group. Leukocyte telomere length was measured through Southern blot technique. Telomere shorten rate was calculate according to telomere length.

**Results**: Leukocyte telomere length decreases with age in type 2 diabetes patients. The mean telomere length in disease group and control group were 6028 ± 76.09 base pair (bp) and 6316 ± 34.54 bp respectively. Telomere length in disease group is shorter than control group(t = 2.83, *P *\< 0.005).Telomere shortening rate is about‐13.67 ± 6.31 bp/year in disease group, while in control group were −12.53 ± 2.32 bp/year. Patients in disease group whose telomere attrition rate is the faster than control group (t = 2.78, *P *\< 0.05).

**Conclusion**: Patients with extreme cardiovascular and cerebrovascular diseases have faster telomere length shortening and shorter telomere length. Telomere length can be used to judge the degree of aging in diabetic patients. The rate of telomere shortening could be used to predict the risk of extreme cardiovascular events in diabetic patients.
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**Objective**: To evaluate the efficacy and safety of autologous implantation of stem cells for patients with peripheral arterial disease (PAD).

**Method**: Randomized controlled trials (RCTs) were identified from CBM (1978˜2018.1), CNKI (1979˜2018.1), Medline(1950˜2018.1), PubMed (1950˜2018.1), EMbase (1970˜2018.1) and Cochrane library Papers of the RCTs of clinical therapeutic studies on PAD treated by autologous implantation of stem cells were included and analyzed by revman5.3 and stata12.0.

**Results**: 23 RCTs involving 993 patients and 1035 limbs were included, with part of trials of relatively low methodological quality. Meta‐analysis indicated autologous stem cell therapy was more effective than conventional therapy on incidence of ulcer healing \[OR=4.58, 95% CI= (2.93,7.16)\], a significant improvement in the ankle‐brachial pressure index (ABI) \[MD=0.14, 95%CI= (0.10,0.18)\],transcutaneous oxygen tension (TcO2) \[MD=12.56, 95%CI= (3.55,21.57)\] and pain‐free walking distance \[MD=178.25, 95%CI= (128.18,228.31)\], a significant reduction in rest pain scores \[MD=‐1.61, 95%CI= (−2.01, −1.21)\], a significant benefit in terms of limb salvage, amputation rate \[OR= 0.49, 95%CI= (0.35,0.69)\] and major amputation rate \[OR= 0.62, 95%CI= (0.39,0.97)\]. 9 trials reported the side effects of autologous stem cell therapy including slight edema of limbs,transient increase of serum creatine phosphokinase, bleeding, pain, infection and cellulitis after puncture or injection, hematocrit, proliferative retinopathy, moderate hypotension during mobilization and severe worsening of CLI in the target leg after injection. No serious side effects were reported. GRADE evidence profile showed all the quality evidence of outcomes were low.

**Conclusions**: Based on the review, autologous stem cell therapy may have positive effect on "no‐option" patients with PAD. However, the evidence is not strong enough due to the low quality evidence, so we can\'t draw a reliable conclusion about the effects of autologous stem cell therapy for PAD at the moment. Further larger, randomized, double blind, placebo‐controlled and multicenter trials are needed.
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**Aims**: The study aimed to investigate the relationship between metabolic syndrome (MS) and risk of cancer in patients with type 2 diabetes (T2DM).

**Methods**: We enrolled 6587 patients with T2DM who were hospitalized in Qingdao Endocrine and Diabetes Hospital from Feb 2005 to Jan 2016. According to the number of MS component each patient had, they were divided into isolated T2DM, T2DM plus 1 component,2 components, 3 components and 4 components, respectively. The IDF Worldwide Definition of the Metabolic Syndrome was applied. Information on the diagnosis of cancer was obtained by matching ICD‐10 codes recorded in local Healthcare medical records database. Prevalence of cancer was compared using Chi‐square test. Logistic regression model was used to evaluate risk of cancer associated with MS.

**Results**: The prevalence of cancer was 4.2% among 6587 patients with T2DM. Female patients had higher prevalence than did male in total or in the MS subgroup. The prevalence of cancer was 3.8%, 3.9%, 3.8%, 5.1% and 5.0% in isolated DM, T2DM plus 1 component of MS, T2DM plus 2, T2DM plus 3 and T2DM plus 4 components, respectively (P for trend \<0.05). Compared with those with less than 3 components, T2DM plus 3 or 4 components had increased risk of having cancer (OR=1.32, 95% CI: 1.04--1.69). Among T2DM patients who had more than 3 components of MS, a specific cluster of increased waist, elevated triglycerides (TG) and decreased High‐Density Lipoprotein Cholesterol (HDL‐C) was associated with the highest prevalence of cancer (10.7%), followed by 8.3% in T2DM patients plus hypertension, elevated TG and decreased HDL‐C and 3.2% in T2DM patients plus hypertension, increased waist and elevated TG (χ^2^ = 26.6, *P *\< 0.05).

**Conclusions**: A cluster of metabolic disorders consisting of increased waist, elevated TG and decreased HDL‐C seems to be oncogenic among Chinese patients with T2DM. For patients in combination with 3 or 4 MS components, it is important to conduct early cancer screening and prevention.
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Aim: To demonstrate the associations between non‐alcoholic fatty liver disease(NAFLD) and chronic microvascular complications in hospitalized type 2 diabetes mellitus(T2DM) population.

**Method**: A total of 3090 patients with T2DM who were admitted to the ward of the department of Peking University People\'s Hospital between January 2012 and September 2017 were enrolled in this study. Patients aged \<18 years, with reported history of chronic liver disease, excessive alcoholic intake (man≥30 g/day, woman≥ 20 g/day), positive HBsAg or HCVAb, eGFR \< 30 ml/min/1.73 m^2^ or incomplete essential data were excluded. A total of 2235 patients were included finally. Clinical characteristics were compared between NAFLD and non‐NAFLD participants. Logistic regression models were used to detect the association between NAFLD (or level of liver fibrosis for individuals with NAFLD) and the prevalence of chronic microvascular complications in T2DM.

**Result**: The prevalence of NAFLD is 60.4% (mean age 57 years). Compared with the non‐NAFLD group, individuals with NAFLD were younger, had shorter diabetic duration and higher levels of BMI, FPG, triglyceride (*P *\< 0.001). The prevalence of diabetic retinopathy(DR)(18.8% vs. 28.5%, P* \< *0.001), diabetic kidney disease(DKD) (22.8% vs. 27.9%, *P *= 0.007) and diabetic neuropathy(DN)(66.1% vs. 70.4%, *P *= 0.041) were lower in NAFLD group. NAFLD was inversely associated with the prevalence of DR(OR:0.732,95%CI:0.566--0.925) and DKD(OR:0.750,95%CI:0.596--0.943) after adjusting age, gender, SBP, BMI, HbA1c, LDL‐c, diabetic duration and there is no relationship between NAFLD and DN. NAFLD fibrosis scores which were used to measure the level of liver fibrosis were categorized as mild, moderate and severe. In multiple Logistic regression models, the ORs for the prevalence of DR and DKD were increasing in moderate(DR OR:1.252, 95%CI:0.749--2.092; DKD OR:1.021, 95%CI:0.673--1.549) and severe group(DR OR:1.291, 95%CI:0.714--2.335; DKD OR:1.936, 95%CI:1.197--3.130) in reference to mild group, after adjusting age, gender, SBP, BMI, HbA1c, LDL‐c and diabetic duration. P for trend was significant only in DKD model (*P *= 0.001).

**Conclusions**: NAFLD is inversely associated with the prevalence of DR and DKD in hospitalized T2DM population. High level of liver fibrosis is relevant to the increasing risk of DKD in T2DM individuals with NAFLD.
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Aim: Transient elastography (Fibroscan) is a measuring instrument for measuring liver hardness and liver fibrosis. In metabolic syndrome (MetS) patients of non‐alcoholic fatty liver disease (NAFLD), the relationship between CAP and the components of metabolic syndrome is unclear. The aim of this study was to investigate the relationship between the components of metabolic syndrome and the Fibroscan of CAP.

**Method**: A total of 918 retired workers and in‐service workers whose included 224 patients with type 2 diabetes who underwent physical examination in the physical examination center of the first affiliated hospital of sun yat‐sen university from January 2018 to March 2018 were included in this study. Through A questionnaire survey, physical examination and blood biochemical examination were conducted and data werecollected. Transient elastic imaging was used to measure CAP. Through statistical software such as SPSS, the relationship between CAP and MetS components was analyzed.

**Result**: There are 876 patients were screened out through inclusion and exclusion criteria. The CAP range from 115--400(248.11) dB/m. Through SPSS, the CAP and MetS components was significantly correlated (R = 0.251, *P *\< 0.001). According to the four groups under different levels of CAP \< 238 dB/m, 238--259 dB/m, 260--291 dB/m, \> 291 dB/m, the prevalence of MetS components differences statistically significant (χ2 = 57.119, *P *\< 0.001), with the increase of number of components of metabolic syndrome, the CAP values increase (*P *\< 0.001).

**Conclusion**: The CAP by transient elastography has a strong correlation with the composition of metabolic syndrome and a positive correlation. The change range of CAP can predict the risk of MetS.
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Aims The study aimed to investigate the relationship between metabolic syndrome (MS) and risk of cancer in patients with type 2 diabetes (T2DM).

**Methods**: We enrolled 6587 patients with T2DM who were hospitalized in Qingdao Endocrine and Diabetes Hospital from Feb 2005 to Jan 2016. According to the number of MS component each patient had, they were divided into isolated T2DM, T2DM plus 1 component,2 components, 3 components and 4 components, respectively. The IDF Worldwide Definition of the Metabolic Syndrome was applied. Information on the diagnosis of cancer was obtained by matching ICD‐10 codes recorded in local Healthcare medical records database. Prevalence of cancer was compared using Chi‐square test. Logistic regression model was used to evaluate risk of cancer associated with MS.

**Results**: The prevalence of cancer was 4.2% among 6587 patients with T2DM. Female patients had higher prevalence than did male in total or in the MS subgroup. The prevalence of cancer were 3.8%, 3.9%, 3.8%, 5.1% and 5.0% in isolated DM, T2DM plus 1 component of MS, T2DM plus 2, T2DM plus 3 and T2DM plus 4 components, respectively (P for trend \<0.05). Compared with those with less than 3 components, T2DM plus 3 or 4 components had increased risk of having cancer (OR=1.32, 95% CI: 1.04--1.69). Among T2DM patients who had more than 3 components of MS, a specific cluster of increased waist, elevated triglycerides (TG) and decreased High‐Density Lipoprotein Cholesterol (HDL‐C) was associated with the highest prevalence of cancer (10.7%), followed by 8.3% in T2DM patients plus hypertension, elevated TG and decreased HDL‐C and 3.2% in T2DM patients plus hypertension, increased waist and elevated TG (χ^2^ = 26.6, *P *\< 0.05). Conclusions A cluster of metabolic disorders consisting of increased waist, elevated TG and decreased HDL‐C seems to be oncogenic among Chinese patients with T2DM. For patients in combination with 3 or 4 MS components, it is important to conduct early cancer screening and prevention.
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Purpose: Previous studies have shown that low serum bilirubin concentrations may be associated with higher prevalence of diabetic complications in type 2 diabetes (T2D). The aim of the present study was to investigate the association between serum total bilirubin (TBIL) and the prevalence of diabetic microvascular complications in Chinese diabetic patients.

**Methods**: A total of 894 hospitalized patients with T2D were investigated in this cross‐sectional study. Funduscopy and microalbuminuria detection were performed to confirm the presence of diabetic retinopathy (DR) and diabetic nephropathy (DN). Subjects were assigned to quartiles based on serum TBIL concentrations (Quartile (Q) 1 \< 8.9 μmol/L; Q2 8.9--11.5 μmol/L; Q3 11.5--13.9 μmol/L; Q4 \> 13.9 μmol/L). Logistic regression analysis was used to determine the association between TBIL and diabetic microvascular complications.

**Results**: The prevalence of DR and DN was significantly lower in Q4 compared with the other three quartiles (Ptrend \< 0.001). After adjustment for multiple confounding factors, TBIL level as a continuous variable showed an inverse association with the presence of diabetic microvascular complications (OR 0.536, 95% CI 0.331--0.869, *P *= 0.011) in T2D patients.

**Conclusions**: Low serum bilirubin levels are significantly associated with diabetic microvascular complications, independently of traditional risk factors. Further investigation is necessary to determine whether serum bilirubin has a prognostic significance on diabetic microvascular complications.
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**Objective**: Patients with diabetes (DM) are at high risk of restenosis after coronary stenting. Information relating the outcome of percutaneous transluminal coronary angioplasty (PTCA) to prediabetes is, however, limited. The study objective was to investigate the relationship between restenosis after PTCA and baseline glucose categories.

**Methods**: We retrospectively analyzed data of 1003 patients (mean age 58.5 ± 4.2 yrs, 61.5% of men, mean history of coronary heart disease 9.5 ± 1.1 yrs) who undertook PTCA at Emergency Department between Jan 2008 and Dec 2011. Baseline measures included blood pressure (BP), fasting plasma glucose, lipid profile, A1c, C‐reactive protein (C‐RP), and 2‐h capillary glucose. All patients had follow‐up coronary angiography 2 year after PTCA. Restenosis was defined as ≧ 50% stenosis in stent or within 5 mm adjacent to stent. The rate of restenosis was compared among patients with normal glucose tolerance (NGT, *n *= 436), impaired glucose regulation (IGR, *n *= 275), and DM (*n *= 292) according to their baseline glucose levels or prior history of DM.

**Results**: Patients with DM had highest levels of body mass index (BMI), BP, triglycerides (TG), and C‐RP, followed by those with IGR and NGT (*P *\< 0.01).The number of lesion was 1.6, 1.8, and 2.5 in patients with NGT, IGR, and DM, respectively (*P *\< 0.05). At year 2, the rate of restenosis were 4.2%, 5.3%, and 12.0% in patients with NGT, IGT, and DM, respectively (*P *\< 0.05). Among DM subgroup, compared with patients with A1c\<8%, those with A1c\>8% had increased rate of restenosis (14.6% vs. 11.2%, *P *\< 0.05). In the logistic regression model, the odd ratio (OR) of having restenosis was 1.46 (95%CI: 1.05--1.87) for DM and 1.10 (95% CI: 1.01--1.25) for IGR, after adjusting for age, history of CHD, BMI, BP, LDL‐C, TG, and C‐RP.

**Conclusions**: Restenosis is more frequent in patients with compared those without DM. Prediabetes is associated with increased risk of restenosis after PTCA during a follow‐up period of 2 year.
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Aim: To investigate the impact of young‐onset type 2 diabetes mellitus (T2DM) on the risk of nonfatal stroke in Chinese people and its gender difference.

**Methods**: A cross‐sectional survey (3B study) was conducted in Chinese patients (\>18 yrs) with T2DM more than 6 months. Demographic information, HbA1C and clinical profile were documented. Logistic regression analysis was performed to obtain odds ratios (OR) for nonfatal stroke in young‐onset T2DM.

**Results**: A total of 25,817 Chinese with T2DM from 104 hospitals were included in the study from 2011 to 2012. A total of 25,454 were analyzed. A total of 2809 (11%) patients were young‐onset T2DM, among which 62% were male. 2576 (10%) patients had nonfatal stroke. Patients with young‐onset T2DM had 1.26‐fold (95% CI 1.11--1.40) risk of nonfatal stroke of those with late‐onset T2DM. Adjustment for duration of diabetes greatly attenuated the effect size for risk of nonfatal stroke (OR 1.03). The risk of nonfatal stroke was higher in male. Using female and late‐onset T2DM as the reference, the risk of nonfatal stroke was 1.32 in male young‐onset T2DM.

**Conclusion**: Young‐onset T2DM increased the risk of nonfatal stroke in Chinese. Most of the increased risk was attributable to longer duration of T2DM. The risk of nonfatal stroke was higher in male young‐onset T2DM patients.
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**Objective**: To study the relationship between non‐alcoholic fatty liver disease (NAFLD) and carotid atherosclerosis and microalbuminuria in patients with type 2 diabetes.

**Methods**: The study population consisted of 2504 patients (M/F: 1520 /984, mean age 60.8 ± 10.4 years) with type 2 diabetes who have been hospitalized in Qingdao Endocrine and Diabetes Hospital between 2007 and 2011 who had no history of alcohol consumption. All subjects had data on anthropometric parameters, fasting triglycerides, total cholesterol (TC), low‐density lipoprotein cholesterol, high‐density lipoprotein cholesterol, glycosylated hemoglobin A1c (HbA1C), creatinine (Scr), tumor necrosis factor‐ α (TNF‐α), and 24‐h urine albumin exerting rate (24hUAER). Doppler ultrasound examination was used to diagnose fatty liver and to measure carotid artery intima‐media thickness (IMT). Carotid artery intimal thickening was diagnosed as IMT≧1 mm. Diabetic nephropathy was diagnosed if 24hUAER≧30 mg/24 h. The difference among groups was compared using analysis of covariance. Multivariate Logistic regression model was used to evaluate risk factors for diabetic micro‐vascular and macro‐vascular complications.

**Results**: NAFLD accounted for 57.4% of all patients. After adjusting for age, gender, disease duration, blood pressure, waist circumference and other factors, patients with NAFLD had increased carotid artery intima‐media thickness (1.11 ± 0.25 vs. 0.87 ± 0.18 mm, *P *\< 0.001) and increased 24‐h urinary albumin quantification (27.53 ± 19.70 vs. 20.34 ± 13.92 mg/24 h, *P *\< 0.01) compared with those without NAFLD. In the multivariate logistic regression model with Carotid artery intimal thickening as the dependent variable, NAFLD was an independent risk factor for IMT thickening, the corresponding OR (95% CI) was 1.89 (1.42, 2.52) after adjusting for age, gender, disease duration, waist circumference, systolic blood pressure, HbA1C, TC, and TNF‐α; In the similar analysis for diabetic nephropathy, NAFLD was also an independent risk factor for diabetic nephropathy, with an OR (95% CI) of 1.67 (1.25, 2.26).

**Conclusion**: In patients with type 2 diabetes, NAFLD is not only associated with increased risk for macro‐vascular but also for micro‐vascular complications. Therefore, intervention and prevention of NAFLD in diabetes patients may be addressed for prevention of macro‐vascular and micro‐vascular complications.
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Introduction: Recent studies suggest that Youth Type 2 Diabetes (YT2D) has a more aggressive phenotype than the late‐onset cohort and associated with earlier complications. This study aims to characterize the cardio‐metabolic risks among Asian YT2D.

**Methods**: This case‐control study recruited 25 Asian YT2D and 15 healthy controls, matched for gender, ethnicity and body mass index (BMI). Cardiovascular risks were evaluated from clinical histories, physical examination, lipid profiles, high sensitivity‐ C‐Reactive Protein (hs‐CRP), fasting glucose, Homeostatic Model of Assessment‐Insulin Resistance (HOMA‐IR), estimated Glomerular Filtration Rate (eGFR) using 'Bedside Schwartz' equation and microalbuminuria. Visceral adiposity was quantified using limited axial computed tomography scan of the abdomen performed at L4--L5 intervertebral level. Metabolic syndrome (MetS) was defined according to International Diabetes Federation criteria.

**Results**: The YT2D had a mean age of 18.5 ± 0.92 years, disease duration of 23 ± 6 months and HbA1C of 8.4 ± 0.37%. Despite similar BMI, YT2D had higher waist‐hip ratio (0.9 ± 0.01 vs. 0.8 ± 0.02, *P *= 0.011) and visceral adipose tissue (78.9 ± 7.58 vs. 53.2 ± 8.45 cm^2^, *P *= 0.035). YT2D had higher insulin resistance as measured by fasting insulin (117.3 ± 16.38 vs. 63.5 ± 9.63pmol/L, *P *= 0.008) and HOMA‐IR (2.6 ± 0.32 vs. 1.1 ± 0.17, *P *\< 0.001), higher hsCRP (3.8 ± 0.73 vs. 1.6 ± 0.41 mg/L, *P *= 0.10) and more atherogenic lipid profile with lower HDL‐C and higher triglyceride, TC:HDL‐C and TG:HDL‐C ratios, but none on statin treatment. About 24% had pre‐hypertension and 36% were hypertensive, but only 8% were on antihypertensive. Nearly two‐third of YT2D had MetS (64% vs. 6.7%, *P *= 0.001) and 40% YT2D had microalbuminuria (compared to 0% in control, *P *= 0.006). The eGFR was higher in YT2DM (138 ± 34 vs. 110 ± 17 ml/min/1.73 m^2^, *P *= 0.002), with 40% showing glomerular hyperfiltration (≥150 mL/min/1.73 m^2^) (vs. 0% in control, *P *= 0.006). Among YT2D, those with microalbuminuria exhibited higher eGFR than those without (158.9 ± 9.18 vs. 124.3 ± 7.9 mL/min/1.73 m^2^, *P *= 0.010).

**Conclusions**: The Asian YT2D, despite a short duration of disease, demonstrated high cardiovascular risk burden across clinical, lipid subtypes, insulin resistance and inflammatory markers. They had high prevalence of microalbuminuria and glomerular hyperfiltration, both strong predictors for cardiovascular and renal complications. Clinical judgement is required to initiate aggressive cardio‐renal protective treatment in this population. Further outcome study in this population is urgently needed.

PP‐159 {#jdi12939-sec-0318}
======

DPP‐IDF‐WPR‐4 inhibitor reduces the risk of developing hypertrophic scars and keloids in diabetic patients: analysis using the National Database of Health Insurance Claims of Japan {#jdi12939-sec-0319}
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**H. Suwanai^1^, M. Sato^1^, R. Watanabe^2^ and H. Matsumura^1^**

^1^Tokyo Medical University, Tokyo, Japan, ^2^Kanagawa University of Human Services, Kanagawa, Japan

Purpose: Hypertrophic scars and keloids, abnormalities due to hyperplasia of collagen fibers, often occur in surgical wounds, but their exact cause and preventive measures are unknown. The administration of dipeptidyl peptidase‐4 (DPP‐IDF‐WPR‐4) inhibitors to humans is expected to suppress fibrosis in wounds and minimize hypertrophic scar and keloid formation. This study aimed to verify the suppressive effect of DPP‐IDF‐WPR‐4 inhibitors on the formation of hypertrophic scars and keloids using data from the National Database of Health Insurance Claims and Specific Health Checkups of Japan (NDB).

**Method**: We performed retrospective cohort study. We extracted data from NDB between April 2013 and March 2015. NDB includes approximately 3.3 billion claims. Patients who underwent median sternotomy in April 2014 were included in the study based on their claimed surgical codes. Exclusion criteria included median sternotomy during the preceding or subsequent 1‐year period, 'scars' or 'keloids' within 1 year prior to the procedure, and death during the study period. Subjects who were prescribeDPPP‐IDF‐WPR‐4 inhibitors between April 2013 and March 2014 comprised the treatment group; subjects who were not prescribed or administereDPPP‐IDF‐WPR‐4 inhibitors during that period comprised the non‐treatment group. Subjects included 5430 patients throughout Japan (3509 men: mean age, 65.1 years; 1921 women: mean age, 66.0 years).

**Results**: Of the 446 subjects who were treated with DPP‐IDF‐WPR‐4 inhibitors within 1 year before the procedure, six (1.35%) developed either hypertrophic scars or keloids within 1 year of the procedure. Of the 4984 subjects who were not treated, 152 (3.05%) were at significantly lower risk for developing hypertrophic scars and keloids (risk ratio, 0.696; *P *= 0.04). Logistic regression analysis was performed to adjust for confounding factors, with history of hypertrophic scar formation as the explained variable anDPPP‐IDF‐WPR‐4 inhibitor treatment, age, sex, diabetes mellitus status, and steroid treatment as explanatory variables. Treatment with DPP‐IDF‐WPR‐4 inhibitors minimised the development of hypertrophic scars and keloids, although it was not statistically significant (treatment odds ratio, 0.512; *P *= 0.12).

**Conclusion**: Treatment with DPP‐IDF‐WPR‐4 inhibitors in diabetic patients minimised the risk of hypertrophic scars and keloids in humans. These results prove a cause‐and‐effect relationship and are highly generalisable to Japanese people.
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**C. Pagnavuth**

Preah Ket Mealea Hospital, Phnom Penh, Cambodia

The aim of observational study was to describe the profile Cambodian DM2 of Preah Ket Mealea Hospital. The study was performed with 135 DM2 patients who came to treat, & followed up at Medicine/Diabetic ward. The patients completed an interviewer‐administered questionnaire such as name, age, sex, address, year of diabetes, past history of getting weight gain before diagnosis of diabetes, waist circumference measurement, &HbA1c levels. In total, 135 patients with mean age of 56.46 + 12.97 were studied. Among 135 patients, 67 were female and 68 were male. Age group distribution of diabetic patients were found in 6% (*n *= 08) from 20 to 29 years old, 5% (*n *= 7) from 30 to 39 years old, 10% (*n *= 13) from 40 to 49 years old, 35% (*n *= 47) from 50 to 59 years old and 44% (*n *= 60) from 60 years old and older. 30% (*n *= 41) were found as newly detected cases. 9 Patients remaining from new cases have had year of diabetes from 1 year to 15 years. 24% (*n *= 32) were found in BMI from 23 to 24.9 kg /m^2^, 41% (*n *= 13) were female &59% (*n *= 19) were male. 40% (*n *= 54) were found in BMI from 25 and over, among them 48% (*n *= 26) were female and 52% (*n *= 28) were male. BMI calculated according to weight before diagnosis of diabetes 23% (*n *= 31) were found in BMI from 23 to 24.9, &61% (N = 83) in BMI from 25 and over. Waist circumference of female \>80 cm, 67% (*n *= 55) were found among 67 female patients, for male \>90 cm 48% (*n *= 32) were found among 68 male patients. The majority of DM2 84% (*n *= 135) were overweight and obese referring to BMI, 61% (*n *= 67) of female &48% (*n *= 68) of male were central obesity referring to waist circumference. The results revealed that over‐weight and obesity was a major risk factor for DM2 among Cambodian people. The characterization of this risk profile will contribute to designing more effective and specific strategies for primary prevention of T2DM among Cambodian people.
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Clinical misdiagnosis of diabetic neuropathy: a case of diabetes with Morton\'s Neuroma {#jdi12939-sec-0323}
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**W.‐L. Chuang**

Lukang Christian Hospital, Changhua County, Taiwan

A 57‐year‐old woman with diabetes presented bilateral lower leg pain and numbness for months and visited the neurology clinic. The pain and numbness symptoms were periodic. Pain and numbness were usually at the dorsum of the foot. Pain was usually more obvious and more severe at right foot. There is no erythematous skin change or swelling in foots. Nerve Conduction Velocity (NCV) studies showed prolonged latencies of F‐wave in bilateral peroneal nerves. According the clinical presentation and NCV results, diabetic neuropathy was diagnosed. Duloxetine was prescribed but then switched to pregabalin because the patient had gastroparesis discomfort after duloxetine use. But pain did not improve after duloxetine or pregabalin use. Then she was referred to the endocrine clinic for further evaluation. Musculoskeletal ultrasound evaluation was arranged and revealed a round to ovoid hypoechoic and well‐defined lesion with length of 60 mm in the intermetatarsal space between big toe and 2nd toe. Sonographic probe also induced tenderness and numbness at the lesion area. The comparison between her foot tracing result and her shoe size identifies that there is not enough space to hold her foot in place. According to sonography images and physical examination and foot tracing results, morton\'s neuroma was diagnosed and to change larger and fit shoes was recommended. By footwear modification, the patient\'s pain and numbness improved. Diabetic neuropathy was a common complication in diabetic patients but sometimes patients with other disorders may present similar symptoms. Physicians should be aware of other causes of pain and numbness. Ultrasonography evaluation is a valuable diagnostic tool for physician to differentiate diagnosis.
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**M. K. Lee^1^ and H. S. Kwon^1^**

^1^Division of Endocrinology and Metabolism, Department of Internal Medicine, Myongji hospital, Gyeonggi‐do, Republic of Korea, ^2^Division of Endocrinology and Metabolism, Department of Internal Medicine, Yeouido St. Mary\'s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

BACKGROUND: The metabolic syndrome is associated with an increased risk of diabetes. In this study, we aim to investigate the incidence rate of type 2 diabetes according to the number of metabolic syndrome components using data from the Korean National Health Insurance Service‐National Sample Cohort (NHIS‐NSC).

**Methods**: Our data include a total of 19,475,643 individuals at the age of 20 years or older with no history of diabetes, between 2009 and 2012. We define metabolic syndrome using the modified criteria of the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III). We assessed the association of the number of metabolic syndrome components or its combinations with incident diabetes over the 5 years of follow‐up using Cox proportional hazards models.

**Results**: Incidence rate of diabetes increased gradually with the number of metabolic syndrome. The multivariable‐adjusted hazard ratios for incident diabetes were 1.40, 1.86, 2.47, 3.16 and 4.50 from one to five components of metabolic syndrome, respectively, compared with those in the absence of its component. Elevated fasting glucose at baseline was the most associated with incident diabetes, the risk being increased by 82%. The combinations that included elevated fasting glucose appeared to be more strongly associated with the risk of diabetes than other combinations with the same number of metabolic syndrome components.

**Conclusions**: The risk of developing diabetes increases as the number of metabolic syndrome components increase. Among the components, elevated fasting glucose is the most powerful predictor of diabetes. Our findings indicate that the risk stratification by the number of metabolic syndrome components and hyperglycemia status can detect individuals with a high risk of diabetes.
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**L. Yingshu, G. Xiaolan and G. Zhengnan**

Central Multiple Hospital of Dalian, Dalian, China

**Objective**: To study the relationship of the neck circumference to metabolic syndrome and its components in patients with type 2 diabetes.

**Methods**: A total of 1220 patients with type 2 diabetes were recruited in Dalian community. The neck circumference (NC), height, weight, waist circumference (WC), systolic blood pressure (SBP), diastolic blood pressure (DBP), total cholesterol (TC), triglycerides (TG), low‐density lipoprotein‐cholesterol (LDL‐C), high‐density lipoprotein‐cholesterol (HDL‐C), fasting plasma glucose (FPG), glycosylated hemoglobin (HbA1c) and uric acid (UA) were measured.

**Results**: (1) The NC was (39.30 ± 2.76)cm in men and (35.33 ± 2.63)cm in women. (2) NC was positively correlated with TC in men; BMI, HbA1c in women; WC, SBP, DBP, TG, FPG and UA in men and women (all *P \< *\<0.05). (3) Adjusted for both age and BMI, NC increased with WC in men and WC, FPG, TG in women. (4) In a secondary analysis of incident metabolic syndrome components as outcome, adjusted for both age and BMI, NC increased with the risk of metabolic syndrome (*OR* =1.40, 95% *CI* 1.21--1.63) and central obesity (*OR*=1.43,95% *CI* 1.20--1.70) in men, while metabolic syndrome (*OR* =1.42,95% *CI* 1.24--1.62), central obesity (*OR* =1.47,95% *CI* 1.22--1.77), hypertension (*OR* =1.12,95% *CI* 1.04--1.22), high TG (*OR* =1.11,95% *CI* 1.04--1.20) and low HDL‐C (*OR* =1.14,95% *CI* 1.06--1.22) in women. (5) The NC of ≥37.1 cm (AUCs 0.806) for men and ≥33.4 cm (AUCs 0.816) for women was the best cutoff point for determining subjects with metabolic syndrome.

**Conclusion**: NC is associated with metabolic syndrome and its components even after adjust for age and BMI, and it is an independent risk factor for metabolic syndrome in patients with type 2 diabetes. NC plays an important role in prediction of metabolic syndrome.
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**S. A. Wahab and T. Taib**

Department of Internal Medicine, Faculty of Medicine, University Teknologi MARA, Sungai Buloh Selangor, Malaysia

Introduction: Diabetic patients are more vulnerable to infection as compared to the general population. This is due to the deleterious effect of hyperglycemia on chemotaxis, phagocytosis and neutrophil bactericidal activity. Cellulitis is a common acute bacterial infection affecting the tissues of the dermis and subcutaneous tissues; commonly affecting the lower limb. Previous studies showed that super‐oxidised solution improves healing in diabetic foot infection; however, there are limited data available on super‐oxidised hydrogels. Potassium permanganate has been used for decades as a topical antiseptic. Methodology: This study is aimed to evaluate the reduction of erythema as a sign of improvement of local inflammation; measured as percentage of reduction of total surface area erythema at end‐of‐treatment at day 3; in patients with diabetes mellitus, presenting with lower limb cellulitis. This is a prospective, open‐label, comparative clinical study, between two methods of dressing; super‐oxidised hydrogel and solution dressing compared to potassium permanganate dressing, applied at different sites of the lower limbs with cellulitis changes for 15 min, twice a day and reviewed at end‐of‐treatment at day 3. All patients were on systemic antibiotics.

**Results**: Twenty‐patients with 2 different sites of cellulitis area selected in the same patient, were enrolled after fulfilling inclusion criteria. Patients were considered diabetic if they had a clinician diagnosis of diabetes mellitus as a co‐morbidity. The median age was 65.5 years (IQR 14) and 60% were male patients. Sixty percent had bullous cellulitis and the disease recurrence of cellulitis was up to 40% of the study cohort. Study showed that super‐oxidised hydrogel and solution dressing was more effective in reducing erythema compared to potassium permanganate dressing, with statistically significant difference in percentage of erythema reduction at Day 3 (57.14% vs. 37.01%; *P *= 0.007).

**Conclusion**: Super‐oxidised hydrogel and solution is more effective in improving local erythema as compared to potassium permanganate dressing, in patients with lower limb cellulitis, with co‐morbidity of diabetes mellitus. High prevalence of bullous cellulitis was seen in the diabetic population. Therefore, we would introduce the super‐oxidised hydrogel combined with the solution, as a topical therapy, integrated in the treatment of diabetic lower‐extremity infections involving cellulitis.
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Circulating miR‐29b positively correlates with non‐alcoholic fatty liver disease in a Chinese population {#jdi12939-sec-0331}
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**J. Yan, Y. Li, Y. Zong, F. Jiang and C. Hu**

Shanghai Diabetes Institute of China, Shanghai, China

**Aims**: The early screening of non‐alcoholic fatty liver disease (NAFLD) is of great significance for early detection and intervention in NAFLD. MicroRNAs (miRNAs) are important regulators of metabolic disease, including NAFLD. The aim of this study was to examine the association of serum miR‐29a‐c with NAFLD in a Chinese population.

**Methods**: A total of 276 individuals were enrolled in this study, including 68 controls with no NAFLD or type 2 diabetes (T2D), 73 individuals with NAFLD but no T2D, 68 individuals with T2D but no NAFLD and 67 individuals with both NAFLD and T2D. Real‐time PCR was performed to quantify the serum miR‐29a‐c expression levels.

**Results**: Meta‐analysis from non‐diabetic and diabetic groups indicated that serum miR‐29b, but not miR‐29a or miR‐29c, was positively associated with NAFLD after combining the results (odds ratio \[OR\] =2.04(1.16, 3.58), *P *= 0.013 for miR‐29b). Additionally, we showed that serum miR‐29b was positively correlated with age, triglyceride (TG) levels, and fasting plasma glucose (FPG) levels (all *P *\< 0.05). Multiple stepwise regression analysis showed that age, TG level, and FPG were independently associated with miR‐29b (β  ±  SE=0.004 ± 0.002, *P *= 0.019 for age; β ±

SE=0.110 ± 0.054, *P *= 0.042 for TG; β  ±  SE=0.389 ± 0.161, *P *= 0.016 for FPG).

**Conclusions**: In conclusion, we revealed that serum miR‐29b was associated with NAFLD in a Chinese population‐based study and is a potential biomarker for NAFLD.
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**L. Jin, C. Hu and W. P. Jia**

Shanghai Sixth People\'s Hospital, Shanghai, China

**OBJECTIVE**: Hyperuricemia is a complex disease involving multiple genes, which is caused by the breakdown of blood uric acid homeostasis. In recent years, the prevalence of hyperuricemia has increased year by year, and accompanied by metabolic syndrome and diabetes. Genetic factors play an important role in the development of hyperuricemia. HLA gene polymorphism is related to various complex diseases, and the HLA‐B\*5801 is closely related to the side effect of allopurinol. However, due to the complex of HLA region, it is difficult to resolve the region. In this study, the illumina exome chip was used to genotype the genetic variations of HLA‐B gene region, and the relationship between polymorphism of HLA‐B gene and uric acid, glycolipid metabolism and body fat distribution was analyzed.

**Methods**: We recruited 2371 people from a community in Shanghai. The genetic variation of the HLA‐B exon region was genotyped using the illumina exon chip. These data were analyzed after quality control. The relationship between genetic variation of HLA‐B gene with uric acid, glycolipid metabolism and body fat distribution was analyzed.

**Results**: First, we used the genotyping data to analyze the frequency of the HLA‐B\*5801. According to SNPedia database, this locus can be represented by rs3134792(C) + rs4713518(A) in the Chinese population. The results showed that the frequency of the HLA‐B\*5801 was 7.5%. HLA‐B\*5801 was not associated with uric acid levels (*P *= 0.0808), and this genotype was not associated with glycolipid metabolism and body fat distribution. We found that rs1050458 in the HLA‐B region was significantly associated with uric acid (*P *\< 8.08\*10^−5^), which was not associated with glycolipid metabolism but was significantly associated with BMI, waist circumference, waist‐to‐hip ratio, and visceral fat area.

**Conclusion**: HLA‐B\*5801 is not associated with uric acid levels, glycolipid metabolism and body fat distribution, while rs1050458 is significantly associated with uric acid levels and body fat distribution.
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Universiti Teknologi Mara (UiTM), Sungai Buloh, Malaysia

Introduction: Cardiovascular complications in patients with diabetes mellitus are well‐known. Least studied are the cardiovascular risk in pre‐diabetes patients. Both impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) have high risk of cardiovascular morbidity. A recent study found that dysglycaemia was independently associated with acute coronary events, after adjusting for traditional risk factors. In another study, 2‐h post oral glucose tolerance test (OGTT) predicted major cardiovascular adverse outcomes and mortality.

**Methods**: A cross‐sectional study of 284 patients from Medical clinic. The objectives were to investigate the prevalence of undiagnosed dysglycaemia (diabetes, IFG and IGT) in our medical clinic population, and to investigate its associations with traditional risk factors. Inclusion criteria were age ≥30‐years‐old and no known diabetes or pre‐diabetes. Pregnant patients were excluded. All patients had fasting and 2‐h post OGTT glucose levels taken.

**Results**: The prevalence of undiagnosed dysglycaemia was 36.3% (of which 27.1% were IGT, 5.6% IFG and 9.5% diabetes). Mean age was 61.6 ± 9.8 years old. Gender distribution was 50.9% male and 40.1% female. Race distribution was 46.7% Malay, 38.2% Chinese, and 14.7% Indian. Half (50.9%) were non‐smoker, 33.9% ex‐smoker, and 14.1% active smokers. Only 40 patients (14.1%) had pre‐existing cardiovascular disease. Mean weight was 63.22 ± 13.29 kg, with mean BMI 25.04 ± 5.20 kg/m2. Ninety‐one patients (32.0%) were on systemic steroid, with median dose of 0.00 mg/day (IQR 0.00--0.82 mg/day). Patients with dysglycaemia had significantly higher weight (66.83 ± 13.22 kg, *P *= 0.001), higher BMI (26.01 ± 5.18 kg/m^2^, *P *= 0.017), higher systolic blood pressure (137.6 ± 19.3 mmHg, *P *= 0.009) and diastolic blood pressure (79.7 ± 9.3 mmHg, *P *= 0.048) as compared to the non‐dysglycaemia group. There was no difference in steroid dose between the groups. However, subgroup analysis of patients on the systemic steroid, the prevalence of dysglycaemia increased to 39.6% and diabetes increased to 15.4%.

**Conclusion**: The prevalence of dysglycaemia, especially IFG were high in patients even with no traditional risk factors for diabetes. These patients with dysglycaemia have significantly higher weight, BMI, systolic and diastolic blood pressure. Furthermore, this study underscores the need for early identification of patients with pre‐diabetes to allow for early intervention.
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**M. Ung**

Royal University of Health Sciences, Phnom Penh, Cambodia

**Objective**: This study is conducted in order to find the right treatment of diabetic foot ulcer on early diagnosed Diabetic Mellitus patients who came to have consultation and treatment with doctors at Cambodia‐Korea Diabetes Center. Moreover, when patients receive appropriate treatment, it would reduce the rate of amputation among new patients.

**Methods**: Data of 300 patients who were admitted at Cambodia‐Korea Diabetes Center were collected in this study. The total 300 patients visited in Hospital from January 2017 to January 2018. An estimated 60--80% of patients who present with diabetic foot ulcer are admitted to the hospital. In treating acute foot infections mainly spreading to the bone, patients are always given with antibiotic drugs. A cure foot ulcer depending on patient\'s bed preparation environment room in hospital. In practical use in hospital clean wound with Betadine 10% associate with Nss solution steam at least 30 min a day. Was treating by Antibiotic. As working as teams as orthopedic surgery, doctor and nurse foot care. Those are reasons, we were treating, Diabetic foot ulcer to decease amputation.

**Results**: After getting treatment of diabetic foot ulcer among the 300 patients at Cambodia‐Korea Diabetes Center, the improvement in ulcer healing has been observed with primary healing of up to 65--85%. Diabetic foot should be regarded as a life‐long condition and have to be treated accordingly to prevent recurrence. Long‐term efforts have reduced the amputation up to 37%‐75% in the hospital. The male and female patients whose age was from 50 to 69 years old (65%) had no knowledge on diabetic foot according to the survey done by the questionnaire. And up to 68.3% had no idea on diabetic foot self‐care. Hospitalization 54%, Healed 58%, Non healing 40%.

**Conclusion**: Diabetic foot ulcer in Cambodia is the big challenges due to management of the ulcer were resistance by antibiotic drugs. The patients have poor understanding of the necessity to take medication. The poor patients do not came to hospital for follow up with medical staffs. The patients are poor in understanding of diabetic foot care.
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^1^Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea; Severance Hospital, Seoul, Republic of Korea, ^2^Institute of Endocrine Research, Yonsei University College of Medicine, Seoul, Republic of Korea, ^3^Huh\'s Diabetes Center and the 21st Century Diabetes and Vascular Research Institute, Seoul, Republic of Korea, ^4^Department of Internal Medicine, Myongji hospital, Goyang, Republic of Korea

Relationship between hepatic steatosis or fibrosis and cardiac dysfunction in relation to insulin resistance has been poorly understood. We aimed to investigate whether hepatic steatosis or fibrosis is associated with left ventricular (LV) diastolic dysfunction in patients with type 2 diabetes (T2DM). We studied 454 patients with T2DM, aged 55 years or older (men 22.0%, mean age 64.9 years old), who had undergone liver ultrasonography, pulsed‐wave doppler echocardiography, short insulin tolerance test (SITT), and bioimpedance analysis. Simple hepatic steatosis and steatohepatitis were sonographically defined in the presence or absence of fibrosis according to NAFLD fibrosis scores. Diastolic dysfunction was defined by using peak early (E) to late (A) ventricular filling ratio (E/A) and E‐wave deceleration time (DT). Of 454 patients, 284 (62.6%) had hepatic steatosis, and 273 (60.1%) had diastolic dysfunction. The prevalence of diastolic dysfunction progressively increased according to the presence of hepatic steatosis or fibrosis (52.9%, 62.0%, and 65.3%; normal, simple steatosis, and steatohepatitis, respectively; P for trend\<0.05). Multivariate logistic regression analysis showed significant association between diastolic dysfunction and hepatic steatosis (odds ratio \[OR\]=1.98, 95% confidence interval \[CI\]=1.02--3.90, *P *\< 0.05), after adjusting for glycometabolic parameters, abdominal fat percentages, and SITT. Furthermore, subjects with steatohepatitis had a significantly higher odds for diastolic dysfunction (OR=2.06, 95% CI=1.04--4.11, *P *\< 0.05) compared to subjects with normal or simple steatosis. However, this association was attenuated when SITT was added to the model. In conclusion, hepatic steatosis and steatohepatitis are independently associated with LV diastolic dysfunction in older adults with T2DM, and insulin resistance is a significant confounding factor.
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Soonchunhyang University, Seoul, South Korea

**Background**: Recent studies have shown associations between serum cystatin C levels and vascular complications; however, few have investigated these associations in diabetes without nephropathy. We evaluated the relationship between serum cystatin C and vascular complications in patients with type 2 diabetes mellitus (T2DM) with normal renal function or mild renal impairment.

**Methods**: A total of 806 consecutive patients with T2DM who were admitted to the diabetes center of Soonchunhyang University Hospital for blood glucose control were retrospectively reviewed. Patients with nephropathy were excluded. Subjects were categorized into quartiles of serum cystatin C levels (Q1, ≤0.65 mg/L; Q2, 0.66˜0.79 mg/L; Q3, 0.80˜0.94 mg/L; and Q4, ≥0.95 mg/L). Multivariate logistic regression was conducted for the risk of vascular complications.

**Results**: The proportion of patients with diabetic retinopathy (DR), coronary heart disease (CHD) and stroke increased across the serum cystatin C quartiles (p for trend\<0.001). After adjustment for confounding factors, the highest serum cystatin C level remained a significant risk factor for DR (odds ratio \[OR\] 1.929, 95% confidence interval \[CI\] 1.030--3.614, *P *= 0.040). Compared with Q1, a significant positive association was observed between serum cystatin C and CHD in Q2 (OR 7.321, 95% CI 1.560--34.361, *P *= 0.012), Q3 (OR 6.027, 95% CI 1.324--27.435, *P *= 0.020) and Q4 (OR 8.122, 95% CI 1.755--37.577, *P *= 0.007). No associations were observed between cystatin C and stroke after additional adjustment for confounding variables.

**Conclusion**: Serum cystatin C levels are independently associated with DR and CHD, suggesting that cystatin C may be useful for identifying patients with T2DM without nephropathy who are at high risk for vascular complications.
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Introduction: Diabetes mellitus (DM) is a major public health concern in Malaysia. The Finnish Diabetes Risk Score (FINDRISC) is one of the most frequently used instruments for assessing the risk of DM in the following 10 years Methodology: A cross‐sectional study was carried out among the health care providers in Hospital Tuanku Jaafar with no known DM. All individuals completed the FINDRISC questionnaire. The total diabetes risk score (TDRS) derived from the FINDRISC questionnaire for each participant was the summation of all the scores. The risk of developing T2DM within 10 years was classified as follows: low (\<7), slightly elevated (7--11), moderately elevated (12--14), high (15--20) and very high (\>20). Oral Glucose Tolerance Test (OGTT) was performed in those participants with moderately elevated, high and very high risk category.

**Results**: A total of 203 participants were enrolled. The age of the participants ranged from 19 to 57 years old with a mean age of 33.50 ± 9.02 years. There were 127 (62.6%) females. Pertaining the 8 variables of FINDRISC, 87.2% of the participants were \<45 years old; 56.2% fell into the lower Body Mass Index (BMI) category; 63.1% has waist circumference \<94(Male); \<80 (Female); 37.4% of them had exercise or physical activity ≥30 min/day; 70.9% consumed vegetables, fruits or berries everyday; 93.6% not on antihypertensive; 96.1% no history of raised blood glucose documented prior and 43.8% had no family history of DM.. The mean TDRS was 6.7 ± 3.87. Most of the participants fell in the slightly elevated category (107, 52.7%). OGTT was performed to 22 participants with moderately elevated and high risk category. We identified a case of impaired glucose tolerance, and a case of DM. The prevalence of DM is 4.5% in these categories.

**Conclusion**: FINDRISC questionnaire is a simple yet useful tool for the screening of DM. Despite the medical knowledge and awareness of modifiable risk factors, our health care providers still at risk for DM.
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**N. Takzaree, A. Takzaree and N. Daneshvar**

Tehran University of Medical Sciences, School of Medicine, Anatomy Department, Tehran, Iran

Accelerating wound healing is now considered as a principle clinical treatment and increasing the quality and speed of healing which has always been emphasized by the scientists. Propolis and honey are natural bee products with wide range of biological and medicinal properties. This study was aimed to determine the synergistic effect of honey and propolis in wound healing of rat skin. 75 diabetic Wistar rats weighing 200--250 gr were placed under general anesthesia and sterile conditions. Then a square shape wound with 1.5\* 1.5 mm dimension was made on the back of the neck. Animals were randomly divided into control, honey, propolis, combined honey propolis and phenytoin 1% groups, respectively. Rats were randomly divided into the following groups: 4^th^, 7 ^th^ and, 14 ^th^ days of treatment in each period of study. Wound area in the experimental group were covered once daily with a fixed amount of thyme honey, propolis, propolis and honey and phenytoin cream (1%), control group did not receive any treatment. For histological studies, during the fourth, seventh and fourteenth day\'s rats were sacrificed and samples were taken from the wound and adjacent skin. After histological staining fibroblast, neutrophils, macrophages and vascular sections were counted in wound bed. The macroscopic and microscopic evaluations showed that the percentage of wound healing on different days in the experimental and control groups were significant (*P *\< 0.05). The macroscopic and microscopic evaluation showed that the percentage of wound healing on different days in combined propolis and honey experimental group was significantly different with the control group (Multivariate ANOVA test) (*P *\< 0.05). combined application of propolis and honey on the open wound healing in rats has a synergistic effect.
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^1^Department of Metabolism, Endocrinology, and Molecular Medicine, Osaka City University Graduate School of Medicine, Osaka, Japan, ^2^Department of Nephrology, Osaka City University Graduate School of Medicine, Osaka, Japan, ^3^Department of Premier Preventive Medicine, Osaka City University Graduate School of Medicine, Osaka, Japan, ^4^Department of Vascular Medicine, Osaka City University Graduate School of Medicine, Osaka, Japan

Omentin is an adipokine expressed in visceral adipose tissue and has biological effects against insulin resistance and atherosclerosis in rodents. Previous studies have shown that plasma omentin levels were decreased in individuals with obesity, metabolic syndrome, type 2 diabetes, or coronary artery disease. However, no study has examined in detail the clinical significance of plasma omentin levels in patients with type 2 diabetes. In this study, we explored the factors associated with plasma omentin levels in Japanese patients with type 2 diabetes. A total of 428 patients with type 2 diabetes were included in this study. Fasting plasma omentin levels were measured by ELISA. Visceral and subcutaneous fat area were measured by dual bioelectrical impedance analysis for a part of subjects (*n *= 112). The medians of age, duration of diabetes, BMI, eGFR, and plasma omentin level were 65 years old, 11 years, 25.0 kg/m^2^, 67.0 ml/min/1.73 m^2^, and 572 ng/mL, respectively. Ninety one (21%) subjects had cardiovascular diseases (CVDs) which were confirmed by medical records. Plasma omentin levels showed a positive correlation with plasma adiponectin levels (ρ=0.420, *P *\< 0.001) and were inversely correlated with parameters of obesity and insulin resistance (IRI, HOMA‐R, triglycerides, and HDL‐C). On the other hand, positive correlations were found between plasma omentin levels and age, systolic blood pressure, and serum creatinine levels. Among parameters related to obesity, visceral fat area showed the strongest association with plasma omentin levels even after adjustment with age, sex, eGFR, and BMI. Multiple regression analysis revealed that age, HbA1c, HDL‐C were positively, while BMI and eGFR were negatively associated with plasma omentin levels after further adjustment for sex, blood pressure, triglycerides, and LDL‐C. Finally, subjects with CVDs showed higher plasma omentin levels than those without CVDs. Multiple logistic analysis revealed that older age, male sex, and lower eGFR, but not plasma omentin levels, were independently associated with CVDs. In summary, this study revealed that (1) an inverse relationship between omentin and visceral adiposity in patients with type 2 diabetes and that (2) elevated plasma levels of omentin in diabetic patients with CVDs due partly to older age and renal dysfunction.
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^1^Taichung Veterans General Hospital, Taiwan, R.O.C., ^2^National Taiwan University Hospital, R.O.C., ^3^National Health Research Institutes, Taiwan, R.O.C., ^4^Taipei Renji Hospital, R.O.C., ^5^The Diabetes Association of the Republic of China (Taiwan)

PURPOSE: Previous researches reported that 32 to 35% of diabetic patients achieved a glycated hemoglobin (HbA1c) target of \<7.0% in Taiwan. With increased available treatments modalities and care models, the objective of this study was to examine quality control in the diabetic patients from the Taiwan Diabetes Registry (TDR).

**Methods**: The Diabetes Association of the Republic of China (Taiwan) launched in October, 2015 which comprised three patient groups, including those ever participating the quality control study in diabetes in 2006 and 2011(group 1), type 1 diabetes (group 2), and type 2 diabetes diagnosed within one year (group 3). The percentage of attaining targets for (HbA1c) less than 7%, blood pressure (BP) less than 130/80 mmHg or 140/90 mmHg, low‐density lipoprotein cholesterol (LDL‐C) less than 100 mg/dL, all 3 (ABC controls), and no hypoglycemia within 3 months at the baseline enrollment was obtained.

**Results**: Until May 31, 2018, a total of 5,417 diabetic patients, including 1,218 in group 1 (mean±SD, 66.5 ± 12.6 years; M/F 645/573), 1,088 in group 2 (33.9 ± 14.0 years; M/F 435/653), and 3,111 in group 3 (55.1 ± 13.9 years; M/F 1759 /1352), entered the study. The attained percentage of various metabolic goals in group 1, 2, and 3 was 37.0%, 28.0%, and 38.5%, respectively for HbA1c\<7%, 67.9%, 63.5%, and 42.0% for LDL‐C \< 100 mg/dL, 34.1%, 73.1%, and 35.7% for BP\<130/80 mmHg, 64.9%, 85.7%, and 67.8% for BP\<140/90 mmHg, 83.9%, 19.3%, and 92.0% for no hypoglycaemia within three months, and 10.3%, 9.9%, and 7.5% for all 3 ABC controls with BP\<130/80 mmHg, or 19.1%, 12.4%, and 13.9% for all three ABC controls with BP\<140/90 mmHg.

**Conclusions**: As new treatment modalities and diabetes care become available, the proportion of patients in TDR achieving ABC targets improved gradually. Further monitoring of diabetic treatment qualities remains necessary.
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Kurashiki Central Hospital, Kurashiki, Japan

**Background and Aim**

The elderly patients with type 2 diabetes mellitus (T2DM) usually develop microangiopathies and decrease insulin secretion. The aim of this study was to clarify the affecting factors on residual insulin secretion and diabetic microangiopathies in elderly T2DM.

**Methods**: The study included a total of 1115 elderly T2DM individuals who admitted to our hospital between October 2006 and September 2015. (1)At first, the patients were divided into two groups which indicating same age to exclude factor of aging; elderly onset aged group who developed T2DM at 65 years and older (Group A), and non‐elderly onset present elderly group who developed T2DM at less than 65 years old (Group B). (2)Secondary, in order to analyze the influence of the aging, we also compared Group A with juvenile group who developed T2DM under the age of 35 (Group C) with adjusted same duration to Group A. The logistic regression analysis and clinical statistics were performed.

**Results**: Logistic regression analysis revealed that in all diabetic microangiopathies, duration of T2DM was a significant explanatory variables. In order of Group A, B, and C, the average age was 75.2 ± 5.6(Mean±SD), 75.0 ± 4.2, and 27.6 ± 6.2 years old, and duration of T2DM was 4.8 ± 5.1, 22.5 ± 9.4, and 4.6 ± 5.3 years, respectively. The peripheral serum C‐peptide (CPR) was measured by glucagon load test to indicate residual insulin secretion. The average ΔCPR was 2.03 ± 1.23, 1.57 ± 1.10, and 2.81 ± 1.97 ng/ml, respectively. The merger rate of diabetic microangiopathies was the following; 61.1%, 78.3%, and 22.3% for neuropathy, 32.0%, 60.6%, and 19.1% for retinopathy, and 39.3%, 48.4%, and 28.7% for nephropathy, respectively. These data showed that longer duration of T2DM significantly decreased insulin secretion and developed diabetic microangiopathies in elderly patients when comparing at the same age. And also the aging significantly decreased insulin secretion and developed more diabetic microangiopathies when comparing at the same duration of T2DM.

**Conclusion**: Duration of T2DM and aging are indicated to be more important affecting factors to decrease insulin secretion and to progress diabetic microangiopathies in elderly T2DM.
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**F. Sun, L. Wang, J. Ming, B. Gao and Q. Ji**

Xijing Hospital, The First Affiliated Hospital of The Fourth Military Medical University, Xi\'an, China

Purpose: There is no consensus in whether the biomedical impedance anthropometrics (BIA) exhibited better predictive performance for diabetes (DM) than simple anthropometric parameters. The aims of the prospective study are firstly to compare the association between various anthropometric measures, BIA and diabetes in a northwestern Chinese population.

**Method**: The data used at baseline was a part of the China National Diabetes and Metabolic Disorders Study conducted in Shaanxi province, conducted from June 2007 to May 2008. The individuals at baseline were invited to participate in a follow‐up evaluation between June 2012 and October 2013. The association between indicators at baseline and newly developed diabetes was assessed by binary logistic regression analysis. Body fat percentage (BF%), fat mass index (FMI) were evaluated by biomedical impedance. Results: This study sample included 633 non‐DM individuals, with 39.8% males. 39 (6.2% of total subjects) were diagnosed as DM after 5 years. The subjects in the highest quartile of the baseline FMI level had over a 6 times greater risk of developing DM as compared to that of the subjects in the lowest quartile after adjustment (RR: 6.08, 95% CI: 1.13--32.8). WC (RR: 3.12, 95%CI: 0.54--17.9). Body mass index (BMI) (RR: 2.11, 95%CI: 0.43--10.2), weight to height ratio (WHtR) (RR: 3.92, 95%CI: 0.73--21.0), BF% (RR: 5.78, 95%CI: 1.02--32.7) showed no significant meaning. In women, the subjects in the highest quartile of the baseline BF% levels had over a 8 times greater risk of developing DM as compared to the lowest quartile after adjustment (RR:8.61, 95% CI: 1.05--70.6). WC (RR: 2.95, 95%CI: 0.58--15.0), BMI (RR: 6.25, 95%CI: 0.75--52.5), WHtR (RR: 2.47, 95%CI: 0.46--13.2), FMI (RR:0.90,95%CI:0.35--2.35) at baseline showed no statistical meaning. The areas under ROC curve of baseline FMI for diagnosing DM was 0.683 (95%CI: 0.6240--0.738) in men, the corresponding cutoff of FMI level was 10.11, .the areas under ROC curve of baseline BF% for diagnosing DM was 0.701(95%CI: 0.651--0.747) in women, the corresponding cutoff of BF level was 31.9%.

**Conclusion**: Indicators of BIA had better predict value of diabetes than anthropometrics. FMI, BF% were appropriate for predicting DM in men and women, respectively.
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^1^Myongji Hospital, Goyang‐si, South Korea, ^2^Yonsei University College of Medicine, Department of Internal Medicine, Seoul, South Korea, ^3^International Healthcare Center, Asan Medical Center, Seoul, South Korea, ^4^Huh\'s Diabetes Center and the 21st Century Diabetes and Vascular Research Institute, Seoul, South Korea

Relationship between hepatic steatosis or fibrosis and cardiac dysfunction in relation to insulin resistance has been poorly understood. We aimed to investigate whether hepatic steatosis or fibrosis is associated with left ventricular (LV) diastolic dysfunction in patients with type 2 diabetes (T2DM). We studied 454 patients with T2DM, aged 55 years or older (men 22.0%, mean age 64.9 years old), who had undergone liver ultrasonography, pulsed‐wave doppler echocardiography, short insulin tolerance test (SITT), and bioimpedance analysis. Simple hepatic steatosis and steatohepatitis were sonographically defined in the presence or absence of fibrosis according to NAFLD fibrosis scores. Diastolic dysfunction was defined by using peak early (E) to late (A) ventricular filling ratio (E/A) and E‐wave deceleration time (DT). Of 454 patients, 284 (62.6%) had hepatic steatosis, and 273 (60.1%) had diastolic dysfunction. The prevalence of diastolic dysfunction progressively increased according to the presence of hepatic steatosis or fibrosis (52.9%, 62.0%, and 65.3%; normal, simple steatosis, and steatohepatitis, respectively; *P* for trend\<0.05). Multivariate logistic regression analysis showed significant association between diastolic dysfunction and hepatic steatosis (odds ratio \[OR\]=1.98, 95% confidence interval \[CI\]=1.02--3.90, *P *\<* *0.05), after adjusting for glycometabolic parameters, abdominal fat percentages, and SITT. Furthermore, subjects with steatohepatitis had a significantly higher odds for diastolic dysfunction (OR=2.06, 95% CI=1.04--4.11, *P *\<* *0.05) compared to subjects with normal or simple steatosis. However, this association was attenuated when SITT was added to the model. In conclusion, hepatic steatosis and steatohepatitis are independently associated with LV diastolic dysfunction in older adults with T2DM, and insulin resistance is a significant confounding factor.
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**Background**: Diabetes is known as one of the high burden diseases around the world. Malaysia has the highest prevalence of diabetes mellitus in Southeast Asia region, however there were limited data available on survival outcome among diabetes patients in Malaysia.

**Aims**: This study aims to determine the survival outcome for diabetes mellitus in Malaysia. In addition, this study also aims to identify the all‐cause of death within five years among patients with both Type 1 diabetes mellitus (T1DM) and Type 2 diabetes mellitus (T2DM).

**Methods**: This is a cohort study using secondary data from a national diabetes registry (Malaysia). The demographic and clinical details of diabetes mellitus patients were captured from an Audit of Diabetes Control and Management (ADCM), Malaysia between 1st January 2009 and 31st December 2009. Patients in government health clinics throughout Malaysia aged 18 years and above were notified on ADCM. These patients' records were then matched with the National Death Record (NDR) at the end of year 2013 based on national Identity Card (IC) number to determine status of mortality within five years and also the causes of death were classified based on ICD‐10, 2016.

**Results**: There were 70 220 patients notified in the registry in year 2009 and 99.1% was T2DM. Majority were female with age more than 55 years. The top diabetes complication among T1DM was retinopathy (5.1%) while among T2DM was nephropathy (7.4%). The mortality rate among T1DM patients was reported as 1.6 persons per 100 person‐years; compared with 1.4 persons‐years among T2DM patients. Survival among male was poorer than female with ratio of 1.67 in T1DM and 1.45 in T2DM. The top three all‐cause of death in both types (T1DM vs. T2DM) were Diseases of circulatory system (33.8% vs. 28.4%), Infection and parasites diseases (32.5% vs. 19.7%) and Disease of respiratory system (6.5% vs. 16.0%).

**Conclusion**: T1DM patients reported poorer survival compared to T2DM. Male patients have poorer survival in both T1DM and T2DM. The main causes of death among both T1DM and T2DM patients were heart disease and infection.

PP‐179 {#jdi12939-sec-0358}
======

An evaluation of retina disease awareness programme (RDAP) -- A selangor state experience {#jdi12939-sec-0359}
-----------------------------------------------------------------------------------------

**Z. Z. Asnir^1^, B. Kadas^2^, D. A. Hussain^3^ and N. F. Ngah^4^**

^1^Hospital Ampang, Selangor, Ampang, Malaysia, ^2^NCD Unit, Selangor State Health Department, Shah Alam, Malaysia, ^3^Hospital Kuala Lumpur, Malaysia, ^4^Hospital Shah Alam, Shah Alam, Malaysia

Brief statement of purpose of study: Diabetic retinopathy (DR) contributed to 10% of the causes of blindness in Malaysia according to National Eye Survey II 2014. DR screening at the level of Health Clinics in Selangor was less than 30% in 2014. Retina Disease Awareness Programme (RDAP) was introduced in 2015 with the collaboration of the Ministry of Health Malaysia, Standard Chartered Bank, Selangor State Health Department and Selangor Ophthalmology and Optometry team. Two non‐mydriatic fundus cameras were donated to Selangor to augment the existing screening programme. There are two approaches of the programme: 1) RDAP Mobile, rotation of the two donated fundus among the health clinics without fundus camera facility, 2) RDAP outreach, Ophthalmology team from each hospital in the state supported the programme by doing outreach screening programmes in various Health Clinics on Saturdays. This study is to evaluate the RDAP through uptake rate of the screening and to determine the prevalence of DR detected during the screening programme.

**Method**: Data were collected retrospectively from all the Health Clinics for RDAP mobile and all the Hospitals for RDAP outreach in the period of 2 years (January 2016 until December 2017).

**Results**: A total of 15,398 patients were screened during RDAP mobile programme. Of these, 13,853 (90%) were diabetic patients. The screening found 79% of patients had no DR, 3.7% had mild to moderate NPDR, and 1.5% was detected to have sight threatening DR. In the RDAP outreach, of the 4846 patients screened 3708 (76%) were diabetic patients. Of these, 80% had no DR. However a higher prevalence of NPDR and sight threatening DR were detected, 13.7% and 4.8% respectively. DR screening rate increased after the establishment of RDAP, with 68.5% of DM patients were screened in 2017.

**Conclusions**: Early detection and early treatment of DR can prevent substantial visual loss. Thus a successful screening programme is essential.
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Hyperglycaemia due to metabolic changes during the state of critical illness requires medical attention, especially among diabetic patients. High blood glucose is associated with poor clinical outcomes in critically ill patients. While several previous studies found that critically ill patients with diabetes had more infectious complications, poorer clinical outcomes including higher mortality rate, the association between pre‐existing diagnosis of diabetes and clinical outcomes remain unclear. This study aimed to investigate the association between a pre‐existing diagnosis of diabetes and energy‐protein adequacy as well as clinical outcomes in critically ill patients.

**Method**: A prospective observational study was conducted in general intensive care unit (ICU), University Malaya Medical Centre (UMMC). Exclusion criteria for this study include critically ill patients with age \<18 years old, pregnant mothers, patients diagnosed with hospital acquired infection and incomplete medical records. Patients were followed up to 14 days or until discharge, whichever came earlier. Subjects were categorized as diabetic and non‐diabetic patient based on their pre‐existing diagnosis. Comparison between diabetic and non‐diabetic patients was evaluated and association between pre‐existing diabetes diagnosis and clinical outcomes as well as energy‐protein adequacy was investigated. Statistical test used for analysis were independent simple t‐test, Mann‐Whitney, Chi‐square and correlation tests.

**Result**: A total of 102 critically ill patients were included in this study of which 47% were patients with pre‐existing diagnosis of diabetes. Diabetic patients (*n *= 48) were significantly older (59.98 ± 14.43 vs. 48.61 ± 17.62, *P *= 0.001), had higher random blood sugar (10.46 ± 2.33 vs. 8.58 ± 2.07, *P *\< 0.001), number of comorbidities and mNUTRIC score (7.0 ± 2.0 vs. 5.50 ± 2.0, *P *\< 0.001) than non‐diabetic patients (*n *= 54). Energy and protein adequacy were higher among diabetics. Diabetic critically ill patients have longer mechanical ventilation days and ICU stay. This study found no association between pre‐existing diagnosis of diabetes and mechanical ventilation days, sepsis, organ failure, hospital acquired infection, ICU and hospital mortality. This study found no association between energy‐protein adequacy and clinical outcomes among diabetic patients. There was association between protein adequacy and prolonged mechanical ventilation among the non‐diabetic critically ill patients, *P *= 0.041.

**Conclusion**: A pre‐existing diagnosis of diabetes is not associated with poorer clinical outcomes in critically ill patients.
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**Aims/Introduction**

The QT interval prolongation plays a causal role in life‐threatening arrhythmia and becomes a risk factor for a sudden cardiac death. We previously reported that type 2 diabetic patients with microvascular complications have longer corrected QT (QTc) interval than those without. However, therapeutic effects on the QTc interval are unclear. In the present study, we assessed the changes in QTc interval and glycemic control in patients who newly received insulin therapy.

**Methods**: Patients with type 2 diabetes admitted to our hospital for glycemic control and insulin initiation (*n *= 47, aged 39--85 years, 11 women and 36 men) were enrolled. Clinical measurements were taken on admission and discharge and hospitalization was 15 \[14--16\] (median \[interquartile range\]) days. The QT interval was measured manually in lead II on the electrocardiogram and QTc intervals were calculated by the Bazett\'s formula. Associations with the change of QTc interval and other clinical parameters were investigated.

**Results**: Clinical characteristics at admission were as follows; fasting blood glucose was 203 ± 55 (mean ± SD)　mg/dL, glycated hemoglobin was 10.2 ± 2.0%, glycated albumin was 28.2 ± 9.3%, body mass index was 24.7 ± 3.7 kg/m^2^. QTc interval was shortened from 437 ± 23 msec at admission to 428 ± 26 msec at discharge (*P *= 0.0003). ΔQTc interval was positively correlated with Δfasting blood glucose (−88 ± 62 mg/dL, r = 0.46, *P *= 0.0011), Δglycated albumin (−3.7 ± 4.2%, r = 0.34, *P *= 0.0021) and negatively correlated with the doses of insulin at discharge (24.2 ± 14.8 units/day, r = −0.31, *P *= 0.036).

**Conclusions**: Improvement of hyperglycemia by insulin therapy can decrease QTc interval and may reduce the risk of life‐threatening arrhythmia associated with QT prolongation in patients with type 2 diabetes.
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Purpose of Study: Diabetes Mellitus (DM) is a major public health concern in Malaysia. The serial National Health and Morbidity Survey (NHMS) showed a worrying increasing prevalence of diabetes mellitus of 17.5% in adults of 18 years and above (3.5 million adults). Diabetic retinopathy (DR) is a known microvascular complication of DM that can lead to a devastating morbidity resulting in PERMANENT BLINDNESS. As DR is asymptomatic in early stages, these patients are susceptible to late diagnosis and treatment. The best way to detect DR early is by regular screening. Tele Diabetic Retinopathy (Tele‐DR) system was introduced in Terengganu to ensure good diabetic retinopathy screening coverage and early referral to the ophthalmology team. The Tele‐DR system begins in 2008 by placing non‐mydriatic fundus camera at selected Health Clinics (KK) in each district in Terengganu. The camera is linked to Tele‐DR software that allows all fundus images taken at Health Clinics being uploaded into the system and being reviewed by trained graders. Following image review, a self generated referral letter (with appointment date) would be self downloaded by the managing team at Health Clinics. Methodology: Data was collected retrospectively via the Tele‐DR system for Kuala Terengganu District from 2014--2016. Three health centers in Kuala Terengganu were included in this study.

**Result**: A total of 9 673 patients in Kuala Terengganu were screened from 2014--2016, with an increasing trend from 2 938 in 2014 to 3 826 in 2016. An increasing trend of Diabetic Retinopathy detection was observed from 10%, 16.8% and 15.3% by year, respectively. The study also revealed a worrying increasing trend of sight threatening DR from 4.08% in 2014, to 6.77% (2016) from all being screened, which range from 38.45% to 44.35% of all diabetic retinopathy detected by that year.

**Conclusion**: Tele‐DR system is a reliable, sensitive, cost effective and user friendly system for DR screening. It enables an effective two‐way communication between primary healthcare providers and ophthalmologists using web‐based technology system in ensuring effective screening in preventing blindness secondary to untreated diabetic retinopathy.
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**Introduction**: Patients with diabetes mellitus are at high risk of lower‐extremity infection due to complications of immune dysfunction, diabetic neuropathy and peripheral vascular disease. Skin breakdown causes portal of entry for bacteria, resulting in cellulitis. Clinicians need to ascertain the severity of the infection to provide adequate treatment. However, a validated score for cellulitis is currently not available.

**Objective**: To utilize an adapted cellulitis severity score with descriptive clinical parameters and to correlate severity with socio‐demographics and risks. To assess the internal consistency of the cellulitis severity score in diabetic lower extremity infection. Methodology: The clinical parameters of cellulitis were evaluated in a prospective, pilot evaluation of 20 patients with diabetes mellitus, hospitalised with a clinical diagnosis of lower limb cellulitis. We included patients with the presence of clinical signs of erythema, warmth and oedema and involving limbs with total surface area of erythema ≥ 75 cm^2.^.The cellulitis severity score was adapted from a previous study, measuring seven clinical parameters which are erythema, warmth, tenderness, oedema, ulceration, drainage and fluctuance. Each parameter is scored 0--3 (none, mild, moderate, and severe), with maximum score of 21.

**Results**: The median total severity score was 13 (IQR 4), with the most distribution scored within 8 to 14 (55%). Erythema was severe in 75% of subjects, 60% had severe warmth, and 55% had severe tenderness and fluctuance. Both moderate and severe oedema occurred in 45% of subjects. The internal consistency of this scoring method was stratified by Cronbach\'s alpha and was high in this study (\>0.8). There was a statistically significant positive correlation of cellulitis severity score with bullous type cellulitis (r = 0.474, *P *=* *0.035) but no significant correlation for age (r = −0.281, *P *=* *0.231) and gender (r = −0.018, *P *=* *0.941).

**Conclusion**: Cellulitis severity score is simple and practical, which can be easily replicated in any clinical setting for the objective assessment of the severity of cellulitis in diabetic lower extremity infection. Severe erythema, warmth, tenderness and fluctuance were observed during hospitalisation. Bullous type cellulitis was moderately correlated with the severity score.
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Impaired insulin secretion and insulin resistance are major pathophysiological factors in the development of type 2 diabetes. Most Japanese patients with type 2 diabetes do not have insulin resistance and insulin secretion in Japanese individuals is reported to be less than half that in Whites. 1,5‐anhydroglucitol (1,5‐AG) reflects short‐term glucose status, postprandial hyperglycemia and glycemic variability in patients with type 2 diabetes. Furthermore, 1,5‐AG is closely correlated with decreased insulin secretion capacity even in individuals without diabetes. The aim of this study was to determine whether 1,5‐AG was a useful marker for predicting the incidence of type 2 diabetes in a Japanese population. We performed a population‐based cohort study in a medical checkup center at Ayabe Municipal Hospital in Japan. Of the 1,052 participants (575 males and 477 females, 55.2 ± 11.2 years), 76 participants (7.2%) were diagnosed with type 2 diabetes after 5 years of follow‐up. The cut‐off value for 1,5‐AG associated with the incidence of type 2 diabetes was 17.3 μg/mL. The incidence rate of type 2 diabetes was 5.0% (39/784) in participants with an 1,5‐AG \> 17.3 μg/mL and 13.8% (37/268) in those with an 1,5‐AG ≤ 17.3 μg/mL. The adjusted odds ratio of 1,5‐AG ≤ 17.3 μg/mL for the progression of type 2 diabetes was 3.55 (95% CI, 2.05--6.17). We also found a very high‐risk group for type 2 diabetes by introducing the 1,5‐AG criterion (≤17.3 μg/mL) into the diagnosis of prediabetes using the HbA1c criterion (5.7--6.4%). The adjusted odds ratio of the highest‐risk group (HbA1c ≥ 5.7% and 1,5‐AG ≤ 17.3 μg/mL) compared with the lowest‐risk group (HbA1c \< 5.7% and 1,5‐AG \> 17.3 μg/mL) was 34.41 (95% CI, 12.27--124.17). Furthermore, even participants with a low HbA1c level (\< 5.7%), low 1,5‐AG ratio group (≤ 17.3 μg/mL) had an increased risk for the future development of type 2 diabetes (odds ratio, 5.59; 95% CI, 1.41--23.77). This study indicated that measurement of 1,5‐AG could be a technique for identifying individuals at high risk for progression to type 2 diabetes in a Japanese population.
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Introduction: Mauriac syndrome (MS) was first described in year 1930 by Pierre Mauriac in children with type 1 diabetes mellitus (T1DM). It is mainly characterized by growth and pubertal failure together with extreme hepatomegaly, transaminitis with histological findings of glycogen accumulation within the hepatocytes. It is a rare complication in patients with poor glycaemic control and displaying certain pattern of genetic predisposition. Methodology & Analysis: We reviewed 3 patients with Mauriac syndrome in our clinic since 2008. Patient 1: 13‐year‐old boy, with TIDM since age of 5 and frequently defaulted follow‐up. His HbA1c ranged 11--15%. He has stunted growth and pubertal delay, hepatomegaly and transaminitis, which prompted extensive work‐up. Liver biopsy confirmed glycogen hepatopathy. However, his disease control remained poor. He presented with generalized oedema, increasing hepatomegaly (liver span 17 cm) and transaminitis. His liver enzymes fluctuated dramatically while his insulin treatment was intensified. After a month of supervised treatment, his hepatomegaly improved and transaminitis resolved. Patient 2: 15‐year‐old boy, with TIDM for 5 years and HbA1c ranged 10.5--13.5%. He presented with hepatomegaly (liver span 19 cm) and transaminitis. Liver biopsy confirmed glycogenic hepatopathy. Concomitantly, he had other complications including parotid swelling and glaucoma. However, he has no delayed puberty or stunted growth. Patient 3: 10‐year‐old girl, with TIDM for 6 years and HbA1c ranged 13--16%. She has short stature, dyslipidaemia, and complications including recurrent abscesses at injection sites and cataract. She defaulted follow‐up for 10 months and was noted to have hepatomegaly (liver span 16 cm) with transaminitis. She was planned for referral to hepatologist but she defaulted follow‐up. Discussion: Our report highlights the difficulty in managing MS in achieving targeted glycaemic control, compounded by their poor psychosocial aspects. We had to exclude other causes of hepatomegaly such as autoimmune, infectious or metabolic causes. In our series, one had relapsing and remitting pattern of transaminitis.

**Conclusion**: It is important for clinicians to have increase awareness for MS, especially in poorly controlled T1DM patients for timely diagnosis and management. With aggressive glycaemic control, the syndrome is reversible.
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**Aim**: To find out the prevalence of MetS among T1D patients and to identify its associated factors.

**Methods**: T1D patients attending Diabetes Unit, KEMHRC, Pune were evaluated for prevalence of MetS. We used harmonizing criteria Alberti et al 2009, MetS was defined as any 3 of: elevated waist circumference, triglyceride, BP, fasting plasma glucose/known diabetic and reduced HDL cholesterol. Among micro‐vascular complications, a fundus photographs biothesiometer Urine Albumin Creatinine Ratio Clinical characteristics were compared between T1D patients with and without MetS. Overweight was defined using WHO, MGRS 2007 criteria. Analysis was adjusted for age and gender. Factors contributing to increased risk of MetS were assessed using multiple logistic regression.

**Results**: y (1mth --42y) \[median (min.‐max.)\]y (1y -- 52 The prevalence of individual diagnostic criterion for MetS was 33% (\>= 90th percentile waist circumference), 9% (TG\>=150 mg/dl), 10% (BP\>130/85 or BP lowering Meds), 49% \[HDL‐c \< 40 mg/dl (men and children) & HDL‐c \< 50 mg/dl (women)\]. The overall prevalence of MetS was 25.2%, 4.5% of patients had \>=4 components. MetS prevalence was associated with age (\<18y: 14%, 18--40y: 27%, \>40y: 57%). T1D patients with MetS were older, diagnosed with T1D later in age and had longer duration of diabetes. They had higher BMI (45% overweight), body fat % and also higher Total Daily Insulin Dose/kg body weight, 2/3rd had HbA1C\>7.5% and 40% had at least one micro‐vascular complication. CV event was reported among only 2 patients and both of them had MetS. On logistic regression, factors increasing the risk for MetS were age at diagnosis (\>16 years, RR: 3.28 CI: 1.02, 10.49), duration of diabetes (\>10 years, RR: 2.5 CI:1.01,6.33) and being overweight (RR:5.17 CI:1.61,16.64); gender and glycemic control were not related.

**Conclusion**: MetS is common among Indian T1D patients. Commonest contribution was from low HDL‐c. In clinical practice, simple measurements like waist circumference and HDL‐c provide useful indicator for diagnosing MetS.
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**Background and Aim**

The prevalence of non‐alcoholic fatty liver disease (NAFLD) is increasing worldwide due to rise of obesity and diabetes mellitus (DM). Obesity also has been closely associated with obstructive sleep apnoea (OSA) and increases cardiovascular risk. Non‐invasive assessment of carotid intima‐media thickness (CIMT) by high‐resolution carotid B‐mode ultrasonography is widely used as a reliable index of subclinical atherosclerosis. This study aimed to determine the relationships between NAFLD and severity cardiovascular risk via CIMT measurements in a group of OSA with type 2 DM patients.

**Methods**: In this cross‐ sectional study, 90 patients with OSA following sleep study examinations were categorized in two groups: group I including 45 patients with NAFLD and DM, group II including 45 non‐diabetic patients with NAFLD. CIMT were measured by sonographist blind to the group.

**Results**: Mean CIMT was significantly higher in type 2 DM group comparing with non‐diabetic group, 0.088 ± 0.031 mm vs. 0.075 ± 0.016 mm (*P *\< 0.05). In diabetic groups, there is significant higher numbers of patients with dyslipidaemia and ischaemic heart disease. However, after controlling the confounders, which includes sex, smoking, hypertension, obesity and hyperlipidemia, there was statistical significant of CIMT between group I and group II (*P *\< 0.05). Multiple regression for group I showed OR 0.455 which is not significant. CIMT is also significantly higher in patients with more severe NAFLD.

**Conclusion**: Based on our findings, there is a significant association between the presence of NAFLD and atherosclerosis in patients with type 2 diabetes mellitus. CIMT is independent predictor for atherosclerosis in high risk patient with type 2 DM and OSA.
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Background: Under Diabetes Medication Adherence Clinic (DMTAC), pharmacists collaborate with physicians in assisting diabetic patients to improve their medication adherence level and glycemic control. With Cardiovascular disease (CVD) being the major cause of death in patients with Type 2 Diabetes Mellitus (T2DM), the relationship between satisfactory glucose control and incidence of cardiovascular hospitalization for T2DM patients in HTAR, Klang has yet to be established.

**Objectives**: The objectives of this study were to measure the difference in HbA1c during patients' enrolment into DMTAC (pre) and upon completion of four DMTAC visits (post), and to compare the incidence of CVD hospitalization in patients who have and have not achieved target HbA1c level of \<7% after the fourth DMTAC visit.

**Methods**: A retrospective study on all T2DM patients who have completed at least 4 visits under DMTAC during the period from January 2012 and December 2017 in HTAR was conducted. Comparison on the difference in HbA1c at baseline and at fourth DMTAC visit, as well as the incidence of hospitalization due to CVD in these patients was evaluated.

**Results**: A total of 98 patients were included in the analysis. Results demonstrated a significant reduction in the mean HbA1c after the fourth DMTAC visit, at 0.43% with a p‐value of 0.033. The incidence of CVD hospitalization is 1.1% in patients who have not achieved target HbA1c, and none was reported in patients who have achieved treatment target. The difference is not significant with a p‐value of \<0.995.

**Conclusions**: Pharmacist‐physician collaboration at DMTAC HTAR has effectively improved glycemic control in patients with T2DM. However, due to small sample size, we were unable to establish the beneficial effect of improvement in glucose control on CVD hospitalization rate in T2DM patients in HTAR. A better‐designed study may allow further assessment on the benefits of achieving HbA1c target in lowering macro‐ and microvascular events amongst HTAR DMTAC patients.
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**R. Sauriasari**

Faculty Of Pharmacy, Depok, Jawa Barat, Indonesia

Background: An accurate renal function measurement is important to diagnose and predict the progression of early diabetic nephropathy. Type IV collagen (COL4) and TGF‐β1 (Transforming Growth Factor) have been reported correlated with Urine Albumin to Creatinine Ratio (UACR), but it is still unknown whether they have potentiality to be an earlier biomarker of diabetic nephropathy or not. This study aimed to determine the urinary COL4 and TGF‐β1 concentration as a glomerular biomarker in T2DM patients and to know its correlation with UACR and eGFR.

**Methods**: This cross‐sectional study included 62 normoalbuminuric type 2 diabetes mellitus (T2DM) patients, 27 albuminuric T2DM patients, and 10 nondiabetic subjects at Pasar Minggu Community Health Center. Urinary COL4 and TGF‐β1 concentration was measured by ELISA, UACR was measured using immunoturbidimetry and an enzymatic colorimetric method. The eGFR value was calculated based on serum creatinine using CKD‐EPI equation.

**Results**: Urinary COL4 was found to be higher in albuminuria compared to normoalbuminuria T2DM patients (*P *=* *0.017). In addition, urinary COL4 has moderate positive correlation with UACR (*r *=* *0.336, *P *=* *0.001), but not with eGFR (*r *=* *−0.099, *P *=* *0.355). Multivariate analysis results showed that association between COL4 and UACR was confounded by HbA1c, diastolic blood pressure, exercise habit and age. In addition, urinary TGF‐β1 was also increased in albuminuria (326.49 ± 48.98), compared to normoalbuminuria (290.54 ± 30.71) and non‐DM subjects (229.83 ± 31.90), but not differ statistically (*P *=* *0.790). No correlation between urinary TGF‐β1 with UACR (r = −0.084, *P *=* *0.410) and eGFR (r = 0.155, *P *=* *0.125), but correlated with systolic blood pressure (r = −0.224, *P *=* *0.026).

**Conclusion**: There is an increase of urinary COL4, significantly and also TGF‐β1, but not significantly in albuminuria condition. The association between COL4 and TGF‐β1 with UACR was confounded by several factors, including HbA1c, blood pressure, exercise habit and age. Since COL4 and TGF‐β1 could be interfered by many factors, including hypertension and its medication, they might not independently associated with renal function in diabetes. In the other hand, HbA1c was the most predictor for UACR, independent from the other factors.

PP‐190 {#jdi12939-sec-0381}
======

Potassium, acidosis and cardiovascular outcomes in diabetic ketoacidosis: preliminary findings {#jdi12939-sec-0382}
----------------------------------------------------------------------------------------------
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^1^Monash University, Subang Jaya, Malaysia, ^2^Pusat Perubatan Universiti Kebangsaan Malaysia, Cheras, Malaysia

Statement of Purpose: Potassium is severely depleted during diabetic ketoacidosis (DKA), negatively affecting cardiovascular (CV) outcomes. Diuresis initiates loss of potassium which is exacerbated by extent of acidosis. Itself, acidosis also adversely affects CV outcomes. It was intended to correlate CV outcomes in DKA patients when potassium level was adjusted with pH.

**Method**: Retrospective cross‐sectional patient data of 3 years i.e. 2015 -- 2017 was obtained from PPUKM. Adult patients with DKA i.e. having hyperglycemia or euglycemia, ketones & blood pH below 7.300 at time of admission were noted. Any episode of potassium being below 3.5 mmol/L was recorded as hypokalemia. Demographic, clinical and biochemical profiles were analysed using SPSS 16. Being in early stage of conduct, data is concluded at 33 cases.

**Results**: Mean age of respective patients was 46.8 (16.7) years. Two patients were pre‐established cases of CV disease, excluding hypertension. Mean level of serum glucose and ketones was 35.7 ± 13.2 mmol/L and 5.8 ± 2.5 mmol/L, respectively. On average, patients were moderately acidotic with admission pH and bicarbonate of 7.172 ± 0.132 and 11.7 ± 4.3 mmol/L, respectively. Average potassium level at time of admission was 4.6 ± 1.1 mmol/L which was within normal range. Although pH‐adjusted corrected potassium level for these patients was 3.61 ± 0.6 mmol/L, time to initiate potassium resuscitation was 6.5 h from the time of admission. Within this time, 6\* patients were experiencing clinical hypokalemia (2.9 ± 0.3 mmol/L) at time of admission. As for cardiac profiling, electrocardiogram was obtained for 10 patients. Of 6\* hypokalemic patients, 3 were experiencing ST and T wave abnormality, and 1 was facing abnormal repolarization as well.

**Conclusion**: Most DKA treatment guidelines recommend potassium supplementation after establishing urinary output, and prior to initiate insulin. However, none of the guideline advocates to adjust level of potassium with acidosis (pH). Using such adjustment will be helpful to avoid unwanted hypokalemia, and for health care professionals to get correct picture of serum potassium level thereby reducing frequency of hypokalemia and misinterpreting pseudohyperkalemia at admission of DKA patients. We remain sure that results from this study will help to modify existing guidelines for better CV management and outcomes in DKA patients.
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**Background and Aims**

Major Adverse Cardiac Events (MACE) are contributed to high morbidity and mortality in patients with Acute Coronary Syndrome (ACS). Admission hyperglycemia is considered to be associated with MACE as well as other clinical factors. This study aims to investigate the impact of admission hyperglycemia as traditional risk factor on development of MACE in ACS patients. Materials and

**Methods**: Our study is an observational 7‐day cohort study which was conducted in Dr. Cipto Mangunkusumo Hospital from January--December 2017. All patients aged ≥30 years old admitted to emergency department with the diagnosis ACS were recruited. Incident of MACE was recorded during the 7‐day follow up. Admission hyperglycemia was defined as having random venous blood glucose level of \>118 mg/dL at admission. We recorded history of diabetes, hypertension, dyslipidemia, its respective treatment, duration of diabetes, history of smoking, and alcohol consumption. Classification of ACS diagnosis, onset of chest pain, MACE and extension of infarct were also assessed. We also measured blood pressure, waist circumference, and body mass index (BMI).

**Results**: Eighty‐four patients admitted with ACS were included in the analysis, 65 subjects had hyperlglycemia at admission. During 7‐day follow up, the incident of MACE was 19% (16/84). Proportion of MACE was 20% in hyperglycemia group and 15% in normoglycemia group with no significant difference (13/65 versus 3/19, *P *= 0.22). Hyperglycemic group was associated with STEMI and a more extensive infarct. Fischer\'s Exact Test was performed to assess differences in MACE incidence between hyperglycemia and normoglycemia group. In multivariate analysis, the extent of infarction \[7.47 (1.27--43.91) *P *= 0.026\] and mean of blood glucose during hospitalization \[1.02 (1.00--1.05) *P *= 0.049\] were significantly associated with the development of MACE in a 7‐day of follow‐up. Conclusion: The difference between proportion of MACE in hyperglycemia and normoglycemia group was not found to be significant. Infarct size and average of blood glucose during hospitalization were associated with MACE in this study.
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Background: Diabetes mellitus has been reported to be a strong independent risk factors for recurrent stroke. However, further investigations on the risk factors of recurrent stroke specifically among the patients with type 2 diabetes mellitus (T2DM) is limited, and this supports the importance of this study. The objective of this study was to determine the risk factors associated with recurrent stroke in patients with T2DM.

**Methods**: The data from 4622 patients with T2DM was obtained from the Malaysian National Stroke Registry. Univariate analysis was performed to differentiate between subject with and without recurrent stroke in term of demographics, laboratory data such as the systolic blood pressure, clinical presentation during the first stroke event, prior medications and medication upon discharged from the first stroke event. The significant factors determined from the univariate analysis were further investigated using logistic regression to assess the association between the factors and the risk of having recurrent stroke. The data was analyzed using SPSS version 22.

**Results**: Based on the logistic regression, the predictive risk factors of recurrent stroke were IHD (odds ratio (OR), 3.455; 95% CI \[1.885--6.333\]; (*P *\< 0.0001), hyperlipidemia (OR, 1.83; 95% CI \[1.081--3.097\]; (*P *= 0.024), moderate Glasgow Coma Scale interpretation (OR, 2.032; 95% CI \[1.016--4.227\]; *P *= 0.045) and given diuretics upon discharged from the first stroke event (OR, 3.498; 95% CI \[1.506--8.128\]; *P *= 0.004). On the contrary, having ethnicity of other than Malay, Chinese and Indian as well as given beta‐blocker upon discharged lowers the risk of having recurrent stroke in subjects with T2DM with (OR,0.062; 95% CI \[0.023--0.168\], *P *\< 0.001, and OR, 0.186; 95% CI \[0.054--0.64\]; *P *= 0.008), respectively.

**Conclusion**: There are a number of significant independent risk factors of recurrent stroke among patients with T2DM. The results in this study may help to add into the knowledge related to this issue and guide the prevention of recurrent stroke, targeted to the T2DM population.
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**Background and Aims**

Dysglycemia, consisting of diabetes mellitus (DM), impaired glucose tolerance (IGT) and impaired fasting glucose (IFG), is a common comorbid of COPD. Prevalence of dysglycemia in COPD is recognized, however data on associated factors and contribution of exacerbations are scarce. Thus, this study aimed to determine the prevalence associated factors of dysglycemia among COPD patients and its effects on inflammatory markers. Materials and

**Methods**: This is a cross‐sectional study involving patients with established COPD aged 30 years and above (*n *= 186) attending Universiti Teknologi MARA respiratory specialist clinic. Those on long‐term corticosteroid therapy, active malignancy or in peripartum periods were excluded. Patients were divided into those with or without hospital admission for exacerbation in the past year. All participants had glycated hemoglobin level and inflammatory marker Interleukin‐6(IL‐6) concentration assessment, and patients with no prior diagnosis of dysglycemia underwent oral glucose tolerance test (OGTT).

**Results**: 76 patients (40.9%) had history of admission for COPD exacerbation, 27(35.5%) of them were known diabetics. Among the remaining 110 patients with stable COPD, 29 (26.4%) were known diabetics. Mean age was 67.85 ± 9.08 years, mean body mass index (BMI) 25.17 ± 6.08 kg/m^2^, and majority were male (95.2%). Incidence of new dysglycemia was 40.8%(*n *= 20) and 34.6%(*n *= 28) in the exacerbation and stable groups respectively (*P *= 0.574). Weight of \>65 kg (OR2.282,CI 1.26--4.12, *P *= 0.006), overweight (OR2.59, CI 1.40--4.77, *P *= 0.002), hypertension (OR0.49,CI 0.27--0.89, *P *= 0.019) and hospital admission of more \>6 cumulative days per year (OR 2.89,CI 1.04--8.03, *P *= 0.035) were significant factors for developing dysglycemia, and patients with weight\>65 kg and hospital admission of\>6 days a year were 2.7 and 4.5 times more likely to develop dysglycemia, respectively. IL‐6 concentration was positively correlated with cumulative days of hospital admission (r = 0.376, *P *= 0.001), with no significant correlations with other variables.

**Conclusion**: This study revealed near doubling of prevalence of dysglycemia including newly diagnosed T2DM among COPD patients, following a standard oral glucose challenge test. Patients with features of metabolic syndrome, more disease exacerbations, frequent and longer hospital stays are more likely to develop dysglycemia. Hence, this study highlights the importance of screening for dysglycemia among COPD patients, especially in those who are at risk.
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**Background**: Chronic Kidney Disease (CKD) is a major cause of illness and death of patients with type 2 diabetes mellitus (T2DM). The objective of this study was to determine the different stages of CKD and medications used in T2DM patients follow up in health clinics in Seremban district.

**Methods**: We examined the routinely collected data of T2DM patients from 11 public health clinics in Seremban District for the year 2017. Systematic random sampling was done from the National Diabetes Registry database. A total of 7722 T2DM patients' data were included. The Modification of Diet in Renal Disease (MDRD) formula was used to calculate the estimated GFR (eGFR). CKD was defined by the presence of decreased GFR \<60 mL/min per 1.73 m^2^.

**Results**: The mean age of T2DM patients in this study was 61.8 years and mean duration of diabetes was 9.5 (S.D 6.4) years. CKD prevalence was 20.1%, however there was 23.7% missing data on serum creatinine. Females consisted of 57.8%, Malays 58.2%, Chinese 23.6% and Indians 17.6%. CKD prevalence by stage was Stage‐2 (eGFR 60--89):36.4%, Stage‐3(eGFR 30--59): 17.8%, Stage‐4 (eGFR 29--15): 1.8%; and Stage‐5 (eGFR\<15): 0·5%. Medications used were metformin (68%), sulphonylurea (44.1%), insulin (36.1%), anti‐platelet (31.8%), ACE‐inhibitor (51.7%), ARB (11.4%), calcium channel blocker (56.3%), beta blocker (32%), diuretic (24.9%), statin (75.5%) and fibrate (4.8%). Among those with CKD Stage‐4 and Stage‐5, about 22.6% were still on metformin which is not recommended by guideline.

**Conclusion**: CKD among the T2DM patients has a high prevalence in primary health clinics and this is consistent with the estimated global prevalence of between 20 to 40%. A systematic determination of eGFR may contribute to an early diagnosis, thus allowing intervention during the initial stages of the disease when treatment is more efficient.
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Diabetes mellitus (DM) represents a medical problem affecting millions of people globally. Diabetic Nephropathy (DN) is a major diabetic complication that leads to end‐stage renal disease (ESRD). However, microvascular changes that usually occur after long‐standing of DM are detected at an early stage. This study aims to identify candidate proteins in diabetic patients that differ in the disease state relative to control using a proteomic approach. Two‐dimensional gel electrophoresis (2‐DE) was performed to identify differentially expressed proteins in the plasma from 3 groups of patients; control (CON, *n *= 5), early diabetic (ED, *n *= 5) and established diabetic (ESD, *n *= 5). Plasma samples were treated using the Multiple Affinity Removal System Spin Cartridge HU‐6 (Agilent) to remove high abundance protein. The proteins were displayed using 13 cm, pH 3--10 isoelectric focusing strips for the first dimension and 12% acrylamide gel electrophoresis for the second dimension. Coomassie staining visualised protein spots, imaged by employing a Gel Doc TM XR+ Imager (BioRad), were compared and analysed using PDQuest software (BioRad). The QTOF LCMS/MS were utilised for detecting the role of the identified proteins. Three sets of analysis were designed to compare the upregulation and downregulation of differences between; CON/ED group; CON/ESD group and ED/ESD group. The analysis identified 25 unique proteins from 12 significant spots. All spots were detected upregulated except for three spots demonstrated downregulation which was two in CON/ED and one in CON/ESD group of analysis. The identified proteins expressed may be involved in the development and progression of diabetes and the pathogenesis of DN. Further studies are needed to explore.
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Early weight loss with SGLT2i did not predict 1‐year weight loss in Thai patients with type 2 diabetes mellitus {#jdi12939-sec-0394}
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**T. Yotsapon, C. Phawinpon, Y. Nalin, M. Areeya, B. Siriwan, W. Ekgaluck, K. Sirinate and H. Thep**

Diabetes and Thyroid Center, Theptarin Hospital, Bangkok, Thailand

Background: Our previous real‐world data revealed that while glycemic control from SGLT2i could maintain beyond one year, weight loss gradually rebounded after the first 6 months and then backed to baseline body weight after one year. Objective

To examine whether early responders (ER) in term of weight reduction from SGLT2i will predict long‐term weight reduction at 1 year. Materials and

**Methods**: Using our previous real‐world data in patients with type 2 diabetes who had been treated with SGTL2i, we performed a post‐hoc analysis by defining ERs as patients who achieved weight loss of ≥5% at 3 months. The ability to predict response status at 1 year was evaluated by the positive predictive value (PPV; proportion of patients with an early response who had ≥5% weight loss at 1 year) and the negative predictive value (NPV; proportion of patients with an early non‐response who had \<5% weight loss at 1 year). The success criteria of weight loss of ≥3 kgs were also examined.

**Results**: A total of 189 patients with diabetes (females 50.3%, baseline BMI 29.9 ± 6.1 kg/m^2^, baseline A1C 8.8 ± 1.6%) were prescribed SGLT2i during 2014--2016. A post‐hoc analysis was performed in 104 patients who had serial data after 3 months. At 3 months, 24.0% (25/104) of patients achieved weight loss of ≥5% and 34.6% (36/104) of patients achieved weight loss of ≥3 kgs. The proportion of ER losing ≥5% of their bodyweight at 1 year was only 54.5% (12/22)and the proportion of ER losing ≥3 kgs at 1 year was only 48.6% (18/37).By using criteria of achieved weight loss of ≥5% at 3 months, PPV and NPV were only 0.55 and 0.84, respectively. The change in bodyweight was only weakly correlated with the change in A1C from baseline to the last follow‐up period.

**Conclusions**: Our data demonstrated that the predictive nature of an early response in weight reduction to SGLT2i treatment did not predict long‐term weight loss benefits at 1 year. Further studies should be done towards a better understanding of responders versus non‐responders for weight reduction effects of SGLT2i.
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Use of renin‐angiotensin‐aldosterone system (RAAS) blockade in thai diabetic kidney disease patients: the gap between standard and practice {#jdi12939-sec-0396}
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**N. Soontaree, T. Yotsapon, B. Siriwan, V. Somboon, T. Chattip, W. Ekgaluck, K. Sirinate and H. Thep**

Diabetes and Thyroid Center, Theptarin Hospital, Bangkok, Thailand

Background: Current guidelines recommended renin‐angiotensin‐aldosterone system (RAAS) blockade as an organ‐protective agent in diabetic kidney disease (DKD) patients. Previously, our audit data revealed achievement rate of urine albumin screening at 75% in general patients with diabetes and less than 80% of those patients with albuminuria received RAAS blockade. This study aimed to evaluate the rate of RAAS blockade in patients with type 2 diabetes (T2DM) who already developed DKD and highlight the reasons which some patients did not receive RASS blockade according to recommendations. Materials and

**Methods**: From 2015 to 2017, all T2DM with moderate to severe DKD (GFR 15--60 ml/min/1.73 m^2^) who had completed data of diabetic complications screening were registered in our DKD registry. Patients who had chronic kidney disease from other secondary causes were excluded. Clinical data and reasons not to start RAAS blockade were collected.

**Results**: A total of 162 DKD patients (females 50.6%, mean age 71.1 ± 10.0 years, duration of diabetes 19.5 ± 9.4 years, body mass index (BMI) 27.3 ± 4.7 kg/m^2^, A1C 7.4 ± 1.4%, GFR 45.5 ± 13.6 ml/min/1.73 m^2^, insulin usage 39.5%, diabetic retinopathy 27.2%) were included in the study. Based on urinary albumin excretion rate (UAER), patients were divided into 3 groups (normoalbuminuric patients 31.5%, microalbuminuric patients 43.8%, macroalbuminuric patients 24.7%). Overall rate of RAAS blockade was only at 71.0% (ACEI 16.5%, ARB 83.5%). Compared with DKD patients with albuminuria, normoalbuminuric DKD patients were much less in receiving RAAS blockade (27% vs. 73%). The usage of RAAS blockade decreased as DKD advanced. The three most common reasons to not start this medication from treating clinicians composed of afraid of worsening renal function deterioration (56.8%), normotensive normoalbuminuric DKD patients (15.9%) and failure to recognize DKD status in treating patients (13.6%).

**Conclusion**: Our routine clinical practice among diabetologists showed that RAAS blockade is still underutilized among DKD patients who would benefit most from this medication. Around one‐third of DKD patients had normoalbuminuria but have progressive renal insufficiency. Efforts to evaluate and improve quality care of DKD patients with moderate to severe impaired GFR should be done to ensure provision of adequate RASS blockade treatment.
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**S. Butadej^1^, Y. Thewjitcharoen^1^, N. Yenseung^1^, A. Malidaeng^1^, S. Vongterapak^1^, C. Thammawiwat^1^, S. Krittiyawong^1^ and T. Himathongkam^1^**

^1^Diabetes and Thyroid Center, Theptarin Hospital, Bangkok, Thailand

**Background and Objective**

Insulin degludec, an ultra‐long acting insulin analogue, became available in Thailand from October 2016. Although the clinical trial results revealed less nocturnal hypoglycemia, the data from real‐world settings is limited especially in Asian patients. This study aimed to evaluate the effectiveness, safety, and patient satisfaction with insulin degludec. Materials and

**Methods**: From October 2016 to September 2017, all patients who started to use insulin degludec at least 3 months were observed prospectively and quality of life was evaluated with WHOQOL‐BREF. Level of satisfaction was evaluated with 7‐point Likert scale. Glycemic fluctuation from paired iPro2 continuous glucose monitoring (CGM) obtained 4--6 weeks apart were also evaluated from a subset of patients with T1DM who switched from insulin glargine to insulin degludec.

**Results**: A total of 57 patients (T2DM 78%, females 52.6%, mean age 57.1 ± 15.9 years, duration of diabetes 16.8 ± 8.8 years, BMI 27.2 ± 5.4 kg/m^2^, baseline A1C 9.3 ± 2.3%, median duration of treatment 8 months) were included in the study. At 3 months, mean A1C reduction were 0.8% and the proportion of all patients attaining A1C ≤ 7% increased from 17.5% to 25.6%. Among previously insulin‐treated patients, the daily median insulin dose decreased from 48 units/day to 38 units/day at 3 months. At 3 months, the frequency of self‐reported nocturnal hypoglycemia was reduced by 46.9% (from 19.6% to 10.4%) and severe hypoglycemia were reduced by 41.6% (from 3.6% to 2.1%). Patient satisfaction showed a sustained improvement throughout the duration of study. In four T1DM patients who had paired CGM data, insulin degludec provided greater reductions in intraday glycemic variability evaluated by mean amplitude of glucose excursion (MAGE) and interday glycemic variability evaluated by mean of daily differences (MODD). Paired CGM data also revealed a greater reduction of time outside the interstitial glucose target range.

**Conclusion**: Our data suggested that effectiveness of insulin degludec was consistent with the results seen in clinical trials with less risk of patients‐reported nocturnal hypoglycemia, and a significant reduction in glycemic control. Patients also reported higher treatment satisfaction. More long‐term data are needed to establish the role of this ultra‐long acting insulin in real‐world settings.
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The effects of caffeine on oxidative stress, small intestinal glucose absorption, muscle glucose uptake and inhibition of key enzymes linked to type 2 diabetes {#jdi12939-sec-0400}
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**R. Reddy and M. S. Islam**

Biomedical Research Laboratory, Department of Biochemistry, School of Life Sciences, University of KwaZulu‐Natal, Durban, South Africa

Several reports have shown that consumption of coffee or caffeine containing drinks are associated with the reduction of type 2 diabetes (T2D) related symptoms, promotes weight loss and acts as an antioxidant. However the mechanisms behind these effects are still unclear. This study was aimed at investigating the anti‐oxidative, anti‐diabetic, and anti‐obesogenic potentials of caffeine by using several experimental models. Caffeine was analyzed for its antioxidant activity vis‐à‐vis 2,2‐diphenyl‐1‐picrylhydrazyl (DPPH) scavenging activity, ferric reducing ability (FRAP) and nitric oxide scavenging ability; inhibition of key enzymes linked to T2D as well as its effect on oxidative enzymes in Fe^2+^‐induced oxidative stress in pancreatic tissue. Caffeine was also investigated for its role in the inhibition of small intestinal glucose absorption in isolated rat jejunum and muscle glucose uptake. The results show that caffeine exhibited strong concentration‐dependent anti‐oxidant potential, however it did not possess powerful α‐glucosidase, α‐amylase and anti‐lipase inhibitory effects. The results obtained showed that caffeine was an effective inhibitor of lipid peroxidation. It also increased muscle glucose uptake and decreased small intestinal glucose absorption under *ex vivo* condition. Data of this study suggest that caffeine has the ability to ameliorate T2D‐associated symptoms and can be used in antidiabetic foods and food products. However, further studies with experimental animals and humans are warranted to confirm the results from this study.
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Should sulfonylurea be discontinued or maintained the lowest dose when starting ipragliflozin? A multicentre observational study in Japanese patients with type 2 diabetes. {#jdi12939-sec-0402}
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**K. Takahashi^1^, K. Y. Cho^1^, A. Nakamura^1^, T. Atsumi^1^ and H. Miyoshi^1,2^**

^1^Department of Rheumatology, Endocrinology and Nephrology Faculty of Medicine and Graduate School of Medicine Hokkaido University, Sapporo, Japan, ^2^Division of Diabetes and Obesity, Hokkaido University Graduate School of Medicine, Sapporo, Japan

**Background and Aims**

We investigated the difference in efficacy and safety between discontinuation and maintaining the lowest dose of sulfonylurea when adding a sodium‐glucose cotransporter 2 inhibitor (SGLT2i). Materials and

**Methods**: In this multicentre, prospective, parallel‐group observational study, 200 patients with type 2 diabetes treated with sulfonylurea and with a need to add ipragliflozin were enrolled and divided into two groups: discontinued sulfonylurea (Discontinuation group) or maintained sulfonylurea but at the lowest dose (Low‐dose group) when adding ipragliflozin. We compared the two groups after 24 weeks using propensity score matching to adjust for differences between the groups.

**Results**: In the matched cohort (58 patients in each group), baseline characteristics of both groups were balanced. At baseline, the average age, body weight, and HbA1c were 58.8 years, 27.7 kg/m2, and 7.57%, respectively. The primary outcome of the proportion of patients with non‐exacerbation in HbA1c after 24 weeks was 91.4% in the Low‐dose group and 75.9% in the Discontinuation group, a significant difference (*P *= 0.024). However, body weight was significantly decreased in the Discontinuation group compared with the Low‐dose group (−4.4 ± 2.1 kg vs. −2.9 ± 1.9 kg, *P *\< 0.01). Similarly, liver enzyme improvement was more predominant in the Discontinuation group. A logistic regression analysis showed that high‐density lipoprotein cholesterol (HDL‐C) (Odds ratio (OR) 0.90; 95% confidence interval (CI) 0.84--0.97, *P *\< 0.01), age (OR 0.83; 95% CI 0.70--0.99, *P *\< 0.01), and sulfonylurea dose (OR 0.09; 95% CI 0.01--0.72, *P *\< 0.01) were independent factors associated with non‐exacerbation of HbA1c in the Discontinuation group. Using a receiver operating characteristic curve analysis, the cut‐off values for non‐exacerbation of HbA1c in the Discontinuation group were 48 mg/dL for HDL‐C, 1.0 mg/day for sulfonylurea dose, and 62 years for age.

**Conclusions**: The purpose of using ipragliflozin should be considered on the decision to discontinue or maintain sulfonylurea at the lowest dose. In addition, low HDL‐C level, low dose of sulfonylurea, and younger age were possible markers to not show worsening of glycaemic control by discontinuing sulfonylurea.
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The effect of sleeve gastrectomy in blood glucose management for obese diabetes patients at five years post operation {#jdi12939-sec-0404}
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**S. Mao**

Chimei‐medical Center, Tainan, Taiwan

The worldwide prevalence of obesity is an ever increasing current issue. The comorbidities of obesity have become a sizable medical expense for countries around the world. Diabetes patients with long‐term obesity can have negative impacts to their blood glucose levels and metabolic syndrome. Therefore, weight‐loss procedure can be utilized for patient blood glucose and weight management with good clinical results.

**Methods**: The subject is a 58‐year‐old diabetic male that has over 10 years of oral medication as well as insulin injection treatment history (C‐peptide 3.97 ng/dl on May 21th, 2013). The patient was also diagnosed with cardiovascular disease, and underwent cardiac catheterization and drug‐eluting stent implantation. The weight reduction procedure assessment performed by the general surgical department with referral by the cardiologist. The patient underwent sleeve gastrectomy on June 26th, 2013 (height: 165 cm, weight: 103 kg, body mass index: 38). The post operation follow‐up was performed during outpatient services (general surgical, cardiology, and nutrition department).

**Results**: The patient experienced 18 kg of weight loss at 3 month post‐operation. The glycated hemoglobin level (A1C) stabilized to an average of 6.5 at 2 years after the operation (May 1st: 10.3 → July 10th: 8.7 → Aug. 6th, 2013: 7.7 → April, 2014: 6.4).,The insulin and oral medication usage was also improved (AC sugar control May 1st:189 mg/dl → July 10th: 133 mg/dl → Aug. 6th, 2013: 113 mg/d → April, 2014: 103; Insulin injection: NPH: 30u→ 20u→ 15u→ 10u). Other than good blood glucose management, the patient\'s blood lipid, uric acid, and simple body fat measurement were all improved after surgery. The patient has started to ingest regular food, and was educated by the nutritionist for choosing a low fat diet as well as incorporating exercise in his daily routine.

**Conclusion**: Many clinical weight‐loss procedures have utilized Roux‐en‐Y gastric bypass for treating diabetes. However, Roux‐en‐Y gastric bypass is associated with more comorbidities and nutrition related complication. The subject in this study was able to exhibit good blood glucose management after receiving sleeve gastrectomy with incorporation of post‐operation diet and exercise. Therefore, it is suggested that sleeve gastrectomy can be used in treating diabetes patient with moderate obesity.
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Reduction in glucose fluctuations in elderly patients with type 2 diabetes using repaglinide: a randomized controlled trial of repaglinide vs. sulfonylurea {#jdi12939-sec-0406}
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**K. Omori, H. Nomoto, A. Nakamura, T. Takase, K. Y. Cho, T. Atsumi and H. Miyoshi**

Hokkaido University Graduate School of Medicine, Sapporo, Japan

**Aims**: Glinides are antidiabetic drugs that enhance the early phase of insulin secretion, but have been considered to be less effective at lowering blood glucose than sulfonylureas. However, glinides possess the lower risk of hypoglycaemia and the greater effect on postprandial hyperglycaemia, and are particularly recommended for use in elderly patients with type 2 diabetes. We investigated the efficacy and safety of repaglinide compared with sulfonylurea for the treatment of elderly patients. Materials and

**Methods**: In this multi‐centre, prospective, randomized, open‐label, controlled trial, 57 elderly lean patients with type 2 diabetes who were being treated with sulfonylureas were studied. They were either switched to repaglinide (Repa group) or continued a sulfonylurea (SU group) for 12 weeks. The primary outcome comprised the change in glycaemic control and among the secondary outcomes was the presence of hypoglycaemia and drug compliance.

**Results**: Greater improvements in glycated albumin (GA) and GA to HbA1c ratio (GA/HbA1c) were observed in the Repa group (⊿GA, SU +0.12% vs. Repa −1.15%; ⊿GA/HbA1c, SU +0.01 vs. Repa −0.13; each *P *\< 0.01), although HbA1c was not significantly different between two groups (SU +0.02% vs. Repa −0.07%). When the Repa group was subdivided according to whether GA improved, the SU dose before switching to repaglinide was significantly smaller and HOMA‐β was significantly higher in the GA improvement subgroup.

**Conclusions**: Switching from SU to Repa improved GA and GA/HbA1c, and had favourable effects on glucose fluctuation in elderly patients with type 2 diabetes.
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SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in type 2 diabetes and cardiovascular disease {#jdi12939-sec-0408}
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**Y.‐h. Lee^1^, S. R. Kim^2^, S. H. Kim^1^, J. H. Kim^1^, B.‐W. Lee^1^, J.‐S. Kim^1^, E. S. Kang^1^ and B.‐S. Cha^1^**

^1^Yonsei University College of Medicine, Seoul, South Korea, ^2^National Health Insurance Service Ilsan Hospital, Goyang, South Korea

SGLT2 inhibitors significantly reduce cardiovascular events in humans with T2D; however, the underlying mechanism remains unclear. Activation of NLRP3 inflammasome and subsequent IL‐1β release induces atherosclerosis and heart failure. Recently, it was revealed that ketone bodies, i.e. β‐hydroxybutyrate (BHB), suppress activation of NLRP3 inflammasome in macrophages. As SGLT2 inhibitors cause increases in serum BHB by pharmacologic profile, we assessed the effect of SGLT2 inhibitor on NLRP3 inflammasome activity. In a randomized, active‐controlled study, a total of 61 patients with T2D and high cardiovascular risk (mean age and HbA1C were 64.4 years and 7.32%, respectively) received SGLT2 inhibitor or sulfonylurea for 30 days. NLRP3 inflammasome activation was analyzed in macrophages and the serum levels of glucose, BHB, and insulin from baseline to the end of treatment were tested. While SGLT2 inhibitor\'s glucose‐lowering capacity was similar to sulfonylurea, it significantly decreased IL‐1β secretion compared to baseline (2,394 ± 236 to 1,748 ± 295 pg/mL, *P *\<* *0.001), whereas sulfonylurea treatment had no effect on IL‐1β secretion (2,273 ± 279 to 2,755 ± 331 pg/mL, *P *=* *0.05) (time × group interaction *P *\<* *0.001). SGLT2 inhibitor caused a significant increase in fasting serum BHB and decrease in fasting serum insulin, while sulfonylurea had no significant effects on these measurements. In addition, we performed ex vivo experiments using macrophages to investigate whether BHB and insulin could affect NLRP3 inflammasome activity. BHB dose‐dependently inhibited IL‐1β secretion from macrophages. However, co‐treatment with insulin attenuated the inhibitory effect of BHB on NLRP3 inflammasome activation. In conclusion, SGLT2 inhibitors attenuate NLRP3 inflammasome activation, in part, via increased serum BHB and decreased serum insulin and glucose, which might help to explain the cardioprotective effects of SGLT2 inhibitor in humans.
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Switching to IDegAsp was effective for improving glycaemic control of patients treated with long‐acting insulin. {#jdi12939-sec-0410}
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**H. Fujita, Y. Ueba, T. Yasuda, Y. Kanai, E. Mori, S. Yonemitsu and S. Muro**

Osaka Red Cross Hospital, Osaka, Japan

Purpose: Insulin degludec/insulin aspart (IDegAsp) is a soluble combination of two individual insulin analogues in one product. Adding rapid‐acting insulin to patients treated with long‐acting insulin is expected to improve glycaemic control by lowering postprandial plasma glucose level.

**Methods**: Retrospective data were extracted from medical record. A total of 34 patients with type 2 diabetes mellitus visited to the Osaka Red Cross Hospital, Osaka, Japan, in December 2015 and December 2017, and switching to IDegAsp from long‐acting insulin were enrolled in this study.

**Results**: The mean (±SD) age of the patients was 69.9 ± 11.1 years and the mean duration of diabetes was 19.8 ± 10.7 years. The mean HbA1c level at before switching to IDegAsp and 4 weeks after switching was 8.70 ± 1.17%, 8.40 ± 1.09% (95%CI −0.45 to 1.06, *P *\< 0.01), glycated albumin (GA) level was 24.6 ± 4.64%, 22.7 ± 4.09% (95%CI 0.10 to 4.19, *P *\< 0.01), GA/HbA1c ratio was 2.85 ± 0.51, 2.73 ± 0.46 (95%CI −0.17 to 0.45, *P *\< 0.01), respectively. GA level was decreased more than 0.2% in 25 patients after 4 weeks, and was unchanged or increased in 9 patients. HbA1c level before stitching was 8.90 ± 1.19% and 8.17 ± 0.90% respectively (95%CI −0.19 to 1.65, *P *= 0.057), GA level was 25.4 ± 4.29% and 22.5 ± 4.91% respectively (95%CI −0.73 to 6.55, *P *= 0.057). There was no significant difference in age, the duration of disease and insulin dose between the two groups.

**Conclusion**: Switching to IDegAsp was effective for improving glycaemic control of patients treated with long‐acting insulin and it was suggested that it is effective especially in patients with high HbA1c level. Improvement of GA/HbA1c ratio may represent the effect of adding rapid‐acting insulin. Further study is necessary to evaluate long term effects.
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Safety and tolerability of empagliflozin in East Asian patients with type 2 diabetes: pooled analysis of Phase I‐III clinical trials {#jdi12939-sec-0412}
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**D. Yabe^1,2^, A. Yasui^3^, L. Ji^4^, M.‐K. Lee^5^, R. C. W. Ma^6^, T.‐J. Chang^7^, T. Okamura^3^, C. Zeller^8^, S. Kaspers^9^, J. Lee^9^, S. Kohler^9^ and Y. Seino^1,10^**

^1^Kansai Electric Power Medical Research Institute, Kobe, Japan, ^2^Kyoto University, Kyoto, Japan, ^3^Nippon Boehringer Ingelheim Co., Ltd, Tokyo, Japan, ^4^Peking University People\'s Hospital, Beijing, China, ^5^Sungkyunkwan University School of Medicine, Seoul, South Korea, ^6^The Chinese University of Hong Kong, Hong Kong SAR, China, ^7^National Taiwan University Hospital, Taipei City, Taiwan, ^8^Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany, ^9^Boehringer Ingelheim International GmbH & Co. KG, Ingelheim, Germany, ^10^Kansai Electric Power Hospital, Osaka, Japan

**Aims**: We investigated the safety and tolerability of empagliflozin in East Asian patients with type 2 diabetes (T2DM).

**Methods**: Data were pooled from patients with T2DM randomized 1:1:1 to placebo, empagliflozin 10 mg, or empagliflozin 25 mg in 15 Phase I--III trials. Adverse events (AEs) were analyzed in the subgroup of patients from East Asian countries.

**Results**: In total, 709, 724 and 708 East Asian patients received placebo, empagliflozin 10 mg and empagliflozin 25 mg, respectively; total exposure was 953, 1072, and 1033 patient‐years in these groups, respectively. The incidence of any AEs, severe AEs, serious AEs, and AEs leading to discontinuation was not higher in patients treated with empagliflozin than placebo. The incidence of hypoglycemia differed according to glucose‐lowering medication used at baseline. The incidence of events consistent with urinary tract infection was numerically lower with empagliflozin (5.3--5.8/100 patient‐years) than placebo (7.2/100 patient‐years). Events consistent with genital infection occurred more frequently with empagliflozin (1.5--1.7/100 patient‐years) than placebo (0.2/100 patient‐years). The incidence of AEs consistent with volume depletion was similar across treatment groups (0.8--1.4/100 patient‐years) but higher with empagliflozin 25 mg vs. placebo in patients aged ≥65 years (3.5 vs. 2.0/100 patient‐years). Rates of bone fractures, renal AEs, venous thromboembolic events, hepatic injury, lower limb amputation and diabetic ketoacidosis were similar or not higher with empagliflozin than placebo.

**Conclusions**: In this pooled analysis, empagliflozin was well tolerated in East Asian patients with T2DM based on \>3,000 patient‐years' exposure, consistent with results from the overall analysis population.
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Increased grip strength with sodium‐glucose cotransporter 2 inhibitors in men, especially in men of 75 years of old {#jdi12939-sec-0414}
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**Y. Suzuki**

Hdc Atlas Clinic, Ichibancho, Chiyoda ku, Japan

We examined the change in maximal hand grip strength before and after SGLT2 inhibitor treatment. The study included 92 men with type 2 diabetes in Japanese. The men had a mean (SD) age of 62.8 (10.2) years, baseline BMI of 25.6 (4.5), and HbA1c of 7.0% (1.3%). The patients were treated with ipragliflozin 50 mg, luseogliflozin 2.5 mg, or dapagliflozin 5 mg or 10 mg daily for at least 4 weeks. Overall results have been published already in the reference 1 in 2016. The results of subanalysis showed that the men had increased grip strength in both hands under 75 y/o. (*P *\<* *0.01, paired *t* test). Interestingly, the elderly men had increased grip strength over 75 y/o. in the right hand. These findings were contrary to our prediction because SGLT2 inhibition can reduce lean tissue mass in addition to fat mass, especially in the elderly people. We speculate that the patients were educated about appropriate exercise, which attenuates skeletal muscle loss via intracellular regulation of muscle anabolism and proteolysis. Additionally, patients compensate for the negative energy balance caused by SGLT2 inhibition by increasing carbohydrate intake, leading to anabolism, which may change the catabolic‐anabolic balance set point in muscle. In conclusion, our result of subanalysis here suggests that it is not always necessary to worry about sarcopenia even with the men of type 2 diabetes over 75 y/o. As for women, we could not analysis the result because of the few number of total subjects.
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**L. Tang^1^, Q. Du^1^, S. Xu^1^, C. Feng^2^ and L. Li^1^**

^1^Shengjing Hospital Affiliated To China Medical University, Shenyang, China, ^2^The General Hospital of Shenyang Military, Shenyang, China

**Objective**: To investigate the association of lipid profiles and triglyceride‐glucose (TyG) index at the first visit with the risk of gestational diabetes mellitus (GDM).

**Methods**: A total of 545 pregnant women were divided into normal glucose tolerance (NGT, *n *= 157) and GDM (*n *= 388) according to 75 g oral glucose tolerance test. The characteristic and metabolic indexes were compared. Logistic regression was used to analyze the risk factors of GDM during pregnancy. Receiver operating characteristic curve predicted the threshold of each indicator affecting the occurrence of GDM.

**Results**: The results showed that the level of TG (2.09 \[1.44, 2.94\] vs. 1.47 \[1.02, 2.64\] mmol/L, *P *=* *0.030), TyG index (1.75 \[1.38, 2.13\] vs. 1.16 \[0.84, 1.70\], *P *\<* *0.001), and TG/HDL‐C (1.30 \[0.86, 1.74\] vs. 0.96 \[0.71, 1.44\], *P *=* *0.022) in GDM were significantly higher than NGT. Maternal age, pre‐gestational weight, pre‐gestational maximum weight, pre‐gestational BMI, proportion of overweight and obesity, prenatal weight, first‐degree relatives family history of diabetes, acanthosis, and the incidence of previous adverse pregnancy outcomes were also higher in GDM (*P *\<* *0.05). After adjusted confounding factors, TyG index (odds ratio \[OR\]=24.138, 95% confidence interval \[CI\] 4.1667--139.862, *P *\<* *0.001) was a risk factor for GDM. With the increase of TyG index, the risk of GDM increased significantly (*P *\<* *0.05).

**Conclusion**: Pregnant women with TyG index \> 1.38 was prone to occur GDM during pregnancy.
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-----------------------------------------------------------------------------------------------------------

**W. H.‐H. Sheu^1^, C. M. Khoo^2^, A. Mithal^3^, L. Ji^4^, J. Chan^5^, H. M. Nguyen^6^, K. Suastika^7^, S. P. Chan^8^, B. Matawaran^9^, K.‐H. Yoon^10^, A. O. Y. Luk^5^ and C. Deerochanawong^11^**

^1^Taichung Veterans General Hospital, Taichung, Taiwan, ^2^National University Health System, Singapore, Singapore, ^3^The Medicity, Gurgaon, Haryana, India, ^4^Peking University People\'s Hospital, Peking, China, ^5^The Chinese University of Hong Kong, Hong Kong, China, ^6^FV hospital, HCMC, Vietnam, ^7^Sanglah General Hospital, Bali, Indonesia, ^8^Sime Darby Medical Centre, Kuala Lumper, Malaysia, ^9^University of Santo Tomas hospital, Manila, Philippines, ^10^Seoul St. Mary\'s Hospital, The Catholic University of Korea School of Medicine, Seoul, Korea, ^11^Rajavithi hospital, Bangkok, Thailand

**Background**: The early‐onset and increased prevalence rates of T2DM predispose Asian populations to an elevated risk of CVD. Treatment with SGLT‐2 inhibitors (SGLT2i) has been shown to significantly reduce the risk of CV events in T2DM patients with established or high risk of CVD. A comprehensive review of SGLT2i studies in the Asian population and a practical clinical guidance of their use in the Asian T2DM population is lacking. Aims To consolidate the existing literature on SGLT2i in Asian T2DM patients and to produce a consensus statement on their clinical use.

**Methods**: A panel of 12 endocrinology experts from China, Hong Kong, India, Indonesia, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam critically analyzed recommendations from international guidelines and published results of the clinical trials of SGLT2i in the Asia Pacific region. The panel reviewed and achieved consensus on a series of recommendations supported by scientific evidence and experts' clinical opinion.

**Results**: Data from 43 clinical studies (duration range: 8--104 weeks) in Asian T2DM patients evaluating the effects of six SGLT2i (Dapagliflozin, Canagliflozin, Empagliflozin, Ipragliflozin, Luseogliflozin and Tofogliflozin), two CVOTs (Empagliflozin, Canagliflozin) and three real‐world studies were reviewed. In Asian T2DM patients, treatment with SGLT2i as monotherapy or in combination with other anti‐diabetic therapies resulted in significant reductions in HbA1c levels (range: −0.11% to −1.26%). In addition, SGLT2i treatment was associated with substantial reductions in BP (range: SBP, −1.1 to −9.4 mmHg; DBP, −0.3 to −5.6 mmHg) and body weight (range: −0.5 to −4.02 kg), and preservation of renal function. These effects of SGLT2i in Asian T2DM patients are consistent with those observed in studies of Caucasian patients. A series of statements on the use of SGLT2i in Asian patients with T2DM and high CV risk were discussed and consensus generated following multiple rounds of review and voting.

**Conclusions**: SGLT2i exert pleiotropic effects on various CV risk factors and represent an evidence‐based therapeutic option for the management of CVD in patients with T2DM. This consensus statement aims to provide contemporary guidance to clinicians in the Asia Pacific region on the use of SGLT2i in the effective management of CV risk.
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A consensus statement on the clinical use of SGLT‐2 inhibitors in the management of Asian patients with T2DM and central obesity {#jdi12939-sec-0420}
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**A. Mithal^1^, K.‐H. Yoon^2^, C. Deerochanawong^3^, L. Ji^4^, J. Chan^5^, H. M. Nguyen^6^, K. Suastika^7^, S. P. Chan^8^, B. Matawaran^9^, C. M. Khoo^10^, A. O. Y. Luk^5^ and W. H.‐H. Sheu^11^**

^1^The Medicity, Gurgaon, Haryana, India, ^2^Seoul St. Mary\'s Hospital, The Catholic University of Korea, School of Medicine, Seoul, Korea, ^3^The Medicity, Gurgaon, India, ^4^Peking University People\'s Hospital, Peking, China, ^5^The Chinese University of Hong Kong, Hong Kong, China, ^6^FV hospital, HCMC, Vietnam, ^7^Sanglah General Hospital, Bali, Indonesia, ^8^Sime Darby Medical Centre, Kuala Lumper, Malaysia, ^9^University of Santo Tomas hospital, Manila, Philippines, ^10^National University Health System, Singapore, Singapore, ^11^Taichung Veterans General Hospital, Taichung, Taiwan

**Background**: Asian type 2 diabetes mellitus (T2DM) patients have lower BMI but higher prevalence of visceral adiposity compared with Caucasians. Sustained weight loss and decrease in visceral adiposity improve glycemic control and are important management goals in T2DM, because visceral adiposity is associated with impaired insulin sensitivity. Treatment with SGLT‐2 inhibitors (SGLT2i) results in weight loss in patients with T2DM. There is a need to review the effect of SGLT‐2i on Asian T2DM patients with central obesity.

**Aims**: To consolidate the existing literature on the effects of SGLT2i on body weight and adiposity in Asian T2DM patients and to establish a consensus statement on their clinical use in the management of T2DM patients with central obesity.

**Methods**: A panel of 12 endocrinology experts from China, Hong Kong, India, Indonesia, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam critically reviewed the published results of clinical trials of SGLT2i in T2DM and current management practices in the Asia‐Pacific region. The panel reviewed and achieved consensus on a series of recommendations supported by scientific evidence and experts' clinical opinion.

**Results**: Data from 43 clinical studies in Asian T2DM patients evaluating the effects of six SGLT2i (Dapagliflozin, Canagliflozin, Empagliflozin, Ipragliflozin, Luseogliflozin and Tofogliflozin) and two CVOTs (Empagliflozin, Canagliflozin) were reviewed. Treatment with SGLT2i resulted in significant reductions in body weight, ranging from −0.5 to −4.02 kg (study duration range: 8--104 weeks), which can be attributed initially to glycosuria and later to the reduction in total body fat mass, visceral adiposity, and subcutaneous adiposity. The changes in body weight and adiposity were associated with a positive effect on patient‐reported treatment satisfaction and QoL measures. A series of statements on the use of SGLT2i in the management of obese patients with T2DM were discussed and consensus generated following multiple rounds of review and voting.

**Conclusions**: Most patients with T2DM are obese/overweight and SGLT2i may offer an effective therapeutic option for the management of these patients. This consensus statement aims to provide contemporary guidance to clinicians in the Asia‐Pacific region on the use of SGLT2i in the effective management of T2DM patients with central obesity.
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A 12 week, randomized clinical study to assess the effects of *Momordica charantia* (bitter melon) on blood glucose in pre‐diabetic patients {#jdi12939-sec-0422}
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**B. Kim, Y. Choi, S. Kwon and S. Oak**

Kosin University College of Medicine, Busan, South Korea

The purpose of this study was to investigate the effect of bitter melon extracts on glucose metabolism, insulin resistance and various metabolic parameters in pre‐diabetic patients. Among the people who visited the Kosin University Hospital for health screening or visited the outpatient clinic between the ages of 18 and 80 years, patients with pre‐diabetes, 100--125 mg / dl in fasting blood glucose: or 5.6 ˜ 6.4% in glycated hemoglobin were included. Patients were randomly assigned to the bitter melon extract group and placebo group. A 75 g oral glucose tolerance test (OGTT) was performed before the start of the study and 3 months after the administration drugs. A total of 76 patients were randomly assigned to initiate the study. 11 persons were dropped out of the study, and 33 subjects in the bitter melon group and 32 subjects in the placebo group were the final analysis subjects. The blood glucose levels after 75 g OGTT were decreased in the bitter melon group after 3 months of fasting, 30 min, 60 min, and 120 min after glucose ingestion, especially glucose level of 30 min decreased statistically significantly. On the other hand, there was no change in blood glucose levels in the baseline and 3 months after OGTT in the placebo group. HOMA‐IR, HOMA‐β, and insulinogenic index levels were not different between baseline and 3 months in both groups. Glucagon levels and α‐glucosidase activities were all lower in the bitter melon group after 3 months. In particular, bitter melon group showed a significant decrease in glucagon at 120 min of OGTT after 3 months. In the placebo group, there were no differences in glucagon and α‐glucosidase activities and between baseline and 3 months. In conclusion, bitter melon has a glucose lowering effects in pre‐diabetic patients, not because of changes in insulin resistance or capacity of insulin secretion, but because of glucagon and α‐glucosidase activity suppression.
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Efficacy of switching from DPP4 inhibitor to GLP‐1 with type 2 diabetes in real clinical practice {#jdi12939-sec-0424}
-------------------------------------------------------------------------------------------------

**B. Kim, Y. Choi, S. Kwon, S. Oak**

Kosin University College of Medicine, Busan, South Korea

Previous several clinical trials have suggested better outcomes of HbA1c and body weight reduction after switching from DPP4 inhibitors to GLP‐1 analogues. However, there is no report whether the result are similar in real clinical condition with various patient conditions and background medications. Therefore, we purposed to confirm GLP‐1 analogues are how much more effective after switching from DPP4 inhibitors in real clinical practices with Korean T2DM patients. Data from patients with T2DM who aged above 18 years and had been used GLP‐1 analogue longer than 3 months between April 2016 and December 2017 at Kosin University Gospel Hospital were reviewed retrospectively. From a total 125 patients, we excluded patients who had not previously used DPP‐IDF‐WPR‐4 inhibitors (*n *= 39) and those who discontinued GLP‐1 analogue before 3 months (*n *= 40). After switching from DPP4 inhibitors to GLP‐1 analogues, significant weight loss was observed at first follow up: from 72.1 ± 9.8 to 70.6 ± 10.5 kg; the mean difference −1.5 kg (*P *= 0.002). Switching to GLP‐1 analogues led to great reduction in HbA1c at first follow up: from 9.2 ± 1.4 to 8.3 ± 1.5%; the mean difference −0.9% (*P *\< 0.0001). Blood pressure was decreased after switching; however, it was not significant. It is the first time to monitor the efficacy of switching from DPP4 inhibitors to GLP‐1 analogues in real clinical practice. In conclusion, switching from DPP4 inhibitors to GLP‐1 analogues has larger efficacy for glucose lowering and weight reduction even in real clinical practice.
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Clinical experience of metformin in patients with hyperglycemia in pregnancy {#jdi12939-sec-0426}
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**L. Tang, Y. Bai, L. Li, R. Du and L. Li**

Shengjing Hospital Affiliated To China Medical University, Shenyang, China

**Objective**: To evaluate the efficacy and safety of metformin in patients with hyperglycemia in pregnancy.

**Methods**: Data of a total of 135 cases diagnosed gestational diabetes mellitus (GDM), overt diabetes mellitus (ODM), and pre‐gestational diabetes mellitus (PGDM) were collected. Patients were divided into insulin group (*n *= 60), including women who only received insulin treatment, and metformin group (*n *= 75), including women who received insulin and metformin treatment. The clinical data, maternal weight and insulin dosage between groups were analyzed.

**Results**: Pre‐gestational body mass index (BMI) and prenatal weight in the metformin group were greater than those in the insulin group, and the initial basis, mealtime and total insulin dosage were greater in the metformin group of PGDM; however, the increase of insulin dosage in the metformin group was also significantly lower than that in the insulin group (*P *\< 0.05 or *P *\< 0.01). Patients with insulin dosage more than 100 U/d, less increase of insulin dosage in the metformin group was observed (*P *\<* *0.05); and the incidence of macrosomia was lower (*P *=* *0.002). Patients with pre‐gestational BMI greater or equal to 28 kg/m^2^, the increase of basal, mealtime, and total insulin dosage in the metformin group was also significantly lower than that in the insulin group (*P *\<* *0.05).

**Conclusions**: Treatment combined with metformin during pregnancy can significantly reduce insulin dosage; and it may be a new option for women with hyperglycemia in pregnancy, especially for obesity or patients with high insulin dosage.
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Safety and efficacy of ertugliflozin in Asian patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: VERTIS‐Asia {#jdi12939-sec-0428}
----------------------------------------------------------------------------------------------------------------------------------------------------

**L. Ji^1^, Y. Liu^2^, H. Miao^3^, Y. Xie^4^, M. Yang^5^, W. Wang^5^, Y. Mu^5^, P. Yan^5^, S. Pan^6^, B. Lauring^7^, S. Liu^8^, S. Huyck^7^, Y. Wang^8^ and S. G. Terra^9^**

^1^Peking University People\'s Hospital, Beijing, China, ^2^Yancheng First People\'s Hospital, Yancheng, China, ^3^The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China, ^4^Pingxiang People\'s Hospital, Pingxiang, China, ^5^Pfizer (China) R&D Co., Shanghai, China, ^6^Pfizer Inc., New York, NY, USA, ^7^Merck & Co., Inc., Kenilworth, NJ, USA, ^8^Merck & Co., Beijing, China, ^9^Pfizer Inc., Andover, MA, USA

**Purpose**: Ertugliflozin, a selective inhibitor of sodium‐glucose cotransporter 2 (SGLT2), is approved in the United States and European Union for treatment of adults with type 2 diabetes mellitus (T2DM). This phase 3, randomized, double‐blind, 26‐week multicenter study (NCT02630706) evaluated the efficacy and safety of ertugliflozin in Asian adults with T2DM. Ertugliflozin was also evaluated in the Chinese subpopulation.

**Methods**: Overall, 506 Asian adults, including 406 (80.2%) from Mainland China, with T2DM and inadequate glycemic control (HbA1c 7.0--10.5%) on metformin monotherapy (≥1500 mg/d for ≥8 weeks) were randomized 1:1:1 to receive placebo (*n *= 167), ertugliflozin 5 mg (*n *= 170) or 15 mg (*n *= 169).

**Results**: Baseline characteristics were similar across groups. Overall, 55.5% of patients were male with mean (±standard deviation) age 56.5 (±9.1) years, T2DM duration 7.0 (±5.1) years, body weight (BW) 70.3 (±11.5) kg, BMI 26.0 (±3.2) kg/m^2^, HbA1c 8.1 (±0.9) %, eGFR 99.3 (±19.7) ml/min/1.73 m^2^. At Week 26, reductions from baseline in HbA1c, BW, FPG, and systolic blood pressure (SBP) were significantly greater and significantly more patients had an HbA1c \<7.0% with ertugliflozin vs. placebo. Least squares mean (95% CI) change at Week 26 for placebo, ertugliflozin 5 mg, and ertugliflozin 15 mg, respectively, was: HbA1c --0.2% (--0.3, --0.08), --1.0% (--1.1, --0.9), and --0.9% (--1.0, --0.8); BW --1.2 kg (--1.5, --0.8), --3.0 kg (--3.3, --2.6), and --3.2 kg (--3.5, --2.8); FPG --6.7 mg/dL (--11.6, --1.8), --37.1 mg/dL (--41.7, --32.5), and --34.5 mg/dL (--39.2, --29.8); SBP 0.2 mmHg (--1.6, 2.0), --5.1 mmHg (--6.8, --3.4), and --3.9 mmHg (--5.6, --2.2). At Week 26, 16.2%, 38.2%, and 40.8% of patients receiving placebo, ertugliflozin 5 mg, and ertugliflozin 15 mg, respectively, had an HbA1c \<7.0%. Results were similar in the Chinese subpopulation. Overall incidence of adverse events was similar with placebo, ertugliflozin 5 mg, and ertugliflozin 15 mg (59.3%, 56.5%, 53.3%). Incidence of symptomatic hypoglycemia was higher with ertugliflozin 15 mg vs. placebo (4.7% vs. 0.6%; *P *=* *0.019), and 2.4% with ertugliflozin 5 mg. Results were similar in the Chinese subpopulation.

**Conclusion**: Ertugliflozin significantly improved glycemic control and reduced BW and SBP in Asian patients, including the Chinese subpopulation, with T2DM inadequately controlled on metformin monotherapy. Ertugliflozin was generally well tolerated.
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Effect of antidiabetic agents on the amount of body fat and skeletal muscles: examination with the dual impedance method. {#jdi12939-sec-0430}
-------------------------------------------------------------------------------------------------------------------------

**A. Teshima^1,2^, R. Ito^1^, K. Yanagi^1^, J. Shikuma^1^, H. Suwanai^1^, R. Suzuki^1^, T. Miwa^1^ and M. Odawara^1^**

^1^Tokyo Medical University Hospital, Shinjuku, Japan, ^2^Niiza‐Shiki Chuo general hospital, Shiki, Japan

**Background and Purpose**

Recent studies have reported that sodium glucose cotransporter 2 inhibitors (SGLT2‐i) reduce body fat and muscles. Insulin and sulfonylureas (SU) increase body fat, biguanides alleviate fatty liver and glucagon‐like peptide‐1 (GLP‐1) receptor agonists reduce body weight. However, there is insufficient evidence for the effects of these antidiabetics on body composition. Hence, after measuring the body composition of patients with type 2 diabetes (T2DM) at our hospital, we retrospectively examined the data.

**Methods**: Participants were 102 Japanese outpatients with T2DM who were receiving antidiabetics (age, 57.5 ± 12.4 years; BMI, 28.48 ± 6.85 kg/m^2^; diabetes mellitus duration, 8.3 ± 6.7 years; HbA1c, 8.09 ± 1.58%) and who started a nutrition counselling class at our hospital between April 2014 and March 2015, and attended for at least one year. At the class, we used the dual impedance method to measure their body composition in terms of the levels of body water, protein, minerals, body fat, body fat percentage, skeletal muscles, and waist and hip circumferences. We then analyzed the data of body composition over 12 months.

**Results**: Following 12 months, the levels of HbA1c, BMI, AST, ALT, systolic blood pressure, and diastolic blood pressure significantly decreased (8.23 ± 1.71% to 7.39 ± 1.32%, 28.29 ± 6.61 to 27.99 ± 5.95 kg/m^2^, 32.8 ± 19.3 to 28.3 ± 15.5I U/L, 42.0 ± 35.6 to 33.3 ± 23.9I U/L, 137.1 ± 20.5 to 133.2 ± 18.9 mmHg, 79.6 ± 12.8 to 77.0 ± 11.8 mmHg, respectively). As for body composition following the 12‐month class, only body fat mass significantly decreased (26.30 ± 12.76 to 25.43 ± 11.86 kg). We also compared effects of the antidiabetics. Among the insulin group (*n *= 22), skeletal muscles were maintained significantly compared to non‐insulin group (δ of skeletal muscles, 0.19 ± 0.64 and −0.11 ± 0.41 kg, *P *\< 0.05). In the SU group (*n *= 19), body fat significantly increased (1.49 ± 3.12 and −1.21 ± 2.40 kg, *P *\< 0.01). In the metformin group (*n *= 68), skeletal muscles were significantly maintained (0.15 ± 1.35 and −0.73 ± 1.44 kg, *P *\< 0.05). In the GLP‐1 group (*n *= 24), body fat significantly decreased (−1.94 ± 2.24 and −0.23 ± 2.81 kg, *P *\< 0.05)

**Conclusion**: This study shows that some antidiabetics potentially affect the amount of body fat and skeletal muscles. The use of insulin, especially in elderly patients, has the potential risk of hypoglycemia and hypoglycemia‐induced falls. However this study shows that insulin and metformin potentially maintain skeletal muscles.
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Pitfalls in diagnosing the type of diabetes mellitus in the young patient {#jdi12939-sec-0432}
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**C. H. Ong, S. S. Dharan, P. V. R. Dass and R. Skantha**

Medical Department, Hospital Sultan Abdul Halim, Sungai Petani, Malaysia

Type 2 Diabetes mellitus amongst the young is increasing worldwide and in Malaysia. However, many clinicians are more comfortable in assuming its type 1 till proven otherwise. This case report is about a 25‐years‐old Indian lady who was diagnosed with type 1 diabetes mellitus in 2015, with poorly controlled diabetes. Autoimmune insulin antibodies were positive but her c‐peptide was within range at the point of diagnosis. She developed renal failure within 3 years, and was admitted in early 2018 for acute pulmonary edema with underlying advanced chronic kidney disease, interestingly patient was euglycemic in ward for a few days despite withholding insulin. As such, a repeat c‐peptide was sent in 2018, and it turned out to be high. Given the raised c‐peptide and euglycemic state despite not giving insulin, we can now conclude that throughout the years, this patient in fact has type 2 diabetes mellitus rather than type 1.

The idea that young people do not have type 2 diabetes is a myth, and this case clearly depicts this misconception. Correctly classifying a patient as type 1 or type 2 diabetes is important as the armamentarium of treatments differs.
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Effect of metformin added to insulin on glycemic control and insulin sensitivity in adolescents with type 1 diabetes: A 24‐week, prospective, randomized clinical trial {#jdi12939-sec-0434}
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**W. Xu, S. Luo, W. Liang, H. Deng, Z. Wu, X. Zheng, J. Yan, B. Yao and J. Weng**

Department of Endocrinology and Metabolism, Guangdong Provincial Key Laboratory of Diabetology, the Third Affiliated Hospital of Sun Yat‐sen University, Guangzhou, China

**Background**: Many adolescents with T1D characterized by less optimal glucose control and more weight gain on lager dose of insulin requirement partly due to the decreased insulin sensitivity (IS). Whether adding metformin which could increase IS will improve glucose control and IS in this population is still unclear.

**Methods**: This 24‐week trial involved T1D patients aged 12--18 years whose HbA1c were 7.5%‐10% on daily insulin dose ≥ 0.8U/kg/d. Patients were randomized to metformin group (metformin ≤ 1500 mg/d added to insulin) and control group (insulin alone). IS was estimated by the equation from the SEARCH study (logeIS = 4.64725 -- 0.02032 × waist -- 0.09779 × HbA1c −0.00235 × Triglyceride). All subjects underwent a 48‐h to 72‐h continuous glucose monitoring both at baseline and 24 weeks to measure glycemic variability, represented by standard deviation of blood glucose (SDBG), the mean amplitude of glycemic excursions (MAGE), and absolute means of daily differences (MODD). Primary outcome was change in HbA1c from baseline to 24 weeks. Secondary outcomes included change in body mass index (BMI), waist circumference, IS, glycemic variability, and total daily insulin dose.

**Results**: 17 T1D patients (10 males, 7 females) with BMI 18.33 ± 1.71 Kg/m^2^, HbA1c 9.22 ± 1.69% and total daily insulin 1.03 ± 0.23 U/kg were enrolled. The baseline characteristics between metformin group (*n *= 9) and control group (*n *= 8) were even. After 24‐week intervention, the mean changes in glucose control, including the change in HbA1c (0.0 ± 0.7 vs. −0.4 ± 0.7) and glucose variability (SDBG: 0.06 ± 0.82 vs. 0.24 ± 1.49; MAGE: −0.44 ± 2.93 vs. −1.28 ± 6.97; MODD: 1.47 ± 1.26 vs. 0.81 ± 1.30) were not different between groups. And the changes in BMI (0.08 ± 1.36 vs. 0.91 ± 1.00), waist circumference (0.8 ± 3.3 vs. 3.6 ± 2.7), IS (−0.04 ± 0.11 vs. −0.12 ± 0.31) and total daily insulin dose (0.05 ± 0.08 vs. 0.11 ± 0.32) were also similar between groups. Gastrointestinal adverse events were reported in 1 patient in metformin group and 1 in control group. Incidences of hypoglycemia were not different between groups.

**Conclusion**: 24‐week adjunct therapy with metformin in adolescents with T1D was commonly well tolerated but did not improve glycemic control, and had no impact on IS, body weight and daily insulin dose. High‐quality, large sample, and long‐term follow‐up clinical trials are needed to confirm these conclusions.
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The elevation of hematocrit after administration of SGLT‐2 inhibitors does not correlate with plasma osmolarity in Japanese subjects with type 2 diabetes {#jdi12939-sec-0436}
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**Y. Wada^1^, Y. Hamamoto^2^, Y. Iwasaki^1^, Y. Nakatani^3^, J. Fujikawa^1^, S. Honjo^1^, M. Aizawa‐Abe^1^, K. Iwasaki^1^, S. Yoshiji^1^ and A. Hamasaki^1^**

^1^Kitano Hospital, Osaka, Japan, ^2^Kansai Electric Power Hospital, Osaka, Japan, ^3^Kinki University, Osakasayama, Japan

We investigated the mechanism of hematocrit elevation after administration of sodium‐glucose cotransporter 2 (SGLT‐2) inhibitors by examining the correlation between hematocrit and several parameters reflecting diuretic effects in subjects with type 2 diabetes. A total of 79 subjects (male : *n *= 54, age : 54.0 ± 9.7 SD years, BMI : 29.4 ± 4.4 kg/m^2^, HbA1c : 8.7 ± 1.1%) with type 2 diabetes who were newly administered SGLT‐2 inhibitors from July 2014 to November 2016 were retrospectively identified from our database. The subjects with HbA1c less than 7.0% before administration of the drug or who showed decrease in hematocrit during the study period were excluded. Changes in HbA1c, hematocrit, urine specific gravity, uric acid, serum creatinine and plasma osmolarity levels between before and 30, 60, 90 and 120 days after the administration of the drugs were evaluated. Plasma osmolarity was calculated by the formula (2 x (Na\[mEq/L\] + K\[mEq/L\])) + (BUN\[mg/dl\] / 2.8) + (glucose\[mg/dl\] / 18). HbA1c was significantly decreased (30d: −0.58 ± 0.54%; *P *\< 0.001, 60d: −0.88 ± 1.05; *P *\< 0.001, 90d: −0.76 ± 1.17; *P *\< 0.001, 120d: −0.78 ± 1.53; *P *\< 0.001). Hematocrit was increased immediately after and remained high over 120 days (2.1 ± 1.6%; *P *= 0.001, 2.1 ± 2.4; *P *= 0.02, 3.1 ± 2.3; *P *\< 0.001, 2.6 ± 2.1; *P *\< 0.001). Urine specific gravity was also increased (0.027 ± 0.140 g/ml; *P *\< 0.001, 0.005 ± 0.010; *P *\< 0.001, 0.006 ± 0.010; *P *\< 0.001, 0.007 ± 0.011; *P *\< 0.001). However, uric acid, serum creatinine and plasma osmolarity did not show change. No correlations were observed between changes in hematocrit and serum creatinine, uric acid or plasma osmolarity. Second, we investigated the change in red blood cell indices which is reported to be associated with blood rheological properties. While MCV and MCH did not show any change, MCHC showed significant decrease during the study period (−0.35 ± 0.78 g/dl; *P *= 0.03, −0.16 ± 0.97; *P *= 0.13, −0.50 ± 1.01; *P *\< 0.001, −0.31 ± 0.98; *P *= 0.03) suggesting that increased hematocrit did not lead to increase in blood viscosity. In conclusion, our data indicate that the elevation of hematocrit after the administration of SGLT‐2 inhibitors is unlikely to be caused by hemo‐concentration via diuretic effect. In addition, decreased MCHC might play a role in the reduction of cardiovascular events through rheological change of blood.
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Vitamin D level in relation to metabolic parameters in type 2 diabetes mellitus {#jdi12939-sec-0438}
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**H.‐A. Seo, K.‐H. Bae and E.‐H. Kim**

Daegu Fatima Hospital, Daegu, South Korea

**Purpose**: We investigated the association between vitamin D status and metabolic syndrome related biochemical parameters in patients with type 2 diabetes mellitus.

**Method**: A total of 429 subjects with type 2 diabetes mellitus were included. Vitamin D status was assessed from serum concentrations of 25‐hydroxyvitamin D3 \[25(OH)D3\]. The level of hemoglobin A1C (Hba1c), fasting glucose, insulin, C‐peptide and lipid profiles were examined concurrently.

**Result**: The mean age of total subjects was 58.84 ± 15.0. The level of 25(OH)D3 was 18.69 ± 10.01 ng/mL. In univariate analysis, 25(OH)D3 levels were found to be inversely associated with fasting glucose and HbA1c (r = −0.462, *P *\< 0.001 and r = −0.337, *P *\< 0.001 respectively). After adjusted by age and creatinine levels, the negative correlation between 25(OH)D3 and glucose status was retained. Fasting glucose and HbA1c were correlated with 25(OH)D3 (r = −0.473, *P *\< 0.001 and r = −0.301, *P *\< 0.001 respectively). There was no significant association between vitamin D statue and lipid profiles in both univariate and multivariate analysis.

**Conclusion**: In this study, we founded that vitamin D status is closely associated with glucose status, but not lipid profiles. Vitamin D supplementation may have a role in glycemic control in diabetes mellitus type 2.
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**Purpose**: Ashitaba: Angelica keiskei is a perennial belonging to Umbelliferae, a Japanese native origin, widely native to Izu Oshima island, Japan. This study aimed to clarify the relationship among lifestyle habits related to Ashitaba, degree of sleep disorder and diabetic serum parameters of type 2 diabetes.

**Method**: Among type 2 diabetes patients coming to Oshima Medical Center, for those who got the consent between February 5, 2018 and March 31, 2018, self‐administered survey was carried out. This study was a series of Ashitaba Study (UMIN000031141).

**Result**: There were 79 eligible subjects out of 106 subjects. They consisted of 51 males and 28 females, aged 69.8 ± 9.7 years old, BMI 25.2 ± 3.7 kg/m\^2, LDLc 108.7 ± 28.5 mg/dL, nonHDLc 135.4 ± 35.7 mg/dL, TG 140.9 ± 88.0 mg/dL, HbA1c 7.0 ± 0.8%, Diabetes affected years 15.3 ± 11.6. 72 subjects had Ashitaba regularly, while Ashitaba consuming frequency was 5.4 ± 6.2 days/month. There were 41 subjects of cultivating Ashitaba at home and 32 subjects of obtaining Ashitaba on foot. PSQI results consisted of C1:1.1 ± 0.8, C2:1.1 ± 0.9, C3:1.1 ± 0.9, C4:0.5 ± 0.9, C5:0.9 ± 0.5, C6:0.4 ± 1.0, C7:0.4 ± 0.7 and PSQI value:5.6 ± 3.2. There were 35 subjects with PSQI value over 5.5. Ashitaba home growers were older (72.3 ± 7.4 vs. 65.9 ± 10.6, *P *\< 0.05), lower for LDLc (102.2 ± 26.2 vs. 115.8 ± 28.5, *P *\< 0.05), lower for C6(0.2 ± 0.7 vs. 0.7 ± 1.2, *P *\< 0.05). Those who obtains Ashitaba on foot was lower for C1(0.9 ± 0.7 vs. 1.3 ± 0.7, *P *\< 0.05), C7(0.2 ± 0.5 vs. 0.6 ± 0.7, *P *\< 0.01) and PSQI value (4.7 ± 2.8 vs. 6.4 ± 2.9, *P *\< 0.01). Ashitaba consuming frequency and HDLc showed correlation (α = 0.322, *P *\< 0.01).

**Conclusion**: Type 2 diabetes patients coming to Oshima Medical Center were obese elderly groups with relatively good glycemic control, and 44.3% of them had sleep disorders. 91.1% of type 2 diabetes patients regularly consumed Ashitaba and Ashitaba consuming frequency rate correlated with HDLc value. Type 2 diabetes patients have the possibility to improve lipid related serum values and degree of sleep disorders by cultivating Ashitaba at home and obtaining them on foot.
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**Background**: Nine types of DPP‐IDF‐WPR‐4 inhibitors (DPP‐IDF‐WPR‐4i) are currently used in Japan. Each drug has different characteristics, and one of them is different dosing frequency: once‐daily, twice‐daily, or once‐weekly. Real world evidence describing the impact of such dose frequency on persistence and adherence of type 2 diabetes mellitus (T2DM) therapy with DPP‐IDF‐WPR‐4i is limited in Japan.

**Objectives**: We compared the treatment persistence and adherence of DPP‐IDF‐WPR‐4is among once‐daily, twice‐daily and once‐weekly in patients with T2DM in Japan.

**Methods**: We analysed the administrative claims data between May 1st, 2015 and June 30th, 2016 for Japanese patients with T2DM using the Medical Data Vision (MDV) database. Eligible patients were adults (aged ≥18 years) with an ICD‐10 code for type 2 diabetes, and at least one prescription of DPP‐IDF‐WPR‐4i. Main outcome measures were persistence with treatment and adherence at 12 months. Persistence was measured by the time to discontinuation of the 1st treatment line and assessed by the persistence rate at 12 months. Adherence was measured using the proportions of days covered (PDC) and non‐adherence was defined as a PDC ≤ 80%. We compared these measures between treatment patterns as a whole and stratified by untreated (UT) and previously treated (PT) patients who switched from other antidiabetics.

**Results**: A total of 20,116 patients (UT: 7,288 patients, PT: 12,828 patients) were included. In UT patients, the most commonly prescribed index therapy of DPP‐IDF‐WPR‐4i was once‐daily (87.1%), followed by twice‐daily (12.7%) and once‐weekly (0.2%). In PT patients, the most common index dosing frequency was once‐daily (83.1%), followed by twice‐daily (16.2%) and once‐weekly (0.7%). Persistence at 12 months with index was higher in UT and PT patients with once‐daily (Median time/persistence rate: UT; 553.0 days/66.8%, PT; 569.0 days/71.3%) than with twice‐daily (UT; 525.0 days/61.0%, PT; 558.0 days/68.6%) and once‐weekly (UT; 161.5 days/35.7%, PT; 504.0 days/64.0%). PDC was ≥0.80 with once‐daily and twice‐daily in both groups.

**Conclusion**: The most common frequency dosing was once‐daily in Japan. T2DM patients treated with DPP‐IDF‐WPR‐4i were more persistent with once‐daily therapy than with twice‐daily and once‐weekly therapy. The reasons of low persistence and adherence in twice‐daily and once‐week dosing should be investigated further.
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**R. Tian**

Shan xi Provincial People\'s Hospital, Tai Yuan, China

**Objective**: To compare the diagnostic value of the glomerular filtration rate estimated equations CKD‐EPIcr, CKD‐EPIcys, and MDRD in patients with diabetic nephropathy combined with hypertension.

**Methods**: Eighty‐nine patients with diabetic nephropathy had examined by the renal dynamic imaging in our hospital were enrolled in this study. The patients were divided into observation group and control group for hypertension. The cross‐sectional survey of all patients included sex, age, glycated hemoglobin, blood pressure, and urine micro‐white. Protein, triglycerides, cholesterol, low‐density lipoprotein, high‐density lipoprotein, cystatin C, serum creatinine, with or without fundus lesions, estimated eGFR using the above formula and analyze the diagnostic accuracy of different eGFR formulas in this population.

**Results**: For above 60 years old patients with diabetic nephropathy, the accuracy of the estimated eGFR values for each formula was higher, regardless of whether or not the patients had hypertension, There was no significant difference from the standard value (*P *\> 0.05). For 18--59 years old diabetic patients, the MDRD and CKD‐EPIcr in the diabetic nephropathy non‐hypertension group had statistically significant differences compared with the standard values (*P *= 0.003,0.018) (*P *\> 0.05); the estimated CKD‐EPIcys in the diabetic nephropathy with hypertension group was statistically significant different from the standard values (*P *= 0.001) (*P *\> 0.05).

**Conclusion**: In the elderly population, whether the merger of hypertension has little effect on the estimation formula. Among the 18--59 years old people, the CKD‐EPIcys formula is more accurate in estimating the eGFR value of the diabetic nephropathy non‐hypertensive person. The estimates of the MDRD and CKD‐EPIcr formulas are more accurate when the diabetic nephropathy are combined with hypertension.
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**Background**: A growing number of insulin‐treated patients require high doses of insulin. In Malaysia, approximately 30% of insulin users are on premixed insulin regimen. Those who fail premixed insulin are usually intensified with multiple daily insulin injections (MDI).

**Aims**: The study aimed to evaluate the comparative efficacy of Continuous Subcutaneous Insulin Infusion (CSII) versus MDI in insulin resistant type 2 diabetics sub‐optimally controlled with premixed insulin (defined as HbA1c≥8%). Methodology: This was a 12‐months randomized controlled trial with a single‐arm cross‐over in the continuation phase. The participants entered an 8‐weeks dose optimisation run‐in period to achieve minimum 1.0 U/kg/day followed by randomisation into CSII and MDI.After 6 months, the MDI arm crossed over to CSII for another 6 months. The primary endpoint was change in mean glycated haemoglobin between baseline and 6 months. The secondary endpoints were safety, metabolic profiles, total daily insulin (TDD) and within group change in HbA1c from 6 months to 12 months.(ClinicalTrials.gov number:NCT03112538).

**Results**: 25 participants in CSII group and 25 in MDI group completed 6 months follow‐up. In the continuation phase, 20 participants from MDI group completed additional 6 months of CSII therapy. The baseline demographic data were similar in both groups with mean duration of diabetes 13.8 years and mean glycated haemoglobin 10%. At 6 months, mean glycated haemoglobin decreased by 2·1%(SD 1.17) in the CSII group and 1.2%(SD 1.74) in the MDI group, resulting in a between‐group treatment difference of --0·92%(95% CI −1.766, −0.816 *P *= 0.032). At 12 months, there was a further reduction in HbA1c by 1.0%(SD 0.87 *P *\< 0.001) in the MDI group that crossed over to CSII. At 6 months, TDD/kg/day was 1.0(IQR 0.37) with CSII versus 1.2(IQR 0.35) for MDI (*P *= 0.018).At 12 months, there was a further reduction in TDD/kg/day by 0.2(IQR 0.19 *P *\< 0.001) in the crossover group. TDD was 91.3(SD 31.38) vs. 110.9(SD 35.42) (95% CI −38.59,‐0.53 *P *= 0.044) between the 2 groups at 6 months. At 12 months, TDD further reduced by 15.8(SD 16.86 *P *\< 0.001) with CSII. There was no significant difference in weight and blood pressure in the crossover group. There was no ketoacidosis or severe hypoglycaemia.

**Conclusion**: Insulin pump therapy is effective for insulin resistant type 2 DM patients who failed intensified premixed insulin.
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Sulphonylureas are mostly combined with metformin once the latter fails to bring HbA1c to target in Malaysian Type 2 Diabetes (T2D) patients. In this study, we aimed to identify the significant clinical and sociodemographic predictors of secondary sulphonylurea failure in Malaysian T2D patients. This prospective study was conducted in seven out‐patient clinics across Malaysia from September 2014 to April 2017. Patients were included if they had T2D, aged ≥ 18 years and treated with maximum doses of sulphonylurea and metformin for ≥ 1 year. If the patients were on other concurrent antidiabetic agents or insulin, not adherent to medications, had history of pancreatic surgery or renal impairment (eGFR \< 30 ml/min), they were excluded. The sociodemographic and clinical information of subjects was recorded at baseline. Their fasting plasma glucose and fasting plasma c‐peptide blood levels were taken at baseline using which the Homeostatic model assessment of beta cell function (HOMA2‐B) and insulin resistance (HOMA2‐IR) were calculated. Secondary sulphonylurea failure was defined as HbA1c \> 7.0% (53 mmol/mol) after a 12‐months follow‐up. A binary logistic regression model (SPSS Version 21.0) was used to identify its significant predictors. The incidence of secondary sulphonylurea failure in the 401 subjects included in the final analysis was 65.3%. Among its significant predictors were Malay race, residing in the eastern peninsular Malaysia region, lower body mass index, longer duration of diabetes, lower pancreatic beta cell function (HOMA2‐B), increased insulin resistance (HOMA2‐IR), non‐attainment of HbA1c ≤ 7.0% (53 mmol/mol) at baseline and not having sulphonylurea‐induced hypoglycemia (*P *\< 0.05). In subjects living in the eastern peninsular Malaysia region, the risk of secondary sulphonylurea failure was 5.1 times \[OR =5.060 (1.341 −19.097), *P *= 0.017\] higher than subjects in other regions. Subjects who did not experience sulphonylurea‐induced hypoglycemia had a 2.4 times \[OR = 2.373 (1.268 -- 4.438), *P *= 0.007\] increased odds for secondary sulphonylurea failure than those who did. In conclusion, the identification of subpopulations of Malaysian T2D patients who are at increased risk to fail sulphonylurea therapy may aid the clinicians in using other appropriate treatment strategies for optimization of glucose control, hence delaying the progression of diabetes‐related complications in them.
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**Objectives**: Patients with type 2 diabetes often complain of pollakiuria, especially nocturia, after the initiation of sodium glucose co‐transporter 2 (SGLT2) inhibitors because of the diuretic effect. Because tofogliflozin has the shortest half‐life among SGLT2 inhibitors (5.3 h), pollakiuria might be improved. We compared the glycemic variability and urinary frequency in patients administered tofogliflozin versus other SGLT2 inhibitors.

**Methods**: Nine patients (mean 59 ± 6 years of age) with type 2 diabetes who had been administered SGLT2 inhibitors were studied. Tofogliflozin was administered for four of eight consecutive days, and dapagliflozin or empagliflozin was administered as the control drug for the other four days. The blood glucose levels were evaluated using a continuous glucose monitoring system.

**Results**: Although the mean glucose levels were significantly lower (*P *\< 0.01) during the tofogliflozin periods than in those using the control drugs (after breakfast: 177 ± 26 vs. 194 ± 30 mg/dL, after lunch: 159 ± 31 vs. 171 ± 27 mg/dL, after dinner: 167 ± 23 vs. 184 ± 36 mg/dL, and 24 h: 156 ± 33 vs. 164 ± 37 mg/dL, respectively), there were no significant differences in the mean glucose levels at night (0:00--6:00: 156 ± 33 vs. 164 ± 37 mg/dL). Similarly, the area under the curve (AUC) for glucose levels \>180 mg/dL was significantly lower (*P *\< 0.01) in the tofogliflozin periods than in those using control drugs (after breakfast: 1993 ± 3133 vs. 3964 ± 3862 min mg/dL, after lunch: 1201 ± 2500 vs. 1386 ± 2421 min mg/dL, after dinner: 1113 ± 2663 vs. 3110 ± 4287 min mg/dL, and 24 h: 5165 ± 12,584 vs. 8639 ± 16,023 min mg/dL, respectively) with no significant difference between the AUC of glucose \>180 mg/dL at night (964 ± 3874 vs. 428 ± 1865 mg/dL). Hypoglycemia (glucose levels \<70 mg/dL) was not observed in either period. The urinary frequency tended to be lower in the tofogliflozin periods than in those using control drugs (6.0 ± 1.6 vs. 6.9 ± 2.2 times in 24 h and 0.7 ± 0.6 vs. 0.9 ± 0.7 times at night, respectively).

**Conclusions**: Tofogliflozin is considered to have a better glucose‐lowering effect without nocturnal hypoglycemia and a lower urinary frequency than other SGLT2 inhibitors.
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**Aims**: The aim of this prospective, single arm study is to evaluate the efficacy of luseogliflozin on hepatic fat content and HbA1c in T2DM patients with NAFLD.

**Methods**: Forty T2DM patients with NAFLD (28 males and 12 females) were treated with luseogliflozin 2.5 mg/day for 24 weeks. Primary endpoints are changes in HbA1c and MRI‐hepatic fat fraction (MRI‐HFF) which evaluated hepatic fat content from baseline. We also evaluated the efficacy and safety such as various tests and the assessment of adverse events (AE).

**Results**: Luseogliflozin significantly decreased not only HbA1c but also MRI‐HFF compared at the end of 24‐week treatment period with baseline (HbA1c: 7.29 ± 0.65 vs. 7.00 ± 0.67%, *P *= 0.002, MRI‐HFF: 21.46 ± 7.17 vs. 15.66 ± 6.82%, *P *\< 0.001). And body weight (75.62 ± 13.96 vs. 74.19 ± 13.71 kg, *P *\< 0.001), BMI (27.76 ± 3.62 vs. 27.16 ± 1.01 kg/m^2^, *P *\< 0.001), AST (40.7 ± 22.2 vs. 31.9 ± 18.2 IU/L, *P *\< 0.001), ALT (54.7 ± 28.2 vs. 42.4 ± 26.5 IU/L, *P *\< 0.001), FPG (142.0 ± 30.3 vs. 135.4 ± 25.6 mg/dl, *P *= 0.04) and serum ferritin levels (120.7 ± 90.4 vs. 90.1 ± 79.1 ng/ml, *P *\< 0.001) significantly reduced compared with baseline. On the other hand, hepatic fibrosis markers unchanged from baseline (Type IV collagen 7s: 5.08 ± 1.16 vs. 4.88 ± 0.92 ng/ml, *P *= 0.094, Mac2‐BPGi: 0.67 ± 0.36 vs. 0.66 ± 0.41, *P *= 0.833).Change in MRI‐HFF was significantly correlated with change in body weight (R = 0.34, *P *= 0.032), BMI (R = 0.32, *P *= 0.045), AST (R = 0.34, *P *= 0.032), ALT (R = 0.55, *P *\< 0.001), FPG (R = 0.39, *P *= 0.015) or serum ferritin (R = 0.39, *P *= 0.015). AEs occurred in 25 patients but there were no serious. Data represented mean±SD.

**Conclusion**: These findings suggest that luseogliflozin exhibits the potential effect for decreasing MRI‐HFF in addition to hypoglycemic effect in T2DM. Furthermore change in ALT which strongly correlated with change in hepatic fat content may become a marker for hepatic steatosis symptoms. Luseogliflozin can be a novel promising agent for the treatment of T2DM patients with NAFLD.
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This study was conducted to investing the efficacy and safety of SGLT2 inhibitor in Japanese patients with type 2 diabetes. SGLT2 inhibitor was administered to a total of 134 out‐patients treated with or without other oral hypoglycemic agents, insulin, or GLP‐1 receptor agonist for 12 months. With regard to results, improvements were observed in the HbA1c value from 7.9 ± 1.2% to 7.2 ± 0.8%(*P *\< 0.001), body weight from 79.9 ± 15.7 kg to 79.2 ± 16.5 (*P *\< 0.001), systolic blood pressure from 136.3 ± 17.1 mmHg to 127.9 ± 15.2 mmHg (*P *\< 0.001), eGFR from 79.9 ± 25.3 ml/min/1.73 m^2^ to 84.8 ± 26.8 ml/min/1.73 m^2^ (*P *\< 0.05), HDLc from 49.3 ± 11.1 mg/dL to 53.7 ± 12.5 ma/dL (*P *\< 0.005), AST from 32.4 ± 24.1 IU to 21.4 ± 9.8 IU (*P *\< 0.005), ALT from 46.0 ± 42.4 IU to 30.5 ± 19.0 IU (*P *\< 0.005). As adverse events of SGLT2 inhibitor treatment, urinary tract infection and sexually transmitted disease in 9 cases and diabetic ketosis in 4 cases (diabetic ketoacidosis in one case), bulimia in 3 cases, pollakisuria in 2 cases were observed. Urinary tract infection and sexually transmitted disease were observed in patients who were 8 women and one man, and they onset within 6 months after the start of SGLT2 inhibitor. Regarding diabetic ketosis, almost cases were not severe, but one pneumonia patient continued the meditation of SGLT2 inhibitor, and developed DKA. SGLT2 inhibitor is relatively well‐tolerated and effective for the treatment of Japanese patients with type 2 diabetes.
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**Purpose**: The physiological stability and robustness of plasma C‐peptide makes it suitable for accessing insulin secretion and beta cell function. This study attempted to compare estimation of beta cell function (BCF) in T2DM on oral antidiabetics through calculation of HOMA1 (utilising insulin) and HOMA2 (utilizing either insulin or c‐peptide level).

**Method**: A cross‐sectional study was conducted across five recruitment sites in Kuching, Sarawak. A total of 78 subjects taking metformin monotherapy at 2 g/day and 159 subjects taking full dose combination therapy (metformin 2 g/day with gliclazide 320 mg/day) were recruited. BCF was calculated using HOMA1 equations and HOMA2 calculator. Plasma insulin and C‐peptide level were measured using TOSOH two‐site immunoenzymometric assay.

**Results**: The patients recruited (58.2% female) had mean age of 59.15 years and diabetes duration of 8.55 years. Mean (SD) fasting insulin level was 12.05 (7.22) μU/ml, and not statistically significantly different between both groups. Mean fasting C‐peptide level was 3.12 (1.38) ng/ml, significantly higher in Metformin + Gliclazide group (*P *= 0.0121). The coefficient of variation for fasting insulin level was 0.599 while that for fasting C‐peptide was 0.442, indicating less variation in fasting C‐peptide level. Fasting C‐peptide level is 7.636 (95% CI: 6.977, 8.295) times higher than fasting insulin level when compared in the same unit of pmol/L with a R^2^ of 0.689. HOMA1‐B% had a mean of 80.70 (SD=133.48) compared to HOMA2‐B% (calculated using insulin) 65.17 (SD=48.77) and HOMA2‐B% (calculated using C‐peptide) 91.12 (SD=63.44). The coefficient of variation calculated was 1.654, 0.748 and 0.696, respectively, indicating that HOMA1‐BCF had the largest variation in estimation of BCF.HOMA1‐B% was calculated using a linear equation while HOMA2‐B% was calculated using the HOMA2 calculator utilizing a non‐linear solution. However, there are limitations in the HOMA2‐BCF calculator where the accepted range for insulin is 20--400 pmol/L and C‐peptide is 0.2--3.5 nmol/L.

**Conclusion**: HOMA2‐B% is a better estimator of BCF as compared to HOMA1‐B% due to the less variation among subjects. HOMA2‐B% utilizing C‐peptide level appears to be more promising compared to that using insulin level but this warrants further investigations for utilization in clinical setting.
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**Aims**: We assessed the cost‐effectiveness of empagliflozin in Japan based on the Asian subgroup analysis of the EMPA‐REG OUTCOME trial.

**Methods**: In the EMPA‐REG OUTCOME trial, empagliflozin reduced the risk of cardiovascular (CV) and renal events in patients with type 2 diabetes and established CV disease. Cost‐effectiveness analysis based on the overall population of the EMPA‐REG OUTCOME trial was reported previously by using lifetime discrete event simulation model. The same modeling frame was adapted to evaluate the cost‐effectiveness of treatment with empagliflozin added to standard of care (SoC) compared to SoC in Japan. The time to relevant clinical events and the hazard ratios were derived from an Asian subgroup analysis of the EMPA‐REG OUTCOME trial. The costs for each event were estimated from Japanese medical claims data. Direct medical cost, life expectancy and quality‐adjusted life years (QALYs) were calculated from a payers' perspective.

**Results**: Treatment with empagliflozin was estimated to increase life expectancy by 3.9 year and 2.1 QALYs while total cost increased by 814,764 yen (6,267 € at an exchange rate of 1 €=130 yen) compared to treatment with SoC. The incremental cost‐effectiveness ratio (ICER) was 384,636 yen/QALY (2,959 €/QALY). In the sensitivity analysis, there was no case which was in excess of the reference value of ICER in the pilot introduction for price revision in Japan, 5 million yen/QALY (38,462 €/QALY).

**Conclusions**: Based on the Asian subgroup analysis of the EMPA‐REG OUTCOME trial, our results suggest that empagliflozin is highly cost‐effective compared with SoC in Japan.
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**Background**: T2D with young‐onset (YOD) and chronic kidney disease (CKD) often need insulin treatment with under‐reporting of pattern of insulin usage. Aim: To examine patterns of glycaemic control in insulin‐treated T2D with YOD (diagnosed before 40 year old) and CKD \[estimated glomerular filtration rate (eGFR)\<60 ml/min/1.73 m^2^\] in Asia.

**Methods**: Among 97,852 T2D enrolled into the JADE Register from 11 countries/cities (2007--2017), cross‐sectional analysis of baseline characteristics in 16,551 (16.9%) insulin‐users \[China (*n *= 1,396), Hong Kong (*n *= 3,816), India (*n *= 6,715), Indonesia (*n *= 290), Korea (*n *= 250), Malaysia (*n *= 298), Philippines (*n *= 1,688), Singapore (*n *= 112), Taiwan (*n *= 556), Thailand (*n *= 243) and Vietnam (*n *= 1,187)\] was performed. We examined the associations of insulin regimens with HbA1c and self‐reported hypoglycaemia (≥once/month *versus* \<once/month) with adjustments of potential confounders including total daily dose of insulin (TDD; unit/kg/day).

**Results**: A total of 13,182 patients had complete data for analysis \[age (mean±SD)=58.8 ± 11.7 years, BMI=26.3 ± 4.7 kg/m^2^, disease duration=12.8 ± 8.3 years, 75.3% on concomitant oral glucose‐lowering drugs, 22.7% had cardiovascular disease, 28.5% had CKD\]. The insulin regimens included basal‐only (51.9%), basal‐bolus (23.1%), premixed (17.6%) and bolus‐only (7.3%), with respective HbA1c of 8.7 ± 1.9%, TDD \[median (interquartile range)\] of 0.27 (0.18--0.47); 8.9 ± 1.9%, 0.71 (0.43--1.14); 8.7 ± 2.1%,0.53 (0.39--0.70) and 8.9 ± 2.1%, 0.57 (0.35--0.98) (*P *\< 0.001 for both). More YOD received basal‐bolus insulin (28.6% *versus* 20.4%; *P *\< 0.001) compared to late‐onset diabetes, yet with higher HbA1c (8.8 ± 1.9% *versus* 8.6 ± 1.9%; *P *\< 0.001). More patients with CKD received premixed insulin (21.3% *versus* 16.2%; *P *\< 0.001) and reported hypoglycaemia (24.0% *versus* 16.5%; *P *\< 0.001) than non‐CKD counterparts. In multivariable regression analysis, compared to basal‐only, premixed insulin usage \[β −0.27%, 95% confidence interval (CI) −0.40, −0.14\] was independently associated with lower HbA1c, but not basal‐bolus (β −0.07%, CI −0.18, 0.04) or bolus‐only regimens (β −0.001%, CI −0.17, 0.17). Premixed, basal‐bolus and bolus‐only regimens had adjusted odds ratios of 5.03 (CI 4.17, 6.08), 1.43 (CI 1.21, 1.69) and 1.60 (CI 1.23, 2.06) for hypoglycaemia, respectively.

**Conclusion**: Basal‐only was the commonest insulin regimen in T2D, whereas T2D on premixed insulin had highest risk of self‐reported hypoglycemia. YOD on basal‐bolus regimen had suboptimal control despite higher percentage was put on basal‐bolus regimen than late‐onset T2D. More CKD patients with T2D received premixed insulin and reported hypoglycaemia than their non‐CKD counterparts. Disclosures: ESHL and LLL declared no potential conflicts of interest relevant to this work. APSK and JCNC have served as consultant and speaker supported by Eli Lilly and company. TL, KW, KK and TT are employee and stock holder of Eli Lilly and Company. Grant/support information: This work was supported by Eli Lilly and Company, Indianapolis, Indiana, USA.
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**Introduction**: Post‐prandial hyperglycemia is an independent risk factor for macrovascular complications. Voglibose, an alpha‐glucosidase inhibitor decreases post‐prandial glucose (PPG) effectively. There are limited data of Voglibose in Asian Indian patients with T2DM.

**Objective**: The objective of this study was to assess efficacy and safety of Voglibose in Asian Indian patients with T2DM in real‐life scenario.

**Methodology**: A non‐interventional, multi‐centre, prospective, observational study enrolled adult Asian Indian T2DM patients with inadequately controlled blood glucose (HbA1c 7--10%), on lifestyle modification and/or antidiabetic drugs. Voglibose was added to existing anti‐diabetic medications and dose of existing anti‐diabetic medications were modified. Dose of Voglibose was individualized. A 12‐week follow‐up was done to assess the effect on glycemia, weight and vital parameters, using students' paired t test. Adverse events, if any were noted. Study was conducted as per the Indian and International Standards of Good Clinical Practices. Patient informed consent was obtained and study protocol was reviewed and approved by institutional ethics committee.

**Results**: Total 2004 patients were screened at 39 centers; 1614 patients were enrolled and 1444 completed the study. The mean age was 53.82 years and male: female ratio was 1.6:1. Significant improvement in glycemic parameters were noted; HbA1c reduced by 1.02 ± 0.97% \[95% CI: 0.97 to 1.07, *P *\< 0.001\]; PPG by 52.15 ± 57.31 mg/dL \[95% CI: 49.19 to 55.11, *P *\< 0.001\] and fasting plasma glucose (FPG) by 27.04 ± 42.82 mg/dL \[95% CI: 24.83 to 29.25, *P *\< 0.001\]. Significant improvement in systolic/ diastolic BP and heart rate was also noted. Voglibose was well tolerated, only 19 patients reported adverse events (AE) out of which 03 patients discontinued Voglibose due to AE.

**Conclusion**: This large, multi‐centre, observational study in real‐life scenario highlights efficacy and safety of Voglibose in improvement of glycemic parameters in Asian Indian patients.
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**Purpose**: To evaluate comprehensively the efficacy and safety of GLP‐1RA, DPP‐IDF‐WPR‐4 inhibitor and SGLT2 inhibitor as adjunct therapy with insulin in patients with type 1 diabetes.

**Methods**: Published evidence was searched in MEDLINE and EMBASE from the databases began until April 2018. Randomized controlled trials in patients with type 1 diabetes evaluating the effects of adding GLP‐1RA, DPP‐IDF‐WPR‐4 inhibitor and SGLT2 inhibitor as adjunct therapy with insulin therapy on glucose control will be included.

**Results**: Totally 23 studies were identified, among which 12 studies included GLP‐1RA, 4 studies included DPP‐IDF‐WPR‐4 inhibitor and 6 studies included SGLT2 inhibitor as adjunct therapy in patients with type 1 diabetes. Compare with placebo, GLP‐1RA in combination with insulin led to significant reductions in HbA1c (weighted mean difference (WMD)= −0.20%, 95%CI: −0.25 to −0.15%, *P *\< 0.01), body weight (WMD= −3.88 kg, 95%CI: −4.67 to −3.09 kg, *P *\< 0.01) and insulin dose (WMD= −3.77u/day, 95%CI: −5.63 to −1.90u/day, *P *\< 0.01), and similar risk of hypoglycemia (odds ratio (OR)= 1.23, 95%CI: 0.92˜1.64, *P *= 0.17). Compare with placebo, DPP‐IDF‐WPR‐4 inhibitor in combination with insulin resulted in similar changes in HbA1c (WMD= −0.15%, 95%CI: −0.34˜0.04%, *P *= 0.13), body weight (WMD= 0.10 kg, 95%CI: −0.94˜1.14 kg, *P *= 0.85), insulin dose (WMD= −2.78u/day, 95%CI: −5.82˜0.26u/day, *P *= 0.07) and risk of hypoglycemia (OR= 2.17, 95%CI: 0.17˜8.08, *P *= 0.55). Compare with placebo, SGLT2 inhibitor as adjunct therapy with insulin exhibited significant reductions in HbA1c (WMD= −0.44%, 95%CI: −0.50 to −0.39%, *P *\< 0.01), body weight (WMD= −3.21 kg, 95%CI: −3.24 to −3.17 kg, *P *\< 0.01), and insulin dose (WMD= −6.28u/day, 95%CI: −7.40 to −5.16 u/day, *P *\< 0.01), but a higher risk of hypoglycemia (OR= 1.90, 95%CI: 1.35˜2.66, *P *\< 0.01).

**Conclusions**: Compare with placebo, the efficacy in glucose control, body weight control and reduction in insulin dose were superior in the combination therapy of GLP‐1RA, DPP‐IDF‐WPR‐4 inhibitor and SGLT2 inhibitor with insulin in patients with type 1 diabetes while the risk of hypoglycemia should be taken care of.
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**Background/Aims**: Japanese patients with T2DM generally have free access to diabetes specialists (specialists) and non‐specialists. Differences in diabetes care by specialists and non‐specialists might affect patients' self‐care behaviors and outcomes. This study aimed to evaluate differences in OAD selection and self‐care behaviors between specialists' and non‐specialists' patients using baseline data from RESPOND.

**Method**: RESPOND is a prospective, observational study of 1,500 drug‐naïve Japanese T2D patients initiating one OAD that assesses prescription changes and adherence to self‐care behaviors during two years of follow‐up. Characteristics of patients initiating different OADs were compared between specialists and non‐specialists, and self‐care behaviors were evaluated using the Summary of Diabetes Self‐Care Activities (SDSCA) questionnaire.

**Result**: Patients initiating metformin (MET) (specialist/non‐specialists, *n *= 125/112), DPP4 inhibitors (specialist/non‐specialists, *n *= 334/496), or SGLT2 inhibitors (SGLT2is) (specialist / non‐specialists, *n *= 86/193) were analyzed for prescription trends. Patients initiating other OADs, such as sulfonylureas, were few (specialist / non‐specialists, *n *= 72/67). For younger patients, MET were more frequently prescribed by specialists. Non‐specialists prescribed SGLT2is more frequently than specialists in all age groups. Mean baseline SDSCA scores for general diet, diabetes specific diet, sugar testing and foot check scores were similar between specialists' and non‐specialists' patients. Exercise score was significantly higher for specialists' patients than non‐specialists' (2.2 ± 2.1 versus 1.9 ± 2.1; *P *\< 0.05). Analysis of SDSCA\'s diet‐related items revealed that the patient proportion receiving practical advice by specialists was larger than non‐specialists: "Follow a low‐fat eating plan" 54.2% *versus* 48.0% (*P *\< 0.05); "Follow a predetermined calories plan" 41.2% *versus* 29.6% (*P *\< 0.001); "Eat lots of food high in dietary fiber" 31.5% *versus* 25.5% (*P *\< 0.05); "Eat lots of vegetables" 66.7% *versus* 60.2% (*P *\< 0.05); "Limit eating fruits ≤80 kcal" 23.8% *versus* 12.2% (*P *\< 0.001); and "Avoid eating sweets" 62.5% *versus* 56.1% (*P *\< 0.05). More specialists' patients had education on healthy diet compared to non‐specialists' (52.7% *versus* 27.8%). Regardless of specialists or non‐specialists, large patient population had exercise education (66.7% versus 70.0%), however, few patients had foot care education (5.9% *versus* 2.0%).

**Conclusion**: The results suggest important differences exist for practical diet instructions between specialists' and non‐specialists' patients. These differences could affect diabetes self‐care activities and potentially patient outcomes.
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**Objective**: To explore the current status of individualized care of inpatients with diabetes and analyze the reasons.

**Methods**: 152 inpatients with diabetes were selected in the department of Endocrinology and Metabolism of a tertiary hospital in Chengdu by purposive sampling from November 2017 to May 2018 and investigated by demographic questionnaires and Individualized Care‐Patient Scales.

**Results**: The total score of Individualized Care‐Patient Scales‐A (ICS‐P‐A) and Individualized Care‐Patient Scales‐B (ICS‐P‐B) were 4.79 ± 0.43 and 4.88 ± 0.23 respectively. From high to low, the dimensions of ICS‐P‐A were clinical characteristics, personal life characteristics and participation willingness, the dimensions of ICS‐P‐B were clinical care, personal life care and decisional control over care.

**Conclusion**: The current status of individualized care of inpatients with diabetes was better but nurses paid more attention on clinical characteristics. More attention should be paid to patients' subjective participation intention in the quality care services in the future, and encourage them to participate in decision‐making and make a plan of nursing measures.
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**Objective**: Data of nationwide glycemic control and hypoglycemic treatment patterns in newly diagnosed type 2 diabetes in China is vacant. The aim of this study was to assess the evolution of treatment patterns for newly diagnosed type 2 diabetes patients and the clinical outcomes during 12‐month follow up.

**Research Design and Methods**: This is an observational prospective cohort study with 12 months of follow up. Patients with a diagnosis of type 2 diabetes less than 6 months were enrolled in. HbA1c levels and hypoglycemic treatment patterns were collected at baseline and at every 3 months of follow up for 12 months.

**Results**: A total of 79 hospitals from six major geographic regions in China were recruited, consisting of 5770 participants. The mean HbA1c was 8.4 ± 2.5% (68 ± 19 mmol/mol) at baseline and decreased to 6.7 ± 1.2% (50 ± 9 mmol/mol) at 12 months with 68.5% of these patients achieving the target of HbA1c \<7% (53 mmol/mol) at 12 months. At baseline, 44.6% of the patients were without hypoglycemic medications, 37.7% had oral hypoglycemic agents and 17.7% received insulin treatment. Determinants of change in HbA1c were treatment patterns, comorbidities, baseline characteristics as obesity and smoking, regions and tiers of hospitals. Associated factors with treatment alterations were time of follow‐up, treatment patterns, patient reported reasons as the economic factors and poor efficacy.

**Conclusions**: The glycemic control and the hypoglycemic treatment patterns and alterations with the associated factors in newly diagnosed type 2 diabetes patients throughout China were first outlined.
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**Purpose**: The aim of this meta‐analysis was to find the associations between metformin use and the risks of vitamin B12 deficiency, anemia and neuropathy in patients with diabetes.

**Methods**: The database of PubMed, Web of Knowledge, Cochrane Library and Embase were searched to identify studies including all controlled studies on relationships between metformin use and vitamin B12, anemia or neuropathy in patients with diabetes, which were published in English prior to March 2018. The pooled risk ratio (RR) and 95% confidence interval (CI) were calculated to compare the risks of vitamin B12 deficiency, anemia and neuropathy in diabetic patients on metformin treatment vs. those without metformin use. The mean difference (MD) and 95% CI were calculated to compare the levels and changes of serum vitamin B12 concentration (pmol/L) from baseline in diabetic patients on metformin treatment vs. those without metformin use.

**Results**: A total of 30 studies were included in the analyses. Compared to patients without metformin use, patients with metformin treatment has significantly higher risk of vitamin B12 deficiency (RR=2.28; 95% CI \[1.63, 3.21\]; P* \< *0.001), significantly lower levels of serum vitamin B12 concentration (MD=‐64.71pmol/L; 95% CI \[−75.52, −53.91\]pmol/L; P* \< *0.001), and significantly greater decrease in serum vitamin B12 concentration from baseline (MD=‐14.68%; 95% CI \[−17.98, −11.39\]%; P* \< *0.001). Additionally, analyses of the few currently available studies did not reveal significant difference in risk of anemia (RR=0.93; 95% CI \[0.79, 1.09\]; *P *= 0.36), and neuropathy (RR=0.84; 95% CI \[0.62, 1.13\]; *P* = 0.25) between patients on metformin therapy vs. those who were not.

**Conclusion**: Metformin use was significantly associated with the risk of vitamin B12 deficiency and the level of vitamin B12 was significantly lower in patients with metformin use compared with those without metformin use.
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**Purpose**: We previously showed that ipragliflozin ameliorated fatty liver in a relatively small number of Japanese patients with type 2 diabetes. In the current study, we investigated the factors associated with fatty liver remission via treatment with ipragliflozin in a larger sample size.

**Methods**: This subanalysis was obtained from our multi‐center prospective observational study, which included 200 Japanese patients with type 2 diabetes who were undergoing outpatient treatment from February 2015 to July 2017. After obtaining the patients' informed consent, once daily ipragliflozin (50 mg/day) was administered for 24 weeks. Several clinical parameters, including fasting plasma glucose (FPG), HbA1c, lipid profiles, and liver function, were compared before and after 24 weeks of treatment. The extent of fatty liver was estimated using a fatty liver index (FLI), comprising body mass index (BMI), waist circumference, gamma‐glutamyl transferase, and triglycerides (TGs). Because FLI \<30 can be used to rule out hepatic steatosis, patients with FLI \<30 were excluded from the analysis. Based on the FLI after 24 weeks of treatment with ipragliflozin, these patients were classified into a remission group (FLI \<30) and a non‐remission group (FLI ≥30). Multivariate logistic regression analysis was performed to identify factors that are independently associated with FLI remission.

**Results**: Of the 150 patients included in this subanalysis, there were 39 in the remission group and 111 in the non‐remission group. Body weight, BMI, waist circumference, aspartate aminotransferase (AST), alanine aminotransferase (ALT), TGs, non‐high‐density lipoprotein cholesterol (non‐HDL), and FLI in the remission group were significantly lower compared with those of the non‐remission group. There were no differences in FPG and HbA1c between the two groups. Logistic regression analysis showed that the baseline FLI (Odds ratio 0.86; 95% confidence interval 0.81--0.90, *P *\< 0.01) was an independent factor associated with FLI remission. Using a receiver operating characteristic (ROC) analysis, the adequate cutoff value for FLI remission was 50. The area under the FLI ROC curve was 0.93.

**Conclusions**: The results of this study suggest that patients with a fatty liver who have a lower FLI were more likely to attain remission by the treatment with ipragliflozin.
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**Objective**: We designed this prospective, nationwide multicenter, observational cohort study with 12‐month of follow up, with the aim to evaluate the burden of glycemic control, blood pressure control, lipid control for newly diagnosed type 2 diabetes patients in China.

**Research Design and Methods**: Patients with a diagnosis of type 2 diabetes less than 6 months were enrolled in. HbA1c levels and hypoglycemic treatment patterns were collected at baseline and at every 3 months of follow up for 12 months.

**Results**: A total of 79 hospitals from six major geographic regions in China were recruited, consisting of 5770 participants. After 12‐month treatment, 31.5% of them still failed to achieve the goal of HbA1c\<7.0%, 16.3% could not reach the target of BP control (BP \< 140/90 mmHg), and 51.8% failed to achieve the recommended LDL‐c \< 2.6 mmol/L. The proportions of patients that reached the three combined therapeutic targets doubled from 11.6% to 29.5% after one‐year follow‐up. Compared to those patients with baseline HbA1c \< 7.0%, patients with baseline HbA1c ≥ 7.0% had higher possibilities of failing to reach adequate glycemic control (RR = 2.04; *P *\< 0.0001), BP control and LDL‐c control during the follow‐up visits. Patients with obesity tended to have higher possibilities of failure in glucose control (RR = 1.05; *P* = 0.0044), BP control (RR = 1.62; *P *\< 0.0001) and LDL‐c control (RR = 1.09; *P* = 0.0009). The active smokers had a higher possibility of failure in glycemic control than non‐smokers (RR = 1.06; *P* = 0.0021), and patients with physical activities had a lower possibility of failure in lipid control than patients without exercises. Compared to patients without medications, newly diagnosed patients with one OHA had lower possibilities of failure in glycemic control (RR = 0.93; *P *\< 0.001), BP control (RR = 0.83; *P *\< 0.001) and LDL‐c control (RR = 0.92; *P *\< 0.001).

**Conclusions**: This study outlined the burdens of glycemic control, blood pressure control and lipid control, identified residual gaps in the quality of care and risk‐factor control, and revealed the factors influencing these gaps in newly diagnosed type 2 diabetes patients in China.
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**Aims**: To comprehensively evaluate the efficacy and safety of initial combination therapy compared with monotherapy in different anti‐diabetes treatment groups in drug‐naïve type 2 diabetes patients. Materials and

**Methods**: A systematic search of Medline and other searching systems was performed for studies published until April 2017. Randomized clinical trials of initial combination therapy with hypoglycemic agents comparing with monotherapy were included. Weighted mean difference (WMD) and relative risks (RRs) were calculated.

**Results**: A total of 36 studies were included. Compared with metformin monotherapy, initial combination therapy of metformin with another anti‐diabetes drug exhibited significant reductions in HbA1c (*P *\< 0.001) and most of the combination therapies had similar risk of hypoglycemia (*P *\> 0.05), except for combinations of sulfonylurea/glinide and metformin or combinations of thiazolidinedione and metformin. Compared with dipeptidyl peptidase‐4 (DPP‐IDF‐WPR‐4) inhibitor monotherapy, initial combination therapy of DPP‐IDF‐WPR‐4 inhibitor with another anti‐diabetes drug showed significant decreases in HbA1c (*P *\< 0.001) and similar risk of hypoglycemia (*P *\> 0.05). Compared with monotherapy of other anti‐diabetes drugs, initial combination therapies also resulted in significant HbA1c reductions, similar risk of hypoglycemia and similar risks of other adverse events.

**Conclusions**: Initial combination therapies compared with monotherapies resulted in significantly reduced glucose levels in different anti‐diabetes treatment groups in drug‐naïve type 2 diabetes patients and most of them with similar risks of hypoglycemia and adverse effects.
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**Background**: Treatment strategy for diabetes should take the cost‐effectiveness into consideration, with the heavy burden of diabetes and its complications both in China and in the world, but the cost‐effectiveness and the outcomes comparisons between the new emerging drug dapagliflozin and metformin treatment have not been well studied yet.

**Method**: The cost effectiveness and the simulated macro‐ and micro‐vascular outcomes of dapagliflozin versus metformin were estimated by using the Cardiff Diabetes Model, by using indirect comparative efficacy data from meta‐analysis results of dapagliflozin or metformin monotherapy, combination therapy with oral hypoglycemic agents and combination therapy with insulin.

**Results**: Totally, 71 studies were included in the meta‐analysis for the monotherapy and add‐on therapy of dapagliflozin or metformin. Cardiff Diabetes Model analysis indicated that total events predicted of non‐fatal ischemic heart disease were similar between dapagliflozin and metformin treatment arms (122.62 vs. 119.04). Total events predicted of non‐fatal myocardial infarction as well as fatal myocardial infarction were also similar between dapagliflozin and metformin treatment arms (124.25 vs. 107.87, 177.38 vs. 190.59, respectively). For cost analysis, the total discounted costs accumulated over the lifetime on dapagliflozin treatment arm was 8,626 Chinese yuan higher than metformin treatment arm for an individual patient, and the quality adjusted life years (QALYs) gained with dapagliflozin treatment was 0.8 more than metformin treatment. This resulted in an incremental cost‐effectiveness ratio of 10,729 yuan per QALY gained for dapagliflozin treatment arm versus metformin treatment arm. Simulated progression of HbA1c between dapagliflozin treatment and metformin treatment over the modeled time horizon was similar.

**Conclusion**: The cost‐effectiveness result showed that dapagliflozin treatment was more cost‐effective compared with metformin treatment for Chinese type 2 diabetes patients.
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**Background**: What exactly mechanisms that could contribute to the reduction of cardiovascular (CV) mortality by empagliflozin (EMPA‐REG OUTCOME Study) were less clear but the rapid reduction within 2 to 3 months in CV events in empagliflozin‐treated subjects suggested a hemodynamic mechanism of action.

**Objectives**: To evaluate that sodium‐glucose cotransporter‐2 (SGLT‐2) inhibitors (empagliflozin or dapagliflozin) would have a relatively rapid effect (28 ± 7 days) on either hemodynamic marker (NT pro‐BNP), or metabolic markers (apolipoprotein B and hs‐CRP) which are possible mechanisms that could contribute to the reduction of CV mortality. Materials &

**Methods**: This single center, open‐label, prospective study included 34 patients with type 2 diabetes (A1c 8.1 ± 0.79%, body mass index (BMI) 28.88 ± 4.04 kg. m^−2^). Patients were allocated to receive empagliflozin (*n *= 21; 9 were patients with established CV diseases) or dapagliflozin (*n *= 13) as add‐on treatment. Fasting blood samples were collected before and 28 ± 7 days after this intervention. Comparison of body weight (BW), blood pressure (BP), estimated glomerular filtration rate (eGFR), fasting plasma glucose (FPG), lipid profiles, ketone, NT‐proBNP, apolipoprotein B, and hs‐CRP were performed using the paired t test.

**Results**: During 28 ± 7 days, SGLT‐2 inhibitors significantly decreased BW, BP, FPG, and plasma triglycerides. There were trends of lowering the percentage change of NT‐proBNP (−0.88 ± 55.45%), apolipoprotein B (−0.12 ± 20.13%) and hs‐CRP (−39.82 ± 132.83%), but they were not all significantly changed. Whereas, eGFR and serum ketone did not significantly increase.

**Conclusions**: These study findings might emphasize that CV benefit of SGLT‐2 inhibitors in the treatment of patients with type 2 diabetes would have an early effect on both hemodynamic and metabolic markers. In addition, the CV benefit of SGLT‐2 inhibitors (empagliflozin, dapagliflozin) might be a class effect.
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**Background**: Some diabetic patients who had coronary artery disease (CAD) took clopidogrel treatment. Clopidogrel may affect fibrinogen level decreased. Some studies have shown that haemostatic factor especially hyperfibrinogenemia is implicated as a source of atherosclerosis. In other hand, clopidogrel resistance might occurred in type 2 diabetes patient, in which one of considered etiology factor is body mass index (BMI). In some studies, fibrinogen level in type 2 diabetes is correlated with BMI.

**Objective**: This study has been undertaken to analyze the correlation between BMI and fibrinogen level as risk factor in type 2 diabetes mellitus with clopidogrel treatment.

**Method**: A retrospective study from medical recorded in January 2000--2018 by recording demographic data and laboratory results from diabetes private clinic in Surabaya. All data were analyzed to see the correlation between two variable using Pearson test.

**Result**: From 61 subjects, mean age 60.56 ± 10.99; the majority of male 47 people (77%). All subjects are diabetic patients who received clopidogrel treatment. BMI and Fibrinogen level data is distributed normally. Fibrinogen median 317 mg/dL and interquartile range 103 mg/dL. BMI median 25.39 and interquartile range 6.8. Bivariate analyze BMI and fibrinogen level is associated significantly with p value\<0.05, *r* = 0.450. From comparison analysis using one way anova (*P *\< 0.05), patients with normal BMI (36,1%) had lower mean fibrinogen level (270.58 mg/dL) compared with overweight (19%), and obese (17%) fibrinogen level (328.84 mg/dL, 341.88 mg/dL respectively).

**Conclusion**: BMI and Fibrinogen level in type 2 diabetic patients with clopidogrel therapy associated significantly in this study.
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**Introduction**: Whether patients' fear of hypoglycemia may affect the decision of second line anti‐diabetes medication and subsequent glycemic control is not clear.

**Method**: DISCOVER was a multi‐country, multicenter, observational, prospective, longitudinal cohort study. At baseline, patients' fear of hypoglycemia was assessed using the Hypoglycemia Fear Survey (HFS). In this study, we analyzed the associations of baseline HFS Worry subscale (HFS‐W) and the use of second line insulin secretagogues (IS, sulfonylureas or meglitinides) or insulin, and changes in glycated hemoglobin (HbA1c) at 6 months and 1 year later.

**Results**: A total of 7301 patients (mean age 56.3 ± 11.9 years, mean HbA1c 8.4 ± 1.7%) were analyzed. The mean HFS‐W was 6.89 ± 11.4. We divided patients into three groups according to their HFS‐W (0, 1--8, and ≧9; *n *= 3292, 2084, and 1925, respectively). The respective mean HbA1c was 8.4 ± 1.7, 8.4 ± 1.6, and 8.6 ± 1.7% (*P* = 0.002), while the rate of first line IS use was 30.3, 33.3, and 33.4% (*P* = 0.023), respectively. In Hierarchical logistic model adjusted for confounders, patients with an HFS‐W of 1--8 (odds ratio 0.83 \[95% CI 0.73--0.95\]) or ≧9 (odds ratio 0.84 \[95% CI 0.71--0.98\]) were less likely being prescribed with IS or insulin as a second line treatment, compared with those who had an HFS‐W of 0. Compared to the use of second line non‐IS, second line IS or insulin was associated with a greater HbA1c reduction from baseline to 6 months and 1 year among patients who had an HFS‐W of 0 or 1--8, but not in patients with an HFS‐W ≧9.

**Conclusions**: Patients with a higher HFS‐W were less likely being prescribed with IS or insulin as a second line treatment. The use of second line IS or insulin was more effective in HbA1c reduction than the use of non‐IS in patients with an HFS‐W of 0 or 1--8, but not in patients with an HFS‐W ≧9.
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Peking University People\'s Hospital, Beijing, China

**Objective**: Our aim was to investigate factors influencing glycemic control in patients with type 2 diabetes. RESEARCH DESIGN AND

**Methods**: The 499 diabetic patients enrolled from a multicenter, prospective study were divided into two groups: newly diagnosed type 2 diabetic patients (NDM group, *n *= 158), and patients with poor glycemic control with oral hypoglycemic agents (DM group, *n *= 341). Serum glycated albumin (GA), HbA1c, fasting blood glucose, and C‐peptide were assayed at baseline. All subjects were prescribed a new therapy and followed up for 91 days. Indexes were tested on days 14, 28, and 91. Glycemic control was determined according to HbA1c at day 91 with HbA1c \<7% (53 mmol/mol) considered good.

**Results**: The average HbA1c at day 91 was 6.7% (50 mmol/mol) and 7.4% (57 mmol/mol) in the NDM and DM groups, respectively. In the whole population and in the DM group, C‐peptide at baseline (OR = 0.757, 95% CI 0.634--0.904, *P *=* *0.002), diabetic duration (OR = 1.127, 95%CI 1.074--1.184, *P *\<* *0.001), BMI (OR = 1.099, 95% CI 1.034--1.168, *P *=* *0.003), changes in GA at 14 (OR = 1.094, 95% CI 1.023--1.169, *P *=* *0.008) and 28 (OR = 1.141, 95% CI 1.067--1.221, *P *\<* *0.001) days independently predicted glycemic control. In the NDM group, the change of GA at 28 days was the only predictor of glycemic control (OR = 1.195, 95% CI 1.036--1.378, *P *=* *0.014).

**Conclusions**: GA was a better predictor of glycemic control in patients with newly diagnosed diabetes.
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**Objective**: Type 2 diabetes mellitus (T2DM) is a complex disease and the glycemic control grows more difficult as time goes on and use of insulin is required for adequate glycemic control in many patients. However, for patients who are not to be controlled by insulin, an add‐on therapy of additional antidiabetics can be a proper option. Thus, this study aimed at demonstrating superiority of gemigliptin, a dipeptidyl peptidase‐4 inhibitor, in glycemic control as an add‐on therapy compared to placebo in patients on insulin alone or on insulin in combination with metformin stably for 8 weeks without dose adjustment.

**Method**: In this multinational, randomized, placebo‐controlled, double‐blind, phase 3 trial, a total of 290 T2DM patients who had been taking stably long‐acting, intermediate‐acting, or pre‐mixed insulin alone or on insulin in combination with metformin (≥1000 mg/day) for 8 weeks prior to screening, but couldn\'t achieve adequate glycemic control were randomized (2:1) to gemigliptin (*n *= 193) or placebo (*n *= 97). The randomized subjects participated in the treatment period for 24 weeks. The primary endpoint was the change in HbA1c from baseline after 24 weeks.

**Results**: Twenty four weeks after randomization (baseline), the adjusted mean of change from baseline in HbA1c of the gemigliptin group was −0.816%, and the adjusted mean difference between the two groups was −0.685% \[95% CI (−0.941%, −0.429%)\] (*P *\< 0.0001). The differences in proportions achieving HbA1c \< 7% and HbA1C \<6.5% of gemigliptin group were 34.0% and 12.2%, respectively, which were statistically significant compared to the placebo group (*P* = 0.0012 and 0.0014 respectively). The incidence rate of adverse events was similar in gemigliptin group and placebo group (40.6% and 39.6%, respectively), and the hypoglycemia incidence was similar between both groups (15.1% and 15.6%, respectively).

**Conclusion**: This study demonstrated that gemigliptin add‐on therapy significantly improved glycemic control relative to placebo without increasing hypoglycemia in T2DM patients on insulin alone or combined with metformin.

PP‐245 {#jdi12939-sec-0491}
======

The effect of family history on glycemic control in patients with newly diagnosed type 2 diabetes mellitus {#jdi12939-sec-0492}
----------------------------------------------------------------------------------------------------------
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**Objective**: This study was to investigate the effect of family history (FH) of diabetes mellitus (DM) on glycemic control in patients with newly diagnosed type 2 DM.

**Methods**: From a total of 130 patients with newly diagnosed type 2 DM, we analyzed data that FH of diabetes, body mass index (BMI), HbA1c, fasting plasma glucose (FPG), postprandial plasma glucose, fasting C‐peptide, postprandial C‐peptide, lipid profiles, and participation for education of diabetes management. At first follow‐up laboratory test, after 3 months, the outcome of glycemic control in patients with FH was compared to that in patients without FH.

**Results**: Initial HbA1c level at the diagnosed time was higher in patients with FH than in patients without FH (8.8 ± 2.7; 7.9 ± 2.0%, *P* = 0.04). In first follow‐up HbA1c level, however, no significant difference was in both groups (6.49 ± 0.94; 6.44 ± 0.97%, *P* = 0.794). A difference of HbA1c (▵HbA1c) between the diagnosed time and the first follow‐up time was greater in patients with FH (2.32 ± 2.64; 1.47 ± 2.05%, *P *\< 0.005). In participation for education of DM management, no significant difference was found in patients with FH compared with those without FH (68.9; 59.4%, *P* = 0.264). In sub‐group analysis for people with FH, patients with siblings who were diagnosed with DM were older than patients with parents who were diagnosed with DM (57.9 ± 10.1; 43.7 ± 10.6 years, *P *\< 0.005). Initial HbA1c level was higher and significant interval change of follow‐up HbA1c were in patients with parents who were diagnosed with DM.

**Conclusions**: In our study, people with FH presented high initial HbA1c and rapidly improved plasma glucose status. It is suggested that patients maybe neglect their diabetes' occurrence despite their FH. But the results of glycemic control are more effect in patients with FH perhaps because of their surrounding environment\'s supports. Therefore, we suggest that it is necessary to perform a regular glucose level test for early detect of DM in people with FH of DM.
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**Purpose**: Most patient who are diagnosed type 2 DM (T2DM) have insulin resistance. With the presence of insulin resistance come other health problems such as obesity, hyperlipidemia, and cardiovascular disease (CVD). CVD are the leading causes of death and severe neurological symptoms in the world. The use of oral antidiabetic drugs (OADs) are very common in the worldwide, several studies have investigated that OADs (i.e., DPP4 inhibitors, rosiglitazone) are associated with the risks of CVD, limited research has shown that all types of OADs and the risk of CVD. Our aim was to study the impact of OADs in patients with T2DM and CVD

**Method**: A search was conducted in MEDLINE via PubMed for all human studies published between June 2008 and June 2018 reporting CVD and the relationship of OADs in patients with T2DM.

**Result**: A total of 376 articles were found. After the analysis of the accurate criteria using the PRISMA method, 20 articles were identified for inclusion ((oral antidiabetic drugs) AND (cardiovascular disease)). Most studies were conducted in Europe. Adolescents diagnosed with T2DM were evaluated in all studies. In 10 studies, SGLT2 inhibitor and metformin can reduce the risk of CVD (heart failure, myocardial infarction), 6 studies demonstrated that pioglitazone can reduce insulin resistance.

**Conclusion**: Long‐term treatment with metformin, SGLT2 inhibitor or pioglitazone promotes the prevention of CVD and reduction of insulin resistance. We demonstrated that patients with T2DM can use metformin, SGLT2 inhibitor or pioglitazone to protected diabetic patients from CVD worsened. Comment: We only investigate relationship between OADs and CVD, not include insulin and glucagon‐like peptide 1 agonist, this is to increase the evidence of the study population, The study is a comprehensive survey of the primary studies of the highest level of evidence.
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**Objective**: The DISCOVER study, initiated to provide more global real‐world data on the management of type 2 diabetes (T2D), aims to describe the disease management patterns and a broad range of associated outcomes in patients with T2D initiating a second‐line glucose‐lowering therapy in routine clinical practice. Baseline characteristics of Korean participants are reported.

**Methods**: DISCOVER is a multinational prospective longitudinal observational (non‐interventional) study that collects information from patients, healthcare providers, healthcare system characteristics, treatment patterns, and factors influencing changes in therapy. Additionally, disease control (e.g. achievement of glycated haemoglobin target), management of associated risk factors (e.g. hypercholesterolemia, hypertension), and healthcare resource utilization are also included. Microvascular and macrovascular complications, incidence of hypoglycaemic events, and patient‐reported outcomes will also be reported during the 3‐year follow‐up period.

**Results**: A total of 15,992 patients from 38 countries were enrolled globally from December 2014. The first patient was enrolled in the Republic of Korea and a total of 236 patients have been enrolled across 13 local sites. Korean subjects had a shorter mean duration of T2D and baseline mean HbA1c was 7.6%, which was lower than the regional (Western Pacific) and overall population, where mean HbA1c was above 8%. Other countries included in the Western Pacific Region are Australia, China, Japan, Malaysia and Taiwan. All investigators were endocrinologist whereas in regional data this percentage was only 39.3%. Most of the centres were university/teaching hospitals. Most Korean participants (57.2%) had \>13 years of education and 95.3% were covered by public health insurance. Metformin monotherapy was the most common first‐line therapy and 56.4% added a dipeptidyl‐peptidase IV inhibitor as second‐line.

**Conclusion**: DISCOVER study provides insights into the current management of T2D patients at local, regional and global levels. Baseline characteristics revealed that initiation of second line therapy is later than expected, despite current guidelines recommendations. Even in Korea, although lower than other countries, mean HbA1c was higher than the Korean Diabetes Association\'s recommendation of HbA1c ≥ 6.5% for second‐line therapy initiation. Further analyses to investigate the associated factors for such clinical inertia and outcomes comparison between countries are needed from these real world clinical practice data.
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**Introduction & Objectives**: In 2008, USFDA (United States Food and Drug Administration) issued guidance for evaluating cardiovascular risk of antidiabetic drugs. Post the issuance of the guidance, about nine cardiovascular outcome trials (CVOTs) have been completed. Other than the primary publication, various other publications have appeared in literature with descriptive data or additional analyses. We aimed to look at the pattern of publication of data from these nine CVOTs.

**Methods**: CVOTs selected were as mentioned in ADA Standard of Medical Care in Diabetes -- 2018. Publications were searched on 8th May 2018 in PubMed using "\<the name of the drug\>AND\<the name of the trial\>", with the filter of English language. Articles listed were then screened. Only the original articles with descriptive or inferential data from the trial population (entire population or subgroups) were included. Articles combining data from these CVOTs with other trials (of the same or the other drug) were excluded. All other types of articles (like reviews, meta‐analysis, commentaries, editorials, modelling, etc.) were excluded.

**Results**: CVOTs of these nine molecules were included. The number of articles published based on CVOT data of these drugs were: 19 (saxagliptin), 13 (alogliptin), 15 (sitagliptin), 3 (lixisenatide), 12 (liraglutide), 1 (semaglutide), 3 (exenatide QW), 15 (empagliflozin), 10 (canagliflozin). Data published in the articles included: primary analyses data of CVOT; rationale, design and baseline characteristics; subgroup analysis (like subgroups based on renal disease, race, age, etc.); analysis for long‐term efficacy outcomes (heart failure, stroke, renal disease, etc.); analysis for long‐term safety outcomes (fracture, cancer, pancreatitis, etc.); association of a parameter(s) or a biomarker (s) with various key outcomes, etc.

**Conclusions**: Mandated by regulatory bodies, CVOTs are a source of large‐scale data and provide the opportunity for assessing not just cardiovascular safety of the drugs but also some additional analyses, Data from these publications can provide optimal ways to utilize the newer anti‐diabetic drugs in practice.
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**Background and Aims**: BRIGHT is the first head‐to‐head clinical trial comparing the efficacy and safety of the long‐acting second‐generation insulin analogs insulin glargine (Gla‐300; 300 U/ml) and insulin degludec (IDeg‐100; 100 U/ml). Materials and

**Methods**: In this 24‐week, multinational, open‐label, parallel‐group, treat‐to‐target trial (NCT02738151), 929 insulin‐naïve T2DM adults (mean HbA1c, 8.6%; DM duration, 10.6 years; BMI, 31.5 kg/m^2^), inadequately controlled with oral antihyperglycemic drugs ± GLP‐1 RAs, were randomized 1:1 to once‐daily Gla‐300 or IDeg‐100. The primary endpoint was HbA1c change from baseline to week 24 (non‐inferiority margin 0.3%). Secondary endpoints included hypoglycemia, blood glucose levels, and adverse events.

**Results**: Non‐inferiority of Gla‐300 versus IDeg‐100 was demonstrated for the primary endpoint (LS mean difference −0.05 \[95% CI −0.15 to 0.05\]). Gla‐300 had similar fasting SMPG reduction to IDeg‐100 (−58.1 ± 1.2 vs. −59.2 ± 1.2; LS mean difference 1.08 \[95% CI −1.94 to 4.10\]), with final daily insulin doses of 0.54 and 0.43 U/kg from starting evening doses, per label, of 0.2 U/kg and 10 U/day (0.12 U/kg), respectively. Incidence of anytime (24 h) confirmed (≤70 mg/dL) or severe hypoglycemia was comparable for Gla‐300 versus IDeg‐100 over the 24‐week period (66.5 vs. 69.0%, respectively), as were event rates (\[events/participant‐year\] 9.34 vs. 10.83). During the titration period (day 1 to week 12), incidence and rates of anytime (24 h) confirmed (≤70 mg/dL) or severe hypoglycemia were lower with Gla‐300 versus IDeg‐100 (incidence 47.4 vs. 54.3%, odds ratio 0.74 \[95% CI 0.57 to 0.97\]; event rates 8.08 vs. 10.47; rate ratio 0.77 \[95% CI 0.62 to 0.96\]). No between‐treatment differences in incidence or rates were seen during weeks 13--24. Rates of treatment‐emergent adverse events (AEs) were similar for both therapies (43.7 vs. 47.8%), as were rates of serious treatment‐emergent AEs (4.5 vs. 4.3%).

**Conclusion**: In summary, BRIGHT showed that Gla‐300 provides similar glycemic control to IDeg‐100, with comparable hypoglycemia over the full study period and during weeks 13--24, but less hypoglycemia during the titration period, in previously inadequately controlled, insulin‐naïve adults with T2DM.
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**Background and Aims**: Empowering individuals to self‐titrate their basal insulin may help to reduce rates of sub‐optimal titration often observed in clinical practice, and help more people achieve HbA1c goals. Here we compare the results from the recently completed TAKE CONTROL study, which evaluated self‐titration and physician‐led titration of insulin glargine 300 U/mL (Gla‐300) in people with type 2 diabetes, with comparable studies (AT.LANTUS and ATLAS) of insulin glargine 100 U/mL (Gla‐100). Materials and

**Methods**: All 3 studies were 24‐week, multicenter, randomized, open‐label, parallel‐group studies. TAKE CONTROL and AT.LANTUS enrolled insulin naïve and previously treated participants; ATLAS enrolled insulin naïve only. Fasting blood glucose targets were 80--130 mg/dL (4.4--7.2 mmol/L) in TAKE CONTROL, ≤100 mg/dL (5.5 mmol/L) in AT.LANTUS, and ≤110 mg/dL (6.1 mmol/L) in ATLAS.

**Results**: Mean diabetes duration was approximately 13 years in TAKE CONTROL, 12 years in AT.LANTUS, and 9--10 years in ATLAS. Mean baseline HbA1c was between 8.4 and 8.9%. Self‐titration statistically significantly lowered mean HbA1c by 0.97 to 1.40% versus physician‐led titration (0.84 to 1.25%; *P *\< 0.05 for all 3 studies). Total basal insulin dose per day increased from baseline to end of treatment for all studies, and mean change from baseline was higher for self‐titration versus physician‐led titration (TAKE CONTROL: 15.6 U vs. 11.2 U; AT.LANTUS: 21.6 U vs. 18.7 U; ATLAS: not reported). The incidence of severe hypoglycemia was similar between titration arms in all 3 studies (0.3--1.1% of patients), while rates of symptomatic hypoglycemia ranged from 25.6--36.0%. Nocturnal hypoglycemia occurred least frequently in the AT.LANTUS study (3.2--4.1%) but was more commonly observed in the TAKE CONTROL (8.0--11.4%) and ATLAS studies (6.5--16.4% respectively). Rates of treatment‐emergent adverse events (TEAEs) were highest in the AT.LANTUS study (48.0--49.4%) and similar between the TAKE CONTROL and ATLAS studies (32.1--35.0%), while rates of serious TEAEs were low for all 3 studies (1.8--5.1%).

**Conclusion**: Both Gla‐300 and Gla‐100 were effective in improving glycemic control. Self‐titration with Gla‐300 resulted in significantly improved glycemic control versus physician‐led titration, as demonstrated previously with Gla‐100, without increased hypoglycemia.
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**Background and Aims**: People with type 2 diabetes (T2D) who fast during Ramadan are at increased risk of hypoglycemia, especially if treated with insulin. This is the first randomized controlled trial comparing efficacy and safety of Lixisenatide (Lixi) versus sulphonylurea (SU), both combined with basal insulin (BI), in people with T2D fasting during Ramadan. Materials and

**Methods**: Adults with T2D, diagnosed for ≥1 year with insufficient glycemic control with BI + SU intending to fast during Ramadan, were randomized 1:1 to receive BI + subcutaneous Lixi or oral SU in this phase IV, 12--22‐week trial (NCT02941367). Primary endpoint: percentage of people with ≥1 documented symptomatic hypoglycemic event (plasma glucose ≤70 mg/dL; 3.9 mmol/L) during Ramadan fast. Secondary endpoints included HbA1c, weight, BI dose, and safety.

**Results**: In total, 184 people were randomized (Lixi \[*n *= 92\]; SU \[*n *= 92\]; safety population). For Lixi versus SU, respectively, 3.3% (3/91) versus 8.9% (8/90) had ≥1 documented symptomatic hypoglycemic event (intent‐to‐treat population \[*n *= 181\]; Lixi \[*n *= 91\]; SU \[*n *= 90\]; OR: 0.34; 95% CI: 0.09, 1.35) during Ramadan, while the percentage of people with any hypoglycemic event was 3.3% versus 15.2% (OR: 0.17 \[95% CI: 0.05, 0.61\]; difference: --0.12 \[95% CI: --0.20, --0.04\]) during the pre‐Ramadan period and 4.3% versus 17.4% (OR: 0.22 \[95% CI: 0.07, 0.68\]; difference: --0.13 \[95% CI: --0.22, --0.04\]) during Ramadan. Total people with any hypoglycemia was 15.8% overall with 5.4% versus 26.1% (OR: 0.16 \[95% CI: 0.06, 0.44\]) for Lixi versus SU, respectively. Least squares mean (standard error) absolute change from baseline to post‐Ramadan for Lixi versus SU, respectively were: HbA1c (%), --0.43 (0.11) versus --0.49 (0.11); weight (kg), --2.1 (0.27) versus --1.4 (0.27); and BI dose (units), 2.44 (0.63) versus 3.24 (0.64). Treatment‐emergent adverse events for Lixi versus SU, respectively, were 17.4% versus 16.3% during Ramadan.

**Conclusion**: The percentage of people experiencing ≥1 symptomatic hypoglycemic event during Ramadan was numerically lower with Lixi. Any hypoglycemia was clinically and statistically significantly lower in Lixi plus BI compared to SU added to BI. HbA1c and weight fell despite a slight increase in BI dose in both arms. No specific safety concerns were raised.
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The aim of this study was to assess the efficacy and safety of Neuro‐Fuzzy Logic insulin infusion (NFA) protocol compared to standard insulin infusion protocol in inpatients admitted with hyperglycaemia. This study was a six‐month, open‐label, randomised controlled trial of 50 patients who were admitted with hyperglycaemia in non‐critical care wards and whom were required continuous insulin infusion treatment. They were randomised to either NFA protocol (*n *= 25) or the standard insulin infusion protocol (*n *= 25). The primary outcomes were to compare duration of time to reach target blood glucose (BG), mean BG and glycaemic variability (GV) of the protocols by assessing mean average glucose excursion (MAGE). The secondary outcomes were to compare the safety of the protocols in terms of hypoglycaemia events as well as assessing the glycaemic variability of the two protocols by other GV indices. The NFA protocol had halved the time taken to reach target blood glucose of 7.8 mmol/L at 5.80 ± 3.61 hrs compared to 11.84 ± 11.42 hrs in the standard protocol with *P* = 0.032. The overall mean BG was significantly lower in the NFA protocol, 8.25 ± 1.27 mmol/L compared to the standard protocol, 10.92 ± 3.94 mmol/L with *P* = 0.002 throughout the intervention period. In terms of MAGE, the NFA protocol showed no difference compared to the standard protocol, *P* = 0.099. However, in other GV indices, the NFA protocol performed better than the standard protocol. Both insulin protocols did not show significant difference in terms of hypoglycaemia event of ≤3.9 mmol/L with *P* = 0.416. None of the patients in the study had severe hypoglycaemia of ≤2.2 mmol/L. In conclusion, this study demonstrated that the NFA protocol is safe and more effective than the standard insulin infusion protocol; hence, potentially can bring clinical benefits such as reducing length of hospital stay, lowering in‐hospital‐related complications and reducing financial health cost.
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**Background**: The prevalence of type 2 diabetes mellitus in Malaysia rose over the years as shown by the WHO in 2016 and National Health and Morbidity Survey (NHMS) despite multiple interventions. A holistic approach is warranted in an attempt to intensify diabetic treatment in a resource‐limited public tertiary centre.

**Aims and Methods**: Through our Diabetes Intensive Clinic (DIC) under the Department of Medicine, we prospectively looked at Hospital Sungai Buloh\'s poorly controlled diabetic patients in terms of changes in HbA1C, body weight, total insulin and LDL‐cs. Seventeen patients from our medical outpatients' clinic with HbA1c ≥ 10% and on insulin therapy were recruited and reviewed by physician, diabetic counsellors, and pharmacists each with specific job repertoire. A talk by our physiotherapist was also included. Dietary adjustments were made according to Asian meals with the help from our dietitians. Pharma sponsored glucometers and strips were provided to monitor of their home blood glucose level. Patients were reviewed monthly by diabetic counsellors while every three monthly by physician and others. At the end of 6 months, the four outcomes were reviewed and discussed.

**Results**: 60% of patients were obese using the Asian cut off while only about a quarter of patients had an LDL‐c levels of less than 2.5 mmol/L. At the end of 6 months, all patients showed a reduction in HbA1c with the largest number (8 patients) had a reduction of between 2 and 4%. The mean HbA1c prior to initiation of intensive intervention was 12.8 ± 1.7 while the mean HbA1c after 6 months was 8.6 ± 1.5 (*P *\<* *0.001). However, body weight increased in everyone but 2 of the patients at the end of 6 months.

**Conclusion**: This study shows that with frequent reminder and constant motivation, we can alter patients' lifestyles and improve their overall diabetes control as well as inspire their families. The DIC provides a stepping stone for inclusion of more poorly controlled diabetic patients but need to be prolonged to see favourable changes on weight. Limitations include the absence of a group exercise training as part of lifestyle modifications.
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**Background**: Before launching of SGL−2 inhibitor, triple combination of TZD with metformin and DPP−4 inhibitor was best option for delaying progression of diabetes. SGLT−2 inhibitor can be used as first line combination therapy with metformin, but add‐on therapy to usual dual combination of metformin with DPP−4 inhibitor that improves basic pathophysiology of diabetes will be favorable in terms of body weight and cardiovascular risk reduction, but it is not covered by national insurance in this country. We thought that reduction of body weight will be more efficient when substituting the TZD to SGLT‐2 inhibitor and tried to know the difference in glucose lowering effect between them. Subject and

**Method**: In 40 patients with triple combination with metformin, DPP‐IDF‐WPR‐4 inhibitor and 15 mg of pioglitazone -- the usual dose in this country, pioglitazone was changed to 10 mg of dapagliflozin without changing the dose of metformin and DPP−4 inhibitor. After 3 or 4 months from switching, HbA1c level and body weight change were assessed.

**Result**: The mean age was 59.8 ± 10.1 and duration of diabetes was 12.5 ± 5.9 years. The BMI was 29.7 ± 4.8 and it was relative higher than usual Korean type 2 diabetic patients because one of the reason of changing to dapagliflozin was body weight problem. The HbA1c level was decreased in 70% of patients and the mean reduction was 0.55 ± 0.34%. Body weight was decreased in all patients and the mean reduction was 3.47 ± 1.91 kg.

**Conclusion**: Triple combination of SGLT−2 inhibitor with metformin and DPP−4 inhibitor was superior to TZD not only in body weight, but also in glucose lowering effect. So, SGLT−2 inhibitor can be another better option for improving comprehensive aspects of type 2 diabetes in triple combination therapy.

PP‐255 {#jdi12939-sec-0511}
======
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**Objective**: Visceral Leishmaniasis is a macrophage associated disorder for the treatment of which antimony based drug like Sodium Antimony Gluconate has been the first choice in the recent past. About 5 percent of the patients may develop insulin dependent diabetes mellitus. It appears to have a direct action on pancreatic beta cells, resulting in initial insulin release followed by impaired insulin secretion. Within this context we looked into alternate therapies of treatment along with SAG on triggering the CD2 epitope.

**Methods**: We have evaluated the effect of combining CD2 with conventional antimonial (sb) therapy in protection in BALB/c mice infected with either drug sensitive or resistant strain of Leishmania donovani with 3 million parasites via‐intra‐cardiac route. Mice were treated with anti CD2 adjunct SAG sub‐cutaneously twice a week for 4 weeks. Assessment for measurement of weight, spleen size, anti‐Leishmania antibody titer, T cell and anti‐leishmanial macrophage function was carried out day 0, 10, 22 and 34 post treatments. Insulin levels were also determined on the same intervals.

**Results**: The combination therapy was shown boosting significant proportion of T cells to express CD25 compared to SAG monotherapy. Although, the level of IFN‐γ was not statistically different between combination vs. monotherapy (*P* = 0.298) but CD2 treatment even alone significantly influenced IFN‐ γ production than either SAG treatment (*P* = 0.045) or with CD2 adjunct SAG treatment (*P* = 0.005) in Ld‐S strain as well as in Ld‐R strain. The influence of CD2 adjunct treatment was also documented in anti‐leishmanial functions in macrophages. Interestingly insulin levels were observed to be optimal on supplementing SAG along with CD2.

**Conclusion**: SAG along with CD2 could be used as a potential therapy to overcome incidences of Diabetes mellitus during Visceral Leishmaniasis.
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**Introduction**: Diabetic End‐Stage renal disease (ESRD) tend to have increased risk of cardiovascular morbidity and mortality. In addition to poor glycemic control, glycemic variability (GV) had been shown to aggravate the risk. Liraglutide, a glucagon‐like peptide‐1 receptor agonist (GLP‐1) and Linagliptin, a dipeptidyl peptidase‐4 inhibitor work in incretin pathway to provide glucose reduction with very low risk of hypoglycaemia and safely used in ESRD. GLP‐1 also has been shown to provide cardiovascular benefits beyond glucose optimization. Objective

To assess the GV using Liraglutide compared to Linagliptin given on hemodialysis day in addition to standard treatment.

**Methods**: A Quasi‐experimental, pilot study was conducted among T2DM patients using insulin on regular haemodialysis (HD). GV were monitored on 4 consecutive days using continuous glucose monitoring system. Day 1; HD with Linagliptin 5 mg and Day 3; HD with subcutaneous Liraglutide 0.6 mg (given in addition to their own usual insulin). Whereas Day 2 and Day 4 were non‐HD days (NHD). Data were analysed for Mean and SD of 24‐h glycaemic value, Continuous overall net glycaemic action (CONGA) and M‐Value. CONGA is used to assess intraday variability and the M‐value is to assess the effect of glucose swing.

**Results**: A total of 18 patients with median age and duration of dialysis of 61.28 years (IQR 55.75--64.50) and 24.00 months (IQR 15.75--26.25) respectively were recruited. On HD, the median of 24‐h glycemic value mean and SD were significantly reduced in patient receiving Liraglutide compared to Linagliptin \[8.60 (IQR 7.63--9.53) vs. 10.38 (8.82--14.37), *P *\< 0.05 and 2.16 (IQR 1.70--2.54) vs. 3.27 (2.35--4.75), *P *\< 0.05 respectively\]. The CONGA and M‐value were also lower on Liraglutide compared to Linagliptin \[7.75 (IQR 6.58--9.07) vs. 9.66 (IQR 7.73--14.67) and 5.30 (IQR 2.04--7.84) vs. 15.59 (IQR 6.68--23.40), *P *\< 0.001 respectively\]. The mean, SD, CONGA and M‐value in NHD post Liraglutide were lower compared to post Linagliptin but statistically not significant.

**Conclusion**: Insulin treated diabetic patient whom received Liraglutide given on hemodialysis day were associated with less glycemic variability compared to Linagliptin.
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**Purpose**: Clinical inertia is defined as a failure of doctors to initiate or intensify therapy when indicated. We explore the factors associated with clinical inertia in treatment of patients with type 2 diabetes.

**Methods**: Patients with type 2 diabetes were retrospectively extracted from the medical database in our hospital according to the following inclusion criteria: 1) HbA1c levels 7.0% or higher in January 2014; 2) age 20 years or more and less than 65 years; 3) treatment with or without oral anti‐hyperglycemic agents (OADs). Patients with history or ongoing treatment of insulin or GLP‐1 receptor agonist were excluded. The index date was defined when HbA1c levels became elevated to 7.0% or higher before January 2014. Treatment intensification (TI) was defined as implementation of a new OAD or insulin or GLP‐1 receptor agonist. HbA1c levels of the study participants were followed from the index date until December 2017.

**Results**: We extracted 211 patients from the database. Among them, 47 patients received TI within one year from the index date (Group A), while 74 patients received TI later than one year from the index date (Group B). The remaining patients did not receive TI throughout the study period. The characteristics of the two groups at the index date were: Group A vs. Group B; age, 53.7 ± 8.5 vs. 53.7 ± 8.7 years; HbA1c, 7.8 ± 1.3 vs. 7.6 ± 0.8%; number of OADs prescribed before TI, 1.0 ± 0.9 vs. 1.8 ± 1.1 (*P *\<* *0.01), and duration from the index date to TI, 6.5 ± 3.9 vs. 29.5 ± 13.2 months (*P *\<* *0.01). The rate of achieving HbA1c \< 7.0% after TI was significantly higher in Group A compared with that in Group B (*P *\<* *0.05). In multiple regression analysis, duration between the index date and the period of TI was correlated with the number of OADs prescribed before TI (*P *\<* *0.01).

**Conclusion**: Clinical inertia is more likely to occur when the number of prescribed OADs is higher. Treatment options that enable doctors to more readily intensify treatment may prevent clinical inertia.
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Non‐alcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM) frequently coexist, and NAFLD is highly prevalent among patients with type 2 diabetes. Sodium glucose cotransporter 2 (SGLT2) inhibitors are a new class of oral hypoglycemic agents that acts by increasing renal glucose excretion in proximal tubules, and these are expected to help prevent and/or attenuate fatty liver disease with T2DM. This study investigated the effects of empagliflozin, one of SGLT2 inhibitors, on fatty liver assessed by hepatic steatosis index (HSI) in patients with T2DM. Also, we examined the factors that related with the improvement of fatty liver. We analyzed the data from our prospective observational study of patients with T2DM in Chung‐ang University Hospital. After obtaining patients' informed consent, once‐daily empagliflozin (10 mg/day) was added to their ongoing antihyperglycemic therapy for 12 weeks. Several clinical parameters, including fasting plasma glucose (FPG), HbA1c, lipid profiles and liver function, were compared before and after 12 weeks of treatment. A total of 34 patients completed the protocol in the original prospective observational study. Of these, ten patients were excluded, and the remaining 24 (nine men and 15 women) were included in the analysis. The mean age was 51.8 ± 9.1 years and the average duration of diabetes was 4.8 ± 2.7 years. After 12 weeks, body weight, and BMI significantly decreased. Levels of FPG, HbA1c, and alanine aminotransferase also decreased significantly. Also, HSI decreased slightly from 41.3 ± 3.9 to 40.5 ± 3.3 after 12 weeks of empagliflozin treatment (*P *\< 0.001). Multiple linear regression analysis showed that the changes in body weight had a significant positive correlation with the changes in HSI after adjustment for the age, gender, baseline FPG, HbA1c, body weight, or changes in HbA1c (standardized partial regression coefficient = 0.532, *P* = 0.017). However, changes in FPG or HbA1c were not related with the changes in HIS. In conclusion, empagliflozin improved fatty liver indices assessed using HSI in Korean patients with T2DM. The improvement in HSI might be related with the body weight reduction.
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Outpatient clinic of a hospital is often overcrowded with first‐time coming patients. However, traditional blood glucose caring process and data transfer at outpatient unit are inefficient and complicated. Starting from patient check‐in to clinical practice areas to check‐out, several procedures, staffs and locations are involved. The purpose of this study was to assess the workflow improvement of implementing Computer Supported Cooperative Work (CSCW) for glucose management in an outpatient clinic. A typical blood glucose management process in the outpatient clinic of Shanghai Jiao Tong University Affiliated Sixth People\'s Hospital takes 8 different tasks, at least 12 min, and two manual verifications and four data transcriptions must be finished. The patient must move from four work stations and meet five stakeholders. A novel blood glucose management system, the Overall GM700 Pro Blood Glucose Management System (GM700Pro), which utilizing CSCW technology was implemented in the outpatient clinic to improving the workflow. GM700 Pro works through Dispatch Agent functioning: 1. Performs active blood glucose measurement task assignment and data transfer after docking with hospital HIS/LIS/NIS system; 2. With Pattern Analysis Engine interaction, blood glucose data are presented on user interface according to the Compare‐Pattern‐Fluctuation (CPF)‐based Structured Glucose Probing Method, allowing clinicians to monitor blood glucose data in real‐time at different workplaces. Through adopting the GM700Pro the workflow was cut down to 3 steps and took about 4 min. Work efficiency was improved by 62.5% and flow time was reduced by 1/3. Error reduction and increased staff productivity were observed by removing manual verification, physical data copy, and document transition. The innovated work model keeps patients' past outpatient blood glucose test data available for retrieval at any time, and also facilitates physicians to obtain more comprehensive medical condition data, provides large data platforms for scientific research in the long term.
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**L. Xu and Y. Li**

The First Affiliated Hospital of Sun Yat‐sen University, Guangzhou, China

**Aims**: Short‐term intensive insulin therapy induces long‐term drug‐free euglycemic remission in half of patients with newly diagnosed type 2 diabetes mellitus (T2DM) but causes an increased risk of hypoglycemia. Studies identifying the impact of hypoglycemia are necessary.

**Methods**: We analyzed data from three randomized prospective trials conducted at our institution from 2002 to 2015. A continuous subcutaneous insulin infusion (CSII) was provided to achieve the glycemic goals and then maintained for 14 days.

**Results**: Patients who attained one‐year drug‐free glycemic remission were younger (48.06 ± 9.85 vs. 50.95 ± 11.70 years, *P* = 0.037) and had a higher body mass index (BMI) (25.53 ± 3.52 vs. 24.66 ± 3.20 kg/m^2^, *P* = 0.046) than those who did not. Notably, the median number of episodes of mild hypoglycemia with nadir glucose values of 3.0--3.9 mmol/L was higher in the remission group than in the non‐remission group (5 (6) vs. 2 (5), *P *\< 0.001). However, the number of episodes of clinically significant hypoglycemia (\<3.0 mmol/L) was insignificantly lower in the remission group (0 (1) vs. 0 (1), *P* = 0.273). Patients with higher glucose levels (glycated hemoglobin (HbA1c), fasting plasma glucose (FPG) and postprandial glucose (PPG)) and lower β‐cell functions (homeostasis model assessment of β‐cell function (HOMA‐B)) at baseline faced a greater risk of clinically significant hypoglycemia (OR = 2.02, 95% CI 1.40--2.92, *P *\< 0.001). According to the logistic regression analysis, mild hypoglycemic episodes were positively and independently related to long‐term glycemic remission.

**Conclusions**: Mild hypoglycemic episodes during CSII therapy are related to better long‐term drug‐free glycemic remission in patients with newly diagnosed T2DM. However, clinically significant hypoglycemia is not correlated and should be avoided.
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**Background and Aims**: In recent years, the effect of adjuvant metformin to intensive insulin therapy in type 1 diabetes had been investigated. Guidelines recommend that metformin can improve glucose control in adults who are overweight and obese, but evidence in support of this is limited. Therefore, we conducted a systematic review and meta‐analysis to explore the efficacy and safety of metformin in adults with type 1 diabetes. Materials and

**Methods**: We comprehensively searched four databases: PubMed, Embase, Cochrane Library, and Scopus, with the terms"metformin" and" diabetes mellitus, type 1" or "type 1 diabetes"or"insulin dependent diabetes" before January, 2018. All randomized controlled trials (RCTs) published in English and fulfilled the predefined inclusion criteria, including 1) patients aged above 18 years, and 2) using a parallel design or crossover design of metformin versus placebo treatment, were selected. We conducted statistical analyses using the Review Manager 5.2.

**Results**: Ten RCTs containing 726 adults with type 1 diabetes were identified from 969 records. Metformin was associated with reduction in body weight (−2.29, 95% confidence interval (CI) −3.72 to −0.85, *P *=* *0.0002), daily insulin‐dose requirements (−4.97, 95% CI −6.99 to −2.95, *P *\<* *0.0001), fasting plasma glucose (FPG) (−4.6, 95% CI −6.2 to −3, *P *\<* *0.0001), total cholesterol (−0.23, 95% CI −0.40 to −0.05, *P *=* *0.01) and LDL cholesterol (−0.20, 95% CI −0.33 to −0.08, *P *=* *0.002) in adults with type 1 diabetes. No clear evidence indicated that metformin improved HbA1c, triglycerides or HDL cholesterol levels. The safety analysis showed that metformin did not increase the risk of severe hypoglycemia, gastrointestinal adverse events or diabetic ketoacidosis events. In addition, glucose variability measured by continuous glucose monitoring system was evaluated in three of these studies. No difference of glucose variability reflected by continuous overlapping net glycemic action, mean glycaemia and standard deviation of the glucose measurements was found between metformin group and placebo group.

**Conclusions**: Compared to placebo, adding metformin to insulin reduced insulin dose requirement, body weight, FPG and lipid levels, but had no impact on lowering HbA1c and improving glycemic variability among adult patients with type 1 diabetes. More high‐quality clinical trials with larger samples should be conducted to support these findings.
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^1^Peking University People\'s Hospital, Beijing, China^2^People\'s Hospital of Tibet Autonomous Region, Lhasa, China

**Objective**: To detect the impact of metformin exposure on lactate level and its associated factors in Tibetan type 2 diabetic patients living at high‐altitude area.

**Methods**: Our hospital sits 3600 meters above sea level. We retrospectively reviewed the in‐patients' documents since November 2016 to December 2017 in our department. We selected those who did not receive metformin at least for three months, and initiated metformin during their stay in the hospital. Firstly, we compared the lactate level before and after the metformin treatment. We then did the subgroup analysis according to the participants' age (youth group: ≤44 years old, middle‐age group: 45--59 years old, elderly group: ≥60 years old), baseline lactate level (lactate level\<2 mmol/L, 2.00--3.99 mmol/L and ≥4.00 mmol/L) and the degree of baseline oxygen saturation (hypoxia group: SpO2 ≤ 90%, non‐hypoxia group: SpO2 \> 90%). Finally, we analyzed the associated factors which may influence the lactate level after the metformin exposure by logistic regression test.

**Results**: There were 132 patients recruited, including 98 male patients. Mean age was 52 ± 12 years old. There was no significant difference between the lactate level before and after metformin exposure. For the sub‐group analysis, we found that the lactate level did not show any significant change after the metformin treatment among different age groups or oxygen saturation groups. However, in the normal lactate level group and hyperlactatemia group, we did see a statistically elevation of the lactate level after the exposure of metformin. Reversely, a significant decrease of the lactate level was seen in the severe hyperlactatemia group after the metformin exposure. There were 73 patients (55.3%) who had an elevated lactate level after the metformin treatment. By binary logistic regression analysis, we found that baseline lactate level (*P *\< 0.001, OR = 0.019, 95% CI 0.002--0.159) and degree of the oxygen saturation (*P* = 0.04, OR = 1.092, 95% CI 1.004--1.187) were associated factors leading to the elevation of the lactate level after the metformin treatment.

**Conclusion**: Metformin treatment does not lead to the elevation of lactate level in Tibetan type 2 diabetic patients at high‐altitude area. From our study, we conclude that metformin can be safely used in high‐altitude residents.
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**O. N. Danish, M. Masni, M. N. Nurain and H. Zanariah**

Putrajaya Hospital, Putrajaya, Malaysia

Owning to the rising epidemic of obesity worldwide, distinguishing between various types of diabetes, especially in children and adolescence has become more challenging. Assessment of the pancreatic autoantibodies and β‐cell function are useful to distinguish between various types of diabetes, but is underutilised in routine clinical practice. We describe a 24‐year‐old lady with childhood‐onset of diabetes at the age of 11 years old, was initially labelled as type 1 diabetes (T1D) and received multiple dose insulin. For the past 13 years, she had only twice admission for diabetic ketoacidosis despite being non‐adherence with insulin. Her parents and elder brother are diagnosed as type 2 diabetes (T2D). She was on 0.78 units/kg total daily insulin dose. Her body mass index was 28.5 kg/m^2^. Diabetes mellitus autoantibodies (anti‐insulin, anti‐islet cell, anti GAD antibody and anti‐IA2) were negative; however, tests were sent after 13 years of diagnosis. More than 90% of patients with newly diagnosed T1D have more than one of these autoantibodies positive at diagnosis. However, false negative can occur when testing is done far away from diagnosis, as the titres will diminish over the course of the disease. We proceeded with stimulated C‐peptide measurement using mixed‐meal tolerance test (MMTT). Various methods to measure C‐peptide have been used to aid in the diagnosis and classification of diabetes, but the gold standard is MMTT. The choices of liquid meals depend on the commercial products available locally. As for our local setting, we found that Ensure Vanilla™ is a decent alternative. Her peak serum c‐peptide level was 2.046 nmol/L at 90 min supporting the diagnosis of T2D. Her bolus insulin was discontinued and she remained in good glycaemic control with oral agents and basal insulin. In conclusion, classifications of diabetes based on phenotypical characteristics are difficult, especially in children and adolescence. Tests for pancreatic autoantibodies and β‐cell function are recommended and may be considered for patients on insulin who want to switch to oral agents.
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^1^Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia, ^2^Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Shatin, Hong Kong, ^3^Asia Diabetes Foundation, Shatin, Hong Kong, ^4^Department of Primary Care Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia, ^5^Department of Medical Sciences, School of Healthcare and Medical Sciences, Sunway University, Bandar Sunway, Selangor, Malaysia.

**Background**: Care fragmentation, ineffective patient‐provider communication and insufficient self‐management support hinder effective care delivery for diabetes mellitus in Malaysia. Aim: To examine the effectiveness of the multicomponent JADE Programme on cardiometabolic control among socioculturally diverse patients with type 2 diabetes (T2D) in a public setting in Malaysia.

**Methods**: In this 24‐month multi‐national randomized quality improvement programme, 1187 patients were recruited from Malaysia and randomized into 1) comprehensive assessment (CA) by nurses guided by the JADE portal with built‐in care protocols (J) (*n *= 590) and 2) issue of personalized report using the JADE risk engines with decision support and ≥2 phone/face‐to‐face contacts by nurses (J+R+N) (*n *= 597). All patients had CA at baseline, 1‐ and 2‐year. We examined the changes of HbA1c, systolic/diastolic blood pressures (BP), LDL‐cholesterol and ABC targets attainment rate (HbA1c\<7%, BP\<130/80 mmHg or LDL‐cholesterol\<2.6 mmol/L) from baseline, adjusted for sex, ethnicity, study site, time‐varying age, disease duration and medication use.

**Results**: Both J+R+N and J groups had comparable baseline characteristics. Of 1187 patients (age = 60.1 ± 10.4 years, disease duration = 11.7 ± 8.4 years, HbA1c = 7.8 ± 1.8%, body mass index \[BMI\] = 27.9 ± 5.1 kg/m^2^), one‐quarter had pre‐existing cardiovascular‐renal diseases. Only one‐third attained ≥2 ABC targets at baseline. There were 26.5% Malay, 23.9% Chinese and 49.5% Indian, with Malay having worse baseline cardiometabolic profile. Compared to the J group, the J+R+N group had greater reductions in fasting plasma glucose (FPG; −0.38 versus 0.19 mmol/L, *P* = 0.002), systolic BP (−5.2 versus −1.9 mmHg, *P* = 0.009) and LDL‐cholesterol (−0.19 versus −0.05 mmol/L, *P* = 0.024) at 1‐year. The favourable effects of J+R+N intervention on FPG (−0.33 versus 0.39 mmol/L, *P* = 0.002) and systolic BP (−5.2 versus −1.8 mmHg, *P* = 0.016) were sustained at 2‐year, albeit HbA1c tended towards significance (−0.18% versus 0.06%, *P* = 0.05). At 2‐year, compared to Malay, Chinese were more likely to attain HbA1c\<7% (adjusted odds ratio \[aOR\] 1.47, 95% confidence interval \[CI\] 1.08, 1.98), LDL‐cholesterol\<2.6 mmol/L (aOR 1.39, CI 1.04, 1.86) and ≥2 ABC targets (aOR 1.50, CI 1.15, 1.96), but not observed in Indian.

**Conclusion**: Care organisation using a doctor‐nurse team with information technology, personalized reporting and patient empowerment enhanced healthcare quality in Malaysia. Patient‐centred and culturally‐appropriate interventions may further improve health behaviours and reduce disparities.
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**L. Zhu, Y. R. A. Lam and S.‐Y. Goh**

Department of Endocrinology, Singapore General Hospital, Singapore

**Aim**: The past decade has seen a steady increase in prevalence of diabetes mellitus worldwide, along with a corresponding sharp rise in healthcare cost of diabetes. The pressing need to equip physicians with up‐to‐date knowledge in diabetes management led to publication of two Appropriate Care Guides (ACGs), on management of pre‐diabetes and type 2 diabetes mellitus by the Ministry of Health, Singapore in 2017. We aim to study the impact of these guides on physicians' clinical practice.

**Method**: A survey of twenty questions was circulated to practising physicians in Singapore. Information pertaining to practice setting, current prescribing practice in diabetes management, awareness of key messages in ACGs, and influence of ACGs on diabetes management was obtained.

**Results**: A total of 220 physicians participated: 1/3 from primary care and 2/3 hospital‐based including endocrinologists, cardiologists, nephrologists, internists and trainees. 40.8% of participants had greater than ten years of clinical practice. Survey on prescribing habits of physicians revealed that most of the participants (94.1%) chose metformin as first‐line oral glucose‐lowering agent. Prevailing prescribing preference for second‐line agents were sulfonylureas (57.3%), dipeptidyl peptidase‐4 inhibitors (23.2%) and sodium‐glucose co‐transporter 2 inhibitors (SLGT2i) (22.7%). Majority of physicians (78.2%) were aware of the publication of ACGs, but only 36.8% had read the guides, and 33.2% had made changes to their clinical practice based on recommendations from ACGs. Most participants (86.4%) found the amount of information on the 6‐page and 8‐page ACGs just right. The biggest impact ACGs had on the prescribing habits of physicians was an increased tendency to prescribe SGLT2i. Barriers to successful implementation of ACGs included physicians' choice to base decisions on own experience, lack of perceived benefits for patients, and insufficient resources to implement recommendations made by ACGs.

**Conclusion**: Since its publication, ACGs have influenced the practice of many physicians. However, there exist a number of barriers to physician guideline adherence, and further work is needed to narrow the gap between recommended standards and delivered care.
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^1^Apollo Sugar Clinic, Mumbai, ^2^Apollo Sugar Clinic, Bhubaneswar, ^3^Apollo Sugar Clinic, Hyderabad, ^4^Apollo Sugar Clinic, Chennai, ^5^Apollo Sugar Clinic, Mysore, ^6^Apollo Sugar Clinic, Bangalore

**Purpose**: MyDoseCoach (MDC) digital dosing resource is a US FDA approved smartphone APP that can help healthcare providers (HCP) implement remotely, a dose adjustment plan of once‐daily basal insulin regimen. The objectives of this pilot project were to evaluate the glycemic parameters and basal insulin dose of patients who used the APP as well record the user experience from patients and physicians.

**Methods**: Consenting type 2 diabetes (T2D) patients, who were indicated for basal insulin use (Insulin Glargine‐100) were included in this 12‐week pilot project. The study was conducted between September 2017 and January 2018 in Apollo Sugar Clinics. The starting dose of basal insulin was 10U at bedtime or higher, as per the physician\'s discretion. Fasting plasma glucose (FPG) target range in the APP was pre‐set as 90--120 mg/dL along with a standard titration algorithm. Patients were instructed and trained to perform daily fasting self‐monitoring blood glucose (SMBG) and enter the readings in the MDC APP and titrate their daily basal insulin dose, based on the APP recommendations.

**Results**: Data of 137 patients who completed the 12‐week period are presented. The mean (SD) age was 52.8 (11.0) years, 57% males and 43% females and mean body mass index was 27 (4.1) kg/m2. The mean FPG reduced from 188(70) to 129(57) mg/dL, with a mean reduction of 59 mg/dL. The mean (SD) A1C reduced from 9.9(1.7) to 7.2 (1.4) %, a mean reduction of 2.7%. The average basal insulin dose also increased from 15U at baseline to 23U at the end of 12 weeks. 38% of patients achieved HbA1c (\<7%) target after 12 weeks and 20% of the patients achieved FPG target goal of 90--120 mg/dL. No symptomatic hypoglycemia or hospitalization due to hypoglycaemia was reported during the study. The APP was very simple and easy to adopt, as reported by patients and physicians.

**Conclusion**: Results of this 12‐week pilot project conducted in India, indicate that the MDC APP‐IDF‐WPR‐aided titration of basal insulin is an effective, safe, and user‐friendly technology‐enabled option for optimizing basal insulin dose in patients with T2D.
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**Background**: Although there have been many reports of singleton pregnancies with gestational diabetes mellitus (GDM), there have only been a few on twin pregnancies. In the future, the multiple pregnancy rate may increase owing to an increase in infertility treatments, and such pregnancies have an increased risk of GDM.

**Methods**: This is a retrospective cohort study of women who underwent screening for GDM in Yokohama City University Medical Center from January 2011 to December 2016. A total of 307 twin pregnancies were divided into a group satisfying the diagnostic criteria of GDM (GDM group: 48 cases) and a group that did not (non‐GDM group: 259 cases). In the same period, there were 869 singleton pregnancies complicated by GDM. Information on gestational diabetes status, gestational diabetes risk factors, and pregnancy outcomes was ascertained.

**Results**: Patients with twin pregnancies had slightly a higher rate of GDM than did singleton pregnancies (14.8% vs. 12.9% *P* = 0.31). Women with GDM twin pregnancies were older than those with non‐GDM twin pregnancies (35.5 ± 0.8 vs. 32.8 ± 0.3, *P *\< 0.001), had higher pre‐pregnancy body mass index (BMI, 22.4 ± 0.5 kg/m2 vs. 20.5 ± 0.2 kg/m2, *P *\< 0.01) and were more likely to have received infertility treatment (23.3% vs. 12.1%, *P* = 0.04). Body weight gain during pregnancy was suppressed in the GDM group (+9.1 ± 0.7 kg vs. +12.1 ± 0.3 kg, *P *\< 0.001). There were no significant differences in the rates of primiparity (52.1% vs. 42.4%, *P* = 0.27), the frequency of monochorionic or dichorionic twins, or placenta weight (878.0 ± 281.8 g vs. 903 ± 211.2 g, *P* = 0.32). Five patients (11.6%) underwent insulin therapy, and all patients had good glycemic control during pregnancy (glycoalbumin, 11.9 ± 0.2%). No infant had a birthweight \>4000 g. There was no difference in the rate of composite adverse infant outcomes between the GDM and non‐GDM groups, including gestational week at delivery, birth weight, caesarean delivery, and proportion of large for gestational date children.

**Conclusions**: Although twin pregnancies tended to be complicated with GDM, intriguingly there was no difference in the outcomes of pregnancy and newborns, owing to proper glycemic control and body weight.
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**N. N. Chan, C. F. Yee and K. F. D. Wong**

Dr. Norman Chan Clinic, Hong Kong, Hong Kong SAR

**Objectives**: Efficacy of glargine U300 has been ascertained in worldwide clinical trials, but local data is lacking. This is the first local study to assess the efficacy of glargine U300 in real‐world practice.

**Methods**: This is a single‐center, real‐world study conducted in Hong Kong. A retrospective chart review was conducted on Type 1 diabetic (T1DM) and Type 2 diabetic (T2DM) patients who newly started glargine U300, either insulin‐naïve or switching from other basal insulins (glargine U‐100 or detemir). Data of A1C, dose and body weight (at baseline and the latest follow‐up visit) was collected (from November 2016 -- December 2017) for analysis.

**Results**: Fifty‐seven (*N* = 57) consecutive patients over a 13‐month period were included in the analysis. Forty were T2DM and 17 were T1DM. Of these patients, 68.4%, 10.5% and 10.5% was using glargine U100, detemir and other insulins at baseline respectively, while 10.5% was insulin naïve. The average baseline A1C was 8.9%. After using glargine U300 for a mean follow‐up period of 25.6 weeks, the overall A1C was significantly reduced by 0.93 ± 1.73% (*P *\< 0.001) to a final value of 7.97%. Consistent efficacy was seen in both T1DM & T2DM patients, with a significant A1C reduction of 0.76 ± 1.39% (*P* = 0.038) and 1.00 ± 1.87% (*P* = 0.002) respectively. Higher proportion of patients achieved A1C ≤ 7% (35.1% vs. 15.8%; *P* = 0.003) and ≤7.5% (47.4% vs. 29.8%; *P* = 0.031) at the latest follow‐up than baseline. Most of the patients had an improved (64.9%) or stable (15.8%) A1C. Subgroup analysis also showed that HbA1C improved significantly regardless of treatment duration, with 1.16% (*P* = 0.002) and 0.59% reduction (*P* = 0.017) in patients with less than and more than 6‐month follow‐up respectively. No dose difference (30.8 vs. 28.7 unit; *P* = 0.203) and weight change (76.2 vs. 76.6 kg; *P* = 0.55) was found.

**Conclusions**: The results showed that initiating or switching to glargine U300 led to a significant improvement in glycemic control in both T1DM and T2DM patients, with no dose or weight increase, at least in the short term in a real‐world setting.
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**H. Tamura**
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**Objective**: The dipeptidyl peptidase‐4 inhibitor (DPP4‐I) is effective to control diabetes mellitus, but its effect for cardiovascular risk reduction is not established. On the other hand, the sodium glucose cotransporter 2 inhibitor (SGLT2‐I) has marked cardiovascular risk reduction by using empagliflozin (EMPAREG OUTCOME study) and canagliflozin (CANVAS trial). So we evaluated the metabolic and cardiovascular parameters in diabetic patient who is well controlled by using DPP4‐I, before and after changing to SGLT2‐I.

**Method**: Well controlled diabetic patient (*n *= 115, male 71 age 58.2 ± 10.6, female 44 age 62.0 ± 10.4, HbA1c 6.9 ± 0.8) who has obesity (BMI 30.6 ± 5.6) and treated with DPP4‐I and without SGLT2‐I was evaluated after changing DPP4‐I to SGLT2‐I. DPP4‐I used for are 39 Sitagliptin, 15 Linagliptin, 22 Vildagliptin, 29 Alogliptin, 7 Teneligliptin. SGLT2‐I used for are 37 Ipragliflozin, 11 Luseogliflozin, 33 Canagliflozin, 27 Empagliflozin, 7 Tofogliflozin. Blood glucose, HbA1c, body weight (BMI), systolic and diastolic blood pressure, heart rate, serum creatinine, estimated‐GFR, urinary protein, uric acid, LDL and HDL cholesterol, triglyceride, AST, ALT, and gamma‐GTP are evaluated before and after changing to SGLT2‐I from DPP4‐I.

**Result**: After changing to SGLT2‐I from DPP4‐I, HbA1c decreased from 6.9 ± 0.8 to 6.8 ± 0.5% (NS), blood glucose decreased from 143.8 ± 51.7 to 132.2 ± 39.2 mg/dL (NS), BMI decreased from 30.5 ± 4.3 to 29.5 ± 4.3. The systolic blood pressure decreased from 138.8 ± 17.1 to 1135.9 ± 14.1 mmHg (NS). Serum creatinine showed no significant change (0.73 ± 0.2 to 0.73 ± 0.2 mg/dL). Serum uric acid decreased from 5.5 ± 1.3 to 5.0 ± 1.2 mg/dL (*P *\< 0.05). Triglyceride decreased from 175.8 ± 107.4 to 148.5 ± 80.1 mg/dL (*P *\< 0.05) but LDL and HDL cholesterol did not show significant change. Gamma‐GTP decreased from 53.1 ± 49.0 to 37.5 ± 24.6 (*P *\< 0.05). AST decreased from 31.0 ± 19.3 to 25.2 ± 9.9, and ALT also decreased from 41.2 ± 32.7 to 32.7 ± 20.0, but not significant.

**Conclusion**: The effect for controlling blood glucose is similar between DPP4‐I and SGLT2‐I. But SGLT2‐I has multiple aspect for changing cardiovascular parameters (blood pressure) and metabolic parameters (body weight, lipid profile, liver function, uric acid). So SGLT2‐I may has dominant effect to protect cardiovascular disease than DPP4‐I.
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**Aims**: To comprehensively evaluate the efficacy and safety of initial combination therapy compared with monotherapy in different anti‐diabetes treatment groups in drug‐naïve type 2 diabetes patients. Materials and

**Methods**: A systematic search of Medline and other searching systems was performed for studies published until December 2017. Randomized clinical trials of initial combination therapy with hypoglycemic agents comparing with monotherapy were included. Weighted mean difference (WMD) and relative risks (RRs) were calculated.

**Results**: A total of 36 studies were included. Compared with metformin monotherapy, initial combination therapy of metformin with another anti‐diabetes drug exhibited significant reductions in HbA1c (*P *\< 0.001) and most of the combination therapies had similar risk of hypoglycemia (*P *\> 0.05), except for combinations of sulfonylurea/glinide and metformin or combinations of thiazolidinedione and metformin. Compared with dipeptidyl peptidase‐4 (DPP‐IDF‐WPR‐4) inhibitor monotherapy, initial combination therapy of DPP‐IDF‐WPR‐4 inhibitor with another anti‐diabetes drug showed significant decreases in HbA1c (*P *\< 0.001) and similar risk of hypoglycemia (*P *\> 0.05). Compared with monotherapy of other anti‐diabetes drugs, initial combination therapies also resulted in significant HbA1c reductions, similar risk of hypoglycemia and similar risks of other adverse events.

**Conclusions**: Initial combination therapies compared with monotherapies resulted in significantly reduced glucose levels in different anti‐diabetes treatment groups in drug‐naïve type 2 diabetes patients and most of them with similar risks of hypoglycemia and adverse effects.
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**Purpose**: Poor blood glucose control in hospital, leading to serious illness. When blood glucose continues to ≧ 180 mg/dL, insulin should be used. However, people\'s misconceptions and fears about the use of insulin therapy have led to delays in the treatment of insulin and delayed treatment. So hope to use the Shared Decision Making (SDM) model to reach a consensus on treatment options, ensure the rational use of insulin, increase patient medical compliance, achieve blood glucose control.

**Methods**: The medical team discusses with the patient. The doctor proposes to dispose of empirical data, provides reference for the patient, helps the patient to understand and clarify wrong ideas about insulin therapy through comparison and selection, and finally decides the treatment method he wants. Educator use videos to illustrate the role of insulin to clarify the facts and reduce anxiety. Using insulin teaching tools to teach insulin delivery techniques. Strengthen the importance of self‐monitoring of blood glucose and solve problem skills.

**Results**: Of the 109 people, the use of insulin continued to increase from 8 to 85 before and after hospitalization, and the rate of insulin injection increased to 78%. Self‐monitoring of blood glucose increased from 10.1% to 45.% (\<.001).Comparing 3 months A1C decreased from 10.2% to 7.3% .(\<.001).

**Conclusions**: The initial operation of the SDM model was in hospitalized hyperglycemia. It was found that the use of insulin in the inpatient period was 92.7%, and A1C decreased by 2.9%. Therefore, through the use of communication and use of tools to help patients to understand the disease and treatment, to reach a consensus, increase the patient\'s medical compliance, to achieve effective blood sugar control. Comments: The first attempt of the SDM model can see results. In the future, we can create standard operating procedures based on this experience, expect to help more hospitalized hyperglycemic patients, and even extend the benefits to more patients with more diseases.
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**Objective**: Tempeh is a soybean‐based fermented food in Indonesia that are rich in antioxidants (isoflavones mainly genistein), dietary fibre and protein as well as fermented bacteria, the nutrients responsible to act as a functional foods. This study aimed to systematically review the evidences human studies on the role of tempeh in modulating glucose homeostasis.

**Method**: A systematic literature searches in Pubmed database using the Standard Medical Subject Headings (MeSH) terms. The search keyword included "Tempeh and glucose homeostasis", "tempeh and diabetes" and "fermented soybean OR tempeh AND glucose homeostasis OR diabetes OR glycemic control" presented in title, keyword or abstract without time limitation. Primary outcomes valuated were parameters related to improve glucose control and insulin sensitivity, glucose homeostasis, reduce insulin resistance, fasting blood glucose, HbA1c, to prevent attenuates the progression T2DM, its effect on glucose‐related parameters are unclear.

**Results**: A total of 9 studies were obtained after including the term 'fermented soybean' on the searched. From these studies, there were some negative effects after consumption of soybean product and fermentation, for example no significant between soy consumer and non soy consumer for T2DM, no effect on glucose after 6 months consumption of fermented soy bean (isoflavone 60 mg/day), the data did not support the role of soya protein improving of glycemic control of T2DM, there was no benefit of soy product or isoflavone with respect to risk T2DM. Only one study used tempeh in comparison to legumes conducted in Indonesian among elderly with type 2 diabetes, which did not find significant (*P *\> 0.05) between placebo and control improvement in fasting plasma glucose after 4‐weeks consumption. However, fasting blood glucose reduced in this study. Other negative effect of genistein, daidzein, and flavonoid was, it inhibit thyroid peroxide human (TPO).

**Conclusion**: A well‐designed, placebo‐controlled clinical trials with validated outcome variables are needed to determine the effect of tempeh on glucose homeostasis.
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^1^Qingdao Endocrine and Diabetes Hospital, Fuzhou Road 81, Qingdao, 266000, China, ^2^Observational Research Centre, Payer & Real World Evidence, Global Medicine Development, Astrazeneca RD, Pepparedsleden 1, Molndal, 431 83, Sweden, ^3^Global Regulatory and Patient Safety Quality Assurance, Global Medicine Development, Astrazeneca AB, Pepparedsleden 1, Molndal, 431 83, Sweden, ^4^R & D information China, Astrazeneca, Liangjing Road 199, Pudong, Shanghai, 201203, China

**Background**: Few studies were performed to examine dyslipidemia management in Chinese patients with type 2 diabetes (T2DM).

**Objective**: To study the frequency of prescriptions of lipid lowering drugs to patients with T2DM who were hospitalized in the Qingdao Endocrine and Diabetes Hospital for the first time from 2006 to 2012 in Qingdao, China and to identify factors that may affect treatment selection.

**Methods**: Electronic medical records (EMR) of 12,361 (of which 6,696 men) T2DM patients, who were newly admitted to the Hospital were collected and analyzed. Information on demographic, first anthropometric and laboratory measurements, and lipid lowering drugs administrated to patients was extracted from EMRs. Diagnoses of diabetes, dyslipidemia and cardiovascular events were based on international standard diagnostic criterion.

**Results**: On average, 63% of patients were prescribed statins, 11% fibrates, and only 0.4% with both. Only 2 patients received ezetimibe treatment, and about 25% of patients with elevated lipid did not receive any medications. This observed treatment pattern was not substantially changed over past 6 years. Social Medical Insurance (SMI) beneficiaries received more statins (64%) compared with those who were covered by commercial insurances (61%, X^2^ = 19.37, *P* = 0.03). The treatment decision did not appear to be associated with baseline measures collected upon admission to the hospital (gender, occupation, education, prior history of cardiovascular disease, current diagnosis of coronary heart disease or peripheral vascular artery atherosclerosis, body mass index, glucose or blood pressure).

**Conclusion**: In this diabetic patient cohort, statins monotherapy was most frequently observed, followed by the fibrates monotherapy. The rate of dual medication with statins and fibrates was extremely low. SMI beneficiaries were more likely to receive a prescription of statins.
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**Dr X. Zhao, Dr. X. Gang and Dr G. Wang**

The First Hospital of Jilin University, Changchun, China

**Background**: Cardiovascular disease is considered as an important factor for increased mortality in patients with diabetes, while it remains unclear about the influence of bariatric surgery on cardiovascular risks in Chinese diabetic patients. Thus, we aimed to explore the impact of Roux‐en‐Y gastric bypass surgery (RYGB) on cardiovascular risks in Chinese diabetic patients with obesity.

**Methods**: Twenty Chinese patients with T2DM and obesity undergoing RYGB surgery were included in this study. Cardiovascular risk factors including metabolic parameters were measured before and 18 month after surgery. Besides, 10‐year cardiovascular risk was calculated by UKPDS risk engine before and 18‐month after surgery. Linear regression analysis was performed on CHD risk, stroke risk and baseline metabolic parameters.

**Results**: Complete remission of diabetes was achieved in 90% patients with significant improvements blood pressure, BMI, glucose and lipid metabolism (*P *\< 0.05). No significant differences were found in LDL‐C level (*P* = 0.642) and HOMA‐β (*P* = 0.391). 10‐year cardiovascular risk of coronary heart disease reduced from 13.05% to 3.81% with 71% reduction (*P *\< 0.001), and 10‐year risk of stroke reduced from 19.66% to 14.22% with 28% reduction (*P* = 0.002). In subgroup analysis, we found Chinese diabetic patients who were women, \<45 years old, BMI\<35 kg/m^2^, DM duration\>5 years, using non‐insulin therapy presented more obvious improvements in estimated 10‐year cardiovascular risk at 18‐month after RYGB surgery. Regression analysis results showed WHR, age, LDL‐C and HbA1c were the most important factors influencing final CHD or stroke risk after RYGB surgery (*P *\< 0.01).

**Conclusion**: Besides improvements in body weight, glucose and lipid metabolism, RYGB surgery is an effective treatment to reduce cardiovascular risk in Chinese diabetic patients with obesity.

PP‐275 {#jdi12939-sec-0551}
======

The characteristics of patients with long remission after short‐term insulin intensive therapy {#jdi12939-sec-0552}
----------------------------------------------------------------------------------------------

**X. Wan, Z. Huang and Y. Li**

Sun Yat‐sen Universities, Guangzhou, China

**Aims**: In our previous study, some patients with newly diagnosed type 2 diabetes mellitus can maintain euglycaemia without hypoglycemic agents after 2‐week intensive insulin therapies for long time. But the others didn\'t respond well to the treatment. To identify patients who would get long‐remission from this treatment, a retrospective study was conducted to compare the characters between them.

**Methods**: An observation of 160 patients with newly diagnosed T2DM (103 male, aged 50 ± 10 ys, HbA1C 11 ± 2.1%) after 2‐week therapy was studied remission rate.

**Results**: After the termination of short‐term CSII, 65.6% patients maintained long‐remission more than 1‐year, 18.1% patients got short‐remission less than 1‐year, and 16.3% patients did not get remission from the therapy. Age, BMI and glucose metabolism at baseline were not significantly different among three groups. As the table below showed, the long‐remission patients have statistically lower FPG, PPG, A1c and better HOMA‐B just after therapy.

**Conclusions**: In conclusion, the beta cell function (which test by HOMA‐B) might affect the remission rate mainly by the better improved metabolism of glucose and lipids.
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**A. Li^1^, D. Zhang^1^, L. Jing^1^, Y. Sun^1^, J. Li^1^, L. Liu^1^, D. Lu^1^, Y. Wang^2^, X. Guo^1^ and J. Zhang^1^**

^1^Peking University First Hospital, Beijing, China, ^2^iHealth Labs Inc., Beijing, China

**Objective**: We aim to investigate the management efficacy for diabetes in an Shared Care model of a multi‐disciplinary team consisting of physician, dietitian, nurse educator, exercise specialist and remote care manager.

**Methods**: We collected the data of patients treated in Diabetes Shared Care Clinic in Peking University First Hospital from 2016 Oct to 2018 Jun. Regular follow‐up rate, laboratory tests during follow‐ups, scaling evaluation for self‐care ability and daily expenditure of anti‐diabetic drugs were analyzed. Paired sample t‐test was used to determine the difference between the samples with normal distribution, while Wilcoxon Nonparametric Test was used to determine the differences between non‐normal distribution samples.

**Results**: A total of 653 patients were regularly followed up with age of 56.9 ± 12.1 years old, BMI of 26.0 ± 3.7 Kg/m^2^, and disease duration of 10.1(2.8, 16.6) years. Regular follow‐up rate of each quarterly visit was 80.5--87.2%. During the follow‐up, glycemic control rate (HbA1c\<7%) increase from baseline 37.0% to 57.0--65.4%, the rate of cholesterol control (LDL‐c \< 2.6 mmol/L) was stable around 52.0--65.1%, blood pressure control rate (\<140/90 mmHg) was 44.9--56.3%, and 16.4--16.9% of patients achieved all 3 target goals in last two quarterly visits. In the scaling evaluation, the situation improved significantly in glucose monitor under doctor\'s advice, foot self‐examination and compliance of medication indicating a significant improving in self‐management of diabetes \[2 (0, 5.25) vs. 3 (1, 6)point, *Z *=* *−2.186, *P *\<* *0.05; 1 (0, 7) vs. 4 (0, 7) point, *Z *=* *−3.650, *P *\<* *0.0005; 7 (7, 7) vs. 7 (7, 7) point, *Z *=* *−2.259, *P *\<* *0.05, respectively\]. The daily expenditure of anti‐diabetic drugs last quarterly visit increased significantly between first visit and last quarterly visit \[10.6(4.2, 21.6) vs. 11.9(4.7,23.2), *Z *=* *−4.018, *P *\<* *0.0001\].

**Conclusions**: Internet plus Diabetes Shared Care clinic significantly improved follow‐up rate and self‐management ability, and efficiently improved and maintained the control of metabolic targets.
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**Y. Ma, S. Gong, M. Li, X. Huang, X. Gao, M. Hu, X. Han and L. Ji**

Departments of Endocrinology and Metabolism, Peking University People\'s Hospital, Peking University Diabetes Center, Beijing, China

**Aims**: HNF1A‐MODY caused by hepatocyte nuclear factor‐1 alpha gene (HNF1A) is one of the most common subtypes of maturity onset diabetes of the young (MODY). It is autosomal and dominant diabetes characterized by early‐onset (often before the age of 25 years), decreased but reserved pancreatic B‐cell function. Most HNF1A‐MODY patients are sensitive to sulfonylureas and can be taken off insulin treatment after molecular diagnosis. However, it is not cost‐effective to apply genetic testing to all patients in Chinese in the present time. In this study, we aimed to establish a new clinical strategy based on previous studies and validated it in a Chinese young early‐onset type 2 diabetes cohort. Subjects and

**Methods**: Six clinical, biochemical and anamnestic items that best characterize a typical HNF1A‐MODY patient were defined and the C‐statistics of every item for discriminating HNF1A‐MODY were analyzed in our cohort including 445 non‐related patients with clinically diagnosed young early onset type 2 diabetes. Then the items of which the C‐statistic were significantly higher than 0.5 were selected. We combined these items and compared the combinations. The new clinical strategy based on a score system consisting of three items including normal high‐density lipoprotein cholesterol (HDL‐c) and triglycerides, high‐sensitivity C‐reactive protein \< 0.75 mg/L and body mass index \< 28 kg/m^2^ was established.

**Results**: The C‐statistic of the new clinical strategy was 0.908 (95%CI 0.877--0.933). Compared to solely item (normal HDL‐c and triglycerides), the p value of C‐statistic difference was \< 0.0001, the net reclassification improvement was 0.139, *P *\< 0.001. The sensitivity of 'score = 3' in our study could reach 87.5%, and the specificity 93.1%.

**Conclusions**: Our new strategy based on a score of Combined multiple clinical screening indexes is useful for discriminating HNF1A‐MODY from early‐onset type 2 diabetes and their individualized treatment.
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^1^Singapore General Hospital, Singapore, Singapore, ^2^Ajou University School of Medicine, Suwon, South Korea, ^3^Singapore and SingHealth Duke‐NUS, Singapore, Singapore, ^4^University of North Carolina, Chapel Hill, USA, ^5^Keio University School of Medicine, Tokyo, Japan, ^6^Karolinska Institutet, Stockholm, Sweden, ^7^University of Oslo, Oslo, Norway, ^8^University of Ulm, Ulm, Germany, ^9^University of Manitoba, Winnipeg, Canaga, ^10^Baker Heart and Diabetes Institute, Melbourne, Australia, ^11^Tel Aviv University and Maccabi Healthcare Israel, Tel Aviv, Israel, ^12^Statisticon AB, Uppsala, Sweden, ^13^AstraZeneca, Gaithersburg, USA, ^14^AstraZeneca, Wilmington, USA, ^15^AstraZeneca, Oslo, Norway, ^16^AstraZeneca, Luton, UK, ^17^AstraZeneca, Gothenburg, Sweden, ^18^AstraZeneca, Cambridge, UK, ^19^University of Missouri‐Kansas City, Kansas City, USA

Sulphonylureas (SU) are widely used in type 2 diabetes (T2D), particularly in resource‐constrained regions. The advent of newer classes of oral glucose lowering drugs like sodium glucose cotransporter 2 inhibitors (SGLT2i) challenge traditional treatment paradigms. Clinical trials demonstrate a lower risk of cardiovascular (CV) events with SGLT2i., while CV outcomes associated with SUs remain poorly defined and large comparative studies are lacking. We compared the risk of death, hospitalization for heart failure (HHF), MI and stroke in patients starting SGLT2i vs. SU, using real‐world data from three major world regions -- Asia/Pacific, North America and Europe/Israel (S. Korea, Japan, Singapore, Australia, USA, Canada, Sweden, Norway, Germany, and Israel). Patients initiating SGLT2i or SU were identified via national registries, claims, and medical records. Propensity scores for SGLT2i initiation were developed in each country, with 1:1 matching. Hazard ratios were assessed by country and pooled using weighted meta‐analysis, with an intent‐to‐treat approach. After propensity‐match, there were 335,542 episodes of treatment initiation in each group; ˜29% had established CVD at baseline. As a proportion of total exposure in the SGLT‐2i group, 56.6% of treatment episodes were with dapagliflozin, 25.4% canagliflozin, 11.7% empagliflozin and 6.4% other SGLT‐2i. In the SU group, 64.9% of treatment episodes were with glimepiride, 19.1% with glipizide, 10.5% on gliclazide and the remaining 5.5% on other SUs. Initiation of SGLT2i vs. SU was associated with significantly lower risk of death (HR 0.59, 95%CI 0.53--0.66), HHF (HR 0.70, 95%CI 0.61--0.79), death or HHF (HR 0.58; 95% CI 0.50--0.67), MI (HR 0.77, 95%CI 0.67--0.87) and stroke (HR 0.73, 95%CI 0.68--0.78) (*P *≤ 0.001 for all). Effects were consistent across countries and regions. In a large cohort of T2D patients seen in clinical practice across 10 countries, 72% without established CVD, initiation of SGLT2i was associated with lower risk of CV events (including stroke) and death compared with SU.
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**L. Zhang^1,2^, J. Wang^1^, Q. Wang^1^, X. Yin^1^, W. Meng^1^ and Y. Dong^1,2^**

^1^Qingdao Endocrine & Diabetes Hospital, Qingdao, China^2^Weifang Medical University, Weifang, China

**Objective**: The study aimed to investigate the different effect of 7‐point or 5‐point glucose monitoring on medical costs, glycemic control and the incidence of hypoglycemia in hospitalized patients with Type 2 diabetes (T2DM).

**Methods**: A total of 1000 patients with T2DM (490 male and 510 female cases) with complete medical records from Qingdao endocrine and diabetes hospital were included between 2006 and 2013. The average age was 61.5 years and the mean disease duration 6.68 years. According to the frequency of daily monitoring of blood glucose during hospitalization, patients were divided into 2 groups: 5‐point group and 7‐point group. Patients in 5‐point group received fasting blood glucose (FBG), 2‐h blood glucose (2hBG) after breakfast, 2hBG after lunch, 2hBG after dinner and bedtime blood glucose tests. Patients in 7‐point group received additional tests of pre‐lunch glucose and pre‐dinner blood glucose. Blood glucose monitoring was performed using Johnson & Johnson SureStep blood glucose meter. Comparison of two groups includes duration of in‐hospital stay, medical costs, glycemic control and the incidence of hypoglycemia.

**Results**: Patients in 7‐point glucose monitoring group had significantly shorter hospital stay (14.4 v.s. 16.6 days) and less total medical costs (10324.4 v.s. 12087.5 CNY) compared with 5‐point group (*P *\< 0.05). Laboratory examination cost did not differ significantly between groups (*P *\> 0.05). At discharge, fasting glucose and 2‐h glucose decreased significantly compared with baseline levels. In 7‐point group, FPG decreased by 2.41 mmol/L and 2hPG by 3.9 mmol/L. In the 5‐point group, the corresponding figures were 2.07 mmol/L and 3.6 mmol/L, respectively. The incidence of hypoglycemia were 24.2% in 7‐point group and 33.1% in 5‐point group (*P *\< 0.05).

**Conclusions**: In‐hospital 7‐point daily glucose monitoring improves patient adherence to treatment, shorten hospital stay, reduce medical cost, improve blood glucose control, and reduce the incidence of hypoglycemia.
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**N. Osman, B. M. Yusof, A. Ismail, A. Azlan and A. Abd Hamid**

Universiti Putra Malaysia, UPM Serdang SELANGOR, Malaysia

Glycemic inadequacy among individual with type 2 diabetes (T2DM) is a major issue highlighting the potential role of functional foods to help achieving good glycemic target. Ulam is one of the functional foods potentially expanded as adjuvant therapy. The interest is growing in Malaysia; however, documented data are scarce. This cross‐sectional study aimed to determine the ulam consumers among individuals with T2DM and their perception in relation to glycemic control. A total of 91 individuals with T2DM (age = 58.23 ± 10.4; duration of diabetes = 11.91 ± 8.1; HbA1c = 8.9 ± 2.1) who attended medical outpatient clinic from a selected government hospital participated in the study. Their socio‐demographic characteristics, medical background, nutritional status and ulam intakes were assessed. About seven in ten of individuals with T2DM consumed ulam in regular basis. There are no differences in HbA1c between ulam consumers (HbA1c = 8.99 ± 0.2) versus non‐consumers (HbA1c = 8.15 ± 1.8). The most common types of ulam include winged bean (Psophocarpus tetragonolobus), ulam raja (Cosmos Caudatus) and fern (Athyrium esculentum). They perceived (82.6%) that ulam can help to reduce glucose after meal. Some of them (81.2%) even perceived that ulam can help to cure diabetes. This study suggests that ulam did not have any significant effect on overall glycemic control. Further study on ulam intakes, overall vegetables intakes and postprandial blood glucose should be conducted to get overall view of beneficial effects of ulam on T2DM.
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**D. Wang and B. Duan**

Heilongjiang Provicial Hospital, China, Harbin, China

**Objective**: To investigate the curable effect of exenatide or glargine on the Type 2 Diabetic Patients with secondary failure of oral hypoglycemic drugs and their relationships with TNFα. Method Ninety‐nine type 2 diabetic patients with secondary failure of oral hypoglycemic drugs were randomly divided into three groups: group A (*n* = 30), group B (*n* = 30) and group Con (*n* = 39), which were respectively treated with exenatide, glargine and original oral hypoglycemic drugs. After 28 days, blood pressure, fast blood glucose, and 2 h postgrandial blood glucose, triglyceride, total cholesterol and plasma TNFα were observed and compared with pretreatment in three groups.

**Results**: (1) Fast blood glucose, and 2 h postgrandial blood glucose, triglyceride and plasma TNFα were significantly improved in group A and group B after changing the drugs, but not changed in group Con. (2) There were significantly declines of in fast blood glucose, and 2 h postgrandial blood glucose, triglyceride and plasma TNFα in group A and Group B compared to group Con after 28‐day treatment. TNFα and 2 h postgrandial blood glucose were lower in group A than group B after four‐week treatment. (3) There were a significantly positive correlation between TNFα and fast blood glucose, and 2 h postgrandial blood glucose, triglyceride, total cholesterol (*r *=* *0.451、0.675、0.584、0.426,respectively, *P *\<* *0.05). Multivariate analysis indicated 2 h postgrandial blood glucose was the independent risk factor of TNFα (β = 0.514,*P *\<* *0.05). (4) No severe side effects were observed in three groups.

**Conclusion**: Exenatide and glargine could improve the glucose and lipid control, and exenatide might have the greater effects.
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**Objective**: To study the correlation between body mass index (BMI) and glycosylated hemoglobin (HbA1c), glycated albumin (GA) in certain blood glucose level.

**Methods**: An epidemiological survey of diabetes in Pinggu District of Beijing was conducted in this study from March 2012 to May 2013. A total of 4,002 residents aged 26 to 76 were surveyed. The difference in HbA1c and GA between BMI quartile subgroups was compared according to fasting plasma glucose (FPG) and 2hPG stratification in oral glucose tolerance test (OGTT), and the correlation between BMI and HbA1c, GA was analyzed by multiple linear regressions model.

**Results**: After the stratification was carried out according to 4 ≤ FPG* \< *6 mmol/L, 6 ≤ FPG* \< *7 mmol/L, 7 ≤ FPG* \< *8 mmol/L and FPG≥8 mmol/L, when 4 ≤ FPG* \< *6 mmol/L and 6 ≤ FPG* \< *7 mmol/L, there was a significant difference in HbA1c level between the BMI quartile subgroups (*P *\<* *0.01). With the increase in BMI, HbA1c level showed an increasing tendency. When 4 ≤ FPG* \< *6 mmol/L, 6 ≤ FPG* \< *7 mmol/L and FPG≥8 mmol/L, there was a significant difference in GA level between the BMI quartile subgroups (*P *\<* *0.01). With the increase in BMI, GA level showed a decreasing tendency. After the stratification was carried out according to 2 ≤ 2hPG* \< *6 mmol/L, 6 ≤ 2hPG* \< *8 mmol/L, 8 ≤ 2hPG* \< *10 mmol/L and 2hPG≥10 mmol/L, a significant difference was found in HbA1c level between BMI quartile subgroups in various stratifications (*P *\<* *0.01). With the increase in BMI, HbA1c level showed an increasing tendency. In the multiple linear regression model, after adjustment for age, gender, smoking history, history of alcohol intake, systolic pressure, hemoglobin, neutrophil count, red blood cell distribution width, BMI was positively correlated with HbA1c (FPG β 0.018,P* \< *0.01; 2hPG β 0.018,P* \< *0.01), BMI was negatively correlated with GA (FPG β −0.094,P* \< *0.01; 2hPG β −0.081,P* \< *0.01).

**Conclusion**: Within the range of certain FPG and 2hPG level, BMI is independent of blood glucose level, positively correlated with HbA1c and negatively correlated with GA.
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**Objective**: To compare the effects of different initial insulin dose regimens during the short‐term insulin intensive treatment in newly diagnosed type 2 diabetes patients, in order to investigate the rational of formula based initiation regimen.

**Methods**: Fifty six patients with newly diagnosed type 2 diabetes, 33 males and 23 females, aged 27--65 years old, BMI 25.43 ± 2.90 kg/m^2^, were randomly assigned into 2 groups: the formula group (whose insulin dose was initiated according to the formula recommended in our previous study, 28 cases) and the empirical group (according to current guidelines, 28 cases). Short‐term intensive insulin therapy was performed, and the glycemic goal was gradually achieved. The time to glycemic goal (TGG), TDD‐1, the frequency of hypoglycemia and the glycemic variability were compared.

**Results**: The average TGG in the formula group (2.68 ± 1.44 days) is shorter than that in the empirical group (3.61 ± 1.60 days, *P *\< 0.05). There is no significant difference in the initial insulin dose (44.28 ± 9.10 IU, *P *\> 0.05) of the formula group compared with the TDD‐1 (46.91 ± 13.26 IU), whereas the initial insulin dose (34.09 ± 5.21 IU, *P *\< 0.05)of the empirical group is less than TDD‐1. Compared with the TDD‐1, while 70% of the estimate TDD‐1(eTDD‐1),which is calculated according to the formula as the initial insulin regimen, may not meet the requirements (*P *\< 0.001), 100% of the eTDD‐1 is also too much for them (*P *\< 0.001).All the indicators for glycemic variability such as mean MBG, MGSD, M value, MAGE and LAGE during the initial three days are not significantly different between the two groups (*P *\> 0.05). There is also no significant difference between 2 groups in the incidence of hypoglycemia (*P *\> 0.05).

**Conclusion**: Formula based initial insulin regimen is helpful in shortening TGG without increasing within‐day glycemic variability or hypoglycemia events. It is recommended that 80% of the eTDD‐1 can be used as the initial insulin regimen for the intensive treatment in most newly diagnosed T2DM patients.
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**Y. Li^1,2^, Y. Zhou^1^, Y. Zhu^1^, M. Zhang^1^ and Y. Liu^1^**

^1^The Affiliated Sir Run Run Hospital of Nanjing Medical University, Nanjing, China, ^2^The 2nd Hospital of Jilin University, Changchun, China

Patients with brittle diabetes are more prone to extreme swings in blood glucose levels, resulting in frequent bouts of hyper‐ or hypo‐glycemia. The intestinal microbiota plays an important role in regulating glucose homeostasis. We therefore investigated the effect of fecal microbiota transplantation (FMT) from healthy donors on glycemic stability in recipients with brittle diabetes. A total of 24 patients with brittle diabetes participated in this clinical trial and received FMT treatment for three consecutive days. Profiles of blood glucose, blood lipids, serum metabolites and fecal metabolites were all examined at baseline and at 1 month, 3 months, 6 months post‐FMT intervention. We also analyzed compositions of subjects' gut microbiota at the same timepoints. Compared with baseline, FMT intervention significantly improved blood glucose homeostasis in those recipients. The most striking observation was reduced glycemic fluctuations and a decreased incidence of asymptomatic hypoglycemia. We also observed dramatic changes in serum metabolites after FMT, including decreased levels of branched‐chain fatty acids and aromatic amino acids. Furthermore, levels of fecal short chain fatty acids (SCFAs), especially that of butyrate, were significantly increased at 1 month post‐FMT treatment, in keep with increased butyrate‐producing bacteria. FMT significantly improved glucose homeostasis in patients with brittle diabetes. The beneficial effects of FMT on glycemic stability are associated with changes in intestinal microbiota and serum/fecal metabolites.
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-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Z. Surong and S. Yunfeng**
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**Aim**: To assess the effects of SGLT‐2 inhibitors on body weight, waist circumference and blood pressure in patients with T2DM.

**Methods**: The PubMed, Cochrane Library, EMBASE, CBM, CNKI, VIP and WanFang databases was searched to identify randomized controlled trials of SGLT‐2 inhibitors vs. placebo in effects of SGLT‐2 inhibitors on blood pressure and body weight. Retrieval time from database establishment to January 2018. According to the criteria of inclusion and exclusion, literature was screened. The quality was assessed according to the Cochrane Handbook for Systematic Reviews of Interventions Version 5.1. The RevMan 5.3 software was used for Meta‐analysis. The I^2^ was used to test the heterogeneity and 0.05 was used as the test level.

**Results**: A total of 45 RCTs involving 26581 patients with T2DM (17339 cases in SGLT‐2 inhibitor group and 9242 cases in the control group). The published languages was English. Compared with the control, the SGLT‐2 inhibitor showed a reduction of 1.36 cm on waist circumference, 95%CI (−1.62, −1.10). Body weight were significantly decreased in SGLT‐2 inhibitors \[total WMD = −1.83Kg, 95% CI (−2.09, −1.56), *P *\<* *0.01\], the reduction of body weight was \[WMD = −1.81Kg, 95%CI (−1.98, −1.64), *P *\<* *0.01\]; \[WMD = −2.13 kg, 95% CI (−3.79, −0.47),*P *\<* *0.01\]; \[WMD = −1.75Kg,95% CI (−2.05, −1.45),*P *\<* *0.01\] and \[WMD = −1.57Kg, 95% CI (−1.99, −1.15),*P *\<* *0.01\] respectively by dapagliflozin, canagliflozin, empagliflozin and ipragliflozin. Weight loss was positively correlated with medication time and BMI. Compared with the control, SGLT‐2 inhibitors was associated with more reduction on systolic blood pressure level \[total WMD = −3.82 mmHg, 95%CI (−4.14, −3.49), *P *\<* *0.01\]. Treatment with canagliflozin resulted in a superior reduction on systolic blood pressure level \[WMD = −4.01 mmHg, 95% CI (−4.52, −3.49), *P *\<* *0.01\]. The treatment effect of SGLT‐2 inhibitors on diastolic blood pressure was \[WMD = −1.66 mmHg, 95% CI (−1.87, −1.44), *P *\<* *0.01\] relative to control.

**Conclusion**: SGLT‐2 inhibitors can effectively reduce body weight, waist circumference and blood pressure in patients with T2DM. Weight loss was positively correlated with medication time and BMI. Treatment with canagliflozin maybe resulted in a superior reduction on body weight and systolic blood pressure.
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The incidence of LADA in newly diagnosed diabetic patients and their relationship with autoimmune thyroid disease (AITD) {#jdi12939-sec-0574}
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**J. Liao, X. Lai**

The Second Affiliated Hospital of Nanchang University, Nanchang, China

**Objective**: The purpose of this study was to assess the incidence of LADA in newly diagnosed diabetic patients, explore the clinical characteristic of LADA, and their relationship with AITD.

**Methods**: Collected on June 2016‐December 2017 in the second affiliated hospital of nanchang university endocrine outpatient and hospitalization of patients with newly diagnosed with diabetes, based on inclusion and exclusion criteria, we are get the total number of 310 cases, among them, the LADA group 19 cases, T1DM group of 11 cases, the T2DM group 280 cases. Record all conform to the standard of the patient\'s general information, and glucose determination, lipid metabolism, thyroid autoantibodies detection, analysis among the three groups.

**Results**: 1. The incidence of LADA was 6.1%. 2. In terms of demographic characteristics, at the age of onset. Lady with T2DM group in BMI, hip circumference, waist circumference, systolic blood pressure and sanduo a few symptoms was statistically significant (*P *\< 0.05), in T1DM group and LADA ketoacidosis occurred on also have statistical significance (*P *\< 0.05). 3. According to the comparison of C peptide level in patients with T2DM group were higher than in LADA group (*P *\< 0.05), but blood sugar 2 h after meal is lower (*P *\< 0.05); 4. The cholesterol of T2DM group was lower than that in LADA group, and the cholesterol level was higher than that in T1DM group (*P *\< 0.05). 5. AITD 28 cases, 12% of the total, of which 3 cases of LADA group patients, accounts for 27%, T1DM group had 2 cases, accounted for 22%, 23 cases of T2DM group, accounting for 8%.

**Conclusion**: (1) In this study, the incidence rate of LADA was 6.1%,(2) the body slants thin, high cholesterol, low incidence of LADA patients age, level of islet function worse than islet function in patients with T2DM, and have the characteristics of the clinical features of T1DM and T2DM. (3) The newly diagnosed diabetes mellitus with autoimmune thyroid disease is 28, accounting for 12%, type 2 diabetes is the largest, so routine screening of autoimmune thyroid disease is recommended.
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Artificial pregnancy woman GDM nutritional care case report {#jdi12939-sec-0576}
-----------------------------------------------------------

**S. Mao**

Chimei‐medical Center, Tainan, Chinese Taipei

This case is 37 years old Occupation: Accounting High School graduation, Lifestyle: No smoking and drinking, Family history: father has a history of diabetes, no past diseases, Obstetric history: G4P2AA1,the last menstruation: 104/5/2, surgery history 2011/8/13 Laparoscopic : left salpingectomy、2015/6/10 Trans Vaginal Oocyte Retrieval、2015/6/13 Embryo transfer progress of disease,the patient was treated with an ectopic pregnancy in 2011 and removed the left side of the fallopian tube. She was done artificially pregnancy conceived successfully in 2015. She was routinely pregnant with 24 weeks of pregnancy to perform a sugar water test. Her blood glucose level was 280 mg/dl. She was referred to dietitians and metabolicians by insulin injection Detmir 5u →7u/qd (still NSD).with modest physical activity and diet control a 2998 gram healthy baby girl was successfully body height:50 cm, Apgar score: 1'‐\>8 = \> 5'--\>9 delivered by natural in 38 weeks gestational,at nutrition OPD dietitian understands patient at home diet patten and wants to control weight during pregnancy at10 kg, food GI value introduction, at home SMBG about 100--130 mg/dl,HbA1c:7.3(104/11/21) →6.5(105/1/16),The woman had undergone artificial pregnancy, developed gestational diabetes, successfully used an insulin diet control and exercise then SMBG birth to a healthy baby, and had routine postpartum blood glucose examination medication use Meformine 1\# tid. Care guidelines follow ADA GDM.
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Culturally sensitive patient -- centered educational program for self management of type two diabetes: A randomized controlled trial {#jdi12939-sec-0578}
------------------------------------------------------------------------------------------------------------------------------------

**B. Al Lenjawi**

Hamad Medical Corporation, Doha, Qatar

**Objective**: To assess the effectiveness of a culturally sensitive, structured education programme (CSSEP) on biomedical, knowledge, attitude and practice measures among Arabs with type two diabetes. Research designs and methods. A total of 430 patients with type II diabetes mellitus living in Doha, Qatar were enrolled in the study. They were randomized to either intervention (*n *= 215) or a control group (*n *= 215). A baseline and one‐year interval levels of biomedical variables including HbA1C, lipid profile, urine for microalbuminuria; in addition to knowledge, attitude and practice (KAP) scores were prospectively measured. The intervention was based on theory of empowerment, health belief models and was culturally sensitive in relation to language (Arabic), food habits and health beliefs. It consisted of four educational sessions for each group of patients (10--20 patients per session), lasting for 3--4 h. The first session discussed diabetes pathophysiology and complications; while the second session discussed healthy life style incorporating the Idaho plate method; and the third session dealt with exercise benefits and goal setting and the fourth session concentrated enhancing attitude and practice using counselling techniques. Outcomes were assessed at base line and 12 months after intervention.

**Results**: After 12 months participation in the intervention was shown to have led to a statistically significant reduction in HbA1C in the (CSSEP) group (−0.55 mmol/L, *P* = 0.012), fasting blood sugar (−0.92 mmol/L, *P* = 0.022), body mass index (1.70, *P* = 0.001) and albumin/creatinine ratio (−3.09, *P* \< 0.0001) but not in the control group. The intervention group also had improvement in Diabetes knowledge (5.9%, *P* \< 0.0001), attitude (6.56%, *P* \< 0.0001), and practice (6.52%, *P* = 0.0001).

**Conclusion**: This study demonstrates the effectiveness of culturally sensitive, structured, group‐based diabetes education in enhancing biomedical and behavioural outcomes in Diabetic patients.
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Relationship among subcutaneous fat, insulin resistance, and changes of plasma fibroblast growth factor‐21 levels after short‐term multiple daily insulin injection in patients with type 2 diabetes mellitus {#jdi12939-sec-0580}
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**C. Jung^1^, B. Kim^1^, D. Choi^1^, C. Kim^1^ and J. Mok^1^**

Soonchunhyang University Hospital, Bucheon‐si, South Korea

**Objective**: To investigate the change of plasma fibroblast growth factor 21 (FGF21) and its predictive factor after short‐term multiple daily insulin injection (MDI) treatment in poorly controlled type 2 diabetes mellitus (T2DM).

**Methods**: A retrospective, cross‐sectional study of T2DM patients (27 male, 34 female, mean age of 55 years) admitted for glucose control was conducted in a University hospital. Patients were treated with MDI about two weeks. Plasma FGF21 levels were assessed just before and after short‐term insulin therapy and participants were subdivided into three groups according to the baseline fating FGF21 levels and the changes of FGF21 levels (delta (Δ)FGF21, level after insulin therapy minus level just before insulin therapy). Subcutaneous fat thickness (SFT) and visceral fat thickness (VFT) were evaluated with abdominal ultrasonography.

**Results**: Mean plasma FGF21 after MDI was significantly decreased (from 293.1 to 208.2 pg/mL, *P* = 0.026). After MDI treatment, 37 patients (60.7% of all subjects, group with ∆FGF2 ≤ 0) showed decreased plasma FGF21 level, whereas 24 patients (39.3% of all subjects, group with ∆FGF21 \> 0) showed increased FGF21 level. The mean HDL‐C level significantly decreased and triglyceride level increased across baseline FGF21 tertiles (*P* = 0.026, *P* =\< 0.001, respectively). The mean HOMA‐IR level showed increasing trend across baseline FGF21 tertiles (3.0 vs. 4.1 vs. 6.7, *P* = 0.061). There were significant differences in SFT across delta FGF21 tertiles and absolute delta FGF21 tertiles (16.8 vs. 11.1 vs. 13.7 cm, *P* = 0.004, 11.6 vs. 13.4 vs. 16.5 cm, *P* = 0.004, respectively). In univariate linear regression analysis, baseline FGF21 level, HOMA‐IR, SFT and fibrate use showed significant positive correlation with delta FGF21 level. However, only baseline FGF21 and SFT were significantly associated with delta FGF21 level after multivariate adjustment (0.75 \[0.6 to 0.89\], 6.83 \[2.16 to 11.49\], respectively).

**Conclusion**: This result suggests that parameters representing insulin resistance showed higher levels across baseline FGF21 tertiles. Plasma FGF21 changed significantly after short‐term MDI treatment. Change of FGF21 level after MDI treatment is independently associated with SFT in patients with T2DM.
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Association between ethnicity and longitudinal changes in HbA1c among type 2 diabetes patients {#jdi12939-sec-0582}
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**E. Ahmad^1,2^, S. Rampal^1^ and N. Bhoo‐Pathy^1^**

^1^Julius Centre University of Malaya, Department of Social and Preventive Medicine, Faculty of Medicine, University of Malaya, Malaysia, ^2^Ministry of Health Malaysia

**Background/Objective**: The prevalence of type 2 diabetes in Malaysia continues to escalate across all ethnicities. Poor glycemic control contributes to the development of diabetes‐related complications, and ethnicity is hypothesized to influence glycaemic control. We aimed to determine the association between ethnicity and glycemic control among patients with type 2 diabetes.

**Methods**: A retrospective cohort study comprising 338,349 primary care patients registered in the Malaysia National Diabetes Registry from the year 2011 until 2015 was conducted. All major ethnic groups in Malaysia were included, consisting of Malays, Chinese, Indian, Indigenous Sabah (consisted of Kadazan, Dusun, Bajau and Other Sabah) and Indigenous Sarawak (consisted of Iban, Bidayuh, Melanau and Other Sarawak). Linear mixed effect model with random intercept was used to analyze longitudinal association between ethnicity and changes in HbA1c level for every five years of having diabetes.

**Results**: In the final adjusted model, for every 5 years of having diabetes, Chinese and Indian patients had 0.1% significantly lower HbA1c level \[Chinese and Indian: β = −0.1 (95%CI −0.13, −0.07), p‐value \<0.001\], whereas the Dusun and Indigenous Sarawak had 0.2% and 0.1%, significantly higher HbA1c level compared to Malay \[(Dusun: β = 0.2 (95%CI 0.07, 0.41), p‐value 0.005), Indigenous Sarawak: β = 0.1 (95%CI 0.01, 0.22), p‐value 0.025)\]. Bidayuh and Other Sarawak contributed to the significant association amongst Indigenous Sarawak. Bidayuh had 0.3% while Other Sarawak had 0.4% higher HbA1c level for every five years of having diabetes, compared to Malay.

**Conclusion**: Ethnicity appears to be a significant predictor of glycemic control in patients with type 2 diabetes. In multi‐ethnic settings such as Malaysia, health programs aiming for early detection of diabetes, improvement of health literacy in diabetes and provision of supportive care should be tailored according to the needs of the various ethnic groups.
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Efficacy and safety of 20 and 40 mg atorvastatin in moderate and high risk Korean postmenopausal women with dyslipidemia {#jdi12939-sec-0584}
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**J. Moon and G. Koh**

Department of Internal Medicine, Jeju National University Hospital, Republic of Korea, Jeju‐City, South Korea

Postmenopausal women have a more atherogenic lipid profile and a higher risk of coronary artery diseases (CAD) compared with premenopausal women. There have been few studies on the high‐intensity statin therapy in Asian patients. The aim of this study was to evaluate the efficacy and safety of 20 and 40 mg atorvastatin therapy in moderate and high‐risk Korean postmenopausal women with dyslipidemia. This study was a prospective, open‐label, single‐arm clinical trial conducted in three teaching hospitals. Main inclusion criteria were postmenopausal women and moderate and high cardiovascular risk groups according to the guideline from the Korean Society of Lipid & Atherosclerosis (KSoLA). After a wash‐out period for 4 weeks, participants received 20 mg atorvastatin for 8 weeks, and then 20 or 40 mg atorvastatin for 8 weeks (week 16). The atorvastatin dose was increased to 40 mg at week 8 if the low‐density lipoprotein cholesterol (LDL‐C) goal was not attained. The primary endpoint was percent change in LDL‐C from baseline to week 16 in the full analysis set. In total, 44 patients were enrolled: 35 into the full analysis set and 37 into the safety analysis set. Twenty‐eight (75.6%) of the participants have diabetes. At week 16, the changes in LDL‐C from baseline were −45.8 ± 13.3% (146.2 ± 25.1 mg/dL to 79.0 ± 24.4 mg/dL, *P *\< 0.0001). Total cholesterol, triglyceride and apoB also decreased by 33.0 ± 9.9% (227.8 ± 28.8 mg/dL to 150.6 ± 30.2 mg/dL, *P *\< 0.0001), 15.9 ± 34.9% (147.8 ± 73.8 mg/dL to 111.3 ± 45.7 mg/dL, *P *\< 0.001) and 34.6 ± 14.2% (112.6 ± 19.8 mg/dL to 73.2 ± 19.3 mg/dL, *P *\< 0.0001), respectively. There were no significant changes in HDL‐C (−0.3 ± 12.8%, *P *\> 0.1), apoAI (0.9 ± 11.6%, *P *\> 0.1) and hsCRP (56.3 ± 211.3%, *P *\> 0.1). One patient experienced a treatment‐related mild adverse event. There were no adverse event‐related treatment discontinuations or withdrawals. In conclusion, 20 and 40 mg atorvastatin administered to dyslipidemic Korean postmenopausal women with moderate and high risk effectively improved the lipid profile and was safe and well tolerated.
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Method study on the relative contributions of postprandial and basal glucose to overall hyperglycemia and HbA1c {#jdi12939-sec-0586}
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**J. Ma, H. He and X. Ran**

Diabetic Foot Care Center, Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu, China

**Objective**: To explore a more accurate method to evaluate the relative contributions of postprandial glucose (PPG) and basal glucose (BG) to HbA1c in the hyperglycemia subjects by using continuous glucose monitoring system (CGMS). Research Design and

**Methods**: Continuous glucose monitoring (CGM) was conducted in 490 subjects \[ Normal glucose tolerance (NGT) 92, Impaired glucose tolerance (IGT) 36, Newly‐diagnosed T2DM (NDDM) 131 and drug‐treated T2DM (T2DM) 231\]. The relative contribution of BG and PPG to overall hyperglycemia in 398 hyperglycemia patients was calculated according to 6.1 mmol/L (method A), 5.6 mmol/L (method B) and 24‐h glucose curve of NGT (method C) as baseline criteria, respectively.

**Results**: The relative contribution of PPG to HbA1c is gradually reduced from IGT group to the T2DM group. The relative contributions of PPG to excess hyperglycemia calculated by method A, B and C for IGT were 80.85%, 72.36% and 67.84%; for NDDM were 48.76%, 39.63% and 37.85%; for T2DM were 39.46%, 33.22% and 31.47%; for total T2DM were 42.82%, 35.54% and 33.78%, respectively (*P \< *0.01). Compared with the method C, the relative contribution of PPG was overestimated for about 9.04% when choosing 6.1 mmol/L as baseline, and about 1.76% when 5.6 mmol/L as baseline (*P \< *0.01).

**Conclusion**: The 6.1 mmol/L as baseline criteria is inappropriate in the study of relative contributions of BG and PPG to HbA1c. The 24 h glucose curve of NGT should be the first choice and it more precise since it concerns the physiological fluctuations in NGT after meals. However, the 5.6 mmol/L can be used as an alternative baseline criteria when lack of 24 h glucose curve of NGT.
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The incidence of dawn phenomenon (DP) in patients with type 2 diabetes mellitus according to different criteria and its impact on blood glucose fluctuation {#jdi12939-sec-0588}
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**J. Ma, H. He, C. Wang and X. Ran**

Diabetic Foot Care Center, Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu, China

**Objective**: The aim of this study was to investigate the incidence of dawn phenomenon (DP) according to the different criteria and its impact on blood glucose fluctuation in T2DM. To find a way to accurately calculate the prevalence of the DP and guide the treatment of T2DM. Research Design and

**Methods**: This study was conducted in a total of 170 individuals with T2DM who were selected for final analysis after screening for eligibility among a total population of 231 subjects who underwent CGMS for 3 consecutive days. All subjects were divided into 3 groups according to the level of HbA1c (HbA1c \< 7.0%、7.0% ≤ HbA1c \< 8.0%、HbA1c ≥ 8%). DP was defined by two parameters according to the previous research (the absolute increase of blood glucose level from nocturnal nadirs to prebreakfast value, ΔBG \> 0.5 mmol/L or 1.1 mmol/L). The participants were secondarily separated by presence/absence of a DP based on the definitions above. The impact on blood glucose fluctuation of two groups was assessed according to MBG, SDBG, CONGA, MAGE, etc.

**Results**: When defined ΔBG \> 0.5 mmol/L as the criteria, the prevalence of the DP was 65.29%. When defined ΔBG \> 1.1 mmol/L as the cut‐off value, the prevalence of the DP was 45.88%. By using the two parameters criteria, the Duration, MBG, SDBG, CONGA and MAGE were higher when compared with DP groups and non‐DP groups based on different level of HbA1c. Multiple stepwise regression showed that the MAGE was related to the presence of DP in T2DM when defined ΔBG \> 1.1 mmol/L as the cut‐off value. The average ΔBG was 1.00 mmol/L when calculated by CGMS, and it was better to determine the cut‐off value of ΔBG \> 1.1 mmol/L (20 mg/dl). The mean impact on HbA1c and 24‐MBG were 0.3% and 0.89 mmol/L, respectively.

**Conclusion**: DP is a very frequent event in T2DM and not only impacts the overall blood glucose control but also exaggerates blood glucose fluctuations. To be clinically relevant, ΔBG \> 1.1 mmol/L (20 mg/dl) has a better sense of significance and should be taken as the quantitative criterion of the DP.
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The relative and absolute contributions of postprandial and basal glucose to overall hyperglycemia and HbA1c in type 2 diabetes {#jdi12939-sec-0590}
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**J. Ma, H. He, D. Chen, C. Wang and X. Ran**

Diabetic Foot Care Center, Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu, China

**Research Design and Methods**: Continuous glucose monitoring (CGM) was conducted in all subjects. The relative contribution of BG and PPG to overall hyperglycemia in 398 hyperglycemia patients was calculated according to 6.1 mmol/L (method A), 5.6 mmol/L (method B) and 24‐h glucose curve of NGT (method C) as baseline criteria, respectively. The area under the curve above the baseline criteria was the excess hyperglycemia, named AUC‐T,AUC‐PPG means the 4 h glucose incremental area above pre‐prandial glucose values that accessed just before starting breakfast, lunch and dinner. The postprandial contribution to overall hyperglycemia was calculated as AUC‐PPG‐Total/ AUC‐T×100%.

**Results**: 490 subjects were enrolled in this study, included Normal glucose tolerance (NGT) 92, Impaired glucose tolerance (IGT) 36, Newly‐diagnosed T2DM (NDDM) 131 and drug‐treated T2DM (T2DM) 231. The average age was 53.03 ± 12.00 yr and the average HbA1c value was 6.96 ± 1.26% (ranging from 4.5 to 12.7%). From IGT group to NDDM group, Age, BMI, TG, TC, LDL‐C also gradually rise (P* \< *0.05). NDDM group had a higher level on SBP, DBP, HbA1c, TG, TC, LDL‐C parameters and a lower level on HDL‐C compared with T2DM group who have been treated by drugs. The relative contributions of PPG to excess hyperglycemia calculated by method A, B and C for IGT were 80.85%, 72.36% and 67.84%; for NDDM were 48.76%, 39.63% and 37.85%; for T2DM were 39.46%, 33.22% and 31.47%; for total T2DM were 42.82%, 35.54% and 33.78%, respectively (*P \< *0.01). Compared with the method C, the relative contribution of PPG was overestimated for about 9.04% when choosing 6.1 mmol/L as baseline, and about 1.76% when 5.6 mmol/L as baseline (*P \< *0.01).

**Conclusion**: The 6.1 mmol/L as baseline criteria is inappropriate in the study of relative contributions of BG and PPG to HbA1c. The 24 h glucose curve of NGT should be the first choice and it more precise since it concerns the physiological fluctuations in NGT after meals. However, the 5.6 mmol/L can be used as an alternative baseline criteria when lack of 24 h glucose curve of NGT.
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Reduction of insulin requirement in type 1 diabetes induced by BCG vaccinations: a case report {#jdi12939-sec-0592}
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**A. H. A. Tajuddin^1^, G. Siah^2^, N. A. Wahab^3^, N. Mustafa^3^, N. Sukor^3^ and N. Kamaruddin^3^**

^1^International Islamic University Malaysia, Kuantan Pahang, Malaysia, ^2^National Heart Institute, Kuala Lumpur Wilayah Persekutuan, Malaysia, ^3^National University of Malaysia, Cheras Kuala Lumpur, Malaysia

**Introduction**: Bacillus Calmette‐Guerin (BCG) vaccinations reverse disease by restoring insulin secretion in a rodent model of type 1 diabetes. It stimulates innate immunity by inducing the host to produce tumor necrosis factor (TNF), which, in turn, kills disease‐causing autoimmune cells and restores pancreatic beta‐cell function through regeneration.

**Case Presentation**: This is a case of a 32‐year‐old woman with history of gestational diabetes on Metformin, who presented again at 10 months postpartum with significant weight loss over 1 month period and severe diabetic ketoacidosis. Her family history was negative for diabetes and her BMI was normal (22.5 kg/m2). At diagnosis, her C‐peptide was 81 pmol/L with anti‐GAD Ab positivity of \>2000 U/L, while her HbA1c was 16%. She attained partial remission after 1 month of insulin initiation, which sustained for 6 months. Subsequently, she resumed 4 injections with total insulin dose of 36 to 40 units/day. Her continuous glucose monitoring readings showed episodes of hypoglemia (min 3.2 mmol/L) and hyperglycemia (max 10.6 mmol/L) while on that regime. We decided to give her two 0.1 ml intradermal injections containing BCG 3.2 × 106 colony‐forming units/injection at 6 and 7 months after the onset of her type 1 diabetes respectively, and followed by yearly BCG vaccination thereafter. Interestingly, we observed that her insulin requirement has slowly reduced after her third BCG vaccination. At 32 weeks post first BCG vaccination, she survived Ramadhan fasting month with a single prandial insulin at pre dinner (8 to 16 units/day) without any episode of ketoacidosis. Her SBGM ranged from 5--8 mmol/L with total calories intake of 1200--1500 kcal/day throughout the fasting period. This was further supported by improvement of HbA1c from 8.1% to 6.5% and increment of C‐peptide to 112pmol/L.

**Conclusion**: This case demonstrated significant metabolic and clinical benefits of BCG vaccination in type 1 diabetic patient as early as 32 weeks post first injection. Nonetheless, further clinical trial is needed to assess its long term effects in subjects of all ages and durations of diabetes.
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Clinical characteristics of empagliflozin responders in patients with type 2 diabetes {#jdi12939-sec-0594}
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**J. Yoo^1^, W. Lee^1^, Y. Cho^1^ and Y. Kang^2^**

^1^Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea, ^2^International Healthcare Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea

**Object**: We aimed to investigate the clinical factors affecting the therapeutic efficacy of empagliflozin in subjects with type 2 diabetes mellitus (T2DM).

**Methods**: We enrolled 507 T2DM subjects who aged 20--80 years and had been prescribed empagliflozin 10 or 25 mg as add‐on therapy for \> 90 consecutive days. Changes in HbA1c from baseline (%) in subgroups were assessed.

**Results**: The younger subjects (≤50 years) had a better glycemic response than did those aged 51--60 years (1.08 ± 0.12 vs. 0.73 ± 0.09, *P* = 0.039) and those aged \> 60 (1.08 ± 0.12 vs. 0.44 ± 0.08, *P *\< 0.001). No significant difference by BMI was observed (*P* = 0.685). Subjects with the highest baseline HbA1c (\> 9%) had a better response than did those with baseline HbA1c ≤ 7.5% (1.79 ± 0.13 vs. 0.50 ± 0.06, *P *\< 0.001) and 7.5--9% (1.79 ± 0.13 vs. 0.06 ± 0.05, *P *\< 0.001). Subjects with an eGFR \> 90 ml/min/1.73 m2 demonstrated a better response than did those with an eGFR ≤ 90 mL/min/1.73 m^2^ (0.91 ± 0.07 vs. 0.48 ± 0.09, *P *\< 0.001). Subjects with shorter T2DM duration (\<10 years) showed a greater response that did those with longer disease duration (≥10 years). By multivariate linear regression analysis, shorter T2DM duration (β = −0.028; *P *\< 0.001), higher baseline HbA1c (β = 0.573; *P *\< 0.001) and higher eGFR (β = 0.014; *P *\< 0.001) demonstrated a positive association with the HbA1c reduction.

**Conclusion**: A glucose‐lowering effect of empagliflozin is more evident in T2DM patients with higher baseline HbA1c, better renal function and shorter T2DM duration.
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A randomized, before‐after self‐control, multi‐center clinical study observing Glargine dosage difference in T2DM patients with similar fasting glucose level receiving insulin by either needle‐free syringes or insulin pens {#jdi12939-sec-0596}
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**Y. Xing and Q. Ji**

Xijing Hospital, FMMU, Xi\'an, China

**Objective**: This study was performed to evaluate and compare the dosage of insulin Glargine injected by needle‐free syringes and traditional insulin pens into the self‐controlled patients, who have the similar condition of fasting blood glucose level.

**Methods**: This study was a randomized, prospective, open‐label, before‐after study, two‐group, multicenter trial. 63 patients with T2DM were enrolled in this study. Each subjects received subcutaneous insulin Glargine injection by needle‐free injector and insulin pen in a randomized sequence. The insulin dosage were compared between the two groups while the fasting blood glucose level of all subjects were maintained between 4.4 to 6.0 mmol/L. The inclusion criteria were: age between 18 and 70 years, 18 Kg/m^2^ ≤ BMI ≤ 30Kg/m^2^, diagnosed with T2DM and course of disease is more than half a year, received oral drug therapy (excluding secretagogues) or insulin Glargine (dose between 12 IU to 50 IU), received insulin Glargine more than one month, venous fasting blood glucose between 5.0 to 9.0 mmo/L. To evaluating the patient\'s Injection experience, all the subjects completed the questionnaire.

**Result**: In comparison with the patients in insulin pen group, patients in needle‐free injector group showed same or better glycemic control (5.63 ± 0.51比5.63 ± 0.54) at the end of the study. The dosage of insulin in needle‐free injector group (16.16u/day) is obviously lower than that in the traditional insulin pen group (19.42u/day), the result has statistical significance (*P *\< 0.001). After finishing all treatment cycles, a questionnaire survey form was provided for each patient to assess their acceptance and tolerance in use of the jet injectors and the pens. The form included a few short‐answer questions for the aspects of satisfaction, ease of use, fear to the injection, acceptance, and skin injury. Most of the patients prefer the insulin treatment of the needle free injectors than insulin pens.

**Conclusions**: The usage of needle free injector can save insulin dosage while provide same good glycemic control. These results indicated that the benefit of the jet injectors in treatment of the diabetes was obviously superior to the pen injection, which not only reduce the side effects from high insulin dosage but also obviously reduce the fear from patients to the injection and helpful improving the compliance of patients.
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GLP‐1 receptor agonists reduce body fat mass predominantly compared to muscle mass: retrospective cohort study {#jdi12939-sec-0598}
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**S. Kubota^1,2^, H. Kuwata^1,2,3^, D. Yabe^2^, Y. Hamamoto^1,2^, T. Kurose^2^ and Y. Seino^1,2^**

^1^Center for Diabetes, Endocrinology and Metabolism, Kansai Electric Power Hospital, Osaka, Japan, ^2^Yutaka Seino Distinguished Center for Diabetes Research, Kansai Electric Power Medical Research Institute, Kobe Hyogo, Japan, ^3^Center for Metabolism and Clinical Nutrition, Kansai Electric Power Hospital, Osaka, Japan

**Background and Aims**: Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) are known to reduce body weight, but the change in body composition when reducing body weight is not elucidated. This study aimed to investigate the effect of GLP‐1RAs on body composition in Japanese patients with type 2 diabetes (T2D). Materials and

**Methods**: Medical records of Kansai Electric Power Hospital (Osaka, Japan) during the period from June 2010 to December 2017 were retrospectively analyzed. The patients with T2D who started GLP‐1RAs treatment and were examined body composition before and one year after initiation of GLP‐1RAs treatment by BIA device (Inbody S10 or S20) were analyzed. Only the patients whose concomitant anti‐diabetic drugs were metformin, sulfonyl urea or insulin were included. The patients who changed diabetes treatment during the period, who were pregnant, receiving chemotherapy, using steroids, or with severe disease which might affect body composition were excluded. Data were analyzed using paired t‐test. Values are shown as mean±SD.

**Results**: A total of 121 patients was analyzed (M/F = 80/41, insulin user: *n *= 29, age (year): 59.5 ± 11.2, Duration (year): 12.0 ± 8.3, HbA1c (%): 8.2 ± 1.5). Body weight was significantly decreased one year after the initiation of GLP‐1RA (74.1 ± 17.2 to 70.7 ± 15.9 kg, *P *\< 0.01), with decrease in BMI (27.5 ± 5.4 to 26.2 ± 4.9 kg/m2, *P *\< 0.01), body fat mass (24.9 ± 5.4 to 22.7 ± 9.1 kg, *P *\< 0.01), body fat percentage (32.9 ± 9.7 to 31.7 ± 9.1%, *P *\< 0.01), skeletal muscle mass (27.0 ± 6.8 to 26.2 ± 6.8 kg, *P *\< 0.01), lean mass (49.3 ± 11.3 to 48.0 ± 11.2 kg, *P *\< 0.01), and skeletal mass index (SMI; 7.76 ± 1.27 to 7.57 ± 1.30, *P *\< 0.01). By contrast, skeletal muscle percentage showed significant increase (36.6 ± 0.06 to 37.0 ± 0.06%, *P *\< 0.05) suggesting the relative increase of muscle mass in body composition.

**Conclusion**: GLP‐1RAs significantly reduce body fat mass and body fat percentage while increasing skeletal muscle percentage for one year in Japanese type 2 diabetes. The predominant body fat reducing effect of GLP‐1RAs was suggested in contrast to preserved skeletal muscle mass.
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**Objective**: To explore the discrepancy of HbA1c for diagnosis of diabetes mellitus and prediabetes in highland dwellers with different hemoglobin level.

**Methods**: A total of 909 health volunteers without known diabetes living in Tibet altitude (average altitude is above 3000 m) were recruited. Subjects were divided into three groups according to the hemoglobin (Hb) level. Normal Hb group (*n *= 460), high Hb group (*n *= 332) and high altitude polycythemia (HAPC) group (*n *= 112). 75 g glucose tolerance tests (OGTT) were performed, FBG, 2 h‐PG, HbA1c, blood routine and biochemical indexes were tested. Systolic blood pressure (SBP), diastolic blood pressure (DBP) and body mass index (BMI) were measured. Receiver operating characteristic curves (ROC) were plotted based on the criteria given by WHO in 1999 and the best threshold, areas (AUC) under the curves, specificity, sensitivity for HbA1c were compared among three groups.

**Results**: Among Normal Hb group, high Hb group and HAPC group, the best threshold of HbA1c for detecting DM was 6.1%, 6.5% and 7.1% respectively, the AUC for detecting DM was 0.96, 0.91 and 0.74 respectively, the specificity for detecting DM was 0.94, 0.90 and 0.82 respectively, the sensitivity for detecting DM was 0.87, 0.82 and 0.57 respectively. The best threshold of HbA1c for detecting Pre‐DM was 5.8%, 5.9% and 6.2% respectively, the AUC for detecting Pre‐DM was 0.73, 0.72 and 0.61 respectively, the specificity for detecting Pre‐DM was 0.77, 0.68 and 0.57 respectively, the sensitivity for detecting Pre‐DM was 0.59, 0.68 and 0.67 respectively.

**Conclusion**: The cut‐off point of HbA1c detecting DM elevated with the increase of Hb level. HbA1c may not suitable for recognizing the DM or Pre‐DM in HAPC population.
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**Introduction**: Ramadhan remains a significant challenge for Type 2 Diabetes Mellitus (T2DM) patients. There is increased risk of glycaemic variability due to changes in dietary habits but there is also potential for weight loss. Both Liraglutide and Dapagliflozin has similar glycaemic and weight reduction effects and has been proven to be safe for use in Ramadan. This study aimed to demonstrate efficacy of Liraglutide compared to Dapagliflozin in Ramadhan.

**Methods**: We performed a prospective study of T2DM patients attending Primary Care and Endocrinology Clinic in UiTM Specialist Centre. We selected patients who would be fasting during Ramadan 2018 and were randomized to receive either Liraglutide or Dapagliflozin. All patients will be prescribed standard diet and Ramadan advice. Weight was recorded pre‐ and post‐Ramadan and participants performed fasting and post‐prandial blood glucose monitoring 2 times per week (6 points per day) in Ramadan.

**Results**: A total of 16 patients completed the study, 10 in the Dapagliflozin group and 6 in the Liraglutide group. Median age and HbA1c were 58 ± 7.4 years and 8.5 ± 1.5%, respectively. Liraglutide resulted in a non‐significant greater weight loss compared to Dapagliflozin, weight difference of 2 ± 2.1 kg and 1.4 ± 2.2 kg (*P* = 0.76). Percentage weight loss was also higher but not significant in the Liraglutide group at 2.7 ± 2.7% vs. 2.0 ± 3.1% (*P* = 0.705). In terms of glycaemic control, there is an overall improvement in both groups. Liraglutide showed negligible superiority over Dapagliflozin with mean fasting glucose of 6.5 ± 1.6 mmol/L and 6.9 ± 1.6 mmol/L respectively (*P* = 0.73). Post‐prandial mean glucose showed similar pattern, Liraglutide group 7.8 ± 2.7 mmol/L compared to 8.6 ± 3.1 mmol/L in the Dapagliflozin group (*P* = 0.89).

**Conclusion**: Both Liraglutide and Dapagliflozin display efficacy in improving glycaemic variability together with weight reduction in Ramadan. Liraglutide appears to be potentially superior regarding both aforementioned aspects, however there are confounding factors. Further studies with larger numbers and longer duration would be useful to support these findings and their validity.
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**Objective**: To study the effect of the mode of inpatient blood glucose management team (IBGMT) combined with internet‐based glucose monitoring system (IBGMS) on the situation of hyperglycemia quality control in gastroenterological surgery patients.

**Methods**: The study included hyperglycaemia patients from June 1,2017 to November 30,2017 in gastroenterological surgery, it used the mode of IBGMT combined with IBGMS to control hyperglycaemia actively; hyperglycaemia patients from June 1,2016 to November 30,2016 were treated with routine consultation control mode to control hyperglycaemia. Two different control mode groups were compared according to the average blood glucose, the proportion of patients without diabetes history, detection rate of hyperglycemia, incidence of hyperglycemia (blood glucose \> 7.8 mmol/L) and severe hyperglycemia (blood glucose \> 16.7 mmol/L), incidence of hypoglycemia (blood glucose ≤3.9 mmol/L) and severe hypoglycaemia (blood glucose ≤2.8 mmol/L), the control rate of target blood glucose, detection rate of glycosylated hemoglobin, hospital length of stay (LOS).

**Results**: There were 244 hyperglycaemia patients in team management group (TMG), compared with 224 hyperglycaemia patients in routine consultation group (RSG). There was no significant difference in age and gender between the two groups. Compared with RSG, TMG had no statistical difference in the proportion of patients without diabetes history, higher detection rate of hyperglycemia (*P *\< 0.05),lower average blood glucose level (*P \< *0.01), lower incidence of hyperglycemia (*P *\< 0.05) and severe hyperglycemia (*P *\< 0.01), no significant difference in the incidence of hypoglycemia (*P* = 0.482) and severe hypoglycemia (*P* = 0.197),higher control rate of target blood glucose (*P *\< 0.01),higher detection rate of glycated hemoglobin (*P *\< 0.05).The hospital LOS in TMG was shorter than that in RSG (*P* = 0.30), but there was no significant difference.

**Conclusion**: The mode of IBGMT combined with IBGMS could improve the situation of hyperglycemia in gastroenterological surgery patients effectively.
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**Introduction**: Recent guidelines have advocated using anti‐hyperglycaemic agents with weight losing properties for overweight and obese patients. Dulaglutide is a new glucagon‐like peptide 1 (GLP‐1) receptor agonist administered weekly for type‐2 diabetes patients. Dulaglutide was able to induce reduction in A1c, fasting blood glucose and weight by 0.7--1.5%, 0.72--2.39 mmol/L, and 1.3--3 kg respectively.

**Methods**: We reviewed 7 patients in our center being treated with Dulaglutide. The patient\'s anthropological measurements were measured monthly while their fasting blood glucose (FBG), blood pressure and A1c 3 monthly.

**Results**: Most of our patients had diabetes less than 5 years (71.4%). The min pre‐Dulaglutide body mass index (BMI) was 36.27 kg/m^2^ (30.69 -- 42.78), with 3 patients in class I obesity, 3 patients in class II obesity, and 1 patient in class III obesity. Weight circumference for males and females were 103.25 cm 89.42 cm respectively, both exceeding the cut‐off values for central obesity. The average pre‐Dulaglutide FBG and A1c were 7.7 mmol/L and 8.6% respectively. After commencement of Dulaglutide for one month, 5 out of 7 patients demonstrated a reduction of 0.5--5.3% of weight loss (0.4--4.8 kg). We expect a sustained reduction in the patient\'s weight, BMI, waist circumference, FBS and A1c. Only 3 patients reported side effects, mainly gastrointestinal symptoms. There was no report of hypoglycaemia.

**Conclusion**: Our early experience with Dulaglutide demonstrated results comparable to the other trials. We anticipate further benefits in reduction of weight, BMI, waist circumference, FBG and A1c in at least 3 months of Dulaglutide usage with minimal report of hypoglycaemia.
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**Introduction**: Chronic hyperglycemia and post‐excursion hyperglycemia had been established as independent risk factors for diabetic complications. Recently, the concept of glycemic triumvirate, which encompasses chronic hyperglycemia, hypoglycemia and glycemic variability (GV) being favored as the main pathophysiology in diabetic outcome mainly cardiovascular complications. In Malaysia, cardiovascular disease attributed to one‐third of all death in diabetic hemodialysis patients with a 3‐fold increase in mortality as compared to non‐diabetic patients.

**Objective**: This study is performed to determine magnitude of post‐dialysis rebound hyperglycemia, GV and their contributing factors. Methodology: 150 patients on haemodialysis were recruited, 93 patients had end‐stage‐diabetic‐renal disease (DM‐ESRD) and 57 patients had end‐stage‐non‐diabetic renal disease (NDM‐ESRD). Post‐dialysis rebound hyperglycemia and GV indices (standard deviation \[SD\] and %co‐variant \[%CoV\]) were obtained from 11‐point and 7‐point self‐monitoring blood glucose (SMBG) profiles during hemodialysis day (HD) and non‐hemodialysis day (NHD). GV were analysed between HD vs. NHD in DM‐ESRD patients as well as those with NDM‐ESRD.

**Results**: Mean blood glucose during dialysis‐day was 9.33 \[SD 2.7, %CoV 30.6%\] mmol/L in DM‐ESRD compared to 6.07 \[SD 0.85, %CoV 21.3%\] mmol/L in NDM‐ESRD (*P* =\< 0.01). Post‐dialysis rebound hyperglycaemia occurred in 71% of patients (*n *= 105. This spike was pronounced in DM‐ESRD compared to NDM‐ESRD (83.5% vs. 53.6%; OR 4.39 \[95% CI 2.05 -- 9.42\]). Significantly higher GV indices were observed in DM‐ESRD compared to NDM‐ESRD during HD and NHD day especially in group with HbA1c 8--10% (*P* =\< 0.01). Furthermore, GV indices tended to be higher on HD compared to NHD (*P* =\< 0.01). Asymptomatic hypoglycemia was observed in 18% of patients (*n *= 21), mostly during first‐hour of hemodialysis. Higher HbA1c levels and older age were the main factors contributing to higher post‐dialysis rebound hyperglycemia and GV and in this study (*P *\< 0.05). Correlation between HbA1c and mean blood glucose in this population is moderate with *r* ^2^ = 0.58.

**Conclusion**: Diabetic patients on haemodialysis are at increased risk of post‐dialysis rebound hyperglycemia and fluctuations in blood glucose on hemodialysis‐days with high HbA1c level and old age being two significant contributing factors. Since this group of patients are vulnerable to CVD mortality urgent attention is needed to rectify it.

PP‐304 {#jdi12939-sec-0609}
======

The comparison of the additive effects of sitagliptin or pioglitazone to the failure with maximal doses of metformin and sulfonylurea combination in type 2 diabetes {#jdi12939-sec-0610}
--------------------------------------------------------------------------------------------------------------------------------------------------------------------

**T. Kim, H. Kim and S. Beom**

Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul Medical Center, Seoul, South Korea

We explored the additive effects of sitagliptin or pioglitazone to the failure with maximal doses of metformin and sulfonylurea combination in patients with type 2 diabetes. Through the chart review, patients who were given additional doses of either sitagliptin or pioglitazone because they were unable to control their blood sugar levels (HbA1c≥7.5%) despite receiving metformin ≥1,000 mg/day and glimepiride ≥6 mg/day were selected. Prescription claims were extracted from January 1, 2009, to January 1, 2010. Blood glucose and lipid metabolism results were analyzed for selected subjects for 12 months after drug administration. Thirty‐nine patients on sitagliptin (20 men, aged 58.4 ± 1.7 years \[mean ± SE\], BMI 26.6 ± 0.7 kg/m^2^, HbA1c 8.3 ± 1.0, HOMA‐IR 3.9 ± 0.4, and HOMA‐β 40.4 ± 3.6%) and thirty‐one patients on pioglitazone (20 men, aged 59.4 ± 1.4 years, BMI 23.9 ± 0.5 kg/m^2^, HbA1c 8.7 ± 1.3, HOMA‐IR 3.3 ± 0.5, and HOMA‐β 22.8 ± 3.9%) were studied. In the sitagliptin group, there was no significant change in HbA1c at 6 and 12 months, but statistical significance was observed only in the change of fasting blood glucose (FBG) at 12 months compared with baseline (*P *\< 0.05). In the pioglitazone group, significant changes in HbA1c were observed at 6 and 12 months compared with baseline (*P *\< 0.05), and significant changes in FBG and postprandial blood glucose (PPG) were observed at 12 months (*P *\< 0.001 and *P *\< 0.05). Compared with the lipid profile, the decrease in LDL cholesterol was significant only in the sitagliptin group (*P *\< 0.05). Significant changes in BMI, BP, renal function, hepatic function, HOMA IR, and HOMA β were not observed in both groups. In this study, the addition of sitagliptin or pioglitazone in patients not responding to metformin and sulphonylurea resulted in a statistically significant decrease in fasting blood glucose and LDL cholesterol in the sitagliptin group and a statistically significant lowering of HbA1c, FBG and PPG in the pioglitazone group, respectively.

PP‐305 {#jdi12939-sec-0611}
======

Immediate changes of parameters after SGLT2 inhibitors in Japanese subjects with type 2 diabetes {#jdi12939-sec-0612}
------------------------------------------------------------------------------------------------

**S. Nakatani^1^, S. Ueno^1,2^, T. Haraguchi^1,2^, Y. Yamaguchi^1,2^, R. Nakashima^1^, Y. Fujita^1,2^, S. Kubota^1,2^, S. Okamoto^1,2^, H. Kuwata^1,2^, K. Watanabe^1^, T. Hyo^1^, N. Tanaka^1,2^, D. Yabe^2^, Y. Hamamoto^1,2^ and Y. Seino^1,2^**

^1^Center for Diabetes, Endocrinology and Metabolism, Kansai Electric Power Hospital, Osaka, Japan^2^Yutaka Seino Distinguished Center for Diabetes Research, Kansai Electric Power Medical Research Institute, Kobe, Hyogo, Japan

**Introduction**: Sodium‐glucose cotransporter 2 (SGLT2) inhibitors reduce blood glucose levels by inhibiting reabsorption of glucose from primary urine independent of insulin. Because of the mechanism of action, body weight is often reduced by SGLT2 inhibitors, but fluid reduction through its diuretic effect and increased ketone production are matters of concern. In this study, to elucidate the factors affecting the effects of SGLT2 inhibitors, we examined immediate changes of parameters and the correlations between them before and after initiation of SGLT2 inhibitors.

**Methods**: The patients who were initiated SGLT2 inhibitors from June 2016 to June 2017 were identified from our database retrospectively, and those who had data of 24‐hr urine test before and after administration were extracted. The parameters such as body weight (BW), 24‐h urinary glucose excretion (UGE), average of 7‐point blood glucose levels (ABG), blood ketone body level (Ket), hematocrit (Ht), heart rate (HR), and eGFR before and 3 days after SGLT2 inhibitors were evaluated. HbA1c was evaluated before and 1 month after. Values are represented as means±SD.

**Results**: A total of 46 subjects (male/female = 28/18, age:59.6 ± 10.5 years, BW:77.0 ± 12.8 kg, HbA1c:9.0 ± 1.3%) were enrolled. The distribution of SGLT2 inhibitors was as follows: Tofogliflozin, Empagliflozin, Dapagliflozin, Canagliflozin and Luseogliflozin = 6, 6, 4, 8 and 22). UGE significantly increased from 19.4 ± 32.7 to 62.6 ± 27.2 g/day (*P *\< 0.001) with reduction in ABG from 195.9 ± 43.0 to 154.4 ± 24.9 mg/dL (*P *\< 0.001). Ket showed significant increase (76.2 ± 58.7 to 257.5 ± 196.4 μmol/L; *P *\< 0.001), showing correlation with UGE after SGLT2 inhibitor (*r* = 0.358; *P* = 0.02). eGFR showed significant decrease (79.8 ± 20.2 to 70.9 ± 17.3 mL/min/1.732; *P *\< 0.001), and UGE after SGLT2 inhibitor was positively correlated with eGFR. Ht and HR did not show any difference (40.9 ± 4.0 to 40.4 ± 3.9%; *P* = 0.499, 80 ± 13 to 81 ± 12/min; *P* = 0.326). HbA1c was deceased by −1.5% after one month.

**Conclusion**: Our data indicate that glucose‐lowering effect of SGLT2 inhibitor was achieved through increased UGE, but significantly increased UGE may result in increased Ket. Reduction in eGFR was observed immediately after the initiation of SGLT2 inhibitor without any significant findings of fluid reduction.
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Abstract objective With the advantage of low in cost and high in accuracy, fasting blood glucose (FBG) test was widely used in the screening of diabetes. CDS suggest that one with FBG\>6.1 mmol/L should go having an OGTT test. However, we found many diabetics with Polycythemia having low FBG in routine work, suggesting that the cut‐point of 6.1 mmol/L may not suitable for the diabetic screening in Polycythemia patients. So, we conduct a study to find out the best cut‐off point of FBG for diabetic screening in Polycythemia patients. Methods A total of 527 male Tibetan were recruited during 2016 and 2017. Subjects were divided into two groups basing on the concentration of hemoglobin. OGTT test was performed for the diagnosis of diabetes. Cut‐off points and AUC of FBG between two groups were calculated based on ROC curve analysis. And sensitivity, specificity and youden index were calculated. Results A total of 527 volunteers were divided into normal group (Hb\<180 g/L) and Polycythemia group (Hb≥180 g/L). DBP, FBG, 2hBG and LDL were different between two groups (*P *\< 0.05). The AUC were 0.9391 and 0.8744 respectively, and the cut‐off point was 6.1 and 5.7, respectively. In normal group, the sensitivity and specificity were 0.88 and 0.95, respectively. In Polycythemia group, the sensitivity and specificity were 0.83 and 0.79 for the cut‐off point of 5.7 mmol/L, which were 0.63 and 0.91 for the cut‐off point of 6.1 mmol/L. Conclusion When the target population was Polycythemia patients, the cut‐off points of 6.1 mmol/L in FBG will result in low sensitivity, and the cut‐off points to 5.7 mmol/L should be a better choice.
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**Objective**: Today we can use few medications with efficacy and safety in type 2 diabetic patients (T2DM) with renal dysfunction, though they account for almost half of Japanese T2DM. Alogliptin is a selective inhibitor of dipeptidyl peptidase 4 (DPP‐IDF‐WPR‐4) titrated with renal function level. In order to evaluate the efficacy and safety of alogliptin based on renal function in T2DM, we designed prospective observational study (eGFR study).

**Methods**: To evaluate efficacy and safety of alogliptin based on renal function in T2DM, we have evaluated the dosage of alogliptin, the glycemic control, eGFR, body weight, and the frequency of hypoglycemia and adverse events in T2DM registered with this study from August 2011 to February 2015 in our hospital.

**Results**: Study participants were all Japanese and 95 male and 30 female. Mean age was 65.8 ± 10.9 years, HbA1c was 7.6 ± 1.0%, fasting plasma glucose was 134.3 ± 26.7 mg/dl, eGFR was 67.6 ± 18.9 ml/min./1.73 m2, body weight was 66.9 ± 18.9 kg, the dosage of alogliptin was 21.1 ± 6.3 mg. After 156 weeks of follow‐up, HbA1c was 7.0 ± 0.7% (*P *\< 0.01), fasting plasma glucose was 132.9 ± 31.2 mg/dl (ns), eGFR was 66.0 ± 15.7 ml/min./1.73 m2 (*P *\< 0.01), and body weight was 65.1 ± 13.3 kg (ns). Between two groups keeping good glycemic control for 52 weeks or not, we found the association with body weight gaining. There were 9 reports of hypoglycemia in the cases with sulfonylurea, but there were no severe hypoglycemia. A total of 2 cardiovascular events were reported. We have no report of cerebrovascular event, cancer or death.

**Conclusion**: Treatment with alogliptin in Japanese T2DM is effective and safety at least in 156 weeks of follow‐up. We need to accumulate more cases, especially with moderate and severe renal dysfunction, and keep following up for more years, in order to evaluate the long‐term efficacy and safety of alogliptin based on renal function in T2DM.
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**Aims**: This study was designed to assess possible relationship of long‐term glucose‐lowering effects of hypoglycemic drugs especially in patients taking dipeptidyl‐peptidase 4 inhibitor (DPP‐IDF‐WPR‐4i)　and metformin (Met) with intake of macro‐nutrients. Materials and

**Methods**: Changes in hemoglobin A1c (HbA1c) as well as estimated intake of macro‐nutrients and the baseline characteristics were obtained for Japanese individuals with type 2 diabetes who was initiated and continued DPP‐IDF‐WPR‐4i or Met monotherapy without any prescription change for 1 year. The retrospective analysis at a single hospital between September 1, 2006 and June 30, 2017. Each of patients were categorized into two groups: Group A which included patients who was taking DPP‐IDF‐WPR‐4i and whose HbA1c levels were increased ≥0.4% from 6 month to 1 year; dA, same as taking Met; mA, and Group B which included patients whose HbA1c levels were maintained \<0.4% from 6 month to 1 year taking DPP‐IDF‐WPR‐4i; dB same as taking Met; mB. Self‐administered 3‐day food records were analyzed for estimated intake of macro‐nutrients using Healthy Maker Pro (Mushroomsoft Co., Ltd., Japan).

**Results**: The 98 individuals were divided into four groups: Group dA (*n* = 10, age 58.8 ± 4.2 year, HOMA‐IR 1.7 ± 0.9, HOMA‐β30.6 ± 25.2), Group mA (*n* = 8, age 53.9 ± 2.4 year, HOMA‐IR 2.6 ± 1.4,HOMA‐β75.5 ± 59.0), Group dB (*n* = 53, age 65.2 ± 1.6 year, HOMA‐IR 2.0 ± 1.5, HOMA‐β40.0 ± 32.8), Group mB (*n* = 27 age 53.4 ± 12.8 year, HOMA‐IR 3.1 ± 1.7,HOMA‐β70.9 ± 100.5). There is no statistical difference among baseline of each two groups. Total energy intake was significantly greater in Group dA (1960 ± 84 kcal/day) than that of Group dB (1730 ± 32 kcal/day). Interestingly, fat intake was significantly greater in Group dA (64.4 ± 21.8 g/day) than that of Group dB (52.3 ± 13.0 g/day) while carbohydrate and protein intake did not differ between the two groups. On the other hand, the groups taking metformin did not have any significant difference.

**Conclusion**: Among only for the patients receiving DPP‐IDF‐WPR‐4i, those who consumed more total energy and fats resulted in deterioration of HbA1c‐lowering effects. It is suggesting that diet play an important role in maintaining glucose lowering especially the patients using DPP‐IDF‐WPR‐4i.
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**N. Samingan^1^, N. A. M. Amin^2^, S. Z. Yaakop^1^, A. Z. Azriyanti^1^ and M. J. Yazid^1^**

^1^Paediatric Endocrine Unit, University Malaya Medical Centre, ^2^Paediatric Endocrine Unit, Hospital Putrajaya

Global rising of childhood obesity has resulted in parallel rise in the prevalence of Type 2 diabetes mellitus (T2DM) in children. We aim to describe the demographic profile, clinical features and effect of different treatment modalities to the hba1c level in this group of patients.

**Methods**: This is a retrospective study of paediatric patients diagnosed with T2DM in University Malaya Medical Centre from 2008 to 2018. Patients' notes were reviewed and data of demographic, anthropometry, clinical presentations and history were obtained. Effects of treatment are assessed by looking at the difference of hba1c values after 3 to 6 months of treatment initiation.

**Results**: A total of 59 cases of T2DM were diagnosed from 2008 to 2018. A total of 33 (56%) patients were female. Mean age at diagnosis was 12.4 years old. Almost half of the patients, 31 (53%) aged under 12 years old. The youngest patient was a 6‐year‐old girl. Fifty‐two percent of the patients were Malay (31); eighty percent (46) were obese, with the presence of acanthosis nigricans. Forty‐four patients (75%) had family history of T2DM and half had exposure to diabetes in utero. Most patients presented with osmotic diuresis symptoms (33 (56%)), 4 (7%) of them had DKA. Almost one‐fifth were diagnosed after routine obesity screening. One in 10 had positive autoantibodies. Average hbA1c at presentation was 11.6%, which dropped to 7.7% after 3 months and raised to 8.8% at 1‐year follow‐up. Mean c‐ peptide and insulin level was 3.46 ng/ml and 29.5 mU/L, respectively. Eight patients (13%) had nephropathy on presentation. Eighty percent received (46) either combination of metformin and insulin or metformin only. Seven percent (4) received insulin only while no medical treatment in 7% (6) of the patients. Hbaic dropped the most in the insulin only group (−5.70) followed by the combination group and metformin only group (−4.86 and −4.17) and the least (−0.2) in no treatment group.

**Conclusion**: T2DM can present early in childhood. Almost one‐tenth had positive autoantibodies. One‐fifth was diagnosed after screening in high risk group. Better hbaic level was achieved after anti diabetes medication.
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**G. Hsu**

EclaireMD Foundation, Woodside California, United States

Based on his research, the author developed two glucose prediction tools. He was able to reduce his FPG from 185 mg/dL to 119.6 mg/dL (28 lbs weight reduction), daily glucose from 279 mg/dL to 117 mg/dL, and A1C from 10% to 6.1%.

He examined correlations between FPG and PPG, carbs and sugar intake, and exercise amount but found all were below 7% (very low). After analyzing thousands of data points, he discovered the major cause, *Weight*.

Based on 25,000 data of 1,449 days, (1/1/2014 -- 12/20/2017), he found 85% correlation between FPG and Weight. In the time series diagram, it shows two high peak periods and two low valley periods of Weight, and the FPG curve following the Weight curve like its 'twin'. In spatial analysis diagram of BMI vs. FPG (without time factor), there is a 'quasi‐linear' equation existing between two coordinates of BMI and FPG from point A (24.5, 98.0) to point B (27.0,148.0). The stochastic (random) distribution of data has 2 clear 'concentration bands' stretched from lower left corner toward upper right corner. The +/‐ 10% band covers 65% of total data and the +/‐ 20% band covers 93% of total data. Only the remaining 7% of total data are influenced by other 5 secondary factors.

After capturing the basic characteristics, the author then developed a practical tool to predict each day\'s FPG value. The final prediction accuracy is 98.3% with 80% correlation between predicted and actual FPG values.
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**S. Shahnaz^1,2^ and M. Iqbal^1,2^**

^1^Ziauddin University Karachi, Karachi, Pakistan, ^2^Faculty of Pharmacy, University of Sindh, Jamshoro, Jamshoro, Pakistan

**Background**: Pakistan in under the stage of development. Among many diseases, the diabetes is one of them. The exact figure of prediabetic peoples is still questionable in various parts of country. Mostly, the values of glucose were high in patients that may leads to permanent disease.

**Objective**: The aims of this study were to evaluate the number of pre‐diabetic persons among rural community and also to assess their life style. Methodology: A total of 1000 persons were enrolled via random sampling method. The design of study was descriptive and cross‐sectional. The locations of study were rural areas of district Hyderabad, Pakistan. The duration of study was 01 year (March 2016 to March 2017). The results were assessed with the help of approved statistical tools.

**Result**: Out of total patients (*n* = 1000), the frequency of pre‐diabetic peoples was *n* = 591. The most common age of pre‐diabetic patients were noted among 30--35 years. The maximum peoples were belonged to male gender as compared to female under the category of pre‐diabetic peoples. The Quality of life (QoL) was very low. The knowledge regarding the diabetes was also not satisfied.

**Conclusion**: The current study clearly demonstrated the finding of peoples who were residing the rural areas of Hyderabad. So there should be proper diagnosis according to international diabetes federation guideline and also disseminate the proper knowledge to our local community with the help of Pharmacist or other health care providers.
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**T. Kondo, N. Miyakawa, H. Motoshima, N. Ishii, M. Igata, K. Yoshinaga, D. Kukidome, T. Senokuchi, J. Kawashima, T. Matsumura and Prof E. Araki**

Kumamoto University, Kumamoto, Japan

In April 14th and 16th, 2016, Kumamoto area in Japan was severely damaged by massive M7 class earthquakes. To examine the influences of these earthquakes on glycemic control and stress factors in diabetic outpatients regularly cared in diabetic clinic of Kumamoto University Hospital, sequential HbA1c, glycated albumin, other biochemical parameters, life style associated questionnaire and Impact of Event Scale‐Revised (IES‐R) scores were analyzed. A total of 557 patients were enrolled and data were collected from 13 months before to 13 months after the earthquakes. In patients with type 1 diabetes (T1D) or specific types of diabetes due to other causes, glycemic control was not altered during the observational period. This glycemic stability in T1D may result from self‐management of insulin doses (increase in 7% and decrease in 20% of patients). In patients with type 2 diabetes (T2D), HbA1c was decreased by 0.11% (from 7.33% to 7.22%) at 1--2 months after the earthquakes compared to that before the earthquakes, and increased at 3--4, 6--7 and 12--13 months after the earthquakes. The reduction of HbA1c at after 1--2 months in T2D was associated with 'restoration of lifelines in two weeks' and 'sufficiency of sleep'. The glycemic deterioration at after 3--4 months was related to 'shortage of anti diabetic agents' and 'insufficient amount of food', and at after 12--13 months that was connected to 'largely destroyed of houses" and "changes in working environments'. IES‐R, representing disaster associated stress levels were positively correlated with 'age', 'delayed restoration of lifelines', 'self‐managements of anti diabetic agents' and 'increased amount of activity', and negatively associated with 'early restoration of lifelines' and 'sufficiency of sleep'. Thus, the glycemic control, associated factors and stress levels are altered in chronological order. Post‐disaster diabetic medical care must consider these corresponding points in accordance with the time period.
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**K. Linat^1^, A. N. Yom^2^ and S. U. M. Satha^1,3^**

^1^University of Health and Sciences, ^2^Royal of Academic of Cambodia, ^3^Department of Internal Medicine "A", Calmette Hospital

**Introduction**: Type 2 diabetes is a chronic disease that could lead to many serious complications. Despite the advances in diagnosis and new treatments, a comprehensive management of type 2 diabetes should also include the patients' self‐management. The knowledge, attitude and practice of the patients are very important. The healthcare providers play a key role in transmitting the knowledge, attitude and practice regarding type 2 diabetes to patients.

**Objectives**: The aim of this study is to evaluate the level of knowledge, attitude and practice regarding type 2 diabetes of 6th year medical students at the University of Health sciences, Cambodia.

**Materials and Methods**: This is a cross‐sectional study involving calculated sample size of 189 students at University of Health sciences, Cambodia. After validating by two senior local endocrinologists, the questionnaires were pilot with 15 students to evaluate their coherence suitability to the local context. Face‐to‐face interviews were held to fill questionnaires with the agreement of the students. The data was analyzed by using STATA 13.1.

**Results**: 189 medical students (119 females and 70 males) participated in the study. Mean age of the students was 23.9 (+/‐0.9). More than half of them were originated from provinces (70.9%) and others were from the capital (29.1%). The knowledge score was 11.95 (+/‐1.12) out of 13, representing 91.94%. The attitude was 16.3 (+/‐1.93) out of 20, representing 81.24%. The practice score was 6.00 (+/‐0.93) out of 7, representing 85.79%. Beside from the university, the sources of the information about the knowledge, attitude and practice toward type 2 diabetes were mainly conferences and social media.

**Conclusion**: The result of the study showed that the knowledge, attitude and practice regarding type 2 diabetes among year 6th medical students at the university of health science was high.
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**X. Jiang^1^, M. Li^1^, H. Jiang^1^ and L. Ji^2^**

^1^Peking University, Beijing, China, ^2^Peking University People\'s Hospital, Beijing, China

**Aims**: To test a model including variables of diabetes self‐efficacy, diabetes distress, diabetes knowledge, patients' education level and diabetes self‐management (DSM) behaviors.

**Methods**: A multicenter, cross‐sectional study design was used. A sample of 265 adults with type 2 diabetes was interviewed, using the demographic information questionnaire, the scale of the Self‐Efficacy for Diabetes, the Diabetes Distress Scale, the diabetes‐related knowledge questionnaire, and the scale of Summary of Diabetes Self Care Activities. Structural equation modeling was performed with 10,000 bootstrap samples using AMOS 23.0.

**Results**: The final model provided a good fit to the data (χ^2^ \[22, *N* = 265\] = 9.192, df = 5, *P *=* *0.102, Normed Fit Index = 0.972, Root‐Mean Square Error of Approximation = 0.056). Diabetes self‐efficacy had the strongest direct effect on DSM behaviors (β = 0.550, *P *=* *0.000). Diabetes knowledge (β = 0.167, *P *=* *0.004) and patients' employment status (β = −0.130, *P *=* *0.009) had a direct effect on DSM behaviors. The association between diabetes knowledge and DMS behaviors was partially mediated by diabetes self‐efficacy (bootstrap mean = 0.160; 95% CI: 0.088, 0.237), explaining 49.08% of the total effect of diabetes related knowledge on DSM behaviors. The association between diabetes distress and DMS behaviors (bootstrap mean = −0.113; 95% CI: −0.192, −0.043), and patients' education level and DMS behaviors (bootstrap mean = 0.102; 95% CI: 0.047, 0.165) were completely mediated by diabetes self‐efficacy.

**Conclusions**: The results of the final model highlight the importance of diabetes self‐efficacy in predicting DSM behaviors and the mediating role of diabetes self‐efficacy in the association between diabetes knowledge and DSM behaviors, diabetes distress and DSM behaviors, and patients' education level and DSM behaviors. Meanwhile, DSM behaviors are also directly affected by diabetes knowledge and employment status. The results of the model can help to develop culturally sensitive interventions that are evidence‐ and theory‐based. Interventions that provide diabetes knowledge, reduce diabetes distress, and enhance diabetes self‐efficacy have the potential to promote changes in self‐management behaviors among Chinese adults with type 2 diabetes.
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**J. Parikh**

Om Diabetes Research Centres And Clinics, Thane West, India

**Aims and Objectives**: To Establish Relationship Between Concept Of Preventive Diabetology And Glycemic Outcome Measuring Glycosylated Hemoglobin in India.

**Methods**: A total of 9120 Type 2 persons with diabetes registered at Om Diabetes Research Centre were as routine procedure evaluated---personal, family history, BMI, W/H ratio, vital parameters, systemic examination, routine biochemistry, ophthalmic, cardiac, foot analysis were recorded. All these patients were given free education material on Primary Prevention: Lifestyle Modification, Genetic Counseling. Health Promotion in High‐Risk Group. Secondary Prevention: Early Diagnosis, Proper Treatment and Monitoring of Diabetes to Maintain Quality of Life and Prevent Complications. Tertiary Prevention: To Reduce Morbidity, Mortality by Timely Intervention of Complications and Reduce Psychological and Financial Burden by Institution of Rehabilitation Measures. All patients were invited for free patient educational lectures at periodical intervals .The lectures were focused on role of lifestyle modification and emphasize on regular monitoring to prevent complications. During the lectures patients were also motivated with prizes and praises and performance certificates.

Out of 8688 patients who attended such activities 3069 patients regularly visited Om Diabetes Research centre for regular follow‐ups and biochemical tests for more than 8 years. All these patients mean glycosylated HbA1C was calculated as per national HbA1C -- STD Bio‐Rad ‐Diastat Analyzer.

**Results**: Out of 3069 patients, 10% (n‐305) had Normal HbA1C (less than or equal to 6%), 40% (n‐1235) had good control (HbA1C between 6 to 7%), 28% (n‐867) had fair control (HbA1C between 7 to 8%), 11% (n‐335) had poor control (HbA1C between 8 to 9%), 11%(n‐327) had very poor control (HbA1C more than 9%).

**Conclusion**: 50% patients had good control HbA1C below 7% and this observation was statistically highly significant. 78% patients had fair control (HbA1C less than or equal to 8) correlating positive results of preventive diabetology with better glycemic control. Direct involvement of treating diabetologist resulted in better mindset control and target oriented approach to create curiosity for knowledge and result oriented implementations goals in diabetic patients.
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**M. Mohidin^1^, P. Chong^2^, S. Teo^2^ and I. Zulkipli^1^**

^1^PAPRSB Institute of Health Sciences, Universiti Brunei Darussalam, Bandar Seri Begawan, Brunei Darussalam, ^2^RIPAS Hospital, Bandar Seri Begawan, Brunei Darussalam

**Background**: Diabetes Mellitus (DM) is a preventable health problem with increasing prevalence worldwide. Health literacy plays an important role in determining the outcomes of diabetes management.

**Methods**: The objectives were to investigate the knowledge level of patients with diabetes on their condition and evaluate the association between health literacy and glycemic control. Participants were recruited consecutively amongst patients attending the Diabetes Clinic at RIPAS Hospital, Brunei Darussalam. The data collection tool consisted of demographic information, the Michigan Diabetes Knowledge Test (MDKT), a validated, self‐administered questionnaire to test respondents' knowledge of their condition and the level of glycaemic control (HbA1c). Quantitative data were analysed using Statistical Packages for Social Sciences version 23.0.

**Results**: One hundred and eighteen patients participated in the study. Majority (69.5%) of respondents had inadequate diabetes knowledge levels. Chi‐square tests revealed patients' education level (χ^2^ = 8.646, *P* = 0.013) and monthly income (χ^2^ = 12.686, *P* = 0.02) were associated significantly with the diabetes knowledge level. No association was found between diabetes knowledge level and glycemic control.

**Conclusion**: Educational programmes are warranted to improve health literacy and knowledge of diabetes among patients. Effectiveness of patient education interventions should be assessed to ensure translation to clinical outcomes such as glycaemic control.
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**D. Png, M. Lee, P. Koh, P. Sharda, T. Lee, J. Tong, C. Sonarno, W. Chui, S. Fun, C. Chua, H. Tan, E. Yeoh, C. Sum, S. Lim and T. Subramanium**

Admiralty Medical Centre, Singapore, Singapore

**Objective**: Patient empowerment forms the cornerstone of diabetes care. However, the specific impact of group‐based diabetes education on patients' knowledge and diabetes control has not been thoroughly evaluated in Singapore. The aim of this study was to evaluate the effect of group‐based diabetes education programmes on the outcomes of diabetes care.

**Methods**: Patients with Type 2 diabetes attended a 3‐h workshop (topics include overview of diabetes management and complications) conducted by trained diabetes nurse educators and a dietician on diabetes education from July 2017 to April 2018. Of the 10 workshops, 6 were in English, 3 in Mandarin, 1 in Malay. Participants completed a 15‐question quiz on diabetes knowledge prior to the programme and the same questions, in a different sequence, as post‐workshop quiz. HbA1c was collected before and within 6 months after the workshop.

**Results**: A total of 49 people participated in the programme. There were 77.6% attendees in English sessions, 16.3% in Mandarin and 6.1% in Malay. There were 67.3% females, mean age (1SD) was 55.9 (13.3) years, mean duration of diabetes 7.1 (6.9) years. There was significant improvement in mean quiz scores \[baseline 53.7 (25.3)% compared to 75.8 (21.7)% post‐programme, *P *\< 0.001\]. The baseline quiz score was not significantly correlated with age, duration of diabetes, and baseline HbA1c. Post‐programme quiz score was positively correlated with reduction of HbA1c (Pearson correlation, *r* = 0.3, *P *\< 0.05). There was a significant reduction in HbA1c done within 6‐months post‐programme \[baseline 8.4 (1.4) % compared to 7.7 (1.4)%, *P *\< 0.001\].

**Conclusion**: This 3‐h workshop was associated with increased knowledge and improvement in glycaemic control within 6 months of the programme. Whether the durability of this effect can be sustained will need to be studied with longer term follow up.
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**T. M. Yeong^1^, G. S. Harvinder Kaur^2^, L. C. Li2, L. E. Lyn3 and C. S. Hing^4^**

^1^Diabetes Nurse Educator, Healthcare Clinic, International Medical University, Bukit Jalil, Kuala Lumpur, Malaysia, ^2^Division of Nutrition and Dietetics, School of Health Sciences, International Medical University, Bukit Jalil, Kuala Lumpur, Malaysia, ^3^Department of Pharmacy Practice, School of Pharmacy, International Medical University, Bukit Jalil, Kuala Lumpur, Malaysia, ^4^Clinical Skills and Simulation Centre, International Medical University, Clinical Campus, Seremban, Negeri Sembilan, Malaysia

**Background**: Managing diabetes in nursing homes is a challenge due to poor cognitive functions of residents and lack of knowledge and skills amongst the carers. This study investigated the impact of a multidisciplinary team‐based approach to improve diabetes self‐care knowledge and skills amongst the residents and carers residing in nursing homes.

**Methods**: Forty‐five residents with Type 2 Diabetes (T2D) and 16 carers from four nursing homes around Klang Valley participated in this study. A multi‐disciplinary team consisting of diabetes nurse educator, physicians, pharmacists and dietitians provided diabetes education and care over 6 months. Residents and carers were educated on nutrition and exercise, self‐monitoring of blood glucose (SMBG), medication intake, foot‐care and hypoglycaemia management using group and individual educational approaches over 8 visits. Pre‐ and post‐assessment of diabetes knowledge and self‐care skills were done using validated questionnaires. Independent‐ and Paired T‐test were used to determine the change in knowledge and care.

**Results**: The mean age of the residents was 69 ± 11 years and 51% were females. Twenty‐four percent of the residents were on diet control, with 49% on oral anti‐diabetes agents and 27% on insulin treatment. Upon providing diabetes education, diabetes knowledge scores amongst carers (Pre: 50 ± 14 vs. Post: 74 ± 12, *P *\< 0.001) and residents (Pre: 33 ± 22 vs. Post: 70 ± 15, *P *\< 0.001) improved significantly. Initially, SMBG was not practiced in the nursing homes. However, upon education, all the residents had their SBMG monitored regularly. One third of the residents on insulin treatment had frequent hypoglycaemia episodes with carers oblivious to the management. Post intervention, the carers significantly improved their hypoglycaemia knowledge and management skills (Pre: 1 ± 1 vs. Post: 7 ± 1, *P *\< 0.001) and SMBG skills (Pre: 2 ± 3 vs. 8 ± 1, *P *\< 0.001), resulting in no further hypoglycaemia incidences. Forty percent of the residents received medication adjustments and in line, HbA1c improved significantly from 9.1 ± 2.0% to 7.6 ± 1.9%, *P* = 0.001 after 6 months.

**Conclusion**: Multidisciplinary diabetes management and care improved diabetes outcomes in nursing homes. A team‐based approach can be recommended for diabetes care in community setting. This study was supported by International Medical University Cares.
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Department of Diabetology and Nephrology, Ogaki Municipal Hospital, Ogaki, Japan

**Background**: Appropriate glycated hemoglobin (HbA1c) levels delay the onset and progression of diabetic complications. However, HbA1c does not reflect intraday and interday glycemic excursions such as hypoglycemia or postprandial hyperglycemia. The aim of this study is to characterize fluctuations in blood glucose levels with flash glucose monitoring (FGM) and to observe the course of patients in whom this information was used to direct their daily medical treatment.

**Methods**: This 12‐week, retrospective observational study involved diabetic patients who wore the FreeStyle Libre Pro^®^ device for 2 weeks. Changes in HbA1c and body mass index (BMI) were observed by clinical phenotype of diabetes and manifestations of glucose variability. The frequency of hypoglycemic events was analyzed in patients who performed blood glucose self‐monitoring. Because the FGM measurements were invisible to participants for 2 weeks, we divided patients into those who received a check‐up 1 or 2 weeks after starting to wear the device and compared their change in HbA1c.

**Results**: Of 114 patients who received a FGM device at Ogaki Municipal Hospital, 92 were enrolled in the study (type 1: *n* = 12, type 2: *n* = 75, other: *n* = 5). Overall, the mean change in HbA1c and BMI from baseline to week 12 was 0.80% (*P *\< 0.001) and 0.21 kg/m^2^ (*P* = 0.0058), respectively. Postprandial hyperglycemia was observed in 78 of 92 patients (83%) and was associated with a greater, non‐statistically significant reduction in HbA1c at week 12 than treatment for other glucose profile manifestations (0.89% vs. 0.63%, *P* = 0.19). Only nutritional guidance and FGM use was associated with a similar reduction in HbA1c at week 12 compared with medication regimen changes (0.83% vs. 0.77%, *P* = 0.73). The frequency of hypoglycemic events was lower at week 12 compared with baseline. A trend towards a greater reduction in HbA1c was observed in patients who received a check‐up 1 week after FGM use compared with those with a check‐up 2 weeks afterwards (0.94% vs. 0.72%, *P* = 0.14).

**Conclusion**: Visualization of glucose variability with a FGM device was safe and might improve glucose profiles regardless of clinical phenotype. Receiving medical advice 1 week after FGM use might contribute to a more desirable clinical course.
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**R. Y.‐Y. Chiou^1,2^, Assoc. Prof S.‐. C. Chang^1,3^ and Assoc. Prof D.‐A. Wu^1,3^**

^1^Tzu Chi University, Hualien, Taiwan, ^2^Yu‐Li Veterans Hospital, Hualien/Yu‐Li, Taiwan, ^3^Hualien Tzu Chi Hospital, Hualien, Taiwan

**Introduction**: People with diabetes have been increasing in the past decade in Taiwan. Healthcare providers cannot assist diabetes patients immediately while their symptoms occurred. If patients could recognize, identify and treat the symptoms earlier, this might avoid a lot of unnecessary acute or chronic complications.

**Aim**: To explore the perception of symptoms for diabetic patients and their self‐care behaviors for symptoms relief and to examine related factors of socio‐demographic characteristics. One hundred and sixty‐one participants were recruited from the diabetes clinics in three regional hospitals at Hualien. Garcia\'s Diabetes Symptom Self‐care Inventory (DSSCI) was translated into Chinese to be the tool to approach diabetic patient\'s symptoms, self‐care behaviors and outcomes.

**Results**: An average of 14.4 symptoms occurred among participants. The top four major symptoms of frequency were loss of interest in sex, blurred vision, sleep problems and memory loss. The top four major symptoms of importance were blurred vision, numbness or tingling (limbs), sleep problems and sensitivity to noise or light. The most widely used self‐care was "rest". The best way to improve the symptoms was "eat or drink something." Overall, the participants who adopted the self‐care behaviors to relieve the symptoms could achieve a good improvement in diabetes care.

**Conclusion**: This study will serve as an important reference or precursor for the future studies in the fields of diabetes care and clinical practice. DSSCI met the principles of patient‐centered diabetes care and could be a useful tool for the diabetes symptom‐related study in Taiwan.
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**T. Kanamaru^1^, C. Ito^2^, N. Nakamura^3^, K. Ideno^4^, Y. Koshikawa^5^, Y. Kamiya^5^, F. Suzuki^5^ and J. Yoshida^5^**

^1^Shumei Universty, Yachiyo, Chiba, Japan, ^2^Kimitsu Chuo Hospital, Kisarazu, Chiba, Japan, ^3^Chiba University, Chiba, Japan, ^4^Toho University, Ota‐ku, Tokyo, Japan, ^5^Chiba University Hospital, Chiba, Japan

Diabetes education in hospitals has changed in Japan since hospital stays have been shortened. The present study aimed to identify difficulties and coping strategies among Japanese nurses in pediatric wards who educate children diagnosed with type 1 diabetes and their families. We recruited four nurses who had educated children diagnosed with type 1 diabetes and their families in a pediatric unit. The findings of semi‐structured interviews that addressed their difficulties with such education and their coping strategies in the era of shorter hospital stays were inductively analyzed. The Ethics Review Broad at Chiba University approved the study. The nurses felt that they had insufficient time to completely educate children and their families about managing diabetes by themselves or to intervene when psychosocial aspects became destabilized upon diagnosis. Education in pediatric wards mostly comprises acquiring injection skills, managing continuous subcutaneous insulin infusions, monitoring blood glucose, and coping with hypoglycemia, which does not leave as much time as before for teaching diabetes pathology, self‐management, and complications. The nurses also felt that they had no time to intervene and help relieve increasing anxiety in children and their families. The nurses coped with these constraints by making time for education, changing the education program, focusing on psychosocial aspects and the lives of children and their families soon after hospital admission, and sharing information with inpatient and outpatient nurses about the acquisition of self‐management skills by children and their families. Shortened hospital stays have imposed time constraints on nurses that often result in the incomplete education of children and their families about diabetes after admission to hospital. A systematic education program that continues from inpatient to outpatient must be developed. This study was supported by a grant from the Japan Academy of Diabetes Education and Nursing.
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^1^Universiti Putra Malaysia, Serdang, Malaysia, ^2^Pusat Perubatan Universiti Kebangsaan Malaysia, Cheras, Malaysia

**Introduction**: Entertainment‐education (EE) *enter‐educate, edutainment or infotainment* projects combine entertainment and education to increase knowledge, encourage favourable attitudes and motivate people to take socially responsible action in their own lives. A range of communication platforms including theatre, radio, television, games, social media has been used in diabetes care. Education is an essential component of diabetes care, but the impacts of EE on the disease has not been evaluated. We assessed the range of EE used in diabetes care and evaluate the effects on health outcomes.

**Method**: We identified studies through Pubmed. We included the published primary studies to improve management of diabetes mellitus at primary, secondary and tertiary levels. Descriptive analysis was used.

**Findings**: We found and reviewed 14 studies. Nine studies examined patients with type 1 diabetes mellitus (T1DM), one study on patients with type 2 diabetes mellitus (T2DM) and the remainder four studies focussed on primary prevention of T2DM. Eight were prospective evaluation studies, five randomized controlled trials with only one qualitative study. The interventions for T1DM and T2DM utilised technology‐related games. For prevention of T2DM, a variety of approaches was used: web game, culturally relevant radio novella, health‐related fotonovelas booklets, and social marketing. Majority of the studies were conducted in USA, with others in Japan, Italy, Netherlands, and Iran. The outcomes included assessment of usability, user satisfaction, improved knowledge as well as management of the disease. Only two studies included clinical outcomes of glycaemic control, blood glucose, and glycosylated haemoglobin.

**Conclusion**: Current research on the use of EE in diabetes management is limited and focused on T1DM. Although there were initial improvements in both behavioral and clinical outcomes, the harm of technology‐related games needs to be evaluated intensively and extensively. EE in the management of T2DM is scarce. More research is clearly needed to determine further how EE can best be utilized to impact health outcomes in primary, secondary and tertiary diabetes care (T1DM and T2DM) as well as determining the optimal delivery platforms and potential mechanisms of change. Despite hypoglycaemia being an important complication in T1DM and older T2DM, none of the studies included this safety measure.
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**Background**: Diabetes is a chronic disease that requires patients to be able to self‐manage the condition. Diabetes self‐management education, the process of teaching patients has been considered an important part of diabetes management. Prior to 2016, referrals to diabetes educators were from clinicians via phone calls without a clear guidelines. To improve management and appropriate referrals of inpatients, a new referral tool named "Diabetes Risk Criteria (DRC)" was implemented. The aim of DRC tool is to have a systematic referral process and facilitate ward nurses to identify inpatients to refer to diabetes educators timely.

**Objectives**: To evaluate the effectiveness of Diabetes Risk Criteria (DRC) tool and reduction of HbA1C within 6 months of receiving diabetes education.

**Methods**: We reviewed inpatients referral using DRC tool, between 1 August 2016 and 31 December 2016. This review included HbA1C levels at baseline and within 6 months of study were retrieved from the health information system.

**Results**: Total 669 patients were referred using DRC tool (70.6% male, mean age 59.1 years). Average of referral had increased from 55 per month to 133 per month using DRC tool. Referral with risk criteria of HbA1C \> 8% was 79.8%; newly diagnosed type 2 diabetes 5.4%; Diabetic Ketoacidosis / Hyperosmolar Hyperglycemia acidosis 0.6%; New to subcutaneous insulin therapy 13.9%; Change in insulin therapy/regimen 9.3%; Severe hypoglycemia 1.6%; recurrent hypoglycemia 3.6%; Persistent raised blood glucose 20%. After adjusting for baseline and within 6 months of HbA1C, only 342 subjects with complete HbA1C result at pre and post receiving diabetes education were reviewed. HbA1C within 6 months had decreased by 1.2% (*P* = 0.001).

**Conclusions**: The Diabetes Risk Criteria (DRC) tool had increased the number of inpatients referral to diabetes educators significantly. This referral system demonstrating that ward nurses were able to identify appropriate referral of inpatients with diabetes, enhancing their timely review by the diabetes educators, and results in a statistically significant decrease in HbA1C levels.
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**R. Sakai**

Kyoto Prefectural University Of Medicine, Graduate School Of Medical Science, Kyoto, Japan

**Aims**: The relationship between the glycemic control and living alone is unclear. Thus, we examined the relationship between the glycemic control and living alone in patients with type 2 diabetes.

**Methods**: In this cross‐sectional study, we evaluated lifestyle factors by a questionnaire method. We defined living alone as a positive answer of question: "Are you living alone?" We extracted the values of HbA1c from the electronic medical record for 1 year, and calculated the average HbA1c values, the standard deviation (SD) and the coefficient of variation (CV) of HbA1c. The CV was defined as follows: CV = (SD/average HbA1c)×100. We examined the differences in clinical and metabolic parameters between those who was living alone and those who was not. To investigate the effect of living alone on glycemic control, we performed multiple regression analysis including various variables: age, duration of diabetes, body mass index (BMI), exercise, smoking, alcohol drinking, insulin treatment, insulin secretagogues, average HbA1c and living alone.

**Results**: Among 175 men and 98 women, 32 patients (18.3%) in men and 16 patients (16.3%) in women were living alone. Among men, average HbA1c of patients with living alone was significantly higher than that of patients without (7.6 (1.0) vs. 7.2 (0.8) %, *P *=* *0.024). In addition, SD and CV of HbA1c of patients with living alone was significantly higher than that of patients without (0.35 (0.17--0.62) vs. 0.24 (0.16--0.36), *P *\<* *0.001, and 0.05 (0.02--0.08) vs. 0.03 (0.02--0.05), *P *\<* *0.001). On the other hand, among women, HbA1c (7.1 (1.0) vs. 7.3 (0.8) %, *P *=* *0.423), SD (0.18 (0.09--0.32) vs. 0.24 (0.17--0.35), *P *=* *0.794) and CV (0.02 (0.01--0.04) vs. 0.03 (0.02--0.04), *P *=* *0.876) of HbA1c were not different between patients with living alone and those without. In addition, among men, living alone (standardized regression coefficient* *= 0.13, *P *=* *0.028) was associated with CV of HbA1c after adjusting covariates.

**Conclusion**: Living alone is associated with blood glucose variability in patients with type 2 diabetes in men but not women.
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**A. D. F. Wisnawa^1^, G. B. S. Wirawan^1^, Y. H. L. Setiawan^1^, N. P. D. U. Darmayanti^1^, I. I. Pratiwi^1^, P. Aryani^2^ and A. K. Sari^2^**

^1^Undergraduate Student at Medical Faculty of Udayana University, Denpasar, Bali, Indonesia, ^2^Department of Community and Public Medicine, Udayana University/Sanglah Hospital, Denpasar, Bali, Indonesia

**Introduction**: Prevalence of diabetes mellitus (DM) is increasing worldwide. Understanding determinants of DM screening behavior is important to develop better preventive. DM screening behavior in Indonesia has not been fully investigated before. This research attempts to give preliminary report to determine the predictors of DM screening behavior in sample rural Indonesian community especially in Bali.

**Methods**: This analytic cross‐sectional study recruited sample population over 18‐years old adults without prior history of DM diagnosis visiting a public primary care facility in Payangan, Bali. All respondent were asked to fill a self‐administered questionnaire. DM Screening behavior is defined as history of random blood glucose examination in the last two years. Determinants measured include sex, age, education level, distance to healthcare, transportation, insurance, healthcare utilization, physical activity, hypertension, obesity, perception of control, optimism bias, worry, DM risk perception, and symptoms of DM. Meanwhile, obesity was defined by Body Mass Index (BMI)\>25 kg/m^2^ or waist circumference more than normal for his or her sex.

**Results**: We obtained 70 respondents in the study with mean age 39.54 years old (95CI 36.46--42.63), 62.9% male, and 64.3% with education level high school or higher. From bivariate analysis variable obesity have significant association with DM screening behavior (*P *\< 0.05). Multivariate binary logistic regression identified 5 out of 15 potential determinants as statistically significant of DM screening behavior are level education, obesity, healthcare utilization, optimism bias and DM risk perception. DM screening behavior increased with high level education (OR 9.660, 95CI 1.189--78.480; *P *\< 0.05), increased of healthcare utilization (OR 9.456, 95CI 1.287--69,612; *P *\< 0.05), and obesity (OR 12.954, 95CI 1.720--97.733; *P *\< 0.05). However, the likelihood decreased with high optimism bias (OR 0.199, 95CI 0.054--0.878; *P *\< 0.05), and high DM risk perception (OR 0.284, 95CI 0.098--0.824; *P *\< 0.05).

**Conclusion**: We identified level education, healthcare utilization, obesity as positive determinants meanwhile optimism bias and diabetes mellitus risk perception were negative determinants of DM screening behavior in rural community in Indonesia, Bali. Cave of this study is limited sample size. As such, further studies with bigger sample size are necessary to learn the cause behind the peculiar results.
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^1^Department of Psychosocial Oncology, National Cancer Centre Singapore, ^2^Department of Endocrinology, Singapore General Hospital, Singapore

**Background**: Young adulthood presents a challenging period for most with diabetes. Psychological factors and diabetes‐related distress exacerbate the inability to self‐manage effectively, with resultant poorer control. We report the outcomes of a clinical psychology service delivered within the framework of a multi‐disciplinary clinic from March 2017 to June 2018.

**Method**: Young adults attending the Young Adults with Diabetes (YAD) clinic (mean age 23.4 ± 4.5y) in Singapore General Hospital were offered sessions with the clinical psychologist. The YAD clinic has been providing a one‐stop geographical setting for the endocrinologist, diabetes nurse educator, dietitian, social worker to administer care since 2011. HbA1c, HADS‐A and HADS‐D and PAID scores at baseline, and the most recent post‐intervention HbA1c were recorded. Pearson\'s correlations and independent and paired samples t‐tests were used.

**Results**: Of 155 YAD, 36 were offered psychological evaluation. 217 scheduled sessions for 28 patients (78%F/21%M) were held over 15 months, with a 29% no‐show rate. 20 had type 1 diabetes, 5 had type 2 diabetes, 3 had monogenic diabetes. At baseline, 16/28 (57%) had moderate to severe anxiety (HADS‐A \> 8); 11/28 (39%) had moderate to severe depression (HADS‐D \> 8), levels of diabetes‐related distress were high (mean PAID 43 ± 19). HADS‐A positively correlated with HADS‐D and PAID (*r* = 0.49, *P* = 0.014; *r* = 0.50, *P* = 0.007 respectively), but neither correlated with HbA1c. HADS‐D negatively correlated with HbA1c (*r* = −0.41, *P* = 0.032). The most recent post‐intervention HbA1c showed a significant decrease from baseline (HbA1c 10.5 ± 2.4% vs. 9.2 ± 2.1%, *P* = 0.005). This decrease was clearly demonstrated in the anxious group (HbA1c change: −1.8%, *P* = 0.008) but not in the non‐anxious group (HbA1c change: −0.6%, *P *\> 0.05). HbA1c decrease from baseline was 1.33--1.36% in both depressed and non‐depressed groups but only significant in the latter (*P* = 0.03). 3/28 (10.7%) have been discharged from psychology care with significant improvements to PAID scores (54.2 ± 19.6 vs. 15.8 ± 10.1, *P* = 0.02). There were falls in HbA1c, HADS‐A and HADS‐D levels that were non‐significant because of the small number of individuals.

**Conclusions**: In this group with high baseline levels of anxiety, depression and diabetes‐related distress, psychological intervention in the context of a multi‐disciplinary clinic improved glycaemic control. This was particularly in the group with higher baseline anxiety levels.
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**Objectives**: Several lifestyle factors have been associated with an increased risk of nonalcoholic fatty liver disease (NAFLD). However, whether lifestyle factors are related to the risk of NAFLD remains unknown. The aim of the present study was to evaluate the association between lifestyle habits and the risk of NAFLD.

**Methods**: An observational study of 240,252 people was performed using the Specific Health Check and Guidance System in Japan. Inclusion criteria included being aged 40 to 65 years. Exclusion criteria included chronic liver disease (NAFLD, alcoholic liver injury, viral hepatitis), HCV antibody positive, HBs antigen positive, smoking, diabetes medication, and chronic renal failure and end stage renal disease. The subjects of survey were 9,884 men and 18,459 women. The height and weight of the subjects were measured, and information concerning lifestyle habits (eating speed, physical activity, exercise habits, gait speed, alcohol drinking, smoking, and restorative sleep, weight gain since age 20 of ≥ 10 kg was obtained using a self‐administered questionnaire. NAFLD was using criteria equal to liver fat \>5.6% (based on the Dallas Heart Study). Time‐dependent Cox proportional hazard models were used to calculate hazard ratio (HR) and 95% confidence interval (CI) with adjustment for age, BMI and lifestyle factors.

**Results**: Over a mean follow‐up period of 3.8 years, 570 men (5.8%) and 2,078 (11.3%) women participants newly developed NAFLD. After adjusting for confounders, age (HR 0.98, 95%CI 0.97--0.99), HbA1c (1.78, 1.36--2.33), BMI (1.10, 1.05--1.16), eating snack after supper (1.45, 1.17--1.79) in men, age (1.03, 1.03--1.04), HbA1c (1.27, 1.09--1.49), BMI (1.03, 1.00--1.05), weight gain since age 20 of ≥ 10 kg (1.28, 1.11--1.47), slow walking speed (1.14, 1.04--1.25), in women were associated with an increase of NAFLD.

**Conclusions**: These findings suggest that several changes of lifestyle factors were associated with an increase of NAFLD. Lifestyle modification targeting these factors is required to prevent NAFLD.
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**H. P. Gunawardena, N. V. S. Dharshika, D. Ganegoda and K. A. C. Madumali**

Department of Applied Nutrition, Faculty of Livestock, Fisheries & Nutrition, Wayamba University of Sri Lanka, Makandura, Gonawila (NWP), Sri Lanka and De Soyza Maternal Hospital, Colombo 8.

Gestational diabetes mellitus (GDM) is on rise parallel to type 2 diabetes mellitus (T2DM) in Sri Lanka. GDM shows definite upward trend in Sri Lanka. Tight blood sugar control during the pregnancy is important to improve the adverse outcomes of GDM. Lifestyle modification in GDM women is important for improving the pregnancy outcomes and T2DM prevention. Therefore, present qualitative content analysis study was conducted with the objective of assessing lifestyle perceptions of GDM women on glycaemic control. Thirty six women (mean age, 31 ± 4.0 years) with diagnosed with GDM in 24th to 36th week of pregnancy who referred to the antenatal clinics of the De Soyza Maternal Hospital were recruited as subjects. In‐depth interviews were conducted with participants, using semi‐structured questionnaire. Interviews were audio taped and transcribed verbatim. Content analysis was carried out and data were coded in NVivo Software. Content analysis highlighted three themes as possible management strategies to achieve the glycaemic control and barriers for adhering to a proper dietary practices and physical activity recommendations and enablers for adhering to a proper dietary practices and physical activity recommendations. Possible management strategies were featured with dietary and physical activity management to achieve the glycaemic control. Dietary management was consisted of advice from professionals, avoiding foods, amount of foods and views on dietary modifications. Role of physical activity in controlling GDM and personal beliefs were the components of glycaemic control through physical activity. Food aversions, difficulties in preparing food, frequent hunger and low income were the barriers for adhering to a balanced diet. In adhering to recommended level of physical activities, lack of time, lack of motivation, personal health issues, lack of support and advices from health professionals and personal beliefs were recognized as barriers. Proper advice and support from health staff, self‐motivation and maternal and foetal health were the main enablers identified for dietary and physical activity adherence. Therefore, findings of the present study suggest that it is essential to provide adequate educational and social support to GDM women prior and after the delivery to achieve better glycaemic control.
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^1^RMRC ICMR, NE REGION, MoHFW, GOVT OF INDIA, Dibrugarh Assam, India, ^2^MDRF (Chennai), Chennai Tamil Nadu, India, ^3^ICMR RMRC, Dibrugarh Assam, India, ^4^Tripura, Kunjabon Tripura, India, ^5^Mizoram, Aizawl Mizoram, India, ^6^Arunachal Pradesh, Naharlagun Arunachal Pradesh, India, ^7^New Delhi, New Delhi New Delhi, India

**Objective**: 1) Implementing the high response rates in the surveyed communities for better policy decision making process 2) To know how the existing educational literacy in the community can make an impact in shaping robust public health programs.

**Methods**: Cross‐sectional, community‐ based survey was carried out on adults of both sexes, aged 20 years and above. Sample size was calculated separately for urban and rural areas. Assuming an expected prevalence of 10% in urban areas and 4% in the rural areas, allowing a relative error of 20% on these, a non response rate of 20% and an error of 5%, the sample size was estimated to be 1200 in urban areas and 2800 in rural with a total of 4,000 individuals/state and the total sample size in the selected 04 states of NE Region of India was 16,000 nos.

**Results**: The overall response category rates in the subjects ranges from Tripura State 96.10%, Arunachal Pradesh State 96.30%, Assam State 97.90% and Mizoram State 99.10% which was an encouraging sign. In Arunachal Pradesh (*n* = 4022) the educational literacy status till primary level was 21.80%, Tripura (*n* = 3803) 28.60%, Assam (*n* = 3892) 36.10% and in Mizoram (*n* = 4079) 57.20%. In the subjects having tenth standard education and above, the educational literacy status in Mizoram State was 30%, Assam State 35.80%, Arunachal Pradesh State 47.60% and Tripura State 52.20% respectively. Nearly 88.4% of the urban residents and 64.4% of rural residents in Assam, 89% urban and 71.5% of rural residents in Mizoram, 76.3% of the urban residents and 60.5% of rural residents in Arunachal Pradesh and 89.5% of urban residents and 66% of rural residents in Tripura they knew about diabetes. In the subjects the knowledge of diabetes, 78% Urban and 49.2% Rural in Assam, 83.7% Urban and 68.2% Rural in Mizoram, 63% Urban and 46% Rural in Arunachal Pradesh and 77% Urban and 66.5% Rural residents in Tripura that prevalence of diabetes at higher trends.

**Conclusion**: As educational qualification and literacy rates are closely linked together, continuation in investing on educational sector for the population is of utmost importance.
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**Aims**: The purpose of this study was to evaluate the effect of the smart phone diabetes management application (APP) on blood glucose control. The primary aim was change in glycated hemoglobin (HbA1c) between groups after 6 months. The second aims were change in patient‐reported diabetes knowledge, Self‐care behaviors, empowerment ability, anxiety, and other clinical (blood pressure) and laboratory (lipid) values.

**Methods**: A 3‐group randomized clinical trial was conducted comparing conventional diabetes management to two kinds of management with smart phone APP. A total of 234 diabetic patients were aged 21--65 years, with average HbA1c levels (9.38 ± 1.27)%, and were divided into 3 groups. Group A: conventional management group; Group B: Self‐management with smart phone APP; Group C: interactive management with smart phone APP. Patients in Group C received some reminder messages and real‐time feedback of APP.

**Results**: 194 of the 234 patients completed 6 month follow‐up (83.9%). After 6 month management, the amplitude of HbA1c reduction in different groups was (1.35 ± 1.52)% in Group A, (1.48 ± 1.51)% in Group B and (2.07 ± 1.58)% in Group C. The HbA1c in Group C was decreased more significantly than Group A and Group B (*P *\< 0.05). The control rate of HbA1c (HbA1c \<7%)were 22.2% in Group A, 28.4% in Group B and 36.8% in Group C. The control rate in which Group C was remarkably higher than in Group A (*P* = 0.04). After 6‐month management, The HDL level of Group C was significantly higher than that of Group A. The score of diabetes knowledge (MDKT)and the empowerment of diabetes (DES‐SF) in the Group C were significantly higher than those in the Group A, and the Zung self‐rating anxiety scale score (SAS) was significantly lower than that in Group A (*P *\< 0.05).

**Conclusion**: Diabetic patients with smart phone APP online interactive management achieved statistically significant improvements in HbA1c, blood lipid metabolism, diabetes knowledge and self‐care behaviors.
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**Aims**: 1) To investigate psychological aspects of diabetic patients from their own viewpoints using a questionnaire (BUKK‐SW). 2) To analyze the relationship between 'stress' and 'well‐being' (trustable relationships and a sense of internal fulfillment) with a medical indicator such as HbA1c, to elucidate psychological factors that influence the self‐care of diabetes.

**Methods**: 1) Questionnaire: BUKK‐SW, which was developed to measure a degree of mental health using stress and well‐being as indicators of '4 factors of stress' and '2 factors of well‐being'. 2) Subjects: 2153 patients with diabetes and 679 healthy individuals. 3) Period of study: September‐October 2017. 4) The results of the questionnaire BUKK‐SW were statistically processed and analysed.

**Results**: 1) "Stress" and "well‐being" level of the patients tended to be lower than those of the healthy individuals, especially "well‐being" was significantly low (*P *\< 0.001). Nevertheless 70% of the patients blamed themselves for having diabetes. This result would be interpreted that the low patients' stress recognition level reflects the possibility that patients with diabetes lack awareness of their disease, and that low well‐being level represents their psychological characteristics that they have low level‐feelings of self‐affirmation and happiness, which lead to the sense of 'loss of fulfillment' and drive them to escape from reality or to become dependent. These psychological characteristics observed in patients are highly likely to be internal factors that prevent their willingness to perform positive self‐care. 2) The correlation coefficient between HbA1c, stress, and age were not clear, but it was made sure that the interaction between stress and well‐being and ages would affect the condition of diabetes. 3) The wellbeing score was not associated with HbA1c level. Discussion: This cross‐sectional study revealed some aspects of psychological issues which patients with diabetes may have, but the whole picture has not become clear yet. Additional analysis and longitudinal investigation focusing on each individual using the 'case study method' should be considered for further analysis.
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Introduction: Inadequate knowledge about diabetes and access to healthcare in rural Indian settings lead to underdiagnosis of diabetes and sub‐optimal diabetes control. Project Diabetes with Dignity (DWD) aimed to test the feasibility and effectiveness of a model of enhanced diabetes care through empowerment of Accredited Social Health Activists (ASHAs; community health workers), in a rural setting in India.

**Methods**: DWD was conducted with 416 adults (30--70 years) with diabetes in Baramati, Pune District, over a study duration of one year. Intervention area included all villages under two sub‐centres of one Primary Health Centre (PHC) in Baramati. Control area included all villages under three sub‐centres of another PHC in Baramati. ASHAs screened all adults for diabetes in each of the selected villages, and implemented the six month DWD intervention (counselling patients/family; monthly house‐to‐house visits; community awareness‐raising) in the intervention area. Difference in changes in glycated hemoglobin (HbA1c), lipids, urine microalbumin, blood pressure, body mass index (BMI) and waist circumference (WC) between patients with diabetes in intervention vs. control areas, from baseline to end‐line, were assessed through laboratory/clinical examination and analyzed via a mixed‐effects regression model. Confounding factors, including age, socioeconomic status, gender, duration of diabetes, tobacco/alcohol use, and knowledge about diabetes, were adjusted in the models.

**Results**: About 52% patients belonged to the intervention group. The difference in absolute change in mean HbA1c from baseline to end line in intervention (8.79% \[95% CI 8.45--9.13\] to 8.23% \[95% CI 7.41--9.05\]) vs. control group (8.75% \[95% CI 8.38--9.11\] to 9.66% \[95% CI 8.79--10.53\]) was statistically significant (*P* = 0.010). A similar statistically significant decline in low‐density lipoprotein cholesterol in the intervention group vs. control group was observed (*P* = 0.005). Changes for other clinical indicators were not found to be statistically significantly different between the two groups (*P *\> 0.05).

**Conclusion**: DWD was effective in improving glycemic parameters in subjects with diabetes. Capacity building of community health workers for prevention and management of diabetes in rural settings is recommended.
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Purpose: Studies show that high blood sugar during hospitalization is related to poor prognosis, so blood glucose control is very important. Based on this, the hospital set up a hyperglycemic group and expects to achieve optimal goals for blood sugar control in inpatients.

**Methods**: 1. Establishment of a hyperglycemia group: Metabolic physician, dietitians, and health teachers meet to discuss, when the hospital patient\'s blood glucose level ≧300 mg/dl reaches two times, The hospital information system prompted the referral of the hyperglycemia group to intervene in the patient\'s blood glucose control during hospitalization. 2. Physicians and patients discuss the treatment plan, and diabetes teachers teach diabetes health education: insulin injections, self‐monitoring of blood glucose, and dietitian nutrition education 3. After discharge phone tracking reminded to return to hospital.

**Results**: 109 people were involved in diabetes education. A1C decreased from 10.2% to 7.3% statistically significant (\<.001) The self‐monitoring rate of blood glucose increased from 10.1% to 45.9%, the self‐monitoring of blood glucose increased from 0.9% to 40.4% four times a week, and the number of people who The Diabetes Care Network increased from 16.5% to 47.7%.

**Conclusions**: Involved in the glycemic control of diabetic patients inpatient. Significantly improve the A1C after discharge, and increase their willingness to self‐monitor blood glucose in diabetes patients. They also join the Diabetes Care Network to obtain cross‐team care and effective self‐management to achieve optimal glycemic control.

**Comments**: Among 106 hospitalized patients with diabetes with a total age of more than 65 years old and initial onset patient are total 74 people (67.9%), therefore more time was needed health education, but no full‐time staff responsible provide timely and effective diabetes health education. If the future can a full‐time staff to be responsible for this business, resolve the problem of providing timely and effective health education to improve the quality of diabetes care in patients with diabetes.
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**Objectives**: To design a cloud computing‐based Healthcare Software‐as‐a‐Service (SaaS) Platform (HSP) for delivering healthcare diabetic follow‐up management services with low cost, high clinical value, and high usability.

**Methods**: We analyzed the architecture requirements of an HSP, including the interface, business services, cloud SaaS, quality attributes, privacy and security, and multi‐lingual capacity. For cloud‐based SaaS services, we focused on Diabetic Follow‐up Service (DFS) content services, basic clinical decision functional services, and mobile services. Ucloud\'s cloud computing for Infrastructure‐as‐a‐Service (IaaS) and Platform‐as‐a‐Service (PaaS) was used. We established a long‐term file and prognosis tracking service plan for each patient who needs follow‐up service, collecting the crowd sourced data.

**Results**: The functional and software views of an HSP were designed in a layered architecture. External systems can be interfaced with the HSP using SOAP and REST/JSON. The multi‐tenancy model of the HSP was designed as a shared database, with a separate schema for each tenant through a single application, although healthcare diabetic follow‐up data can be physically located on a cloud or in a hospital, depending on regulations. The DFS services were categorized into rule‐based services for management of diabetic chronic diseases, improvement of patients' satisfaction, and medical knowledge services.

**Conclusions**: The SAAS cloud platform is based on the Internet and does not require hardware construction. It is beneficial for the efficient management of big data for follow‐up of patients with diabetes. We expect that cloud‐based SAAS cloud platform will allow our hospital, also other small and mid‐sized hospitals, in addition to large‐sized hospitals, to adopt information infrastructures and health information technology with low system operation and maintenance costs.
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**S. Au^1^, J. Leung^1^ and H. Lam^1^**

^1^Ruttonjee and Tang Shiu Kin Hospitals, Hong Kong, Hong Kong SAR

**Introduction**: Postprandial hyperglycemia occurs frequently in diabetes patients, especially for the high risk group of which discharged from hospital due to illness, change in diet, intervention or change in medications during hospitalization. Close monitoring of Meal‐Based Blood Glucose Monitoring (MBBGM) at home after hospital discharge is essential to achieve good glycemic control. Studies suggested that structured MBBGM could achieve better glycaemia control than haphazard monitoring. Objective

To evaluate if structured MBBGM for discharged diabetes patients could achieve better glycemic control.

**Method**: A structured MBBGM Reporting Form was given to patients upon hospital discharge to report pre‐and 2‐h postprandial blood glucose (2‐hrpp) in pairs with food diary. All in‐patients age 18--75 years referred to diabetes nurse from June to November 2015 with Glycaeted Haemoglobin (HbA1c) checked within 2 months of admission were included in the study.

**Results**: 71 individuals with diabetes were included (36--75 years old, mean+SD: 58.79 + 9.39, male 63.4%). Among the 61 patients (85.9%) who had improvement in HbA1c, 73.8% of them had Self‐Blood Glucose Monitoring (SMBG). MBBGM group (testing pre‐and 2‐hrpp at three main meals) showed greatest reduction in HbA1c levels (−4.86 ± 2.92%) compared with those testing SMBG 1--2 meals (−2.71%± 2.39%)) or without monitoring (−1.68%± 2.16%)). MBBGM group achieved better Key Performance Indicator (KPI) of HbA1c \<7% vs. no monitoring group (66.7% vs. 19%; Odds Ratio 0.14, 95%CI 0.03--0.63).

**Conclusions**: SMBG has to be integrated into clinical and self‐management plans. MBBGM helps patients understand the impact of food intake, physical activity and medications on blood glucose levels. This study showed that MBBGM with food diary and structured counseling program could improve the glycemic status and achieve KPI target in patients with diabetes after hospital discharge.
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**C. Li**

Beijing Tsinghua Changgung Hospital, Beijing, China

**Objective**: To evaluate the effect of case management model based on mobile medical treatment on self‐management knowledge, attitude, behavior and blood glucose control of type 2 diabetes patients in China.

**Methods**: The participants were randomly assigned to a 3‐month case management (CM) group (*n* = 50 or control group (*n* = 50). CM group received case management based on mobile health (Dnurse) provided by the team composed of doctors and nurse case manager. The control group received routine therapy and education, mobile health just used the blood glucose monitoring record and self‐ management tool. Results

The baseline data between the two groups was comparable. The total score of diabetes self‐management knowledge, attitude and behavior, as well as the score of attitude and behavior in CM group were higher than the control group (*P *\< 0.01). HbA1c in CM group was lower than that of the control group (*P *\< 0.05). CM group submitted SMBG data 2441 times, 49.8 times per capita, and the control group 2058 times, 41.2 times per capita. The proportion of the average fasting blood glucose (FPG), average 2 h postprandial blood glucose (2 h PBG), high blood glucose and low blood glucose in CM group were lower than that of the control group (*P *\< 0.05).

**Conclusion**: Case management model based on mobile health can improve diabetes self‐management knowledge, attitude and behavior, effectively reduce the average FPG, 2 h PBG, the proportion of high blood sugar and low blood sugar and reduce glycosylated hemoglobin level.
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**E. Fisher^1^, Y. Liu^2^, M. Coufal^3^, Y. Tang^1^, C. Cai^2^ and W. Jia^2^**

^1^Peers for Progress, University of North Carolina, Chapel Hill North Carolina, United States, ^2^Shanghai Jiao Tong University Affiliated Sixth People\'s Hospital, Shanghai, China, ^3^Asian Center for Health Education, Plano Texas, United States

**Purpose**: The Shanghai Integration Model coordinates primary care in Community Health Centers (CHCs) with hospital‐based specialty care. A key component is the deployment of volunteer peer leaders to promote patient engagement in integrated care and daily self management. This study reports on 6‐month results of peer leader programs in nine Shanghai CHCs.

**Method**: Nine CHCs recruited 1223 persons with diabetes. A subset of 333 were selected who were eligible for or prescribed insulin. Volunteer peer leaders were recruited by the CHCs and trained in diabetes knowledge, basic communication and support skills, and program protocols. Common intervention elements included: kick‐off events, monthly group‐based peer support meetings with interactive activities led by CHC staff or co‐led with peer leaders, individual peer leader follow‐up, informal activities such as walking groups led by peer leaders, individual support from peer leaders, monthly supervision for peer leaders, and ongoing technical assistance for CHC staff. At baseline and after 6 months, HbA1c was assessed and participants completed the Chinese Attitudes to Starting Insulin Questionnaire (Ch‐ASIQ). Analyses compared CHCs that had initiated intervention, "Intervention" vs. CHCs in delayed implementation, "Delayed."

**Results**: Reductions in HbA1c from baseline to 6 months were greater in Intervention than Delayed CHCs (*P *\< 0.02). For those with baseline HbA1c \>7.5%, average HbA1c reduction in the Intervention CHCs was 0.65 (from 8.77 to 8.12%), in contrast to 0.38 (8.78 to 8.40%) in the Delayed CHCs. In the subset of subjects identified as eligible for or prescribed insulin, those in Intervention CHCs saw greater improvements on the Ch‐ASIQ (*P *\< 0.024) than those in Delayed CHCs: reduced negative attitudes and fear, increased self efficacy and availability of time and support for insulin use.

**Conclusions**: Encouraging 6‐month results suggest that 1) Group and individual peer support is feasible in "real world" settings of Shanghai CHCs, and 2) Peer leaders may be effective in improving attitudes toward recommended insulin therapy and improving glycemic control. Assessments at 12‐ and 18‐months will evaluate continued sequential implementation and effects of peer support as part of integrated care for diabetes self‐management in Shanghai.
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**K. Marawa**

Diabetes Fiji Inc., Suva, Fiji

**Background**: Diabetes prevalence in adults in the Pacific Islands Region is among the highest in the world (WHO, two thousand and ten), and Fiji is no exception that the increasing incidence of complications due to diabetes is clear evidence that there is a need for alternate measures to combat this avalanche. It also is imminently necessary for diabetics to take ownership of their ailments and be actively involved in managing their diabetes. Diabetes Fiji Inc and World Diabetes Foundation initiated a four‐ year project by with capacity building of health care provider and establishing Diabetes community peer group in identified communities with high prevalence of diabetes. Aim: Empowering people living with Diabetics to take ownership of their health through the creation of Diabetes Community Peer Groups (DCPG). World‐wide experiences with DCPGs have shown them to be an effective and successful tool in managing diabetes and its complications. It develops a sense of camaraderie and enhances sharing of knowledge amongst the peers.

**Method**: The target was to establishe eight community peer groups in the three divisions; by the end of the third year we have successfully established thirty‐one groups. From consultation with the Sub Divisional Medicals Officer, Sub Divisional Health Sisters and zone nurses, Diabetes Community Peer Groups were established in communities with:•high number people living with diabetes who neglect to attend regular clinics•communities with high number of people living with diabetes and with co morbidities•those considered high risk as identified through screening.

After a community is identified the Program coordinator accompanied by zone nurses conduct consultation with villages headsman, village heath worker and people living with Diabetes on the program and the Terms of reference (TOR) that outlines the scope of work. If the parties agreed on the TOR, a leader is elected by the group who will be responsible for the functions and safekeeping of consumables. The Program coordinator then gathers baseline data of each member. Based on the finding the activities for the year are ascertained. In most cases, complication assessment has not been done. These are then carried out prior to the peer leaders training. In this training leaders are trained on their roles, and functions of the group, reporting, and engaging member in activities that enhance their lifestyles. Discussion: The groups were assisted with diabetes screening equipment, sphygmomanometer and weight scale for regular assessment during their weekly meetings. Results are then recorded by the group leaders. Members were able to discuss issues and challenges pertaining to their health. Through peer sharing most have been empowered and motivated to make positive changes. The medical team visits the peer groups according to the schedules developed.

**Results**: The peer groups successfully conducted an open day during a SOPD clinic day and demonstrated skills acquired during peer meeting such as cooking demonstration, simple exercises, demonstration of foot wash and members shared their personal testimonies. The biggest impact nonpeer members living with diabetes is seeing peer groups conducts awareness and demonstration instead of health professional and their motivational testimonies. The program has also strengthened family support as members visited domiciliary cases and conduct awareness in their respective communities. Also the groups established their own backyard garden. A member with above knee amputation to both limbs challenged others with his vegetable garden. Members have seen significant improvement in kidney functions (Egfr), HbA1c and lipid profile. Clinic nurses have also noted a reduction in defaulter\'s members in turn to look out for each other and encourage one and other to attend regular clinic.

**Drawback**: •unavailability of transport, medical professional and reagent for testing from the Ministry of Health•turnover of Peer group members•laxity in few of the group leaders and members

**Way forward**: The Diabetes Peer Group program is one of the initiatives that can be used to empower people living with diabetes to improvement their health status, prevent complication and assist the health department in community outreaches. They are also powerful advocates of healthy living.
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**H.‐J. Tsai^1^, Y.‐H. Huang^1^, Y.‐C. Chen^2^ and Y.‐C. C.‐C. Hsieh^2^**

^1^Center of Diabetes Education, Yuanlin Christian Hospital, Taiwan, ^2^Endocrinology, Yuanlin Christian Hospital, Taiwan

**Purpose**: Research indicates that the diversity of health education intervention, such as individual health education, speech law, group health education, discussions and telephone consultation, effectively improve the patient\'s glycated hemoglobin. Therefore, health education program using multiple tools offer different health education models, the use of propaganda lectures to enhance the prevention of health knowledge, and then combined with other health education intervention tools and multimedia to enhance the case for self‐care awareness, to achieve good control of blood sugar goals.

**Methods**: The use of multimedia teaching materials and health education tools such as Diabetes Conversations MAP and STENO text card guide tools to help patients find the motivation to change. Through blood glucose insulin dose adjustment, strengthen skills training; supplemented by telephone interviews to track to understand and help patients resolve difficulties and problems.

**Result**: Received 100 people, Weekly number of movements by the 3.44 to 3.83, monitoring of blood glucose increased from 2.59 to 3.11,A1c decreased from 10.8 to 9.5%, triglycerides 240 decreased to 189 mg / dL, above all of statistically significant differences. LDL cholesterol decreased from 240 to 189.7 mg / dL.

**Conclusions**: Through execution program to improve HbA1c of 1.3%, we can see that groups health education with multimedia health education, to discuss each other via patients, patients clarify doubts strengthen awareness. The professionals call timely intervention, with home self‐monitoring of blood glucose values, adjusting the diet, exercise or insulin dose, the effective control of blood sugar, enhance self‐care ability and self‐confidence. Comments: The plan to import a diversified health education mode, A1C improved by 1.3 per cent, found the source of the patient to provide more information and increase interest in learning, and empowerment, can effectively improve blood sugar. In the future such as to timely import diversified health education mode, for enhancing the knowledge and skills of patients with diabetes and improve self‐care behaviors, achieve target glycemic control, it will be one of the most advantageous way of health education.
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**N. Lin^1,2^, M. Aung^1^, K. Than^1^, K. Ko^1,2^ and A. Aung^1,2^**

^1^Yangon General Hospital, Yangon, Myanmar, ^2^University of Medicine 1, Yangon, Myanmar

Prevalence of type 2 diabetes is growing in Myanmar reaching 10.5% of a total population of 52 million and pre -- diabetes is 19.7%. Myanmar Diabetes Care Programme was launched in 2017 with the collaboration of Ministry of Health and Denmark Embassy aiming to implement 4 strategic plans, 1. Health care provider (HCP) training, 2. Diabetes Centre of Excellence, 3. Care of diabetes in children 4. Diabetes registry. This programme is supported by Novo Nordisk and is agreed to be organised by diabetologists from university of medicine 1, 2, 3 from Myanmar.

**Objective**: The aim of the HCP training is to provide health education about comprehensive management of T2DM and its complications to 2000 Myanmar HCP all across the country from 2017 to 2020. Methodology: The programme includes 1. Training of trainers 2. 500 HCP per year will be trained from 2017--2020 and evaluation of output will be assessed by pretest posttest questionnaires 3. Diabetes screening in both rural and urban areas.

**Results**: The midterm review of effectiveness of HCP training showed that there were 759 health care providers who were trained from 2017--2018. There were 390 doctors and 125 nurses who were trained in 2017 at Yangon and Mandalay. In 2018, 2 training sessions were conducted, 1 in Myitkyina and 1 in Pathein for 244 HCP (140 doctors and 104 nurses). Training sessions cover the epidemiology, pathophysiology, screening, diagnosis and monitoring of type 2 diabetes, management of acute complications, diabetes and chronic complications, rational choice of medications and insulin therapy. Pretest posttest assessment were described as 32% vs. 57% in Yangon, 45% vs. 58% in Mandalay, 28% vs. 52% in Myitkyina and 40% vs. 54% in Pathein.

**Conclusion**: The objectives of the HCP education was fulfilled to the target at the midterm review but the effectiveness was not statistically significant in some areas due to different levels of knowledge, attitude and performance of trainees. We aim to get more satisfactory result at the end of the programme in 2020.
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**L. F. Woo^1^, S. F. Liew^1^, S. Soo^2^ and W. F. Chew^1^**

^1^Universiti Tunku Abdul Rahman, Cheras, Kajang, Malaysia, , ^2^University Hospitals of Morecambe Bay, Ashton Road Lancaster, United Kingdom

**Background**: The prevalence of Type 2 diabetes in Malaysia has been increasing over the past 20 years particularly in the young adults. Successful prevention of diseases depends on several factors, including knowledge of the disease. Despite this, many have reported that diabetes‐related knowledge in young adults from developing countries is still below satisfactory level. Objective

This study aims to determine the level of diabetes related knowledge and its associated factors among young adults attending a local university in Klang Valley.

**Methods**: A cross‐sectional study was carried out from Oct 2014 to January 2015 through self‐administered questionnaire on diabetes related knowledge with the aim to collect socio‐demographic data. Non‐health sciences students in their year 1 and year 2 studies were recruited randomly. Height and weight were measured to obtain the body mass index (BMI).

**Results**: A total of 227 university students had participated in the survey (median age = 19; IQR 19,20). Majority of them (57%) were female. The diabetes‐related knowledge in this study cohort was generally low, with median score of 47.8% (IQR 39.1, 60.9). Of these, the knowledge on the risk factors of diabetes was particularly lacking (median score = 40%). Obese respondents had significantly higher score compared to their peers, who are underweight (57.61% ± 17.21% vs. 45.80% ± 11.60%, *P *\<* *0.05). Sharing from family members is the most reported source of diabetes‐related knowledge (61.2%); followed by information from websites (46.7%).

**Conclusions**: The level of diabetes related knowledge among the respondents was generally poor, particularly in regards to its risk factors. Most respondents obtain their knowledge through non‐professional sources such as family members and websites. It is thus important for health educators to tailor awareness programme focusing on this young adult to fill this information gap.
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**B. Lim, A. Ngoh and M. N. Eio**

Association of Diabetes Educators (Singapore), Singapore

**Background**: Arising of prevalence in diabetes has led Association of Diabetes Educators (Singapore) to develop a training program for the community health volunteers to support the shortage of formal health care providers. The education training project aims to equip volunteers to develop skill sets in performing blood glucose and blood pressure measurements to support health screening events in the community.

**Method**: The Association of Diabetes Educators (Singapore) collaborated with resident constituency committee group and voluntary organizations from 3 March 2018 to 28 July 2018 to provide basic diabetes education training program for volunteers to reach out the community. 76% (N: 32) of volunteers with prior community volunteering experiences were assigned to attend a 4 h training program, and volunteers without volunteering experiences of community service were provided of an eight (8) hours training. The training program comprises of didactic lectures on diabetes and hypertension, training videos and sharing of challenges in interacting with public. A direct observation of volunteers on hands on performance of blood glucose and blood pressure measurements were done during the classrooms and in the community events. Volunteers were invited to participate in online voluntary and anonymous reflective learning survey upon post training.

**Results**: A total of three training sessions were conducted by two regular diabetes educators and attended by forty two volunteers with age 21 -- 72 years old over period of five months. There were four community health screening events organized at different locations for volunteers to perform real life blood glucose tests and blood pressure measurements in the public events with the supervision of same diabetes educators after the training sessions. The volunteers who supported community health screening activities were observed being confident in performing tasks and positive in interacting with public. There were seventeen volunteers participated in online reflective learning survey. 94% (N: 16) of the volunteers reported to have above secondary education level. 100% (N: 17) shared positive learning experiences in diabetes education program when asked what they have learnt. For question on why does training matter to them -- 70% (N: 12) replied for self‐awareness, or to support as peer to people living with diabetes. When asked what might/should be done better in our care setting -- 82% (N:14) replied to provide more community training with hands on experiences; show care and concerns to people with diabetes when in contact; encourage active lifestyle to prevent diabetes and others. Discussion and

**Conclusion**: The diabetes education training program has successfully integrated learning for volunteers from the classroom to the community. Reduce reliance on health professionals to support the community health activities.
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^1^Universiti Teknologi Mara (uitm), Sungai Buloh, Malaysia

**Introduction**: Dysglycemia, defined as type 2 diabetes mellitus (T2DM), impaired glucose tolerance (IGT) and impaired fasting sugar (IFG), is a well‐known comorbidity in patients with chronic obstructive airway disease (COPD). The prevalence of T2DM in patients with COPD has been reported to be 12%. Another large population study demonstrated that patients with COPD have an overall higher risk of T2DM even after adjusting for confounding factors such as sex, age, and steroid use.

**Methods**: This was a cross sectional study of 130 patients with COPD attending Respiratory Clinic at Pusat Perubatan UiTM. The objective was to determine the sensitivity and specificity of fasting blood glucose (FBG), 2‐h post prandial glucose (2HPPG), and HbA1c in detecting undiagnosed dysglycaemia in patients with COPD. The inclusion criteria were patients with established diagnosis of COPD according to the Global Initiative for Chronic Obstructive Lung Disease Guideline 2016, with no existing T2DM age 30 years and above. We excluded patients with asthma, malignancy, and on long term corticosteroid therapy for other reasons. All patients had their blood samples taken for FBG and HbA1c, and oral glucose tolerance test (OGTT) with plasma glucose withdrawn after 2 h.

**Results**: We found that the FBG had sensitivity of 1.00 and specificity of 0.72 (CI 0.63--0.80, *P* =\< 0.001). While the negative predictive value was 100%, it performed poorly as positive predictive value of 33.3% (CI 27.2--40.2, *P* =\< 0.001). As for the 2HPPG, its sensitivity was 1.00 and specificity was 0.99 (CI 0.93--1.00, p=\<0.001). It has high positive and negative predictive values of 97.9% (CI 87.0--99.7, *P* =\< 0.001) and 100% respectively. HbA1c on the other hand, had low sensitivity and specificity, with value of 0.23 (CI 0.11--0.38) and 0.57 (CI 0.46--0.67) respectively (*P* = 0.023). The positive predictive value was only 18.8% (CI 11.0--30.1) and negative predictive value of 62.2% (CI 56.3--67.8, *P* = 0.023). The cumulative steroid dose, either systemic or inhaled, between the dysglycaemia and non‐dysglycaemia were not significant.

**Conclusion**: This study showed that 2HPPG has the highest sensitivity and specificity as compared to FBG and HbA1c in detecting undiagnosed dysglycaemia in patients with COPD.
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**N. Chuman**

Naragakuen University, Nara City, Japan

**Objective**: The objective of this study was to intervene in the self‐regulation (SR) of type 2 diabetes patients in order to determine the effects of intervention based on language and behavior as related to behavioral changes in a group that achieved SR.

**Method Subjects**: The subjects consisted of 14 patients who underwent intervention during the course of SR and who had successfully achieved SR. Intervention: A support program was prepared based on SR and used in intervention for promoting SR for 3 months. Analysis: Language and behavior representing behavioral changes were analyzed in self‐monitoring, self‐judgment and self‐reaction during the course of SR in the group that successfully achieved SR.

**Results**: Self‐monitoring: The patients could achieve their goals by recording their actions and adopted behavior such as increasing the amount of walking and adjusting meal contents. Self‐judgment: The patients experienced the importance of diet and understood the value of recuperative behavior based on statements indicating that they were praised by friends for having lost weight or that their blood sugar levels had gone up due to the amount of food eaten and meal contents. They also had a sense of achievement an experienced success when the number of steps on their pedometer increased, and all patients led their lives with an awareness of changes in body weight and HbA1c levels. Self‐reaction: The patients found value in striving towards a goal and adopted recuperative behavior through internal attribution in the form of behaving in a certain way for one\'s own benefit. Changes in Hb1Ac Level: Hb1Ac level was observed to improve by 0.1% to 2.1% in 10 of the 14 patients.

**Discussion**: There were many members of a group of patients who achieved SR who succeeded in improving Hb1Ac levels as a result of reflecting back on their behavior at the stage of self‐monitoring, and this is thought to have resulted in a successful experience that caused the patients to find value in their recuperative behavior while also obtaining the positive self‐reaction of taking responsibility for controlling their own Hb1Ac level.
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**K. Fujiwara, T. Matsuoka, D. Fujiwara, S. Kamei, M. Tomono, J. Hirohata, Y. Yasuda and T. Takechi**

Kurashiki Central Hospital, Kurashiki Okayama, Japan

**Aim**: Our hospital is an acute hospital with 1166 beds. We established DIST (Diabetes Inpatient Support Team) to improve blood glucose control at the perioperative period. Therefore we evaluate the activity effect of DIST and will report it.

**Methods**: DIST member is consists of diabetic specialist, diabetic certificated nurse, certificated dietician, pharmacist and clerks, DIST conference is held twice a week, every Tuesday and Friday. DIST conference is performed intervention for glycemic control by extracting patients out of all patients with poor blood glucose control (voluntary blood glucose over 200 mg/dl or HbA1c over 7.0%) in surgical wards (digestive surgery, orthopedics, respiratory surgery, cardiovascular surgery, brain surgery, otolaryngology, plastic surgery, urology, gynecology). We evaluated the glycemic improvement with blood glucose level before breakfast at hospitalization (before intervention) and before discharge (after intervention) and also indicated the number of diabetes diagnosed for the first time by DIST conference.

**Results**: The number of objective patients was 137 (78 males and 59 females) in DIST conference during 2017, with mean age 73 years, mean HbA1c 6.4%, mean blood glucose 214 mg/dl. Main contents of the intervention (more than one) were diabetes internal medicine visit: 53 cases, HbA1c measurement: 31 cases, blood glucose measurement: 24 cases, and there were other changes in meals, introduction of outpatient visits, foot care etc. The blood glucose change after DIST intervention significantly improved with average improvement blood glucose at −22.5 mg / dl and blood glucose improvement rate at 11.1%. Eleven out of 46 patients who were considered to have no diabetes at the DIST conference were diagnosed with diabetes mellitus and were able to lead to diabetes intervention.

**Conclusion**: DIST conference afforded not only the perioperative glycemic improvement, but also the newly diagnosed of diabetes mellitus to the patient who has not been pointed out.
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**K. Yokota and A. Fujita**

Hannan Municipal Hospital, Hannan City Osaka, Japan

**Objective**: To create and evaluate a 'self‐foot‐care educational program (SFCEP)' for prevention of type 2 diabetes foot disease and aggravation of foot ulceration.

**Methods**: This study was designed as a single‐center, exploratory, and randomized controlled trial. Patients with type 2 DM were assigned to either an SFCEP group or a conventional education program (CEP) group. According to each program, they received foot‐care education that was conducted once a month for four times in the SFCEP group but only one time in the CEP group. For the trails, 29 patients with type 2 DM were randomized to the SFCEP group and 26 patients with type 2 DM were similarly assigned to the CEP group. No significant difference in patient background regarding type 2 history existed between the groups. We evaluated foot‐care confidence points at 3 months and 6 months as the primary endpoints; secondary endpoints were self‐monitoring ability points, self‐foot‐care score, removal rate of skin debris after washing with detergent, and foot‐skin symptoms (dryness, coldness, numbness, appearance) at 3 months and 6 months.

**Results**: Foot‐care self‐confidence points of the SFCEP vs. CEP group at the time before education, 3 months later, and 6 months later were 1418 vs. 1477, 1473 vs. 1426, and 1510 vs. 1092, respectively (*P *\< 0.0001). Removal rate of skin debris, after washing with detergent, of the SFCEP vs. CEP group was 68.5 + /‐ 12.25% vs. 53.1 + /‐ 17.84% (*P* = 0.045). Significant differences were observed in foot symptoms and conditions in the feeling of dryness and cooling of the feet in the SFCEP group. Furthermore, appropriate foot‐care behavior was observed in this intervention group, with the participants customizing their own techniques of foot care.

**Conclusion**: This study confirms that SFCEP enhances foot‐care self‐confidence and self‐monitoring ability, raises the degree of skin cleaning (removal rate of skin debris), and improves foot‐skin conditions, compared with CEP. These capabilities strongly imply the effectiveness of SFCEP in preventing the occurrence or worsening of diabetic foot diseases.
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**K. Okazaki, N. Takahashi and M. Suematsu**

Nagoya University, Nagoya, Japan

Diabetes related distress is common for patients with type 2 diabetes (T2D), which exacerbates glycemic control through negative effects on emotional and physical well‐being and self‐care behaviors. Diabetes Distress Scale (DDS) is a widely used instrument to measure diabetes related distress. The aim of this study was to develop the Japanese version of the DDS (DDS‐J) and examine its psychometric properties. DDS‐J was developed conceptually equivalent to the original English version by forward and backward translations and adjustments of inappropriate terms. The investigation was conducted in 204 T2D patients at outpatient department of 2 hospitals in Aichi, Japan from February to May 2017. Cronbach\'s α was used to assess reliability, and factor analysis to analyze validity. The 5‐item World Health Organization Well‐Being Index (WHO‐5) and Patient Health Questionnaire‐9 (PHQ‐9) scale were adopted to evaluate the criteria‐related validity. The scores of DDS‐J, WHO‐5 and PHQ‐9 were calculated, then their relationship analyzed using Pearson correlation analysis. Of the studied patients, mean age was 64.0 years‐old, 62.3% were male, mean duration of T2D was 13.3 year, and mean HbA1c was 7.6%. Among them, 17.9% were treated with any kinds of injection therapy. Four factors of regimen‐related distress (RD), emotional burden (EB), physician‐related distress (PD), and diabetes‐related interpersonal distress (ID) were extracted by exploratory factor analysis. This factor structure was the same as the original one. The overall Cronbach\'s α was 0.91, while ones for RD, EB, PD, and ID were 0.86, 0.87, 0.73 and 0.86, respectively. The test‐retest reliability using intraclass correlation was 0.68. The total DDS‐J score was 24.4 ± 18.7, WHO‐5 15.3 ± 5.4 and PHQ‐9 3.5 ± 4.4 (mean ± SD). The total DDS‐J score showed a weak but significant correlation with WHO‐5 (*r* = −0.376, *P *\< 0.01) and PHQ‐9 (*r* = 0.425, *P *\< 0.01). In conclusion, DDS‐J have good validity and reliability, and can be used as an effective tool to assess diabetes related distress of Japanese adult T2D patients. Furthermore, diabetes related distress is associated with well‐being and depression in the studied patients.
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**P. Ling^1^, S. Luo^1^, J. Yan^1^, X. Zheng^1^, D. Yang^1^, X. Zeng^2^ and J. Weng^1^**
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**Objective**: To assess the effectiveness of mobile health application TangTangQuan (TTQ) in management of type 1 diabetes (T1D) in China.

**Methods**: TTQ is designed to provide diabetes self‐management education (DSME) for patients with T1D. The innovation of TTQ is to break the isolation of individual T1D patients by socializing their self‐management data, and let them find the "patients like me". TTQ included four major modules: personal diabetes diary, games for DSME, peer support communities and online education courses. Patients recorded and uploaded their diabetes diary via TTQ, and peer patients or family members were able to make comments, or share their own experiences, or interact with the up loaders under the posts. Free download and registration of TTQ was available in major APP stores for mobiles in China since September 2015. The self‐report demographic and clinical data were collected through TQQ.

**Results**: During September 2015 and July 2018, a total of 11,064 patients (M/F,5385/5679) aged 21.18 ± 14.74 yrs, with duration of T1D 1.63(0.48,7.37)yrs, have signed up and joined the management of TTQ, from 21 provinces in China and there were 25.82% newly diagnosed patients. Fifty two percent were 18 to 45 yrs old whose HbA1c were 6.58 ± 1.53% and 42.32% were less than 18 yrs old whose HbA1c were 6.71 ± 1.85%. Thirty one percent of them were active in peer support communities including sharing their experiences in management of T1D. Among 5709 patients with duration of diabetes ≥1 year who have used TTQ for ≥1 year, SMBG frequency was 1.25/week (0.25, 6.25)/week and 1.50/week (0.50,7.56)/week (*P *\< 0.001), HbA1c was 6.68 ± 1.79% and 6.32 ± 1.40%(*P *\< 0.001), the frequency of hypoglycemia was 5.00/week (2.75, 8.75) and 4.75/week (2.75,7.75) (*P* = 0.019) before and after one year use of TTQ, respectively.

**Conclusions**: TTQ has the potential to be a novel intervention for engaging T1D patients and their families in positive communication to support DSME.
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**X. Chang^1^, L. Guo^2^**

^1^Peking Union Medical College, Beijing, China, ^2^Beijing Hospital, Beijing, China

**Objective**: To explore the relationship between lipids profile and body composition in the old adults.

**Method**: The relationship between body composition and lipids profile was examined in 181 adults (60--88 years, 67 males, 114 females). According to the results of body composition, hand grip strength, and body mass index, they were assigned to four groups: Normal (N, *n* = 75), Sarcopenia (S, *n* = 16), Obesity (O, *n* = 69), Sarcopenic Obesity (SO, *n* = 21). The lipids profile of four groups were analyzed.

**Results**: The prevalence of sarcopenia and sarcopenic obesity in participants were 16.4%, 7.5% in male and 22.8%, 14.0% in female, respectively. Only high density lipoprotein‐cholesterol (HDL‐C) level and the prevalence of low HDL‐C had a significant difference among four groups. The level of HDL‐C: SO \< O \<S \<N, the prevalence of low HDL‐C: SO \>O\>S\>N. In a multiple logistic regression analysis, the odds ratio for low level of HDL‐C risk increased in group SO\[compared to group N, the odds ratio in group SO were 5.120 (1.267--20.694). After adjusting for age and sex, the odds ratio for low level of HDL‐C risk was still higher in group SO \[compared to group N, the odds ratio was 5.173 (0.999--26.796)\].

**Conclusion**: Sarcopenic obesity patients had a lower level of HDL‐C in old adults, body composition may be a new target for intervention of dyslipidemia.
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**M. Islam and S. Mansoor**

Department of Biochemistry, University of Kwazulu‐Natal, Durban, South Africa

**Background**: Overweight, obese and type 2 diabetic patients usually try to control their calorie intake from sugar and consume nonnutritive sweeteners (NNS) for the management of hyperglycemia as well as type 2 diabetes (T2D). Acesulfame‐K, Aspartame, Neotame, Saccharin and Sucralose are some of the most widely consumed sweeteners all over the world. However there is an ongoing debate regarding the safety and their effects in the people with metabolic diseases.

**Aim**: To investigate the possible anti‐oxidative and anti‐diabetic properties of some commonly used non‐nutritive sweeteners *in vitro*. Materials and

**Materials and Methods**: The antioxidant activity of 5 above‐mentioned NNS were determined by measuring their free radical scavenging activity (DPPH method), ferric (Fe^3+^) reducing antioxidant power (FRAP), nitric oxide (NO) and hydroxyl radical scavenging activity (HRS) assays. The inhibitory activity of sweeteners on some key enzymes linked to T2D and obesity such as α‐amylase, α‐glucosidase and lipase were also investigated. All assays were done in triplicate and carried out *in vitro*.

**Results**: Although most of the sweeteners demonstrated dose‐dependent anti‐oxidant activity via DPPH method, very low antioxidant activities were observed via FRAP, NO and HRS assays. However, most of the NNS showed significant lipase inhibitory effects, when only saccharin showed dose‐dependent and strong α‐glucosidase inhibitory effects. The activity of α‐amylase was not affected by any NNS.

**Conclusion**: The results of this study suggest that saccharin can be the most beneficial sweetener for overweight, obese or diabetic patients compared to others. However, further *in vivo* and clinical studies are needed to confirm these results.
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^1^Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, ^2^Division of Diabetes and Obesity, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, ^3^Clinical Research and Medical Innovation Center, Hokkaido University Hospital, Sapporo, Japan, ^4^Department of Psychiatry, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ^5^Institute for the Promotion of Business‐Regional Collaboration, Hokkaido University, Sapporo, Japan, ^6^Hokkaido Industrial Technology Center, Hakodate, Japan

**Background and Aims**: Red algae were reported to improve glucose and lipid metabolism in a rat model, but these effects have received little investigation. We focused on *Palmaria palmata*, a red alga that grows in the northern area of Japan, and investigated its effect on lipid metabolism and glycemic control in Japanese population. Materials and Methods

We conducted an 8‐week, randomized, double‐blind, placebo‐controlled, parallel group comparison trial. The study enrolled Japanese participants aged ≥20 years and \<60 years with LDL cholesterol (LDL‐C) ≥120 mg/dL. After providing informed consent, the participants were randomly assigned to take either capsules containing *P. palmata* 2 g/day (*P. palmata* group) or placebo capsule (Placebo group) just before their morning meal and dinner. The primary outcome was changed in LDL‐C from baseline to week 8. The secondary outcomes were changes in lipid profiles other than LDL‐C and glycemic control. The study protocol conformed with the principles of the Declaration of Helsinki. The study was registered at the University Hospital Medical Information Network (UMIN) Center under identifier UMIN 000028799.

**Results**: Among 110 participants initially enrolled, 109 (73 women; 36 men) were randomized for the trial. Of them, 103 participants completed the study protocol (*P. palmata* group: 51; placebo group: 52). Six subjects declined to participate in randomization and trial initiation. There were no significant differences in changes in LDL‐C, body mass index, waist circumference, HbA1c, nor fasting plasma glucose between the two groups. However, change in triglyceride (TG) showed significant improvement in female participants only (−9.0 (−25.0, 5.0) in *P. palmata* group vs. −1.0 (−11.0, 19.0) in the placebo group; *P* = 0.016). In *P. palmata* group, the changes in insulin (correlation coefficient = 0.43; *P* = 0.010), HOMA‐IR (correlation coefficient = 0.42; *P* = 0.013), and HOMA‐β (correlation coefficient = 0.36; *P* = 0.036) had significant positive correlations with change in TG.

**Conclusions**: The present study showed that *P. palmata* had little effect on LDL‐C or glycemic control. However, TG levels could be ameliorated by administration of *P. palmata* in women.
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**C. Phawinpon, T. Yotsapon, W. Kewalin, S. Patitta, D. Onwara, C. Panita, K. Sallaya and H. Thep**

Diabetes and Thyroid Center, Theptarin Hospital, Bangkok, Thailand

**Background and Objectives**: Current diet research has recently shifted from a traditional focus on the role of single nutrients to emphasis on dietary patterns. However, no previous diet quality data were reported in Thai food. Therefore, this study is aimed to examine how scores on 3 previously published diet quality indices -- Thai Healthy Eating Index (THEI), Alternative Healthy Eating Index 2010 (AHEI2010), and American Diabetes Association (ADA) dietary score are related to nutrients composition and glycemic control among Thai people with type 2 diabetes mellitus (T2DM). Materials and

**Methods**: A cross‐sectional study of dietary intakes based on 3‐day food records were done in outpatients with T2DM at Theptarin hospital, Bangkok. We used 3 validated dietary quality scoring systems to evaluate dietary quality. Each individual index component was scored with a higher score reflecting greater adherence to dietary recommendations. Then, we classified each index score into quartile or category and examine its relationship with nutrients composition and glycemic control.

**Results**: A total of 213 diabetes patients (females 49%, mean age 58.4 ± 10.5 years, BMI 26.8 ± 4.6 kg/m^2^, duration of diabetes 12 ± 9 years, A1C 7.1 ± 1.2%, insulin treatment 19%) participated in this study. The mean THEI score was 52.6 ± 10.5 out of 110, the mean modified AHEI2010 score was 25.7 ± 8.6 out of 80, and the mean ADA dietary score was 4.8 ± 1.6 out of 10. Only 42% of patients were classified as fair to good classification according to THEI. No association and agreement were found between these indices (Pearson\'s correlation \< 0.3, Cronbach\'s alpha 0.148). When comparing between quartile 1 and 4, only THEI can discriminate amounts of total fat, saturated fat and sodium intake. No association was found between glycemic control and dietary quality scoring systems.

**Conclusions**: Our results revealed that food‐based dietary indices could highlight the area of weakness for dietary intakes of Thai T2DM. THEI is the only one scoring system which could reflect dietary fat intake. Further studies should be done to explore the clinical utility of THEI in predicting diabetic complications and/or as a tool to measure the effect of dietary interventions.
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**Background**: Dietary assessments for estimating nutrient intakes are the foundation of nutrition‐related research. While the 24‐h recall is commonly used in a large cross‐sectional survey; underreporting of food intake by dietary recall had been a consistent finding in previous studies from Western population. Whether these two methodological differences affect reliability data in Thai patients with type 2 diabetes mellitus (T2DM) is unknown.

**Objectives**: The purpose of this study is to compare the mean nutrient intakes calculated from 24‐h recalls compared with 3‐day food records in Thai patients with T2DM. Materials and

**Methods**: A cross‐sectional study of outpatients with T2DM in Theptarin hospital, Bangkok was done with estimated dietary nutrients intake data from 3‐day food record (2 workdays and 1 weekend day). All food records were analyzed for nutrient intake using the INMUCAL software, which was developed by the Institute of Nutrition, Mahidol University. Trained dietitians also conducted face‐to‐face interviews to collect dietary data within a past 24 h. Correlations between two methods were evaluated.

**Results**: A total of 194 diabetes patients (females 48%, mean age 58.8 ± 10.2 years, BMI 26.6 ± 4.5 kg/m^2^, baseline A1C 7.0 ± 1.2%, insulin treatment 20%) participated in the study. According to 3‐day food record, the average energy intake was 1491 ± 447 Kcal with percentages of energy from carbohydrate, protein, and fat were 51%, 17%, and 31%, respectively. No statistical significant were found in means of energy, carbohydrate, protein, fat, saturated fat, added sugar and fiber between 2 methods. However, a 24‐h food recall modest underestimated mean sodium intake (2960 g VS. 3243 g, *P* = 0.019) and overestimated added sugar (46 g VS. 41 g, *P* = 0.018) when compared with 3‐day food records. Additionally, the 24‐h food recall and 3‐day food record showed limit agreement (*rc* \< 0.5) on all calculated results.

**Conclusions**: A simple 24‐h recall by trained dietitians could estimate group means of energy, macronutrient intakes, and fiber with adequate reliability when compared with 3‐day food records but not suitable for individual level. Further investigation in developing validated diabetes‐specific food frequency questionnaire should be done to estimate long‐term dietary consumption among Thai diabetic patients.
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**Background**: Despite the known importance of diet modification, many adults with type 2 diabetes mellitus (T2DM) struggle to adopt and maintain a clinically recommended diet. The food exchange system group similar foods, which based on nutrient composition, together into "exchange" groups, so that one may be exchanged for another in the same group. The Thai food exchange system is published since 2004; however, there has been little research done to validate its clinical utility especially in T2DM.

**Objectives**: This study aimed to compare estimated macronutrient intakes between food exchange system with dietary data analyzed with the food composition table from the INMUCAL software (Institute of Nutrition, Mahidol University) among Thai T2DM. Materials and

**Methods**: 3‐day food records from a cross‐sectional study in outpatients with T2DM at Theptarin hospital, Bangkok were analyzed for estimated nutrients intakes with the INMUCAL software. The diet records were re‐analyzed by Thai food exchange system. Paired t‐test, Bland‐Altman plots, and Lin\'s Concordance Correlation Coefficient (LCCC) were performed to assess the agreement and validity of the Thai food exchange system.

**Results**: A total of 213 diabetes patients (females 49%, mean age 58.4 ± 10.5 years, body mass index 26.8 ± 4.6 kg/m^2^, median duration of diabetes 10 years, baseline A1C 7.1 ± 1.2%, insulin treatment 19%) participated in the study. According to analysis of INMUCAL, the mean calorie intake was 1,494 ± 439 kcal/day and mean intake for carbohydrate, protein, fat was 188 ± 56 g, 64 ± 22 g, and 53 ± 21 g respectively. The analysis of Thai food exchange system revealed that calculated dietary intakes were comparable with the results from INMUCAL (mean calories intake 1,552 ± 453 kcal/day, carbohydrate 199 ± 62 g, protein 68 ± 23 g and fat 54 ± 21 g. No significant differences were found between the results of two methods. The Bland‐Altman plots and the LCCC demonstrated strong agreement for each macronutrient (*rc* \> 0.8).

**Conclusions**: Apart from helping individual diabetic patients monitor their food portion sizes and give variety to structured meal plan, the food exchange systems are comparable to INMUCAL and useful for dietitians as a simple tool to dietary assessment in both individual level and epidemiological nutritional research.
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**Background**: Diabetes patients are at much higher risk for fracture compared with patients without diabetes who have the same bone mineral density scores. Suboptimal dietary calcium intake affected the peak bone mass in young people and the retention of bone mass in adults. Maintaining a calcium intake of at least 1,000--1,200 mg/day had been recommended; however, the recent systematic review revealed that many countries in Asia have average dietary calcium intake less than 500 mg/day and poor vitamin D status. Whether this alarming situation occurs in Thai type 2 diabetes is unknown.

**Objectives**: This study aimed to clarify estimated dietary calcium intake data among Thai patients with type 2 diabetes. Materials and

**Methods**: A cross‐sectional study of outpatients with T2DM in Theptarin hospital, Bangkok was done with estimated dietary calcium intake data from 72‐h food record. All food records were analyzed for nutrient intake using the INMUCAL software, which was developed by the Institute of Nutrition, Mahidol University. Correlation between calcium intake and other parameters were also evaluated.

**Results**: A total of 213 diabetes patients (females 49%, mean age 58.4 ± 10.5 years, body mass index 26.8 ± 4.6 kg/m^2^, median duration of diabetes 10 years, baseline A1C 7.1 ± 1.2%, insulin treatment 19%) participated in the study. The mean calorie intake was 1,504 ± 430 kcal/d and mean intake for each macronutrient was acceptable (Carbohydrate 51%, Protein 17%, Fat 32%). However, the mean intake of estimated dietary calcium was at only 366 ± 164 mg/day and only 0.5% of patients could consume at least 1,000 mg/day from dietary sources. No association was found between calcium intake and age, gender, socioeconomic status, total energy intake, or glycemic control.

**Conclusions**: This study draws attention to high‐risk patients where calcium intake needs to be assessed and continued efforts are needed to increase calcium intake in diabetic patients. Nationally representative data of estimated calcium intake focused on diabetic patients should be surveyed and calcium supplements might be necessary to preserve bone health in diabetic patients.
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**R. Watase, K. Ohashi, K. Ono and A. Ishikawa**

Kobe University, Kobe Hyogo, Japan

**Purpose**: Although many studies have shown glucose‐lowering action with exercise, some diabetic patients cannot do exercises due to the effect of complications. Stretching is one of the low‐load exercises for diabetics; however, few studies have reported on the effects of stretching on the glucose‐lowering action. Therefore, the purpose of this study was to obtain the fundamental data about the effects of static stretching on the glucose‐lowering action.

**Methods**: This study recruited 14 healthy young adult men (21.4 ± 1.0 years; mean age ± standard deviation). First, they kept sitting for 15 min. Then, they immediately took a 350 ml can of carbonated beverage containing about 40 g carbohydrates and kept sitting for 30 min. Finally, they performed passive static stretching or kept rested in decubitus position for 30 min. We set four conditions: stretching of the whole body, stretching of the upper body, stretching of the lower body, and keeping at rest in decubitus position, randomly. The muscles were stretched manually for 30 s. We set the interval relaxation period for 15 s. The stretching was performed until maximum tension without pain. They measured blood glucose three times by themselves: fasting phase, 30 min after taking the beverage, and just after stretching phase.

**Results**: Blood glucose 30 min after taking the beverage increased significantly compared to fasting phase (*P *\< 0.01) in all conditions. Blood glucose after stretching phase decreased significantly compared to 30 min after taking the beverage (*P *\< 0.01) in all conditions. Fasting blood glucose had no significant differences compared to after stretching phase. Changes in blood glucose had no significant differences in all conditions. Because the subjects were healthy young adult men who were able to inhibit too much reduction of blood glucose level by stretching, the same alteration of blood glucose levels in all conditions was observed.

**Conclusion**: These results suggested that the glucose‐lowering action by 30 min passive static stretching was similar to keeping at rest in decubitus position in healthy young adult men who took about 40 g carbohydrates regardless of the parts of stretching.
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^1^Department of Dietetics, National Taiwan University Hospital Hsin‐chu Branch, Hsinchu City, Chinese Taipei, ^2^Department of Family Medicine, National Taiwan University Hospital Hsin‐Chu Branch, Hsinchu City, Chinese Taipei

Malnutrition has been associated with adverse outcomes such as functional disability, morbidity, mortality, and longer stays in the hospital. It is also a risk factor for frailty, particularly in older people. Diabetic patients compared to non‐diabetics were characterized by an increased incidence of malnutrition and decreased survival rate. Physical function and psychological factors apparently contribute to dietary condition. Identification of those related status and treatment of malnutrition earlier can lead to improved clinical outcomes. The dietary intake, functional and psychological condition, and other related factors may need to be investigated for older patients with type 2 diabetes mellitus (DM) who were hospitalized and malnourished.

**Objective**: We compared the differences of functional and depression status of geriatric malnutrition patients screened by Mini Nutritional Assessment (MNA) tool and Nutrition Risk Screening 2002 (NRS 2002) with or without diabetes mellitus.

**Methods**: We screened all hospitalized patients aged 65 years or older by Mini Nutritional Assessment (MNA) and Nutrition Risk Screening 2002 (NRS 2002) from April to November of 2014 and excluded patients with confusion, terminal cancer and non‐malnutrition caused by hypoalbuminuria. A total of 374 patients were screened and asked for attending the project if they were malnourished from screening. There were 160 patients included and their demographic characteristics, 3‐day 24‐h diet recalls, anthropometric and biochemical data, Activities of Daily Living (ADL) results and The Geriatric Depression Scale (GDS‐SF) scores were collected and analyzed.

**Results**: The mean age of 160 subjects (84 men and 76 women) was 77.0 ± 6.8 years old. According to ADL and GDS‐SF results, 43.5% of the patients were functionally dependent and 47.5% of them were with mild to severe depression. The results showed that body mass index (BMI), mid‐arm circumference (MAC) were significantly different between diabetes and non‐diabetes geriatric patients (*P *\< 0.01 and *P *\< 0.05 respectively). However, patients' ADL and GDS‐SF scores were not shown differences between these two groups.

**Conclusions**: About half of the hospitalized geriatric patients had functional and depressive problems and those were related to their nutritional status. However, it showed no differences of functional and psychosocial status for malnutrition patients with or without diabetes.
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^1^Kobe University Graduate School of Health Sciences, Kobe Hyogo, Japan, ^2^Division of Rehabilitation, Department of Clinical Practice and Support, Hiroshima University Hospital, Hiroshima, Japan, ^3^Kobe University Hospital, Diabetes and Endocrinology, Kobe Hyogo, Japan, ^4^Kobe University Graduate School of Medicine, Department of Internal Medicine Division of Diabetes and Endocrinology, Kobe Hyogo, Japan

**Purpose**: About 422 million adults were living with diabetes in 2014 globally according to the World Health Organization. One of the fundamental treatments for diabetes is exercise therapy. Diabetic nephropathy is one of the most important diabetic complications. We needed to consider the intensity of the exercise for diabetes patients with renal dysfunction. We focused on the exercise environment in the viewpoints of the change of hemodynamics affected by water pressure. Liver‐type fatty acid binding protein (L‐FABP) is newly developed renal function test. The purpose of this study was to clarify the effects of 4‐week underwater treadmill walking on L‐FABP among type 2 diabetes patients with depressed renal function.

**Methods**: Four type 2 diabetes patients (mean age: 55.5 years old, three males and one female) with renal dysfunction \[estimated glomerular filtration rate (eGFR) \< 90 mL/min/1.73 m^2^\] participated voluntarily in this study. They walked on the treadmill belt at 40% VO2 max for 30 min twice a week for 4 weeks. Two conditions were set: exercise in the water (W‐condition) and exercise on the ground (C‐condition). This was a randomized, crossover trial. The water depth and temperature in the W‐condition were set below the xiphoid process level and about 30°C, respectively. Urine was collected before and after the 4‐week walking program intervention in each condition.

**Results**: There were one stage G2 patient (eGFR: 60--89) and three stage G3a patients (eGFR: 45--59) in this study. The pre‐ and post‐intervention mean L‐FABP in the W‐condition was 4.48 and 3.95 μg/gCr, and that in C‐condition were 6.43 and 9.78 μg/gCr. We observed increased L‐FABP in two patients and decreased L‐FABP in two patients in the W‐condition, whereas L‐FABP was increased in all patients in the C‐condition.

**Conclusion**: Renal blood flow seemed to be maintained during exercise in water. As diabetes patients suffer from diabetic nephropathy, underwater walking to improve blood glucose control could be beneficial.
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**Objective**: Malnutrition is an independent determinant of morbidity and mortality in haemodialysis patients. Diabetes is the most common cause of end‐stage renal disease. This study aims to investigate the correlations between diabetes (DM) status and nutritional markers in maintenance haemodialysis patients.

**Method**: We studied patients \<1 year of vintage at the time of joining NKFS. For this study, we included patients who joined NKFS from January 2014 to December 2017. At the time of joining, dietitians assessed patient\'s nutritional status, which included Subjective Global Assessment (SGA), body mass index (BMI), handgrip strength (HGS), self‐reported appetite and activities of daily living (ADL). SGA ≤ 5 was classified as malnourished. The patients included in this study had their blood tested for albumin, normalised protein catabolic rate (nPCR), potassium, phosphate, pre‐urea and pre‐creatinine within 2 months after joining NKFS. Independent T‐test and One‐way ANOVA were performed to test for differences between DM status and nutritional markers, Chi‐square was performed to look at relation between DM status and nutritional status. Significance level was set at *P *\< 0.05.

**Result**: Of the 1626 haemodialysis patients, 63.7% are aged ≥60 year‐old, 55.2% male, 57.2% Chinese and 75.7% are diabetes. BMI was significantly higher in diabetic patients (DM:24.4 ± 4.84 kg/m2 vs. Non‐DM:22.5 ± 4.64 kg/m2, *P* = 0.000). Albumin (DM:36.0 ± 3.45 g/L vs. Non‐DM:37.1 ± 3.35 g/L, *P* = 0.000), nPCR (DM:0.95 ± 0.25 g/kg/d vs. Non‐DM:1.03 ± 0.26 g/kg/d, *P* = 0.000), phosphate (DM:4.6 ± 1.40 mg/dL vs. Non‐DM:4.8 ± 1.49 mg/dL, *P* = 0.034), pre‐urea (DM:116.2 ± 35.08 mg/dL vs. Non‐DM:125.6 ± 35.67 mg/dL, *P* = 0.000) and pre‐creatinine (DM:6.8 ± 1.96 mg/dL vs. Non‐DM:8.2 ± 2.38 mg/dL, *P* = 0.000) showed that they were significantly lower in diabetic patients. There was no significant difference found between potassium for both groups (*P* = 0.774). HGS for both hands were significantly lower in diabetic patients (Left:DM:8.5 ± 6.56 kg vs. Non‐DM:11.4 ± 8.13 kg, *P* = 0.000; Right:DM:10.7 ± 7.02 kg vs. Non‐DM:13.2 ± 8.21 kg, *P* = 0.00). Diabetic patients also reported significantly poorer appetite (*P* = 0.000), more likely to be ADL dependent (*P* = 0.000), and higher risk of being malnourished (*P* = 0.000), compared to non‐diabetic patients.

**Conclusion**: This study shown that diabetic patients undergoing haemodialysis are at higher risk of malnutrition. They presented with significantly lower HGS, SGA score and nutritional‐related biochemical markers than non‐diabetic patients. Diabetic patients undergoing haemodialysis also has decreased appetite and ADL dependence. Timely intervention to address patient\'s barriers that limit dietary intake may improve nutritional status in these patients.
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**Aim**: The aim of this study was to investigate the osteoporosis prevalence and the risks of postmenopausal women and elderly men in Gansu province.

**Method**: This cross‐sectional study involved 3359 postmenopausal women and 3205 elderly males who were randomly selected from 7 areas in Gansu province. Areal bone mineral density (BMD) (g/cm^2^) was measured at the distal one‐third radius of the non‐stressed forearm using dual‐energy X‐ray absorptiometry (DXA: Osteometer MediTech). Factors related to osteoporosis were analyzed.

**Results**: The prevalence of osteoporosis in the entire study population was 9.65% for postmenopausal women and 8.08% for elderly males by WHO criteria, while the rate of osteopenia were 27.09% for postmenopausal women and 26.68% for elderly males. Risk of osteoporosis was significantly associated with age, menopause age, duration of menopause, body mass index (BMI), educational level, and alcohol consumption in postmenopausal women. In elderly men, age, BMI, current smoking, alcohol consumption, physical activity, and sun exposure were associated with osteoporosis. The bone turnover markers osteocalcin (OC) and C‐terminal cross‐linked telopeptides of type I collagen (b‐CTX) were inversely correlated with BMD in both genders; serum P and 25(OH)D had no significant correlation with BMD. Serum Ca showed a positive effect on BMD in elderly men only.

**Conclusion**: The osteoporosis prevalence of postmenopausal women and the men aged over 60 years in Gansu province is presented. Risk of osteoporosis was significantly associated with age, menopause age, years since menopause, BMI, and educational level in postmenopausal women. In elderly men, age, BMI, and current smoking were associated with osteoporosis. This study also found that higher OC and b‐CTX level were associated with lower BMD. Poor 25(OH)D, Ca, P status were not associated with an increased risk of low BMD.
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**Z. Lim, C. Lee, Z. H. Liang, C. F. Yee and C. H. Lim**

Dietetics Department, The National Kidney Foundation ^NKFS^, Singapore

**Objective**: Anorexia, presence of GI symptoms, chewing and swallowing problems are common amongst haemodialysis (HD) patients. These factors are associated with inadequate dietary intake which is the main etiology of malnutrition. Meanwhile, various studies have shown that diabetic status pose increased risk in malnutrition. This study investigated the impact of self‐reported factors (appetite, gastrointestinal symptoms, chewing and swallowing function) on nutritional status of diabetic HD patients.

**Method**: Diabetic patients who have dialysis vintage \<1 year at the point of joining The National Kidney Foundation Singapore (NKFS) from July 2014 to June 2015 were included. Subjective Global Assessment (SGA) scores and body mass index (BMI) were assessed by dietitians and self‐reported factors were collected at the point of joining NKFS. Serum albumin (S‐Alb) was collected within 2 months after patients joined NKFS. SGA score ≤5 was categorized as malnourished. Independent T‐test and Mann‐Whitney U test were used to study the impact of self‐reported factors on nutrition markers. Significance level was set at *P *\< 0.05.

**Results**: 268 diabetic HD patients were included in this study (67.5% aged ≥60 year‐old, 57.5% male, 57.1% Chinese, average BMI = 24.6 kg/m^2^). 32.8% of patients reported fair to poor appetite; 43.3% reported fair to poor chewing function; 5.2% reported fair to poor swallowing function and 6% reported gastrointestinal (GI) symptoms. 23.5% has S‐Alb below 35 g/L and 53.7% were malnourished with SGA ≤5. We found that diabetic HD patients with poorer appetite have significantly lower S‐Alb (Good:37.2 ± 3.5 g/L vs. Fair to poor:36.1 ± 3.0 g/L, *P* = 0.011) and higher chance to have SGA score ≤5 (*P* = 0.000). Meanwhile, no significant associations were found between other self‐reported factors with nutritional status of these patients.

**Conclusion**: In conclusion, diabetic HD patients with poorer appetite have increased risk of malnutrition and lower in S‐Alb. Both malnutrition and hypoalbuminemia in HD patients correlates strongly with mortality and morbidity. Thus, self‐reported appetite can be considered as simple, quick and cost‐effective nutritional screening tools to detect malnutrition in diabetic HD patients for early nutritional intervention. Further research is needed to investigate the relationship of disturbed appetite with overall food intake and nutritional outcomes of diabetic HD patients.
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**W. Jie, Y. Mo, Y. Li, D. Liu, Y. Hu, J. Dai, L. Chen, H. Wu and L. Chen**

Jiangsu Province Geriatric Institute, Nanjing, China

**Objective**: Low handgrip strength (HGS), as a marker of poor muscle strength, is linked to the prevalence of type 2 diabetes Mellitus (T2DM) which increase healthcare costs. Few studies have been reported among elderly people in China. The study was undertaken to investigate the association between HGS and prevalence of T2DM among Chinese elderly community people.

**Methods**: In a cross‐sectional design, 279 subjects aged over 60 years old were interviewed by a questionnaire and the DM diagnostic was self‐reported. Anthropometric measurements, such as sex, weight, height, body mass index (BMI), smoking, drinking, SBP, DBP, disease history and handgrip strength, were obtained by trained researcher. According to the tertiles of HGS, subjects were divided into three groups: low HGS group (*n* = 92), middle HGS group (*n* = 94) and high HGS group (*n* = 93). The ANOVA, χ^2^ test and logistic repression were performed to statistic analysis.

**Results**: The 279 subjects that were included in the study had a mean age of 72.43 ± 6.38 years, with 38.0% males (*n *= 106) and 62.0% females (*n *= 173). Mean BMI was 23.40 ± 3.14 kg/m^2^. BMI、SBP、DBP and prevalence of hypertension and heart disease were not significantly different between three groups. Lower HGS corresponded with increased age and higher prevalence of T2DM. Two logistic regression models were fitted to examine the association between HGS and T2DM. Individuals with 1 kg increased have 2.8% T2DM risk decreased after adjusting for age sex, and BMI (model 1, OR = 0.972,CI: 0.953--0.993, *P* = 0.010) and 3.3% T2DM risk decreased with further adjustment for smoking and drinking (model 2, OR = 0.967,CI: 0.944--0.989, *P* = 0.005).

**Conclusions**: Higher HGS was associated with lower prevalence of T2DM among elderly community population. It suggests that handgrip strength may be investigated as a target for intervention or a marker to identify people at risk of type 2 diabetes mellitus. Health professionals should encourage activities to preserve muscle strength, thereby preventing incidence of diabetes in older community people.
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Impact of lifestyle modifications on obesity parameters at different time intervals in newly diagnosed patients with type 2 diabetes mellitus {#jdi12939-sec-0728}
---------------------------------------------------------------------------------------------------------------------------------------------

**H. Kour, S. Goudar and V. A. Kothiwale**

J.N Medical College, Belagavi, India

**Background**: Central obesity is a significant predictor of development in type 2 diabetes mellitus and is associated with four fold increased in relative risk of diabetes among young adults. Exercise is considered as one of the three cornerstones of management of diabetes. Hence, the present study was carried out to evaluate the impact of lifestyle modifications on obesity parameters in young adults with newly diagnosed type 2 diabetes mellitus.

**Objectives**: To study the effects of six months structured exercise therapy on anthropometric and biochemical parameters in young adults with newly diagnosed T2DM on dietary control and anti‐diabetic drug of age group 20--45 years.

**Methods**: The present study was conducted in the Research Laboratory, Department of Physiology, J.N Medical College, KAHER, Belagavi. Institutional Ethics Committee Approval and individual Informed consent was obtained. The total of 148 patients were enrolled as per inclusion criteria and then randomly divided into Diabetic group and Interventional Group. The Primary Outcome measures were BMI, Body Fat%, WHR, HbA1c and Lipid Profile. The intervention therapy was six months of individually designed program consisting of aerobic and resistance exercises. First two weeks of the regimen consisted of supervised exercise training in Research Laboratory, Department of Physiology. Later on the participants were advised to continue the exercise at their home regularly. Difference between two groups for categorical data was evaluated by Chi‐square test. Differences between two groups for continuous data was evaluated by unpaired 't" test. Trends of improvement were evaluated by repeated measures of ANOVA. Analysis was carried out by IBM, SPSS. Statistics 22.0.

**Results**: Anthropometric determinants differed with a significant difference in BMI, waist circumference, WHR, HbA1c and Lipid Profile at 2nd month, 4th month and 6 months respectively (*P *\< 0.001). No significant difference was observed in Body Fat%.

**Conclusion**: Diabetic control in younger adults is a daunting challenge to the healthcare system. Exercise therapy along with dietary control and anti‐diabetic medication has a positive influence on anthropometric indices.

PP‐364 {#jdi12939-sec-0729}
======

Caffeine reduces oxidative stress in vitro and inhibits small intestinal glucose absorption and increases muscle glucose uptake ex vivo {#jdi12939-sec-0730}
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**M. Islam and R. Reddy**

University of Kwazulu‐Natal, Durban, South Africa

**Background**: Several reports have shown that consumption of coffee or caffeine containing drinks are associated with the reduction of type 2 diabetes (T2D) related symptoms, promotes weight loss and acts as an antioxidant. However the mechanisms behind these effects are still unclear. Aim: This study was aimed at investigating the anti‐oxidative, anti‐diabetic, and anti‐obesogenic potentials of caffeine by using several experimental models. Materials and

**Methods**: Caffeine was analyzed for its antioxidant activity vis‐à‐vis 2,2‐diphenyl‐1‐picrylhydrazyl (DPPH) scavenging activity, ferric reducing ability (FRAP) and nitric oxide scavenging ability; inhibition of key enzymes linked to T2D as well as its effect on oxidative enzymes in Fe^2+^‐induced oxidative stress in pancreatic tissue. Caffeine was also investigated for its role in the inhibition of small intestinal glucose absorption in isolated rat jejunum and muscle glucose uptake.

**Results**: The results show that caffeine exhibited strong concentration‐dependent anti‐oxidant potential, however it did not possess powerful α‐glucosidase, α‐amylase and anti‐lipase inhibitory effects. The results obtained showed that caffeine was an effective inhibitor of lipid peroxidation. It also increased muscle glucose uptake and decreased small intestinal glucose absorption under *ex vivo* condition.

**Conclusion**: Data of this study suggest that caffeine has the ability to ameliorate T2D‐associated symptoms and can be used in antidiabetic foods and food products. However, further studies with experimental animals and humans are warranted to confirm the results from this study.
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**Z. Jia^1^, H. Zhang^2^, M. Wang^1^, M. Zhang^1^, L. Fu^1^, H. Jiang^1^ and G. Zhang^3^**

^1^First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China, ^2^GetWell, Shenzhen, China, ^3^The Wellness Institute Powered by Seven Oaks General Hospital, Winnipeg Manitoba, Canada

**Purpose**: The aim of this study was to explore the application effect of portable muscle oxygen meter, heart rate monitor combined with mobile APP and exercise management platform in type 2 diabetes management.

**Methods**: Thirty‐four subjects, who were discharged from a general hospital during the period of May 2017 and June 2018, participated in this study. All of them were required to do fast walking or slow jogging 150 min each week for 24 consecutive weeks at home. They went to the health management center for four stages of 4‐min walk test on treadmill every two weeks, in which the heart rate and muscle oxygenation (SmO2) were captured and VO2 max was estimated. All the information was uploaded to the management platform automatically. The professionals modified the prescribed exercise based on the SmO2 change during test. The lab values were recorded before and after the intervention for comparison.

**Results**: The exercise time at home of this group was 312.78 ± 112.59 min/week, and all of them were returned to the health management center for treadmill test regularly as required. The VO2max was 8.75 ± 1.82 METs and 9.00 ± 1.74 METs before and after intervention respectively. The p‐values for glycated hemoglobin, fasting blood glucose, cholesterol, triglyceride, low‐density lipoprotein and high‐density lipoprotein were all less than 0.05. Also, the SmO2 performance was highly improved including the lowest value and total decline during the whole test. After intervention, the subjects were able to complete the test with lower heart rate and it increased slowly during the four stages with speed increased gradually compared with the initial test.

**Conclusion**: Heart rate, muscle oxygenation, glucose metabolism and lipid metabolism were improved after intervention. The results suggest that the combination of portable muscle oxygen meter, heart rate monitor and the management platform are effective for guiding the patients' long‐term exercise at home and will be of great significance to type 2 diabetes management.
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**K. Y. Tsoi^1^, W. H. Tam^2^, R. S. M. Chan^1^, M. A. Hanson^3^ and R. C. Wan Ma^1^**

^1^Department of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, ^2^Department of Obstetrics and Gynaecology, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, ^3^Institute of Developmental Sciences, Southampton University, UK

**Background**: Optimal maternal nutrition has a positive influence on the long‐term risk of non‐communicable diseases for the mothers and future generations. Early identification of malnutrition is important; however, administration of traditional dietary assessment requires trained personnel and is time consuming.

**Method**: A nutritional questionnaire was developed by International Federation of Gynaecology and Obstetrics (FIGO), including 9 closed‐end questions on diet quality and practice. Questions were translated to Traditional Chinese for this study use. The aim of the study was to evaluate the effectiveness of this nutritional questionnaire for assessing dietary quality and identifying dietary problems in early pregnancy. In this cross‐sectional study, healthy pregnant women between 12--14 weeks of gestation, were recruited from the antenatal clinic at the Prince of Wales Hospital. Women were invited to answer the FIGO nutritional questionnaire and completed a food frequency questionnaire (FFQ), which consisted of ˜200 local food. Background information, anthropometric measurements of the mothers were obtained. Mothers were followed up to examine for association with pregnancy outcome. Mann‐Whitney U Test was performed to study the correlation between FIGO nutritional questionnaire and FFQ.

**Results**: Ninety‐seven women were included in the analysis. The mean age was 32.0 ± 3.3, mean BMI 21.7 ± 3.49 and 40% were primigravida. The overall dietary intake was assessed by FFQ. The mean daily energy intake was 1978.9 ± 581.5 kcal, 50% had iron intake meeting the recommendation and only 24% had calcium intake meeting the recommendation. The intake of calcium was significantly associated with women who responded positive to the question "consume dairy products every day" in FIGO questionnaire (*P *\< 0.001). However, no association was found between calculated iron intake and responses to the question "eat meat or chicken 2--3 times per week" (*P* = 0.163) in FIGO nutritional questionnaire.

**Conclusion**: Inadequate calcium and iron intake in early pregnancy appear to be common among pregnant women in Hong Kong. The FIGO nutritional questionnaire could be a useful tool for healthcare professionals to identify important nutritional gaps in early pregnancy. Further analysis of dietary assessment and antenatal outcomes are currently on‐going. Acknowledgement: This study arose in part from the work of the FIGO Working Group on Adolescent, Preconception and Maternal Nutrition.
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**D. Mao^1^, L. Y. Yuen^1^, C. S. Ho^2^, C. C. Wang^1^, D. S. Sahota^1^, M. H. Chan^2^, T. T. Lao^1^, R. C. Ma^3^ and W. H. Tam^1^**

^1^Department of Obstetrics and Gynaecology, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR, ^2^Department of Chemical Pathology, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR, ^3^Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR

**Introduction**: We recently reported the effect in utero exposure to maternal hyperglycaemia on children\'s risk of abnormal glucose tolerance, obesity and higher blood pressure (BP) at 7 years of age in subjects who had joined Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study. The finding was reproduced in the multicentre HAPO follow up studies from 10 HAPO study centres when the children were 10--14 years of age. Vitamin D deficiency in pregnancy, which is prevalent in many countries, was shown to be associated with several adverse pregnancy outcomes and children\'s future health risk.

**Objective**: To investigate the association of maternal and umbilical cord vitamin D status with children\'s glycaemic levels at 7 years of age.

**Methods**: Mothers who had joined the HAPO study, along with their children were assessed 7 years post‐delivery for anthropometry, blood pressure (BP) and OGTT after an overnight fasting for 8 h. We assayed the mid‐gestation maternal serum and umbilical cord serum for total vitamin D (25‐OHD) levels, using a liquid chromatography tandem mass spectrometry method, which can separate the biological inactive 3‐epi‐25(OH)D3 from 25(OH)D3, an isomer commonly present in infants.

**Results**: The mean maternal and umbilical cord 25‐OHD levels were 56.2 ± 19.5 nmol/L and 42.8 ± 18.0 nmol/L respectively; 41.4% mothers were vitamin D deficient (25‐OHD levels \<50 nmol/L). Lower umbilical cord, but not maternal, 25‐OHD level was negatively associated with children\'s fasting and 120 min glucose levels of the OGTT, independent of maternal age, GDM status, GWG at pregnancy, mode of delivery, children\'s age and gender. The risk of prehypertension/hypertension (defined as BP ≥ 90^th^ percentile) was significantly lower \[adjusted odds ratio (95% CI) of 0.62 (0.41--0.95), with every 1 SD rise in the umbilical cord 25‐OHD level\] in boys, independent of the above confounders, as well as maternal hypertensive status at follow up.

**Discussion**: The result suggests that in utero vitamin D status may be an independent factor for children\'s future risk of hyperglycaemia and hypertension and there may be a gender effect. Further study is required to explore the association when the children grow older.
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**Y. Fujita^1^, N. Sakurai^2^, K. Ikeda^1^, F. Mano^1^, F. Furuya^1^, D. Shibata^3^, T. Ara^4^, N. Matsuo^1^, Y. Oguri^1^, H. Minamino^1^, N. Isomura^1^, T. Goto^4^, Y. Matsumura^5^, T. Kawada^4^ and N. Inagaki^1^**

^1^Department of Diabetes, Endocrinology and Nutrition, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ^2^Center for Information Biology, National Institute of Genetics, Mishima, Japan, ^3^Department of Technology Development, Kazusa DNA Research Institute, Kisarazu, Japan, ^4^Laboratory of Molecular Functions of Food, Division of Food Science and Biotechnology, Graduate School of Agriculture, Kyoto University, Uji, Japan, ^5^Laboratory of Quality Analysis and Assessment, Division of Agronomy and Horticultural Science, Graduate School of Agriculture, Kyoto University, Uji, Japan

Environmental factors such as excessive or imbalanced dietary intake have a critical role in the pathogenesis of life style‐related diseases including diabetes and obesity. Nutrition education contributes to the prevention of these diseases by improving dietary habits. However, it is difficult to obtain accurate data from individual dietary records. Novel biomarkers of dietary intake are required to accurately assess nutrition and nutrition education. Metabolomics is the ideal approach for the development of biomarkers of macronutrient intake. As a pilot study, we performed metabolomic analysis using human samples after test meal (Terumeal(R)). After intake of the test meal, increases and/or decreases in peaks detected by LC/MS analysis were distinguished in human plasma and urine samples. By annotation analysis, indicators of food composition including fruits and shellfish emerged in the human samples. Correlation analysis of the metabolomic data of the test meal itself and the human samples revealed that many components derived from Terumeal (R) could be detected, and that the values were altered time‐dependently after meal in human samples. Based on findings from this study, we established a protocol for the development of biomarkers of macronutrient intake by integrated analysis of metabolome data both in human samples and various food compositions. Next, we performed metabolomic analysis using human samples after rice or white bread as representatives of carbohydrate, a component of macronutrient. Samples in 8 healthy volunteers were taken 7 times over a period of 24 h. Evident increases in peaks by LC/MS analysis were detected after white bread intake, but were not detected after rice intake in human plasma samples. Components derived from white bread or its derivatives modified in the body were detected in human plasma samples after white bread intake. Thus, integrated analysis of metabolome data both in human samples and various food compositions revealed candidates for biomarkers of white bread intake. In conclusion, we found a novel approach for developing biomarkers of macronutrient intake. Our specific goal is to identify biomarkers of dietary intake that can be used clinically to evaluate nutrition education. Further development of biomarkers of macronutrient intake will be made possible by our approach.
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**Y. Lim^1^, Y. Park^2^, S. Ahn^2^ and J. Ohn^1^**

^1^Division of General Internal Medicine, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoungnam‐si, South Korea, ^2^Medical Research Collaborating Center, Seoul National University Bundang Hospital, Seoungnam‐si, South Korea

**Purpose of the Study**: Cumulative evidence suggests that coffee consumption may have beneficial effects on diabetes mellitus (DM). However, few studies have considered the types of coffee consumed and the additives used. Coffee prepared using instant coffee mix is the most common type of coffee consumed in Korea. The purpose of this study was to investigate the relationship between consumption of coffee and additives and the prevalence of DM.

**Methods**: We analyzed subjects, aged 19 years and older, using cross‐sectional data from the Korean National Health and Nutrition Examination Survey 2012--2016. Weighted subjects were 29,359,027. Coffee consumption level, types of coffee consumed, and the additives used were assessed based on a semi‐quantitative food frequency questionnaire. We compared general characteristics according to the status and frequency of coffee consumption using chi‐squared tests (for categorical variables) and ANOVA (for continuous variables).

**Results**: The mean of the highest quartile of coffee, syrup, and creamer amount was 44, 31, and 31 mL/week, respectively. The characteristics of the study subjects are presented as stratified by the amount of frequency of coffee, syrup, and creamer consumption. As the amount of coffee consumption increased, the amount of coffee additives increased. Frequent coffee drinkers tended to be older, current smokers, frequent alcohol drinkers. The amount of coffee, syrup, and creamer consumption was associated with higher levels of fasting blood sugar, glycated hemoglobin (HbA1c), total cholesterol, triglyceride, mean energy and carbohydrate intake. In addition, the amount of coffee, syrup, and creamer consumption was associated with higher prevalence of overweight, impaired fasting glucose, hypercholetererolemia, hypertriglyceridemia. In contrast to the syrup consumption, the amount of coffee consumption was associated with higher income and education level.

**Conclusions**: Our findings suggest that coffee consumption is positively associated with diabetes risk in Korean adults, perhaps deriving from excessive intake of syrup and creamer. A variety studies have shown that coffee consumption is inversely associated with DM because the studies considered populations that primarily consumed filtered coffee. The unique consumption pattern of Korean may explain the discrepancies between our findings and the results of previous studies.
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**C.‐H. Hsia and H.‐Y. Su**

Department of Nutrition, Taipei Medical University Hospital, Taipei, Chinese Taipei

**Introduction**: Coronary heart disease is the main cause of death in diabetes mellitus (DM). The incidence of coronary heart disease in DM is 2--5 times higher than non‐DM. The prevalence of major vascular disease in diabetes is about 30% in Taiwan. The purpose of our study is to investigate the malnutrition status in acute coronary syndrome (ACS) in‐patients in Taipei Medical University Hospital (TMUH) between DM and non‐DM.

**Methods**: All patients were diagnosed with ACS in TMUH. Among 251 patients recruited from March 2017 to April 2018, we assessed the anthropometric data, NRS‐2002 and clinical data in these patients.

**Results**: We recruited 251 patients (194 male, 57 female) with mean age 63.5 ± 14.6 years and mean body mass index (BMI) 25.83 ± 5.07 kg/m^2^. The rate of normal nutrition was 34.5%, mild malnutrition risk was 44.2%, moderate malnutrition risk was 17.3%, and severe malnutrition risk was 4%. The BMI in none, mild, moderate and severe malnutrition risk were 27.39 ± 4.92 kg/m^2^, 25.58 ± 3.73 kg/m^2^, 25.97 ± 4.85 kg/m^2^ and 19.65 ± 2.06 kg/m^2^, respectively. The malnutrition risk is modestly negatively correlated with BMI (*r* = −0.301, *P *\<* *0.05). Ninety patients (35.9%) were diabetes (64 male,26 female). The NRS score in DM patients was significantly higher than non‐DM patient (1.83 ± 1.39 vs. 1.16 ± 1.55, *P *\<* *0.05). Compare to non‐DM patients, DM patients had lower normal nutrition rate (13.3% vs. 46.9%), and higher rate of moderate and severe malnutrition risk (28.9% vs. 16.8%). Although the BMI was higher in DM than in non‐DM patients (26.82 ± 4.68 vs. 25.52 ± 4.70, *P *\<* *0.05), their malnutrition risk was more severe. DM patients with poor blood glucose control (A1C \> 9.0%) had higher BMI (*r* = 0.175, *P *\<* *0.05).

**Conclusion**: In our study, we found ACS in‐patients who had severe malnutrition status had the lower BMI. Although the BMI was higher in ACS with DM patients, they still had higher malnutrition risk.

PP‐371 {#jdi12939-sec-0743}
======

Dietary, lifestyle, and behaviour changes of patients with overweight/obesity and type 2 diabetes participating in a structured lifestyle intervention based on a trans‐cultural diabetes specific nutrition algorithm {#jdi12939-sec-0744}
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**G. S. Harvinder Kaur^1^, W. S. S. Chee^1^, O. Hamdy^2^, J. I. Mechanick^3^, A. Barua^4^, V. K. M. Lee^5^, M. A. Siti Zubaidah^6^ and H. Zanariah^7^**
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**Background**: Trans‐cultural Diabetes Nutrition Algorithm (tDNA), developed by international diabetes and nutrition experts, was culturally adapted for Malaysians. The tDNA provides a healthy lifestyle guide based on initial risk evaluation. Self‐efficacy, defined as one\'s ability to perform specific behaviours in challenging situations, predicts successful weight loss and maintenance. Improved self‐efficacy demonstrated better dietary adherence and glycaemic control in type 2 diabetes (T2D) patients. This study evaluated the efficacy of tDNA versus usual T2D care on diet, exercise, and self‐efficacy in T2D patients in a primary care setting.

**Methods**: Secondary outcomes of 230 overweight/obese T2D patients, who participated in a dietary and lifestyle intervention trial (Chee WSS, et al. BMJ Open Diabetes Research and Care, 2017), were analysed. Patients received either the Malaysian customised tDNA care or usual T2D care (UC) for 6 months. The tDNA group received structured low‐calorie meal plan (1200--1500 kcal/day), diabetes‐specific meal replacements (1--2 servings/day), and increased exercise (150 min/week). The tDNA group also received either motivational interviewing (tDNA‐MI) or conventional counselling (tDNA‐CC). UC group received standard dietary and exercise advice using conventional counselling. Patients' self‐efficacy was assessed using Weight Efficacy Lifestyle (WEL) questionnaire. Self‐efficacy was rated on a 0--9 scale

0 indicating 'not confident' and 9 indicating 'very confident' to resist eating. Increased WEL scores indicated higher self‐efficacy to resist eating.

**Results**: Compared to baseline, tDNA‐MI ate lowest calories (−574 ± 43 kcal/day, *P *\< 0.001) than tDNA‐CC (−458 ± 47 kcal/day, *P *\< 0.001) and UC (−171 ± 46 kcal/day, *P* = 0.002) groups. The tDNA‐MI engaged in longer duration of exercise (188 ± 16 min/week, *P *\< 0.001) than tDNA‐CC (149 ± 24 min/week, *P* = NS) and UC (106 ± 14 min/week, *P* = NS) groups. Positive changes in WEL scores indicated higher self‐efficacy to resist eating in tDNA‐MI (26 ± 2, *P *\< 0.001) and tDNA‐CC (15 ± 3, *P *\< 0.001) groups than UC group (−6 ± 2, *P* = 0.029). As a likely consequence, A1C reduction was greater in tDNA‐MI (−1.1 ± 0.1%, *P *\< 0.001) than tDNA‐CC (−0.5 ± 0.1%, *P* = 0.001) and UC (−0.2 ± 0.1%, *P* = NS) groups. Weight loss was also significantly greater in tDNA‐MI (−6.9 ± 1.3 kg, *P *\< 0.001) than tDNA‐CC (−5.3 ± 1.2 kg, *P *\< 0.001) and UC (−0.8 ± 0.5 kg, *P* = NS) groups.

**Conclusion**: Dietary, lifestyle, and behaviour of overweight/obese T2D patients improved with structured lifestyle intervention through a culturally adapted nutrition algorithm. Motivational interviewing counselling further enhanced these outcomes as part of diabetes management optimization.
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**T. H. T. Nguyen**

National Geriatric Hospital, Hanoi, Vietnam

Nutritional status is an important element for the wellness among the elderly. 1) Objectives: To assess the nutritional status of the elderly by using the Mini‐Nutrition Assessment Short Form (MNA‐SF) tool, and describe the relationship among related factors in elderly outpatients in National Geriatric Hospital; 2)

**Methods**: A cross‐sectional study was conducted. We recruited 183 patients aged ≥ 60 years at the Outpatient Department at the National Geriatric Hospital from June to September, 2015. Patients were asked to evaluate their nutritional status using the MNA‐SF. Socio‐demographic, diabetic treatment information, frailty, exhaustion, cognitive function, functional independence, hand grip strength and 4 m walk test were collected. Multivariate regression was used to determine factors associated with nutritional status; 3)

**Results**: The mean of age was 69.52 (SD = 6.758) with 31% patients at risk of malnutrition and malnourished. A significant association was found between the nutritional status and exhaustion, cognitive impairment, functional independence, hand grip strength, and walk time (4 m walk test). There is also an association between risk of malnutrition and frailty, poor education, and poor grip strength; 4).

**Conclusions**: Our results suggest that frailty was significantly associated with risk of malnutrition. Thus, early screening, assessment, and intervention may improve the nutritional status of seniors.
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Rapamycin‐insensitive companion of mTOR (Rictor) exists in circulation by the form of exosome vesicles and is downregulated in obese subjects. {#jdi12939-sec-0748}
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**Q. Ge, X. Chen, Q. Zhen, Z. Wang, M. Wu and X. Xiao**

The First Affiliated Hospital of Chongqing Medical University, Chongqing, China

**Objective**: To explore protein profiles contained in circulating exosome vesicles (EVs) from lean and simple obese subjects and investigate whether the EV proteins differentially regulated in obesity were associated with βcell function.

**Methods**: A total of 25 healthy lean and 22 obese volunteers were recruited from June to December 2017. Their βcell functions were estimated by 75‐g oral glucose tolerance test and fasting C‐peptide, and body fat distributions by dual energy X‐ray absorptiometry. The EV protein profiles were detected by Quantitative Proteomic Analysis (TMT technology) and verified by Western blot and ELISA.

**Results**: A total number of 529 proteins were detected in plasma EVs and 29 proteins were differentially regulated in simple obese subjects compared to healthy lean subjects. Among them, the Rapamycin‐insensitive companion of mTOR (Rictor), an essential component of mTOR complex 2 (mTORC2), was downregulated by 65% in obesity (average Obese/Lean ratio = 0.35, *P *=* *0.007). By subsequent Western blot and ELISA, we verified that both the total and the phosphorylated form of Rictor existed in EVs and protein levels of both forms were less in obese subjects than lean ones (for total Rictor: 0.21 ± 0.04 *vs*.0.15 ± 0.05, *P *=* *0.005; for phosphorylated Rictor: 0.33 ± 0.09 *vs*. 0.25 ± 0.08, *P *=* *0.02). The phosphorylated Rictor in EVs correlated negatively with the BMI (*r* = −0.35, *P *=* *0.043), HOMA insulin resistance index (*r* = −0.35, *P *=* *0.046), fasting insulin (*r* = −0.36, *P *=* *0.042), fasting C‐peptide (*r* = −0.41, *P *=* *0.017) and ratio of fasting C‐peptide to fasting glucose (FCP/G) (*r* = −0.42, *P *=* *0.014), which has been shown as a marker of βcell mass. Moreover, the correlation between Rictor and waist circumference (*r* = −0.34, *P* = 0.053), visceral fat mass (*r* = −0.34, *P *=* *0.054) showed a trend following a linear relationship. Multiple Stepwise Regression showed that Rictor was associated independently with FCP/G (β = −0.42, *P *=* *0.014).

**Conclusions**: The total and phosphorylated Rictor protein existed in circulation by the form of EVs and was downregulated in obese subjects. The circulating phosphorylated Rictor was associated negatively and independently with βcell mass. This newly identified EV protein may probably serve as a new mechanism linking obesity to the compensatory hyperplasia of βcells under condition of obesity.
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Influence of plate size on actual & perceived energy intake in adults: A laboratory study {#jdi12939-sec-0750}
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**Mr J. Cheah, Assoc. Prof R. Jamaluddina and Ms N. Mohamad**

UPM, Serdang, Malaysia

The obesity epidemic is a major public health concern as it markedly increases morbidity and mortality of population. Energy intake directly impact our weight status, one of the factors that can influence the energy intake is environmental factor---the size of plate. The plate size can provide visual cues of served food amount and potentially influence the food intake. The main objectives of the present study were to measure and compare the lunch intake of foods among university students in the context of two different plate sizes under controlled laboratory conditions. In this laboratory study, we engaged 58 participants (45 female, 13 male) from Faculty of Medicine and Health Sciences, Universiti Putra Malaysia. On separate experimental days, participants were invited to serve themselves a lunch from buffet containing white rice, chicken dish and stir‐fried vegetable using small (7 inch/18 cm) and large (9 inch/23 cm) diameter plate. Anthropometric parameters, perceived energy intake, actual energy intake and socio‐demographic information were collected. There was significant difference in actual and perceived energy intake between the 2 plates size (*P *\< 0.001). The participants underestimated the energy intake on large plate and overestimated the energy intake on small plate. It was found that BMI positively correlated with actual and perceived energy intake, but not for socio‐demographic factor. We conclude that small plate size could be used as weight loss intervention to reduce total energy intake that will be beneficial to the obesity population. Reduction of energy intake could be as simple as reducing the size of plate during dining.
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Nutritional deficiencies in severe obesity: a multiethnic Asian cohort. {#jdi12939-sec-0752}
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**P. Lee^1^, S. Ganguly^1^, J. Dixon^2^, H. Tan^1^, C. Lim^1^ and K. Tham^1^**

^1^Singapore General Hospital, Singapore, Singapore, ^2^Baker Heart and Diabetes Institute, Melbourne Victoria, Australia

**Background**: Micronutrient deficiencies are highly prevalent in patients seeking metabolic‐bariatric surgery (MBS), although literature remains scant in Asia. In this study, we assess the prevalence of nutritional deficiencies in MBS patients with clinically severe obesity in Singapore and examine factors associated with the deficiencies.

**Methods**: This is a prospective, observational study of 577 consecutive patients with clinically severe obesity scheduled to undergo MBS. Nutritional and metabolic profile including renal panel, lipid panel, calcium, phosphate, intact parathyroid hormone (iPTH), 25‐hydroxyvitamin D (25(OH)D), vitamin B12, folate, ferritin, iron studies, haemoglobin, albumin, alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase were analysed.

**Results**: Mean age was 40.6 ± 10.3 years, 61.2% female, and mean BMI 42.4 ± 8.4 kg/m^2^. The cohort consists primarily of Chinese (40.6%), Malay (28.9%) and Indian (24.8%) patients. 92.9% had vitamin D insufficiency (25(OH)D \< 30 mcg/L), 67.3% had vitamin D deficiency (25(OH)D \< 20 mcg/L) and 9.8% had severe vitamin D deficiency (25(OH)D \< 10 mcg/L). 34.7% had raised iPTH. Younger age, female gender and higher BMI were independent factors associated with lower 25(OH)D. There was an inverse relationship between iPTH and 25(OH)D, with an inflection point at 25(OH)D of approximately 20 mcg/L. Folate deficiency was present in 31% and vitamin B12 deficiency in 9.5% of the cohort. Serum ferritin levels were low in 29.3%. ALT and AST were raised in 13.0% and 17.2% respectively. 25(OH)D levels were lower among Indian and Malay patients as compared to Chinese counterparts. Ferritin, serum iron, albumin, ALT and AST were also significantly higher in Chinese compared to Malay and Indian.

**Conclusion**: Vitamin D deficiency was the most common micronutrient deficiency observed in our multi‐ethnic Asian cohort presenting for MBS. iPTH levels were negatively correlated with vitamin D at 25(OH)D \< 20mcg/L. Ethnic differences in nutritional and metabolic status were observed, notably 25(OH)D, ALT, AST, ferritin and iron levels.
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Glucose Intolerance Dyslipidemia and fatty liver disease in overweight and obese children {#jdi12939-sec-0754}
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**D. Asma^1^, A. Salima^1^, M. Samia^2^, E. Ghada^3^ and E. Abubaker^4^**

^1^Pediatric Endocrinology Department, Mafraq Hospital, P O Box 2951, Abu Dhabi, United Arab Emirates, ^2^Pediatric Clinic, Police Health Services, Abu Dhabi, ^3^Primary Health Care Center, BaniYas, Abu Dhabi, ^4^Biochemistry Department, Shaikh Khalifa Medical City, Abu Dhabi

**Background**: Obesity is increasingly seen in children and youth. It is linked to major health concerns including glucose intolerance, dyslipidemia, fatty liver disease and type II diabetes. We aim to study the prevalence obesity comorbidities children and adolescents in Abu Dhabi, UAE.

**Methods**: A descriptive, cross‐sectional study conducted on children referred with obesity. BMI centiles plotted and standardized waist circumference (WC) was generated. Family history of metabolic syndrome was recorded. Fasting lipid, glucose, insulin, HbA1c and liver transaminases were analysed. Patients who had high fasting glucose or HbA1c had standard oral glucose tolerance test and those with elevated liver transaminases had liver ultrasound scans.

**Results**: A total of 216 participants were recruited. Mean ± SD age was 10.58 ± 2.996 years. A total of 147 patients (74.2%) were insulin resistant. A total of 7 patients were diagnosed with diabetes. A total of 87 (43.5%) had an indication for OGTT; 26 elevated fasting, 50 elevated HbA1c, 11 had both. A total of 15 patients (8.2%) had impaired glucose tolerance and 37 (18.1) had impaired fasting. A total of 5 patients of 11 with impaired fasting (45.5%) and 8 patients of 50 elevated HbA1c (17.4%) had glucose intolerance. 55.3% had dyslipidemia; 11.7% had high cholesterol, 28.6% high triglyceride, 32.7% high LDL and 18.0% low HDL. 51 (84%) had either elevated transaminases. All had liver US, 43 had FLD. WC was strongly associated with dyslipidemia and FLD (P 0.04, 0.003).

**Conclusions**: Insulin resistance is common in overweight and obese children. Higher yield of glucose intolerance is obtained when screening utilized combination of high fasting glucose and HbA1c. Dyslipidemia is common in overweight, obese children. FLD is prevalent in those with elevated liver transaminases. WC is an easy tool that can be utilized to screen for dyslipidemia and FLD in overweight and obese children.
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Transcriptional expression of NLRP1 in subcutaneous adipose tissue predicts weight loss in severely obese individuals after bariatric surgery {#jdi12939-sec-0756}
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**A. Moh^1^, A. Cheng^2^, L. B. Khim^1^ and L. S. Chi^1,3^**

^1^Clinical Research Unit, Khoo Teck Puat Hospital, Singapore, Singapore, ^2^Department of General Surgery, Khoo Teck Puat Hospital, Singapore, Singapore, ^3^Saw Swee Hock School of Public Health, National University Hospital, Singapore, Singapore

**Background**: Mounting evidence suggests that obesity initiates activation of low‐grade inflammation, which in reverse promotes weight gain. Inflammasomes are multimeric protein complexes of the innate immune system implicated to participate in low‐grade inflammation. Activation of inflammasomes by excessive nutrients causes proteolytic activation of caspase‐1, thus leading to the maturation of interleukin (IL)‐1β, which is a pro‐inflammatory cytokine released by immune cells infiltrating the adipose tissue. Bariatric surgery is recognized as the most effective treatment for weight loss. We postulate that the expression of inflammasomes in adipose tissue predicts weight loss after bariatric surgery.

**Methods**: The transcriptional expression of inflammasome components including NOD‐like receptor (NLR) family pyrin domain containing 1 (NLRP1), NLRP3, absent in melanoma 2 (AIM2), caspase‐1 and IL‐1β was assessed in both subcutaneous (SC) and visceral (VF) adipose tissue harvested during bariatric surgery \[*N* = 36, mean body mass index (BMI): 41.8 ± 7.6 kg/m^2^\] using reverse transcription coupled with quantitative polymerase chain reaction. Univariate and multivariate linear regression analyses were performed to evaluate the association between natural log‐transformed relative expression levels of inflammasome‐related genes (normalized against housekeeping gene GAPDH) and percentage loss in BMI at one year post‐bariatric surgery.

**Results**: Significantly higher relative mRNA expression levels of AIM2, caspase‐1 and IL‐1β (all *P *\< 0.05), but not NLRP1 and NLRP3, were observed in VF when compared to SC at baseline. Elevated relative expression of SC NLRP1 (B = −11.55, 95% CI = −20.44--‐2.65, *P* = 0.011) and VF AIM2 (B = −55.67, 95% CI = −109.12--‐2.21, *P* = 0.041) was associated with greater percentage loss in BMI univariately. The relationship between SC NLRP1 mRNA and outcome persisted after adjustment for age, gender, ethnicity, baseline BMI and type of bariatric surgery (B = −10.42, 95% CI = −18.61--‐2.23, *P* = 0.013).

**Conclusions**: Increased mRNA expression of NLRP1 in subcutaneous adipose tissue may predict success of weight loss one year after bariatric surgery. However, the role of NLRP1 in weight regulation remains to be determined.
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Analysis of factors related to the success rate and reliability of transient elastography Fibroscan^®^ {#jdi12939-sec-0758}
------------------------------------------------------------------------------------------------------

**W. Deng, Z. Huang and Y. Li**

The First Affiliated Hospital Of Sun Yat‐sen University, Guangzhou, China

**Objective**: With the increased prevalence of obesity and diabetes, so thus the morbidity of non‐alcoholic fatty liver disease, the latter is a well‐known sign for metabolic syndrome. Transient elastography Fibroscan ^®^ has been recognized as the first choice among the non‐invasive tools for evaluating hepatic steatosis and stiffness by multiple liver disease guidelines. The study herein assessed the factors related to the success rate and reliability of Fibroscan^®^.

**Methods**: A total of 788 volunteers (23.5% males) from year 2018 staffs' physical checkup in our hospital were recruited. The association between success rate, median to IQR ratio of the liver stiffness measurement (LSM) and that of age, body mass index, waist circumference of the participants, operator\'s experience were analyzed.

**Results**: Mean age of the participants were 53.8 ± 15.4 years, BMI were 23.6 ± 3.0 kg/m^2^, waist circumference were 81.1 ± 9.3 cm. The median controlled attenuation parameter (CAP) was 242 (IQR 63) dB/m, and the median LSM were 4.0 (IQR 1.3) kpa. Detection failure and unreliable measurements were occurred in 1.4% of all the participants. Success rate decreased significantly with increased age (*P *=* *0.0384), BMI (*P *=* *0.0359) and waist circumference (*P *=* *0.0007). With the accumulated number of examinations in the same operator, thus increased the success rate (*P *\<* *0.0001 after correction for age and BMI) and reliability of the measurement (*P *=* *0.0026). An operator with more than 300 examinations could be deemed as experienced operator.

**Conclusion**: The success rate and reliability of Fibroscan^®^ were affected by increased age, body mass index and waist circumference. Fixed operator even without previous expertise in ultrasound could also achieve very high success rate and reliable measurements using Fibroscan^®^ after a short term training.
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Glycaemic status amongst overweight and obese adolescents: MyBFF\@school study {#jdi12939-sec-0760}
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**F. Mansor^1^, F. A. Roslan^1^, M. Y. Jalaludin^2^, F. M. Zain^7^, J. Y. H. Hong^7^, R. M. W. M. Zain^1^, N. Z. I. A. Kamil^1^, A. Yahya^3^, Z. Ishak^5^, R. Selamat^6^ and A. H. Mokhtar^4^**

^1^Diabetes and Endocrine Unit, Institute for Medical Research, Malaysia, ^2^Department of Paediatrics, Faculty of Medicine, University of Malaya, Malaysia, ^3^Department of Social and Preventive Medicine, Faculty of Medicine, University of Malaya, Malaysia, ^4^Department of Sport Medicine, Faculty of Medicine, University of Malaya, Malaysia, ^5^Department of Educational Psychology and Counselling, Faculty of Education, University of Malaya, Malaysia, ^6^Nutrition Division, Ministry of Health Malaysia, ^7^Department of Paediatrics, Hospital Putrajaya, Malaysia

**Background**: With the rising prevalence of obesity and type 2 diabetes (T2D) in obese children, it is crucial to detect disturbed glucose metabolism as early as possible in order to prevent T2D development. Additionally, pre‐diabetes presents significant morbidity in children with obesity. The aim of this study was to assess the frequency of prediabetes/diabetes during the screening of a school‐based obesity intervention program.

**Methods**: This is part of MyBFF\@school, an intervention program among overweight and obese adolescents, carried out in the central zone of Peninsular Malaysia (*n *= 1049 secondary school students). In this study, only 503 overweight/obese students (median body mass index (BMI) z‐score 2.15 ± 0.74, median age of 13.76 years old), who consented and completed fasting blood tests (glucose, HbA1c and lipid profiles) were analyzed. Fasting blood glucose (FBG) level was determined by glucose oxidase method (Randox Glucose Reagent Kits, UK) and HbA1c, a glycated hemoglobin measurement by Adams HA‐8160 HbA1c analyzer which uses a cation exchange HPLC method. Elevated HbA1c is defined as -- Normal: \<5.6%; Pre‐diabetes: 5.6--6.2%; Diabetes: ≥6.3%. Fasting blood glucose is categorized as ‐Normal: \<5.6 mmol/L; impaired fasting glucose (IFG): 5.6 -- 6.9 mmol/L; Diabetes: ≥7.0 mmol/L.

**Results**: Overall, 400 students (79.6%) had normal glycaemia, while 103 (20.4%) had elevated HbA1c or FBG levels. Five students have both increased HbA1c and FBG. Among the latter, based on HbA1c test, 16.1% (*n *= 81) of participants were identified as prediabetes and 1.7% (*n *= 9) as diabetes. Among these 9 diabetic students from HbA1c diagnosis, 4 of them were identified as diabetes, 2 were with pre‐diabetes and 3 as normal by blood glucose levels. By using FBG, 20 students (*n *= 3.9%) had impaired fasting glucose, while only 4 students (0.8%) were detected as diabetic. Participants who were detected with elevated HbA1c and FBG were referred and managed by paediatric endocrinologists involved in this study.

**Conclusions**: The frequency of dysglycaemia among apparently healthy overweight and obese adolescents is high. The results demonstrate the importance of screening for these known comorbidities. It is important to have the resources and a multi‐disciplinary team to follow children and their families through treatment.
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Insulin Resistance Assessed by Homeostasis Model Assessment (HOMA) across Asian BMI Categories in a Sarawakian Type 2 Diabetes Mellitus (T2DM) Cohort on Oral Antidiabetics {#jdi12939-sec-0762}
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**S. Tan^1^, A. Lim^1^, X. Tiong^1^, A. Fong^1,2^ and F. Tan^3^**

^1^Clinical Research Centre, Sarawak General Hospital, Kuching, Malaysia, ^2^Department of Cardiology, Sarawak Heart Centre, Kuching Sarawak, Malaysia, ^3^Department of Medicine, Sarawak General Hospital, Kuching Sarawak, Malaysia

**Purpose**: To investigate estimation of insulin resistance through HOMA across Asian BMI categories in a Sarawakian T2DM cohort on oral antidiabetics (OAD).

**Method**: A cross‐sectional study was conducted across five recruitment sites (primary care clinics and tertiary centres) in Kuching, Sarawak. A total of 234 subjects on two most commonly used OADs (metformin and gliclazide) were recruited. Forty‐two variables (demographics, comorbidities, anthropometric measurements and laboratory investigations) were included in statistical analysis. Insulin resistance (IR) was estimated via HOMA1 equations and HOMA2 calculator.

**Results**: Subjects recruited had a mean age of 59.00 years and T2DM duration of 7.17 years with mean BMI of 28.50 kg/m^2^ (SD 5.27). BMI was categorised according to WHO Asian BMI classification: 18.5--22.9 kg/m^2^ (normal; 11.1%), 23--24.9 kg/m^2^ (pre‐obese; 13.7%), 25--29.9 kg/m^2^ (obese class I; 43.2%), 30--34.9 kg/m^2^ (obese class II; 22.6%) and ≥35 kg/m^2^ (obese class III; 9.4%). HOMA1‐IR and HOMA2‐IR increased across the BMI categories and subsequently plateaued at obese class II. The mean (SD) of HOMA1‐IR across the categories were 1.58 (0.63), 2.52 (1.30), 4.31 (2.93), 5.88 (3.32) and 5.62 (2.12); p‐value \<0.0001. The mean (SD) of HOMA2‐IR across the categories were 0.73 (0.28), 1.12 (0.46), 1.71 (1.02), 2.30 (0.99) and 2.26 (0.72); p‐value \<0.0001. After adjusting for gender, age, ethnicity and T2DM duration, the means of both HOMA1‐IR and HOMA2‐IR were still significantly different (*P *\< 0.0001). Post‐hoc analyses of HOMA1‐IR and HOMA2‐IR showed significant differences between all BMI categories except for between obese class II and III. The dispersion of HOMA‐IR was the largest in obese class I category despite having the largest proportion of subjects. In addition, white blood count (*P* = 0.0016), ALT (*P* = 0.0006), ALT/AST ratio (*P* = 0.0022), diastolic blood pressure (*P* = 0.0002) and TG/HDL ratio (*P* = 0.0203) were significantly different across the BMI categories.

**Conclusion**: Insulin resistance increased with Asian BMI categories but plateaued at obesity class II in a Sarawakian T2DM cohort on OADs. The increasing insulin resistance concurs with higher cardiovascular risk in obese patients. The high cardiovascular risk of obese T2DM patients calls for more aggressive interventions targeting insulin resistance.

PP‐381 {#jdi12939-sec-0763}
======

The correlation of LONP1 mRNA expression with obesity in the human visceral adipose tissue {#jdi12939-sec-0764}
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**J. H. Lee^1,2^, J. E. Kim^2^, S.‐B. Jung^2^, S. E. Lee^2^, Y. E. Kang^1,2^, J. M. Kim^1,2^, K. H. Joung^1,2^, H.‐S. Yi^1,2^, B. J. Ku^1,2^, Y. B. Ko^3^, K. H. Lee^3^, M. Shong^1,2^ and H. J. Kim^1,2^**

^1^Department of Internal Medicine, Chungnam National University Hospital, Daejeon, Republic of Korea, ^2^Research Center for Endocrine and Metabolic disease, Daejeon, Republic of Korea, ^3^Department of Obstetrics and Gynecology, Chungnam National University Hospital, Daejeon, Republic of Korea

**Purpose**: The Mitochondrial Lon protease, also called LonP1 is a major regulator of mitochondrial metabolism. We investigated the *LONP1* mRNA expression in adipose tissue associated with obesity.

**Methods**: We obtained omental adipose tissue from 48 females with normal glucose tolerance undergoing gynecologic surgery. We examined the mRNA expression of *LONP1* in visceral adipose tissue using quantitative RT‐PCR, and performed correlation analysis of this expression with the clinical characteristics of the subjects

**Results**: The mean age of study subjects was 42.5 ± 5.8 years old and mean body mass index (BMI) was 23.4 ± 3.5 kg/m^2^. The *LONP1* mRNA level was significantly correlated with BMI (*r* = 0.308, *P* = 0.05), but not with age (*r* = −0.007, *P* = 0.964) or HOMA‐IR (*r* = 0.211, *P* = 0.185) Conclusion : The LONP1 mRNA expression of human visceral adipose tissue was positively correlated with obesity.
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**L. B. Kui^1^, C. H. Hin^2^, T. X. Ting^2^, M. L. Y. Zher^2^, C. Y. Ping^2^, V. R. Sambamoorthy^2^, C. Y. Hin^2^, Y. Y. Lek^2^, K. Y. Chien^1^ and F. T. H. Sieng^1^**

^1^Endocrine Unit, Department of Medicine, Sarawak General Hospital, Kuching, Malaysia, ^2^Department of Medicine, Sarawak General Hospital, Kuching, Malaysia, ^3^Clinical Research Centre, Sarawak General Hospital, Kuching, Malaysia

**Background**: Recent studies reported a shift in public perception of overweight and obesity. Little is known about Malaysian\'s perception of obesity.

**Methods**: We conducted a cross‐sectional study on public perception of body weight status compared to measure BMI. General public who visited our hospital were asked whether they consider themselves 'underweight', 'about right', or 'overweight'. Anthropometric, demographic parameters, the presence of obesity related co‐morbidities and knowledge about BMI were recorded. BMI was classified according to 2004 WHO (Asian) classification. Body weight perception deviation (BWPD) was defined as dissociation of subjects' perception from their actual BMI category.

**Results**: A total of 825 (56.7% female) multi‐ethnic subjects (36.6% Sarawak Dayaks, 35% Malay and 21.9% Chinese) were recruited. Their mean age was 40.6 ± 14.2 years, mean BMI 26.87 kg/m^2^. 4.5% were underweight, 21% normal, 32.1% overweight and 42.4% obese. Gender, race, education level, monthly household income and rural‐urban residency didn\'t differ across different BMI categories. Married subjects were more likely to be overweight/obese (*P *\< 0.001). Increase BMI was associated with increased number of comorbidities (*P *\< 0.001). Overweight and obese groups had significantly higher incidence of hypertension, DM and dyslipidemia (*P *\< 0.001), but not gout, osteoarthritis or OSA. Smokers were less presented in the overweight and obesity group (*P *\< 0.001). 40% of subjects had BWPD. BWPD was most overt among overweights (71.3%, *P *\< 0.001), where 67.2% of subjects perceived themselves as normal. Comparatively, BWPD was less in obese subjects with 21.7% considered themselves as normal. Male had more BWPD compared to female, 47.1% vs. 34.6% (*P *\< 0.001). On univariate analysis, knowledge of BMI decreased BWPD significantly (36.4% vs. 43.5%; *P *\< 0.035); and increasing age was associated with BWPD, with 13% increase likelihood of deviation in every 10‐year of age increment. Education level, race, monthly household income, obesity‐related comorbidity and marital status didn\'t influence body weight perception significantly.

**Conclusions**: BWPD is common in our population, especially among overweights and male gender. It is postulated that BWPD decreases the tendency to seek help for weight management. Thus, effort to improve public\'s body weight perception plays an important role to curb the continuous increasing trend of obesity prevalence.
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**Y. Li, L. Guo and X. Zhao**

Beijing Hospital, Beijing, China

**Objective**: We aimed to estimate total and trimester‐specific effects of gestational weight gain (GWG) as well as weight gain patterns on gestational diabetes mellitus (GDM).

**Methods**: This is a retrospective cohort study of singleton live births in Beijing Hospital between September 2016 and November 2017,containing 2478 cases. We collected pre‐pregnancy body mass index (BMI),trimester‐specific gestational weight gain and the result of OGTT. People were classified into inadequate GWG,excessive GWG and normal GWG. Logistic regression and chi‐square test were used to assess the independent associations of GWG,the combination of pre‐pregnancy BMI and GWG as well as weight gain patterns with GDM.

**Results**: As for total GWG,the incidence of GDM in women with inadequate weight gain and normal weight gain were 27.0% and 16.1%. Women with inadequate total GWG had an increased likelihood of GDM (OR 2.203,95%CI 1.680--2.887). Combining pre‐pregnancy BMI with GWG, the risk of GDM increase with the pre‐pregnancy BMI increase. Obesity women who gain less weight had the highest risk of GDM. As for the early trimester of pregnancy, inadequate GWG was associated with an increased risk of GDM (OR 1.364,95%CI 1.021--1.823).Both inadequate and excessive weight gain before OGTT were associated with an increased risk of GDM. The risk of GDM increase with higher pre‐gestational BMI. Obesity women who have inadequate GWG early in pregnancy had the highest risk of GDM. As for the late trimester of pregnancy, inadequate GWG late was associated with increased odds of GDM (OR 2.686,95%CI 2.015--3.581). Moreover, analyzing the joint effects of late GWG and pre‐pregnancy BMI, in the overweight/obesity women, the risk of GDM increased. Different weight gain patterns have effect on GDM. The risk of GDM is highest in women who gain excessive weight early and gain inadequate weight late (OR 3.149,95%CI 1.980--5.008).

**Conclusions**: The total GWG and trimester‐specific GWG can affect the maternal metabolism. Total GWG below the IOM guideline increases the risk of GDM and weight gain more early then less later can increase the risk of GDM significantly.
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^1^Faculty of Medicine, Universiti Teknologi MARA, Sungai Buloh, Selangor, Malaysia, ^2^Department of Paediatrics, Hospital Sungai Buloh, Sungai Buloh, Selangor, Malaysia

**Introduction**: The increasing trend of childhood obesity worldwide is alarming. Parental perception of children\'s weight status and early recognition of obesity are therefore vital to facilitate referral and reduce the risk of future complications. The objectives of this study were to ascertain the parental perception of their children\'s weight status and to identify the socio‐demographic factors associated with childhood obesity.

**Methods**: This cross‐sectional study included a total of 245 children aged between 5 to 12 years old. These children were recruited from the paediatric wards in a local hospital following informed consent. Body mass index (BMI) was calculated for each participant and then classified into either normal or overweight/obese group (BMI \> 85th percentile). The parents responded to self‐administered questionnaires which assessed the socio‐demographic details, lifestyle and environmental information. Data were analyzed using SPSS.

**Results**: One hundred and fifty‐seven participants (65.2%) had normal BMI while 88 subjects (34.8%) were overweight/obese. A total of 83.4% were Malays, 5% were Chinese, 8% percent were Indians and the remaining were other races. There was a significant difference in the parental perception of the children\'s weight status between the normal and overweight/obese (*P* = 0.001). A total of 66% of those parents whose children were overweight/obese had misperception that their children had normal BMI. Socio‐demographic details showed that families with higher household income tend to have children with significantly higher BMI compared to those with lesser income (*P* = 0.029). Having a family history of diabetes or obesity increases the risk of children to have higher BMI.

**Conclusion**: Most parents of children who are overweight or obese have wrong perception of their children\'s weight status. Parents' awareness of obesity among their children should be improved. Higher household income is associated with increased risk of childhood obesity.
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LpD64 improves insulin sensitivity index in obese people during a phase I/II pilot clinical trial {#jdi12939-sec-0772}
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**P. Sirvent^1^, M. Bargetto^1^, N. Macian^2^, S. Boulliau^2^, G. Ducheix^2^, C. Duale^2^, C. Dubray^2^, G. Pickering^2^ and S. Peltier^1^**

^1^Valbiotis, Riom, France, ^2^CIC, Clermont‐Ferrand, France

**Purpose**: Worldwide epidemic of obesity has dramatically grown over the last decades. In 2016, more than 1.9 billion adults were overweight or obese. Insulin resistance is a common feature of obesity, increasing the risk for developing type 2 diabetes. LpD64 has shown promising results in different animal models of obesity to prevent fat mass gain and to improve insulin sensitivity. The aim of this study was to assess the effects of the candidate LpD64 for safety and for improvement of insulin sensitivity in obese subjects.

**Method**: This is a phase I/II open trial conducted with twenty male obese volunteers (Clinical trial NCT03052062). The study included an initial period of supplementation with 2.6 g/day for 12 weeks (V1; V2 = V1 + 12 weeks) followed by an intermediary analysis and a wash‐out period of 2 weeks, then 12 weeks of supplementation with 5.2 g/day (V3 = V2 + 2 weeks; V4 = V3 + 12 weeks). Different safety parameters, in particular hepatic, urinary, renal and hemodynamic, were assessed at all visits. Glycemia and insulinemia were also monitored after taking a standardized breakfast (Breakfast Tolerance Test: BTT) at V3 and V4.

**Results**: Seventeen volunteers completed the trial. The results do not show any clinically significant increase in the various safety parameters, objectifying the very good tolerance of LpD64 for the two doses tested. In addition, LpD64 did not induce an increase in insulin secretion during the BTT. Conversely, we observed a decrease in the glycemia area under the curve (AUC, *P *\< 0.05) and insulinemia AUC (*P *\< 0.01) during the BTT. Insulin sensitivity index during BTT was markedly improved (+33%, *P *\< 0.01) following Lpd64 supplementation.

**Conclusion**: The candidate LpD64 presents a good safety in obese subjects and has shown a clear improvement of insulin sensitivity during this phase I/II open clinical trial, opening the way for a phase II efficacy study.
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Serum Retinol Binding Protein 4 was Positively Associated with Insulin Resistance and Decreased after Laparoscopic Sleeve Gastrectomy in Chinese Obese Patients {#jdi12939-sec-0774}
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**X. Wang, L. Li, C. Zhu, J. Gao, and S. Qu**

Department of Endocrinology and Metabolism, Shanghai Tenth People\'s Hospital, Tongji University, School of Medicine, Shanghai, China

Retinol‐binding protein 4 (RBP4) is implicated in the regulation of energy metabolism and insulin sensitivity. Laparoscopic sleeve gastrectomy (LSG) has been proven effectively in treating T2DM and other obesity‐related comorbidities. We aimed to investigate the association between RBP4 with insulin resistance and the change of RPB4 levels after laparoscopic sleeve gastrectomy (LSG) in Chinese obese patients. Eighty‐two obese patients (34 males and 48 females) were enrolled and 30 subjects (10 males and 20 females) underwent LSG in this study. Anthropometric and glucose metabolic parameters were measured. Serum RBP4 levels were detected by enzyme‐link immunosorbent assay. In all subjects, serum RBP4 levels were positively associated with BMI, OGTT blood glucose at 0, 30, 120, 180mins, fasting insulin, fasting C‐peptide and HOMA‐IR at baseline (all *P *\<* *0.05). Moreover, HOMA‐IR was significantly decreased at 3 and 6 months after LSG (all *P *\<* *0.001). Intriguingly, serum RBP4 levels were also reduced from baseline to 3 and 6 months after LSG (from 43.20 ± 14.27 mg/L to 33.00 ± 12.35 mg/L to 31.87 ± 9.90 mg/L, all *P *\<* *0.01). In conclusion, RBP4 is closely associated with glucose metabolism and insulin resistance in Chinese obese patients. The decreased RBP4 levels may partly account for the improved insulin sensitivity in obese subjects after LSG.
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**X. Wang, J. Chen, L. Li, H. Sun, J. Gao and S. Qu**

Department of Endocrinology and Metabolism, Shanghai Tenth People\'s Hospital, Tongji University, School of Medicine, Shanghai, China

Glucagon‐like peptide‐1 receptor agonist could improve NAFLD with unclear mechanisms. Studies have indicated the role of bone morphogenetic protein 4 (BMP4) in energy metabolism. We aimed to explore whether exenatide could improve NAFLD in high‐fat‐diet (HFD) induced obese mice by regulating BMP4‐related signaling pathway. Fifteen C57BL/6 mice were randomly assigned to 3 groups. Group A and Group B were fed with high‐fat‐diet (HFD) to induce NAFLD while Group C with regular diet (RD) for 24 weeks. Group A and Group B received subcutaneous injection of exenatide at a dose of 10 nmol/kg or vehicle (0.9% NaCl) once daily during the last 8 weeks. Body weight and liver weight were measured. Histochemical analyses of liver were performed. Western blotting showed the change of protein levels in BMP4 related signaling pathway. Eight‐week exenatide treatment significantly decreased body weight in Group A (from 44.08 ± 2.89 g to 39.22 ± 1.88 g, *P *=* *0.045). Group A had lower body weight and liver weight than Group B at 24 weeks (39.22 ± 1.88 g *vs*. 47.34 ± 2.43 g, *P *=* *0.001 and 1.70 ± 0.20 g *vs*.2.48 ± 0.19 g, *P *=* *0.001, respectively). Moreover, Group A had less severe hepatic steatosis than Group B. Western blotting showed that exenatide could prevent HFD‐induced up‐regulation of BMP4 levels and downstream activation of SMAD1 and P38 MAPK signaling pathway in liver. Furthermore, exenatide treatment could reduce BMP4 and enhance UCP1 (an important thermogenin) in brown adipose tissue (BAT). In conclusion, exenatide could improve HFD‐induced NAFLD and enhance thermogenesis in BAT, which may be partly attributed to the inhibition of BMP4 related signaling pathway.
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Effect of laparoscopic sleeve gastrectomy on sex hormone level and ovarian volume in female obesity with PCOS {#jdi12939-sec-0778}
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**J. Gao, M. Zhang, C. Zhu, F. Mei, X. Wang, L. Li and S. Qu**

Department of Endocrinology & Metabolism, Shanghai Tenth People\'s Hospital, Tongji University School of Medicine, Shanghai, China

**Object**: To investigate the effect of LSG on sex hormones and ovarian volume in female obesity with PCOS.

**Subjects and Methods**: A retrospective study was performed in 51 obese female patients with BMI 30--45 kg/m^2^ who underwent LSG from Shanghai Tenth People\'s Hospital from December 2012 to December 2017, 38 of whom were PCOS patients. PCOS diagnosis is based on the Rotterdam standard. The anthropometric indexes, sex hormone and ovarian volume of ultrasound examinations \[left and right ovarian volume, mean ovarian volume (MOV), maximal ovarian volume (MaxOV)\] were observed preoperative and follow‐up at 3 and 6 months after LSG. The metabolic indexes and ovarian volume were compared before and after surgery.

**Results**: Weight loss effects: Compared with preoperative, PCOS patients' weight, BMI, waist circumference and hip circumference were significantly lower at 3 months and 6 months after surgery (*P *\< 0.05).The %EWL reached 56.32% at 3 months after LSG, and the %EWL of 6 months after surgery reached 75.98%. Postoperative sex hormone changes: TT and cFT showed a downward trend at 3 and 6 months after surgery, and SHBG showed an upward trend. The SHBG and cFT at 6 months after operation were statistically significant (*P *\< 0.05). Postoperative ovarian volume changes: MOV, MaxOV, left and right ovary volume all decreased at 6 months after LSG, but there was no statistically significant difference compared to baseline. Compared with patients without PCOS, the preoperative MOV, MaxOV and left ovary volume were significantly larger (*P *\< 0.05). At 6 months after surgery, the MOV, MaxOV, left and right ovary volume of PCOS and non‐PCOS patients were all reduced. The differences in MOV, MaxOV, left and right ovary volume were no longer statistically significant between the two groups.

**Conclusions**: In female obese patients with PCOS, there is an imbalance in sex hormone levels. After LSG, total testosterone decreases, SHBG increases and free testosterone decreases significantly. The MOV was reduced at 6 months after the surgery and was no longer different from non‐PCOS patients. LSG is not only an important treatment for weight loss, but also can effectively improve PCOS and its clinical symptoms in severe obese women.

PP‐389 {#jdi12939-sec-0779}
======

Impact of laparoscopic sleeve gastrectomy on thyroid function profiles in Chinese euthyroid obese patients {#jdi12939-sec-0780}
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**L. Li, X. Wang, J. Gao and S. Qu**

Department of Endocrinology and Metabolism, Shanghai Tenth People\'s Hospital, Tongji University, School of Medicine, Shanghai, China

**Purpose**: There exists close relationship between thyroid function and obesity. Laparoscopic sleeve gastrectomy (LSG) is an effective bariatric surgery for weight loss and obesity‐associated comorbidities. However, only a few studies involve in the alteration of thyroid hormones after LSG with inconsistent results. This study aimed to investigate the impact of LSG on thyroid function profiles in Chinese euthyroid obese subjects.

**Methods**: A retrospective study was performed of prospectively collected data in 36 obese patients (17 males and 19 females) who underwent LSG. Thyroid function profiles (TT4, FT4, TT3, FT3 and TSH, all within normal reference ranges), anthropometric data, and glucose‐lipid metabolic parameters were recorded at baseline, 3 and 6 months after LSG (abbreviated as 3M/6M Post‐LSG). Correlations between TSH with other parameters were evaluated.

**Results**: In all individuals, BMI was dramatically decreased at 3M/6M Post‐LSG accompanied by decreased fasting blood glucose, fasting insulin, fasting C‐peptide, triglyceride and increased HDL‐c (*P *\<* *0.01 or *P *\<* *0.05). FT3, FT4 and TT3 without TT4 levels were gradually declined from baseline to 6M Post‐LSG (*P *\<* *0.01 or *P *\<* *0.05, with slight changes in numerical values and still within their normal reference ranges). TSH levels remained unchanged at 3M/6M Post‐LSG compared with baseline. In females, the TSH decrease (ΔTSH) was positively correlated with BMI decrease (ΔBMI, *P *\<* *0.05), percentage of total weight loss (%TWL, *P *\<* *0.01), and percentage of excess weight loss (%EWL, *P *=* *0.051, approximately significant) at 6M Post‐LSG, while no correlation was observed in males.

**Conclusions**: In summary, we speculate that euthyroid obese subjects are adept at preserving their thyroid function homeostasis despite of morbid obesity at baseline as well as dramatic weight loss and significant improvement of glucose‐lipid metabolism after LSG. In addition, ΔBMI/%TWL/%EWL may be the predictor of improved TSH levels after LSG in female but not male obese patients.
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**N. Z. I. A. Kamil^1,5^, M. Y. Jalaludin^1^, R. M. W. Zin^1,5^, F. M. Zain^2^, H. Y. Hua^2^, A. Yahya^3^, A. H. Mokhtar^4^ and W. N. W. Mohamud^5^**

^1^Department of Paediatrics, Faculty of Medicine, University of Malaya, Kuala Lumpur, ^2^Department of Paediatrics, Putrajaya Hospital, Putrajaya, Malaysia, ^3^Department of Social and Preventive Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, ^4^Department of Sports Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, ^5^Diabetes and Endocrine Unit, Institute For Medical Research, Ministry of Health Malaysia

Due to age‐related developmental differences, diagnosis of metabolic syndrome (MetS) among children has yet to be clearly defined. The purpose of this study was to compare the usefulness of TG: HDL‐C ratio, acanthosis nigricans (AN) and liver biomarkers as screening tools for MetS in obese and overweight children. We used data obtained from MyBFF\@school, a school‐based lifestyle intervention programme involving nutritional, physical activity and psychology modules specific for obese and overweight school children conducted between January and December of 2014. A total of 232 obese and overweight children aged 9--16 years with a complete data set for waist circumference, acanthosis nigricans as well as blood samples assayed for triglyceride, high‐density lipoprotein (HDL‐C), glucose and liver enzymes were included. MetS was determined based on the International Diabetes Federation (IDF) 2007 definition. Out of 232 children, 9.9% (*n *= 23) were found to have MetS. Odds ratio was estimated using multiple logistic regression adjusted for age, gender, pubertal stages and obesity status. Children in the third tertiles of TG: HDL‐C ratio posed 6.0 times higher risk of developing MetS (OR = 5.99; 95% CI = 1.6, 22.4; *P* = 0.008). Meanwhile, the relationship between other parameters (liver enzymes, AN & AST: ALT ratio) and MetS was not statistically significant. Highest area under the curve for ROC (AUROC) was found for TG:HDL‐C ratio (AUC = 0.796, *P *\< 0.001\[95% CI = 0.688,0.904\]). The association between ALT concentration and MetS as well as BMI z‐score across percentiles was further evaluated by quantile regression. Yet, only the degree of obesity was significantly correlated with the higher value of ALT. In conclusion, TG:HDL‐C ratio is a superior marker for identification of MetS in comparison to liver enzymes and AN among obese and overweight children. In this study, we are suggesting a cut‐off value for TG:HDL‐C ratio as \>1.01 (sensitivity = 73.9%, specificity = 63.2%) to screen for MetS among our children population. It would be useful to consider the addition of TG: HDL‐C ratio to the MetS definition as triglycerides and HDL‐cholesterol are the two important lipid measures in the diagnosis of MetS.
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The fasting triglycerides and glucose (TyG) index is more suitable for the identification of metabolically unhealthy individuals in different BMI subgroups of Chinese adult population: a nationwide study {#jdi12939-sec-0784}
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**X. Yu, L. Wang, W. Zhang, A. Jia, S. Xu, Q. Li, J. Ming and Q. Ji**

Department of Endocrinology, Xijing Hospital, Fourth Military Medical University, Xi\'an Shan\'xi, China

**Objectives**: To find out a simple index to identify the metabolic unhealth of the Chinese adult population by comparing common surrogate indexes of insulin resistance (IR).

**Subjects/Methods**: A total of 37 122 individuals (14 579 men and 22 543 women) with complete data records, were screened from the China National Diabetes and Metabolic Disorders Study conducted from June 2007 to May 2008. Receiver operating characteristic curve analysis was mainly performed to compare common surrogate indexes of IR for the identification abilities of metabolically unhealthy individuals.

**Results**: Among the common surrogate indexes of IR, the product of fasting triglycerides and glucose (TyG) presented the highest ORs and 95%CIs for metabolically unhealthy individuals, reaching 76.601 (95% CI 69.259--84.722) for the top quartile as compared with the bottom quartile (*P *\< 0.001) after adjusted. The TyG also showed the highest value for the identification of metabolically unhealthy individuals, with area under the curve values (AUC) of 0.862 for men and 0.874 for women. The AUCs (95%CI) for normal weight, overweight, and obesity were 0.842 (0.833--0.850), 0.841 (0.831--0.850), and 0.838 (0.823--0.852) for men and 0.864 (0.858--0.870), 0.860 (0.851--0.868), and 0.856 (0.844--0.868) for women with no significantly difference among each subgroup. The similar results were observed in individuals without diabetic treatment or diabetes.

**Conclusion**: We propose that TyG index is more simple and suitable for the identification of metabolically unhealthy individuals and who have high risk of cardiometabolic diseases in different BMI subgroups of the Chinese adult population.
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Longer Clinic Consultation Resulted in Greater Weight Loss: A Multidisciplinary Weight Management Clinic Experience {#jdi12939-sec-0786}
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**N. A. E. Warman, A. F. Mohamad and R. A. Ghani**

Universiti Teknologi Mara (uitm), Sungai Buloh, Malaysia

**Background**: Obesity is a major health issue in Malaysia. The prevalence was 30.6% in 2015, increasing yearly. Obesity management is a great challenge to clinicians and patients. Patients face barriers at multiple levels of the social ecology: the individual, interpersonal, and community levels, and lack of motivation.

**Methodology**: A prospective cohort study. Ninety‐three patients referred to obesity clinic were invited to join our Weight Management Programme, a well‐structured 12‐month programme involving various multidisciplinary team: endocrinologist, family medicine, rehabilitation medicine, dietician, and clinical psychologist. There were 7 visits within 12‐month period. From the 93 patients, 58 patients were included in the analysis. The inclusion criteria were patients with BMI ≥30 kg/m^2^ and age 18--55 years old. Exclusion criteria were patients with uncontrolled diabetes mellitus, chronic inflammatory disease, any condition limiting mobility, malignancy, organ failure, secondary cause of obesity, on steroid treatment, and hospital admission within the first 6 months. At first visit, patients were assessed on general health, cardiorespiratory endurance, nutritional and fitness assessments. At 1 month, psychological and endocrine function was assessed. Subsequent visits involved support group counselling, nutritional group counselling, cardiorespiratory endurance, fitness group counselling, and assessment of compliance and motivation. Anthropometric measurements were collected at each visit.

**Results**: Fifty‐eight patients were included in the analysis. The mean age, BMI and HbA1c at baseline were 39.6 ± 13.0 years, 45.7 ± 9.6 kg/m^2^, 6.3 ± 1.2%, respectively. Half of the patients attended more than 50% of the programme. Mean clinic hours was 10.79 ± 5.36 h per‐patient. There was significant mean weight loss of 4.25 ± 9.53 kg (*P* = 0.001) and BMI reduction of 1.47 ± 3.60 kg/m^2^ (*P* = 0.003). 22.4% patients achieved weight loss of more than 5%. Mean weight loss was greater in patients attended more than 50% of the programme (5.90 kg vs. 2.54 kg, *P* = 0.006). Patients attended longer clinic hours lose more weight (*r* = 0.256; *P* = 0.05).

**Conclusion**: This study demonstrated that longer clinic consultation resulted in greater weight loss. This emphasized the need for a multidisciplinary approach in the management of obesity, including clinical psychologist and support group sessions. This well‐structured programme enabled patients to receive a comprehensive treatment conveniently.
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**D. Gupta^1^, K. Singh^2^ and M. Sabharwal^2^**

^1^Public Health Foundation Of India, Gurugram Haryana, India, ^2^Lady Irwin College, University of Delhi, Delhi New Delhi, India, ^3^Lady Irwin College, University of Delhi, Delhi New Delhi, India

**Purpose of Study**: High prevalence of metabolic syndrome (MetS) has been reported among adults of India, but for the adolescent, there is lack of studies. The diagnosis of MetS involves blood testing which is expensive, invasive and time‐consuming and also the prevalence of this syndrome is considerably higher among overweight and obese adolescents in comparison with normal weight. In India, where the funds are limited, blood testing of metabolic features in every adolescent in epidemiological research would be unethical and will lead to wastage of resources. Thus screening becomes justifiable to be used in epidemiological researches. With this background, present study was conducted with the aim to screen and identify school‐going adolescents of Delhi with MetS by using two most frequently used definition. Also, the predictive ability of screening criteria\'s for MetS was assessed. Material and

**Methods**: Cross sectional study with 877 adolescents (12--15 years) of Delhi was conducted between November 2014 and April 2015. Based on the screening criteria, high‐risk subjects were identified. Screening criteria were Body Mass Index (BMI) \>1 SD, Waist Circumference (WC) ≥90 percentile, Waist‐to‐height ratio (WHtR)\> 0.5 and first degree familial history of obesity, diabetes and blood pressure.

**Result**: 33.3% subjects were screened who were at risk of MetS. Prevalence of this syndrome among screened subject was 16.2% and 21.7% based on IDF (2007) and modified NCEP ATP III criteria (2003). Neither gender difference nor any difference was seen between the age group for metabolic syndrome. Higher prevalence of syndrome was reported by modified NCEP ATP III criteria in comparison to IDF criteria. Amongst the screening criteria, WC ≥ 90th percentile had better predictive ability for identification of MetS in comparison with other criteria in both boys and girls and across age groups.

**Conclusion**: Population‐based strategies are needed to address the increasing burden of obesity and its associated consequences like MetS. WC should be incorporated in the school medical check up to quickly identify high‐risk subjects. Also, school authorities should be involved in sensitising the parents on importance of identifying obesity in their child and associated consequences.
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**P. Chen^1^, X. Hou^1^, G. Hu^2^, L. Wei^1^, J. Wu^1^, Y. Liang^1^, Y. Bao^1^ and W. Jia^1^**
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**Background**: Previous studies have reported that visceral adipose tissue is associated with higher risk of diabetes. However, the association of subcutaneous adipose tissue with diabetes risk is controversial. The objective of our study was to assess the associations between abdominal adipose distribution and the risk of newly diagnosed diabetes in Chinese adults.

**Methods**: The Shanghai Nicheng Cohort Study was conducted among Chinese adults aged 45--70 years. Participants (*n *= 12,137) from the baseline study without previously diagnosed diabetes were analyzed. Abdominal Subcutaneous and visceral fat area (SFA and VFA) were measured by magnetic resonance imaging at the umbilical level. Diabetes was newly diagnosed using a 75 g oral glucose tolerance test.

**Results**: After adjusted for age, education, leisure‐time physical activity, smoking habit, alcohol consumption, systolic blood pressure, and family history of diabetes (Model 1), odds ratios (OR) and 95% confidence intervals (CI) of newly diagnosed diabetes for 1 standard deviation increase in SFA were 1.29 (1.19--1.39) in men, and 1.10 (1.03--1.18) in women. When body mass index (BMI), VFA and SFA were further entered into the multivariable‐adjusted model simultaneously (Model 2), the positive association disappeared in men and was reversed in women (OR: 0.86 \[95% CI, 0.78--0.94\]). The multivariable‐adjusted (Model 1) ORs and 95% CIs of newly diagnosed diabetes for each 1 standard deviation in VFA were 1.61 (1.49--1.74) in men, and 1.56 (1.45--1.67) in women. The positive association between VFA and newly diagnosed diabetes remained significant in both sexes after further adjustment for BMI and SFA (Model 2). Areas under the receiver operating characteristic curve of newly diagnosed diabetes predicted by VFA (0.679 \[95% CI, 0.659--0.699\] for men and 0.707 \[95% CI, 0.690--0.723\] for women) were significantly larger than by the other adiposity indicators (VFA/SFA, BMI, waist circumference, and body fat percentage).

**Conclusions**: SFA was beneficial for lower risk of newly diagnosed diabetes in women but was not associated with newly diagnosed diabetes in men after taking general obesity and visceral obesity into account. VFA, however, was a good indicator for likelihood of newly diagnosed diabetes among Chinese adults, independently of BMI and SFA.
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**Background**: Obesity epidemic has become an increasingly important medical problem in adolescents, and hypertension is one of the many associated co‐morbidities. Given the long‐term health consequences of untreated hypertension, we aimed to examine the prevalence of hypertension among overweight and obese adolescents enrolled into a school‐based lifestyle intervention study (MyBFF\@school).

**Methodology**: MyBFF\@school was conducted between February 2016 and August 2016. Blood pressure (BP) readings were obtained from 1036 overweight and obese adolescents aged 13 to 16 years with BMI z‐score exceeded +1 SD according to WHO BMI reference. BP was measured twice, using mercury sphygmomanometer in a seated position, and the average of the two readings was recorded and further classified according to American Academy of Pediatrics guideline (normal BP: \<120/\<80 mmHg; elevated BP: 120/\<80 to 129/\<80 mmHg; stage 1 hypertension: 130/80 to 139/89 mmHg; stage 2 hypertension: ≥140/90 mmHg).

**Results**: The mean systolic and diastolic BP was 111.35 ± 12.27 mmHg and 70.24 ± 9.21 mmHg respectively. Boys had significantly higher systolic BP than girls (112.84 ± 12.30 vs. 110.29 ± 12.15 mmHg, *P *\< 0.01). Overall, 13.7% had elevated BP, 16.8% had stage 1 hypertension and 4.0% had stage 2 hypertension. Morbidly obese adolescents (BMI for age \> +3SD) had significantly higher prevalence of stage 2 hypertension compared to obese (BMI for age \> +2SD) and overweight (BMI for age \> +1SD) adolescents with 17.6%, 3.0% and 1.4%, respectively (*P *\< 0.001). Adolescents with waist circumference ≥90th percentile (abdominal obesity) had significantly higher percentage of stage 1 and stage 2 hypertension when compared to those with normal waist circumference with 20.4% vs. 11.0% and 5.3% vs. 1.8% respectively (*P *\< 0.001). A simple logistic regression showed that abdominally obese adolescents are 2 times more likely to have abnormal BP when compared to those with normal waist circumference (odd ratio = 2.16, 95% CI 1.63, 2.85; *P *\< 0.001).

**Conclusion**: Relatively high prevalence of elevated BP and hypertension among overweight and obese adolescents recorded in this study. Periodic screening and monitoring of BP among these adolescents is recommended to be incorporated into the school health programme.
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Some previous studies revealed the possibility of beneficial effects of heat therapy on body weight or glycemic control in obese subjects or patients with type 2 diabetes (T2DM). The aim of this study was to clarify the significance of habit of taking a bath or shower on metabolic parameters in patients with T2DM. We retrospectively analyzed the results of the questionnaires on non‐exercise activity thermogenesis (NEAT) from our former study. The questionnaires included an item about the frequency of taking a bath or shower. The scores were as follows: Taking a bath or shower once or more a day: 3 points, One or more a week: 2 points, and Hardly ever: 1 point. We studied a difference in metabolic parameter between patients who obtained 3 points and patients who obtained 1--2 points. We also evaluated the correlation between the score and metabolic parameters. We found 87 eligible patients with T2DM. A total of 50 patients obtained 3 points in the question item, 35 patients obtained 2 points and 2 patients obtained 1 point. Body weight and waist circumference were significantly lower in patients who obtained 3 points. Total NEAT score was significantly higher and prevalence of mental disorder was lower in these patients. The points in the question item of taking a bath or shower were positively correlated with total NEAT score and negatively correlated with waist circumference. We also analyzed in female patients (*n *= 43). Body weight, body mass index and waist circumference were significantly lower in patients who obtained 3 points, whereas total NEAT score was higher in these patients. The points in the question item of taking a bath or shower were positively correlated with total NEAT score and negatively with waist circumference. There were no significant differences in any parameters between patients who obtained 3 points and patients who obtained 1--2 points in male subjects. The results suggest that habit of bathing or showering could reflect the daily physical activities well, especially in female. Furthermore, habit of bathing on metabolic parameters might have beneficial effects on metabolic abnormalities. Further study will be needed.
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**Objective**: Lipocalin2, released mainly by osteoblasts, adipocytes, uses variety of pathways to establish closely contact with obesity. This study aimed to investigate serum LCN2 level in Chinese obese women and changes of that after laparoscopic sleeve gastrectomy. To confirm whether alteration of fat mass and bone mineral density is associated with Lipocalin2.

**Methods**: Fifty‐two patients (38 obese females and 14 normal BMI females) were enrolled in this study. A total of 38 obese patients underwent LSG. BMD of arm, leg, T spine, L spine and pelvis were measured by dual‐energy X‐ray absorptiometry, body fat mass and fat distribution were measured with high accuracy by dual‐energy X‐ray absorptiometry and routine anthropometric/laboratory biochemical parameters at baseline, 3 and 12 months after LSG were recorded. Serum LCN2 levels were measured by enzyme‐linked immunosorbent assay.

**Results**: LCN2 in obesity women were higher than in normal women (102.70 ± 27.19 vs. 80.66 ± 19.55, *P* = 0.009). LCN2 were significantly decreased at 3‐ and 12‐month post‐LSG (86.73 ± 26.79 *P *\< 0.001 for 3‐month post‐LSG, 64.79 ± 28.39 *P *\< 0.001 for 12‐month post‐LSG). LSG led to dramatic body fat mass decrease and slightly BMD decrease. Decreased LCN2 was significantly correlated with the variation in L Leg BMD, R Leg BMD and Trunk fat mass, respectively, at 12‐month after LSG.

**Conclusions**: Serum LCN2 levels in obesity women were higher than in normal BMI women and that were gradually decreased after LSG. Decreased LCN2 was significantly correlated with the variation in BMD and fat mass at 12‐month after surgery.
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**Purposes**: The correlation between osteoporosis and obesity has been established both genetically and phenotypically. In addition, genes associated with osteoporosis may also be candidates for obesity. Human *SOST* gene inhibits osteoblastic bone formation by inhibiting the Wnt signaling pathway, which is critical importance for the development and function of osteoblasts. This study aimed to investigate the effect of *SOST* gene polymorphisms and haplotypes on obesity phenotypes in young Chinese men.

**Methods**: We recruited a total of 1,295 individuals from 427 Chinese nuclear families with male‐offspring. The nuclear families were composed of both parents and at least one healthy male child between 20 and 40 years old. Ten tagged single‐nucleotide polymorphisms (SNPs) in *SOST* gene (rs1234612, rs1513670, rs1634330, rs1708635, rs2023794, rs7220711, rs74252774, rs851057, rs851058 and rs865429) were genotyped in all the above people. The total fat mass and total lean mass was measured by dual‐energy X‐ray absorptiometry. We tested whether a single SNP or a haplotype was associated with body mass index (BMI), total fat mass, total lean mass, percentage of lean mass and percentage of fat mass variations using the quantitative transmission disequilibrium test (QTDT).

**Results**: No significant within‐family associations were found between genotypes or haplotypes of the *SOST* gene and BMI, total fat mass, total lean mass, percentage of lean mass and percentage of fat mass. The 1000 permutations that were subsequently simulated were in agreement with these within‐family association results.

**Conclusions**: Our results suggest that the natural variation in *SOST* gene is not a major contributor to the observed variability in obesity phenotypes in Chinese male‐offspring nuclear families. Because ethnic differences in the *SOST* genotypes may exist, other studies in different population are required to confirm such results.
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**Background/Objective**: Health of a child is important determinants of academic performance. With the increasing prevalence of overweight and obesity among children, it is important for us to understand their effect on academic performance. We aim to compare academic performance across weight status among children and to determine the factors influencing the academic performance of overweight and obese children.

**Method**: A total of 928 participants aged 9 to 17 years were recruited from eight randomly selected primary and secondary schools in Kuala Lumpur. Academic performance was based on one examination marks of four subjects; Malay Language, English, Mathematics and Science. The association of the academic performance with independent variable among overweight/obese children was examined using multivariable linear regression.

**Results**: Majority of the respondents were girls (*n *= 617, 66.4%) and Malay (*n *= 852, 91.9%). There was approximately similar proportion between participants from primary (*n *= 465, 51.7%) and secondary (*n *= 463, 48.3%) school. The prevalence of overweight/obesity was 41.2% (*n *= 375). Obese participants reported poorer scores in total performance (*P *=* *0.015), Mathematics (*P *=* *0.031) and Science (*P *=* *0.042) compared to other weight status. In the multivariable linear regression analysis among overweight and obese children, girls had a significantly higher score (ß = 5.86, *P *\<* *0.001) compared to boys. Children of high education parents performed better in academic compared to those with no formal education parents (ßfather = 7.81, *P *\<* *0.001; ßmother = 5.19, *P *=* *0.008). Meanwhile, for every one day absent from school, examination mark is expected to reduce by 0.360 score, provided the other variables remain unchanged (ß *=* −*0.32, P *=* *0.016).

**Conclusion**: Obesity has negative impact on children\'s academic performance. Effective obesity prevention programs are warranted, not only to reduce obesity but also to improve academic performance.
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**Background**: Obesity contributes to the development of dysglycemia. Despite the fact that body mass index and waist circumference are the two most common anthropometric measurements to define obesity, both measures might not completely represent the fat accumulation in the body. Lipid accumulation product (LAP) is an index of lipid accumulation, which is computed from waist circumference and triglycerides. Triglycerides level is included in the equation because elevated triglycerides represent increased lipotoxicity. We aim to study the association of LAP index with spectrum of dysglycemia in Indonesia population.

**Method**: We analyzed the baseline cross‐sectional data from the Indonesian Ministry of Health Cohort Study of Non‐communicable Diseases Risk Factors in Bogor, West Java, comprising 5683 subjects aged 25--65 years old. Association between increased LAP and worsening of dysglycemia spectrum was assessed using linear regression.

**Results**: A total of 1,996 men and 3,687 women were included in this study. The number of subjects with prediabetes and diabetes was 1077 and 388, respectively. Worsening glycemia status was associated with increased LAP index (p for trend \<0.0001). The median \[median (95% CI)\] for LAP index for normoglycemia, prediabetes, and diabetes were 17.58 (8.44--31.53), 29.83 (15.78--48.80), and 40.85 (24.74--65.76) respectively. In men, the median for LAP index for normoglycemia, prediabetes, and diabetes were 12.19 (4.52--28.81), 24.84 (9.54--45.77), and 34.26 (18.80--58.25) (*P* = 0.0001). While in women, the median for LAP index for normoglycemia, prediabetes, and diabetes were 19.87 (11.38--33.50), 31.91 (9.10--49.32), and 42.66 (27.80--68.95) (*P* = 0.0001).

**Conclusions**: Worsening dysglycemia status was associated with increased LAP index. This association was observed for both men and women. However, longitudinal studies are needed to assess the use of LAP index as a predictor for future development of dysglycemia.
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**Background**: Studies have shown that visceral fat plays a relatively more important role in the development of type 2 diabetes (T2DM) than subcutaneous fat. Waist circumference has been commonly used as a proxy for visceral fat; however, it actually measures both visceral and subcutaneous fat. Visceral Adiposity Index (VAI) is an equation model to estimate visceral fat accumulation by using simple anthropometric (waist circumference and body mass index) and laboratory measurements (HDL‐cholesterol and Triglycerides). The VAI index has been reported to better represents the visceral fat accumulation, and better predict the future development of T2DM. To this end, as the VAI index was developed in Caucasian population, we aim to assess whether it can also predict T2DM in Asian population.

**Methods**: We performed a systematic review on all studies in Asian population reporting the use of VAI as a predictor of T2DM which were published within the last five years in English language. We searched in PubMed and Cochrane database using the terms of visceral adiposity index, VAI, type 2 diabetes, Asian, predictor.

**Results**: We retrieved 7 studies, of which 6 of them were performed in China, and 1 in Iran. Four out of 7 studies were prospective cohorts, and 3 of them were cross sectionals. The largest population was 7639 subjects, while the longest period of follow‐up was 15 years. All studies report adjusted odds ratio or hazard ratio ranging from 1.2 to 3.6, which were relatively higher in comparison to studies performed in Caucasian population. This confirms that VAI can be used as an independent predictor for T2DM in Asian population.

**Conclusion**: VAI is a practical equation as a proxy for visceral fat accumulation which can be use as predictor of T2DM among Asian population. However, as most studies were done in China, further studies involving different Asian ethnic groups are needed to confirm this finding.
